<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antiplatelet agents for chronic kidney disease - Natale, P - 2022 | Cochrane Library</title> <meta content="Antiplatelet agents for chronic kidney disease - Natale, P - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008834.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antiplatelet agents for chronic kidney disease - Natale, P - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008834.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008834.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Antiplatelet agents for chronic kidney disease" name="citation_title"/> <meta content="Patrizia Natale" name="citation_author"/> <meta content="Suetonia C Palmer" name="citation_author"/> <meta content="University of Otago Christchurch" name="citation_author_institution"/> <meta content="suetonia.palmer@otago.ac.nz" name="citation_author_email"/> <meta content="Valeria M Saglimbene" name="citation_author"/> <meta content="Marinella Ruospo" name="citation_author"/> <meta content="Mona Razavian" name="citation_author"/> <meta content="The George Institute for Global Health" name="citation_author_institution"/> <meta content="Jonathan C Craig" name="citation_author"/> <meta content="Meg J Jardine" name="citation_author"/> <meta content="NHMRC Clinical Trials Centre" name="citation_author_institution"/> <meta content="Angela C Webster" name="citation_author"/> <meta content="Giovanni FM Strippoli" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD008834.pub4" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/02/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008834.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008834.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008834.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Platelet Aggregation Inhibitors [adverse effects]; Proteinuria; Renal Dialysis; *Renal Insufficiency, Chronic [complications, therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008834.pub4&amp;doi=10.1002/14651858.CD008834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="IYhCEbRn";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008834\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008834\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008834\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008834\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","th","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008834.pub4",title:"Antiplatelet agents for chronic kidney disease",firstPublishedDate:"Feb 28, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008834.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008834.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008834.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008834.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008834.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008834.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008834.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008834.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008834.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008834.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5451 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008834.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/full#CD008834-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/full#CD008834-sec-0163"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/full#CD008834-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/full#CD008834-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/full#CD008834-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/full#CD008834-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/full#CD008834-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/full#CD008834-sec-0153"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/appendices#CD008834-sec-0168"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/supinfo/CD008834StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/supinfo/CD008834StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antiplatelet agents for chronic kidney disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/information#CD008834-cr-0004">Patrizia Natale</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/information#CD008834-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Suetonia C Palmer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/information#CD008834-cr-0006">Valeria M Saglimbene</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/information#CD008834-cr-0007">Marinella Ruospo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/information#CD008834-cr-0008">Mona Razavian</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/information#CD008834-cr-0009">Jonathan C Craig</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/information#CD008834-cr-0010">Meg J Jardine</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/information#CD008834-cr-0011">Angela C Webster</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008834.pub4/information#CD008834-cr-0012">Giovanni FM Strippoli</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/information/en#CD008834-sec-0179">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 February 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008834.pub4">https://doi.org/10.1002/14651858.CD008834.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008834-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008834-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008834-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008834-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008834-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD008834-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008834-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008834-abs-0001" lang="en"> <section id="CD008834-sec-0001"> <h3 class="title" id="CD008834-sec-0001">Background</h3> <p>Antiplatelet agents are widely used to prevent cardiovascular events. The risks and benefits of antiplatelet agents may be different in people with chronic kidney disease (CKD) for whom occlusive atherosclerotic events are less prevalent, and bleeding hazards might be increased. This is an update of a review first published in 2013. </p> </section> <section id="CD008834-sec-0002"> <h3 class="title" id="CD008834-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of antiplatelet agents in people with any form of CKD, including those with CKD not receiving renal replacement therapy, patients receiving any form of dialysis, and kidney transplant recipients. </p> </section> <section id="CD008834-sec-0003"> <h3 class="title" id="CD008834-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies up to 13 July 2021 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. </p> </section> <section id="CD008834-sec-0004"> <h3 class="title" id="CD008834-sec-0004">Selection criteria</h3> <p>We selected randomised controlled trials of any antiplatelet agents versus placebo or no treatment, or direct head‐to‐head antiplatelet agent studies in people with CKD. Studies were included if they enrolled participants with CKD, or included people in broader at‐risk populations in which data for subgroups with CKD could be disaggregated. </p> </section> <section id="CD008834-sec-0005"> <h3 class="title" id="CD008834-sec-0005">Data collection and analysis</h3> <p>Four authors independently extracted data from primary study reports and any available supplementary information for study population, interventions, outcomes, and risks of bias. Risk ratios (RR) and 95% confidence intervals (CI) were calculated from numbers of events and numbers of participants at risk which were extracted from each included study. The reported RRs were extracted where crude event rates were not provided. Data were pooled using the random‐effects model. Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. </p> </section> <section id="CD008834-sec-0006"> <h3 class="title" id="CD008834-sec-0006">Main results</h3> <p>We included 113 studies, enrolling 51,959 participants; 90 studies (40,597 CKD participants) compared an antiplatelet agent with placebo or no treatment, and 29 studies (11,805 CKD participants) directly compared one antiplatelet agent with another. Fifty‐six new studies were added to this 2021 update. Seven studies originally excluded from the 2013 review were included, although they had a follow‐up lower than two months. </p> <p>Random sequence generation and allocation concealment were at low risk of bias in 16 and 22 studies, respectively. Sixty‐four studies reported low‐risk methods for blinding of participants and investigators; outcome assessment was blinded in 41 studies. Forty‐one studies were at low risk of attrition bias, 50 studies were at low risk of selective reporting bias, and 57 studies were at low risk of other potential sources of bias. </p> <p>Compared to placebo or no treatment, antiplatelet agents probably reduces myocardial infarction (18 studies, 15,289 participants: RR 0.88, 95% CI 0.79 to 0.99, I² = 0%; moderate certainty). Antiplatelet agents has uncertain effects on fatal or nonfatal stroke (12 studies, 10.382 participants: RR 1.01, 95% CI 0.64 to 1.59, I² = 37%; very low certainty) and may have little or no effect on death from any cause (35 studies, 18,241 participants: RR 0.94, 95 % CI 0.84 to 1.06, I² = 14%; low certainty). Antiplatelet therapy probably increases major bleeding in people with CKD and those treated with haemodialysis (HD) (29 studies, 16,194 participants: RR 1.35, 95% CI 1.10 to 1.65, I² = 12%; moderate certainty). In addition, antiplatelet therapy may increase minor bleeding in people with CKD and those treated with HD (21 studies, 13,218 participants: RR 1.55, 95% CI 1.27 to 1.90, I² = 58%; low certainty). Antiplatelet treatment may reduce early dialysis vascular access thrombosis (8 studies, 1525 participants) RR 0.52, 95% CI 0.38 to 0.70; low certainty). Antiplatelet agents may reduce doubling of serum creatinine in CKD (3 studies, 217 participants: RR 0.39, 95% CI 0.17 to 0.86, I² = 8%; low certainty). The treatment effects of antiplatelet agents on stroke, cardiovascular death, kidney failure, kidney transplant graft loss, transplant rejection, creatinine clearance, proteinuria, dialysis access failure, loss of primary unassisted patency, failure to attain suitability for dialysis, need of intervention and cardiovascular hospitalisation were uncertain. Limited data were available for direct head‐to‐head comparisons of antiplatelet drugs, including prasugrel, ticagrelor, different doses of clopidogrel, abciximab, defibrotide, sarpogrelate and beraprost. </p> </section> <section id="CD008834-sec-0007"> <h3 class="title" id="CD008834-sec-0007">Authors' conclusions</h3> <p>Antiplatelet agents probably reduced myocardial infarction and increased major bleeding, but do not appear to reduce all‐cause and cardiovascular death among people with CKD and those treated with dialysis. The treatment effects of antiplatelet agents compared with each other are uncertain. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008834-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008834-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008834-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008834-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008834-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008834-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008834-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008834-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD008834-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008834-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008834-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008834-abs-0002" lang="en"> <h3>Are anti‐blood clotting drugs beneficial for people with chronic kidney disease?</h3> <p><b>What is the issue?</b><br/>People with chronic kidney disease (CKD) have an increased risk of heart disease that can block the blood supply to the heart or brain causing a heart attack or stroke. Drugs that prevent blood clots from forming (antiplatelet agents) can prevent deaths caused by clots in arteries in the general adult population. However, there may be fewer benefits for people who have CKD, because blood clots in arteries is a less common cause of death or reason to be admitted to hospital compared with heart failure or sudden death in these people. People with CKD also have an increased tendency for bleeding due to changes in how the blood clots. Antiplatelet agents may therefore be more hazardous when CKD is present. </p> <p><b>What did we do?</b> </p> <p>This updated review evaluated the benefits and harms of antiplatelet agents to prevent cardiovascular disease and death, and the impact on dialysis vascular access (fistula or graft) function in people who have CKD. We identified 90 studies comparing antiplatelet agents with placebo or no treatment and 29 studies directly comparing one antiplatelet agent with another. </p> <p><b>What did we find?</b><br/>Antiplatelet agents probably prevent heart attacks, but do not clearly reduce death or stroke. Treatment with these agents may increase the risk of major and minor bleeding. Clotting of dialysis access was prevented with antiplatelet agents. </p> <p><b>Conclusions</b><br/>The benefits of antiplatelet agents for people with CKD is probably limited to the prevention of a heart attack. The treatment does not appear to prevent stroke or death and probably incurs excess serious bleeding that may require hospital admission or transfusion. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008834-sec-0163" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008834-sec-0163"></div> <h3 class="title" id="CD008834-sec-0164">Implications for practice</h3> <section id="CD008834-sec-0164"> <p>Overall evidence ratings and recommendations for antiplatelet agents to prevent cardiovascular and dialysis access outcomes in people with CKD using the GRADE system for grading evidence are summarised (<a href="./references#CD008834-bbs2-0191" title="GRADE Working Group.Grading of Recommendations Assessment, Development and Evaluation (GRADE). www.gradeworkinggroup.org (last accessed 24 October 2021).">GRADE 2011b</a>). This updated systematic review has shown that antiplatelet agents in people with CKD and HD probably reduces the risk of MI, while the impact on death from any cause, cardiovascular death and stroke is uncertain or there is little evidence of impact from treatment. Treatment incurs major and minor bleeding that may impact the decision‐making process by patients and clinicians balancing the potential benefits and harms of therapy. Antiplatelet agents given at the time of access surgery may reduce thrombosis or failure of vascular access, but effects on dialysis vascular access suitability for dialysis and access maturation are uncertain. The relative benefits of treatment in kidney transplant recipients and with primary prevention strategies in CKD are insufficient to inform practice. Based on absolute risks of clinical outcomes, it might be expected that antiplatelet agents would prevent 13 people with CKD and 3 treated with HD for every 1000 people treated over 1 year (<a href="./full#CD008834-tbl-0001">summary of findings Table 1</a>), while 18 people with CKD and 1 people treated with HD might experience a major bleeding event without strong evidence that treatment prevents death. This implies that the balance of benefits and harms for people with CKD and those treated with dialysis depends on treatment goals and the relative importance of reducing the risk of MI or avoiding a serious bleeding event. </p> </section> <h3 class="title" id="CD008834-sec-0165">Implications for research</h3> <section id="CD008834-sec-0165"> <p>This review shows that there are little data for antiplatelet agents to prevent cardiovascular events in kidney transplant recipients with chronic or acute coronary artery disease. Further, adequately powered placebo‐controlled RCTs are required to determine whether antiplatelet agents provide primary prevention against cardiovascular disease in people with CKD, including kidney transplant recipients, compared with aspirin monotherapy. To inform decisions in clinical practice, powered RCTs on any antiplatelet therapy‐based cardiovascular study should include at least 2000 participants for each stage of CKD to meet the optimal information size criterion and evaluate adequately the confidence in the estimate of effect, with a relative risk reduction of 25% (<a href="./references#CD008834-bbs2-0192" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al.GRADE guidelines 6. Rating the quality of evidence--imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93. [MEDLINE: 21839614]">GRADE 2011c</a>). Specific head‐to‐head studies of antiplatelet agent regimens in individuals with all stages CKD and established atherosclerotic disease, acute coronary syndrome or undergoing percutaneous coronary intervention are required, particularly comparing thienopyridines (prasugrel or ticagrelor) or P2Y antagonists versus clopidogrel, different doses of clopidogrel, glycoprotein IIb/IIIa inhibitors versus another glycoprotein IIb/IIIa inhibitor or adenosine reuptake inhibitors, cilostazol versus sarpogrelate and beraprost sodium versus cilostazol or sarpogrelate. Studies should be designed to use standardised criteria to capture systematically all cardiovascular outcomes and major bleeding events in studies in which severe CKD is not an exclusion criterion. More information is required on the relative benefits of antiplatelet agents compared with other antiplatelet agents in people with CKD and the effects of therapy on cardiovascular mortality and bleeding. The role of antiplatelet agents as a primary prevention strategy to reduce death (any cause) and cardiovascular death in individuals with CKD, dialysis (HD and PD) and kidney transplant without existing cardiovascular disease appears to be a lower research priority. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008834-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008834-sec-0008"></div> <div class="table" id="CD008834-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antiplatelet agents versus control for chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Antiplatelet agents versus control for chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients) </p> <p><b>Settings:</b> all settings involving people with any stage of CKD </p> <p><b>Intervention:</b> antiplatelet agents (abciximab, aspirin, beraprost sodium, cilostazol, clopidogrel, dypiridamole, eptidifibatide, pentoxifylline, picotamide, prasugrel, prostacyclin, sarpogrelate, sulphinpyrazone, ticlopidine, tirofiban, alone or in combination) </p> <p><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antiplatelet agents</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Fatal or nonfatal myocardial infarction</b> </p> <p>Follow‐up: 3 to 61.2 months</p> <p>(median 12 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>All patients (predialysis, dialysis, transplant recipients)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/>(0.79 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15,289 (18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>moderate <sup>1</sup> </b> </p> <p>⊕⊕⊕⊝</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 fewer per 1,000<br/>(1 to 15 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>CKD patients (GFR 15 to 60 mL/min/1.73 m²)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/>(0.74 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11,912 (11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>moderate <sup>1</sup> </b> </p> <p>⊕⊕⊕⊝</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 fewer per 1,000<br/>(1 to 22 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>HD patients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.49 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2929 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>moderate <sup>1</sup> </b> </p> <p>⊕⊕⊕⊝</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 fewer per 1,000<br/>(10 fewer to 8 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Fatal or nonfatal stroke</b> </p> <p>Follow‐up: 3 to 61.2 months</p> <p>(median 12 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>All patients (predialysis, dialysis, transplant recipients)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.64 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,382 (12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>very low <sup>1,2,3</sup> </b> </p> <p>⊕⊝⊝⊝</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/>(7 fewer to 12 more) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>CKD patients (GFR 15 to 60 mL/min/1.73 m²)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.06<br/>(0.64 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7062 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>very low <sup>1,2,3</sup> </b> </p> <p>⊕⊝⊝⊝</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 more per 1,000<br/>(9 fewer to 19 more) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>HD patients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.62<br/>(0.15 to 2.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2872 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>very low <sup>1,2,3</sup> </b> </p> <p>⊕⊝⊝⊝</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 fewer per 1,000<br/>(8 fewer to 16 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Death (any cause)</b> </p> <p>Follow‐up: 0.9 to 88.2 months</p> <p>(median 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>All patients (predialysis, dialysis, transplant recipients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/>(0.84 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>18,241 (35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>low <sup>1,2</sup> </b> </p> <p>⊕⊕⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>74 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4 fewer per 1,000<br/>(12 fewer to 4 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>CKD patients (GFR 15 to 60 mL/min/1.73 m²)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.97<br/>(0.81 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>13,234 (19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>low <sup>1,2</sup> </b> </p> <p>⊕⊕⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>72 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2 fewer per 1,000<br/>(14 fewer to 12 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>HD patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.86<br/>(0.72 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>4523 (14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>low <sup>1,2</sup> </b> </p> <p>⊕⊕⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>87 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>12 fewer per 1,000<br/>(24 fewer to 3 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Cardiovascular death</b> </p> <p>Follow‐up: 0.9 to 88.2 months</p> <p>(median 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>All patients (predialysis, dialysis, transplant recipients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.87<br/>(0.65 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>9606 (21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>very low <sup>1,2,3</sup> </b> </p> <p>⊕⊝⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>36 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 fewer per 1,000<br/>(13 fewer to 5 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>CKD patients (GFR 15 to 60 mL/min/1.73 m²)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.98<br/>(0.60 to 1.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>6525 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>very low <sup>1,2,3</sup> </b> </p> <p>⊕⊝⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>37 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 fewer per 1,000<br/>(15 fewer to 22 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>HD patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.71<br/>(0.47 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2597 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>very low <sup>1,2,3</sup> </b> </p> <p>⊕⊝⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>38 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 fewer per 1,000<br/>(20 fewer to 3 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Major bleeding</b> </p> <p>Follow‐up: 0.7 to 61.2 months</p> <p>(median 6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>All patients (predialysis, dialysis, transplant recipients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.35<br/>(1.10 to 1.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>16,194 (29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>moderate <sup>1</sup> </b> </p> <p>⊕⊕⊕⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>29 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>10 more per 1,000<br/>(3 to 19 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>CKD patients (GFR 15 to 60 mL/min/1.73 m²)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.51<br/>(1.15 to 1.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>11591 (12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>moderate <sup>1</sup> </b> </p> <p>⊕⊕⊕⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>35 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18 more per 1,000<br/>(5 to 34 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>HD patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.90<br/>(0.53 to 1.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>4119 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>moderate <sup>1</sup> </b> </p> <p>⊕⊕⊕⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>13 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 fewer per 1,000<br/>(6 fewer to 7 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Minor bleeding</b> </p> <p>Follow‐up: 0.5 to 84 months</p> <p>(median 6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>All patients (predialysis, dialysis, transplant recipients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.55<br/>(1.27 to 1.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>13,218 (21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>low <sup>1,3</sup> </b> </p> <p>⊕⊕⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>92 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>51 more per 1,000<br/>(25 to 83 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>CKD patients (GFR 15 to 60 mL/min/1.73 m²)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.48<br/>(1.20 to 1.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>11,530 (12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>low <sup>1,3</sup> </b> </p> <p>⊕⊕⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>103 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 more per 1,000<br/>(21 to 86 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>HD patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.87<br/>(0.65 to 5.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1240 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>low <sup>1,3</sup> </b> </p> <p>⊕⊕⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>8 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>7 per 1,000<br/>(3 fewer to 35 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Early access thrombosis (before 8 weeks)</b> </p> <p>Follow‐up: 0.9 to 12 months</p> <p>(median 1.4 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>HD patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.52<br/>(0.38 to 0.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1525 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>low <sup>1,4</sup> </b> </p> <p>⊕⊕⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>200 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>6 fewer per 1,000<br/>(60 to 124 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>CKD:</b> chronic kidney disease; <b>GFR:</b> glomerular filtration rate; <b>HD:</b> haemodialysis; <b>OIS:</b> Optimal Information Size </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Some or all studies were not blinded (participants and/or investigators) </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>3</sup> Evidence certainty was downgraded by one level due to moderate between‐study heterogeneity </p> <p><sup>4</sup> Evidence certainty was downgraded by one level due to imprecision (OIS criteria) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008834-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008834-sec-0009"></div> <section id="CD008834-sec-0010"> <h3 class="title" id="CD008834-sec-0010">Description of the condition</h3> <p>Cardiovascular disease is the leading cause of morbidity and death among people at all stages of chronic kidney disease (CKD) (<a href="./references#CD008834-bbs2-0179" title="CasasJP , ChuaW , LoukogeorgakisS , VallanceP , SmeethL , HingoraniAD , et al.Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet2005;366(9502):2026-33. [MEDLINE: 16338452]">Casas 2005</a>; <a href="./references#CD008834-bbs2-0199" title="KeithDS , NicholsGA , GullionCM , BrownJB , SmithDH .Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Archives of Internal Medicine2004;164(6):659-63. [MEDLINE: 15037495]">Keith 2004</a>; <a href="./references#CD008834-bbs2-0201" title="MannJF , GersteinHC , PogueJ , BoschJ , YusufS .Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Annals of Internal Medicine2001;134(8):629-36. [MEDLINE: 11304102]">Mann 2001</a>; <a href="./references#CD008834-bbs2-0206" title="NorrisK , BourgoigneJ , GassmanJ , HebertL , MiddletonJ , PhillipsRA , et al.Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases2006;48(5):739-51. [MEDLINE: 17059993]">Norris 2006</a>; <a href="./references#CD008834-bbs2-0213" title="SarnakMJ , LeveyAS , SchoolwerthAC , CoreshJ , CulletonB , HammLL , et al.Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension2003;42(5):1050-65. [MEDLINE: 14604997]">Sarnak 2003</a>; <a href="./references#CD008834-bbs2-0225" title="WeinerDE , TighiouartH , AminMG , StarkPC , MacLeodB , GriffithJL , et al.Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. Journal of the American Society of Nephrology2004;15(5):1307-15. [MEDLINE: 15100371]">Weiner 2004a</a>; <a href="./references#CD008834-bbs2-0226" title="WeinerDE , TighiouartH , StarkPC , AminMG , MacLeodB , GriffithJL , et al.Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. American Journal of Kidney Diseases2004;44(2):198-206. [MEDLINE: 15264177]">Weiner 2004b</a>) including kidney transplant recipients (<a href="./references#CD008834-bbs2-0169" title="AakhusS , DahlK , WideroeTE .Cardiovascular morbidity and risk factors in renal transplant patients. Nephrology Dialysis Transplantation1999;14(3):648-54. [MEDLINE: 10193814]">Aakhus 1999</a>; <a href="./references#CD008834-bbs2-0171" title="Australia &amp; New Zealand Dialysis &amp; Transplant Registry.The 42nd Annual Report 2019 (Data to 2018). www.anzdata.org.au/?s=annual+report&amp;data-group=anzdata (accessed 24 October 2021).">ANZDATA 2019</a>; <a href="./references#CD008834-bbs2-0197" title="KasiskeBL .Cardiovascular disease after renal transplantation. Seminars in Nephrology2000;20(2):176-87. [MEDLINE: 10746859]">Kasiske 2000</a>; <a href="./references#CD008834-bbs2-0208" title="OjoAO , HansonJA , WolfeRA , LeichtmanAB , AgodoaLY , PortFK .Long-term survival in renal transplant recipients with graft function. Kidney International2000;57(1):307-13. [MEDLINE: 10620213]">Ojo 2000</a>; <a href="./references#CD008834-bbs2-0223" title="US Renal Data System.USRDS 2010 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. www.usrds.org/annual-data-report/previous-adrs/ (accessed 24 October 2021).">USRDS 2010</a>). Compared with the general population, the risk of cardiovascular disease is increased two‐fold in people with the early stages of CKD (<a href="./references#CD008834-bbs2-0188" title="GoAS , ChertowGM , FanD , McCullochCE , HsuCY .Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.[Erratum in: N Engl J Med. 2008;18(4):4]. New England Journal of Medicine2004;351(13):1296-305. [MEDLINE: 15385656]">Go 2004</a>) and 30‐ to 50‐fold in people who need dialysis (<a href="./references#CD008834-bbs2-0183" title="deJagerDJ , GrootendorstDC , JagerKJ , vanDijkPC , TomasLM , AnsellD , et al.Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA2009;302(16):1782-9. [MEDLINE: 19861670]">de Jager 2009</a>; <a href="./references#CD008834-bbs2-0187" title="FortJ .Chronic renal failure: a cardiovascular risk factor. Kidney International - Supplement2005;99:S25-9. [MEDLINE: 16336573]">Fort 2005</a>) in whom it accounts for half of all deaths (<a href="./references#CD008834-bbs2-0181" title="CollinsAJ .Cardiovascular mortality in end-stage renal disease. American Journal of the Medical Sciences2003;325(4):163-7. [MEDLINE: 12695721]">Collins 2003</a>). Population representative surveys in Australia (<a href="./references#CD008834-bbs2-0174" title="ChadbanSJ , BrigantiEM , KerrPG , DunstanDW , WelbornTA , ZimmetPZ , et al.Prevalence of kidney damage in Australian adults: The AusDiab kidney study. Journal of the American Society of Nephrology2006;14(7 Suppl 2):S131-8. [MEDLINE: 12819318]">AusDiab 2003</a>) and the USA (<a href="./references#CD008834-bbs2-0205" title="National Health and Nutrition Examination Survey. www.cdc.gov/nchs/nhanes.htm (accessed 24 October 2021).">NHANES 2010</a>) have shown that CKD (defined as proteinuria or reduction of glomerular filtration rate (GFR) below 60 mL/min/1.73 m²) affects approximately 16% of the adult population. With the increasing prevalence of some of the known risk factors for CKD, including hypertension, obesity and diabetes (<a href="./references#CD008834-bbs2-0185" title="FieldsLE , BurtVL , CutlerJA , HughesJ , RoccellaEJ , SorlieP .The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension2004;44(4):398-404. [MEDLINE: 15326093]">Fields 2004</a>; <a href="./references#CD008834-bbs2-0200" title="Koren-MoragN , GoldbourtU , TanneD .Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology2006;67(2):224-8. [MEDLINE: 16864812]">Koren‐Morag 2006</a>; <a href="./references#CD008834-bbs2-0203" title="MokdadAH , FordES , BowmanBA , DietzWH , VinicorF , BalesVS , et al.Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA2003;289(1):76-9. [MEDLINE: 12503980]">Mokdad 2003</a>), the burden of CKD and its complications are projected to increase and to contribute significantly to global healthcare expenditure. </p> </section> <section id="CD008834-sec-0011"> <h3 class="title" id="CD008834-sec-0011">Description of the intervention</h3> <p>Excessive platelet activation occurs in CKD, even in the early stages of the disease. Specifically, the expression of P‐selectin, glycoprotein 53 and activated fibrinogen receptor‐1 on the platelet surface membrane is significantly increased in CKD patients. In ESRD, these abnormalities are more pronounced and may lead to access site thrombosis. Platelet activation is heavily implicated in the prothrombotic state observed in CKD patients, and oral antiplatelet agents have been extensively used in these patients (<a href="./references#CD008834-bbs2-0004" title="AlexopoulosD , PanagiotouA , XanthopoulouI , KomninakisD , KassimisG , DavlourosP , et al.Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. Journal of Thrombosis &amp; Haemostasis2011;9(12):2379-85. [MEDLINE: 21985070]XanthopoulouI , PanagiotouA , KomninakisD , DavlourosP , KassimisG , FourtounasK , et al.Prasugrel versus double clopidpogrel maintenance dose in patients on chronic haemodialysis and high on clopidogrel platelet reactivity [abstract no: P2438]. European Heart Journal2011;32(Suppl 1):417. [EMBASE: 70534608]">Alexopoulos 2011</a>). </p> <p>Dipyridamole is a phosphodiesterase inhibitor that reversibly inhibits platelet activation and aggregation by increasing adenosine levels and inhibiting cAMP‐phosphodiesterase (<a href="./references#CD008834-bbs2-0196" title="HungCC , YangML , LinMY , LinHY , LimLM , KuoHT , et al.Dipyridamole treatment is associated with improved renal outcome and patient survival in advanced chronic kidney disease. Kaohsiung Journal of Medical Science2014;30(12):599-607. [MEDLINE: 25476097]">Hung 2014</a>). </p> <p>The antithrombotic action of aspirin is due to inhibition of platelet function by acetylation of the platelet cyclooxygenase (COX) at the functionally important amino acid serine<sub>529</sub>. This prevents the access of the arachidonic acid to the catalytic site of the enzyme at tyrosine<sub>385</sub> and results in irreversible inhibition of platelet‐dependent thromboxane formation (<a href="./references#CD008834-bbs2-0215" title="SchrörK .Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Seminars in Thrombosis &amp; Hemostasis1997;23(4):349-56. [MEDLINE: 9263351]">Schror 1997</a>). </p> <p>P2Y<sub>12</sub> is a G‐protein–coupled receptor that elicits specific intracellular responses to ADP resulting in the activation of the glycoprotein IIb/IIIa receptor. Active metabolites of thienopyridines (ticlopidine and clopidogrel) irreversibly bind to the ADP binding site and thereby prevent intracellular signalling and ADP‐induced platelet aggregation. P2Y<sub>12</sub> antagonists, such as ticagrelor and prasugrel, inhibit adenosine reuptake in erythrocytes and other cells. The latter effect has been attributed to improved platelet inhibition and coronary blood flow and reduced infarct size (<a href="./references#CD008834-bbs2-0193" title="GurbelPA , FoxKA , TantryUS , Ten CateH , WeitzJI .Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease. Circulation2019;139(18):2170-85. [MEDLINE: 31034291]">Gurbel 2019</a>). Cilostazol, a selective reversible phosphodiesterase type III inhibitor, has antiplatelet effects due to subsequent increases in cyclic adenosine monophosphate within platelets. The potential to achieve platelet inhibition with minimal risk of bleeding might be explained by an endothelium‐targeted antithrombotic therapy, that is, reduction of partially activated platelets by improved endothelial function (<a href="./references#CD008834-bbs2-0227" title="WooJS , KimW , LeeSR , JungKH , KimWS , LewJH , et al.Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. American Heart Journal2011;162(6):1018-25. [MEDLINE: 22137075]">Woo 2011</a>). </p> <p>Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide and tirofiban) administered parenterally interfere with platelet activity at the final common pathway of platelet‐induced thrombosis, showing a much greater antiplatelet activity than aspirin with or without clopidogrel at normal doses. In addition to preventing platelet aggregation, GP IIb/IIIa antagonism has the ability to induce the dissolution of platelet‐rich clots by disrupting fibrinogen platelet interaction (<a href="./references#CD008834-bbs2-0219" title="StanglPA , LewisS .Review of currently available GP IIb/IIIa inhibitors and their role in peripheral vascular interventions. Seminars in Interventional Radiology2010;27(4):412-21. [MEDLINE: 22550383]">Stangal 2010</a>). </p> <p>Sulfinpyrazone appears to interfere with the adhesion of platelets to subendothelial structures and atherosclerotic plaques (<a href="./references#CD008834-bbs2-0207" title="OelzO .Action mechanism and clinical indications for thrombocyte aggregation inhibitors [Wirkungsmechanismus und klinische Indikationen der Thrombozytenaggregationshemmer]. Schweizerische Medizinische Wochenschrift. Journal Suisse de Medecine1979;109(10):348-53. [MEDLINE: 424707]">Oelz 1979</a>). </p> </section> <section id="CD008834-sec-0012"> <h3 class="title" id="CD008834-sec-0012">How the intervention might work</h3> <p>Antiplatelet agents prevent arterial occlusion from thrombus via direct prevention of platelet aggregation. Currently available data suggest antiplatelet agents might be beneficial in patients with CKD for primary (<a href="./references#CD008834-bbs2-0172" title="Antithrombotic Trialists' Collaboration.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.[Erratum in: BMJ 2002 Jan 19;324(7330):141]. BMJ2002;324(7329):71-86. [MEDLINE: 11786451]">ATT 2002</a>; <a href="./references#CD008834-bbs2-0048" title="HanssonL , ZanchettiA , CarruthersSG , DahlöfB , ElmfeldtD , JuliusS , et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998;351(9118):1755-62. [MEDLINE: 9635947]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Pressure1997;6(5):313-7. [MEDLINE: 9360003]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Pressure1994;3(5):322-7. [MEDLINE: 7866597]HanssonL .The Hypertension Optimal Treatment study and the importance of lowering blood pressure. Journal of Hypertension - Supplement1999;17(1):S9-13. [MEDLINE: 10340838]JardineM , NinomiyaT , CassA , TurnbullF , GallagherM , ZoungasS , et al.Aspirin benefit increases as eGFR declines: results from a randomised controlled trial in a hypertensive population [abstract no: 086]. Nephrology2010;15(Suppl 4):49. [EMBASE: 70467090]JardineMJ , NinomiyaT , PerkovicV , CassA , TurnbullF , GallagherMP , et al.Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology2010;56(12):956-65. [MEDLINE: 20828648]JonesDW , MillerME , WoffordMR , Anderson DC Jr, CameronME , WilloughbyDL , et al.The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. American Journal of Hypertension1999;12(12 Pt 1-2):1175-80. [MEDLINE: 10619579]JonssonB , HanssonL , StalhammarNO .Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Journal of Internal Medicine2003;253(4):472-80. [MEDLINE: 12653877]KjeldsenSE , HednerT , JamersonK , JuliusS , HaleyWE , ZabalgoitiaM , et al.Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects. Hypertension1998;31(4):1014-20. [MEDLINE: 9535429]KjeldsenSE , KollochRE , LeonettiG , MallionJM , ZanchettiA , ElmfeldtD , et al.Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. Journal of Hypertension2000;18(5):629-42. [MEDLINE: 10826567]KollochRE , RahnKH .The Hypertension Optimal Treatment (HOT) study: results of 12-month treatment related to age [Die 'Hyperyension Optimal Treatment' (HOT)-Studie: Behandlungsergebnisse nach Zwolfmonatiger Therapie in Abhangigkeit vom Alter]. Deutsche Medizinische Wochenschrift1998;123(1-2):1-5. [MEDLINE: 9465848]LeonettiG , ZanchettiA .Principal results of hypertension optimal treatment (HOT) study and their clinical impact. HOT cooperative group. Clinical Hemorheology &amp; Microcirculation1999;21(3-4):217-24. [MEDLINE: 10711746]LithellH , BerglundL .Validation of an oscillometric blood pressure measuring device: a substudy of the HOT Study. Hypertension Optimal Treatment. Blood Pressure1998;7(3):149-52. [MEDLINE: 9758084]ManciaG , OmboniS , ParatiG , ClementDL , HaleyWE , RahmanSN , et al.Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(10):1755-63. [MEDLINE: 11593094]RuilopeLM , SalvettiA , JamersonK , HanssonL , WarnoldI , WedelH , et al.Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology2001;12(2):218-25. [MEDLINE: 11158211]Struijker-BoudierH , SafarM , vanBortelL .Effects of individual risk factors on the incidence of cardiovascular event in the treated hypertensive patients of the Hypertension Optimal Treatment Study. Journal of Hypertension2001;19(11):2105-6. [MEDLINE: 11677378]The Hypertension Optimal Treatment Study (the HOT Study). Blood Pressure1993;2(1):62-8. [MEDLINE: 8193735]WaeberB , LeonettiG , KollochR , McInnesGT .Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension1999;17(7):1041-5. [MEDLINE: 10419079]ZanchettiA , HanssonL , DahlofB , ElmfeldtD , KjeldsenS , KollochR , et al.Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. Journal of Hypertension2001;19(6):1149-59. [MEDLINE: 11403365]ZanchettiA , HanssonL , MenardJ , LeonettiG , RahnKH , WarnoldI , et al.Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(4):819-25. [MEDLINE: 11330886]">HOT 1993</a>; <a href="./references#CD008834-bbs2-0212" title="RuilopeLM , SalvettiA , JamersonK , HanssonL , WarnoldI , WedelH , et al.Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology2001;12(2):218-25. [MEDLINE: 11158211]">Ruilope 2001</a>) and secondary (<a href="./references#CD008834-bbs2-0175" title="BergerAK , DuvalS , KrumholzHM .Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. Journal of the American College of Cardiology2003;42(2):201-8. [MEDLINE: 12875751]">Berger 2003</a>; <a href="./references#CD008834-bbs2-0202" title="McCulloughPA , SandbergKR , BorzakS , HudsonMP , GargM , ManleyHJ .Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. American Heart Journal2002;144(2):226-32. [MEDLINE: 12177638]">McCullough 2002</a>) prevention of cardiovascular events. Antiplatelet agents may have beneficial effects on the kidney, possibly reducing proteinuria and protecting kidney function in people with glomerulonephritis (<a href="./references#CD008834-bbs2-0221" title="TajiY , KuwaharaT , ShikataS , MorimotoT .Meta-analysis of antiplatelet therapy for IgA nephropathy. Clinical &amp; Experimental Nephrology2006;10(4):268-73. [MEDLINE: 17186331]">Taji 2006</a>; <a href="./references#CD008834-bbs2-0113" title="ZäunerI , BöhlerJ , BraunN , GruppC , HeeringP , SchollmeyerP .Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Nephrology Dialysis Transplantation1994;9(6):619-22. [MEDLINE: 7970086]">Zäuner 1994</a>), and improving graft function in kidney transplant recipients (<a href="./references#CD008834-bbs2-0177" title="BonominiV , VangelistaA , StefoniS , ScolariMP , FrascaGM , RaimondiC .Use of defibrotide in renal transplantation in man. Haemostasis1986;16 Suppl 1:48-50. [MEDLINE: 3519383]">Bonomini 1986</a>; <a href="./references#CD008834-bbs2-0033" title="BonominiV , VangelistaA , StefoniS , ScolariMP , FrascàGM , RaimondiC .Use of defibrotide in renal transplantation in man. Haemostasis1986;16 Suppl 1:48-50. [MEDLINE: 3519383]FrascàGM , VangelistaA , RaimondiC , BonominiV .Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (defibrotide): a controlled study. Life Support Systems1986;4(3):231-7. [MEDLINE: 3537545]">Frascà 1986</a>). However, some have reported that the efficacy of antiplatelet agents in CKD might be lower than for other high cardiovascular risk populations (<a href="./references#CD008834-bbs2-0176" title="BestPJ , SteinhublSR , BergerPB , DasguptaA , BrennanDM , SzczechLA , et al.The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal2008;155(4):687-93. [MEDLINE: 18371477]">Best 2008</a>). Despite this, the Kidney Disease Outcomes Quality Initiative guideline program (KDOQI) has supported the use of aspirin for the primary prevention of cardiovascular disease in CKD. Antiplatelet agents appear to have a modest effect on the preservation of arteriovenous fistula patency (<a href="./references#CD008834-bbs2-0019" title="DemberL , AllonM , DelmezJ , DixonB , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00550593] DemberLM , BeckGJ , AllonM , DelmezJA , DixonBS , GreenbergA , et al.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008;299(18):2164-71. [MEDLINE: 18477783]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials2005;2(5):413-22. [MEDLINE: 16317810]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):229A. [CENTRAL: CN-00445067] ">Dember 2005</a>). Their use for fistula preservation and as part of a multifactorial intervention strategy for patients with CKD is advocated by guideline groups (<a href="./references#CD008834-bbs2-0178" title="Caring for Australasians with Renal Impairment (CARI).Vascular access. www.cariguidelines.org/guidelines/dialysis/vascular-access/ (accessed 24 October 2021).">CARI 2000</a>; <a href="./references#CD008834-bbs2-0222" title="UK Renal Association.Cardiovascular disease in CKD. www.renal.org/Clinical/GuidelinesSection/CardiovascularDiseaseInCKD.aspx#Rationale3 (accessed 24 October 2021).">UK Renal Association 2010</a>). </p> </section> <section id="CD008834-sec-0013"> <h3 class="title" id="CD008834-sec-0013">Why it is important to do this review</h3> <p>The previous meta‐analyses did not clearly assess the benefits and harms of antiplatelet agents in people with CKD, including those undergoing dialysis (haemodialysis (HD) and peritoneal dialysis (PD)) and transplant recipients, and recently new studies have been performed in this area in contrast to the general population, people with CKD have a different profile of causes for major cardiovascular events, including a greater preponderance for arrhythmia and congestive heart failure (<a href="./references#CD008834-bbs2-0170" title="AmannK , TyrallaK , GrossML , EifertT , AdamczakM , RitzE .Special characteristics of atherosclerosis in chronic renal failure. Clinical Nephrology2003;60 Suppl 1:S13-21. [MEDLINE: 12940530]">Amann 2003</a>; <a href="./references#CD008834-bbs2-0182" title="CurtisBM , ParfreyPS .Congestive heart failure in chronic kidney disease: disease-specific mechanisms of systolic and diastolic heart failure and management. Cardiology Clinics2005;23(3):275-84. [MEDLINE: 16084277]">Curtis 2005</a>; <a href="./references#CD008834-bbs2-0184" title="DikowR , ZeierM , RitzE .Pathophysiology of cardiovascular disease and renal failure. Cardiology Clinics2005;23(3):311-7. [MEDLINE: 16084280]">Dikow 2005</a>; <a href="./references#CD008834-bbs2-0186" title="FoleyRN , ParfreyPS , HarnettJD , KentGM , MartinCJ , MurrayDC , et al.Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney International1995;47(1):186-92. [MEDLINE: 7731145]">Foley 1995</a>; <a href="./references#CD008834-bbs2-0210" title="RemppisA , RitzE .Cardiac problems in the dialysis patient: beyond coronary disease. Seminars in Dialysis2008;21(4):319-25. [MEDLINE: 18627566]">Remppis 2008</a>), altered pharmacokinetics (<a href="./references#CD008834-bbs2-0204" title="MosenkisA , BernsJS .Use of low molecular weight heparins and glycoprotein IIb/IIIa inhibitors in patients with chronic kidney disease. Seminars in Dialysis2004;17(5):411-5. [MEDLINE: 15461751]">Mosenkis 2004</a>; <a href="./references#CD008834-bbs2-0214" title="ScheenAJ .Medications in the kidney. Acta Clinica Belgica2008;63(2):76-80. [MEDLINE: 18575046]">Scheen 2008</a>) and impaired haemostasis (<a href="./references#CD008834-bbs2-0198" title="KawD , MalhotraD .Platelet dysfunction and end-stage renal disease. Seminars in Dialysis2006;19(4):317-22. [MEDLINE: 16893410]">Kaw 2006</a>; <a href="./references#CD008834-bbs2-0211" title="RemuzziG .Bleeding in renal failure. Lancet1988;1(8596):1205-8. [MEDLINE: 2897015]">Remuzzi 1988</a>; <a href="./references#CD008834-bbs2-0224" title="WattanakitK , CushmanM , Stehman-BreenC , HeckbertSR , FolsomAR .Chronic kidney disease increases risk for venous thromboembolism. Journal of the American Society of Nephrology2008;19(1):135-40. [MEDLINE: 18032796]">Wattanakit 2008</a>; <a href="./references#CD008834-bbs2-0228" title="ZwagingaJJ , IJsseldijkMJ , deGroot PG , VosJ , deBos KuilRL , SixmaJJ .Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma. Arteriosclerosis &amp; Thrombosis1991;11(3):733-44. [MEDLINE: 2029508]">Zwaginga 1991</a>). Compared with people who do not have CKD, these factors might expose the CKD population to a different spectrum of risk and benefit from antiplatelet agents. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008834-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008834-sec-0014"></div> <p>To evaluate the benefits and harms of antiplatelet agents in people with any form of CKD, including those with CKD not receiving kidney replacement therapy, patients receiving any form of dialysis, and kidney transplant recipients. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008834-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008834-sec-0015"></div> <section id="CD008834-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008834-sec-0017"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) of antiplatelet agents in people with CKD were included. </p> </section> <section id="CD008834-sec-0018"> <h4 class="title">Types of participants</h4> <p>Participants with CKD, including those who needed kidney replacement therapy (dialysis), had a functioning kidney transplant, or whose kidney function was impaired (defined as a reduced GFR &lt; 60 mL/min/1.73 m²), the presence of other markers of kidney damage such as proteinuria (KDOQI stages 1 to 5), or an elevated serum creatinine (SCr) level (SCr &gt;120 μmol/L). Data from subgroups of participants with CKD within studies with broader inclusion criteria (e.g. people from the general population, people with diabetes, people with cardiovascular disease) were also included. </p> </section> <section id="CD008834-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Interventions included any antiplatelet agent. Agents could be administered at any dose or route of administration and compared with placebo, no treatment, different dose of the same or different antiplatelet agents, different administration regimens of the same or a different antiplatelet agent, or different combinations of antiplatelet agents. Antiplatelet agents included, but were not limited to: </p> <p> <ul id="CD008834-list-0001"> <li> <p>Acetylsalicylic acid (aspirin)</p> </li> <li> <p>Adenosine reuptake inhibitors (dipyridamole)</p> </li> <li> <p>Adenosine diphosphate receptor inhibitors (ticlopidine and clopidogrel)</p> </li> <li> <p>Phosphodiesterase 3 inhibitors (cilostazol)</p> </li> <li> <p>P2Y₁₂ antagonists (prasugrel, ticagrelor, cangrelor, elinogrel)</p> </li> <li> <p>Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban, defibrotide)</p> </li> <li> <p>Sulphinpyrazone.</p> </li> </ul> </p> <p>We excluded studies comparing antiplatelet agents to anticoagulants.</p> </section> <section id="CD008834-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD008834-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008834-list-0002"> <li> <p>Myocardial infarction (MI) (nonfatal or fatal)</p> </li> <li> <p>Stroke (nonfatal or fatal)</p> </li> <li> <p>Death (any cause)</p> </li> <li> <p>Cardiovascular death</p> </li> <li> <p>Bleeding‐related death</p> </li> <li> <p>Major bleeding</p> </li> <li> <p>Minor bleeding</p> </li> <li> <p>Haemorrhagic stroke</p> </li> <li> <p>Kidney failure (previously referred to as end‐stage kidney disease (ESKD))</p> </li> <li> <p>Kidney transplant graft loss</p> </li> <li> <p>Transplant rejection</p> </li> <li> <p>Dialysis vascular outcomes (failure, early thrombosis, loss of unassisted patency, failure to attain suitability for dialysis, and need for access intervention) </p> </li> <li> <p>Hospitalisation</p> </li> <li> <p>Treatment withdrawal.</p> </li> </ul> </p> </section> <section id="CD008834-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008834-list-0003"> <li> <p>SCr</p> </li> <li> <p>Proteinuria.</p> </li> </ul> </p> </section> </section> </section> <section id="CD008834-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>A systematic and comprehensive literature search was carried out to identify eligible RCTs. There was no language restriction. </p> <section id="CD008834-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> up to 13 July 2021 through contact with the Information Specialist using search terms relevant to this review. The Register contains studies identified from the following sources: </p> <p> <ol id="CD008834-list-0004"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Searches of kidney and transplant journals, and the proceedings and abstracts from major kidney and transplant conferences </p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of search strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available on the <a href="https://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant website</a>. </p> <p>See <a href="./appendices#CD008834-sec-0169">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD008834-sec-0025"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD008834-list-0005"> <li> <p>Reference lists of review articles, relevant studies and clinical practice guidelines.</p> </li> <li> <p>Contacting relevant individuals/organisations seeking information about unpublished or incomplete studies. </p> </li> <li> <p>Grey literature sources (e.g. abstracts, dissertations and theses), in addition to those already included in the Cochrane Kidney and Transplant Register of Studies, were searched. </p> </li> </ol> </p> </section> </section> <section id="CD008834-sec-0026"> <h3 class="title" id="CD008834-sec-0026">Data collection and analysis</h3> <section id="CD008834-sec-0027"> <h4 class="title">Selection of studies</h4> <p>All RCTs enrolling participants with CKD were considered as well as studies in broader populations in which outcome data for subgroups with CKD could be disaggregated. Based on the search strategy described, we identified titles and abstracts that were potentially relevant to this systematic review. Four independent authors screened the titles and abstracts and selected those that met the inclusion criteria. Discrepancies in selection were resolved by discussion or by the review of an experienced arbitrator. Studies reported in non‐English language journals were translated before assessment. </p> </section> <section id="CD008834-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Four authors independently read the full text of extracted articles and included studies that met the inclusion criteria. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used in the analyses. </p> <p>The same independent authors used standardised data forms to extract data on:</p> <p> <ul id="CD008834-list-0006"> <li> <p>Study design</p> </li> <li> <p>Participants: baseline characteristics including age, sex, race, diabetic status (proportion with diabetes), hypertension status (proportion with hypertension), smoking status (proportion of smokers), visceral obesity (proportion with visceral obesity as defined by authors), previous cardiovascular events (proportion with existing cardiovascular disease), and stage of CKD (dialysis, predialysis, transplant) </p> </li> <li> <p>Interventions and comparisons: antiplatelet agent, dose and route of administration, duration of treatment </p> </li> <li> <p>Outcomes: as listed in <a href="#CD008834-sec-0020">Types of outcome measures</a>. </p> </li> </ul> </p> </section> <section id="CD008834-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were assessed independently by two authors using the risk of bias assessment tool (<a href="./references#CD008834-bbs2-0195" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors).Cochrane Handbook for Systematic Reviewsof Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>) (see <a href="./appendices#CD008834-sec-0170">Appendix 2</a>). </p> <p> <ul id="CD008834-list-0007"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD008834-list-0008"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at risk of bias?</p> </li> </ul> </p> </section> <section id="CD008834-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (e.g. such as death, cardiovascular events), results were expressed as risk ratio (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (e.g. creatinine clearance (CrCl), GFR, SCr, proteinuria), the mean difference (MD) and its 95% CI was used. The final results are presented in International System (SI) units. When crude event data were not reported by investigators, available reported risk estimates and their 95% CIs were included in meta‐analyses. </p> </section> <section id="CD008834-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was each participant recruited into the studies.</p> <p>For cross‐over studies, we looked for reporting of paired data in order to estimate within‐user differences. Where no such data were provided, we used data from the first period only in the absence of washout periods to avoid the carry‐over effect. </p> <p>For studies with more than two arms, we treated each pair of arms as a separate pairwise comparison. </p> </section> <section id="CD008834-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>Where possible, data for each outcome of interest were evaluated, regardless of whether the analysis was based on intention‐to‐treat. In particular, dropout rates were investigated and reported in detail, including dropout due to discontinuation of study drug, treatment failure, death, withdrawal of consent, or loss to follow‐up. Corresponding authors of all large studies with broader inclusion were contacted to obtain data for the subgroup of CKD (<a href="./references#CD008834-bbs2-0195" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors).Cochrane Handbook for Systematic Reviewsof Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). </p> </section> <section id="CD008834-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We first assessed the heterogeneity by visual inspection of the forest plot. We then quantified statistical heterogeneity using the I² statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than sampling error (<a href="./references#CD008834-bbs2-0194" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG .Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [MEDLINE: 12958120]">Higgins 2003</a>). A guide to the interpretation of I² values was as follows: </p> <p> <ul id="CD008834-list-0009"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>The importance of the observed value of I² depends on the magnitude and direction of treatment effects and the strength of evidence for heterogeneity (e.g. P‐value from the Chi² test, or a confidence interval for I²) (<a href="./references#CD008834-bbs2-0195" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors).Cochrane Handbook for Systematic Reviewsof Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). </p> </section> <section id="CD008834-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We evaluated asymmetries in the inverted funnel plots (i.e. for systematic differences in the effect sizes between more precise and less precise studies). There are many potential explanations for why an inverted funnel plot may be asymmetric, including chance, heterogeneity, publication and reporting bias (<a href="./references#CD008834-bbs2-0195" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors).Cochrane Handbook for Systematic Reviewsof Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). Insufficient data were available to evaluate the robustness of the results according to publication, namely, publication as a full manuscript in a peer‐reviewed journal versus studies published as abstracts/text/letters/editorials and publication. </p> </section> <section id="CD008834-sec-0035"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using the random‐effects model. The GRADE approach developed by Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE Working Group) was used for evaluating the quality of evidence for outcomes to be reported. Based on the GRADE approach, the quality of a body of evidence, in terms of the extent to which one can be confident that an estimate of effect or association is close to the quantity of specific interest, was defined. </p> </section> <section id="CD008834-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Heterogeneity was explored using subgroup analyses according to the following parameters (where sufficient numbers of studies were available): </p> <p> <ul id="CD008834-list-0010"> <li> <p>Population characteristics</p> <ul id="CD008834-list-0011"> <li> <p>Stage of CKD (pre‐dialysis, dialysis, transplant)</p> </li> <li> <p>Presence or absence of comorbidities (diabetes, hypertension, dyslipidaemia, smoking, obesity, family history of cardiovascular disease, baseline cardiovascular disease); percentage of patients with these comorbidities in each study </p> </li> <li> <p>Age</p> </li> <li> <p>Sex</p> </li> <li> <p>Mean systolic blood pressure (SBP) (&lt; 140 mm Hg versus ≥ 140 mm Hg)</p> </li> <li> <p>Ethnicity (proportion white)</p> </li> <li> <p>Presence or absence of previous cardiovascular events (e.g. primary versus secondary prevention)  </p> </li> <li> <p>Time on dialysis (&lt; 3 years versus ≥ 3 years) and modalities of dialysis (HD versus PD) </p> </li> <li> <p>Time with a functioning transplant (&lt; 3 years versus ≥ 3 years)</p> </li> </ul> </li> <li> <p>Intervention characteristics</p> <ul id="CD008834-list-0012"> <li> <p>Types, doses and route of administration of the antiplatelet agents</p> </li> <li> <p>Duration of intervention (&lt; 6 months, 6 to 12 months, &gt; 12 months).</p> </li> </ul> </li> </ul> </p> </section> <section id="CD008834-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses were undertaken to explore the robustness of findings to key decisions in the review process. We assessed the risks of death (any cause and cardiovascular death), nonfatal and fatal MI, and major bleeding only including studies with adequate allocation concealment, or at low risk of bias due to completeness of follow‐up. Insufficient data were available to perform indirect comparisons of antiplatelet agent versus antiplatelet agent (<a href="./references#CD008834-bbs2-0218" title="SongF , AltmanDG , GlennyAM , DeeksJJ .Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ2003;326(7387):472. [MEDLINE: 12609941]">Song 2003</a>). </p> </section> <section id="CD008834-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD008834-bbs2-0216" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al.Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. www.training.cochrane.org/handbook.">Schunemann 2020a</a>). The 'Summary of findings' tables also includes an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD008834-bbs2-0189" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">GRADE 2008</a>; <a href="./references#CD008834-bbs2-0190" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al.GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [MEDLINE: 21195583]">GRADE 2011a</a>). The GRADE approach defines the quality of a body of evidence as to the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, the precision of effect estimates, and the risk of publication bias (<a href="./references#CD008834-bbs2-0217" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al.Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Schunemann 2020b</a>). We presented the following outcomes in the 'Summary of findings' tables: </p> <p> <ul id="CD008834-list-0013"> <li> <p>MI (fatal or nonfatal)</p> </li> <li> <p>Stroke (fatal or nonfatal)</p> </li> <li> <p>Death (any cause)</p> </li> <li> <p>Cardiovascular death</p> </li> <li> <p>Major bleeding</p> </li> <li> <p>Minor bleeding</p> </li> <li> <p>Early access thrombosis</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008834-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008834-sec-0039"></div> <section id="CD008834-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD008834-sec-0041"> <h4 class="title">Results of the search</h4> <p>Search results are shown in <a href="#CD008834-fig-0001">Figure 1</a>. For this 2021 review update, we screened 407 titles and abstracts identified by the updated search. After full‐text assessment 98 new studies were identified. Fifty‐six new studies (152 reports) were included, 17 (82 reports) were excluded, and 25 ongoing studies were identified. We also identified 233 new reports of 20 existing included studies and 22 new reports of six excluded studies. </p> <div class="figure" id="CD008834-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram; study identification and selection process." data-id="CD008834-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram; study identification and selection process.</p> </div> </div> </div> <p>We reclassified six previously excluded studies as included studies (<a href="./references#CD008834-bbs2-0021" title="Dmoszynska-GiannopoulouA , JanickaL , SokolowskaB , KsiazekA , OrlowskaG , JanickiK .The effect of sulphinpyrazone and alpha-tocopherol on platelet activation and function in haemodialysed patients. International Urology &amp; Nephrology1990;22(6):561-6. [MEDLINE: 2093696]">Dmoszynska‐Giannopoulou 1990</a>; <a href="./references#CD008834-bbs2-0054" title="KamperAM , LinsRL , ZacheeP , Van BergenS , HostenS , DaelemansR .Safety of combining ticlopidine with nadroparin in the routine treatment of chronic hemodialysis patients. Nephron1997;77(4):484-5. [MEDLINE: 9434075]">Kamper 1997</a>; <a href="./references#CD008834-bbs2-0066" title="MovchanEA , ChuprovaAV , TovNL , Vol'vichNV .Desaggregation therapy of acute glomerulonephritis [Dezagregatsionnaia terapiia ostrogo glomerulonefrita]. Klinicheskaia Meditsina2001;79(12):44-7. [MEDLINE: 11840813]">Movchan 2001</a>; <a href="./references#CD008834-bbs2-0088" title="CooperCJ , HallerST , ColyerW , SteffesM , BurketMW , ThomasWJ , et al.Embolic protection and platelet inhibition during renal artery stenting. Circulation2008;117(21):2752-60. [MEDLINE: 18490527]HeW , CheJ , ZhanD , DawsoT , KanjwaS , HalleS , et al.Time dependant changes in systolic blood pressure after renal artery stenting: role of stenosis severity [abstract no: 14283]. Circulation2012;126(21 Suppl 1). [EMBASE: 70958797]KanjwalK , CooperCJ , VirmaniR , HallerS , ShapiroJI , BurketMW , et al.Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy. Catheterization &amp; Cardiovascular Interventions2010;76(1):16-23. [MEDLINE: 20209644]KanjwalK , HallerS , SteffesM , VirmaniR , ShapiroJI , BurketMW , et al.Complete versus partial distal embolic protection during renal artery stenting. Catheterization &amp; Cardiovascular Interventions2009;73(6):725-30. [MEDLINE: 19198007]TianJ , HallerS , PeriyasamyS , BrewsterP , ZhangH , AdlakhaS , et al.Renal ischemia regulates marinobufagenin release in humans. Hypertension2010;56(5):914-9. [MEDLINE: 20823380]YuH , ZhangD , HallerS , KanjwalK , ColyerW , BrewsterP , et al.Determinants of renal function in patients with renal artery stenosis. Vascular Medicine2011;16(5):331-8. [MEDLINE: 21908683]">RESIST 2008</a>; <a href="./references#CD008834-bbs2-0090" title="RubinJ , AdairC , BarnesT , BowerJD .Augmentation of peritoneal clearance by dipyridamole. Kidney International1982;22(6):658-61. [MEDLINE: 6761488]">Rubin 1982</a>; <a href="./references#CD008834-bbs2-0091" title="SalterMC , CrowMJ , DonaldsonDR , RobertsTG , RajahSM , DavisonAM .Prevention of platelet deposition and thrombus formation on hemodialysis membranes: a double-blind randomized trial of aspirin and dipyridamole. Artificial Organs1984;8(1):57-61. [MEDLINE: 6703927]">Salter 1984</a>), and one ongoing study has now been included (<a href="./references#CD008834-bbs2-0031" title="BadveS , HawleyCM , IrishAB , Paul-BrentP .High rate of screening failure in the FAVOURED study [abstract no: PUB345]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):905A. IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al.Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453]IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul-BrentP , et al.Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis-a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804]IrishA , FAVOURED Study Group.High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN-00756870] IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 009]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790]IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. [EMBASE: 70467038]IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul-BrentPA , et al.Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184-93. [MEDLINE: 28055065]IrishAB .The omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo-controlled trial [abstract no: HI-OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2-3. [CENTRAL: CN-01658143] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis-post hoc analysis of the FAVOURED study [abstract no: MO049]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475]ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on the need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology2018;23(Suppl 3):56. [EMBASE: 623841152]ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al.Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract no: SP593]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178]ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract no: FP555]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265]ViecelliA , PascoeE , PolkinghorneK , Paul-BrentP , DarssanD , HooiL , et al.A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115-6. [EMBASE: 612312707]ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul-BrentPA , BadveSV , et al.The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581]ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis - Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217-28. [MEDLINE: 26205903]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study. Nephrology2017;22(10):823-4. [MEDLINE: 27188542]ViecelliAK , PolkinghorneKR , PascoeEM , Paul-BrentPA , HawleyCM , BadveSV , et al.Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS ONE [Electronic Resource]2019;14(3):e0213274. [MEDLINE: 30913208]">FAVOURED 2009</a>). </p> <p>For this 2011 update, 113 studies (475 reports, 51,959 CKD participants, <a href="#CD008834-fig-0001">Figure 1</a>) were included, 29 studies were excluded, and there are 26 ongoing studies. </p> </section> <section id="CD008834-sec-0042"> <h4 class="title">Included studies</h4> <p>The overall characteristics of the included studies are provided in the <a href="./references#CD008834-sec-0186" title="">Characteristics of included studies</a>. Information for three studies (1238 participants: <a href="./references#CD008834-bbs2-0016" title="CreekR .Ticlopidine. Patency of haemodialysis access sites. Guildford Sanofi Winthrop. Internal report1990. ">Creek 1990</a>; <a href="./references#CD008834-bbs2-0025" title="EllS , MihindukulasuriyaJC , O'BrienJR , PolakA , VernhamG .Ticlopidine in the prevention of blockage of fistulae and shunts [abstract no: 332]. Haemostasis1982;12:180. ">Ell 1982</a>; <a href="./references#CD008834-bbs2-0064" title="MiddletonDA , DeichselG .The prophylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole. Boehringer Ingelheim. Internal report1992. ">Middleton 1992</a>) including two internal study reports (<a href="./references#CD008834-bbs2-0016" title="CreekR .Ticlopidine. Patency of haemodialysis access sites. Guildford Sanofi Winthrop. Internal report1990. ">Creek 1990</a>; <a href="./references#CD008834-bbs2-0064" title="MiddletonDA , DeichselG .The prophylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole. Boehringer Ingelheim. Internal report1992. ">Middleton 1992</a>) were only available in a previously published meta‐analysis of antiplatelet agents (<a href="./references#CD008834-bbs2-0172" title="Antithrombotic Trialists' Collaboration.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.[Erratum in: BMJ 2002 Jan 19;324(7330):141]. BMJ2002;324(7329):71-86. [MEDLINE: 11786451]">ATT 2002</a>). For three studies (103 participants), the most complete data were provided in published conference proceedings (<a href="./references#CD008834-bbs2-0022" title="DoddNJ , TurneyJH , WestonMJ .Ticlopidine preserves vascular access for haemodialysis [abstract no: 326F]. In: Proceedings of the VI International Congress of Mediterranean League Against Thrombosis; 1980 Oct 25-26; Montecarlo, Monaco. 1980. ">Dodd 1980</a>; <a href="./references#CD008834-bbs2-0041" title="GonzalezMT , CastelaoAM , VallesM , CruzadoJM , MauriJM .Platelet antiaggregants (PA) could decrease the rate of progression of chronic renal failure (CRF) in diabetic patients (DP) treated previously with angiotensin converting enzyme inhibitors (ACEi) [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:200. [CENTRAL: CN-00509215] ">Gonzalez 1995</a>; <a href="./references#CD008834-bbs2-0098" title="TaberT , MaikranzP , HaagB , DilleyR , GaylordG .Hemodialysis vascular graft stenosis may be altered by low-molecular weight dextran (LMD), but not by aspirin (ASA) [abstract]. Journal of the American Society of Nephrology1992;3(3):397. [CENTRAL: CN-00858239] ">Taber 1992</a>), and for one study (<a href="./references#CD008834-bbs2-0071" title="GuoX .A clinical study to evaluate the efficacy and safety of cilostazol and probucol in combination on patients with diabetic nephropathy. www.clinicaltrials.gov/show/nct01252056 (first received 2 December 2010). ">NCT01252056</a>), information about study characteristics and endpoint data was extracted from www.clinicaltrials.gov. </p> <p>Studies compared antiplatelet agents with placebo or no treatment, or another antiplatelet agent; several studies compared two or more antiplatelet agents. </p> <p> <ul id="CD008834-list-0014"> <li> <p>Ninety studies (40,597 CKD participants) compared an antiplatelet agent to placebo or no treatment (<a href="./references#CD008834-bbs2-0001" title="GoicoecheaM , deVinuesaMS , QuirogaB , VerdallesU , MoralesE , De SequeraP , et al.Aspirin treatment in primary cardiovascular prevention and renal disease progression in CKD patients: a randomized clinical trials (AASER study) [abstract no: FR-PO1065]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):B5. [EMBASE: 633704620]GoicoecheaM , deVinuesaSG , QuirogaB , VerdeE , BernisC , MoralesE , et al.Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study). Cardiovascular Drugs &amp; Therapy2018;32(3):255-63. [MEDLINE: 29943364]GoicoecheaM , Sanchez-NinoMD , OrtizA , deVinuesaMS , QuirogaB , MoralesE , et al.Low dose aspirin increases 15-epi-lipoxin a4 levels in CKD patients [abstract no: SA-PO186]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):726. [EMBASE: 633701100]GoicoecheaM , Sanchez-NinoMD , OrtizA , Garcia de VinuesaS , QuirogaB , BernisC , et al.Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. Prostaglandins Leukotrienes &amp; Essential Fatty Acids2017;125:8-13. [MEDLINE: 28987723]">AASER 2017</a>; <a href="./references#CD008834-bbs2-0002" title="AbacilarAF , AtalayH , DoganOF .Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: a randomized controlled study. Indian Journal of Nephrology2015;25(3):136-42. [MEDLINE: 26060361]">Abacilar 2015</a>; <a href="./references#CD008834-bbs2-0003" title="Abdul-RahmanIS , Al-HowaishAK .Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23-30. [EMBASE: 2007269768]">Abdul‐Rahman 2007</a>; <a href="./references#CD008834-bbs2-0005" title="AndersonM , DewarP , FlemingLB , HackingPM , MorleyAR , MurrayS , et al.A controlled trial of dipyridamole in human renal transplantation and an assessment of platelet function studies in rejection. Clinical Nephrology1974;2(3):93-9. [MEDLINE: 4603996]">Anderson 1974</a>; <a href="./references#CD008834-bbs2-0006" title="AndrassyK , MallucheH , BornefeldH , CombergM , RitzE , JesdinskyH , et al.Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: results of a prospective double blind study. Klinische Wochenschrift1974;52(7):348-9. [MEDLINE: 4600820]">Andrassy 1974</a>; <a href="./references#CD008834-bbs2-0007" title="Di FrancoA , GaudinoM , GirardiLN .Considerations about the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. Journal of Thoracic Disease2016;8(7):E599. [MEDLINE: 27501533]MylesPS , SmithJ , KnightJ , CooperDJ , SilbertB , McNeilJ , et al.Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial: rationale and design. American Heart Journal2008;155(2):224-30. [MEDLINE: 18215590]MylesPS , SmithJA , ForbesA , SilbertB , JayarajahM , PainterT , et al.Stopping vs. continuing aspirin before coronary artery surgery. New England Journal of Medicine2016;374(8):728-37. [MEDLINE: 26933848]MylesPS , SmithJA , ForbesA , SilbertB , JayarajahM , PainterT , et al.Tranexamic acid in patients undergoing coronary-artery surgery [Erratum for: N Engl J Med. 2017 Jan 12;376(2):136-148; PMID: 27774838]. New England Journal of Medicine2017;376(2):136-48. [MEDLINE: 27774838]MylesPS , SmithJA , KaszaJ , SilbertB , JayarajahM , PainterT , et al.Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial. Journal of Thoracic &amp; Cardiovascular Surgery2019;157(2):633-40. [MEDLINE: 30401528]MylesPS , SmithJA , KaszaJ , SilbertB , JayarajahM , PainterT , et al.Tranexamic acid in coronary artery surgery: one-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. Journal of Thoracic &amp; Cardiovascular Surgery2019;157(2):644-52.e9. [MEDLINE: 30459103]">ATACAS 2008</a>; <a href="./references#CD008834-bbs2-0008" title="FujitaT , YuX , KimS , NakamotoH , OrigasaH , KurumataniH , et al.Effects of sustained-release beraprost sodium in patients with primary glomerular disease or nephrosclerosis: the CASSIOPEIR study [abstract no: SA-PO1096]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):4B. [CENTRAL: CN-01657821] NakamotoH , FujitaT , OrigasaH , IsonoM , KurumataniH , OkadaK , et al.A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrology2014;15:153. [MEDLINE: 25233856]NakamotoH , YuXQ , KimS , OrigasaH , ZhengH , ChenJ , et al.Effects of sustained-release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results. Therapeutic Apheresis &amp; Dialysis2020;24(1):42-55. [MEDLINE: 31119846]">CASSIOPEIR 2014</a>; <a href="./references#CD008834-bbs2-0009" title="ChanMK , KwanSY , ChanKW , YeungCK .Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis. American Journal of Kidney Diseases1987;9(5):417-21. [MEDLINE: 3555016]">Chan 1987</a>; <a href="./references#CD008834-bbs2-0010" title="JingJ , MengX , ZhaoX , LiuL , WangA , PanY , et al.Dual antiplatelet therapy in transient ischemic attack and minor stroke with different infarction patterns: subgroup analysis of the CHANCE randomized clinical trial. JAMA Neurology2018;75(6):711-9. [MEDLINE: 29582084]LiJ , WangY , LinJ , WangD , WangA , ZhaoX , et al.Soluble CD40L is a useful marker to predict future strokes in patients with minor stroke and transient ischemic attack. Stroke2015;46(7):1990-2. [MEDLINE: 26012640]LiJ , ZhaoX , MengX , LinJ , LiuL , WangC , et al.High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome: subanalysis of the clopidogrel in high-risk patients with acute nondisabling cerebrovascular events trial. Stroke2016;47(8):2025-30. [MEDLINE: 27328699]LinY , WangA , LiJ , LinJ , WangD , MengX , et al.Impact of glycemic control on efficacy of clopidogrel in transient ischemic attack or minor stroke patients with CYP2C19 genetic variants. Stroke2017;48(4):998-1004. [MEDLINE: 28289237]LiuL , WongKS , LengX , PuY , WangY , JingJ , et al.Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology2015;85(13):1154-62. [MEDLINE: 26330567]LiZ , WangY , ZhaoX , LiuL , WangD , WangC , et al.Treatment effect of clopidogrel plus aspirin within 12 hours of acute minor stroke or transient ischemic attack. Journal of the American Heart Association2016;5(3):e003038. [MEDLINE: 27001965]MaY , LiuY , XuJ , WangY , WangY , DuF .Effect of dual antiplatelet on recurrent stroke in minor stroke or TIA depends on bodyweight. Therapeutics &amp; Clinical Risk Management2018;14:861-70. [MEDLINE: 29773949]PanY , CaiX , JingJ , MengX , LiH , WangY , et al.Stress hyperglycemia and prognosis of minor ischemic stroke and transient ischemic attack: the CHANCE study (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). Stroke2017;48(11):3006-11. [MEDLINE: 29051218]PanY , JingJ , ChenW , MengX , LiH , ZhaoX , et al.Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE.[Erratum in: Neurology. 2019 Aug 13;93(7):322; PMID: 31405943]. Neurology2017;88(20):1906-11. [MEDLINE: 28424269]PanY , JingJ , LiH , WangY , WangY , HeY , et al.Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA. Neurology2016;87(15):1551-6. [MEDLINE: 27613582]PanY , MengX , JingJ , LiH , ZhaoX , LiuL , et al.Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA. Neurology2017;88(11):1081-8. [MEDLINE: 28202699]WangA , LiS , ZhangN , DaiL , ZuoY , WangY , et al.Oxidized low-density lipoprotein to high-density lipoprotein ratio predicts recurrent stroke in minor stroke or transient ischemic attack. Stroke2018;49(11):2637-42. [MEDLINE: 30355199]WangA , XuJ , ChenG , WangD , JohnstonSC , MengX , et al.Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA. Neurology2018;91(10):e947-55. [MEDLINE: 30089614]WangD , GuiL , DongY , LiH , LiS , ZhengH , et al.Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial. Stroke &amp; Vascular Neurology2016;1(2):29-36. [MEDLINE: 28959461]WangqinR , WangX , WangY , XianY , ZhaoX , LiuL , et al.Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA: a subgroup analysis of the CHANCE trial. Stroke &amp; Vascular Neurology2017;2(4):176-83. [MEDLINE: 29507777]WangY , PanY , ZhaoX , LiH , WangD , JohnstonSC , et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial: one-year outcomes. Circulation2015;132(1):40-6. [MEDLINE: 25957224]WangY , WangY , ZhaoX , LiuL , WangD , WangC , et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine2013;369(1):11-9. [MEDLINE: 23803136]WangY , ZhaoX , LinJ , LiH , JohnstonSC , LinY , et al.Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA2016;316(1):70-8. [MEDLINE: 27348249]WuY , ZhouY , PanY , ZhaoX , LiuL , WangD , et al.Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. Pharmacogenomics Journal2018;18(6):713-20. [MEDLINE: 29520080]ZhouY , PanY , WuY , ZhaoX , LiH , WangD , et al.Effect of estimated glomerular filtration rate decline on the efficacy and safety of clopidogrel with aspirin in minor stroke or transient ischemic attack: CHANCE substudy (Clopidogrel in high-risk patients with acute nondisabling cerebrovascular events). Stroke2016;47(11):2791-6. [MEDLINE: 27738237]ZhuB , LiuH , PanY , JingJ , LiH , ZhaoX , et al.Elevated neutrophil and presence of intracranial artery stenosis increase the risk of recurrent stroke. Stroke2018;49(10):2294-300. [MEDLINE: 30355101]">CHANCE 2013</a>; <a href="./references#CD008834-bbs2-0011" title="BangaloreS , BhattDL , StegPG , WeberMA , BodenWE , HammCW , et al.beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circulation: Cardiovascular Quality &amp; Outcomes2014;7(6):872-81. [MEDLINE: 25271049]BergerPB , BhattDL , FusterV , StegPG , FoxKA , ShaoM , et al.Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation2010;121(23):2575-83. [MEDLINE: 20516378]BhattDL , FlatherMD , HackeW , BergerPB , BlackHR , BodenWE , et al.Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology2007;49(19):1982-8. [MEDLINE: 17498584]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial [Erratum in: Am Heart J. 2006 Jan;151(1):247]. American Heart Journal2005;150(3):401. [MEDLINE: 16169314]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine2006;354(16):1706-17. [MEDLINE: 16531616]DasguptaA , SteinhublSR , BhattDL , BergerPB , ShaoM , MakKH , et al.Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). American Journal of Cardiology2009;103(10):1359-63. [MEDLINE: 19427428]EikelboomJW , HankeyGJ , ThomJ , BhattDL , StegPG , MontalescotG , et al.Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation2008;118(17):1705-12. [MEDLINE: 18838564]MakKH , BhattDL , ShaoM , HaffnerSM , HammCW , HankeyGJ , et al.The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. European Heart Journal2009;30(7):857-65. [MEDLINE: 19233855]SteinhublSR , BhattDL , BrennanDM , MontalescotG , HankeyGJ , EikelboomJW , et al.Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding [Summary for patients in Ann Intern Med. 2009 Mar 17;150(6):I-22; PMID: 19293067]. Annals of Internal Medicine2009;150(6):379-86. [MEDLINE: 19293071]WangTH , BhattDL , FoxKA , SteinhublSR , BrennanDM , HackeW , et al.An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal2007;28(18):2200-7. [MEDLINE: 17673448]">CHARISMA 2006</a>; <a href="./references#CD008834-bbs2-0012" title="ChengIK , FangGX , WongMC , JiYL , ChanKW , YeungHW .A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy. Nephrology1998;4(1-2):19-26. [EMBASE: 28282953]ChengIK , FangGX , WongMC , JiYL , YeungH .A randomised prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA glomerulonephritis (IgAN) [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:45. [CENTRAL: CN-00550664] ">Cheng 1998a</a>; <a href="./references#CD008834-bbs2-0013" title="ChristopherTG , SamelsK .A study of aspirin and dipyridamole in slowing the progression of diabetic glomerulosclerosis [abstract]. Kidney International1987;31(1):194. ChristopherTG , SamelsK .A study of the treatment effect of aspirin and dipyridamole in diabetic glomerulosclerosis [abstract]. In: 10th International Congress of Nephrology; 1987 Jul 26-31; London, UK. 1987:56. ">Christopher 1987</a>; <a href="./references#CD008834-bbs2-0015" title="AronowHD , SteinhublSR , BrennanDM , BergerPB , TopolEJ , CREDO Investigators.Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal2009;157(2):369-74. [MEDLINE: 19185647]BeinartSC , KolmP , VeledarE , ZhangZ , MahoneyEM , BouinO , et al.Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Journal of the American College of Cardiology2005;46(5):761-9. [MEDLINE: 16139122]BestPJ , SteinhublSR , BergerPB , DasguptaA , BrennanDM , SzczechLA , et al.The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal2008;155(4):687-93. [MEDLINE: 18371477]BrenerSJ , SteinhublSR , BergerPB , BrennanDM , TopolEJ , CREDO Investigators.Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial. Journal of Invasive Cardiology2007;19(7):287-90. [MEDLINE: 17620671]RingborgA , LindgrenP , JonssonB .The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. European Journal of Health Economics2005;6(4):354-56, 358-62. [MEDLINE: 16267654]SteinhublSR , BergerPB , Mann JT 3rd, FryET , DeLagoA , WilmerC , et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [Erratum in: JAMA. 2003 Feb 26;289(8):987]. JAMA2002;288(19):2411-20. [MEDLINE: 12435254]">CREDO 2005</a>; <a href="./references#CD008834-bbs2-0016" title="CreekR .Ticlopidine. Patency of haemodialysis access sites. Guildford Sanofi Winthrop. Internal report1990. ">Creek 1990</a>; <a href="./references#CD008834-bbs2-0017" title="BergerPB , SteinhublS .Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. Circulation2002;106(17):2284-7. [MEDLINE: 12390961]GerschutzGP , BhattDL , Clopidogrel in Unstable Angina to Prevent Recurrent Events study.The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?American Heart Journal2003;145(4):595-601. [MEDLINE: 12679754]KeltaiM , TonelliM , MannJF , SitkeiE , LewisBS , HawkenS , et al.Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. European Journal of Cardiovascular Prevention &amp; Rehabilitation2007;14(2):312-8. [MEDLINE: 17446813]LewisBS , MehtaSR , FoxKA , HalonDA , ZhaoF , PetersRJ , et al.Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. American Heart Journal2005;150(6):1177-84. [MEDLINE: 16338255]MehtaSR , YusufS , PetersRJ , BertrandME , LewisBS , NatarajanMK , et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet2001;358(9281):527-33. [MEDLINE: 11520521]MehtaSR , YusufS , Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators.The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. European Heart Journal2000;21(24):2033-41. [MEDLINE: 11102254]PetersRJ , MehtaSR , FoxKA , ZhaoF , LewisBS , KopeckySL , et al.Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation2003;108(14):1682-7. [MEDLINE: 14504182]YusufS ,  ZhaoF ,  MehtaSR ,  ChrolaviciusS ,  TognoniG ,  FoxKK , et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [Erratum in: N Engl J Med 2001 Dec 6;345(23):1716; Erratum in: N Engl J Med 2001 Nov 15;345(20):1506]. New England Journal of Medicine2001;345(7):494-502. [MEDLINE: 11519503]">CURE 2000</a>; <a href="./references#CD008834-bbs2-0019" title="DemberL , AllonM , DelmezJ , DixonB , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00550593] DemberLM , BeckGJ , AllonM , DelmezJA , DixonBS , GreenbergA , et al.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008;299(18):2164-71. [MEDLINE: 18477783]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials2005;2(5):413-22. [MEDLINE: 16317810]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):229A. [CENTRAL: CN-00445067] ">Dember 2005</a>; <a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a>; <a href="./references#CD008834-bbs2-0021" title="Dmoszynska-GiannopoulouA , JanickaL , SokolowskaB , KsiazekA , OrlowskaG , JanickiK .The effect of sulphinpyrazone and alpha-tocopherol on platelet activation and function in haemodialysed patients. International Urology &amp; Nephrology1990;22(6):561-6. [MEDLINE: 2093696]">Dmoszynska‐Giannopoulou 1990</a>; <a href="./references#CD008834-bbs2-0022" title="DoddNJ , TurneyJH , WestonMJ .Ticlopidine preserves vascular access for haemodialysis [abstract no: 326F]. In: Proceedings of the VI International Congress of Mediterranean League Against Thrombosis; 1980 Oct 25-26; Montecarlo, Monaco. 1980. ">Dodd 1980</a>; <a href="./references#CD008834-bbs2-0023" title="DonadioJV , AndersonCF , MitchellJC , HolleyKE , IlstrupDM , FusterV .Membranoproliferative glomerulonephritis (MPGN): a prospective clinical trial of platelet inhibitor therapy [abstract]. Kidney International1983;23(1):121. [CENTRAL: CN-00602010] Donadio JV Jr, AndersonCF , Mitchell JC 3rd, HolleyKH , IlstrupDM , FusterV , et al.Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. New England Journal of Medicine1984;310(22):1421-6. [MEDLINE: 6371535]">Donadio 1984</a>; <a href="./references#CD008834-bbs2-0024" title="BagaiA , WhiteJA , LokhnyginaY , GiuglianoRP , Van de WerfF , MontalescotG , et al.Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. American Heart Journal2013;166(3):466-73. [MEDLINE: 24016495]De FerrariGM , Van de WerfF , ArmstrongP , BodeC , LewisBS , TricociP , et al.Contrast induced nephropathy predicts later mortality among patients with non-ST-segment elevation acute coronary syndrome undergoing PCI: a sub-analysis from the EARLY ACS study [abstract no: P3820]. European Heart Journal2011;32(Suppl 1):657. [EMBASE: 70535519]EzekowitzJA , BakalJA , WesterhoutCM , GiuglianoRP , WhiteH , KeltaiM , et al.The relationship between meteorological conditions and index acute coronary events in a global clinical trial. International Journal of Cardiology2013;168(3):2315-21. [MEDLINE: 23416014]FarhanS , ClareRM , JaraiR , GiuglianoRP , LokhnyginaY , HarringtonRA , et al.Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: an analysis from EARLY ACS. International Journal of Cardiology2017;232:264-70. [MEDLINE: 28089149]FarhanS , ClareRM , JaraiR , NewbyLK , MorrowD , GiuglianoRP , et al.Fasting glucose, NT-proBNP, treatment with glycoprotein IIB/IIIA inhibitors, and outcomes in non-st-segment elevation acute coronary syndromes: an analysis from early ACS [abstract no: A14618]. Circulation2013;128(22 Suppl 1). [EMBASE: 71340424]GiuglianoRP , NewbyLK , HarringtonRA , GibsonCM , Van de WerfF , ArmstrongP , et al.The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. American Heart Journal2005;149(6):994-1002. [MEDLINE: 15976780]GiuglianoRP , WhiteJA , BodeC , ArmstrongPW , MontalescotG , LewisBS , et al.Early versus delayed, provisional eptifibatide in acute coronary syndromes. New England Journal of Medicine2009;360(21):2176-90. [MEDLINE: 19332455]HessCN , SchultePJ , NewbyLK , StegPG , DalbyAJ , SchweigerMJ , et al.Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. European Heart Journal: Acute Cardiovascular Care2013;2(3):246-55. [MEDLINE: 24222836]KaulP , TanguayJF , NewbyLK , HochmanJS , WesterhoutCM , CaliffRM , et al.Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. American Heart Journal2013;166(4):723-8. [MEDLINE: 24093853]KlutsteinMW , WesterhoutCM , ArmstrongPW , GiuglianoRP , LewisBS , GibsonCM , et al.Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. American Heart Journal2013;165(4):583-90. [MEDLINE: 23537976]KunadianV , GiuglianoRP , NewbyLK , ZorkunC , GuoJ , BagaiA , et al.Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). American Journal of Cardiology2014;113(8):1297-305. [MEDLINE: 24607027]LopesRD , WhiteJA , TricociP , WhiteHD , ArmstrongPW , BraunwaldE , et al.Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. International Journal of Cardiology2013;167(6):2580-7. [MEDLINE: 22795720]MelloniC , JamesSK , WhiteJA , GiuglianoRP , HarringtonRA , HuberK , et al.Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. American Heart Journal2011;162(5):884-92. [MEDLINE: 22093205]PicciniJP , WhiteJA , MehtaRH , LokhnyginaY , Al-KhatibSM , TricociP , et al.Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. Circulation2012;126(1):41-9. [MEDLINE: 22645292]PrideYB , MohanaveluS , GiuglianoRP , NewbyLK , ZorkunC , KunadianV , et al.Association between angiographic complications during percutaneous coronary intervention and clinical outcomes among patients with acute coronary syndrome: an early ACS angiographic substudy [abstract no: A10394]. Circulation2011;124(21 Suppl 1). [EMBASE: 70620664]PrideYB , MohanaveluS , ZorkunC , KunadianV , GiuglianoRP , NewbyLK , et al.Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. Jacc: Cardiovascular Interventions2012;5(9):927-35. [MEDLINE: 22995880]RoeMT , WhiteJA , KaulP , TricociP , LokhnyginaY , MillerCD , et al.Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. Circulation. Cardiovascular Quality &amp; Outcomes2012;5(2):205-13. [MEDLINE: 22373905]TanguayJF , NewbyLK , HochmanJ , WesterhoutCM , CaliffRM , GibsonCM , et al.Sex differences in high-risk acute coronary syndromes: Insights from early-ACS [abstract]. Journal of the American College of Cardiology2010;55(10 Suppl 1):A120.E1122. [EMBASE: 70096317]TolevaO , WesterhoutCM , SenaratneM , BodeC , LindroosM , ArdissinoD , et al.Association of hub and spoke practice patterns with coronary intervention and outcomes in non ST elevation acute coronary syndromes (NSTE ACS): Insights from the early glycoprotein IIb/IIIa inhibition in NSTE ACS (early-ACS) trial [abstract]. Journal of the American College of Cardiology2011;57(14 Suppl 1):E1101. [EMBASE: 70400778]TolevaO , WesterhoutCM , SenaratneMP , BodeC , LindroosM , SulimovVA , et al.Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial. Catheterization &amp; Cardiovascular Interventions2014;84(6):934-42. [MEDLINE: 24976083]WangT , WhiteJA , GiuglianoRP , TricociP , HarringtonRA , MontalescotG , et al.Upfront clopidogrel use and the efficacy and safety of early eptifibatide use in patients with acute coronary syndrome: An analysis from the early versus delayed provisional eptifibatide in acute coronary syndromes (early ACS) trial [abstract]. Journal of the American College of Cardiology2010;55(10 Suppl 1):A47.E451. [EMBASE: 70095646]WangTY , WhiteJA , TricociP , GiuglianoRP , ZeymerU , HarringtonRA , et al.Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Circulation2011;123(7):722-30. [MEDLINE: 21300952]">EARLY ACS 2005</a>; <a href="./references#CD008834-bbs2-0025" title="EllS , MihindukulasuriyaJC , O'BrienJR , PolakA , VernhamG .Ticlopidine in the prevention of blockage of fistulae and shunts [abstract no: 332]. Haemostasis1982;12:180. ">Ell 1982</a>; <a href="./references#CD008834-bbs2-0026" title="AguirreFV , TopolEJ , AndersonKM , KleimanNS , WeismanHF , FitzPatrickSE , et al.Benefit within patient subgroups receiving c7e3 fab (abciximab) during percutaneous coronary revascularization: subgroup analysis from the EPIC trial. Journal of Invasive Cardiology1996;8 Suppl B:21-9B. [MEDLINE: 10785766]AguirreFV , TopolEJ , FergusonJJ , AndersonK , BlankenshipJC , HeuserRR , et al.Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation1995;91(12):2882-90. [MEDLINE: 7796496]BerkowitzSD , SaneDC , SigmonKN , ShavenderJH , HarringtonRA , TchengJE , et al.Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. Journal of the American College of Cardiology1998;32(2):311-9. [MEDLINE: 9708455]BlankenshipJC , HellkampAS , AguirreFV , DemkoSL , TopolEJ , CaliffRM .Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. American Journal of Cardiology1998;81(1):36-40. [MEDLINE: 9462603]BoehrerJD , KereiakesDJ , NavettaFI , CaliffRM , TopolEJ .Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications. American Journal of Cardiology1994;74(11):1166-70. [MEDLINE: 7977081]CaliffRM , LincoffAM , TchengJE , TopolEJ .An overview of the results of the EPIC trial. European Heart Journal1995;16 Suppl L:43-9. [MEDLINE: 8869018]EPIC Investigators.Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New England Journal of Medicine1994;330(14):956-61. [MEDLINE: 8121459]KhanMM , EllisSG , AguirreFV , WeismanHF , WildermannNM , CaliffRM , et al.Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1998;31(1):31-6. [MEDLINE: 9426014]LefkovitsJ , BlankenshipJC , AndersonKM , StonerGL , TalleyJD , WorleySJ , et al.Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. Journal of the American College of Cardiology1996;28(4):849-55. [MEDLINE: 8837559]LefkovitsJ , IvanhoeRJ , CaliffRM , BergelsonBA , AndersonKM , StonerGL , et al.Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. American Journal of Cardiology1996;77(12):1045-51. [MEDLINE: 8644655]LincoffAM , CaliffRM , AndersonKM , WeismanHF , AguirreFV , KleimanNS , et al.Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1997;30(1):149-56. [MEDLINE: 9207636]MakKH , ChallapalliR , EisenbergMJ , AndersonKM , CaliffRM , TopolEJ .Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. American Journal of Cardiology1997;80(8):985-8. [MEDLINE: 9352964]MarkDB , TalleyJD , TopolEJ , BowmanL , LamLC , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation1996;94(4):629-35. [MEDLINE: 8772681]MoliternoDJ , CaliffRM , AguirreFV , AndersonK , SigmonKN , WeismanHF , et al.Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. American Journal of Cardiology1995;75(8):559-62. [MEDLINE: 7887377]NarinsCR , MillerDP , CaliffRM , TopolEJ .The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1999;33(3):647-53. [MEDLINE: 10080464]ThelMC , CaliffRM , TchengJE , SigmonKN , LincoffAM , TopolEJ , et al.Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. American Heart Journal1999;137(2):264-73. [MEDLINE: 9924160]TopolEJ , CaliffRM , WeismanHF , EllisSG , TchengJE , WorleyS , et al.Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet1994;343(8902):881-6. [MEDLINE: 7908357]TopolEJ , FergusonJJ , WeismanHF , TchengJE , EllisSG , KleimanNS , et al.Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA1997;278(6):479-84. [MEDLINE: 9256222]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. American Heart Journal1998;135(4):S98-106. [MEDLINE: 9539500]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. European Heart Journal1998;19 Suppl D:D59-66. [MEDLINE: 9597523]">EPIC 1994</a>; <a href="./references#CD008834-bbs2-0027" title="EPILOG Investigators.Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New England Journal of Medicine1997;336(24):1689-96. [MEDLINE: 9182212]GhaffariS , KereiakesDJ , LincoffAM , KellyTA , TimmisGC , KleimanNS , et al.Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. American Journal of Cardiology1998;82(1):7-12. [MEDLINE: 9671000]KereiakesDJ , LincoffAM , MillerDP , TchengJE , CabotCF , AndersonKM , et al.Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Circulation1998;97(9):857-64. [MEDLINE: 9521334]KleimanNS , LincoffAM , KereiakesDJ , MillerDP , AguirreFV , AndersonKM , et al.Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation1998;97(19):1912-20. [MEDLINE: 9609084]LincoffAM , MarkDB , TchengJE , CaliffRM , BalaMV , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation2000;102(24):2923-9. [MEDLINE: 11113041]LincoffAM , TchengJE , CaliffRM , KereiakesDJ , KellyTA , TimmisGC , et al.Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. One-year outcome in the EPILOG trial. Circulation1999;99(15):1951-8. [MEDLINE: 10208997]">EPILOG 1997</a>; <a href="./references#CD008834-bbs2-0028" title="ChoL , MarsoSP , BhattDL , TopolEJ .Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial. Journal of Womens Health &amp; Gender-Based Medicine2000;9(7):741-6. [MEDLINE: 11025866]De ServiS .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse events. Data from the Evaluation of Platelets IIb/IIIa Inhibitor for Stenting (EPISTENT) trial [Il pretrattamento con ticlopidina nello stent coronarico e associato a significativa riduzione di eventi avversi. Dati dal trial EPISTENT]. Italian Heart Journal Supplement2001;2(7):805-6. [MEDLINE: 11508303]EPISTENT Investigators.Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet1998;352(9122):87-92. [MEDLINE: 9672272]IslamMA , BlankenshipJC , BalogC , IliadisEA , LincoffAM , TchengJE , et al.Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). American Journal of Cardiology2002;90(9):916-21. [MEDLINE: 12398954]LincoffAM .Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial. American Heart Journal2000;139(2 Pt 2):S46-52. [MEDLINE: 10650316]MarsoSP , LincoffAM , EllisSG , BhattDL , TanguayJF , KleimanNS , et al.Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation1999;100(25):2477-84. [MEDLINE: 10604884]SteinhublSR , EllisSG , WolskiK , LincoffAM , TopolEJ .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation2001;103(10):1403-9. [MEDLINE: 11245644]SteinhublSR , TanWA , FoodyJM , TopolEJ .Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA1999;281(9):806-10. [MEDLINE: 10071001]TopolEJ , MarkDB , LincoffAM , CohenE , BurtonJ , KleimanN , et al.Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.[Erratum in: Lancet 2000 Mar 25;355(9209):1104]. Lancet1999;354(9195):2019-24. [MEDLINE: 10636365]Zwart-van RijkomJE , vanHoutBA .Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb/IIIa Inhibitor For Stenting Trial. European Heart Journal2001;22(16):1476-84. [MEDLINE: 11482921]">EPISTENT 1998</a>; <a href="./references#CD008834-bbs2-0029" title="Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA1992;268(10):1292-300. [MEDLINE: 1507375]">ETDRS 1992</a>; <a href="./references#CD008834-bbs2-0031" title="BadveS , HawleyCM , IrishAB , Paul-BrentP .High rate of screening failure in the FAVOURED study [abstract no: PUB345]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):905A. IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al.Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453]IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul-BrentP , et al.Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis-a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804]IrishA , FAVOURED Study Group.High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN-00756870] IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 009]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790]IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. [EMBASE: 70467038]IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul-BrentPA , et al.Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184-93. [MEDLINE: 28055065]IrishAB .The omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo-controlled trial [abstract no: HI-OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2-3. [CENTRAL: CN-01658143] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis-post hoc analysis of the FAVOURED study [abstract no: MO049]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475]ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on the need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology2018;23(Suppl 3):56. [EMBASE: 623841152]ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al.Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract no: SP593]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178]ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract no: FP555]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265]ViecelliA , PascoeE , PolkinghorneK , Paul-BrentP , DarssanD , HooiL , et al.A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115-6. [EMBASE: 612312707]ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul-BrentPA , BadveSV , et al.The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581]ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis - Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217-28. [MEDLINE: 26205903]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study. Nephrology2017;22(10):823-4. [MEDLINE: 27188542]ViecelliAK , PolkinghorneKR , PascoeEM , Paul-BrentPA , HawleyCM , BadveSV , et al.Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS ONE [Electronic Resource]2019;14(3):e0213274. [MEDLINE: 30913208]">FAVOURED 2009</a>; <a href="./references#CD008834-bbs2-0032" title="FiskerstrandCE , ThompsonIW , BurnetME , WilliamsP , AndertonJL .Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artificial Organs1985;9(1):61-3. [MEDLINE: 3888153]">Fiskerstrand 1985</a>; <a href="./references#CD008834-bbs2-0034" title="FrascàGM , CiancioloG .A clinical trial with defibrotide in IgA nephritis (IgA-GN) with impaired renal function [abstract]. Nephrology Dialysis Transplantation1995;10(6):968. [CENTRAL: CN-00261099] FrascàGM , MartelloM , CanovaC , IsolaE , VangelistaA , BonominiV .Defibrotide treatment and disease progression in patients with IgA nephropathy and impaired renal function at diagnosis. Clinical Drug Investigation1997;13(4):185-91. [EMBASE: 27192802]FrascàGM , MartelloM , SestigianiE , CanovaC , VangelistaA , BonominiV .Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function. Nephrology Dialysis Transplantation1996;11(2):392-3. [MEDLINE: 8700366]">Frascà 1997</a>; <a href="./references#CD008834-bbs2-0035" title="GaedeP , HansenHP , ParvingHH , PedersenO .Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrology Dialysis Transplantation2003;18(3):539-42. [MEDLINE: 12584276]GaedeP , ParvingH , PedersenO .Lack of impact of low-dose acetylsalisyic acid (ASA) on albuminuria in type 2 diabetic patients [abstract no: A0660]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):128A. [CENTRAL: CN-00583369] ">Gaede 2003</a>; <a href="./references#CD008834-bbs2-0036" title="GhorbaniA , AalamshahM , ShahbazianH , EhsanpourA , ArefA .Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian Journal of Nephrology2009;19(2):57-61. [MEDLINE: 20368925]">Ghorbani 2009</a>; <a href="./references#CD008834-bbs2-0037" title="GhorbaniA , Jasemi-ZerganiF .Ticlopidine to prevent primary arteriovenous fistula failure in hemodialysis patients; a randomized controlled trial. Journal of Renal Injury Prevention2013;2(3):109-11. [MEDLINE: 25340144]">Ghorbani 2013</a>; <a href="./references#CD008834-bbs2-0038" title="GiustinaA , PeriniP , DesenzaniP , BossoniS , IannielloP , MilaniM , et al.Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes1998;47(3):423-30. [MEDLINE: 9519749]">Giustina 1998</a>; <a href="./references#CD008834-bbs2-0039" title="GaoC , TomaniakM , TakahashiK , KawashimaH , WangR , HaraH , et al.Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovascular Diabetology2020;19(1):179. [MEDLINE: 33066794]TomaniakM , ChichareonP , Klimczak-TomaniakD , TakahashiK , KogameN , ModoloR , et al.Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Clinical Research in Cardiology2020;109(7):930-43. [MEDLINE: 31925529]VranckxP , ValgimigliM , JuniP , HammC , StegPG , HegD , et al.Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet2018;392(10151):940-9. [MEDLINE: 30166073]">GLOBAL LEADERS 2018</a>; <a href="./references#CD008834-bbs2-0040" title="deMoralesAM , GoicoecheaM , VerdeE , CarbayoJ , BarbieriD , DelgadoA , et al.Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial. Journal of Nephrology2019;32(4):581-7. [MEDLINE: 30949987]GoicoecheaM , Garcia de VinuesaS , QuirogaB , VerdallesU , BarracaD , YusteC , et al.Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. Journal of Nephrology2012;25(6):969-75. [MEDLINE: 22241639]">Goicoechea 2012</a>; <a href="./references#CD008834-bbs2-0041" title="GonzalezMT , CastelaoAM , VallesM , CruzadoJM , MauriJM .Platelet antiaggregants (PA) could decrease the rate of progression of chronic renal failure (CRF) in diabetic patients (DP) treated previously with angiotensin converting enzyme inhibitors (ACEi) [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:200. [CENTRAL: CN-00509215] ">Gonzalez 1995</a>; <a href="./references#CD008834-bbs2-0042" title="GröntoftKC , MulecH , GutierrezA , OlanderR .Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scandinavian Journal of Urology &amp; Nephrology1985;19(1):55-7. [MEDLINE: 3895411]">Gröntoft 1985</a>; <a href="./references#CD008834-bbs2-0043" title="GröntoftK , LarssonR , MulecH , WeissLG , DickinsonJP .Ticlopidine in fistula surgery: double-blind comparison against placebo on the rate of early occlusion of arterio-venous fistulae [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:398. [CENTRAL: CN-00601921] GröntoftKC , LarssonR , MulecH , WeissLG , DickinsonJP .Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scandinavian Journal of Urology &amp; Nephrology1998;32(4):276-83. [MEDLINE: 9764456]">Gröntoft 1998</a>; <a href="./references#CD008834-bbs2-0044" title="GuoZ , HasbachJ , KoschinskyT .Effect of acetylsalicylic acid on renal function of Type 1 diabetic patients with microalbuminuria [Wirkung von Azetylsalizylsaure auf die Nierenfunktion bei Typ-1- Diabetikern mit Mikroalbuminurie. Placebokontrollierte Crossover-Pilotstudie]. Diabetes und Stoffwechsel1998;7(2):41-7. [EMBASE: 28146337]">Guo 1998</a>; <a href="./references#CD008834-bbs2-0045" title="HansenHP , GaedePH , JensenBR , ParvingHH .Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria. Diabetes Care2000;23(12):1742-5. [MEDLINE: 11128344]">Hansen 2000</a>; <a href="./references#CD008834-bbs2-0046" title="HarterHR , BurchJW , MajerusPW , StanfordN , DelmezJA , AndersonCB , et al.Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. New England Journal of Medicine1979;301(11):577-9. [MEDLINE: 112475]">Harter 1979</a>; <a href="./references#CD008834-bbs2-0048" title="HanssonL , ZanchettiA , CarruthersSG , DahlöfB , ElmfeldtD , JuliusS , et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998;351(9118):1755-62. [MEDLINE: 9635947]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Pressure1997;6(5):313-7. [MEDLINE: 9360003]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Pressure1994;3(5):322-7. [MEDLINE: 7866597]HanssonL .The Hypertension Optimal Treatment study and the importance of lowering blood pressure. Journal of Hypertension - Supplement1999;17(1):S9-13. [MEDLINE: 10340838]JardineM , NinomiyaT , CassA , TurnbullF , GallagherM , ZoungasS , et al.Aspirin benefit increases as eGFR declines: results from a randomised controlled trial in a hypertensive population [abstract no: 086]. Nephrology2010;15(Suppl 4):49. [EMBASE: 70467090]JardineMJ , NinomiyaT , PerkovicV , CassA , TurnbullF , GallagherMP , et al.Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology2010;56(12):956-65. [MEDLINE: 20828648]JonesDW , MillerME , WoffordMR , Anderson DC Jr, CameronME , WilloughbyDL , et al.The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. American Journal of Hypertension1999;12(12 Pt 1-2):1175-80. [MEDLINE: 10619579]JonssonB , HanssonL , StalhammarNO .Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Journal of Internal Medicine2003;253(4):472-80. [MEDLINE: 12653877]KjeldsenSE , HednerT , JamersonK , JuliusS , HaleyWE , ZabalgoitiaM , et al.Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects. Hypertension1998;31(4):1014-20. [MEDLINE: 9535429]KjeldsenSE , KollochRE , LeonettiG , MallionJM , ZanchettiA , ElmfeldtD , et al.Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. Journal of Hypertension2000;18(5):629-42. [MEDLINE: 10826567]KollochRE , RahnKH .The Hypertension Optimal Treatment (HOT) study: results of 12-month treatment related to age [Die 'Hyperyension Optimal Treatment' (HOT)-Studie: Behandlungsergebnisse nach Zwolfmonatiger Therapie in Abhangigkeit vom Alter]. Deutsche Medizinische Wochenschrift1998;123(1-2):1-5. [MEDLINE: 9465848]LeonettiG , ZanchettiA .Principal results of hypertension optimal treatment (HOT) study and their clinical impact. HOT cooperative group. Clinical Hemorheology &amp; Microcirculation1999;21(3-4):217-24. [MEDLINE: 10711746]LithellH , BerglundL .Validation of an oscillometric blood pressure measuring device: a substudy of the HOT Study. Hypertension Optimal Treatment. Blood Pressure1998;7(3):149-52. [MEDLINE: 9758084]ManciaG , OmboniS , ParatiG , ClementDL , HaleyWE , RahmanSN , et al.Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(10):1755-63. [MEDLINE: 11593094]RuilopeLM , SalvettiA , JamersonK , HanssonL , WarnoldI , WedelH , et al.Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology2001;12(2):218-25. [MEDLINE: 11158211]Struijker-BoudierH , SafarM , vanBortelL .Effects of individual risk factors on the incidence of cardiovascular event in the treated hypertensive patients of the Hypertension Optimal Treatment Study. Journal of Hypertension2001;19(11):2105-6. [MEDLINE: 11677378]The Hypertension Optimal Treatment Study (the HOT Study). Blood Pressure1993;2(1):62-8. [MEDLINE: 8193735]WaeberB , LeonettiG , KollochR , McInnesGT .Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension1999;17(7):1041-5. [MEDLINE: 10419079]ZanchettiA , HanssonL , DahlofB , ElmfeldtD , KjeldsenS , KollochR , et al.Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. Journal of Hypertension2001;19(6):1149-59. [MEDLINE: 11403365]ZanchettiA , HanssonL , MenardJ , LeonettiG , RahnKH , WarnoldI , et al.Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(4):819-25. [MEDLINE: 11330886]">HOT 1993</a>; <a href="./references#CD008834-bbs2-0049" title="BlankenshipJC , SigmonKN , PieperKS , O'SheaC , TardiffBE , TchengJE , et al.Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial. American Journal of Cardiology2001;88(9):969-73. [MEDLINE: 11703991]GilchristIC , GardnerLH , MuhlesteinJB , ArnoldAM , LincoffAM , CaliffRM , et al.Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience. American Heart Journal1999;138(5 Pt 1):976-82. [MEDLINE: 10539832]MandakJS , BlankenshipJC , GardnerLH , BerkowitzSD , AguirreFV , SigmonKN , et al.Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Journal of the American College of Cardiology1998;31(7):1518-24. [MEDLINE: 9626829]Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet1997;349(9063):1422-8. [MEDLINE: 9164315]TardiffBE , CaliffRM , TchengJE , LincoffAM , SigmonKN , HarringtonRA , et al.Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. Journal of the American College of Cardiology1999;33(1):88-96. [MEDLINE: 9935014]ThelMC , CaliffRM , TardiffBE , GardnerLH , SigmonKN , LincoffAM , et al.Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. American Journal of Cardiology2000;85(4):427-34. [MEDLINE: 10728945]">IMPACT II 1997</a>; <a href="./references#CD008834-bbs2-0050" title="JiaoXM , JiaoXJ , ZhangXG , XuXP , WuJX , YaoL , et al.Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy. Chinese Medical Journal2013;126(22):4395-6. [MEDLINE: 24238537]">Jiao 2013</a>; <a href="./references#CD008834-bbs2-0051" title="OgawaH , NakayamaM , MorimotoT , UemuraS , KanauchiM , DoiN , et al.Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.[Erratum in: JAMA. 2009 May 13;301(18):1882], [Erratum in: JAMA. 2012 Nov 14;308(18):1861]. JAMA2008;300(18):2134-41. [MEDLINE: 18997198]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , NakayamaM , et al.Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk. Circulation Journal2013;77(12):3023-8. [MEDLINE: 24042256]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , NakayamaM , et al.Is long-term low-dose aspirin therapy associated with renal dysfunction in patients with type 2 diabetes? JPAD2 cohort study. PLoS ONE [Electronic Resource]2016;11(1):e0147635. [MEDLINE: 26808136]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , OhtoriiM , et al.Long-term use of low-dose aspirin develops proteinuria in patients with diabetes: A reanalysis of JPAD study [abstract no: 10863]. Circulation2013;128(22 Suppl 1). [EMBASE: 71337722]SaitoY , MorimotoT , OgawaH , NakayamaM , UemuraS , DoiN , et al.Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care2011;34(2):280-5. [MEDLINE: 21270185]">JPAD 2008</a>; <a href="./references#CD008834-bbs2-0053" title="KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. New England Journal of Medicine1974;290(6):304-6. [MEDLINE: 4588285]KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation1975;52(3):497-9. [MEDLINE: 1098808]">Kaegi 1974</a>; <a href="./references#CD008834-bbs2-0054" title="KamperAM , LinsRL , ZacheeP , Van BergenS , HostenS , DaelemansR .Safety of combining ticlopidine with nadroparin in the routine treatment of chronic hemodialysis patients. Nephron1997;77(4):484-5. [MEDLINE: 9434075]">Kamper 1997</a>; <a href="./references#CD008834-bbs2-0056" title="ChangJJ , ConcatoJ , WellsCK , CrowleyST .Impact of adherence to clinical guidelines on mortality in hemodialysis patients [abstract no: SA-PO384]. Journal of the American Society of Nephrology2004;15(Oct):386A. [CENTRAL: CN-00583156] KaufmanJS , O'ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology2003;14(9):2313-21. [MEDLINE: 12937308]KaufmanJS , O’ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract no: A1495]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):291A. ">Kaufman 2003</a>; <a href="./references#CD008834-bbs2-0057" title="KhajehdehiP , RoozbehJ , MostafaviH .A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scandinavian Journal of Urology &amp; Nephrology2002;36(2):145-8. [MEDLINE: 12028688]">Khajehdehi 2002</a>; <a href="./references#CD008834-bbs2-0058" title="KobayashiK , MaedaK , KoshikawaS , KawaguchiY , ShimizuN , NaitoC .Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis: a multicenter collaborative double blind study. Thrombosis Research1980;20(2):255-61. [MEDLINE: 7209880]">Kobayashi 1980</a>; <a href="./references#CD008834-bbs2-0059" title="KontessisPS , JonesSL , BarrowSE , StrattonPD , AlessandriniP , De CosmoS , et al.Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy. Journal of Laboratory &amp; Clinical Medicine1993;121(3):415-23. [MEDLINE: 8445289]">Kontessis 1993</a>; <a href="./references#CD008834-bbs2-0060" title="KooistraMP , vanEsA , MarxJJ , HertsigM , StruyvenbergA .Effects of low dose aspirin on thrombovascular accidents during treatment with rHuEpo: a multicentre, controlled, cross-over study [abstract]. Nephrology Dialysis Transplantation1993;8:277. [CENTRAL: CN-00260772] KooistraMP , vanEsA , MarxJJ , HertsigML , StruyvenbergA .Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrology Dialysis Transplantation1994;9(8):1115-20. [MEDLINE: 7800210]">Kooistra 1994</a>; <a href="./references#CD008834-bbs2-0061" title="KoyamaA , NaritaM , TojoS .Therapeutic effects of dipyridamole on primary glomerulonephritis [abstract]. In: 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan. 1990:12. [CENTRAL: CN-00446186] ">Koyama 1990</a>; <a href="./references#CD008834-bbs2-0063" title="MichieDD , WomboltDG .Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research - Clinical &amp; Experimental1977;22(1 II):196-204. [EMBASE: 8152617]">Michie 1977</a>; <a href="./references#CD008834-bbs2-0064" title="MiddletonDA , DeichselG .The prophylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole. Boehringer Ingelheim. Internal report1992. ">Middleton 1992</a>; <a href="./references#CD008834-bbs2-0065" title="MilutinovicS , GasparovicV , MilutinovicE , Buturovic-PonikvarJ .Ticlopidine improves dialysis clearance of solutes in uremic patients by reducing blood clotting in dialyser fibers. International Journal of Artificial Organs1993;16(5):249-52. [MEDLINE: 8354583]">Milutinovic 1993</a>; <a href="./references#CD008834-bbs2-0066" title="MovchanEA , ChuprovaAV , TovNL , Vol'vichNV .Desaggregation therapy of acute glomerulonephritis [Dezagregatsionnaia terapiia ostrogo glomerulonefrita]. Klinicheskaia Meditsina2001;79(12):44-7. [MEDLINE: 11840813]">Movchan 2001</a>; <a href="./references#CD008834-bbs2-0067" title="MozafarM , SamsamiM , SobhiyehMR , JabbehdariS , FallahZM .Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourology Monthly2013;5(2):762-5. [MEDLINE: 23841041]">Mozafar 2013</a>; <a href="./references#CD008834-bbs2-0068" title="MozafarM , AlborziM , MoradiA .Effects of clopidogrel on longevity of permanent double-lumen catheter patency in dialysis patients: A single-blind placebo-controlled clinical trial. Nephro-Urology Monthly2018;10(2):e58135. [EMBASE: 622226387]">Mozafar 2018</a>; <a href="./references#CD008834-bbs2-0069" title="NakamuraT , UshiyamaC , TakahashiY , TanakaA , ShimadaN , EbiharaI , et al.Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease. Nephron2001;88(1):80-2. [MEDLINE: 11340355]">Nakamura 2001d</a>; <a href="./references#CD008834-bbs2-0070" title="NakamuraT , UshiyamaC , OsadaS , UgaiK , TakahashiY , TanakaA , et al.Effect of dilazep dihydrochloride on serum cardiac troponin T levels in hemodialysis patients. Kidney &amp; Blood Pressure Research2002;25(1):50-4. [MEDLINE: 11834877]">Nakamura 2002b</a>; <a href="./references#CD008834-bbs2-0071" title="GuoX .A clinical study to evaluate the efficacy and safety of cilostazol and probucol in combination on patients with diabetic nephropathy. www.clinicaltrials.gov/show/nct01252056 (first received 2 December 2010). ">NCT01252056</a>; <a href="./references#CD008834-bbs2-0072" title="NybergG , LarssonO , WestbergNG , AurellM , JagenburgR , BlohmeG .A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study. Clinical Nephrology1984;21(3):184-7. [MEDLINE: 6705280]">Nyberg 1984</a>; <a href="./references#CD008834-bbs2-0076" title="BonacaMP , BhattDL , BraunwaldE , CohenM , StegPG , StoreyRF , et al.Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal2014;167(4):437-44. [MEDLINE: 24655690]BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , JensenEC , et al.Long-term use of ticagrelor in patients with prior myocardial infarction. New England Journal of Medicine2015;372(19):1791-800. [MEDLINE: 25773268]BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , CohenM , et al.Prevention of stroke with ticagrelor in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation2016;134(12):861-71. [MEDLINE: 27576775]DellborgM , BonacaMP , StoreyRF , StegPG , ImKA , CohenM , et al.Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: Insights from PEGASUS-TIMI 54 [abstract]. European Heart Journal2017;38(Suppl 1):794-5. [EMBASE: 621235545]LozanoI , RondanJ , VegasJM , SegoviaE .Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):107-8. [MEDLINE: 29301622]MagnaniG , SabatineMS , BhattDL , ChoenM , StegG , StoreyR , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: Insights from the PEGASUS-TIMI 54 trial [abstract]. European Heart Journal2015;36(Suppl 1):520. [EMBASE: 72020712]MagnaniG , StoreyRF , StegG , BhattDL , CohenM , KuderJ , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. European Heart Journal2016;37(4):400-8. [MEDLINE: 26443023]MagnusonEA , BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , et al.Reply: cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):108. [MEDLINE: 29301623]MagnusonEA , LiH , WangK , VilainK , ShafiqA , BonacaMP , et al.Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: results from the PEGASUS-TIMI 54 trial. Journal of the American College of Cardiology2017;70(5):527-38. [MEDLINE: 28750695]MurphySA , BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , et al.Reduction in total cardiovascular events with long-term use of ticagrelor in patients with prior myocardial infarction in the PEGASUS-TIMI 54 trial [abstract no: A17121]. Circulation2015;132(Suppl 3). [EMBASE: 72179983]">PEGASUS‐TIMI 54 2014</a>; <a href="./references#CD008834-bbs2-0080" title="PierucciA , SimonettiBM , PecciG , FeriozziS , MavrikakisG , CinottiGA , et al.Low dose aspirin in patients with lupus nephritis [abstract]. Kidney International1988;33(1):281. [CENTRAL: CN-00583819] PierucciA , SimonettiBM , PecciG , MavrikakisG , FeriozziS , CinottiGA , et al.Acute effects of a thromboxane receptor antagonist on renal function in patients with lupus nephritis [abstract]. Kidney International1987;31(1):283. [CENTRAL: CN-00724956] PierucciA , SimonettiBM , PecciG , MavrikakisG , FeriozziS , CinottiGA , et al.Improvement of renal function with selective thromboxane antagonism in lupus nephritis. New England Journal of Medicine1989;320(7):421-5. [MEDLINE: 2643773]">Pierucci 1989</a>; <a href="./references#CD008834-bbs2-0081" title="AkerblomA , WallentinL , LarssonA , SiegbahnA , BeckerRC , BudajA , et al.Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study. Clinical Chemistry2013;59(9):1369-75. [MEDLINE: 23698074]AkerblomA , WallentinL , SiegbahnA , BeckerRC , BudajA , HorrowJ , et al.Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. American Heart Journal2012;164(5):728-34. [MEDLINE: 23137503]AndellP , JamesSK , CannonCP , CyrDD , HimmelmannA , HustedS , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Journal of the American Heart Association2015;4(10):e002490. [MEDLINE: 26452988]ArmstrongPW , SihaH , FuY , WesterhoutCM , StegPG , JamesSK , et al.ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation2012;125(3):514-21. [MEDLINE: 22179530]ArmstrongPW , WesterhoutCM , FuY , HarringtonRA , StoreyRF , KatusH , et al.Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. American Journal of Medicine2013;126(8):723-9. [MEDLINE: 23795897]BeckerRC , BassandJP , BudajA , WojdylaDM , JamesSK , CornelJH , et al.Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial [Erratum in: Eur Heart J. 2012 Nov;33(21):2750]. European Heart Journal2011;32(23):2933-44. [MEDLINE: 22090660]BellaviaA , WallentinL , OrsiniN , JamesSK , CannonCP , HimmelmannA , et al.Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. Open Heart2017;4(2):e000557. [MEDLINE: 28761675]BrilakisES , HeldC , MeierB , CoolsF , ClaeysMJ , CornelJH , et al.Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. American Heart Journal2013;166(3):474-80. [MEDLINE: 24016496]BuiAH , CannonCP , StegPG , StoreyRF , HustedS , GuoJ , et al.Relationship between early and late nonsustained ventricular tachycardia and cardiovascular death in patients with acute coronary syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation: Arrhythmia and Electrophysiology2016;9(2):e002951. [MEDLINE: 26810596]CapodannoD , CalviV , TamburinoC .Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment. Journal of Cardiovascular Medicine2012;13(2):162-3. [MEDLINE: 22237463]CornelJH , BeckerRC , GoodmanSG , HustedS , KatusH , SantosoA , et al.Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2012;164(3):334-42. [MEDLINE: 22980299]CowperPA , PanW , AnstromKJ , KaulP , WallentinL , Davidson-RayL , et al.Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. Journal of the American College of Cardiology2015;65(5):465-76. [MEDLINE: 25660925]DiNicolantonioJJ , D'AscenzoF , TomekA , ChatterjeeS , NiaziAK , Biondi-ZoccaiG .Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial. International Journal of Cardiology2013;168(3):1739-44. [MEDLINE: 23907035]DiNicolantonioJJ , TomekA .Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial. International Journal of Cardiology2013;168(4):4076-80. [MEDLINE: 23911266]DiNicolantonioJJ , TomekA .Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel. International Journal of Cardiology2013;169(2):145-6. [MEDLINE: 24120213]DucrocqG , SchultePJ , BeckerRC , CannonCP , HarringtonRA , HeldC , et al.Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. Eurointervention2015;11(7):737-45. [MEDLINE: 25254357]FranchiF , JamesSK , GhukasyanLT , BudajAJ , CornelJH , KatusHA , et al.Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y12 receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. Journal of the American Heart Association2019;8(6):e011139. [MEDLINE: 30857464]GiannitsisE , WallentinL , JamesSK , BertilssonM , SiegbahnA , StoreyRF , et al.Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: a Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. European Heart Journal: Acute Cardiovascular Care2017;6(6):500-10. [MEDLINE: 27044282]HagstromE , JamesSK , BertilssonM , BeckerRC , HimmelmannA , HustedS , et al.Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. European Heart Journal2016;37(16):1325-33. [MEDLINE: 26417057]HeldC , AsenbladN , BassandJP , BeckerRC , CannonCP , ClaeysMJ , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology2011;57(6):672-84. [MEDLINE: 21194870]HustedS , JamesS , BeckerRC , HorrowJ , KatusH , StoreyRF , et al.Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circulation. Cardiovascular Quality &amp; Outcomes2012;5(5):680-8. [MEDLINE: 22991347]HustedS , JamesSK , BachRG , BeckerRC , BudajA , HerasM , et al.The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal2014;35(23):1541-50. [MEDLINE: 24682844]JamesS , AkerblomA , CannonCP , EmanuelssonH , HustedS , KatusH , et al.Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2009;157(4):599-605. [MEDLINE: 19332184]JamesS , AngiolilloDJ , CornelJH , ErlingeD , HustedS , KontnyF , et al.Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal2010;31(24):3006-16. [MEDLINE: 20802246]JamesS , BudajA , AylwardP , BuckKK , CannonCP , CornelJH , et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2010;122(11):1056-67. [MEDLINE: 20805430]JamesS , BudajA , AylwardP , BuckKK , CannonCP , CornelJH , et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation2010;122(11):1056-67. [MEDLINE: 20805430]JamesSK , RoeMT , CannonCP , CornelJH , HorrowJ , HustedS , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ2011;342:d3527. [MEDLINE: 21685437]JohanssonA , ErikssonN , BeckerRC , StoreyRF , HimmelmannA , HagstromE , et al.NLRC4 inflammasome is an important regulator of interleukin-18 levels in patients with acute coronary syndromes: genome-wide association study in the PLATelet inhibition and patient Outcomes Trial (PLATO). Circulation. Cardiovascular Genetics2015;8(3):498-506. [MEDLINE: 25747584]KangHJ , ClareRM , GaoR , HeldC , HimmelmannA , JamesSK , et al.Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal2015;169(6):899-905. [MEDLINE: 26027629]KholaifN , ZhengY , JagasiaP , HimmelmannA , JamesSK , StegPG , et al.Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex. American Journal of Medicine2015;128(8):914-9. [MEDLINE: 25818495]KohliP , WallentinL , ReyesE , HorrowJ , HustedS , AngiolilloDJ , et al.Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation2013;127(6):673-80. [MEDLINE: 23277305]KontnyF , UelandT , AukrustP , MichelsenAE , BeckerRC , BertilssonM , et al.Pentraxin 3 (PTX3) predict adverse outcome in acute coronary syndromes-a PLATO biomarker substudy [abstract]. European Heart Journal2014;35(Suppl 1):319. [EMBASE: 71647923]KotsiaA , BrilakisES , HeldC , CannonC , StegGP , MeierB , et al.Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2014;168(1):68-75. [MEDLINE: 24952862]KunadianV , JamesSK , WojdylaDM , ZorkunC , WuJ , StoreyRF , et al.Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). Jacc: Cardiovascular Interventions2013;6(7):671-83. [MEDLINE: 23866179]LevinLA , WallentinL , BernfortL , AnderssonD , StoreyRF , BergstromG , et al.Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. Value in Health2013;16(4):574-80. [MEDLINE: 23796291]LindholmD , VarenhorstC , CannonCP , HarringtonRA , HimmelmannA , MayaJ , et al.Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal2014;35(31):2083-93. [MEDLINE: 24727884]MahaffeyKW , HeldC , WojdylaDM , JamesSK , KatusHA , HustedS , et al.Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology2014;63(15):1493-9. [MEDLINE: 24561148]MahaffeyKW , WojdylaDM , CarrollK , BeckerRC , StoreyRF , AngiolilloDJ , et al.Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2011;124(5):544-54. [MEDLINE: 21709065]NikolicE , JanzonM , HauchO , WallentinL , HenrikssonM , PLATO Health Economic Substudy Group.Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. European Heart Journal2013;34(3):220-8. [MEDLINE: 22719022]OhmanEM , RoeMT .Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany &quot;Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified&quot; (Thromb Haemost 2011; 105.5). Thrombosis &amp; Haemostasis2011;105(5):763-5. [MEDLINE: 21394382]ParkerWA , ErikssonN , BeckerRC , VooraD , AkerblomA , HimmelmannA , et al.Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets2019;30(5):579-88. [MEDLINE: 29851527]PatelMR , BeckerRC , WojdylaDM , EmanuelssonH , HiattWR , HorrowJ , et al.Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. European Journal of Preventive Cardiology2015;22(6):734-42. [MEDLINE: 24830710]Pollack CV Jr, DavoudiF , DiercksDB , BeckerRC , JamesSK , LimST , et al.Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clinical Cardiology2017;40(6):390-8. [MEDLINE: 28598510]RoguinA , MusallamA .Letter by Roguin and Musallam regarding article, &quot;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial&quot;. Circulation2014;129(19):e493. [MEDLINE: 24821831]SciricaBM , BansilalS , DavoudiF , ArmstrongPW , ClareRM , SchultePJ , et al.Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. American Heart Journal2018;202:54-60. [MEDLINE: 29859968]SciricaBM , CannonCP , EmanuelssonH , MichelsonEL , HarringtonRA , HustedS , et al.The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. Journal of the American College of Cardiology2011;57(19):1908-16. [MEDLINE: 21545948]SerebruanyVL , FortmannSD , CherepanovV , LitvinovO , KimMH , MarciniakTA .Excess ticagrelor mortality in the food and drug administration adverse event reporting system: time to recount PLATO trial deaths. American Journal of Medicine2017;130(6):e245-6. [MEDLINE: 28161342]SerebruanyVL .Angiographic outcomes contradict platelet data in the PLATO trial: confusion over official trial substudies. Cardiology2014;127(3):190-5. [MEDLINE: 24457905]SerebruanyVL .Discrepancies in the primary PLATO trial publication and the FDA reviews. International Journal of Cardiology2014;172(1):8-10. [MEDLINE: 24456868]SerebruanyVL .Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review. American Journal of Therapeutics2012;19(2):160-1. [MEDLINE: 22395000]SerebruanyVL .The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent. Cardiology2011;120(3):169-71. [MEDLINE: 22418766]ShimadaYJ , BansilalS , WiviottSD , BeckerRC , HarringtonRA , HimmelmannA , et al.Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal2016;177:1-8. [MEDLINE: 27297843]SihaH , DasD , FuY , ZhengY , WesterhoutCM , StoreyRF , et al.Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. CMAJ Canadian Medical Association Journal2012;184(10):1135-42. [MEDLINE: 22546885]StegPG , HarringtonRA , EmanuelssonH , KatusHA , MahaffeyKW , MeierB , et al.Response to letter regarding article, &quot;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial&quot;. Circulation2014;129(19):e494-5. [MEDLINE: 24821832]StegPG , HarringtonRA , EmanuelssonH , KatusHA , MahaffeyKW , MeierB , et al.Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation2013;128(10):1055-65. [MEDLINE: 23900047]StegPG , JamesS , HarringtonRA , ArdissinoD , BeckerRC , CannonCP , et al.Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation2010;122(21):2131-41. [MEDLINE: 21060072]StoreyRF , AngiolilloDJ , PatilSB , DesaiB , EcobR , HustedS , et al.Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. Journal of the American College of Cardiology2010;56(18):1456-62. [MEDLINE: 20832963]StoreyRF , ArdissinoD , VignaliL , CairnsR , BeckerRC , CannonCP , et al.Ischaemic events and stent thrombosis following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study. Thrombosis &amp; Haemostasis2018;118(2):427-9. [MEDLINE: 29443375]StoreyRF , BeckerRC , HarringtonRA , HustedS , JamesSK , CoolsF , et al.Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. European Heart Journal2011;32(23):2945-53. [MEDLINE: 21804104]StoreyRF , BeckerRC , HarringtonRA , HustedS , JamesSK , CoolsF , et al.Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). American Journal of Cardiology2011;108(11):1542-6. [MEDLINE: 21890085]StoreyRF , JamesSK , SiegbahnA , VarenhorstC , HeldC , YcasJ , et al.Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets2014;25(7):517-25. [MEDLINE: 24127651]SumayaW , WallentinL , JamesSK , SiegbahnA , GabryschK , BertilssonM , et al.Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. European Heart Journal2018;39(13):1078-85. [MEDLINE: 29390064]UelandT , AkerblomA , GhukasyanT , MichelsenAE , AukrustP , BeckerRC , et al.Osteoprotegerin is associated with major bleeding but not with cardiovascular outcomes in patients with acute coronary syndromes: insights from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American Heart Association2018;7(2):e007009. [MEDLINE: 29330256]UelandT , MichelsenA , AukrustP , BeckerR , BertilssonM , JamesSK , et al.Chemokine (CXC motif) ligand 16 (CXCL16) and osteoprotegerin (OPG) as predictors of outcome in patients with acute coronary syndromes (ACS) a PLATO biomarker substudy [abstract]. European Heart Journal2014;35(Suppl 1):486. [EMBASE: 71648554]WallentinL , BeckerRC , BudajA , CannonCP , EmanuelssonH , HeldC , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2009;361(11):1045-57. [MEDLINE: 19717846]WallentinL , BeckerRC , CannonCP , HeldC , HimmelmannA , HustedS , et al.No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. International Journal of Cardiology2014;176(1):300-2. [MEDLINE: 25005338]WallentinL , BeckerRC , CannonCP , HeldC , HimmelmannA , HustedS , et al.Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. International Journal of Cardiology2014;170(3):e59-62. [MEDLINE: 24299581]WallentinL , BeckerRC , JamesSK , HarringtonRA .The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. &quot;Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified&quot; (Thromb Haemost 2011; 105.5). Thrombosis &amp; Haemostasis2011;105(5):760-2. [MEDLINE: 21394383]WallentinL , JamesS , StoreyRF , ArmstrongM , BarrattBJ , HorrowJ , et al.Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet2010;376(9749):1320-8. [MEDLINE: 20801498]WallentinL , LindholmD , SiegbahnA , WernrothL , BeckerRC , CannonCP , et al.Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2014;129(3):293-303. [MEDLINE: 24170388]">PLATO 2009</a>; <a href="./references#CD008834-bbs2-0082" title="Navarro-GonzalezJF , Sanchez-NinoMD , Donate-CorreaJ , Martin-NunezE , FerriC , Perez-DelgadoN , et al.Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease. Diabetes Care2018;41(8):1817-20. [MEDLINE: 29866645]">PREDIAN 2011</a>; <a href="./references#CD008834-bbs2-0083" title="HuynhT , NasmithJ , LuongTM , BernierM , PharandC , Xue-QiaoZ , et al.Complementary prognostic values of ST segment deviation and Thrombolysis In Myocardial Infarction (TIMI) risk score in non-ST elevation acute coronary syndromes: insights from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Canadian Journal of Cardiology 2009 Dec;25(12):e417-21. [MEDLINE: 19960136]HuynhT , PiazzaN , DiBattistePM , SnapinnSM , WanY , PharandC , et al.Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study. International Journal of Cardiology2005;100(1):73-8. [MEDLINE: 15820288]HuynhT , TherouxP , SnapinnS , WanY , PRISM-PLUS Investigators.Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). American Heart Journal2003;146(4):668-73. [MEDLINE: 14564321]Januzzi JL Jr, SnapinnSM , DiBattistePM , JangIK , TherouxP .Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation2002;105(20):2361-6. [MEDLINE: 12021221]MegaJL , MorrowDA , SabatineMS , ZhaoXQ , SnapinnSM , DiBattistePM , et al.Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. American Heart Journal2005;149(5):846-50. [MEDLINE: 15894966]MorrowDA , SabatineMS , AntmanEM , CannonCP , BraunwaldE , TherouxP .Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). American Journal of Cardiology2004;94(6):774-6. [MEDLINE: 15374786]Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New England Journal of Medicine1998;338(21):1488-97. [MEDLINE: 9599103]ServossSJ , WanY , SnapinnSM , DiBattistePM , ZhaoXQ , TherouxP , et al.Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. American Journal of Cardiology2004;93(7):843-7. [MEDLINE: 15050486]SzucsTD , MeyerBJ , KiowskiW .Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial. European Heart Journal1999;20(17):1253-60. [MEDLINE: 10454977]TherouxP , AlexanderJ , PharandC , BarrE , SnapinnS , GhannamAF , et al.Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation2000;102(20):2466-72. [MEDLINE: 11076818]TherouxP , Alexander J Jr, DupuisJ , PesantY , GervaisP , GrandmontD , et al.Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators. American Journal of Cardiology2001;87(4):375-80. [MEDLINE: 11179517]ZhaoXQ , TherouxP , SnapinnSM , SaxFL .Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Circulation1999;100(15):1609-15. [MEDLINE: 10517731]">PRISM‐PLUS 1998</a>; <a href="./references#CD008834-bbs2-0084" title="AkkerhuisKM , DeckersJW , BoersmaE , HarringtonRA , StepinskaJ , MahaffeyKW , et al.Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. European Heart Journal2000;21(5):371-81. [MEDLINE: 10666351]AkkerhuisKM , MaasAC , KlootwijkPA , KrucoffMW , MeijS , CaliffRM , et al.Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of Electrocardiology2000;33(2):127-36. [MEDLINE: 10819406]AlexanderJH , HarringtonRA , TuttleRH , BerdanLG , LincoffAM , DeckersJW , et al.Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology1999;83(8):1147-51. [MEDLINE: 10215274]BoersmaE , PieperKS , SteyerbergEW , WilcoxRG , ChangWC , LeeKL , et al.Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation2000;101(22):2557-67. [MEDLINE: 10840005]BrownRE , HendersonRA , KosterD , HuttonJ , SimoonsML .Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy. European Heart Journal2002;23(1):50-8. [MEDLINE: 11741362]ChangWC , HarringtonRA , SimoonsML , CaliffRM , LincoffAM , ArmstrongPW , et al.Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial. European Heart Journal2002;23(14):1102-11. [MEDLINE: 12090748]DykeCM , BhatiaD , LorenzTJ , MarsoSP , TardiffBE , HogeboomC , et al.Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Annals of Thoracic Surgery2000;70(3):866-71. [MEDLINE: 11016325]GreenbaumAB , HarringtonRA , HudsonMP , MacAulayCM , WilcoxRG , SimoonsML , et al.Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. Journal of the American College of Cardiology2001;37(2):492-8. [MEDLINE: 11216968]HarringtonRA .Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology1997;80(4A):34-8B. [MEDLINE: 9291244]HasdaiD , Holmes DR Jr, CrigerDA , TopolEJ , CaliffRM , WilcoxRG , et al.Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators. American Heart Journal2000;139(3):454-60. [MEDLINE: 10689260]KleimanNS , LincoffAM , FlakerGC , PieperKS , WilcoxRG , BerdanLG , et al.Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation2000;101(7):751-7. [MEDLINE: 10683348]LabinazM , KaulP , HarringtonRA , ChangWC , KleimanNS , SimoonsML , et al.Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. Canadian Journal of Cardiology2004;20(8):773-8. [MEDLINE: 15229770]LabinazM , KilaruR , PieperK , MarsoSP , KittMM , SimoonsML , et al.Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2002;105(3):322-7. [MEDLINE: 11804987]LauerMA , HoughtalingPL , PetersonJG , GrangerCB , BhattDL , SappSK , et al.Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2001;104(23):2772-7. [MEDLINE: 11733393]LincoffAM , HarringtonRA , CaliffRM , HochmanJS , GuerciAD , OhmanEM , et al.Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2000;102(10):1093-100. [MEDLINE: 10973836]MahaffeyKW , HarringtonRA , AkkerhuisM , KleimanNS , BerdanLG , CrenshawBS , et al.Systematic adjudication of myocardial infarction end-points in an international clinical trial. Current Controlled Trials in Cardiovascular Medicine2001;2(4):180-6. [MEDLINE: 11806793]MahaffeyKW , HarringtonRA , SimoonsML , GrangerCB , GraffagninoC , AlbertsMJ , et al.Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation1999;99(18):2371-7. [MEDLINE: 10318656]MarkDB , HarringtonRA , LincoffAM , CaliffRM , NelsonCL , TsiatisAA , et al.Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation2000;101(4):366-71. [MEDLINE: 10653826]MarsoSP , BhattDL , RoeMT , HoughtalingPL , LabinazM , KleimanNS , et al.Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators. Circulation2000;102(24):2952-8. [MEDLINE: 11113045]McClureMW , BerkowitzSD , SparapaniR , TuttleR , KleimanNS , BerdanLG , et al.Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation1999;99(22):2892-900. [MEDLINE: 10359733]PetersonJG , TopolEJ , RoeMT , SappSK , LincoffAM , DeckersJW , et al.Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology2001;87(5):532-6. [MEDLINE: 11230834]PURSUIT Trial Investigators.Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. New England Journal of Medicine1998;339(7):436-43. [MEDLINE: 9705684]RoeMT , HarringtonRA , ProsperDM , PieperKS , BhattDL , LincoffAM , et al.Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation2000;102(10):1101-6. [MEDLINE: 10973837]RonnerE , BoersmaE , AkkerhuisKM , HarringtonRA , LincoffAM , DeckersJW , et al.Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. European Heart Journal2002;23(3):239-46. [MEDLINE: 11792139]RonnerE , BoersmaE , LaarmanGJ , SomsenGA , HarringtonRA , DeckersJW , et al.Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of the American College of Cardiology2002;39(12):1924-9. [MEDLINE: 12084589]SrichaiMB , JaberWA , PriorDL , MarsoSP , HoughtalingPL , MenonV , et al.Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes. American Heart Journal2004;147(1):84-90. [MEDLINE: 14691424]">PURSUIT 1997</a>; <a href="./references#CD008834-bbs2-0085" title="Quarto Di PaloF , ElliA , RivoltaR , ParentiM , PalazziP , ZanussiC .Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide. Transplantation Proceedings1991;23(1 Pt 2):969-71. [MEDLINE: 1989347]">Quarto Di Palo 1991</a>; <a href="./references#CD008834-bbs2-0086" title="BrenerSJ , BarrLA , BurchenalJE , KatzS , GeorgeBS , JonesAA , et al.Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation1998;98(8):734-41. [MEDLINE: 9727542]BrenerSJ , BarrLA , BurchenalJE , WolskiKE , EffronMB , TopolEJ .Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial. American Journal of Cardiology1999;84(6):728-30. [MEDLINE: 10498145]">RAPPORT 1998</a>; <a href="./references#CD008834-bbs2-0087" title="ReamsGP , YoungM , SorkinM , TwardowskiZ , GloorH , MooreH , et al.Effects of dipyridamole on peritoneal clearances. Uremia Investigation1985;9(1):27-33. [MEDLINE: 3915163]">Reams 1985</a>; <a href="./references#CD008834-bbs2-0088" title="CooperCJ , HallerST , ColyerW , SteffesM , BurketMW , ThomasWJ , et al.Embolic protection and platelet inhibition during renal artery stenting. Circulation2008;117(21):2752-60. [MEDLINE: 18490527]HeW , CheJ , ZhanD , DawsoT , KanjwaS , HalleS , et al.Time dependant changes in systolic blood pressure after renal artery stenting: role of stenosis severity [abstract no: 14283]. Circulation2012;126(21 Suppl 1). [EMBASE: 70958797]KanjwalK , CooperCJ , VirmaniR , HallerS , ShapiroJI , BurketMW , et al.Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy. Catheterization &amp; Cardiovascular Interventions2010;76(1):16-23. [MEDLINE: 20209644]KanjwalK , HallerS , SteffesM , VirmaniR , ShapiroJI , BurketMW , et al.Complete versus partial distal embolic protection during renal artery stenting. Catheterization &amp; Cardiovascular Interventions2009;73(6):725-30. [MEDLINE: 19198007]TianJ , HallerS , PeriyasamyS , BrewsterP , ZhangH , AdlakhaS , et al.Renal ischemia regulates marinobufagenin release in humans. Hypertension2010;56(5):914-9. [MEDLINE: 20823380]YuH , ZhangD , HallerS , KanjwalK , ColyerW , BrewsterP , et al.Determinants of renal function in patients with renal artery stenosis. Vascular Medicine2011;16(5):331-8. [MEDLINE: 21908683]">RESIST 2008</a>; <a href="./references#CD008834-bbs2-0089" title="RouzrokhM , AbbasiMR , MirshemiraniAR , SobhiyehMR .The effect of antiplatelet drugs on the patency rate of arterio-venous fistulae in hemodialysis patients. Iranian Journal of Pharmaceutical Research2010;9(4):451-7. [EMBASE: 2011024056]">Rouzrokh 2010</a>; <a href="./references#CD008834-bbs2-0090" title="RubinJ , AdairC , BarnesT , BowerJD .Augmentation of peritoneal clearance by dipyridamole. Kidney International1982;22(6):658-61. [MEDLINE: 6761488]">Rubin 1982</a>; <a href="./references#CD008834-bbs2-0091" title="SalterMC , CrowMJ , DonaldsonDR , RobertsTG , RajahSM , DavisonAM .Prevention of platelet deposition and thrombus formation on hemodialysis membranes: a double-blind randomized trial of aspirin and dipyridamole. Artificial Organs1984;8(1):57-61. [MEDLINE: 6703927]">Salter 1984</a>; <a href="./references#CD008834-bbs2-0093" title="SchulzeR , LangkopfB , SziegoleitW .The effect of dipyridamole on the results of allogenic kidney transplantation [Der Einfluss von Dipyridamol auf die Ergebnisse der allogenen Nieren-transplantation]. Zeitschrift für Urologie und Nephrologie1990;83(5):255-9. [MEDLINE: 2203215]">Schulze 1990</a>; <a href="./references#CD008834-bbs2-0094" title="SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract no: 9P]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):388. [CENTRAL: CN-00485981] SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study. Kidney International1994;45(5):1477-83. [MEDLINE: 8072261]">Sreedhara 1994</a>; <a href="./references#CD008834-bbs2-0095" title="SteinessE , BrunN , SkarsfeldtT , DerwahlKM .Low dose anti-thromboxane reduces urinary albumin in patients with diabetic kidney disease [abstract no: SA-PO148]. Journal of the American Society of Nephrology2018;29:773. [EMBASE: 633731990]">Steiness 2018</a>; <a href="./references#CD008834-bbs2-0096" title="MiletiM , De PetriG , BacchiM , OgliariV , PecchiniF , BufanoG , et al.A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients. Journal of Nephrology1995;8(2):167-72. [EMBASE: 25209311]">STOP 1995</a>; <a href="./references#CD008834-bbs2-0097" title="StorckM , SchillingM , MickleyV , TechtB , AbendrothD .Influence of systemic cyclooxygenase inhibition with single-dose aspisol on kinetics of arachidonic acid metabolites in the venous effluate of transplanted kidney grafts in humans. Transplantation Proceedings1996;28(1):312-3. [MEDLINE: 8644237]">Storck 1996</a>; <a href="./references#CD008834-bbs2-0098" title="TaberT , MaikranzP , HaagB , DilleyR , GaylordG .Hemodialysis vascular graft stenosis may be altered by low-molecular weight dextran (LMD), but not by aspirin (ASA) [abstract]. Journal of the American Society of Nephrology1992;3(3):397. [CENTRAL: CN-00858239] ">Taber 1992</a>; <a href="./references#CD008834-bbs2-0099" title="TangWH , LinFH , LeeCH , KuoFC , HsiehCH , HsiaoFC , et al.Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. Endocrine2014;45(2):293-301. [MEDLINE: 23775007]">Tang 2014</a>; <a href="./references#CD008834-bbs2-0101" title="TayebiP , KazemzadehG , BanihashemA , RavariH .Effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients: a randomized double-blind placebo-controlled trial. Electronic Physician [Electronic Resource]2018;10(1):6135-9. [MEDLINE: 29588811]">Tayebi 2018</a>; <a href="./references#CD008834-bbs2-0103" title="CorreaS , BonacaMP , SciricaBM , MurphySA , GoodrichEL , MorrowDA , et al.Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. Journal of Thrombosis &amp; Thrombolysis2019;47(3):353-60. [MEDLINE: 30511258]GaviriaSC , BraunwaldE , BonacaMP , MurphySA , GoodrichEL , MorrowDA , et al.The efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function: insights from the TRA 2P-TIMI 50 trial [abstract no: 15480]. Circulation2017;136(Suppl 1). [EMBASE: 619986693]MorrowDA , BraunwaldE , BonacaMP , AmerisoSF , DalbyAJ , FishMP , et al.Vorapaxar in the secondary prevention of atherothrombotic events. New England Journal of Medicine2012;366(15):1404-13. [MEDLINE: 22443427]MorrowDA , SciricaBM , FoxKA , BermanG , StronyJ , VeltriE , et al.Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. American Heart Journal2009;158(3):335-41. [MEDLINE: 19699854]">TRA 2P‐TIMI 50 2009</a>; <a href="./references#CD008834-bbs2-0104" title="CornelJH , TricociP , HortonJ , MoliternoD , WallentinL , ArmstrongP , et al.Effects of glycoprotein IIB/IIIA inhibitors in combination with vorapaxar, a platelet thrombin-receptor antagonist, among patients with non-St-segment elevation acute coronary syndromes: insights from the TRACER trial [abstract]. Journal of the American College of Cardiology2013;61(10 Suppl 1):E102. [EMBASE: 71019466]MahaffeyKW , PieperK , VranckxP , TricociP , Van de WerfF , HeldC , et al.Chronic kidney disease is associated with worse outcomes in ACS patients: results from the TRACER trial [abstract]. European Heart Journal2014;35(Suppl 1):687. [EMBASE: 71649310]">TRACER 2013</a>; <a href="./references#CD008834-bbs2-0106" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al.First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473-84. [MEDLINE: 15754269]BaigentC , UK-HARP Steering Committee.Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-PO851]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. [CENTRAL: CN-00444305] ">UK‐HARP‐I 2005</a>; <a href="./references#CD008834-bbs2-0108" title="WatanabeH , NakagawaK , KakihanaM .Long-term effects of sarpogrelate, a selective serotonin receptor antagonist, in diabetic patients with stable angina and chronic kidney disease [abstract no: 11204]. Circulation2011;124(21 Suppl 1). [EMBASE: 70620962]">Watanabe 2011b</a>; <a href="./references#CD008834-bbs2-0109" title="WeseleyS , GoodmanA .The effect of dipyridamole (Di) on the peritoneal dialysis (PD) clearance of creatinine and urea - a double-blind study [abstract]. Kidney International1982;21(1):182. ">Weseley 1982</a>; <a href="./references#CD008834-bbs2-0112" title="YutoJ , EharaY , ShibataK , IwamotoT , YasudaG , YatsuK , et al.Effect of sarpogrelate on fistula patency of forearm arteriovenous anastomisis in uremic patients [abstract no: 276]. Kidney Research &amp; Clinical Practice2012;31(2):A86. [EMBASE: 70814985]">Yuto 2012</a>; <a href="./references#CD008834-bbs2-0113" title="ZäunerI , BöhlerJ , BraunN , GruppC , HeeringP , SchollmeyerP .Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Nephrology Dialysis Transplantation1994;9(6):619-22. [MEDLINE: 7970086]">Zäuner 1994</a>) </p> </li> <li> <p>Twenty‐nine studies (11,805 CKD participants) compared an antiplatelet agent to a second antiplatelet agent (<a href="./references#CD008834-bbs2-0004" title="AlexopoulosD , PanagiotouA , XanthopoulouI , KomninakisD , KassimisG , DavlourosP , et al.Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. Journal of Thrombosis &amp; Haemostasis2011;9(12):2379-85. [MEDLINE: 21985070]XanthopoulouI , PanagiotouA , KomninakisD , DavlourosP , KassimisG , FourtounasK , et al.Prasugrel versus double clopidpogrel maintenance dose in patients on chronic haemodialysis and high on clopidogrel platelet reactivity [abstract no: P2438]. European Heart Journal2011;32(Suppl 1):417. [EMBASE: 70534608]">Alexopoulos 2011</a>; <a href="./references#CD008834-bbs2-0008" title="FujitaT , YuX , KimS , NakamotoH , OrigasaH , KurumataniH , et al.Effects of sustained-release beraprost sodium in patients with primary glomerular disease or nephrosclerosis: the CASSIOPEIR study [abstract no: SA-PO1096]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):4B. [CENTRAL: CN-01657821] NakamotoH , FujitaT , OrigasaH , IsonoM , KurumataniH , OkadaK , et al.A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrology2014;15:153. [MEDLINE: 25233856]NakamotoH , YuXQ , KimS , OrigasaH , ZhengH , ChenJ , et al.Effects of sustained-release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results. Therapeutic Apheresis &amp; Dialysis2020;24(1):42-55. [MEDLINE: 31119846]">CASSIOPEIR 2014</a>; <a href="./references#CD008834-bbs2-0014" title="LeeMH , SuhJW , LeeSP , ParkKW , LeeHY , KangHJ , et al.The effect of cilostazol on the antiplatelet efficacy of patients with moderate renal dysfunction: post-hoc analysis of CILON-T (Influence of cilostazol based triple antiplatelet therapy on ischemic complication after drug eluting stent implantation) trial [abstract no: TCT-495]. Journal of the American College of Cardiology2011;58(20 Suppl 1):B134-5. [EMBASE: 70581865]LeeSP , SuhJW , ParkKW , LeeHY , KangHJ , KooBK , et al.Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: a multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease. Trials [Electronic Resource]2010;11:87. [MEDLINE: 20735821]SuhJW , LeeSP , ParkKW , LeeHY , KangHJ , KooBK , et al.Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. Journal of the American College of Cardiology2011;57(3):280-9. [MEDLINE: 21232664]">CILON‐T 2010</a>; <a href="./references#CD008834-bbs2-0018" title="DashA , MaitiR , BandakkanavarTK , BhaskarA , PrakashJ , PandeyBL .Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: comparison between clopidogrel and low-dose aspirin. International Journal of Preventive Medicine2013;4(8):902-10. [MEDLINE: 24049616]">Dash 2013</a>; <a href="./references#CD008834-bbs2-0030" title="BaumgartnerI , NorgrenL , FowkesFG , MulderH , PatelMR , BergerJS , et al.Cardiovascular outcomes after lower extremity endovascular or surgical revascularization: the EUCLID trial. Journal of the American College of Cardiology2018;72(14):1563-72. [MEDLINE: 30261955]BergerJS , AbramsonBL , LopesRD , HeizerG , RockholdFW , BaumgartnerI , et al.Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Vascular Medicine2018;23(6):523-30. [MEDLINE: 29992857]HaineA , KavanaghS , BergerJS , HessCN , NorgrenL , FowkesFG , et al.Sex-specific risks of major cardiovascular and limb events in patients with symptomatic peripheral artery disease. Journal of the American College of Cardiology2020;75(6):608-17. [MEDLINE: 32057375]HessCN , HuangZ , PatelMR , BaumgartnerI , BergerJS , BlomsterJI , et al.Acute limb ischemia in peripheral artery disease. Circulation2019;140(7):556-65. [MEDLINE: 31238713]HiattWR , FowkesFG , HeizerG , BergerJS , BaumgartnerI , HeldP , et al.Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. New England Journal of Medicine2017;376(1):32-40. [MEDLINE: 27959717]HopleyCW , KavanaghS , PatelMR , OstromC , BaumgartnerI , BergerJS , et al.Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial. Vascular Medicine2019;24(5):422-30. [MEDLINE: 31339474]JonesWS , BaumgartnerI , HiattWR , HeizerG , ConteMS , WhiteCJ , et al.Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation2017;135(3):241-50. [MEDLINE: 27840336]KollsBJ , SappS , RockholdFW , JordanJD , DombrowskiKE , FowkesFG , et al.Stroke in patients with peripheral artery disease. Stroke2019;50(6):1356-63. [MEDLINE: 31092165]Low WangCC , BlomsterJI , HeizerG , BergerJS , BaumgartnerI , FowkesFG , et al.Cardiovascular and limb outcomes in patients with diabetes and peripheral artery disease: the EUCLID trial. Journal of the American College of Cardiology2018;72(25):3274-84. [MEDLINE: 30573030]NorgrenL , PatelMR , HiattWR , WojdylaDM , FowkesFG , BaumgartnerI , et al.Outcomes of patients with critical limb ischaemia in the EUCLID trial. European Journal of Vascular &amp; Endovascular Surgery2018;55(1):109-17. [MEDLINE: 29273390]OlivierCB , MulderH , HiattWR , JonesWS , FowkesFG , RockholdFW , et al.Incidence, characteristics, and outcomes of myocardial infarction in patients with peripheral artery disease: insights from the EUCLID trial. JAMA Cardiology2019;4(1):7-15. [MEDLINE: 30540355]">EUCLID 2017</a>; <a href="./references#CD008834-bbs2-0033" title="BonominiV , VangelistaA , StefoniS , ScolariMP , FrascàGM , RaimondiC .Use of defibrotide in renal transplantation in man. Haemostasis1986;16 Suppl 1:48-50. [MEDLINE: 3519383]FrascàGM , VangelistaA , RaimondiC , BonominiV .Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (defibrotide): a controlled study. Life Support Systems1986;4(3):231-7. [MEDLINE: 3537545]">Frascà 1986</a>; <a href="./references#CD008834-bbs2-0047" title="HidakaS , KobayashiS , IwagamiM , IsshikiR , TsutsumiD , MochidaY , et al.Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease. Renal Failure2013;35(1):43-8. [MEDLINE: 23110683]">Hidaka 2013</a>; <a href="./references#CD008834-bbs2-0052" title="OhtakeT , SatoM , NakazawaR , KondohM , KobayashiS .Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study [abstract no: Su528]. NDT Plus2010;3(Suppl 3):iii487. [EMBASE: 70484748]OhtakeT , SatoM , NakazawaR , KondohM , MiyajiT , MoriyaH , et al.Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2014;18(1):1-8. [MEDLINE: 24499078]">J‐PADD 2014</a>; <a href="./references#CD008834-bbs2-0055" title="KauffmannHM , AdamsMB , HebertLA , WalczakPM .Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905 ]">Kauffmann 1980</a>; <a href="./references#CD008834-bbs2-0057" title="KhajehdehiP , RoozbehJ , MostafaviH .A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scandinavian Journal of Urology &amp; Nephrology2002;36(2):145-8. [MEDLINE: 12028688]">Khajehdehi 2002</a>; <a href="./references#CD008834-bbs2-0062" title="LiangJ , WangZ , ShiD , LiuY , ZhaoY , HanH , et al.High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. Angiology2015;66(4):319-25. [MEDLINE: 24913197]">Liang 2015</a>; <a href="./references#CD008834-bbs2-0066" title="MovchanEA , ChuprovaAV , TovNL , Vol'vichNV .Desaggregation therapy of acute glomerulonephritis [Dezagregatsionnaia terapiia ostrogo glomerulonefrita]. Klinicheskaia Meditsina2001;79(12):44-7. [MEDLINE: 11840813]">Movchan 2001</a>; <a href="./references#CD008834-bbs2-0073" title="OgawaS , MoriT , NakoK , IshizukaT , ItoS .Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):362-8. [MEDLINE: 18235151]">Ogawa 2008</a>; <a href="./references#CD008834-bbs2-0074" title="HanY .Comparison of the pharmacodynamics and pharmacokinetics of ticagrelor versus clopidogrel in patients with chronic kidney disease and non-ST-elevation acute coronary syndromes (OPT-CKD trial) [abstract no: TCT-483]. Journal of the American College of Cardiology2017;70(18 Suppl 1):B200. [EMBASE: 619771602]WangH , QiJ , LiY , TangY , LiC , LiJ , et al.Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. British Journal of Clinical Pharmacology2018;84(1):88-96. [MEDLINE: 28921624]">OPT‐CKD 2018</a>; <a href="./references#CD008834-bbs2-0075" title="OtaK , TeraokaS , AkiwasaT , MimuraN , HirasawaY , SakaiT , et al.Clinical efficacy of E5510 (satigrel), an antiplatelet agent, for preventing blood clotting in the extracorporeal circuit during hemodialysis (3) - A double-blind comparison with ticlopidine hydrochloride. Rinsho Hyoka1996;24(1):9-38. ">Ota 1996</a>; <a href="./references#CD008834-bbs2-0077" title="KimW , KangWY , WooJS .Objectives: The purpose of this study was to determine the functional impact of cilostazol in patients with chronic kidney disease (CKD) undergoing hemodialysis [abstract no: TCT-497]. Journal of the American College of Cardiology2011;58(20 Suppl 1):B135. [EMBASE: 70581866]WooJS , KimW , HaSJ , JeongKH , LeeTW , IhmCG , et al.A comparison of clopidogrel responsiveness in patients with chronic renal failure: results of the adjunctive cilostazol versus high maintenance dose clopidogrel (PIANO) study [abstract no: AS-252]. American Journal of Cardiology2011;107(8 Suppl 1):100-1A. [EMBASE: 70401953]WooJS , KimW , LeeSR , JungKH , KimWS , LewJH , et al.Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. American Heart Journal2011;162(6):1018-25. [MEDLINE: 22137075]">PIANO‐2 CKD 2011</a>; <a href="./references#CD008834-bbs2-0078" title="JeongKH , ChoJH , WooJS , KimJB , KimWS , LeeTW , et al.Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. American Journal of Kidney Diseases2015;65(6):916-24. [MEDLINE: 25622774]JeongKH , LeeTW , KimJS , LeeSY , LeeSH , MoonJY , et al.Platelet reactivity in patients with end stage renal disease receiving clopidogrel compared with ticagrelor: a randomized crossover study [abstract no: FP610]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii276. [EMBASE: 72207028]WooJS , KimW , KimHS , HwangSJ , KimJB , KimSJ , et al.Randomized assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with chronic kidney disease performing hemodialysis [abstract]. European Heart Journal2014;35(Suppl 1):7-8. [EMBASE: 71646762]">PIANO‐3 2015</a>; <a href="./references#CD008834-bbs2-0079" title="KimJS , LeeTW , IhmC , LeeSH , KimSY , LeeSY , et al.Relationship of ticagrelor dose and platelet reactivity in patients with end stage renal disease on hemodialysis [abstract no: FR-PO727]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):529A. KimJS , WooJS , KimJB , KimWS , LeeTW , KimKS , et al.The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. International Journal of Cardiology2017;238:110-6. [MEDLINE: 28342632]KimW , WooJS , KimWS , KimJB , KimHO , KimJM .Pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis [abstract]. European Heart Journal2016;37(Suppl 1):636. [EMBASE: 612284362]">PIANO‐6 2017</a>; <a href="./references#CD008834-bbs2-0081" title="AkerblomA , WallentinL , LarssonA , SiegbahnA , BeckerRC , BudajA , et al.Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study. Clinical Chemistry2013;59(9):1369-75. [MEDLINE: 23698074]AkerblomA , WallentinL , SiegbahnA , BeckerRC , BudajA , HorrowJ , et al.Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. American Heart Journal2012;164(5):728-34. [MEDLINE: 23137503]AndellP , JamesSK , CannonCP , CyrDD , HimmelmannA , HustedS , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Journal of the American Heart Association2015;4(10):e002490. [MEDLINE: 26452988]ArmstrongPW , SihaH , FuY , WesterhoutCM , StegPG , JamesSK , et al.ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation2012;125(3):514-21. [MEDLINE: 22179530]ArmstrongPW , WesterhoutCM , FuY , HarringtonRA , StoreyRF , KatusH , et al.Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. American Journal of Medicine2013;126(8):723-9. [MEDLINE: 23795897]BeckerRC , BassandJP , BudajA , WojdylaDM , JamesSK , CornelJH , et al.Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial [Erratum in: Eur Heart J. 2012 Nov;33(21):2750]. European Heart Journal2011;32(23):2933-44. [MEDLINE: 22090660]BellaviaA , WallentinL , OrsiniN , JamesSK , CannonCP , HimmelmannA , et al.Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. Open Heart2017;4(2):e000557. [MEDLINE: 28761675]BrilakisES , HeldC , MeierB , CoolsF , ClaeysMJ , CornelJH , et al.Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. American Heart Journal2013;166(3):474-80. [MEDLINE: 24016496]BuiAH , CannonCP , StegPG , StoreyRF , HustedS , GuoJ , et al.Relationship between early and late nonsustained ventricular tachycardia and cardiovascular death in patients with acute coronary syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation: Arrhythmia and Electrophysiology2016;9(2):e002951. [MEDLINE: 26810596]CapodannoD , CalviV , TamburinoC .Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment. Journal of Cardiovascular Medicine2012;13(2):162-3. [MEDLINE: 22237463]CornelJH , BeckerRC , GoodmanSG , HustedS , KatusH , SantosoA , et al.Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2012;164(3):334-42. [MEDLINE: 22980299]CowperPA , PanW , AnstromKJ , KaulP , WallentinL , Davidson-RayL , et al.Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. Journal of the American College of Cardiology2015;65(5):465-76. [MEDLINE: 25660925]DiNicolantonioJJ , D'AscenzoF , TomekA , ChatterjeeS , NiaziAK , Biondi-ZoccaiG .Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial. International Journal of Cardiology2013;168(3):1739-44. [MEDLINE: 23907035]DiNicolantonioJJ , TomekA .Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial. International Journal of Cardiology2013;168(4):4076-80. [MEDLINE: 23911266]DiNicolantonioJJ , TomekA .Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel. International Journal of Cardiology2013;169(2):145-6. [MEDLINE: 24120213]DucrocqG , SchultePJ , BeckerRC , CannonCP , HarringtonRA , HeldC , et al.Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. Eurointervention2015;11(7):737-45. [MEDLINE: 25254357]FranchiF , JamesSK , GhukasyanLT , BudajAJ , CornelJH , KatusHA , et al.Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y12 receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. Journal of the American Heart Association2019;8(6):e011139. [MEDLINE: 30857464]GiannitsisE , WallentinL , JamesSK , BertilssonM , SiegbahnA , StoreyRF , et al.Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: a Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. European Heart Journal: Acute Cardiovascular Care2017;6(6):500-10. [MEDLINE: 27044282]HagstromE , JamesSK , BertilssonM , BeckerRC , HimmelmannA , HustedS , et al.Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. European Heart Journal2016;37(16):1325-33. [MEDLINE: 26417057]HeldC , AsenbladN , BassandJP , BeckerRC , CannonCP , ClaeysMJ , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology2011;57(6):672-84. [MEDLINE: 21194870]HustedS , JamesS , BeckerRC , HorrowJ , KatusH , StoreyRF , et al.Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circulation. Cardiovascular Quality &amp; Outcomes2012;5(5):680-8. [MEDLINE: 22991347]HustedS , JamesSK , BachRG , BeckerRC , BudajA , HerasM , et al.The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal2014;35(23):1541-50. [MEDLINE: 24682844]JamesS , AkerblomA , CannonCP , EmanuelssonH , HustedS , KatusH , et al.Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2009;157(4):599-605. [MEDLINE: 19332184]JamesS , AngiolilloDJ , CornelJH , ErlingeD , HustedS , KontnyF , et al.Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal2010;31(24):3006-16. [MEDLINE: 20802246]JamesS , BudajA , AylwardP , BuckKK , CannonCP , CornelJH , et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2010;122(11):1056-67. [MEDLINE: 20805430]JamesS , BudajA , AylwardP , BuckKK , CannonCP , CornelJH , et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation2010;122(11):1056-67. [MEDLINE: 20805430]JamesSK , RoeMT , CannonCP , CornelJH , HorrowJ , HustedS , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ2011;342:d3527. [MEDLINE: 21685437]JohanssonA , ErikssonN , BeckerRC , StoreyRF , HimmelmannA , HagstromE , et al.NLRC4 inflammasome is an important regulator of interleukin-18 levels in patients with acute coronary syndromes: genome-wide association study in the PLATelet inhibition and patient Outcomes Trial (PLATO). Circulation. Cardiovascular Genetics2015;8(3):498-506. [MEDLINE: 25747584]KangHJ , ClareRM , GaoR , HeldC , HimmelmannA , JamesSK , et al.Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal2015;169(6):899-905. [MEDLINE: 26027629]KholaifN , ZhengY , JagasiaP , HimmelmannA , JamesSK , StegPG , et al.Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex. American Journal of Medicine2015;128(8):914-9. [MEDLINE: 25818495]KohliP , WallentinL , ReyesE , HorrowJ , HustedS , AngiolilloDJ , et al.Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation2013;127(6):673-80. [MEDLINE: 23277305]KontnyF , UelandT , AukrustP , MichelsenAE , BeckerRC , BertilssonM , et al.Pentraxin 3 (PTX3) predict adverse outcome in acute coronary syndromes-a PLATO biomarker substudy [abstract]. European Heart Journal2014;35(Suppl 1):319. [EMBASE: 71647923]KotsiaA , BrilakisES , HeldC , CannonC , StegGP , MeierB , et al.Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2014;168(1):68-75. [MEDLINE: 24952862]KunadianV , JamesSK , WojdylaDM , ZorkunC , WuJ , StoreyRF , et al.Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). Jacc: Cardiovascular Interventions2013;6(7):671-83. [MEDLINE: 23866179]LevinLA , WallentinL , BernfortL , AnderssonD , StoreyRF , BergstromG , et al.Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. Value in Health2013;16(4):574-80. [MEDLINE: 23796291]LindholmD , VarenhorstC , CannonCP , HarringtonRA , HimmelmannA , MayaJ , et al.Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal2014;35(31):2083-93. [MEDLINE: 24727884]MahaffeyKW , HeldC , WojdylaDM , JamesSK , KatusHA , HustedS , et al.Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology2014;63(15):1493-9. [MEDLINE: 24561148]MahaffeyKW , WojdylaDM , CarrollK , BeckerRC , StoreyRF , AngiolilloDJ , et al.Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2011;124(5):544-54. [MEDLINE: 21709065]NikolicE , JanzonM , HauchO , WallentinL , HenrikssonM , PLATO Health Economic Substudy Group.Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. European Heart Journal2013;34(3):220-8. [MEDLINE: 22719022]OhmanEM , RoeMT .Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany &quot;Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified&quot; (Thromb Haemost 2011; 105.5). Thrombosis &amp; Haemostasis2011;105(5):763-5. [MEDLINE: 21394382]ParkerWA , ErikssonN , BeckerRC , VooraD , AkerblomA , HimmelmannA , et al.Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets2019;30(5):579-88. [MEDLINE: 29851527]PatelMR , BeckerRC , WojdylaDM , EmanuelssonH , HiattWR , HorrowJ , et al.Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. European Journal of Preventive Cardiology2015;22(6):734-42. [MEDLINE: 24830710]Pollack CV Jr, DavoudiF , DiercksDB , BeckerRC , JamesSK , LimST , et al.Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clinical Cardiology2017;40(6):390-8. [MEDLINE: 28598510]RoguinA , MusallamA .Letter by Roguin and Musallam regarding article, &quot;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial&quot;. Circulation2014;129(19):e493. [MEDLINE: 24821831]SciricaBM , BansilalS , DavoudiF , ArmstrongPW , ClareRM , SchultePJ , et al.Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. American Heart Journal2018;202:54-60. [MEDLINE: 29859968]SciricaBM , CannonCP , EmanuelssonH , MichelsonEL , HarringtonRA , HustedS , et al.The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. Journal of the American College of Cardiology2011;57(19):1908-16. [MEDLINE: 21545948]SerebruanyVL , FortmannSD , CherepanovV , LitvinovO , KimMH , MarciniakTA .Excess ticagrelor mortality in the food and drug administration adverse event reporting system: time to recount PLATO trial deaths. American Journal of Medicine2017;130(6):e245-6. [MEDLINE: 28161342]SerebruanyVL .Angiographic outcomes contradict platelet data in the PLATO trial: confusion over official trial substudies. Cardiology2014;127(3):190-5. [MEDLINE: 24457905]SerebruanyVL .Discrepancies in the primary PLATO trial publication and the FDA reviews. International Journal of Cardiology2014;172(1):8-10. [MEDLINE: 24456868]SerebruanyVL .Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review. American Journal of Therapeutics2012;19(2):160-1. [MEDLINE: 22395000]SerebruanyVL .The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent. Cardiology2011;120(3):169-71. [MEDLINE: 22418766]ShimadaYJ , BansilalS , WiviottSD , BeckerRC , HarringtonRA , HimmelmannA , et al.Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal2016;177:1-8. [MEDLINE: 27297843]SihaH , DasD , FuY , ZhengY , WesterhoutCM , StoreyRF , et al.Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. CMAJ Canadian Medical Association Journal2012;184(10):1135-42. [MEDLINE: 22546885]StegPG , HarringtonRA , EmanuelssonH , KatusHA , MahaffeyKW , MeierB , et al.Response to letter regarding article, &quot;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial&quot;. Circulation2014;129(19):e494-5. [MEDLINE: 24821832]StegPG , HarringtonRA , EmanuelssonH , KatusHA , MahaffeyKW , MeierB , et al.Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation2013;128(10):1055-65. [MEDLINE: 23900047]StegPG , JamesS , HarringtonRA , ArdissinoD , BeckerRC , CannonCP , et al.Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation2010;122(21):2131-41. [MEDLINE: 21060072]StoreyRF , AngiolilloDJ , PatilSB , DesaiB , EcobR , HustedS , et al.Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. Journal of the American College of Cardiology2010;56(18):1456-62. [MEDLINE: 20832963]StoreyRF , ArdissinoD , VignaliL , CairnsR , BeckerRC , CannonCP , et al.Ischaemic events and stent thrombosis following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study. Thrombosis &amp; Haemostasis2018;118(2):427-9. [MEDLINE: 29443375]StoreyRF , BeckerRC , HarringtonRA , HustedS , JamesSK , CoolsF , et al.Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. European Heart Journal2011;32(23):2945-53. [MEDLINE: 21804104]StoreyRF , BeckerRC , HarringtonRA , HustedS , JamesSK , CoolsF , et al.Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). American Journal of Cardiology2011;108(11):1542-6. [MEDLINE: 21890085]StoreyRF , JamesSK , SiegbahnA , VarenhorstC , HeldC , YcasJ , et al.Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets2014;25(7):517-25. [MEDLINE: 24127651]SumayaW , WallentinL , JamesSK , SiegbahnA , GabryschK , BertilssonM , et al.Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. European Heart Journal2018;39(13):1078-85. [MEDLINE: 29390064]UelandT , AkerblomA , GhukasyanT , MichelsenAE , AukrustP , BeckerRC , et al.Osteoprotegerin is associated with major bleeding but not with cardiovascular outcomes in patients with acute coronary syndromes: insights from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American Heart Association2018;7(2):e007009. [MEDLINE: 29330256]UelandT , MichelsenA , AukrustP , BeckerR , BertilssonM , JamesSK , et al.Chemokine (CXC motif) ligand 16 (CXCL16) and osteoprotegerin (OPG) as predictors of outcome in patients with acute coronary syndromes (ACS) a PLATO biomarker substudy [abstract]. European Heart Journal2014;35(Suppl 1):486. [EMBASE: 71648554]WallentinL , BeckerRC , BudajA , CannonCP , EmanuelssonH , HeldC , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2009;361(11):1045-57. [MEDLINE: 19717846]WallentinL , BeckerRC , CannonCP , HeldC , HimmelmannA , HustedS , et al.No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. International Journal of Cardiology2014;176(1):300-2. [MEDLINE: 25005338]WallentinL , BeckerRC , CannonCP , HeldC , HimmelmannA , HustedS , et al.Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. International Journal of Cardiology2014;170(3):e59-62. [MEDLINE: 24299581]WallentinL , BeckerRC , JamesSK , HarringtonRA .The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. &quot;Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified&quot; (Thromb Haemost 2011; 105.5). Thrombosis &amp; Haemostasis2011;105(5):760-2. [MEDLINE: 21394383]WallentinL , JamesS , StoreyRF , ArmstrongM , BarrattBJ , HorrowJ , et al.Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet2010;376(9749):1320-8. [MEDLINE: 20801498]WallentinL , LindholmD , SiegbahnA , WernrothL , BeckerRC , CannonCP , et al.Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2014;129(3):293-303. [MEDLINE: 24170388]">PLATO 2009</a>; <a href="./references#CD008834-bbs2-0088" title="CooperCJ , HallerST , ColyerW , SteffesM , BurketMW , ThomasWJ , et al.Embolic protection and platelet inhibition during renal artery stenting. Circulation2008;117(21):2752-60. [MEDLINE: 18490527]HeW , CheJ , ZhanD , DawsoT , KanjwaS , HalleS , et al.Time dependant changes in systolic blood pressure after renal artery stenting: role of stenosis severity [abstract no: 14283]. Circulation2012;126(21 Suppl 1). [EMBASE: 70958797]KanjwalK , CooperCJ , VirmaniR , HallerS , ShapiroJI , BurketMW , et al.Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy. Catheterization &amp; Cardiovascular Interventions2010;76(1):16-23. [MEDLINE: 20209644]KanjwalK , HallerS , SteffesM , VirmaniR , ShapiroJI , BurketMW , et al.Complete versus partial distal embolic protection during renal artery stenting. Catheterization &amp; Cardiovascular Interventions2009;73(6):725-30. [MEDLINE: 19198007]TianJ , HallerS , PeriyasamyS , BrewsterP , ZhangH , AdlakhaS , et al.Renal ischemia regulates marinobufagenin release in humans. Hypertension2010;56(5):914-9. [MEDLINE: 20823380]YuH , ZhangD , HallerS , KanjwalK , ColyerW , BrewsterP , et al.Determinants of renal function in patients with renal artery stenosis. Vascular Medicine2011;16(5):331-8. [MEDLINE: 21908683]">RESIST 2008</a>; <a href="./references#CD008834-bbs2-0092" title="SchneppM , TeichlerS , MarkauS , RettkowskiO , PriesackJ , DeuberHJ , et al.Platelet function analysis during therapy with clopidogrel in endstage renal disease [abstract]. In: 37th Congress. European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17-20; Nice, France. 2000:191. [CENTRAL: CN-00461687] ">Schnepp 2000</a>; <a href="./references#CD008834-bbs2-0094" title="SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract no: 9P]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):388. [CENTRAL: CN-00485981] SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study. Kidney International1994;45(5):1477-83. [MEDLINE: 8072261]">Sreedhara 1994</a>; <a href="./references#CD008834-bbs2-0098" title="TaberT , MaikranzP , HaagB , DilleyR , GaylordG .Hemodialysis vascular graft stenosis may be altered by low-molecular weight dextran (LMD), but not by aspirin (ASA) [abstract]. Journal of the American Society of Nephrology1992;3(3):397. [CENTRAL: CN-00858239] ">Taber 1992</a>; <a href="./references#CD008834-bbs2-0100" title="BergerPB , BestPJ , TopolEJ , WhiteJ , DiBattistePM , ChanAW , et al.The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal2005;149(5):869-75. [MEDLINE: 15894970]KalyanasundaramA , BlankenshipJC , BergerP , HerrmannH , McClureR , MoliternoD .Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?). Catheterization &amp; Cardiovascular Interventions2007;69(5):623-9. [MEDLINE: 17192960]MoliternoDJ , TopolEJ .A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. American Heart Journal2000;140(5):722-6. [MEDLINE: 11054616]MoliternoDJ , YakubovSJ , DiBattistePM , HerrmannHC , StoneGW , MacayaC , et al.Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet2002;360(9330):355-60. [MEDLINE: 12241774]MukherjeeD , TopolEJ , BertrandME , KristensenSD , HerrmannHC , NeumannFJ , et al.Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. European Heart Journal2005;26(23):2524-8. [MEDLINE: 16107485]RoffiM , MoliternoDJ , MeierB , PowersER , GrinesCL , DiBattistePM , et al.Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation2002;105(23):2730-6. [MEDLINE: 12057986]TopolEJ , MoliternoDJ , HerrmannHC , PowersER , GrinesCL , CohenDJ , et al.Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New England Journal of Medicine2001;344(25):1888-94. [MEDLINE: 11419425]">TARGET 2000</a>; <a href="./references#CD008834-bbs2-0102" title="TengR , MuldowneyS , ZhaoY , BergJK , LuJ , KhanND .Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. European Journal of Clinical Pharmacology2018;74(9):1141-8. [MEDLINE: 29850937]">Teng 2018</a>; <a href="./references#CD008834-bbs2-0105" title="AbaciA .The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses [Prasugrelin ST yukselmeli ve yukselmesiz miyokart enfarktusunde kullanimi: TRITON TIMI 38 caIismasi ve alt grup sonuclari]. Turk Kardiyoloji Dernegi Arsivi2015;43 Suppl 2:1-6. [MEDLINE: 27326444]AntmanEM , WiviottSD , MurphySA , VoitkJ , HasinY , WidimskyP , et al.Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Journal of the American College of Cardiology2008;51(21):2028-33. [MEDLINE: 18498956]BonacaMP , WiviottSD , BraunwaldE , MurphySA , RuffCT , AntmanEM , et al.American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation2012;125(4):577-83. [MEDLINE: 22199016]CapodannoD , TamburinoC .Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International Journal of Cardiology2011;146(2):242-3. [MEDLINE: 21130510]DammanP , deWinterRJ , WallentinL , FoxKA .Letter by Damman et al regarding articles, &quot;Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)&quot; and &quot;American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)&quot;. Circulation2012;126(9):e136-7. [MEDLINE: 22927480]De ServiS , GoedickeJ , SchirmerA , WidimskyP .Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European Heart Journal: Acute Cardiovascular Care2014;3(4):363-72. [MEDLINE: 24818952]GoodnoughLT , SmithPK , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. Journal of Thoracic &amp; Cardiovascular Surgery2013;145(4):1077-82. [MEDLINE: 22995726]HochholzerW , WiviottSD , AntmanEM , ContantCF , GuoJ , GiuglianoRP , et al.Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation2011;123(23):2681-9. [MEDLINE: 21606391]KohliP , UdellJA , MurphySA , CannonCP , AntmanEM , BraunwaldE , et al.Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Journal of the American College of Cardiology2014;63(3):225-32. [MEDLINE: 24140678]MahoneyEM , WangK , ArnoldSV , ProskorovskyI , WiviottS , AntmanE , et al.Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation2010;121(1):71-9. [MEDLINE: 20026770]MarianiM , MarianiG , De ServiS .Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert Review of Cardiovascular Therapy2009;7(1):17-23. [MEDLINE: 19105763]MegaJL , CloseSL , WiviottSD , ShenL , WalkerJR , SimonT , et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet2010;376(9749):1312-9. [MEDLINE: 20801494]MichelsonAD , Frelinger AL 3rd, BraunwaldE , DowneyWE , AngiolilloDJ , XenopoulosNP , et al.Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal2009;30(14):1753-63. [MEDLINE: 19435740]MogabgabO , WiviottSD , CannonCP , SloanS , SabatineMS , AntmanEM , et al.Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(6):555-9. [MEDLINE: 24064010]MontalescotG , WiviottSD , BraunwaldE , MurphySA , GibsonCM , McCabeCH , et al.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet2009;373(9665):723-31. [MEDLINE: 19249633]MurphySA , AntmanEM , WiviottSD , WeerakkodyG , MorocuttiG , HuberK , et al.Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European Heart Journal2008;29(20):2473-9. [MEDLINE: 18682445]O'DonoghueM , AntmanEM , BraunwaldE , MurphySA , StegPG , FinkelsteinA , et al.The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology2009;54(8):678-85. [MEDLINE: 19679245]OjeifoO , WiviottSD , AntmanEM , MurphySA , UdellJA , BatesER , et al.Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Jacc: Cardiovascular Interventions2013;6(2):1275-81. [MEDLINE: 24239201]PakhomovIM .Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial. Kardiologiia2010;50(6):63-7. [MEDLINE: 20659030]PrideYB , TungP , MohanaveluS , ZorkunC , WiviottSD , AntmanEM , et al.Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. Jacc: Cardiovascular Interventions2010;3(8):306-11. [MEDLINE: 20723851]RiesmeyerJS , SalazarDE , WeerakkodyGJ , NiL , WrishkoRE , Ernest CS 2nd, et al.Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. Journal of Clinical Pharmacology2012;52(6):789-97. [MEDLINE: 21628601]SerebruanyVL .Letter by Serebruany regarding article, &quot;Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38&quot;. Circulation2010;122(8):e436. [MEDLINE: 20733108]SmithPK , GoodnoughLT , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology2012;60(5):388-96. [MEDLINE: 22633653]SorichMJ , VitryA , WardMB , HorowitzJD , McKinnonRA .Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis &amp; Haemostasis2010;8(8):1678-84. [MEDLINE: 20492467]UdellJA , BraunwaldE , AntmanEM , MurphySA , MontalescotG , WiviottSD .Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).[Erratum in: JACC Cardiovasc Interv. 2014 Aug;7(8):946 Note: Antman, Elliot M [Corrected to Antman, Elliott M]]. Jacc: Cardiovascular Interventions2014;7(6):604-12. [MEDLINE: 24947719]WilcoxR , IqbalK , CostiganT , Lopez-SendonJ , RamosY , WidimskyP .An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current Medical Research &amp; Opinion2014;30(11):2193-205. [MEDLINE: 25025610]WiviottSD , AntmanEM , GibsonCM , MontalescotG , RiesmeyerJ , WeerakkodyG , et al.Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). American Heart Journal2006;152(4):627-35. [MEDLINE: 16996826]WiviottSD , BraunwaldE , McCabeCH , HorvathI , KeltaiM , HerrmanJP , et al.Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet2008;371(9621):1353-63. [MEDLINE: 18377975]WiviottSD , BraunwaldE , McCabeCH , MontalescotG , RuzylloW , GottliebS , et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2007;357(20):2001-15. [MEDLINE: 17982182]WiviottSD , DesaiN , MurphySA , MusumeciG , RagostaM , AntmanEM , et al.Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. American Journal of Cardiology2011;108(7):905-11. [MEDLINE: 21816379]WrishkoRE , Ernest CS 2nd, SmallDS , LiYG , WeerakkodyGJ , RiesmeyerJR , et al.Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. Journal of Clinical Pharmacology2009;49(8):984-98. [MEDLINE: 19546250]">TRITON‐TIMI 38 2006</a>; <a href="./references#CD008834-bbs2-0107" title="WasedaK , SakaY , TakashimaH , KuritaA , AndoH , SakuraiS , et al.Effect of CYP2C19 genotype on inhibition of platelet aggregation in hemodialysis patients with coronary artery disease [abstract]. Circulation2016;134(Suppl 1):A14237. [EMBASE: 619219587]">Waseda 2016</a>; <a href="./references#CD008834-bbs2-0110" title="XydakisD , PapadagiannakisA , SfakianakiM , VakoutiE , PapachristoforouK .The combination of clopidogrel (CL) and acetylsalicylic acid (ASA) inhibits more effective the platelet activation in haemodialysis patients with acute coronary syndromes (ACS) and high C reactive protein [abstract no: MP370]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:355. [CENTRAL: CN-00509568] ">Xydakis 2004</a>; <a href="./references#CD008834-bbs2-0111" title="YangMY , HanB , XuY , TianLY , ZhangY , QiangYW .The effects of different dose of clopidogrel in elderly patients with unstable angina combining chronic kidney disease [abstract no: P12]. Journal of the American Geriatrics Society2016;64(Suppl 2):S320. [EMBASE: 611887576]">Yang 2016b</a>). </p> </li> </ul> </p> <section id="CD008834-sec-0043"> <h5 class="title">Antiplatelet versus placebo or no treatment studies</h5> <p>Ninety studies comparing an antiplatelet to placebo or no treatment were published between 1974 and 2018. The number of CKD participants ranged from 6 to 4983 participants (median 85 participants) and the mean age of the participants ranged from 29 to 73.4 years. The duration of study follow‐up ranged from 48 hours to 88.2 months (median six months). </p> <p> <ul id="CD008834-list-0015"> <li> <p>Forty‐nine studies were conducted in people with CKD not yet requiring dialysis (37,013 participants: <a href="./references#CD008834-bbs2-0001" title="GoicoecheaM , deVinuesaMS , QuirogaB , VerdallesU , MoralesE , De SequeraP , et al.Aspirin treatment in primary cardiovascular prevention and renal disease progression in CKD patients: a randomized clinical trials (AASER study) [abstract no: FR-PO1065]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):B5. [EMBASE: 633704620]GoicoecheaM , deVinuesaSG , QuirogaB , VerdeE , BernisC , MoralesE , et al.Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study). Cardiovascular Drugs &amp; Therapy2018;32(3):255-63. [MEDLINE: 29943364]GoicoecheaM , Sanchez-NinoMD , OrtizA , deVinuesaMS , QuirogaB , MoralesE , et al.Low dose aspirin increases 15-epi-lipoxin a4 levels in CKD patients [abstract no: SA-PO186]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):726. [EMBASE: 633701100]GoicoecheaM , Sanchez-NinoMD , OrtizA , Garcia de VinuesaS , QuirogaB , BernisC , et al.Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. Prostaglandins Leukotrienes &amp; Essential Fatty Acids2017;125:8-13. [MEDLINE: 28987723]">AASER 2017</a>; <a href="./references#CD008834-bbs2-0007" title="Di FrancoA , GaudinoM , GirardiLN .Considerations about the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. Journal of Thoracic Disease2016;8(7):E599. [MEDLINE: 27501533]MylesPS , SmithJ , KnightJ , CooperDJ , SilbertB , McNeilJ , et al.Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial: rationale and design. American Heart Journal2008;155(2):224-30. [MEDLINE: 18215590]MylesPS , SmithJA , ForbesA , SilbertB , JayarajahM , PainterT , et al.Stopping vs. continuing aspirin before coronary artery surgery. New England Journal of Medicine2016;374(8):728-37. [MEDLINE: 26933848]MylesPS , SmithJA , ForbesA , SilbertB , JayarajahM , PainterT , et al.Tranexamic acid in patients undergoing coronary-artery surgery [Erratum for: N Engl J Med. 2017 Jan 12;376(2):136-148; PMID: 27774838]. New England Journal of Medicine2017;376(2):136-48. [MEDLINE: 27774838]MylesPS , SmithJA , KaszaJ , SilbertB , JayarajahM , PainterT , et al.Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial. Journal of Thoracic &amp; Cardiovascular Surgery2019;157(2):633-40. [MEDLINE: 30401528]MylesPS , SmithJA , KaszaJ , SilbertB , JayarajahM , PainterT , et al.Tranexamic acid in coronary artery surgery: one-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. Journal of Thoracic &amp; Cardiovascular Surgery2019;157(2):644-52.e9. [MEDLINE: 30459103]">ATACAS 2008</a>; <a href="./references#CD008834-bbs2-0008" title="FujitaT , YuX , KimS , NakamotoH , OrigasaH , KurumataniH , et al.Effects of sustained-release beraprost sodium in patients with primary glomerular disease or nephrosclerosis: the CASSIOPEIR study [abstract no: SA-PO1096]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):4B. [CENTRAL: CN-01657821] NakamotoH , FujitaT , OrigasaH , IsonoM , KurumataniH , OkadaK , et al.A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrology2014;15:153. [MEDLINE: 25233856]NakamotoH , YuXQ , KimS , OrigasaH , ZhengH , ChenJ , et al.Effects of sustained-release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results. Therapeutic Apheresis &amp; Dialysis2020;24(1):42-55. [MEDLINE: 31119846]">CASSIOPEIR 2014</a>; <a href="./references#CD008834-bbs2-0009" title="ChanMK , KwanSY , ChanKW , YeungCK .Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis. American Journal of Kidney Diseases1987;9(5):417-21. [MEDLINE: 3555016]">Chan 1987</a>; <a href="./references#CD008834-bbs2-0010" title="JingJ , MengX , ZhaoX , LiuL , WangA , PanY , et al.Dual antiplatelet therapy in transient ischemic attack and minor stroke with different infarction patterns: subgroup analysis of the CHANCE randomized clinical trial. JAMA Neurology2018;75(6):711-9. [MEDLINE: 29582084]LiJ , WangY , LinJ , WangD , WangA , ZhaoX , et al.Soluble CD40L is a useful marker to predict future strokes in patients with minor stroke and transient ischemic attack. Stroke2015;46(7):1990-2. [MEDLINE: 26012640]LiJ , ZhaoX , MengX , LinJ , LiuL , WangC , et al.High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome: subanalysis of the clopidogrel in high-risk patients with acute nondisabling cerebrovascular events trial. Stroke2016;47(8):2025-30. [MEDLINE: 27328699]LinY , WangA , LiJ , LinJ , WangD , MengX , et al.Impact of glycemic control on efficacy of clopidogrel in transient ischemic attack or minor stroke patients with CYP2C19 genetic variants. Stroke2017;48(4):998-1004. [MEDLINE: 28289237]LiuL , WongKS , LengX , PuY , WangY , JingJ , et al.Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology2015;85(13):1154-62. [MEDLINE: 26330567]LiZ , WangY , ZhaoX , LiuL , WangD , WangC , et al.Treatment effect of clopidogrel plus aspirin within 12 hours of acute minor stroke or transient ischemic attack. Journal of the American Heart Association2016;5(3):e003038. [MEDLINE: 27001965]MaY , LiuY , XuJ , WangY , WangY , DuF .Effect of dual antiplatelet on recurrent stroke in minor stroke or TIA depends on bodyweight. Therapeutics &amp; Clinical Risk Management2018;14:861-70. [MEDLINE: 29773949]PanY , CaiX , JingJ , MengX , LiH , WangY , et al.Stress hyperglycemia and prognosis of minor ischemic stroke and transient ischemic attack: the CHANCE study (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). Stroke2017;48(11):3006-11. [MEDLINE: 29051218]PanY , JingJ , ChenW , MengX , LiH , ZhaoX , et al.Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE.[Erratum in: Neurology. 2019 Aug 13;93(7):322; PMID: 31405943]. Neurology2017;88(20):1906-11. [MEDLINE: 28424269]PanY , JingJ , LiH , WangY , WangY , HeY , et al.Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA. Neurology2016;87(15):1551-6. [MEDLINE: 27613582]PanY , MengX , JingJ , LiH , ZhaoX , LiuL , et al.Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA. Neurology2017;88(11):1081-8. [MEDLINE: 28202699]WangA , LiS , ZhangN , DaiL , ZuoY , WangY , et al.Oxidized low-density lipoprotein to high-density lipoprotein ratio predicts recurrent stroke in minor stroke or transient ischemic attack. Stroke2018;49(11):2637-42. [MEDLINE: 30355199]WangA , XuJ , ChenG , WangD , JohnstonSC , MengX , et al.Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA. Neurology2018;91(10):e947-55. [MEDLINE: 30089614]WangD , GuiL , DongY , LiH , LiS , ZhengH , et al.Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial. Stroke &amp; Vascular Neurology2016;1(2):29-36. [MEDLINE: 28959461]WangqinR , WangX , WangY , XianY , ZhaoX , LiuL , et al.Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA: a subgroup analysis of the CHANCE trial. Stroke &amp; Vascular Neurology2017;2(4):176-83. [MEDLINE: 29507777]WangY , PanY , ZhaoX , LiH , WangD , JohnstonSC , et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial: one-year outcomes. Circulation2015;132(1):40-6. [MEDLINE: 25957224]WangY , WangY , ZhaoX , LiuL , WangD , WangC , et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine2013;369(1):11-9. [MEDLINE: 23803136]WangY , ZhaoX , LinJ , LiH , JohnstonSC , LinY , et al.Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA2016;316(1):70-8. [MEDLINE: 27348249]WuY , ZhouY , PanY , ZhaoX , LiuL , WangD , et al.Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. Pharmacogenomics Journal2018;18(6):713-20. [MEDLINE: 29520080]ZhouY , PanY , WuY , ZhaoX , LiH , WangD , et al.Effect of estimated glomerular filtration rate decline on the efficacy and safety of clopidogrel with aspirin in minor stroke or transient ischemic attack: CHANCE substudy (Clopidogrel in high-risk patients with acute nondisabling cerebrovascular events). Stroke2016;47(11):2791-6. [MEDLINE: 27738237]ZhuB , LiuH , PanY , JingJ , LiH , ZhaoX , et al.Elevated neutrophil and presence of intracranial artery stenosis increase the risk of recurrent stroke. Stroke2018;49(10):2294-300. [MEDLINE: 30355101]">CHANCE 2013</a>; <a href="./references#CD008834-bbs2-0011" title="BangaloreS , BhattDL , StegPG , WeberMA , BodenWE , HammCW , et al.beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circulation: Cardiovascular Quality &amp; Outcomes2014;7(6):872-81. [MEDLINE: 25271049]BergerPB , BhattDL , FusterV , StegPG , FoxKA , ShaoM , et al.Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation2010;121(23):2575-83. [MEDLINE: 20516378]BhattDL , FlatherMD , HackeW , BergerPB , BlackHR , BodenWE , et al.Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology2007;49(19):1982-8. [MEDLINE: 17498584]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial [Erratum in: Am Heart J. 2006 Jan;151(1):247]. American Heart Journal2005;150(3):401. [MEDLINE: 16169314]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine2006;354(16):1706-17. [MEDLINE: 16531616]DasguptaA , SteinhublSR , BhattDL , BergerPB , ShaoM , MakKH , et al.Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). American Journal of Cardiology2009;103(10):1359-63. [MEDLINE: 19427428]EikelboomJW , HankeyGJ , ThomJ , BhattDL , StegPG , MontalescotG , et al.Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation2008;118(17):1705-12. [MEDLINE: 18838564]MakKH , BhattDL , ShaoM , HaffnerSM , HammCW , HankeyGJ , et al.The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. European Heart Journal2009;30(7):857-65. [MEDLINE: 19233855]SteinhublSR , BhattDL , BrennanDM , MontalescotG , HankeyGJ , EikelboomJW , et al.Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding [Summary for patients in Ann Intern Med. 2009 Mar 17;150(6):I-22; PMID: 19293067]. Annals of Internal Medicine2009;150(6):379-86. [MEDLINE: 19293071]WangTH , BhattDL , FoxKA , SteinhublSR , BrennanDM , HackeW , et al.An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal2007;28(18):2200-7. [MEDLINE: 17673448]">CHARISMA 2006</a>; <a href="./references#CD008834-bbs2-0012" title="ChengIK , FangGX , WongMC , JiYL , ChanKW , YeungHW .A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy. Nephrology1998;4(1-2):19-26. [EMBASE: 28282953]ChengIK , FangGX , WongMC , JiYL , YeungH .A randomised prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA glomerulonephritis (IgAN) [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:45. [CENTRAL: CN-00550664] ">Cheng 1998a</a>; <a href="./references#CD008834-bbs2-0013" title="ChristopherTG , SamelsK .A study of aspirin and dipyridamole in slowing the progression of diabetic glomerulosclerosis [abstract]. Kidney International1987;31(1):194. ChristopherTG , SamelsK .A study of the treatment effect of aspirin and dipyridamole in diabetic glomerulosclerosis [abstract]. In: 10th International Congress of Nephrology; 1987 Jul 26-31; London, UK. 1987:56. ">Christopher 1987</a>; <a href="./references#CD008834-bbs2-0015" title="AronowHD , SteinhublSR , BrennanDM , BergerPB , TopolEJ , CREDO Investigators.Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal2009;157(2):369-74. [MEDLINE: 19185647]BeinartSC , KolmP , VeledarE , ZhangZ , MahoneyEM , BouinO , et al.Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Journal of the American College of Cardiology2005;46(5):761-9. [MEDLINE: 16139122]BestPJ , SteinhublSR , BergerPB , DasguptaA , BrennanDM , SzczechLA , et al.The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal2008;155(4):687-93. [MEDLINE: 18371477]BrenerSJ , SteinhublSR , BergerPB , BrennanDM , TopolEJ , CREDO Investigators.Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial. Journal of Invasive Cardiology2007;19(7):287-90. [MEDLINE: 17620671]RingborgA , LindgrenP , JonssonB .The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. European Journal of Health Economics2005;6(4):354-56, 358-62. [MEDLINE: 16267654]SteinhublSR , BergerPB , Mann JT 3rd, FryET , DeLagoA , WilmerC , et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [Erratum in: JAMA. 2003 Feb 26;289(8):987]. JAMA2002;288(19):2411-20. [MEDLINE: 12435254]">CREDO 2005</a>; <a href="./references#CD008834-bbs2-0017" title="BergerPB , SteinhublS .Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. Circulation2002;106(17):2284-7. [MEDLINE: 12390961]GerschutzGP , BhattDL , Clopidogrel in Unstable Angina to Prevent Recurrent Events study.The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?American Heart Journal2003;145(4):595-601. [MEDLINE: 12679754]KeltaiM , TonelliM , MannJF , SitkeiE , LewisBS , HawkenS , et al.Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. European Journal of Cardiovascular Prevention &amp; Rehabilitation2007;14(2):312-8. [MEDLINE: 17446813]LewisBS , MehtaSR , FoxKA , HalonDA , ZhaoF , PetersRJ , et al.Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. American Heart Journal2005;150(6):1177-84. [MEDLINE: 16338255]MehtaSR , YusufS , PetersRJ , BertrandME , LewisBS , NatarajanMK , et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet2001;358(9281):527-33. [MEDLINE: 11520521]MehtaSR , YusufS , Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators.The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. European Heart Journal2000;21(24):2033-41. [MEDLINE: 11102254]PetersRJ , MehtaSR , FoxKA , ZhaoF , LewisBS , KopeckySL , et al.Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation2003;108(14):1682-7. [MEDLINE: 14504182]YusufS ,  ZhaoF ,  MehtaSR ,  ChrolaviciusS ,  TognoniG ,  FoxKK , et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [Erratum in: N Engl J Med 2001 Dec 6;345(23):1716; Erratum in: N Engl J Med 2001 Nov 15;345(20):1506]. New England Journal of Medicine2001;345(7):494-502. [MEDLINE: 11519503]">CURE 2000</a>; <a href="./references#CD008834-bbs2-0023" title="DonadioJV , AndersonCF , MitchellJC , HolleyKE , IlstrupDM , FusterV .Membranoproliferative glomerulonephritis (MPGN): a prospective clinical trial of platelet inhibitor therapy [abstract]. Kidney International1983;23(1):121. [CENTRAL: CN-00602010] Donadio JV Jr, AndersonCF , Mitchell JC 3rd, HolleyKH , IlstrupDM , FusterV , et al.Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. New England Journal of Medicine1984;310(22):1421-6. [MEDLINE: 6371535]">Donadio 1984</a>; <a href="./references#CD008834-bbs2-0024" title="BagaiA , WhiteJA , LokhnyginaY , GiuglianoRP , Van de WerfF , MontalescotG , et al.Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. American Heart Journal2013;166(3):466-73. [MEDLINE: 24016495]De FerrariGM , Van de WerfF , ArmstrongP , BodeC , LewisBS , TricociP , et al.Contrast induced nephropathy predicts later mortality among patients with non-ST-segment elevation acute coronary syndrome undergoing PCI: a sub-analysis from the EARLY ACS study [abstract no: P3820]. European Heart Journal2011;32(Suppl 1):657. [EMBASE: 70535519]EzekowitzJA , BakalJA , WesterhoutCM , GiuglianoRP , WhiteH , KeltaiM , et al.The relationship between meteorological conditions and index acute coronary events in a global clinical trial. International Journal of Cardiology2013;168(3):2315-21. [MEDLINE: 23416014]FarhanS , ClareRM , JaraiR , GiuglianoRP , LokhnyginaY , HarringtonRA , et al.Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: an analysis from EARLY ACS. International Journal of Cardiology2017;232:264-70. [MEDLINE: 28089149]FarhanS , ClareRM , JaraiR , NewbyLK , MorrowD , GiuglianoRP , et al.Fasting glucose, NT-proBNP, treatment with glycoprotein IIB/IIIA inhibitors, and outcomes in non-st-segment elevation acute coronary syndromes: an analysis from early ACS [abstract no: A14618]. Circulation2013;128(22 Suppl 1). [EMBASE: 71340424]GiuglianoRP , NewbyLK , HarringtonRA , GibsonCM , Van de WerfF , ArmstrongP , et al.The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. American Heart Journal2005;149(6):994-1002. [MEDLINE: 15976780]GiuglianoRP , WhiteJA , BodeC , ArmstrongPW , MontalescotG , LewisBS , et al.Early versus delayed, provisional eptifibatide in acute coronary syndromes. New England Journal of Medicine2009;360(21):2176-90. [MEDLINE: 19332455]HessCN , SchultePJ , NewbyLK , StegPG , DalbyAJ , SchweigerMJ , et al.Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. European Heart Journal: Acute Cardiovascular Care2013;2(3):246-55. [MEDLINE: 24222836]KaulP , TanguayJF , NewbyLK , HochmanJS , WesterhoutCM , CaliffRM , et al.Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. American Heart Journal2013;166(4):723-8. [MEDLINE: 24093853]KlutsteinMW , WesterhoutCM , ArmstrongPW , GiuglianoRP , LewisBS , GibsonCM , et al.Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. American Heart Journal2013;165(4):583-90. [MEDLINE: 23537976]KunadianV , GiuglianoRP , NewbyLK , ZorkunC , GuoJ , BagaiA , et al.Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). American Journal of Cardiology2014;113(8):1297-305. [MEDLINE: 24607027]LopesRD , WhiteJA , TricociP , WhiteHD , ArmstrongPW , BraunwaldE , et al.Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. International Journal of Cardiology2013;167(6):2580-7. [MEDLINE: 22795720]MelloniC , JamesSK , WhiteJA , GiuglianoRP , HarringtonRA , HuberK , et al.Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. American Heart Journal2011;162(5):884-92. [MEDLINE: 22093205]PicciniJP , WhiteJA , MehtaRH , LokhnyginaY , Al-KhatibSM , TricociP , et al.Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. Circulation2012;126(1):41-9. [MEDLINE: 22645292]PrideYB , MohanaveluS , GiuglianoRP , NewbyLK , ZorkunC , KunadianV , et al.Association between angiographic complications during percutaneous coronary intervention and clinical outcomes among patients with acute coronary syndrome: an early ACS angiographic substudy [abstract no: A10394]. Circulation2011;124(21 Suppl 1). [EMBASE: 70620664]PrideYB , MohanaveluS , ZorkunC , KunadianV , GiuglianoRP , NewbyLK , et al.Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. Jacc: Cardiovascular Interventions2012;5(9):927-35. [MEDLINE: 22995880]RoeMT , WhiteJA , KaulP , TricociP , LokhnyginaY , MillerCD , et al.Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. Circulation. Cardiovascular Quality &amp; Outcomes2012;5(2):205-13. [MEDLINE: 22373905]TanguayJF , NewbyLK , HochmanJ , WesterhoutCM , CaliffRM , GibsonCM , et al.Sex differences in high-risk acute coronary syndromes: Insights from early-ACS [abstract]. Journal of the American College of Cardiology2010;55(10 Suppl 1):A120.E1122. [EMBASE: 70096317]TolevaO , WesterhoutCM , SenaratneM , BodeC , LindroosM , ArdissinoD , et al.Association of hub and spoke practice patterns with coronary intervention and outcomes in non ST elevation acute coronary syndromes (NSTE ACS): Insights from the early glycoprotein IIb/IIIa inhibition in NSTE ACS (early-ACS) trial [abstract]. Journal of the American College of Cardiology2011;57(14 Suppl 1):E1101. [EMBASE: 70400778]TolevaO , WesterhoutCM , SenaratneMP , BodeC , LindroosM , SulimovVA , et al.Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial. Catheterization &amp; Cardiovascular Interventions2014;84(6):934-42. [MEDLINE: 24976083]WangT , WhiteJA , GiuglianoRP , TricociP , HarringtonRA , MontalescotG , et al.Upfront clopidogrel use and the efficacy and safety of early eptifibatide use in patients with acute coronary syndrome: An analysis from the early versus delayed provisional eptifibatide in acute coronary syndromes (early ACS) trial [abstract]. Journal of the American College of Cardiology2010;55(10 Suppl 1):A47.E451. [EMBASE: 70095646]WangTY , WhiteJA , TricociP , GiuglianoRP , ZeymerU , HarringtonRA , et al.Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Circulation2011;123(7):722-30. [MEDLINE: 21300952]">EARLY ACS 2005</a>; <a href="./references#CD008834-bbs2-0026" title="AguirreFV , TopolEJ , AndersonKM , KleimanNS , WeismanHF , FitzPatrickSE , et al.Benefit within patient subgroups receiving c7e3 fab (abciximab) during percutaneous coronary revascularization: subgroup analysis from the EPIC trial. Journal of Invasive Cardiology1996;8 Suppl B:21-9B. [MEDLINE: 10785766]AguirreFV , TopolEJ , FergusonJJ , AndersonK , BlankenshipJC , HeuserRR , et al.Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation1995;91(12):2882-90. [MEDLINE: 7796496]BerkowitzSD , SaneDC , SigmonKN , ShavenderJH , HarringtonRA , TchengJE , et al.Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. Journal of the American College of Cardiology1998;32(2):311-9. [MEDLINE: 9708455]BlankenshipJC , HellkampAS , AguirreFV , DemkoSL , TopolEJ , CaliffRM .Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. American Journal of Cardiology1998;81(1):36-40. [MEDLINE: 9462603]BoehrerJD , KereiakesDJ , NavettaFI , CaliffRM , TopolEJ .Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications. American Journal of Cardiology1994;74(11):1166-70. [MEDLINE: 7977081]CaliffRM , LincoffAM , TchengJE , TopolEJ .An overview of the results of the EPIC trial. European Heart Journal1995;16 Suppl L:43-9. [MEDLINE: 8869018]EPIC Investigators.Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New England Journal of Medicine1994;330(14):956-61. [MEDLINE: 8121459]KhanMM , EllisSG , AguirreFV , WeismanHF , WildermannNM , CaliffRM , et al.Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1998;31(1):31-6. [MEDLINE: 9426014]LefkovitsJ , BlankenshipJC , AndersonKM , StonerGL , TalleyJD , WorleySJ , et al.Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. Journal of the American College of Cardiology1996;28(4):849-55. [MEDLINE: 8837559]LefkovitsJ , IvanhoeRJ , CaliffRM , BergelsonBA , AndersonKM , StonerGL , et al.Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. American Journal of Cardiology1996;77(12):1045-51. [MEDLINE: 8644655]LincoffAM , CaliffRM , AndersonKM , WeismanHF , AguirreFV , KleimanNS , et al.Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1997;30(1):149-56. [MEDLINE: 9207636]MakKH , ChallapalliR , EisenbergMJ , AndersonKM , CaliffRM , TopolEJ .Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. American Journal of Cardiology1997;80(8):985-8. [MEDLINE: 9352964]MarkDB , TalleyJD , TopolEJ , BowmanL , LamLC , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation1996;94(4):629-35. [MEDLINE: 8772681]MoliternoDJ , CaliffRM , AguirreFV , AndersonK , SigmonKN , WeismanHF , et al.Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. American Journal of Cardiology1995;75(8):559-62. [MEDLINE: 7887377]NarinsCR , MillerDP , CaliffRM , TopolEJ .The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1999;33(3):647-53. [MEDLINE: 10080464]ThelMC , CaliffRM , TchengJE , SigmonKN , LincoffAM , TopolEJ , et al.Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. American Heart Journal1999;137(2):264-73. [MEDLINE: 9924160]TopolEJ , CaliffRM , WeismanHF , EllisSG , TchengJE , WorleyS , et al.Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet1994;343(8902):881-6. [MEDLINE: 7908357]TopolEJ , FergusonJJ , WeismanHF , TchengJE , EllisSG , KleimanNS , et al.Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA1997;278(6):479-84. [MEDLINE: 9256222]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. American Heart Journal1998;135(4):S98-106. [MEDLINE: 9539500]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. European Heart Journal1998;19 Suppl D:D59-66. [MEDLINE: 9597523]">EPIC 1994</a>; <a href="./references#CD008834-bbs2-0027" title="EPILOG Investigators.Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New England Journal of Medicine1997;336(24):1689-96. [MEDLINE: 9182212]GhaffariS , KereiakesDJ , LincoffAM , KellyTA , TimmisGC , KleimanNS , et al.Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. American Journal of Cardiology1998;82(1):7-12. [MEDLINE: 9671000]KereiakesDJ , LincoffAM , MillerDP , TchengJE , CabotCF , AndersonKM , et al.Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Circulation1998;97(9):857-64. [MEDLINE: 9521334]KleimanNS , LincoffAM , KereiakesDJ , MillerDP , AguirreFV , AndersonKM , et al.Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation1998;97(19):1912-20. [MEDLINE: 9609084]LincoffAM , MarkDB , TchengJE , CaliffRM , BalaMV , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation2000;102(24):2923-9. [MEDLINE: 11113041]LincoffAM , TchengJE , CaliffRM , KereiakesDJ , KellyTA , TimmisGC , et al.Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. One-year outcome in the EPILOG trial. Circulation1999;99(15):1951-8. [MEDLINE: 10208997]">EPILOG 1997</a>; <a href="./references#CD008834-bbs2-0028" title="ChoL , MarsoSP , BhattDL , TopolEJ .Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial. Journal of Womens Health &amp; Gender-Based Medicine2000;9(7):741-6. [MEDLINE: 11025866]De ServiS .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse events. Data from the Evaluation of Platelets IIb/IIIa Inhibitor for Stenting (EPISTENT) trial [Il pretrattamento con ticlopidina nello stent coronarico e associato a significativa riduzione di eventi avversi. Dati dal trial EPISTENT]. Italian Heart Journal Supplement2001;2(7):805-6. [MEDLINE: 11508303]EPISTENT Investigators.Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet1998;352(9122):87-92. [MEDLINE: 9672272]IslamMA , BlankenshipJC , BalogC , IliadisEA , LincoffAM , TchengJE , et al.Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). American Journal of Cardiology2002;90(9):916-21. [MEDLINE: 12398954]LincoffAM .Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial. American Heart Journal2000;139(2 Pt 2):S46-52. [MEDLINE: 10650316]MarsoSP , LincoffAM , EllisSG , BhattDL , TanguayJF , KleimanNS , et al.Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation1999;100(25):2477-84. [MEDLINE: 10604884]SteinhublSR , EllisSG , WolskiK , LincoffAM , TopolEJ .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation2001;103(10):1403-9. [MEDLINE: 11245644]SteinhublSR , TanWA , FoodyJM , TopolEJ .Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA1999;281(9):806-10. [MEDLINE: 10071001]TopolEJ , MarkDB , LincoffAM , CohenE , BurtonJ , KleimanN , et al.Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.[Erratum in: Lancet 2000 Mar 25;355(9209):1104]. Lancet1999;354(9195):2019-24. [MEDLINE: 10636365]Zwart-van RijkomJE , vanHoutBA .Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb/IIIa Inhibitor For Stenting Trial. European Heart Journal2001;22(16):1476-84. [MEDLINE: 11482921]">EPISTENT 1998</a>; <a href="./references#CD008834-bbs2-0029" title="Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA1992;268(10):1292-300. [MEDLINE: 1507375]">ETDRS 1992</a>; <a href="./references#CD008834-bbs2-0034" title="FrascàGM , CiancioloG .A clinical trial with defibrotide in IgA nephritis (IgA-GN) with impaired renal function [abstract]. Nephrology Dialysis Transplantation1995;10(6):968. [CENTRAL: CN-00261099] FrascàGM , MartelloM , CanovaC , IsolaE , VangelistaA , BonominiV .Defibrotide treatment and disease progression in patients with IgA nephropathy and impaired renal function at diagnosis. Clinical Drug Investigation1997;13(4):185-91. [EMBASE: 27192802]FrascàGM , MartelloM , SestigianiE , CanovaC , VangelistaA , BonominiV .Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function. Nephrology Dialysis Transplantation1996;11(2):392-3. [MEDLINE: 8700366]">Frascà 1997</a>; <a href="./references#CD008834-bbs2-0035" title="GaedeP , HansenHP , ParvingHH , PedersenO .Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrology Dialysis Transplantation2003;18(3):539-42. [MEDLINE: 12584276]GaedeP , ParvingH , PedersenO .Lack of impact of low-dose acetylsalisyic acid (ASA) on albuminuria in type 2 diabetic patients [abstract no: A0660]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):128A. [CENTRAL: CN-00583369] ">Gaede 2003</a>; <a href="./references#CD008834-bbs2-0038" title="GiustinaA , PeriniP , DesenzaniP , BossoniS , IannielloP , MilaniM , et al.Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes1998;47(3):423-30. [MEDLINE: 9519749]">Giustina 1998</a>; <a href="./references#CD008834-bbs2-0039" title="GaoC , TomaniakM , TakahashiK , KawashimaH , WangR , HaraH , et al.Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovascular Diabetology2020;19(1):179. [MEDLINE: 33066794]TomaniakM , ChichareonP , Klimczak-TomaniakD , TakahashiK , KogameN , ModoloR , et al.Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Clinical Research in Cardiology2020;109(7):930-43. [MEDLINE: 31925529]VranckxP , ValgimigliM , JuniP , HammC , StegPG , HegD , et al.Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet2018;392(10151):940-9. [MEDLINE: 30166073]">GLOBAL LEADERS 2018</a>; <a href="./references#CD008834-bbs2-0040" title="deMoralesAM , GoicoecheaM , VerdeE , CarbayoJ , BarbieriD , DelgadoA , et al.Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial. Journal of Nephrology2019;32(4):581-7. [MEDLINE: 30949987]GoicoecheaM , Garcia de VinuesaS , QuirogaB , VerdallesU , BarracaD , YusteC , et al.Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. Journal of Nephrology2012;25(6):969-75. [MEDLINE: 22241639]">Goicoechea 2012</a>; <a href="./references#CD008834-bbs2-0041" title="GonzalezMT , CastelaoAM , VallesM , CruzadoJM , MauriJM .Platelet antiaggregants (PA) could decrease the rate of progression of chronic renal failure (CRF) in diabetic patients (DP) treated previously with angiotensin converting enzyme inhibitors (ACEi) [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:200. [CENTRAL: CN-00509215] ">Gonzalez 1995</a>; <a href="./references#CD008834-bbs2-0044" title="GuoZ , HasbachJ , KoschinskyT .Effect of acetylsalicylic acid on renal function of Type 1 diabetic patients with microalbuminuria [Wirkung von Azetylsalizylsaure auf die Nierenfunktion bei Typ-1- Diabetikern mit Mikroalbuminurie. Placebokontrollierte Crossover-Pilotstudie]. Diabetes und Stoffwechsel1998;7(2):41-7. [EMBASE: 28146337]">Guo 1998</a>; <a href="./references#CD008834-bbs2-0045" title="HansenHP , GaedePH , JensenBR , ParvingHH .Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria. Diabetes Care2000;23(12):1742-5. [MEDLINE: 11128344]">Hansen 2000</a>; <a href="./references#CD008834-bbs2-0048" title="HanssonL , ZanchettiA , CarruthersSG , DahlöfB , ElmfeldtD , JuliusS , et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998;351(9118):1755-62. [MEDLINE: 9635947]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Pressure1997;6(5):313-7. [MEDLINE: 9360003]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Pressure1994;3(5):322-7. [MEDLINE: 7866597]HanssonL .The Hypertension Optimal Treatment study and the importance of lowering blood pressure. Journal of Hypertension - Supplement1999;17(1):S9-13. [MEDLINE: 10340838]JardineM , NinomiyaT , CassA , TurnbullF , GallagherM , ZoungasS , et al.Aspirin benefit increases as eGFR declines: results from a randomised controlled trial in a hypertensive population [abstract no: 086]. Nephrology2010;15(Suppl 4):49. [EMBASE: 70467090]JardineMJ , NinomiyaT , PerkovicV , CassA , TurnbullF , GallagherMP , et al.Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology2010;56(12):956-65. [MEDLINE: 20828648]JonesDW , MillerME , WoffordMR , Anderson DC Jr, CameronME , WilloughbyDL , et al.The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. American Journal of Hypertension1999;12(12 Pt 1-2):1175-80. [MEDLINE: 10619579]JonssonB , HanssonL , StalhammarNO .Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Journal of Internal Medicine2003;253(4):472-80. [MEDLINE: 12653877]KjeldsenSE , HednerT , JamersonK , JuliusS , HaleyWE , ZabalgoitiaM , et al.Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects. Hypertension1998;31(4):1014-20. [MEDLINE: 9535429]KjeldsenSE , KollochRE , LeonettiG , MallionJM , ZanchettiA , ElmfeldtD , et al.Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. Journal of Hypertension2000;18(5):629-42. [MEDLINE: 10826567]KollochRE , RahnKH .The Hypertension Optimal Treatment (HOT) study: results of 12-month treatment related to age [Die 'Hyperyension Optimal Treatment' (HOT)-Studie: Behandlungsergebnisse nach Zwolfmonatiger Therapie in Abhangigkeit vom Alter]. Deutsche Medizinische Wochenschrift1998;123(1-2):1-5. [MEDLINE: 9465848]LeonettiG , ZanchettiA .Principal results of hypertension optimal treatment (HOT) study and their clinical impact. HOT cooperative group. Clinical Hemorheology &amp; Microcirculation1999;21(3-4):217-24. [MEDLINE: 10711746]LithellH , BerglundL .Validation of an oscillometric blood pressure measuring device: a substudy of the HOT Study. Hypertension Optimal Treatment. Blood Pressure1998;7(3):149-52. [MEDLINE: 9758084]ManciaG , OmboniS , ParatiG , ClementDL , HaleyWE , RahmanSN , et al.Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(10):1755-63. [MEDLINE: 11593094]RuilopeLM , SalvettiA , JamersonK , HanssonL , WarnoldI , WedelH , et al.Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology2001;12(2):218-25. [MEDLINE: 11158211]Struijker-BoudierH , SafarM , vanBortelL .Effects of individual risk factors on the incidence of cardiovascular event in the treated hypertensive patients of the Hypertension Optimal Treatment Study. Journal of Hypertension2001;19(11):2105-6. [MEDLINE: 11677378]The Hypertension Optimal Treatment Study (the HOT Study). Blood Pressure1993;2(1):62-8. [MEDLINE: 8193735]WaeberB , LeonettiG , KollochR , McInnesGT .Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension1999;17(7):1041-5. [MEDLINE: 10419079]ZanchettiA , HanssonL , DahlofB , ElmfeldtD , KjeldsenS , KollochR , et al.Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. Journal of Hypertension2001;19(6):1149-59. [MEDLINE: 11403365]ZanchettiA , HanssonL , MenardJ , LeonettiG , RahnKH , WarnoldI , et al.Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(4):819-25. [MEDLINE: 11330886]">HOT 1993</a>; <a href="./references#CD008834-bbs2-0049" title="BlankenshipJC , SigmonKN , PieperKS , O'SheaC , TardiffBE , TchengJE , et al.Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial. American Journal of Cardiology2001;88(9):969-73. [MEDLINE: 11703991]GilchristIC , GardnerLH , MuhlesteinJB , ArnoldAM , LincoffAM , CaliffRM , et al.Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience. American Heart Journal1999;138(5 Pt 1):976-82. [MEDLINE: 10539832]MandakJS , BlankenshipJC , GardnerLH , BerkowitzSD , AguirreFV , SigmonKN , et al.Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Journal of the American College of Cardiology1998;31(7):1518-24. [MEDLINE: 9626829]Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet1997;349(9063):1422-8. [MEDLINE: 9164315]TardiffBE , CaliffRM , TchengJE , LincoffAM , SigmonKN , HarringtonRA , et al.Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. Journal of the American College of Cardiology1999;33(1):88-96. [MEDLINE: 9935014]ThelMC , CaliffRM , TardiffBE , GardnerLH , SigmonKN , LincoffAM , et al.Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. American Journal of Cardiology2000;85(4):427-34. [MEDLINE: 10728945]">IMPACT II 1997</a>; <a href="./references#CD008834-bbs2-0050" title="JiaoXM , JiaoXJ , ZhangXG , XuXP , WuJX , YaoL , et al.Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy. Chinese Medical Journal2013;126(22):4395-6. [MEDLINE: 24238537]">Jiao 2013</a>; <a href="./references#CD008834-bbs2-0051" title="OgawaH , NakayamaM , MorimotoT , UemuraS , KanauchiM , DoiN , et al.Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.[Erratum in: JAMA. 2009 May 13;301(18):1882], [Erratum in: JAMA. 2012 Nov 14;308(18):1861]. JAMA2008;300(18):2134-41. [MEDLINE: 18997198]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , NakayamaM , et al.Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk. Circulation Journal2013;77(12):3023-8. [MEDLINE: 24042256]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , NakayamaM , et al.Is long-term low-dose aspirin therapy associated with renal dysfunction in patients with type 2 diabetes? JPAD2 cohort study. PLoS ONE [Electronic Resource]2016;11(1):e0147635. [MEDLINE: 26808136]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , OhtoriiM , et al.Long-term use of low-dose aspirin develops proteinuria in patients with diabetes: A reanalysis of JPAD study [abstract no: 10863]. Circulation2013;128(22 Suppl 1). [EMBASE: 71337722]SaitoY , MorimotoT , OgawaH , NakayamaM , UemuraS , DoiN , et al.Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care2011;34(2):280-5. [MEDLINE: 21270185]">JPAD 2008</a>; <a href="./references#CD008834-bbs2-0057" title="KhajehdehiP , RoozbehJ , MostafaviH .A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scandinavian Journal of Urology &amp; Nephrology2002;36(2):145-8. [MEDLINE: 12028688]">Khajehdehi 2002</a>; <a href="./references#CD008834-bbs2-0059" title="KontessisPS , JonesSL , BarrowSE , StrattonPD , AlessandriniP , De CosmoS , et al.Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy. Journal of Laboratory &amp; Clinical Medicine1993;121(3):415-23. [MEDLINE: 8445289]">Kontessis 1993</a>; <a href="./references#CD008834-bbs2-0061" title="KoyamaA , NaritaM , TojoS .Therapeutic effects of dipyridamole on primary glomerulonephritis [abstract]. In: 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan. 1990:12. [CENTRAL: CN-00446186] ">Koyama 1990</a>; <a href="./references#CD008834-bbs2-0066" title="MovchanEA , ChuprovaAV , TovNL , Vol'vichNV .Desaggregation therapy of acute glomerulonephritis [Dezagregatsionnaia terapiia ostrogo glomerulonefrita]. Klinicheskaia Meditsina2001;79(12):44-7. [MEDLINE: 11840813]">Movchan 2001</a>; <a href="./references#CD008834-bbs2-0069" title="NakamuraT , UshiyamaC , TakahashiY , TanakaA , ShimadaN , EbiharaI , et al.Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease. Nephron2001;88(1):80-2. [MEDLINE: 11340355]">Nakamura 2001d</a>; <a href="./references#CD008834-bbs2-0071" title="GuoX .A clinical study to evaluate the efficacy and safety of cilostazol and probucol in combination on patients with diabetic nephropathy. www.clinicaltrials.gov/show/nct01252056 (first received 2 December 2010). ">NCT01252056</a>; <a href="./references#CD008834-bbs2-0072" title="NybergG , LarssonO , WestbergNG , AurellM , JagenburgR , BlohmeG .A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study. Clinical Nephrology1984;21(3):184-7. [MEDLINE: 6705280]">Nyberg 1984</a>; <a href="./references#CD008834-bbs2-0076" title="BonacaMP , BhattDL , BraunwaldE , CohenM , StegPG , StoreyRF , et al.Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal2014;167(4):437-44. [MEDLINE: 24655690]BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , JensenEC , et al.Long-term use of ticagrelor in patients with prior myocardial infarction. New England Journal of Medicine2015;372(19):1791-800. [MEDLINE: 25773268]BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , CohenM , et al.Prevention of stroke with ticagrelor in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation2016;134(12):861-71. [MEDLINE: 27576775]DellborgM , BonacaMP , StoreyRF , StegPG , ImKA , CohenM , et al.Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: Insights from PEGASUS-TIMI 54 [abstract]. European Heart Journal2017;38(Suppl 1):794-5. [EMBASE: 621235545]LozanoI , RondanJ , VegasJM , SegoviaE .Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):107-8. [MEDLINE: 29301622]MagnaniG , SabatineMS , BhattDL , ChoenM , StegG , StoreyR , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: Insights from the PEGASUS-TIMI 54 trial [abstract]. European Heart Journal2015;36(Suppl 1):520. [EMBASE: 72020712]MagnaniG , StoreyRF , StegG , BhattDL , CohenM , KuderJ , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. European Heart Journal2016;37(4):400-8. [MEDLINE: 26443023]MagnusonEA , BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , et al.Reply: cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):108. [MEDLINE: 29301623]MagnusonEA , LiH , WangK , VilainK , ShafiqA , BonacaMP , et al.Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: results from the PEGASUS-TIMI 54 trial. Journal of the American College of Cardiology2017;70(5):527-38. [MEDLINE: 28750695]MurphySA , BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , et al.Reduction in total cardiovascular events with long-term use of ticagrelor in patients with prior myocardial infarction in the PEGASUS-TIMI 54 trial [abstract no: A17121]. Circulation2015;132(Suppl 3). [EMBASE: 72179983]">PEGASUS‐TIMI 54 2014</a>; <a href="./references#CD008834-bbs2-0080" title="PierucciA , SimonettiBM , PecciG , FeriozziS , MavrikakisG , CinottiGA , et al.Low dose aspirin in patients with lupus nephritis [abstract]. Kidney International1988;33(1):281. [CENTRAL: CN-00583819] PierucciA , SimonettiBM , PecciG , MavrikakisG , FeriozziS , CinottiGA , et al.Acute effects of a thromboxane receptor antagonist on renal function in patients with lupus nephritis [abstract]. Kidney International1987;31(1):283. [CENTRAL: CN-00724956] PierucciA , SimonettiBM , PecciG , MavrikakisG , FeriozziS , CinottiGA , et al.Improvement of renal function with selective thromboxane antagonism in lupus nephritis. New England Journal of Medicine1989;320(7):421-5. [MEDLINE: 2643773]">Pierucci 1989</a>; <a href="./references#CD008834-bbs2-0082" title="Navarro-GonzalezJF , Sanchez-NinoMD , Donate-CorreaJ , Martin-NunezE , FerriC , Perez-DelgadoN , et al.Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease. Diabetes Care2018;41(8):1817-20. [MEDLINE: 29866645]">PREDIAN 2011</a>; <a href="./references#CD008834-bbs2-0083" title="HuynhT , NasmithJ , LuongTM , BernierM , PharandC , Xue-QiaoZ , et al.Complementary prognostic values of ST segment deviation and Thrombolysis In Myocardial Infarction (TIMI) risk score in non-ST elevation acute coronary syndromes: insights from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Canadian Journal of Cardiology 2009 Dec;25(12):e417-21. [MEDLINE: 19960136]HuynhT , PiazzaN , DiBattistePM , SnapinnSM , WanY , PharandC , et al.Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study. International Journal of Cardiology2005;100(1):73-8. [MEDLINE: 15820288]HuynhT , TherouxP , SnapinnS , WanY , PRISM-PLUS Investigators.Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). American Heart Journal2003;146(4):668-73. [MEDLINE: 14564321]Januzzi JL Jr, SnapinnSM , DiBattistePM , JangIK , TherouxP .Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation2002;105(20):2361-6. [MEDLINE: 12021221]MegaJL , MorrowDA , SabatineMS , ZhaoXQ , SnapinnSM , DiBattistePM , et al.Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. American Heart Journal2005;149(5):846-50. [MEDLINE: 15894966]MorrowDA , SabatineMS , AntmanEM , CannonCP , BraunwaldE , TherouxP .Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). American Journal of Cardiology2004;94(6):774-6. [MEDLINE: 15374786]Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New England Journal of Medicine1998;338(21):1488-97. [MEDLINE: 9599103]ServossSJ , WanY , SnapinnSM , DiBattistePM , ZhaoXQ , TherouxP , et al.Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. American Journal of Cardiology2004;93(7):843-7. [MEDLINE: 15050486]SzucsTD , MeyerBJ , KiowskiW .Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial. European Heart Journal1999;20(17):1253-60. [MEDLINE: 10454977]TherouxP , AlexanderJ , PharandC , BarrE , SnapinnS , GhannamAF , et al.Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation2000;102(20):2466-72. [MEDLINE: 11076818]TherouxP , Alexander J Jr, DupuisJ , PesantY , GervaisP , GrandmontD , et al.Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators. American Journal of Cardiology2001;87(4):375-80. [MEDLINE: 11179517]ZhaoXQ , TherouxP , SnapinnSM , SaxFL .Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Circulation1999;100(15):1609-15. [MEDLINE: 10517731]">PRISM‐PLUS 1998</a>; <a href="./references#CD008834-bbs2-0084" title="AkkerhuisKM , DeckersJW , BoersmaE , HarringtonRA , StepinskaJ , MahaffeyKW , et al.Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. European Heart Journal2000;21(5):371-81. [MEDLINE: 10666351]AkkerhuisKM , MaasAC , KlootwijkPA , KrucoffMW , MeijS , CaliffRM , et al.Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of Electrocardiology2000;33(2):127-36. [MEDLINE: 10819406]AlexanderJH , HarringtonRA , TuttleRH , BerdanLG , LincoffAM , DeckersJW , et al.Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology1999;83(8):1147-51. [MEDLINE: 10215274]BoersmaE , PieperKS , SteyerbergEW , WilcoxRG , ChangWC , LeeKL , et al.Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation2000;101(22):2557-67. [MEDLINE: 10840005]BrownRE , HendersonRA , KosterD , HuttonJ , SimoonsML .Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy. European Heart Journal2002;23(1):50-8. [MEDLINE: 11741362]ChangWC , HarringtonRA , SimoonsML , CaliffRM , LincoffAM , ArmstrongPW , et al.Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial. European Heart Journal2002;23(14):1102-11. [MEDLINE: 12090748]DykeCM , BhatiaD , LorenzTJ , MarsoSP , TardiffBE , HogeboomC , et al.Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Annals of Thoracic Surgery2000;70(3):866-71. [MEDLINE: 11016325]GreenbaumAB , HarringtonRA , HudsonMP , MacAulayCM , WilcoxRG , SimoonsML , et al.Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. Journal of the American College of Cardiology2001;37(2):492-8. [MEDLINE: 11216968]HarringtonRA .Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology1997;80(4A):34-8B. [MEDLINE: 9291244]HasdaiD , Holmes DR Jr, CrigerDA , TopolEJ , CaliffRM , WilcoxRG , et al.Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators. American Heart Journal2000;139(3):454-60. [MEDLINE: 10689260]KleimanNS , LincoffAM , FlakerGC , PieperKS , WilcoxRG , BerdanLG , et al.Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation2000;101(7):751-7. [MEDLINE: 10683348]LabinazM , KaulP , HarringtonRA , ChangWC , KleimanNS , SimoonsML , et al.Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. Canadian Journal of Cardiology2004;20(8):773-8. [MEDLINE: 15229770]LabinazM , KilaruR , PieperK , MarsoSP , KittMM , SimoonsML , et al.Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2002;105(3):322-7. [MEDLINE: 11804987]LauerMA , HoughtalingPL , PetersonJG , GrangerCB , BhattDL , SappSK , et al.Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2001;104(23):2772-7. [MEDLINE: 11733393]LincoffAM , HarringtonRA , CaliffRM , HochmanJS , GuerciAD , OhmanEM , et al.Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2000;102(10):1093-100. [MEDLINE: 10973836]MahaffeyKW , HarringtonRA , AkkerhuisM , KleimanNS , BerdanLG , CrenshawBS , et al.Systematic adjudication of myocardial infarction end-points in an international clinical trial. Current Controlled Trials in Cardiovascular Medicine2001;2(4):180-6. [MEDLINE: 11806793]MahaffeyKW , HarringtonRA , SimoonsML , GrangerCB , GraffagninoC , AlbertsMJ , et al.Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation1999;99(18):2371-7. [MEDLINE: 10318656]MarkDB , HarringtonRA , LincoffAM , CaliffRM , NelsonCL , TsiatisAA , et al.Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation2000;101(4):366-71. [MEDLINE: 10653826]MarsoSP , BhattDL , RoeMT , HoughtalingPL , LabinazM , KleimanNS , et al.Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators. Circulation2000;102(24):2952-8. [MEDLINE: 11113045]McClureMW , BerkowitzSD , SparapaniR , TuttleR , KleimanNS , BerdanLG , et al.Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation1999;99(22):2892-900. [MEDLINE: 10359733]PetersonJG , TopolEJ , RoeMT , SappSK , LincoffAM , DeckersJW , et al.Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology2001;87(5):532-6. [MEDLINE: 11230834]PURSUIT Trial Investigators.Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. New England Journal of Medicine1998;339(7):436-43. [MEDLINE: 9705684]RoeMT , HarringtonRA , ProsperDM , PieperKS , BhattDL , LincoffAM , et al.Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation2000;102(10):1101-6. [MEDLINE: 10973837]RonnerE , BoersmaE , AkkerhuisKM , HarringtonRA , LincoffAM , DeckersJW , et al.Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. European Heart Journal2002;23(3):239-46. [MEDLINE: 11792139]RonnerE , BoersmaE , LaarmanGJ , SomsenGA , HarringtonRA , DeckersJW , et al.Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of the American College of Cardiology2002;39(12):1924-9. [MEDLINE: 12084589]SrichaiMB , JaberWA , PriorDL , MarsoSP , HoughtalingPL , MenonV , et al.Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes. American Heart Journal2004;147(1):84-90. [MEDLINE: 14691424]">PURSUIT 1997</a>; <a href="./references#CD008834-bbs2-0086" title="BrenerSJ , BarrLA , BurchenalJE , KatzS , GeorgeBS , JonesAA , et al.Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation1998;98(8):734-41. [MEDLINE: 9727542]BrenerSJ , BarrLA , BurchenalJE , WolskiKE , EffronMB , TopolEJ .Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial. American Journal of Cardiology1999;84(6):728-30. [MEDLINE: 10498145]">RAPPORT 1998</a>; <a href="./references#CD008834-bbs2-0088" title="CooperCJ , HallerST , ColyerW , SteffesM , BurketMW , ThomasWJ , et al.Embolic protection and platelet inhibition during renal artery stenting. Circulation2008;117(21):2752-60. [MEDLINE: 18490527]HeW , CheJ , ZhanD , DawsoT , KanjwaS , HalleS , et al.Time dependant changes in systolic blood pressure after renal artery stenting: role of stenosis severity [abstract no: 14283]. Circulation2012;126(21 Suppl 1). [EMBASE: 70958797]KanjwalK , CooperCJ , VirmaniR , HallerS , ShapiroJI , BurketMW , et al.Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy. Catheterization &amp; Cardiovascular Interventions2010;76(1):16-23. [MEDLINE: 20209644]KanjwalK , HallerS , SteffesM , VirmaniR , ShapiroJI , BurketMW , et al.Complete versus partial distal embolic protection during renal artery stenting. Catheterization &amp; Cardiovascular Interventions2009;73(6):725-30. [MEDLINE: 19198007]TianJ , HallerS , PeriyasamyS , BrewsterP , ZhangH , AdlakhaS , et al.Renal ischemia regulates marinobufagenin release in humans. Hypertension2010;56(5):914-9. [MEDLINE: 20823380]YuH , ZhangD , HallerS , KanjwalK , ColyerW , BrewsterP , et al.Determinants of renal function in patients with renal artery stenosis. Vascular Medicine2011;16(5):331-8. [MEDLINE: 21908683]">RESIST 2008</a>; <a href="./references#CD008834-bbs2-0095" title="SteinessE , BrunN , SkarsfeldtT , DerwahlKM .Low dose anti-thromboxane reduces urinary albumin in patients with diabetic kidney disease [abstract no: SA-PO148]. Journal of the American Society of Nephrology2018;29:773. [EMBASE: 633731990]">Steiness 2018</a> <a href="./references#CD008834-bbs2-0099" title="TangWH , LinFH , LeeCH , KuoFC , HsiehCH , HsiaoFC , et al.Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. Endocrine2014;45(2):293-301. [MEDLINE: 23775007]">Tang 2014</a>; <a href="./references#CD008834-bbs2-0103" title="CorreaS , BonacaMP , SciricaBM , MurphySA , GoodrichEL , MorrowDA , et al.Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. Journal of Thrombosis &amp; Thrombolysis2019;47(3):353-60. [MEDLINE: 30511258]GaviriaSC , BraunwaldE , BonacaMP , MurphySA , GoodrichEL , MorrowDA , et al.The efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function: insights from the TRA 2P-TIMI 50 trial [abstract no: 15480]. Circulation2017;136(Suppl 1). [EMBASE: 619986693]MorrowDA , BraunwaldE , BonacaMP , AmerisoSF , DalbyAJ , FishMP , et al.Vorapaxar in the secondary prevention of atherothrombotic events. New England Journal of Medicine2012;366(15):1404-13. [MEDLINE: 22443427]MorrowDA , SciricaBM , FoxKA , BermanG , StronyJ , VeltriE , et al.Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. American Heart Journal2009;158(3):335-41. [MEDLINE: 19699854]">TRA 2P‐TIMI 50 2009</a>; <a href="./references#CD008834-bbs2-0104" title="CornelJH , TricociP , HortonJ , MoliternoD , WallentinL , ArmstrongP , et al.Effects of glycoprotein IIB/IIIA inhibitors in combination with vorapaxar, a platelet thrombin-receptor antagonist, among patients with non-St-segment elevation acute coronary syndromes: insights from the TRACER trial [abstract]. Journal of the American College of Cardiology2013;61(10 Suppl 1):E102. [EMBASE: 71019466]MahaffeyKW , PieperK , VranckxP , TricociP , Van de WerfF , HeldC , et al.Chronic kidney disease is associated with worse outcomes in ACS patients: results from the TRACER trial [abstract]. European Heart Journal2014;35(Suppl 1):687. [EMBASE: 71649310]">TRACER 2013</a>; <a href="./references#CD008834-bbs2-0108" title="WatanabeH , NakagawaK , KakihanaM .Long-term effects of sarpogrelate, a selective serotonin receptor antagonist, in diabetic patients with stable angina and chronic kidney disease [abstract no: 11204]. Circulation2011;124(21 Suppl 1). [EMBASE: 70620962]">Watanabe 2011b</a>; <a href="./references#CD008834-bbs2-0113" title="ZäunerI , BöhlerJ , BraunN , GruppC , HeeringP , SchollmeyerP .Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Nephrology Dialysis Transplantation1994;9(6):619-22. [MEDLINE: 7970086]">Zäuner 1994</a>). </p> </li> <li> <p>Thirty‐two studies enrolled HD patients (5097 participants: <a href="./references#CD008834-bbs2-0002" title="AbacilarAF , AtalayH , DoganOF .Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: a randomized controlled study. Indian Journal of Nephrology2015;25(3):136-42. [MEDLINE: 26060361]">Abacilar 2015</a>; <a href="./references#CD008834-bbs2-0003" title="Abdul-RahmanIS , Al-HowaishAK .Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23-30. [EMBASE: 2007269768]">Abdul‐Rahman 2007</a>; <a href="./references#CD008834-bbs2-0006" title="AndrassyK , MallucheH , BornefeldH , CombergM , RitzE , JesdinskyH , et al.Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: results of a prospective double blind study. Klinische Wochenschrift1974;52(7):348-9. [MEDLINE: 4600820]">Andrassy 1974</a>; <a href="./references#CD008834-bbs2-0016" title="CreekR .Ticlopidine. Patency of haemodialysis access sites. Guildford Sanofi Winthrop. Internal report1990. ">Creek 1990</a>; <a href="./references#CD008834-bbs2-0019" title="DemberL , AllonM , DelmezJ , DixonB , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00550593] DemberLM , BeckGJ , AllonM , DelmezJA , DixonBS , GreenbergA , et al.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008;299(18):2164-71. [MEDLINE: 18477783]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials2005;2(5):413-22. [MEDLINE: 16317810]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):229A. [CENTRAL: CN-00445067] ">Dember 2005</a>; <a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a>; <a href="./references#CD008834-bbs2-0021" title="Dmoszynska-GiannopoulouA , JanickaL , SokolowskaB , KsiazekA , OrlowskaG , JanickiK .The effect of sulphinpyrazone and alpha-tocopherol on platelet activation and function in haemodialysed patients. International Urology &amp; Nephrology1990;22(6):561-6. [MEDLINE: 2093696]">Dmoszynska‐Giannopoulou 1990</a>; <a href="./references#CD008834-bbs2-0022" title="DoddNJ , TurneyJH , WestonMJ .Ticlopidine preserves vascular access for haemodialysis [abstract no: 326F]. In: Proceedings of the VI International Congress of Mediterranean League Against Thrombosis; 1980 Oct 25-26; Montecarlo, Monaco. 1980. ">Dodd 1980</a>; <a href="./references#CD008834-bbs2-0025" title="EllS , MihindukulasuriyaJC , O'BrienJR , PolakA , VernhamG .Ticlopidine in the prevention of blockage of fistulae and shunts [abstract no: 332]. Haemostasis1982;12:180. ">Ell 1982</a>; <a href="./references#CD008834-bbs2-0032" title="FiskerstrandCE , ThompsonIW , BurnetME , WilliamsP , AndertonJL .Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artificial Organs1985;9(1):61-3. [MEDLINE: 3888153]">Fiskerstrand 1985</a>; <a href="./references#CD008834-bbs2-0036" title="GhorbaniA , AalamshahM , ShahbazianH , EhsanpourA , ArefA .Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian Journal of Nephrology2009;19(2):57-61. [MEDLINE: 20368925]">Ghorbani 2009</a>; <a href="./references#CD008834-bbs2-0037" title="GhorbaniA , Jasemi-ZerganiF .Ticlopidine to prevent primary arteriovenous fistula failure in hemodialysis patients; a randomized controlled trial. Journal of Renal Injury Prevention2013;2(3):109-11. [MEDLINE: 25340144]">Ghorbani 2013</a>; <a href="./references#CD008834-bbs2-0042" title="GröntoftKC , MulecH , GutierrezA , OlanderR .Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scandinavian Journal of Urology &amp; Nephrology1985;19(1):55-7. [MEDLINE: 3895411]">Gröntoft 1985</a>; <a href="./references#CD008834-bbs2-0046" title="HarterHR , BurchJW , MajerusPW , StanfordN , DelmezJA , AndersonCB , et al.Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. New England Journal of Medicine1979;301(11):577-9. [MEDLINE: 112475]">Harter 1979</a>; <a href="./references#CD008834-bbs2-0053" title="KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. New England Journal of Medicine1974;290(6):304-6. [MEDLINE: 4588285]KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation1975;52(3):497-9. [MEDLINE: 1098808]">Kaegi 1974</a>; <a href="./references#CD008834-bbs2-0054" title="KamperAM , LinsRL , ZacheeP , Van BergenS , HostenS , DaelemansR .Safety of combining ticlopidine with nadroparin in the routine treatment of chronic hemodialysis patients. Nephron1997;77(4):484-5. [MEDLINE: 9434075]">Kamper 1997</a>; <a href="./references#CD008834-bbs2-0056" title="ChangJJ , ConcatoJ , WellsCK , CrowleyST .Impact of adherence to clinical guidelines on mortality in hemodialysis patients [abstract no: SA-PO384]. Journal of the American Society of Nephrology2004;15(Oct):386A. [CENTRAL: CN-00583156] KaufmanJS , O'ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology2003;14(9):2313-21. [MEDLINE: 12937308]KaufmanJS , O’ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract no: A1495]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):291A. ">Kaufman 2003</a>; <a href="./references#CD008834-bbs2-0058" title="KobayashiK , MaedaK , KoshikawaS , KawaguchiY , ShimizuN , NaitoC .Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis: a multicenter collaborative double blind study. Thrombosis Research1980;20(2):255-61. [MEDLINE: 7209880]">Kobayashi 1980</a>; <a href="./references#CD008834-bbs2-0060" title="KooistraMP , vanEsA , MarxJJ , HertsigM , StruyvenbergA .Effects of low dose aspirin on thrombovascular accidents during treatment with rHuEpo: a multicentre, controlled, cross-over study [abstract]. Nephrology Dialysis Transplantation1993;8:277. [CENTRAL: CN-00260772] KooistraMP , vanEsA , MarxJJ , HertsigML , StruyvenbergA .Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrology Dialysis Transplantation1994;9(8):1115-20. [MEDLINE: 7800210]">Kooistra 1994</a>; <a href="./references#CD008834-bbs2-0063" title="MichieDD , WomboltDG .Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research - Clinical &amp; Experimental1977;22(1 II):196-204. [EMBASE: 8152617]">Michie 1977</a>; <a href="./references#CD008834-bbs2-0064" title="MiddletonDA , DeichselG .The prophylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole. Boehringer Ingelheim. Internal report1992. ">Middleton 1992</a>; <a href="./references#CD008834-bbs2-0065" title="MilutinovicS , GasparovicV , MilutinovicE , Buturovic-PonikvarJ .Ticlopidine improves dialysis clearance of solutes in uremic patients by reducing blood clotting in dialyser fibers. International Journal of Artificial Organs1993;16(5):249-52. [MEDLINE: 8354583]">Milutinovic 1993</a>; <a href="./references#CD008834-bbs2-0067" title="MozafarM , SamsamiM , SobhiyehMR , JabbehdariS , FallahZM .Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourology Monthly2013;5(2):762-5. [MEDLINE: 23841041]">Mozafar 2013</a>; <a href="./references#CD008834-bbs2-0068" title="MozafarM , AlborziM , MoradiA .Effects of clopidogrel on longevity of permanent double-lumen catheter patency in dialysis patients: A single-blind placebo-controlled clinical trial. Nephro-Urology Monthly2018;10(2):e58135. [EMBASE: 622226387]">Mozafar 2018</a>; <a href="./references#CD008834-bbs2-0070" title="NakamuraT , UshiyamaC , OsadaS , UgaiK , TakahashiY , TanakaA , et al.Effect of dilazep dihydrochloride on serum cardiac troponin T levels in hemodialysis patients. Kidney &amp; Blood Pressure Research2002;25(1):50-4. [MEDLINE: 11834877]">Nakamura 2002b</a>; <a href="./references#CD008834-bbs2-0089" title="RouzrokhM , AbbasiMR , MirshemiraniAR , SobhiyehMR .The effect of antiplatelet drugs on the patency rate of arterio-venous fistulae in hemodialysis patients. Iranian Journal of Pharmaceutical Research2010;9(4):451-7. [EMBASE: 2011024056]">Rouzrokh 2010</a>; <a href="./references#CD008834-bbs2-0091" title="SalterMC , CrowMJ , DonaldsonDR , RobertsTG , RajahSM , DavisonAM .Prevention of platelet deposition and thrombus formation on hemodialysis membranes: a double-blind randomized trial of aspirin and dipyridamole. Artificial Organs1984;8(1):57-61. [MEDLINE: 6703927]">Salter 1984</a>; <a href="./references#CD008834-bbs2-0094" title="SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract no: 9P]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):388. [CENTRAL: CN-00485981] SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study. Kidney International1994;45(5):1477-83. [MEDLINE: 8072261]">Sreedhara 1994</a>; <a href="./references#CD008834-bbs2-0096" title="MiletiM , De PetriG , BacchiM , OgliariV , PecchiniF , BufanoG , et al.A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients. Journal of Nephrology1995;8(2):167-72. [EMBASE: 25209311]">STOP 1995</a>; <a href="./references#CD008834-bbs2-0098" title="TaberT , MaikranzP , HaagB , DilleyR , GaylordG .Hemodialysis vascular graft stenosis may be altered by low-molecular weight dextran (LMD), but not by aspirin (ASA) [abstract]. Journal of the American Society of Nephrology1992;3(3):397. [CENTRAL: CN-00858239] ">Taber 1992</a>; <a href="./references#CD008834-bbs2-0101" title="TayebiP , KazemzadehG , BanihashemA , RavariH .Effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients: a randomized double-blind placebo-controlled trial. Electronic Physician [Electronic Resource]2018;10(1):6135-9. [MEDLINE: 29588811]">Tayebi 2018</a>; <a href="./references#CD008834-bbs2-0112" title="YutoJ , EharaY , ShibataK , IwamotoT , YasudaG , YatsuK , et al.Effect of sarpogrelate on fistula patency of forearm arteriovenous anastomisis in uremic patients [abstract no: 276]. Kidney Research &amp; Clinical Practice2012;31(2):A86. [EMBASE: 70814985]">Yuto 2012</a>). </p> </li> <li> <p>Three studies were in patients treated with PD (40 participants: <a href="./references#CD008834-bbs2-0087" title="ReamsGP , YoungM , SorkinM , TwardowskiZ , GloorH , MooreH , et al.Effects of dipyridamole on peritoneal clearances. Uremia Investigation1985;9(1):27-33. [MEDLINE: 3915163]">Reams 1985</a>; <a href="./references#CD008834-bbs2-0090" title="RubinJ , AdairC , BarnesT , BowerJD .Augmentation of peritoneal clearance by dipyridamole. Kidney International1982;22(6):658-61. [MEDLINE: 6761488]">Rubin 1982</a>; <a href="./references#CD008834-bbs2-0109" title="WeseleyS , GoodmanA .The effect of dipyridamole (Di) on the peritoneal dialysis (PD) clearance of creatinine and urea - a double-blind study [abstract]. Kidney International1982;21(1):182. ">Weseley 1982</a>). </p> </li> <li> <p>Four studies enrolled kidney transplant recipients (141 participants: <a href="./references#CD008834-bbs2-0005" title="AndersonM , DewarP , FlemingLB , HackingPM , MorleyAR , MurrayS , et al.A controlled trial of dipyridamole in human renal transplantation and an assessment of platelet function studies in rejection. Clinical Nephrology1974;2(3):93-9. [MEDLINE: 4603996]">Anderson 1974</a>; <a href="./references#CD008834-bbs2-0085" title="Quarto Di PaloF , ElliA , RivoltaR , ParentiM , PalazziP , ZanussiC .Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide. Transplantation Proceedings1991;23(1 Pt 2):969-71. [MEDLINE: 1989347]">Quarto Di Palo 1991</a>; <a href="./references#CD008834-bbs2-0093" title="SchulzeR , LangkopfB , SziegoleitW .The effect of dipyridamole on the results of allogenic kidney transplantation [Der Einfluss von Dipyridamol auf die Ergebnisse der allogenen Nieren-transplantation]. Zeitschrift für Urologie und Nephrologie1990;83(5):255-9. [MEDLINE: 2203215]">Schulze 1990</a>; <a href="./references#CD008834-bbs2-0097" title="StorckM , SchillingM , MickleyV , TechtB , AbendrothD .Influence of systemic cyclooxygenase inhibition with single-dose aspisol on kinetics of arachidonic acid metabolites in the venous effluate of transplanted kidney grafts in humans. Transplantation Proceedings1996;28(1):312-3. [MEDLINE: 8644237]">Storck 1996</a>). </p> </li> <li> <p>Two studies enrolled participants with earlier stages of CKD and those treated with HD (673 participants: <a href="./references#CD008834-bbs2-0031" title="BadveS , HawleyCM , IrishAB , Paul-BrentP .High rate of screening failure in the FAVOURED study [abstract no: PUB345]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):905A. IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al.Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453]IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul-BrentP , et al.Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis-a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804]IrishA , FAVOURED Study Group.High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN-00756870] IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 009]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790]IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. [EMBASE: 70467038]IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul-BrentPA , et al.Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184-93. [MEDLINE: 28055065]IrishAB .The omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo-controlled trial [abstract no: HI-OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2-3. [CENTRAL: CN-01658143] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis-post hoc analysis of the FAVOURED study [abstract no: MO049]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475]ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on the need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology2018;23(Suppl 3):56. [EMBASE: 623841152]ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al.Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract no: SP593]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178]ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract no: FP555]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265]ViecelliA , PascoeE , PolkinghorneK , Paul-BrentP , DarssanD , HooiL , et al.A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115-6. [EMBASE: 612312707]ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul-BrentPA , BadveSV , et al.The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581]ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis - Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217-28. [MEDLINE: 26205903]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study. Nephrology2017;22(10):823-4. [MEDLINE: 27188542]ViecelliAK , PolkinghorneKR , PascoeEM , Paul-BrentPA , HawleyCM , BadveSV , et al.Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS ONE [Electronic Resource]2019;14(3):e0213274. [MEDLINE: 30913208]">FAVOURED 2009</a>; <a href="./references#CD008834-bbs2-0043" title="GröntoftK , LarssonR , MulecH , WeissLG , DickinsonJP .Ticlopidine in fistula surgery: double-blind comparison against placebo on the rate of early occlusion of arterio-venous fistulae [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:398. [CENTRAL: CN-00601921] GröntoftKC , LarssonR , MulecH , WeissLG , DickinsonJP .Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scandinavian Journal of Urology &amp; Nephrology1998;32(4):276-83. [MEDLINE: 9764456]">Gröntoft 1998</a>) </p> </li> <li> <p>In one study (<a href="./references#CD008834-bbs2-0106" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al.First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473-84. [MEDLINE: 15754269]BaigentC , UK-HARP Steering Committee.Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-PO851]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. [CENTRAL: CN-00444305] ">UK‐HARP‐I 2005</a>; 448 participants), participants included those with earlier stages of CKD, transplant recipients and participants treated with dialysis (both HD and PD). </p> </li> </ul> </p> <p>In the 90 studies that compared an antiplatelet agent with placebo or no treatment, the interventions included: </p> <p> <ul id="CD008834-list-0016"> <li> <p>Acetylsalicylic acid</p> <ul id="CD008834-list-0017"> <li> <p>Aspirin (16 studies, 6140 participants: <a href="./references#CD008834-bbs2-0001" title="GoicoecheaM , deVinuesaMS , QuirogaB , VerdallesU , MoralesE , De SequeraP , et al.Aspirin treatment in primary cardiovascular prevention and renal disease progression in CKD patients: a randomized clinical trials (AASER study) [abstract no: FR-PO1065]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):B5. [EMBASE: 633704620]GoicoecheaM , deVinuesaSG , QuirogaB , VerdeE , BernisC , MoralesE , et al.Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study). Cardiovascular Drugs &amp; Therapy2018;32(3):255-63. [MEDLINE: 29943364]GoicoecheaM , Sanchez-NinoMD , OrtizA , deVinuesaMS , QuirogaB , MoralesE , et al.Low dose aspirin increases 15-epi-lipoxin a4 levels in CKD patients [abstract no: SA-PO186]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):726. [EMBASE: 633701100]GoicoecheaM , Sanchez-NinoMD , OrtizA , Garcia de VinuesaS , QuirogaB , BernisC , et al.Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. Prostaglandins Leukotrienes &amp; Essential Fatty Acids2017;125:8-13. [MEDLINE: 28987723]">AASER 2017</a>; <a href="./references#CD008834-bbs2-0003" title="Abdul-RahmanIS , Al-HowaishAK .Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23-30. [EMBASE: 2007269768]">Abdul‐Rahman 2007</a>; <a href="./references#CD008834-bbs2-0006" title="AndrassyK , MallucheH , BornefeldH , CombergM , RitzE , JesdinskyH , et al.Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: results of a prospective double blind study. Klinische Wochenschrift1974;52(7):348-9. [MEDLINE: 4600820]">Andrassy 1974</a>; <a href="./references#CD008834-bbs2-0007" title="Di FrancoA , GaudinoM , GirardiLN .Considerations about the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. Journal of Thoracic Disease2016;8(7):E599. [MEDLINE: 27501533]MylesPS , SmithJ , KnightJ , CooperDJ , SilbertB , McNeilJ , et al.Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial: rationale and design. American Heart Journal2008;155(2):224-30. [MEDLINE: 18215590]MylesPS , SmithJA , ForbesA , SilbertB , JayarajahM , PainterT , et al.Stopping vs. continuing aspirin before coronary artery surgery. New England Journal of Medicine2016;374(8):728-37. [MEDLINE: 26933848]MylesPS , SmithJA , ForbesA , SilbertB , JayarajahM , PainterT , et al.Tranexamic acid in patients undergoing coronary-artery surgery [Erratum for: N Engl J Med. 2017 Jan 12;376(2):136-148; PMID: 27774838]. New England Journal of Medicine2017;376(2):136-48. [MEDLINE: 27774838]MylesPS , SmithJA , KaszaJ , SilbertB , JayarajahM , PainterT , et al.Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial. Journal of Thoracic &amp; Cardiovascular Surgery2019;157(2):633-40. [MEDLINE: 30401528]MylesPS , SmithJA , KaszaJ , SilbertB , JayarajahM , PainterT , et al.Tranexamic acid in coronary artery surgery: one-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. Journal of Thoracic &amp; Cardiovascular Surgery2019;157(2):644-52.e9. [MEDLINE: 30459103]">ATACAS 2008</a>; <a href="./references#CD008834-bbs2-0029" title="Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA1992;268(10):1292-300. [MEDLINE: 1507375]">ETDRS 1992</a>; <a href="./references#CD008834-bbs2-0031" title="BadveS , HawleyCM , IrishAB , Paul-BrentP .High rate of screening failure in the FAVOURED study [abstract no: PUB345]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):905A. IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al.Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453]IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul-BrentP , et al.Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis-a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804]IrishA , FAVOURED Study Group.High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN-00756870] IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 009]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790]IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. [EMBASE: 70467038]IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul-BrentPA , et al.Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184-93. [MEDLINE: 28055065]IrishAB .The omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo-controlled trial [abstract no: HI-OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2-3. [CENTRAL: CN-01658143] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis-post hoc analysis of the FAVOURED study [abstract no: MO049]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475]ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on the need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology2018;23(Suppl 3):56. [EMBASE: 623841152]ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al.Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract no: SP593]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178]ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract no: FP555]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265]ViecelliA , PascoeE , PolkinghorneK , Paul-BrentP , DarssanD , HooiL , et al.A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115-6. [EMBASE: 612312707]ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul-BrentPA , BadveSV , et al.The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581]ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis - Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217-28. [MEDLINE: 26205903]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study. Nephrology2017;22(10):823-4. [MEDLINE: 27188542]ViecelliAK , PolkinghorneKR , PascoeEM , Paul-BrentPA , HawleyCM , BadveSV , et al.Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS ONE [Electronic Resource]2019;14(3):e0213274. [MEDLINE: 30913208]">FAVOURED 2009</a>; <a href="./references#CD008834-bbs2-0035" title="GaedeP , HansenHP , ParvingHH , PedersenO .Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrology Dialysis Transplantation2003;18(3):539-42. [MEDLINE: 12584276]GaedeP , ParvingH , PedersenO .Lack of impact of low-dose acetylsalisyic acid (ASA) on albuminuria in type 2 diabetic patients [abstract no: A0660]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):128A. [CENTRAL: CN-00583369] ">Gaede 2003</a>; <a href="./references#CD008834-bbs2-0044" title="GuoZ , HasbachJ , KoschinskyT .Effect of acetylsalicylic acid on renal function of Type 1 diabetic patients with microalbuminuria [Wirkung von Azetylsalizylsaure auf die Nierenfunktion bei Typ-1- Diabetikern mit Mikroalbuminurie. Placebokontrollierte Crossover-Pilotstudie]. Diabetes und Stoffwechsel1998;7(2):41-7. [EMBASE: 28146337]">Guo 1998</a>; <a href="./references#CD008834-bbs2-0045" title="HansenHP , GaedePH , JensenBR , ParvingHH .Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria. Diabetes Care2000;23(12):1742-5. [MEDLINE: 11128344]">Hansen 2000</a>; <a href="./references#CD008834-bbs2-0046" title="HarterHR , BurchJW , MajerusPW , StanfordN , DelmezJA , AndersonCB , et al.Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. New England Journal of Medicine1979;301(11):577-9. [MEDLINE: 112475]">Harter 1979</a>; <a href="./references#CD008834-bbs2-0048" title="HanssonL , ZanchettiA , CarruthersSG , DahlöfB , ElmfeldtD , JuliusS , et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998;351(9118):1755-62. [MEDLINE: 9635947]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Pressure1997;6(5):313-7. [MEDLINE: 9360003]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Pressure1994;3(5):322-7. [MEDLINE: 7866597]HanssonL .The Hypertension Optimal Treatment study and the importance of lowering blood pressure. Journal of Hypertension - Supplement1999;17(1):S9-13. [MEDLINE: 10340838]JardineM , NinomiyaT , CassA , TurnbullF , GallagherM , ZoungasS , et al.Aspirin benefit increases as eGFR declines: results from a randomised controlled trial in a hypertensive population [abstract no: 086]. Nephrology2010;15(Suppl 4):49. [EMBASE: 70467090]JardineMJ , NinomiyaT , PerkovicV , CassA , TurnbullF , GallagherMP , et al.Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology2010;56(12):956-65. [MEDLINE: 20828648]JonesDW , MillerME , WoffordMR , Anderson DC Jr, CameronME , WilloughbyDL , et al.The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. American Journal of Hypertension1999;12(12 Pt 1-2):1175-80. [MEDLINE: 10619579]JonssonB , HanssonL , StalhammarNO .Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Journal of Internal Medicine2003;253(4):472-80. [MEDLINE: 12653877]KjeldsenSE , HednerT , JamersonK , JuliusS , HaleyWE , ZabalgoitiaM , et al.Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects. Hypertension1998;31(4):1014-20. [MEDLINE: 9535429]KjeldsenSE , KollochRE , LeonettiG , MallionJM , ZanchettiA , ElmfeldtD , et al.Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. Journal of Hypertension2000;18(5):629-42. [MEDLINE: 10826567]KollochRE , RahnKH .The Hypertension Optimal Treatment (HOT) study: results of 12-month treatment related to age [Die 'Hyperyension Optimal Treatment' (HOT)-Studie: Behandlungsergebnisse nach Zwolfmonatiger Therapie in Abhangigkeit vom Alter]. Deutsche Medizinische Wochenschrift1998;123(1-2):1-5. [MEDLINE: 9465848]LeonettiG , ZanchettiA .Principal results of hypertension optimal treatment (HOT) study and their clinical impact. HOT cooperative group. Clinical Hemorheology &amp; Microcirculation1999;21(3-4):217-24. [MEDLINE: 10711746]LithellH , BerglundL .Validation of an oscillometric blood pressure measuring device: a substudy of the HOT Study. Hypertension Optimal Treatment. Blood Pressure1998;7(3):149-52. [MEDLINE: 9758084]ManciaG , OmboniS , ParatiG , ClementDL , HaleyWE , RahmanSN , et al.Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(10):1755-63. [MEDLINE: 11593094]RuilopeLM , SalvettiA , JamersonK , HanssonL , WarnoldI , WedelH , et al.Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology2001;12(2):218-25. [MEDLINE: 11158211]Struijker-BoudierH , SafarM , vanBortelL .Effects of individual risk factors on the incidence of cardiovascular event in the treated hypertensive patients of the Hypertension Optimal Treatment Study. Journal of Hypertension2001;19(11):2105-6. [MEDLINE: 11677378]The Hypertension Optimal Treatment Study (the HOT Study). Blood Pressure1993;2(1):62-8. [MEDLINE: 8193735]WaeberB , LeonettiG , KollochR , McInnesGT .Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension1999;17(7):1041-5. [MEDLINE: 10419079]ZanchettiA , HanssonL , DahlofB , ElmfeldtD , KjeldsenS , KollochR , et al.Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. Journal of Hypertension2001;19(6):1149-59. [MEDLINE: 11403365]ZanchettiA , HanssonL , MenardJ , LeonettiG , RahnKH , WarnoldI , et al.Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(4):819-25. [MEDLINE: 11330886]">HOT 1993</a>; <a href="./references#CD008834-bbs2-0051" title="OgawaH , NakayamaM , MorimotoT , UemuraS , KanauchiM , DoiN , et al.Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.[Erratum in: JAMA. 2009 May 13;301(18):1882], [Erratum in: JAMA. 2012 Nov 14;308(18):1861]. JAMA2008;300(18):2134-41. [MEDLINE: 18997198]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , NakayamaM , et al.Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk. Circulation Journal2013;77(12):3023-8. [MEDLINE: 24042256]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , NakayamaM , et al.Is long-term low-dose aspirin therapy associated with renal dysfunction in patients with type 2 diabetes? JPAD2 cohort study. PLoS ONE [Electronic Resource]2016;11(1):e0147635. [MEDLINE: 26808136]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , OhtoriiM , et al.Long-term use of low-dose aspirin develops proteinuria in patients with diabetes: A reanalysis of JPAD study [abstract no: 10863]. Circulation2013;128(22 Suppl 1). [EMBASE: 71337722]SaitoY , MorimotoT , OgawaH , NakayamaM , UemuraS , DoiN , et al.Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care2011;34(2):280-5. [MEDLINE: 21270185]">JPAD 2008</a>; <a href="./references#CD008834-bbs2-0060" title="KooistraMP , vanEsA , MarxJJ , HertsigM , StruyvenbergA .Effects of low dose aspirin on thrombovascular accidents during treatment with rHuEpo: a multicentre, controlled, cross-over study [abstract]. Nephrology Dialysis Transplantation1993;8:277. [CENTRAL: CN-00260772] KooistraMP , vanEsA , MarxJJ , HertsigML , StruyvenbergA .Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrology Dialysis Transplantation1994;9(8):1115-20. [MEDLINE: 7800210]">Kooistra 1994</a>; <a href="./references#CD008834-bbs2-0067" title="MozafarM , SamsamiM , SobhiyehMR , JabbehdariS , FallahZM .Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourology Monthly2013;5(2):762-5. [MEDLINE: 23841041]">Mozafar 2013</a>; <a href="./references#CD008834-bbs2-0097" title="StorckM , SchillingM , MickleyV , TechtB , AbendrothD .Influence of systemic cyclooxygenase inhibition with single-dose aspisol on kinetics of arachidonic acid metabolites in the venous effluate of transplanted kidney grafts in humans. Transplantation Proceedings1996;28(1):312-3. [MEDLINE: 8644237]">Storck 1996</a>; <a href="./references#CD008834-bbs2-0106" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al.First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473-84. [MEDLINE: 15754269]BaigentC , UK-HARP Steering Committee.Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-PO851]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. [CENTRAL: CN-00444305] ">UK‐HARP‐I 2005</a>) </p> </li> <li> <p>Aspirin plus dextran (1 study, 45 participants; <a href="./references#CD008834-bbs2-0098" title="TaberT , MaikranzP , HaagB , DilleyR , GaylordG .Hemodialysis vascular graft stenosis may be altered by low-molecular weight dextran (LMD), but not by aspirin (ASA) [abstract]. Journal of the American Society of Nephrology1992;3(3):397. [CENTRAL: CN-00858239] ">Taber 1992</a>) </p> </li> </ul> </li> <li> <p>Adenosine reuptake inhibitors</p> <ul id="CD008834-list-0018"> <li> <p>Dilazep dihydrochloride (2 studies, 62 participants: <a href="./references#CD008834-bbs2-0069" title="NakamuraT , UshiyamaC , TakahashiY , TanakaA , ShimadaN , EbiharaI , et al.Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease. Nephron2001;88(1):80-2. [MEDLINE: 11340355]">Nakamura 2001d</a>; <a href="./references#CD008834-bbs2-0070" title="NakamuraT , UshiyamaC , OsadaS , UgaiK , TakahashiY , TanakaA , et al.Effect of dilazep dihydrochloride on serum cardiac troponin T levels in hemodialysis patients. Kidney &amp; Blood Pressure Research2002;25(1):50-4. [MEDLINE: 11834877]">Nakamura 2002b</a>) </p> </li> <li> <p>Dipyridamole (7 studies, 615 participants: <a href="./references#CD008834-bbs2-0005" title="AndersonM , DewarP , FlemingLB , HackingPM , MorleyAR , MurrayS , et al.A controlled trial of dipyridamole in human renal transplantation and an assessment of platelet function studies in rejection. Clinical Nephrology1974;2(3):93-9. [MEDLINE: 4603996]">Anderson 1974</a>; <a href="./references#CD008834-bbs2-0061" title="KoyamaA , NaritaM , TojoS .Therapeutic effects of dipyridamole on primary glomerulonephritis [abstract]. In: 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan. 1990:12. [CENTRAL: CN-00446186] ">Koyama 1990</a>; <a href="./references#CD008834-bbs2-0066" title="MovchanEA , ChuprovaAV , TovNL , Vol'vichNV .Desaggregation therapy of acute glomerulonephritis [Dezagregatsionnaia terapiia ostrogo glomerulonefrita]. Klinicheskaia Meditsina2001;79(12):44-7. [MEDLINE: 11840813]">Movchan 2001</a>; <a href="./references#CD008834-bbs2-0087" title="ReamsGP , YoungM , SorkinM , TwardowskiZ , GloorH , MooreH , et al.Effects of dipyridamole on peritoneal clearances. Uremia Investigation1985;9(1):27-33. [MEDLINE: 3915163]">Reams 1985</a>; <a href="./references#CD008834-bbs2-0090" title="RubinJ , AdairC , BarnesT , BowerJD .Augmentation of peritoneal clearance by dipyridamole. Kidney International1982;22(6):658-61. [MEDLINE: 6761488]">Rubin 1982</a>; <a href="./references#CD008834-bbs2-0093" title="SchulzeR , LangkopfB , SziegoleitW .The effect of dipyridamole on the results of allogenic kidney transplantation [Der Einfluss von Dipyridamol auf die Ergebnisse der allogenen Nieren-transplantation]. Zeitschrift für Urologie und Nephrologie1990;83(5):255-9. [MEDLINE: 2203215]">Schulze 1990</a>; <a href="./references#CD008834-bbs2-0109" title="WeseleyS , GoodmanA .The effect of dipyridamole (Di) on the peritoneal dialysis (PD) clearance of creatinine and urea - a double-blind study [abstract]. Kidney International1982;21(1):182. ">Weseley 1982</a>) </p> </li> <li> <p>Dipyridamole plus aspirin (11 studies, 2004 participants: <a href="./references#CD008834-bbs2-0009" title="ChanMK , KwanSY , ChanKW , YeungCK .Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis. American Journal of Kidney Diseases1987;9(5):417-21. [MEDLINE: 3555016]">Chan 1987</a>; <a href="./references#CD008834-bbs2-0013" title="ChristopherTG , SamelsK .A study of aspirin and dipyridamole in slowing the progression of diabetic glomerulosclerosis [abstract]. Kidney International1987;31(1):194. ChristopherTG , SamelsK .A study of the treatment effect of aspirin and dipyridamole in diabetic glomerulosclerosis [abstract]. In: 10th International Congress of Nephrology; 1987 Jul 26-31; London, UK. 1987:56. ">Christopher 1987</a>; <a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a>; <a href="./references#CD008834-bbs2-0023" title="DonadioJV , AndersonCF , MitchellJC , HolleyKE , IlstrupDM , FusterV .Membranoproliferative glomerulonephritis (MPGN): a prospective clinical trial of platelet inhibitor therapy [abstract]. Kidney International1983;23(1):121. [CENTRAL: CN-00602010] Donadio JV Jr, AndersonCF , Mitchell JC 3rd, HolleyKH , IlstrupDM , FusterV , et al.Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. New England Journal of Medicine1984;310(22):1421-6. [MEDLINE: 6371535]">Donadio 1984</a>; <a href="./references#CD008834-bbs2-0041" title="GonzalezMT , CastelaoAM , VallesM , CruzadoJM , MauriJM .Platelet antiaggregants (PA) could decrease the rate of progression of chronic renal failure (CRF) in diabetic patients (DP) treated previously with angiotensin converting enzyme inhibitors (ACEi) [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:200. [CENTRAL: CN-00509215] ">Gonzalez 1995</a>; <a href="./references#CD008834-bbs2-0057" title="KhajehdehiP , RoozbehJ , MostafaviH .A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scandinavian Journal of Urology &amp; Nephrology2002;36(2):145-8. [MEDLINE: 12028688]">Khajehdehi 2002</a>; <a href="./references#CD008834-bbs2-0064" title="MiddletonDA , DeichselG .The prophylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole. Boehringer Ingelheim. Internal report1992. ">Middleton 1992</a>; <a href="./references#CD008834-bbs2-0091" title="SalterMC , CrowMJ , DonaldsonDR , RobertsTG , RajahSM , DavisonAM .Prevention of platelet deposition and thrombus formation on hemodialysis membranes: a double-blind randomized trial of aspirin and dipyridamole. Artificial Organs1984;8(1):57-61. [MEDLINE: 6703927]">Salter 1984</a>; <a href="./references#CD008834-bbs2-0094" title="SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract no: 9P]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):388. [CENTRAL: CN-00485981] SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study. Kidney International1994;45(5):1477-83. [MEDLINE: 8072261]">Sreedhara 1994</a>; <a href="./references#CD008834-bbs2-0101" title="TayebiP , KazemzadehG , BanihashemA , RavariH .Effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients: a randomized double-blind placebo-controlled trial. Electronic Physician [Electronic Resource]2018;10(1):6135-9. [MEDLINE: 29588811]">Tayebi 2018</a>; <a href="./references#CD008834-bbs2-0113" title="ZäunerI , BöhlerJ , BraunN , GruppC , HeeringP , SchollmeyerP .Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Nephrology Dialysis Transplantation1994;9(6):619-22. [MEDLINE: 7970086]">Zäuner 1994</a>) </p> </li> <li> <p>Dypiridamole or aspirin (1 study, 501 participants: <a href="./references#CD008834-bbs2-0089" title="RouzrokhM , AbbasiMR , MirshemiraniAR , SobhiyehMR .The effect of antiplatelet drugs on the patency rate of arterio-venous fistulae in hemodialysis patients. Iranian Journal of Pharmaceutical Research2010;9(4):451-7. [EMBASE: 2011024056]">Rouzrokh 2010</a>) </p> </li> </ul> </li> <li> <p>Adenosine diphosphate receptor inhibitors</p> <ul id="CD008834-list-0019"> <li> <p>Clopidogrel (7 studies, 7931 participants: <a href="./references#CD008834-bbs2-0010" title="JingJ , MengX , ZhaoX , LiuL , WangA , PanY , et al.Dual antiplatelet therapy in transient ischemic attack and minor stroke with different infarction patterns: subgroup analysis of the CHANCE randomized clinical trial. JAMA Neurology2018;75(6):711-9. [MEDLINE: 29582084]LiJ , WangY , LinJ , WangD , WangA , ZhaoX , et al.Soluble CD40L is a useful marker to predict future strokes in patients with minor stroke and transient ischemic attack. Stroke2015;46(7):1990-2. [MEDLINE: 26012640]LiJ , ZhaoX , MengX , LinJ , LiuL , WangC , et al.High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome: subanalysis of the clopidogrel in high-risk patients with acute nondisabling cerebrovascular events trial. Stroke2016;47(8):2025-30. [MEDLINE: 27328699]LinY , WangA , LiJ , LinJ , WangD , MengX , et al.Impact of glycemic control on efficacy of clopidogrel in transient ischemic attack or minor stroke patients with CYP2C19 genetic variants. Stroke2017;48(4):998-1004. [MEDLINE: 28289237]LiuL , WongKS , LengX , PuY , WangY , JingJ , et al.Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology2015;85(13):1154-62. [MEDLINE: 26330567]LiZ , WangY , ZhaoX , LiuL , WangD , WangC , et al.Treatment effect of clopidogrel plus aspirin within 12 hours of acute minor stroke or transient ischemic attack. Journal of the American Heart Association2016;5(3):e003038. [MEDLINE: 27001965]MaY , LiuY , XuJ , WangY , WangY , DuF .Effect of dual antiplatelet on recurrent stroke in minor stroke or TIA depends on bodyweight. Therapeutics &amp; Clinical Risk Management2018;14:861-70. [MEDLINE: 29773949]PanY , CaiX , JingJ , MengX , LiH , WangY , et al.Stress hyperglycemia and prognosis of minor ischemic stroke and transient ischemic attack: the CHANCE study (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). Stroke2017;48(11):3006-11. [MEDLINE: 29051218]PanY , JingJ , ChenW , MengX , LiH , ZhaoX , et al.Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE.[Erratum in: Neurology. 2019 Aug 13;93(7):322; PMID: 31405943]. Neurology2017;88(20):1906-11. [MEDLINE: 28424269]PanY , JingJ , LiH , WangY , WangY , HeY , et al.Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA. Neurology2016;87(15):1551-6. [MEDLINE: 27613582]PanY , MengX , JingJ , LiH , ZhaoX , LiuL , et al.Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA. Neurology2017;88(11):1081-8. [MEDLINE: 28202699]WangA , LiS , ZhangN , DaiL , ZuoY , WangY , et al.Oxidized low-density lipoprotein to high-density lipoprotein ratio predicts recurrent stroke in minor stroke or transient ischemic attack. Stroke2018;49(11):2637-42. [MEDLINE: 30355199]WangA , XuJ , ChenG , WangD , JohnstonSC , MengX , et al.Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA. Neurology2018;91(10):e947-55. [MEDLINE: 30089614]WangD , GuiL , DongY , LiH , LiS , ZhengH , et al.Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial. Stroke &amp; Vascular Neurology2016;1(2):29-36. [MEDLINE: 28959461]WangqinR , WangX , WangY , XianY , ZhaoX , LiuL , et al.Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA: a subgroup analysis of the CHANCE trial. Stroke &amp; Vascular Neurology2017;2(4):176-83. [MEDLINE: 29507777]WangY , PanY , ZhaoX , LiH , WangD , JohnstonSC , et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial: one-year outcomes. Circulation2015;132(1):40-6. [MEDLINE: 25957224]WangY , WangY , ZhaoX , LiuL , WangD , WangC , et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine2013;369(1):11-9. [MEDLINE: 23803136]WangY , ZhaoX , LinJ , LiH , JohnstonSC , LinY , et al.Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA2016;316(1):70-8. [MEDLINE: 27348249]WuY , ZhouY , PanY , ZhaoX , LiuL , WangD , et al.Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. Pharmacogenomics Journal2018;18(6):713-20. [MEDLINE: 29520080]ZhouY , PanY , WuY , ZhaoX , LiH , WangD , et al.Effect of estimated glomerular filtration rate decline on the efficacy and safety of clopidogrel with aspirin in minor stroke or transient ischemic attack: CHANCE substudy (Clopidogrel in high-risk patients with acute nondisabling cerebrovascular events). Stroke2016;47(11):2791-6. [MEDLINE: 27738237]ZhuB , LiuH , PanY , JingJ , LiH , ZhaoX , et al.Elevated neutrophil and presence of intracranial artery stenosis increase the risk of recurrent stroke. Stroke2018;49(10):2294-300. [MEDLINE: 30355101]">CHANCE 2013</a>; <a href="./references#CD008834-bbs2-0011" title="BangaloreS , BhattDL , StegPG , WeberMA , BodenWE , HammCW , et al.beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circulation: Cardiovascular Quality &amp; Outcomes2014;7(6):872-81. [MEDLINE: 25271049]BergerPB , BhattDL , FusterV , StegPG , FoxKA , ShaoM , et al.Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation2010;121(23):2575-83. [MEDLINE: 20516378]BhattDL , FlatherMD , HackeW , BergerPB , BlackHR , BodenWE , et al.Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology2007;49(19):1982-8. [MEDLINE: 17498584]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial [Erratum in: Am Heart J. 2006 Jan;151(1):247]. American Heart Journal2005;150(3):401. [MEDLINE: 16169314]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine2006;354(16):1706-17. [MEDLINE: 16531616]DasguptaA , SteinhublSR , BhattDL , BergerPB , ShaoM , MakKH , et al.Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). American Journal of Cardiology2009;103(10):1359-63. [MEDLINE: 19427428]EikelboomJW , HankeyGJ , ThomJ , BhattDL , StegPG , MontalescotG , et al.Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation2008;118(17):1705-12. [MEDLINE: 18838564]MakKH , BhattDL , ShaoM , HaffnerSM , HammCW , HankeyGJ , et al.The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. European Heart Journal2009;30(7):857-65. [MEDLINE: 19233855]SteinhublSR , BhattDL , BrennanDM , MontalescotG , HankeyGJ , EikelboomJW , et al.Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding [Summary for patients in Ann Intern Med. 2009 Mar 17;150(6):I-22; PMID: 19293067]. Annals of Internal Medicine2009;150(6):379-86. [MEDLINE: 19293071]WangTH , BhattDL , FoxKA , SteinhublSR , BrennanDM , HackeW , et al.An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal2007;28(18):2200-7. [MEDLINE: 17673448]">CHARISMA 2006</a>; <a href="./references#CD008834-bbs2-0015" title="AronowHD , SteinhublSR , BrennanDM , BergerPB , TopolEJ , CREDO Investigators.Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal2009;157(2):369-74. [MEDLINE: 19185647]BeinartSC , KolmP , VeledarE , ZhangZ , MahoneyEM , BouinO , et al.Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Journal of the American College of Cardiology2005;46(5):761-9. [MEDLINE: 16139122]BestPJ , SteinhublSR , BergerPB , DasguptaA , BrennanDM , SzczechLA , et al.The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal2008;155(4):687-93. [MEDLINE: 18371477]BrenerSJ , SteinhublSR , BergerPB , BrennanDM , TopolEJ , CREDO Investigators.Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial. Journal of Invasive Cardiology2007;19(7):287-90. [MEDLINE: 17620671]RingborgA , LindgrenP , JonssonB .The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. European Journal of Health Economics2005;6(4):354-56, 358-62. [MEDLINE: 16267654]SteinhublSR , BergerPB , Mann JT 3rd, FryET , DeLagoA , WilmerC , et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [Erratum in: JAMA. 2003 Feb 26;289(8):987]. JAMA2002;288(19):2411-20. [MEDLINE: 12435254]">CREDO 2005</a>; <a href="./references#CD008834-bbs2-0017" title="BergerPB , SteinhublS .Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. Circulation2002;106(17):2284-7. [MEDLINE: 12390961]GerschutzGP , BhattDL , Clopidogrel in Unstable Angina to Prevent Recurrent Events study.The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?American Heart Journal2003;145(4):595-601. [MEDLINE: 12679754]KeltaiM , TonelliM , MannJF , SitkeiE , LewisBS , HawkenS , et al.Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. European Journal of Cardiovascular Prevention &amp; Rehabilitation2007;14(2):312-8. [MEDLINE: 17446813]LewisBS , MehtaSR , FoxKA , HalonDA , ZhaoF , PetersRJ , et al.Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. American Heart Journal2005;150(6):1177-84. [MEDLINE: 16338255]MehtaSR , YusufS , PetersRJ , BertrandME , LewisBS , NatarajanMK , et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet2001;358(9281):527-33. [MEDLINE: 11520521]MehtaSR , YusufS , Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators.The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. European Heart Journal2000;21(24):2033-41. [MEDLINE: 11102254]PetersRJ , MehtaSR , FoxKA , ZhaoF , LewisBS , KopeckySL , et al.Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation2003;108(14):1682-7. [MEDLINE: 14504182]YusufS ,  ZhaoF ,  MehtaSR ,  ChrolaviciusS ,  TognoniG ,  FoxKK , et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [Erratum in: N Engl J Med 2001 Dec 6;345(23):1716; Erratum in: N Engl J Med 2001 Nov 15;345(20):1506]. New England Journal of Medicine2001;345(7):494-502. [MEDLINE: 11519503]">CURE 2000</a>; <a href="./references#CD008834-bbs2-0019" title="DemberL , AllonM , DelmezJ , DixonB , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00550593] DemberLM , BeckGJ , AllonM , DelmezJA , DixonBS , GreenbergA , et al.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008;299(18):2164-71. [MEDLINE: 18477783]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials2005;2(5):413-22. [MEDLINE: 16317810]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):229A. [CENTRAL: CN-00445067] ">Dember 2005</a>; <a href="./references#CD008834-bbs2-0036" title="GhorbaniA , AalamshahM , ShahbazianH , EhsanpourA , ArefA .Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian Journal of Nephrology2009;19(2):57-61. [MEDLINE: 20368925]">Ghorbani 2009</a>; <a href="./references#CD008834-bbs2-0068" title="MozafarM , AlborziM , MoradiA .Effects of clopidogrel on longevity of permanent double-lumen catheter patency in dialysis patients: A single-blind placebo-controlled clinical trial. Nephro-Urology Monthly2018;10(2):e58135. [EMBASE: 622226387]">Mozafar 2018</a>) </p> </li> <li> <p>Clopidogrel and aspirin (1 study, 200 participants: <a href="./references#CD008834-bbs2-0056" title="ChangJJ , ConcatoJ , WellsCK , CrowleyST .Impact of adherence to clinical guidelines on mortality in hemodialysis patients [abstract no: SA-PO384]. Journal of the American Society of Nephrology2004;15(Oct):386A. [CENTRAL: CN-00583156] KaufmanJS , O'ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology2003;14(9):2313-21. [MEDLINE: 12937308]KaufmanJS , O’ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract no: A1495]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):291A. ">Kaufman 2003</a>) </p> </li> <li> <p>Clopidogrel and prostacyclin (1 study, 96 participants: <a href="./references#CD008834-bbs2-0002" title="AbacilarAF , AtalayH , DoganOF .Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: a randomized controlled study. Indian Journal of Nephrology2015;25(3):136-42. [MEDLINE: 26060361]">Abacilar 2015</a>) </p> </li> <li> <p>Ticlopidine (12 studies, 986 participants: <a href="./references#CD008834-bbs2-0012" title="ChengIK , FangGX , WongMC , JiYL , ChanKW , YeungHW .A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy. Nephrology1998;4(1-2):19-26. [EMBASE: 28282953]ChengIK , FangGX , WongMC , JiYL , YeungH .A randomised prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA glomerulonephritis (IgAN) [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:45. [CENTRAL: CN-00550664] ">Cheng 1998a</a>; <a href="./references#CD008834-bbs2-0016" title="CreekR .Ticlopidine. Patency of haemodialysis access sites. Guildford Sanofi Winthrop. Internal report1990. ">Creek 1990</a>; <a href="./references#CD008834-bbs2-0022" title="DoddNJ , TurneyJH , WestonMJ .Ticlopidine preserves vascular access for haemodialysis [abstract no: 326F]. In: Proceedings of the VI International Congress of Mediterranean League Against Thrombosis; 1980 Oct 25-26; Montecarlo, Monaco. 1980. ">Dodd 1980</a>; <a href="./references#CD008834-bbs2-0025" title="EllS , MihindukulasuriyaJC , O'BrienJR , PolakA , VernhamG .Ticlopidine in the prevention of blockage of fistulae and shunts [abstract no: 332]. Haemostasis1982;12:180. ">Ell 1982</a>; <a href="./references#CD008834-bbs2-0032" title="FiskerstrandCE , ThompsonIW , BurnetME , WilliamsP , AndertonJL .Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artificial Organs1985;9(1):61-3. [MEDLINE: 3888153]">Fiskerstrand 1985</a>; <a href="./references#CD008834-bbs2-0037" title="GhorbaniA , Jasemi-ZerganiF .Ticlopidine to prevent primary arteriovenous fistula failure in hemodialysis patients; a randomized controlled trial. Journal of Renal Injury Prevention2013;2(3):109-11. [MEDLINE: 25340144]">Ghorbani 2013</a>; <a href="./references#CD008834-bbs2-0042" title="GröntoftKC , MulecH , GutierrezA , OlanderR .Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scandinavian Journal of Urology &amp; Nephrology1985;19(1):55-7. [MEDLINE: 3895411]">Gröntoft 1985</a>; <a href="./references#CD008834-bbs2-0043" title="GröntoftK , LarssonR , MulecH , WeissLG , DickinsonJP .Ticlopidine in fistula surgery: double-blind comparison against placebo on the rate of early occlusion of arterio-venous fistulae [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:398. [CENTRAL: CN-00601921] GröntoftKC , LarssonR , MulecH , WeissLG , DickinsonJP .Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scandinavian Journal of Urology &amp; Nephrology1998;32(4):276-83. [MEDLINE: 9764456]">Gröntoft 1998</a>; <a href="./references#CD008834-bbs2-0054" title="KamperAM , LinsRL , ZacheeP , Van BergenS , HostenS , DaelemansR .Safety of combining ticlopidine with nadroparin in the routine treatment of chronic hemodialysis patients. Nephron1997;77(4):484-5. [MEDLINE: 9434075]">Kamper 1997</a>; <a href="./references#CD008834-bbs2-0058" title="KobayashiK , MaedaK , KoshikawaS , KawaguchiY , ShimizuN , NaitoC .Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis: a multicenter collaborative double blind study. Thrombosis Research1980;20(2):255-61. [MEDLINE: 7209880]">Kobayashi 1980</a>; <a href="./references#CD008834-bbs2-0065" title="MilutinovicS , GasparovicV , MilutinovicE , Buturovic-PonikvarJ .Ticlopidine improves dialysis clearance of solutes in uremic patients by reducing blood clotting in dialyser fibers. International Journal of Artificial Organs1993;16(5):249-52. [MEDLINE: 8354583]">Milutinovic 1993</a>; <a href="./references#CD008834-bbs2-0072" title="NybergG , LarssonO , WestbergNG , AurellM , JagenburgR , BlohmeG .A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study. Clinical Nephrology1984;21(3):184-7. [MEDLINE: 6705280]">Nyberg 1984</a>) </p> </li> </ul> </li> <li> <p>Haemorrhagic agents</p> <ul id="CD008834-list-0020"> <li> <p>Pentoxifylline (2 studies, 260 participants: <a href="./references#CD008834-bbs2-0040" title="deMoralesAM , GoicoecheaM , VerdeE , CarbayoJ , BarbieriD , DelgadoA , et al.Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial. Journal of Nephrology2019;32(4):581-7. [MEDLINE: 30949987]GoicoecheaM , Garcia de VinuesaS , QuirogaB , VerdallesU , BarracaD , YusteC , et al.Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. Journal of Nephrology2012;25(6):969-75. [MEDLINE: 22241639]">Goicoechea 2012</a>; <a href="./references#CD008834-bbs2-0082" title="Navarro-GonzalezJF , Sanchez-NinoMD , Donate-CorreaJ , Martin-NunezE , FerriC , Perez-DelgadoN , et al.Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease. Diabetes Care2018;41(8):1817-20. [MEDLINE: 29866645]">PREDIAN 2011</a>) </p> </li> </ul> </li> <li> <p>PAR‐1 antagonist</p> <ul id="CD008834-list-0021"> <li> <p>Vorapaxar (1 study, 4983 participants: <a href="./references#CD008834-bbs2-0103" title="CorreaS , BonacaMP , SciricaBM , MurphySA , GoodrichEL , MorrowDA , et al.Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. Journal of Thrombosis &amp; Thrombolysis2019;47(3):353-60. [MEDLINE: 30511258]GaviriaSC , BraunwaldE , BonacaMP , MurphySA , GoodrichEL , MorrowDA , et al.The efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function: insights from the TRA 2P-TIMI 50 trial [abstract no: 15480]. Circulation2017;136(Suppl 1). [EMBASE: 619986693]MorrowDA , BraunwaldE , BonacaMP , AmerisoSF , DalbyAJ , FishMP , et al.Vorapaxar in the secondary prevention of atherothrombotic events. New England Journal of Medicine2012;366(15):1404-13. [MEDLINE: 22443427]MorrowDA , SciricaBM , FoxKA , BermanG , StronyJ , VeltriE , et al.Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. American Heart Journal2009;158(3):335-41. [MEDLINE: 19699854]">TRA 2P‐TIMI 50 2009</a>) </p> </li> </ul> </li> <li> <p>Phosphodiesterase 3 inhibitors</p> <ul id="CD008834-list-0022"> <li> <p>Cilostazol (3 studies, 483 participants: <a href="./references#CD008834-bbs2-0050" title="JiaoXM , JiaoXJ , ZhangXG , XuXP , WuJX , YaoL , et al.Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy. Chinese Medical Journal2013;126(22):4395-6. [MEDLINE: 24238537]">Jiao 2013</a>; <a href="./references#CD008834-bbs2-0071" title="GuoX .A clinical study to evaluate the efficacy and safety of cilostazol and probucol in combination on patients with diabetic nephropathy. www.clinicaltrials.gov/show/nct01252056 (first received 2 December 2010). ">NCT01252056</a>; <a href="./references#CD008834-bbs2-0099" title="TangWH , LinFH , LeeCH , KuoFC , HsiehCH , HsiaoFC , et al.Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. Endocrine2014;45(2):293-301. [MEDLINE: 23775007]">Tang 2014</a>) </p> </li> <li> <p>Beraprost sodium (1 study, 892 participants: <a href="./references#CD008834-bbs2-0008" title="FujitaT , YuX , KimS , NakamotoH , OrigasaH , KurumataniH , et al.Effects of sustained-release beraprost sodium in patients with primary glomerular disease or nephrosclerosis: the CASSIOPEIR study [abstract no: SA-PO1096]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):4B. [CENTRAL: CN-01657821] NakamotoH , FujitaT , OrigasaH , IsonoM , KurumataniH , OkadaK , et al.A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrology2014;15:153. [MEDLINE: 25233856]NakamotoH , YuXQ , KimS , OrigasaH , ZhengH , ChenJ , et al.Effects of sustained-release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results. Therapeutic Apheresis &amp; Dialysis2020;24(1):42-55. [MEDLINE: 31119846]">CASSIOPEIR 2014</a>) </p> </li> </ul> </li> <li> <p>P2Y<sub>₁₂</sub> antagonists </p> <ul id="CD008834-list-0023"> <li> <p>Ticagrelor (1 study, 4849 participants: <a href="./references#CD008834-bbs2-0076" title="BonacaMP , BhattDL , BraunwaldE , CohenM , StegPG , StoreyRF , et al.Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal2014;167(4):437-44. [MEDLINE: 24655690]BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , JensenEC , et al.Long-term use of ticagrelor in patients with prior myocardial infarction. New England Journal of Medicine2015;372(19):1791-800. [MEDLINE: 25773268]BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , CohenM , et al.Prevention of stroke with ticagrelor in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation2016;134(12):861-71. [MEDLINE: 27576775]DellborgM , BonacaMP , StoreyRF , StegPG , ImKA , CohenM , et al.Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: Insights from PEGASUS-TIMI 54 [abstract]. European Heart Journal2017;38(Suppl 1):794-5. [EMBASE: 621235545]LozanoI , RondanJ , VegasJM , SegoviaE .Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):107-8. [MEDLINE: 29301622]MagnaniG , SabatineMS , BhattDL , ChoenM , StegG , StoreyR , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: Insights from the PEGASUS-TIMI 54 trial [abstract]. European Heart Journal2015;36(Suppl 1):520. [EMBASE: 72020712]MagnaniG , StoreyRF , StegG , BhattDL , CohenM , KuderJ , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. European Heart Journal2016;37(4):400-8. [MEDLINE: 26443023]MagnusonEA , BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , et al.Reply: cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):108. [MEDLINE: 29301623]MagnusonEA , LiH , WangK , VilainK , ShafiqA , BonacaMP , et al.Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: results from the PEGASUS-TIMI 54 trial. Journal of the American College of Cardiology2017;70(5):527-38. [MEDLINE: 28750695]MurphySA , BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , et al.Reduction in total cardiovascular events with long-term use of ticagrelor in patients with prior myocardial infarction in the PEGASUS-TIMI 54 trial [abstract no: A17121]. Circulation2015;132(Suppl 3). [EMBASE: 72179983]">PEGASUS‐TIMI 54 2014</a>) </p> </li> <li> <p>Ticagrelor plus aspirin then ticagrelor alone (1 study, 838 participants: <a href="./references#CD008834-bbs2-0039" title="GaoC , TomaniakM , TakahashiK , KawashimaH , WangR , HaraH , et al.Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovascular Diabetology2020;19(1):179. [MEDLINE: 33066794]TomaniakM , ChichareonP , Klimczak-TomaniakD , TakahashiK , KogameN , ModoloR , et al.Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Clinical Research in Cardiology2020;109(7):930-43. [MEDLINE: 31925529]VranckxP , ValgimigliM , JuniP , HammC , StegPG , HegD , et al.Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet2018;392(10151):940-9. [MEDLINE: 30166073]">GLOBAL LEADERS 2018</a>) </p> </li> </ul> </li> <li> <p>Glycoprotein IIb/IIIa inhibitors</p> <ul id="CD008834-list-0024"> <li> <p>Abciximab (5 studies, 1537 participants: <a href="./references#CD008834-bbs2-0026" title="AguirreFV , TopolEJ , AndersonKM , KleimanNS , WeismanHF , FitzPatrickSE , et al.Benefit within patient subgroups receiving c7e3 fab (abciximab) during percutaneous coronary revascularization: subgroup analysis from the EPIC trial. Journal of Invasive Cardiology1996;8 Suppl B:21-9B. [MEDLINE: 10785766]AguirreFV , TopolEJ , FergusonJJ , AndersonK , BlankenshipJC , HeuserRR , et al.Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation1995;91(12):2882-90. [MEDLINE: 7796496]BerkowitzSD , SaneDC , SigmonKN , ShavenderJH , HarringtonRA , TchengJE , et al.Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. Journal of the American College of Cardiology1998;32(2):311-9. [MEDLINE: 9708455]BlankenshipJC , HellkampAS , AguirreFV , DemkoSL , TopolEJ , CaliffRM .Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. American Journal of Cardiology1998;81(1):36-40. [MEDLINE: 9462603]BoehrerJD , KereiakesDJ , NavettaFI , CaliffRM , TopolEJ .Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications. American Journal of Cardiology1994;74(11):1166-70. [MEDLINE: 7977081]CaliffRM , LincoffAM , TchengJE , TopolEJ .An overview of the results of the EPIC trial. European Heart Journal1995;16 Suppl L:43-9. [MEDLINE: 8869018]EPIC Investigators.Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New England Journal of Medicine1994;330(14):956-61. [MEDLINE: 8121459]KhanMM , EllisSG , AguirreFV , WeismanHF , WildermannNM , CaliffRM , et al.Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1998;31(1):31-6. [MEDLINE: 9426014]LefkovitsJ , BlankenshipJC , AndersonKM , StonerGL , TalleyJD , WorleySJ , et al.Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. Journal of the American College of Cardiology1996;28(4):849-55. [MEDLINE: 8837559]LefkovitsJ , IvanhoeRJ , CaliffRM , BergelsonBA , AndersonKM , StonerGL , et al.Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. American Journal of Cardiology1996;77(12):1045-51. [MEDLINE: 8644655]LincoffAM , CaliffRM , AndersonKM , WeismanHF , AguirreFV , KleimanNS , et al.Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1997;30(1):149-56. [MEDLINE: 9207636]MakKH , ChallapalliR , EisenbergMJ , AndersonKM , CaliffRM , TopolEJ .Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. American Journal of Cardiology1997;80(8):985-8. [MEDLINE: 9352964]MarkDB , TalleyJD , TopolEJ , BowmanL , LamLC , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation1996;94(4):629-35. [MEDLINE: 8772681]MoliternoDJ , CaliffRM , AguirreFV , AndersonK , SigmonKN , WeismanHF , et al.Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. American Journal of Cardiology1995;75(8):559-62. [MEDLINE: 7887377]NarinsCR , MillerDP , CaliffRM , TopolEJ .The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1999;33(3):647-53. [MEDLINE: 10080464]ThelMC , CaliffRM , TchengJE , SigmonKN , LincoffAM , TopolEJ , et al.Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. American Heart Journal1999;137(2):264-73. [MEDLINE: 9924160]TopolEJ , CaliffRM , WeismanHF , EllisSG , TchengJE , WorleyS , et al.Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet1994;343(8902):881-6. [MEDLINE: 7908357]TopolEJ , FergusonJJ , WeismanHF , TchengJE , EllisSG , KleimanNS , et al.Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA1997;278(6):479-84. [MEDLINE: 9256222]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. American Heart Journal1998;135(4):S98-106. [MEDLINE: 9539500]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. European Heart Journal1998;19 Suppl D:D59-66. [MEDLINE: 9597523]">EPIC 1994</a>; <a href="./references#CD008834-bbs2-0027" title="EPILOG Investigators.Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New England Journal of Medicine1997;336(24):1689-96. [MEDLINE: 9182212]GhaffariS , KereiakesDJ , LincoffAM , KellyTA , TimmisGC , KleimanNS , et al.Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. American Journal of Cardiology1998;82(1):7-12. [MEDLINE: 9671000]KereiakesDJ , LincoffAM , MillerDP , TchengJE , CabotCF , AndersonKM , et al.Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Circulation1998;97(9):857-64. [MEDLINE: 9521334]KleimanNS , LincoffAM , KereiakesDJ , MillerDP , AguirreFV , AndersonKM , et al.Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation1998;97(19):1912-20. [MEDLINE: 9609084]LincoffAM , MarkDB , TchengJE , CaliffRM , BalaMV , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation2000;102(24):2923-9. [MEDLINE: 11113041]LincoffAM , TchengJE , CaliffRM , KereiakesDJ , KellyTA , TimmisGC , et al.Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. One-year outcome in the EPILOG trial. Circulation1999;99(15):1951-8. [MEDLINE: 10208997]">EPILOG 1997</a>; <a href="./references#CD008834-bbs2-0028" title="ChoL , MarsoSP , BhattDL , TopolEJ .Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial. Journal of Womens Health &amp; Gender-Based Medicine2000;9(7):741-6. [MEDLINE: 11025866]De ServiS .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse events. Data from the Evaluation of Platelets IIb/IIIa Inhibitor for Stenting (EPISTENT) trial [Il pretrattamento con ticlopidina nello stent coronarico e associato a significativa riduzione di eventi avversi. Dati dal trial EPISTENT]. Italian Heart Journal Supplement2001;2(7):805-6. [MEDLINE: 11508303]EPISTENT Investigators.Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet1998;352(9122):87-92. [MEDLINE: 9672272]IslamMA , BlankenshipJC , BalogC , IliadisEA , LincoffAM , TchengJE , et al.Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). American Journal of Cardiology2002;90(9):916-21. [MEDLINE: 12398954]LincoffAM .Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial. American Heart Journal2000;139(2 Pt 2):S46-52. [MEDLINE: 10650316]MarsoSP , LincoffAM , EllisSG , BhattDL , TanguayJF , KleimanNS , et al.Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation1999;100(25):2477-84. [MEDLINE: 10604884]SteinhublSR , EllisSG , WolskiK , LincoffAM , TopolEJ .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation2001;103(10):1403-9. [MEDLINE: 11245644]SteinhublSR , TanWA , FoodyJM , TopolEJ .Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA1999;281(9):806-10. [MEDLINE: 10071001]TopolEJ , MarkDB , LincoffAM , CohenE , BurtonJ , KleimanN , et al.Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.[Erratum in: Lancet 2000 Mar 25;355(9209):1104]. Lancet1999;354(9195):2019-24. [MEDLINE: 10636365]Zwart-van RijkomJE , vanHoutBA .Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb/IIIa Inhibitor For Stenting Trial. European Heart Journal2001;22(16):1476-84. [MEDLINE: 11482921]">EPISTENT 1998</a>; <a href="./references#CD008834-bbs2-0086" title="BrenerSJ , BarrLA , BurchenalJE , KatzS , GeorgeBS , JonesAA , et al.Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation1998;98(8):734-41. [MEDLINE: 9727542]BrenerSJ , BarrLA , BurchenalJE , WolskiKE , EffronMB , TopolEJ .Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial. American Journal of Cardiology1999;84(6):728-30. [MEDLINE: 10498145]">RAPPORT 1998</a>; <a href="./references#CD008834-bbs2-0088" title="CooperCJ , HallerST , ColyerW , SteffesM , BurketMW , ThomasWJ , et al.Embolic protection and platelet inhibition during renal artery stenting. Circulation2008;117(21):2752-60. [MEDLINE: 18490527]HeW , CheJ , ZhanD , DawsoT , KanjwaS , HalleS , et al.Time dependant changes in systolic blood pressure after renal artery stenting: role of stenosis severity [abstract no: 14283]. Circulation2012;126(21 Suppl 1). [EMBASE: 70958797]KanjwalK , CooperCJ , VirmaniR , HallerS , ShapiroJI , BurketMW , et al.Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy. Catheterization &amp; Cardiovascular Interventions2010;76(1):16-23. [MEDLINE: 20209644]KanjwalK , HallerS , SteffesM , VirmaniR , ShapiroJI , BurketMW , et al.Complete versus partial distal embolic protection during renal artery stenting. Catheterization &amp; Cardiovascular Interventions2009;73(6):725-30. [MEDLINE: 19198007]TianJ , HallerS , PeriyasamyS , BrewsterP , ZhangH , AdlakhaS , et al.Renal ischemia regulates marinobufagenin release in humans. Hypertension2010;56(5):914-9. [MEDLINE: 20823380]YuH , ZhangD , HallerS , KanjwalK , ColyerW , BrewsterP , et al.Determinants of renal function in patients with renal artery stenosis. Vascular Medicine2011;16(5):331-8. [MEDLINE: 21908683]">RESIST 2008</a>) </p> </li> <li> <p>Tirofiban (1 study, 611 participants: <a href="./references#CD008834-bbs2-0083" title="HuynhT , NasmithJ , LuongTM , BernierM , PharandC , Xue-QiaoZ , et al.Complementary prognostic values of ST segment deviation and Thrombolysis In Myocardial Infarction (TIMI) risk score in non-ST elevation acute coronary syndromes: insights from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Canadian Journal of Cardiology 2009 Dec;25(12):e417-21. [MEDLINE: 19960136]HuynhT , PiazzaN , DiBattistePM , SnapinnSM , WanY , PharandC , et al.Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study. International Journal of Cardiology2005;100(1):73-8. [MEDLINE: 15820288]HuynhT , TherouxP , SnapinnS , WanY , PRISM-PLUS Investigators.Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). American Heart Journal2003;146(4):668-73. [MEDLINE: 14564321]Januzzi JL Jr, SnapinnSM , DiBattistePM , JangIK , TherouxP .Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation2002;105(20):2361-6. [MEDLINE: 12021221]MegaJL , MorrowDA , SabatineMS , ZhaoXQ , SnapinnSM , DiBattistePM , et al.Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. American Heart Journal2005;149(5):846-50. [MEDLINE: 15894966]MorrowDA , SabatineMS , AntmanEM , CannonCP , BraunwaldE , TherouxP .Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). American Journal of Cardiology2004;94(6):774-6. [MEDLINE: 15374786]Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New England Journal of Medicine1998;338(21):1488-97. [MEDLINE: 9599103]ServossSJ , WanY , SnapinnSM , DiBattistePM , ZhaoXQ , TherouxP , et al.Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. American Journal of Cardiology2004;93(7):843-7. [MEDLINE: 15050486]SzucsTD , MeyerBJ , KiowskiW .Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial. European Heart Journal1999;20(17):1253-60. [MEDLINE: 10454977]TherouxP , AlexanderJ , PharandC , BarrE , SnapinnS , GhannamAF , et al.Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation2000;102(20):2466-72. [MEDLINE: 11076818]TherouxP , Alexander J Jr, DupuisJ , PesantY , GervaisP , GrandmontD , et al.Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators. American Journal of Cardiology2001;87(4):375-80. [MEDLINE: 11179517]ZhaoXQ , TherouxP , SnapinnSM , SaxFL .Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Circulation1999;100(15):1609-15. [MEDLINE: 10517731]">PRISM‐PLUS 1998</a>) </p> </li> <li> <p>Eptifibatide (3 studies, 5065 participants: <a href="./references#CD008834-bbs2-0024" title="BagaiA , WhiteJA , LokhnyginaY , GiuglianoRP , Van de WerfF , MontalescotG , et al.Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. American Heart Journal2013;166(3):466-73. [MEDLINE: 24016495]De FerrariGM , Van de WerfF , ArmstrongP , BodeC , LewisBS , TricociP , et al.Contrast induced nephropathy predicts later mortality among patients with non-ST-segment elevation acute coronary syndrome undergoing PCI: a sub-analysis from the EARLY ACS study [abstract no: P3820]. European Heart Journal2011;32(Suppl 1):657. [EMBASE: 70535519]EzekowitzJA , BakalJA , WesterhoutCM , GiuglianoRP , WhiteH , KeltaiM , et al.The relationship between meteorological conditions and index acute coronary events in a global clinical trial. International Journal of Cardiology2013;168(3):2315-21. [MEDLINE: 23416014]FarhanS , ClareRM , JaraiR , GiuglianoRP , LokhnyginaY , HarringtonRA , et al.Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: an analysis from EARLY ACS. International Journal of Cardiology2017;232:264-70. [MEDLINE: 28089149]FarhanS , ClareRM , JaraiR , NewbyLK , MorrowD , GiuglianoRP , et al.Fasting glucose, NT-proBNP, treatment with glycoprotein IIB/IIIA inhibitors, and outcomes in non-st-segment elevation acute coronary syndromes: an analysis from early ACS [abstract no: A14618]. Circulation2013;128(22 Suppl 1). [EMBASE: 71340424]GiuglianoRP , NewbyLK , HarringtonRA , GibsonCM , Van de WerfF , ArmstrongP , et al.The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. American Heart Journal2005;149(6):994-1002. [MEDLINE: 15976780]GiuglianoRP , WhiteJA , BodeC , ArmstrongPW , MontalescotG , LewisBS , et al.Early versus delayed, provisional eptifibatide in acute coronary syndromes. New England Journal of Medicine2009;360(21):2176-90. [MEDLINE: 19332455]HessCN , SchultePJ , NewbyLK , StegPG , DalbyAJ , SchweigerMJ , et al.Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. European Heart Journal: Acute Cardiovascular Care2013;2(3):246-55. [MEDLINE: 24222836]KaulP , TanguayJF , NewbyLK , HochmanJS , WesterhoutCM , CaliffRM , et al.Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. American Heart Journal2013;166(4):723-8. [MEDLINE: 24093853]KlutsteinMW , WesterhoutCM , ArmstrongPW , GiuglianoRP , LewisBS , GibsonCM , et al.Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. American Heart Journal2013;165(4):583-90. [MEDLINE: 23537976]KunadianV , GiuglianoRP , NewbyLK , ZorkunC , GuoJ , BagaiA , et al.Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). American Journal of Cardiology2014;113(8):1297-305. [MEDLINE: 24607027]LopesRD , WhiteJA , TricociP , WhiteHD , ArmstrongPW , BraunwaldE , et al.Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. International Journal of Cardiology2013;167(6):2580-7. [MEDLINE: 22795720]MelloniC , JamesSK , WhiteJA , GiuglianoRP , HarringtonRA , HuberK , et al.Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. American Heart Journal2011;162(5):884-92. [MEDLINE: 22093205]PicciniJP , WhiteJA , MehtaRH , LokhnyginaY , Al-KhatibSM , TricociP , et al.Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. Circulation2012;126(1):41-9. [MEDLINE: 22645292]PrideYB , MohanaveluS , GiuglianoRP , NewbyLK , ZorkunC , KunadianV , et al.Association between angiographic complications during percutaneous coronary intervention and clinical outcomes among patients with acute coronary syndrome: an early ACS angiographic substudy [abstract no: A10394]. Circulation2011;124(21 Suppl 1). [EMBASE: 70620664]PrideYB , MohanaveluS , ZorkunC , KunadianV , GiuglianoRP , NewbyLK , et al.Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. Jacc: Cardiovascular Interventions2012;5(9):927-35. [MEDLINE: 22995880]RoeMT , WhiteJA , KaulP , TricociP , LokhnyginaY , MillerCD , et al.Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. Circulation. Cardiovascular Quality &amp; Outcomes2012;5(2):205-13. [MEDLINE: 22373905]TanguayJF , NewbyLK , HochmanJ , WesterhoutCM , CaliffRM , GibsonCM , et al.Sex differences in high-risk acute coronary syndromes: Insights from early-ACS [abstract]. Journal of the American College of Cardiology2010;55(10 Suppl 1):A120.E1122. [EMBASE: 70096317]TolevaO , WesterhoutCM , SenaratneM , BodeC , LindroosM , ArdissinoD , et al.Association of hub and spoke practice patterns with coronary intervention and outcomes in non ST elevation acute coronary syndromes (NSTE ACS): Insights from the early glycoprotein IIb/IIIa inhibition in NSTE ACS (early-ACS) trial [abstract]. Journal of the American College of Cardiology2011;57(14 Suppl 1):E1101. [EMBASE: 70400778]TolevaO , WesterhoutCM , SenaratneMP , BodeC , LindroosM , SulimovVA , et al.Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial. Catheterization &amp; Cardiovascular Interventions2014;84(6):934-42. [MEDLINE: 24976083]WangT , WhiteJA , GiuglianoRP , TricociP , HarringtonRA , MontalescotG , et al.Upfront clopidogrel use and the efficacy and safety of early eptifibatide use in patients with acute coronary syndrome: An analysis from the early versus delayed provisional eptifibatide in acute coronary syndromes (early ACS) trial [abstract]. Journal of the American College of Cardiology2010;55(10 Suppl 1):A47.E451. [EMBASE: 70095646]WangTY , WhiteJA , TricociP , GiuglianoRP , ZeymerU , HarringtonRA , et al.Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Circulation2011;123(7):722-30. [MEDLINE: 21300952]">EARLY ACS 2005</a>; <a href="./references#CD008834-bbs2-0049" title="BlankenshipJC , SigmonKN , PieperKS , O'SheaC , TardiffBE , TchengJE , et al.Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial. American Journal of Cardiology2001;88(9):969-73. [MEDLINE: 11703991]GilchristIC , GardnerLH , MuhlesteinJB , ArnoldAM , LincoffAM , CaliffRM , et al.Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience. American Heart Journal1999;138(5 Pt 1):976-82. [MEDLINE: 10539832]MandakJS , BlankenshipJC , GardnerLH , BerkowitzSD , AguirreFV , SigmonKN , et al.Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Journal of the American College of Cardiology1998;31(7):1518-24. [MEDLINE: 9626829]Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet1997;349(9063):1422-8. [MEDLINE: 9164315]TardiffBE , CaliffRM , TchengJE , LincoffAM , SigmonKN , HarringtonRA , et al.Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. Journal of the American College of Cardiology1999;33(1):88-96. [MEDLINE: 9935014]ThelMC , CaliffRM , TardiffBE , GardnerLH , SigmonKN , LincoffAM , et al.Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. American Journal of Cardiology2000;85(4):427-34. [MEDLINE: 10728945]">IMPACT II 1997</a>; <a href="./references#CD008834-bbs2-0084" title="AkkerhuisKM , DeckersJW , BoersmaE , HarringtonRA , StepinskaJ , MahaffeyKW , et al.Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. European Heart Journal2000;21(5):371-81. [MEDLINE: 10666351]AkkerhuisKM , MaasAC , KlootwijkPA , KrucoffMW , MeijS , CaliffRM , et al.Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of Electrocardiology2000;33(2):127-36. [MEDLINE: 10819406]AlexanderJH , HarringtonRA , TuttleRH , BerdanLG , LincoffAM , DeckersJW , et al.Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology1999;83(8):1147-51. [MEDLINE: 10215274]BoersmaE , PieperKS , SteyerbergEW , WilcoxRG , ChangWC , LeeKL , et al.Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation2000;101(22):2557-67. [MEDLINE: 10840005]BrownRE , HendersonRA , KosterD , HuttonJ , SimoonsML .Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy. European Heart Journal2002;23(1):50-8. [MEDLINE: 11741362]ChangWC , HarringtonRA , SimoonsML , CaliffRM , LincoffAM , ArmstrongPW , et al.Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial. European Heart Journal2002;23(14):1102-11. [MEDLINE: 12090748]DykeCM , BhatiaD , LorenzTJ , MarsoSP , TardiffBE , HogeboomC , et al.Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Annals of Thoracic Surgery2000;70(3):866-71. [MEDLINE: 11016325]GreenbaumAB , HarringtonRA , HudsonMP , MacAulayCM , WilcoxRG , SimoonsML , et al.Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. Journal of the American College of Cardiology2001;37(2):492-8. [MEDLINE: 11216968]HarringtonRA .Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology1997;80(4A):34-8B. [MEDLINE: 9291244]HasdaiD , Holmes DR Jr, CrigerDA , TopolEJ , CaliffRM , WilcoxRG , et al.Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators. American Heart Journal2000;139(3):454-60. [MEDLINE: 10689260]KleimanNS , LincoffAM , FlakerGC , PieperKS , WilcoxRG , BerdanLG , et al.Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation2000;101(7):751-7. [MEDLINE: 10683348]LabinazM , KaulP , HarringtonRA , ChangWC , KleimanNS , SimoonsML , et al.Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. Canadian Journal of Cardiology2004;20(8):773-8. [MEDLINE: 15229770]LabinazM , KilaruR , PieperK , MarsoSP , KittMM , SimoonsML , et al.Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2002;105(3):322-7. [MEDLINE: 11804987]LauerMA , HoughtalingPL , PetersonJG , GrangerCB , BhattDL , SappSK , et al.Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2001;104(23):2772-7. [MEDLINE: 11733393]LincoffAM , HarringtonRA , CaliffRM , HochmanJS , GuerciAD , OhmanEM , et al.Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2000;102(10):1093-100. [MEDLINE: 10973836]MahaffeyKW , HarringtonRA , AkkerhuisM , KleimanNS , BerdanLG , CrenshawBS , et al.Systematic adjudication of myocardial infarction end-points in an international clinical trial. Current Controlled Trials in Cardiovascular Medicine2001;2(4):180-6. [MEDLINE: 11806793]MahaffeyKW , HarringtonRA , SimoonsML , GrangerCB , GraffagninoC , AlbertsMJ , et al.Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation1999;99(18):2371-7. [MEDLINE: 10318656]MarkDB , HarringtonRA , LincoffAM , CaliffRM , NelsonCL , TsiatisAA , et al.Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation2000;101(4):366-71. [MEDLINE: 10653826]MarsoSP , BhattDL , RoeMT , HoughtalingPL , LabinazM , KleimanNS , et al.Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators. Circulation2000;102(24):2952-8. [MEDLINE: 11113045]McClureMW , BerkowitzSD , SparapaniR , TuttleR , KleimanNS , BerdanLG , et al.Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation1999;99(22):2892-900. [MEDLINE: 10359733]PetersonJG , TopolEJ , RoeMT , SappSK , LincoffAM , DeckersJW , et al.Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology2001;87(5):532-6. [MEDLINE: 11230834]PURSUIT Trial Investigators.Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. New England Journal of Medicine1998;339(7):436-43. [MEDLINE: 9705684]RoeMT , HarringtonRA , ProsperDM , PieperKS , BhattDL , LincoffAM , et al.Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation2000;102(10):1101-6. [MEDLINE: 10973837]RonnerE , BoersmaE , AkkerhuisKM , HarringtonRA , LincoffAM , DeckersJW , et al.Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. European Heart Journal2002;23(3):239-46. [MEDLINE: 11792139]RonnerE , BoersmaE , LaarmanGJ , SomsenGA , HarringtonRA , DeckersJW , et al.Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of the American College of Cardiology2002;39(12):1924-9. [MEDLINE: 12084589]SrichaiMB , JaberWA , PriorDL , MarsoSP , HoughtalingPL , MenonV , et al.Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes. American Heart Journal2004;147(1):84-90. [MEDLINE: 14691424]">PURSUIT 1997</a>) </p> </li> </ul> </li> <li> <p>Other</p> <ul id="CD008834-list-0025"> <li> <p>Defibrotide (1 study, 20 participants: <a href="./references#CD008834-bbs2-0034" title="FrascàGM , CiancioloG .A clinical trial with defibrotide in IgA nephritis (IgA-GN) with impaired renal function [abstract]. Nephrology Dialysis Transplantation1995;10(6):968. [CENTRAL: CN-00261099] FrascàGM , MartelloM , CanovaC , IsolaE , VangelistaA , BonominiV .Defibrotide treatment and disease progression in patients with IgA nephropathy and impaired renal function at diagnosis. Clinical Drug Investigation1997;13(4):185-91. [EMBASE: 27192802]FrascàGM , MartelloM , SestigianiE , CanovaC , VangelistaA , BonominiV .Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function. Nephrology Dialysis Transplantation1996;11(2):392-3. [MEDLINE: 8700366]">Frascà 1997</a>) </p> </li> <li> <p>Picotamide (3 studies, 901 participants: <a href="./references#CD008834-bbs2-0038" title="GiustinaA , PeriniP , DesenzaniP , BossoniS , IannielloP , MilaniM , et al.Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes1998;47(3):423-30. [MEDLINE: 9519749]">Giustina 1998</a>; <a href="./references#CD008834-bbs2-0085" title="Quarto Di PaloF , ElliA , RivoltaR , ParentiM , PalazziP , ZanussiC .Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide. Transplantation Proceedings1991;23(1 Pt 2):969-71. [MEDLINE: 1989347]">Quarto Di Palo 1991</a>; <a href="./references#CD008834-bbs2-0096" title="MiletiM , De PetriG , BacchiM , OgliariV , PecchiniF , BufanoG , et al.A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients. Journal of Nephrology1995;8(2):167-72. [EMBASE: 25209311]">STOP 1995</a>) </p> </li> <li> <p>Sarpogrelate (2 studies, 132 participants: <a href="./references#CD008834-bbs2-0108" title="WatanabeH , NakagawaK , KakihanaM .Long-term effects of sarpogrelate, a selective serotonin receptor antagonist, in diabetic patients with stable angina and chronic kidney disease [abstract no: 11204]. Circulation2011;124(21 Suppl 1). [EMBASE: 70620962]">Watanabe 2011b</a>; <a href="./references#CD008834-bbs2-0112" title="YutoJ , EharaY , ShibataK , IwamotoT , YasudaG , YatsuK , et al.Effect of sarpogrelate on fistula patency of forearm arteriovenous anastomisis in uremic patients [abstract no: 276]. Kidney Research &amp; Clinical Practice2012;31(2):A86. [EMBASE: 70814985]">Yuto 2012</a>) </p> </li> <li> <p>Sulphinpyrazone (3 studies, 108 participants: <a href="./references#CD008834-bbs2-0021" title="Dmoszynska-GiannopoulouA , JanickaL , SokolowskaB , KsiazekA , OrlowskaG , JanickiK .The effect of sulphinpyrazone and alpha-tocopherol on platelet activation and function in haemodialysed patients. International Urology &amp; Nephrology1990;22(6):561-6. [MEDLINE: 2093696]">Dmoszynska‐Giannopoulou 1990</a>; <a href="./references#CD008834-bbs2-0053" title="KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. New England Journal of Medicine1974;290(6):304-6. [MEDLINE: 4588285]KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation1975;52(3):497-9. [MEDLINE: 1098808]">Kaegi 1974</a>; <a href="./references#CD008834-bbs2-0063" title="MichieDD , WomboltDG .Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research - Clinical &amp; Experimental1977;22(1 II):196-204. [EMBASE: 8152617]">Michie 1977</a>) </p> </li> <li> <p>Sulphonamide derivative (1 study, 6 participants: <a href="./references#CD008834-bbs2-0080" title="PierucciA , SimonettiBM , PecciG , FeriozziS , MavrikakisG , CinottiGA , et al.Low dose aspirin in patients with lupus nephritis [abstract]. Kidney International1988;33(1):281. [CENTRAL: CN-00583819] PierucciA , SimonettiBM , PecciG , MavrikakisG , FeriozziS , CinottiGA , et al.Acute effects of a thromboxane receptor antagonist on renal function in patients with lupus nephritis [abstract]. Kidney International1987;31(1):283. [CENTRAL: CN-00724956] PierucciA , SimonettiBM , PecciG , MavrikakisG , FeriozziS , CinottiGA , et al.Improvement of renal function with selective thromboxane antagonism in lupus nephritis. New England Journal of Medicine1989;320(7):421-5. [MEDLINE: 2643773]">Pierucci 1989</a>) </p> </li> <li> <p>Thromboxane synthetase inhibitor (1 study, 15 participants: <a href="./references#CD008834-bbs2-0059" title="KontessisPS , JonesSL , BarrowSE , StrattonPD , AlessandriniP , De CosmoS , et al.Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy. Journal of Laboratory &amp; Clinical Medicine1993;121(3):415-23. [MEDLINE: 8445289]">Kontessis 1993</a>) </p> </li> <li> <p>SER150 (novel anti‐thromboxane) (1 study, 72 participants: <a href="./references#CD008834-bbs2-0095" title="SteinessE , BrunN , SkarsfeldtT , DerwahlKM .Low dose anti-thromboxane reduces urinary albumin in patients with diabetic kidney disease [abstract no: SA-PO148]. Journal of the American Society of Nephrology2018;29:773. [EMBASE: 633731990]">Steiness 2018</a>) </p> </li> <li> <p>Vorapaxar (1 study, 1477 participants: <a href="./references#CD008834-bbs2-0104" title="CornelJH , TricociP , HortonJ , MoliternoD , WallentinL , ArmstrongP , et al.Effects of glycoprotein IIB/IIIA inhibitors in combination with vorapaxar, a platelet thrombin-receptor antagonist, among patients with non-St-segment elevation acute coronary syndromes: insights from the TRACER trial [abstract]. Journal of the American College of Cardiology2013;61(10 Suppl 1):E102. [EMBASE: 71019466]MahaffeyKW , PieperK , VranckxP , TricociP , Van de WerfF , HeldC , et al.Chronic kidney disease is associated with worse outcomes in ACS patients: results from the TRACER trial [abstract]. European Heart Journal2014;35(Suppl 1):687. [EMBASE: 71649310]">TRACER 2013</a>) </p> </li> </ul> </li> </ul> </p> <section id="CD008834-sec-0044"> <h6 class="title">Vascular access studies</h6> <p>We identified 31 studies that reported dialysis vascular access endpoints in 6449 participants (<a href="./references#CD008834-bbs2-0002" title="AbacilarAF , AtalayH , DoganOF .Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: a randomized controlled study. Indian Journal of Nephrology2015;25(3):136-42. [MEDLINE: 26060361]">Abacilar 2015</a>; <a href="./references#CD008834-bbs2-0003" title="Abdul-RahmanIS , Al-HowaishAK .Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23-30. [EMBASE: 2007269768]">Abdul‐Rahman 2007</a>; <a href="./references#CD008834-bbs2-0005" title="AndersonM , DewarP , FlemingLB , HackingPM , MorleyAR , MurrayS , et al.A controlled trial of dipyridamole in human renal transplantation and an assessment of platelet function studies in rejection. Clinical Nephrology1974;2(3):93-9. [MEDLINE: 4603996]">Anderson 1974</a>; <a href="./references#CD008834-bbs2-0006" title="AndrassyK , MallucheH , BornefeldH , CombergM , RitzE , JesdinskyH , et al.Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: results of a prospective double blind study. Klinische Wochenschrift1974;52(7):348-9. [MEDLINE: 4600820]">Andrassy 1974</a>; <a href="./references#CD008834-bbs2-0016" title="CreekR .Ticlopidine. Patency of haemodialysis access sites. Guildford Sanofi Winthrop. Internal report1990. ">Creek 1990</a>; <a href="./references#CD008834-bbs2-0019" title="DemberL , AllonM , DelmezJ , DixonB , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00550593] DemberLM , BeckGJ , AllonM , DelmezJA , DixonBS , GreenbergA , et al.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008;299(18):2164-71. [MEDLINE: 18477783]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials2005;2(5):413-22. [MEDLINE: 16317810]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):229A. [CENTRAL: CN-00445067] ">Dember 2005</a>; <a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a>; <a href="./references#CD008834-bbs2-0022" title="DoddNJ , TurneyJH , WestonMJ .Ticlopidine preserves vascular access for haemodialysis [abstract no: 326F]. In: Proceedings of the VI International Congress of Mediterranean League Against Thrombosis; 1980 Oct 25-26; Montecarlo, Monaco. 1980. ">Dodd 1980</a>; <a href="./references#CD008834-bbs2-0025" title="EllS , MihindukulasuriyaJC , O'BrienJR , PolakA , VernhamG .Ticlopidine in the prevention of blockage of fistulae and shunts [abstract no: 332]. Haemostasis1982;12:180. ">Ell 1982</a>; <a href="./references#CD008834-bbs2-0031" title="BadveS , HawleyCM , IrishAB , Paul-BrentP .High rate of screening failure in the FAVOURED study [abstract no: PUB345]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):905A. IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al.Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453]IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul-BrentP , et al.Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis-a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804]IrishA , FAVOURED Study Group.High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN-00756870] IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 009]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790]IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. [EMBASE: 70467038]IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul-BrentPA , et al.Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184-93. [MEDLINE: 28055065]IrishAB .The omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo-controlled trial [abstract no: HI-OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2-3. [CENTRAL: CN-01658143] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis-post hoc analysis of the FAVOURED study [abstract no: MO049]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475]ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on the need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology2018;23(Suppl 3):56. [EMBASE: 623841152]ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al.Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract no: SP593]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178]ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract no: FP555]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265]ViecelliA , PascoeE , PolkinghorneK , Paul-BrentP , DarssanD , HooiL , et al.A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115-6. [EMBASE: 612312707]ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul-BrentPA , BadveSV , et al.The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581]ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis - Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217-28. [MEDLINE: 26205903]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study. Nephrology2017;22(10):823-4. [MEDLINE: 27188542]ViecelliAK , PolkinghorneKR , PascoeEM , Paul-BrentPA , HawleyCM , BadveSV , et al.Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS ONE [Electronic Resource]2019;14(3):e0213274. [MEDLINE: 30913208]">FAVOURED 2009</a>; <a href="./references#CD008834-bbs2-0032" title="FiskerstrandCE , ThompsonIW , BurnetME , WilliamsP , AndertonJL .Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artificial Organs1985;9(1):61-3. [MEDLINE: 3888153]">Fiskerstrand 1985</a>; <a href="./references#CD008834-bbs2-0036" title="GhorbaniA , AalamshahM , ShahbazianH , EhsanpourA , ArefA .Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian Journal of Nephrology2009;19(2):57-61. [MEDLINE: 20368925]">Ghorbani 2009</a>; <a href="./references#CD008834-bbs2-0037" title="GhorbaniA , Jasemi-ZerganiF .Ticlopidine to prevent primary arteriovenous fistula failure in hemodialysis patients; a randomized controlled trial. Journal of Renal Injury Prevention2013;2(3):109-11. [MEDLINE: 25340144]">Ghorbani 2013</a>; <a href="./references#CD008834-bbs2-0042" title="GröntoftKC , MulecH , GutierrezA , OlanderR .Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scandinavian Journal of Urology &amp; Nephrology1985;19(1):55-7. [MEDLINE: 3895411]">Gröntoft 1985</a>; <a href="./references#CD008834-bbs2-0043" title="GröntoftK , LarssonR , MulecH , WeissLG , DickinsonJP .Ticlopidine in fistula surgery: double-blind comparison against placebo on the rate of early occlusion of arterio-venous fistulae [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:398. [CENTRAL: CN-00601921] GröntoftKC , LarssonR , MulecH , WeissLG , DickinsonJP .Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scandinavian Journal of Urology &amp; Nephrology1998;32(4):276-83. [MEDLINE: 9764456]">Gröntoft 1998</a>; <a href="./references#CD008834-bbs2-0046" title="HarterHR , BurchJW , MajerusPW , StanfordN , DelmezJA , AndersonCB , et al.Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. New England Journal of Medicine1979;301(11):577-9. [MEDLINE: 112475]">Harter 1979</a>; <a href="./references#CD008834-bbs2-0053" title="KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. New England Journal of Medicine1974;290(6):304-6. [MEDLINE: 4588285]KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation1975;52(3):497-9. [MEDLINE: 1098808]">Kaegi 1974</a>; <a href="./references#CD008834-bbs2-0056" title="ChangJJ , ConcatoJ , WellsCK , CrowleyST .Impact of adherence to clinical guidelines on mortality in hemodialysis patients [abstract no: SA-PO384]. Journal of the American Society of Nephrology2004;15(Oct):386A. [CENTRAL: CN-00583156] KaufmanJS , O'ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology2003;14(9):2313-21. [MEDLINE: 12937308]KaufmanJS , O’ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract no: A1495]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):291A. ">Kaufman 2003</a>; <a href="./references#CD008834-bbs2-0058" title="KobayashiK , MaedaK , KoshikawaS , KawaguchiY , ShimizuN , NaitoC .Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis: a multicenter collaborative double blind study. Thrombosis Research1980;20(2):255-61. [MEDLINE: 7209880]">Kobayashi 1980</a>; <a href="./references#CD008834-bbs2-0060" title="KooistraMP , vanEsA , MarxJJ , HertsigM , StruyvenbergA .Effects of low dose aspirin on thrombovascular accidents during treatment with rHuEpo: a multicentre, controlled, cross-over study [abstract]. Nephrology Dialysis Transplantation1993;8:277. [CENTRAL: CN-00260772] KooistraMP , vanEsA , MarxJJ , HertsigML , StruyvenbergA .Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrology Dialysis Transplantation1994;9(8):1115-20. [MEDLINE: 7800210]">Kooistra 1994</a>; <a href="./references#CD008834-bbs2-0063" title="MichieDD , WomboltDG .Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research - Clinical &amp; Experimental1977;22(1 II):196-204. [EMBASE: 8152617]">Michie 1977</a>; <a href="./references#CD008834-bbs2-0064" title="MiddletonDA , DeichselG .The prophylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole. Boehringer Ingelheim. Internal report1992. ">Middleton 1992</a>; <a href="./references#CD008834-bbs2-0065" title="MilutinovicS , GasparovicV , MilutinovicE , Buturovic-PonikvarJ .Ticlopidine improves dialysis clearance of solutes in uremic patients by reducing blood clotting in dialyser fibers. International Journal of Artificial Organs1993;16(5):249-52. [MEDLINE: 8354583]">Milutinovic 1993</a>; <a href="./references#CD008834-bbs2-0067" title="MozafarM , SamsamiM , SobhiyehMR , JabbehdariS , FallahZM .Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourology Monthly2013;5(2):762-5. [MEDLINE: 23841041]">Mozafar 2013</a>; <a href="./references#CD008834-bbs2-0068" title="MozafarM , AlborziM , MoradiA .Effects of clopidogrel on longevity of permanent double-lumen catheter patency in dialysis patients: A single-blind placebo-controlled clinical trial. Nephro-Urology Monthly2018;10(2):e58135. [EMBASE: 622226387]">Mozafar 2018</a>; <a href="./references#CD008834-bbs2-0089" title="RouzrokhM , AbbasiMR , MirshemiraniAR , SobhiyehMR .The effect of antiplatelet drugs on the patency rate of arterio-venous fistulae in hemodialysis patients. Iranian Journal of Pharmaceutical Research2010;9(4):451-7. [EMBASE: 2011024056]">Rouzrokh 2010</a>; <a href="./references#CD008834-bbs2-0094" title="SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract no: 9P]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):388. [CENTRAL: CN-00485981] SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study. Kidney International1994;45(5):1477-83. [MEDLINE: 8072261]">Sreedhara 1994</a>; <a href="./references#CD008834-bbs2-0096" title="MiletiM , De PetriG , BacchiM , OgliariV , PecchiniF , BufanoG , et al.A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients. Journal of Nephrology1995;8(2):167-72. [EMBASE: 25209311]">STOP 1995</a>; <a href="./references#CD008834-bbs2-0098" title="TaberT , MaikranzP , HaagB , DilleyR , GaylordG .Hemodialysis vascular graft stenosis may be altered by low-molecular weight dextran (LMD), but not by aspirin (ASA) [abstract]. Journal of the American Society of Nephrology1992;3(3):397. [CENTRAL: CN-00858239] ">Taber 1992</a>; <a href="./references#CD008834-bbs2-0101" title="TayebiP , KazemzadehG , BanihashemA , RavariH .Effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients: a randomized double-blind placebo-controlled trial. Electronic Physician [Electronic Resource]2018;10(1):6135-9. [MEDLINE: 29588811]">Tayebi 2018</a>; <a href="./references#CD008834-bbs2-0112" title="YutoJ , EharaY , ShibataK , IwamotoT , YasudaG , YatsuK , et al.Effect of sarpogrelate on fistula patency of forearm arteriovenous anastomisis in uremic patients [abstract no: 276]. Kidney Research &amp; Clinical Practice2012;31(2):A86. [EMBASE: 70814985]">Yuto 2012</a>). Generally, these studies were small; only five studies included more than 500 participants (<a href="./references#CD008834-bbs2-0019" title="DemberL , AllonM , DelmezJ , DixonB , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00550593] DemberLM , BeckGJ , AllonM , DelmezJA , DixonBS , GreenbergA , et al.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008;299(18):2164-71. [MEDLINE: 18477783]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials2005;2(5):413-22. [MEDLINE: 16317810]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):229A. [CENTRAL: CN-00445067] ">Dember 2005</a>; <a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a>; <a href="./references#CD008834-bbs2-0064" title="MiddletonDA , DeichselG .The prophylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole. Boehringer Ingelheim. Internal report1992. ">Middleton 1992</a>; <a href="./references#CD008834-bbs2-0089" title="RouzrokhM , AbbasiMR , MirshemiraniAR , SobhiyehMR .The effect of antiplatelet drugs on the patency rate of arterio-venous fistulae in hemodialysis patients. Iranian Journal of Pharmaceutical Research2010;9(4):451-7. [EMBASE: 2011024056]">Rouzrokh 2010</a>; <a href="./references#CD008834-bbs2-0096" title="MiletiM , De PetriG , BacchiM , OgliariV , PecchiniF , BufanoG , et al.A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients. Journal of Nephrology1995;8(2):167-72. [EMBASE: 25209311]">STOP 1995</a>), and sixteen studies enrolled fewer than 100 participants (<a href="./references#CD008834-bbs2-0002" title="AbacilarAF , AtalayH , DoganOF .Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: a randomized controlled study. Indian Journal of Nephrology2015;25(3):136-42. [MEDLINE: 26060361]">Abacilar 2015</a>; <a href="./references#CD008834-bbs2-0003" title="Abdul-RahmanIS , Al-HowaishAK .Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23-30. [EMBASE: 2007269768]">Abdul‐Rahman 2007</a>; <a href="./references#CD008834-bbs2-0005" title="AndersonM , DewarP , FlemingLB , HackingPM , MorleyAR , MurrayS , et al.A controlled trial of dipyridamole in human renal transplantation and an assessment of platelet function studies in rejection. Clinical Nephrology1974;2(3):93-9. [MEDLINE: 4603996]">Anderson 1974</a>; <a href="./references#CD008834-bbs2-0006" title="AndrassyK , MallucheH , BornefeldH , CombergM , RitzE , JesdinskyH , et al.Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: results of a prospective double blind study. Klinische Wochenschrift1974;52(7):348-9. [MEDLINE: 4600820]">Andrassy 1974</a>; <a href="./references#CD008834-bbs2-0025" title="EllS , MihindukulasuriyaJC , O'BrienJR , PolakA , VernhamG .Ticlopidine in the prevention of blockage of fistulae and shunts [abstract no: 332]. Haemostasis1982;12:180. ">Ell 1982</a>; <a href="./references#CD008834-bbs2-0032" title="FiskerstrandCE , ThompsonIW , BurnetME , WilliamsP , AndertonJL .Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artificial Organs1985;9(1):61-3. [MEDLINE: 3888153]">Fiskerstrand 1985</a>; <a href="./references#CD008834-bbs2-0036" title="GhorbaniA , AalamshahM , ShahbazianH , EhsanpourA , ArefA .Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian Journal of Nephrology2009;19(2):57-61. [MEDLINE: 20368925]">Ghorbani 2009</a>; <a href="./references#CD008834-bbs2-0037" title="GhorbaniA , Jasemi-ZerganiF .Ticlopidine to prevent primary arteriovenous fistula failure in hemodialysis patients; a randomized controlled trial. Journal of Renal Injury Prevention2013;2(3):109-11. [MEDLINE: 25340144]">Ghorbani 2013</a>; <a href="./references#CD008834-bbs2-0042" title="GröntoftKC , MulecH , GutierrezA , OlanderR .Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scandinavian Journal of Urology &amp; Nephrology1985;19(1):55-7. [MEDLINE: 3895411]">Gröntoft 1985</a>; <a href="./references#CD008834-bbs2-0046" title="HarterHR , BurchJW , MajerusPW , StanfordN , DelmezJA , AndersonCB , et al.Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. New England Journal of Medicine1979;301(11):577-9. [MEDLINE: 112475]">Harter 1979</a>; <a href="./references#CD008834-bbs2-0053" title="KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. New England Journal of Medicine1974;290(6):304-6. [MEDLINE: 4588285]KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation1975;52(3):497-9. [MEDLINE: 1098808]">Kaegi 1974</a>; <a href="./references#CD008834-bbs2-0063" title="MichieDD , WomboltDG .Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research - Clinical &amp; Experimental1977;22(1 II):196-204. [EMBASE: 8152617]">Michie 1977</a>; <a href="./references#CD008834-bbs2-0065" title="MilutinovicS , GasparovicV , MilutinovicE , Buturovic-PonikvarJ .Ticlopidine improves dialysis clearance of solutes in uremic patients by reducing blood clotting in dialyser fibers. International Journal of Artificial Organs1993;16(5):249-52. [MEDLINE: 8354583]">Milutinovic 1993</a>; <a href="./references#CD008834-bbs2-0098" title="TaberT , MaikranzP , HaagB , DilleyR , GaylordG .Hemodialysis vascular graft stenosis may be altered by low-molecular weight dextran (LMD), but not by aspirin (ASA) [abstract]. Journal of the American Society of Nephrology1992;3(3):397. [CENTRAL: CN-00858239] ">Taber 1992</a>; <a href="./references#CD008834-bbs2-0101" title="TayebiP , KazemzadehG , BanihashemA , RavariH .Effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients: a randomized double-blind placebo-controlled trial. Electronic Physician [Electronic Resource]2018;10(1):6135-9. [MEDLINE: 29588811]">Tayebi 2018</a> <a href="./references#CD008834-bbs2-0112" title="YutoJ , EharaY , ShibataK , IwamotoT , YasudaG , YatsuK , et al.Effect of sarpogrelate on fistula patency of forearm arteriovenous anastomisis in uremic patients [abstract no: 276]. Kidney Research &amp; Clinical Practice2012;31(2):A86. [EMBASE: 70814985]">Yuto 2012</a>). </p> <p>Ticlopidine was most the commonly administered (9 studies, 884 participants: <a href="./references#CD008834-bbs2-0016" title="CreekR .Ticlopidine. Patency of haemodialysis access sites. Guildford Sanofi Winthrop. Internal report1990. ">Creek 1990</a>; <a href="./references#CD008834-bbs2-0022" title="DoddNJ , TurneyJH , WestonMJ .Ticlopidine preserves vascular access for haemodialysis [abstract no: 326F]. In: Proceedings of the VI International Congress of Mediterranean League Against Thrombosis; 1980 Oct 25-26; Montecarlo, Monaco. 1980. ">Dodd 1980</a>; <a href="./references#CD008834-bbs2-0025" title="EllS , MihindukulasuriyaJC , O'BrienJR , PolakA , VernhamG .Ticlopidine in the prevention of blockage of fistulae and shunts [abstract no: 332]. Haemostasis1982;12:180. ">Ell 1982</a>; <a href="./references#CD008834-bbs2-0032" title="FiskerstrandCE , ThompsonIW , BurnetME , WilliamsP , AndertonJL .Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artificial Organs1985;9(1):61-3. [MEDLINE: 3888153]">Fiskerstrand 1985</a>; <a href="./references#CD008834-bbs2-0037" title="GhorbaniA , Jasemi-ZerganiF .Ticlopidine to prevent primary arteriovenous fistula failure in hemodialysis patients; a randomized controlled trial. Journal of Renal Injury Prevention2013;2(3):109-11. [MEDLINE: 25340144]">Ghorbani 2013</a>; <a href="./references#CD008834-bbs2-0042" title="GröntoftKC , MulecH , GutierrezA , OlanderR .Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scandinavian Journal of Urology &amp; Nephrology1985;19(1):55-7. [MEDLINE: 3895411]">Gröntoft 1985</a>; <a href="./references#CD008834-bbs2-0043" title="GröntoftK , LarssonR , MulecH , WeissLG , DickinsonJP .Ticlopidine in fistula surgery: double-blind comparison against placebo on the rate of early occlusion of arterio-venous fistulae [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:398. [CENTRAL: CN-00601921] GröntoftKC , LarssonR , MulecH , WeissLG , DickinsonJP .Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scandinavian Journal of Urology &amp; Nephrology1998;32(4):276-83. [MEDLINE: 9764456]">Gröntoft 1998</a>; <a href="./references#CD008834-bbs2-0058" title="KobayashiK , MaedaK , KoshikawaS , KawaguchiY , ShimizuN , NaitoC .Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis: a multicenter collaborative double blind study. Thrombosis Research1980;20(2):255-61. [MEDLINE: 7209880]">Kobayashi 1980</a>; <a href="./references#CD008834-bbs2-0065" title="MilutinovicS , GasparovicV , MilutinovicE , Buturovic-PonikvarJ .Ticlopidine improves dialysis clearance of solutes in uremic patients by reducing blood clotting in dialyser fibers. International Journal of Artificial Organs1993;16(5):249-52. [MEDLINE: 8354583]">Milutinovic 1993</a>), followed by aspirin (6 studies, 917 participants: <a href="./references#CD008834-bbs2-0003" title="Abdul-RahmanIS , Al-HowaishAK .Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23-30. [EMBASE: 2007269768]">Abdul‐Rahman 2007</a>; <a href="./references#CD008834-bbs2-0006" title="AndrassyK , MallucheH , BornefeldH , CombergM , RitzE , JesdinskyH , et al.Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: results of a prospective double blind study. Klinische Wochenschrift1974;52(7):348-9. [MEDLINE: 4600820]">Andrassy 1974</a>; <a href="./references#CD008834-bbs2-0031" title="BadveS , HawleyCM , IrishAB , Paul-BrentP .High rate of screening failure in the FAVOURED study [abstract no: PUB345]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):905A. IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al.Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453]IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul-BrentP , et al.Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis-a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804]IrishA , FAVOURED Study Group.High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN-00756870] IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 009]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790]IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. [EMBASE: 70467038]IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul-BrentPA , et al.Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184-93. [MEDLINE: 28055065]IrishAB .The omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo-controlled trial [abstract no: HI-OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2-3. [CENTRAL: CN-01658143] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis-post hoc analysis of the FAVOURED study [abstract no: MO049]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475]ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on the need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology2018;23(Suppl 3):56. [EMBASE: 623841152]ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al.Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract no: SP593]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178]ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract no: FP555]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265]ViecelliA , PascoeE , PolkinghorneK , Paul-BrentP , DarssanD , HooiL , et al.A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115-6. [EMBASE: 612312707]ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul-BrentPA , BadveSV , et al.The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581]ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis - Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217-28. [MEDLINE: 26205903]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study. Nephrology2017;22(10):823-4. [MEDLINE: 27188542]ViecelliAK , PolkinghorneKR , PascoeEM , Paul-BrentPA , HawleyCM , BadveSV , et al.Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS ONE [Electronic Resource]2019;14(3):e0213274. [MEDLINE: 30913208]">FAVOURED 2009</a>; <a href="./references#CD008834-bbs2-0046" title="HarterHR , BurchJW , MajerusPW , StanfordN , DelmezJA , AndersonCB , et al.Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. New England Journal of Medicine1979;301(11):577-9. [MEDLINE: 112475]">Harter 1979</a>; <a href="./references#CD008834-bbs2-0060" title="KooistraMP , vanEsA , MarxJJ , HertsigM , StruyvenbergA .Effects of low dose aspirin on thrombovascular accidents during treatment with rHuEpo: a multicentre, controlled, cross-over study [abstract]. Nephrology Dialysis Transplantation1993;8:277. [CENTRAL: CN-00260772] KooistraMP , vanEsA , MarxJJ , HertsigML , StruyvenbergA .Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrology Dialysis Transplantation1994;9(8):1115-20. [MEDLINE: 7800210]">Kooistra 1994</a>; <a href="./references#CD008834-bbs2-0067" title="MozafarM , SamsamiM , SobhiyehMR , JabbehdariS , FallahZM .Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourology Monthly2013;5(2):762-5. [MEDLINE: 23841041]">Mozafar 2013</a>). The combination of dipyridamole and aspirin was prescribed to 1720 participants in four studies (<a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a>; <a href="./references#CD008834-bbs2-0064" title="MiddletonDA , DeichselG .The prophylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole. Boehringer Ingelheim. Internal report1992. ">Middleton 1992</a>; <a href="./references#CD008834-bbs2-0094" title="SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract no: 9P]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):388. [CENTRAL: CN-00485981] SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study. Kidney International1994;45(5):1477-83. [MEDLINE: 8072261]">Sreedhara 1994</a>; <a href="./references#CD008834-bbs2-0101" title="TayebiP , KazemzadehG , BanihashemA , RavariH .Effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients: a randomized double-blind placebo-controlled trial. Electronic Physician [Electronic Resource]2018;10(1):6135-9. [MEDLINE: 29588811]">Tayebi 2018</a>), three studies evaluated clopidogrel (1070 participants: <a href="./references#CD008834-bbs2-0019" title="DemberL , AllonM , DelmezJ , DixonB , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00550593] DemberLM , BeckGJ , AllonM , DelmezJA , DixonBS , GreenbergA , et al.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008;299(18):2164-71. [MEDLINE: 18477783]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials2005;2(5):413-22. [MEDLINE: 16317810]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):229A. [CENTRAL: CN-00445067] ">Dember 2005</a>; <a href="./references#CD008834-bbs2-0036" title="GhorbaniA , AalamshahM , ShahbazianH , EhsanpourA , ArefA .Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian Journal of Nephrology2009;19(2):57-61. [MEDLINE: 20368925]">Ghorbani 2009</a>; <a href="./references#CD008834-bbs2-0068" title="MozafarM , AlborziM , MoradiA .Effects of clopidogrel on longevity of permanent double-lumen catheter patency in dialysis patients: A single-blind placebo-controlled clinical trial. Nephro-Urology Monthly2018;10(2):e58135. [EMBASE: 622226387]">Mozafar 2018</a>), two studies evaluated sulphinpyrazone (78 participants: <a href="./references#CD008834-bbs2-0053" title="KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. New England Journal of Medicine1974;290(6):304-6. [MEDLINE: 4588285]KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation1975;52(3):497-9. [MEDLINE: 1098808]">Kaegi 1974</a>; <a href="./references#CD008834-bbs2-0063" title="MichieDD , WomboltDG .Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research - Clinical &amp; Experimental1977;22(1 II):196-204. [EMBASE: 8152617]">Michie 1977</a>), and single studies assessed dipyridamole (27 participants: <a href="./references#CD008834-bbs2-0005" title="AndersonM , DewarP , FlemingLB , HackingPM , MorleyAR , MurrayS , et al.A controlled trial of dipyridamole in human renal transplantation and an assessment of platelet function studies in rejection. Clinical Nephrology1974;2(3):93-9. [MEDLINE: 4603996]">Anderson 1974</a>), picotamide (832 participants: <a href="./references#CD008834-bbs2-0096" title="MiletiM , De PetriG , BacchiM , OgliariV , PecchiniF , BufanoG , et al.A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients. Journal of Nephrology1995;8(2):167-72. [EMBASE: 25209311]">STOP 1995</a>) and sarpogrelate (79 participants: <a href="./references#CD008834-bbs2-0112" title="YutoJ , EharaY , ShibataK , IwamotoT , YasudaG , YatsuK , et al.Effect of sarpogrelate on fistula patency of forearm arteriovenous anastomisis in uremic patients [abstract no: 276]. Kidney Research &amp; Clinical Practice2012;31(2):A86. [EMBASE: 70814985]">Yuto 2012</a>). One study each assessed the combination of clopidogrel and aspirin (200 participants: <a href="./references#CD008834-bbs2-0056" title="ChangJJ , ConcatoJ , WellsCK , CrowleyST .Impact of adherence to clinical guidelines on mortality in hemodialysis patients [abstract no: SA-PO384]. Journal of the American Society of Nephrology2004;15(Oct):386A. [CENTRAL: CN-00583156] KaufmanJS , O'ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology2003;14(9):2313-21. [MEDLINE: 12937308]KaufmanJS , O’ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract no: A1495]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):291A. ">Kaufman 2003</a>), the combination of dextran and aspirin (45 participants: <a href="./references#CD008834-bbs2-0098" title="TaberT , MaikranzP , HaagB , DilleyR , GaylordG .Hemodialysis vascular graft stenosis may be altered by low-molecular weight dextran (LMD), but not by aspirin (ASA) [abstract]. Journal of the American Society of Nephrology1992;3(3):397. [CENTRAL: CN-00858239] ">Taber 1992</a>), the combination of clopidogrel and prostacyclin (96 participants: <a href="./references#CD008834-bbs2-0002" title="AbacilarAF , AtalayH , DoganOF .Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: a randomized controlled study. Indian Journal of Nephrology2015;25(3):136-42. [MEDLINE: 26060361]">Abacilar 2015</a>), and the combination of aspirin or dipyridamole (501 participants: <a href="./references#CD008834-bbs2-0089" title="RouzrokhM , AbbasiMR , MirshemiraniAR , SobhiyehMR .The effect of antiplatelet drugs on the patency rate of arterio-venous fistulae in hemodialysis patients. Iranian Journal of Pharmaceutical Research2010;9(4):451-7. [EMBASE: 2011024056]">Rouzrokh 2010</a>). The duration of the intervention varied from one month to 61,2 months, with a median of five months. </p> <p>Studies evaluated whether treatment maintained patency of an arteriovenous fistula (10 studies, 1765 participants: <a href="./references#CD008834-bbs2-0002" title="AbacilarAF , AtalayH , DoganOF .Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: a randomized controlled study. Indian Journal of Nephrology2015;25(3):136-42. [MEDLINE: 26060361]">Abacilar 2015</a>; <a href="./references#CD008834-bbs2-0006" title="AndrassyK , MallucheH , BornefeldH , CombergM , RitzE , JesdinskyH , et al.Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: results of a prospective double blind study. Klinische Wochenschrift1974;52(7):348-9. [MEDLINE: 4600820]">Andrassy 1974</a>; <a href="./references#CD008834-bbs2-0019" title="DemberL , AllonM , DelmezJ , DixonB , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00550593] DemberLM , BeckGJ , AllonM , DelmezJA , DixonBS , GreenbergA , et al.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008;299(18):2164-71. [MEDLINE: 18477783]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials2005;2(5):413-22. [MEDLINE: 16317810]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):229A. [CENTRAL: CN-00445067] ">Dember 2005</a>; <a href="./references#CD008834-bbs2-0032" title="FiskerstrandCE , ThompsonIW , BurnetME , WilliamsP , AndertonJL .Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artificial Organs1985;9(1):61-3. [MEDLINE: 3888153]">Fiskerstrand 1985</a>; <a href="./references#CD008834-bbs2-0036" title="GhorbaniA , AalamshahM , ShahbazianH , EhsanpourA , ArefA .Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian Journal of Nephrology2009;19(2):57-61. [MEDLINE: 20368925]">Ghorbani 2009</a>; <a href="./references#CD008834-bbs2-0037" title="GhorbaniA , Jasemi-ZerganiF .Ticlopidine to prevent primary arteriovenous fistula failure in hemodialysis patients; a randomized controlled trial. Journal of Renal Injury Prevention2013;2(3):109-11. [MEDLINE: 25340144]">Ghorbani 2013</a>; <a href="./references#CD008834-bbs2-0042" title="GröntoftKC , MulecH , GutierrezA , OlanderR .Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scandinavian Journal of Urology &amp; Nephrology1985;19(1):55-7. [MEDLINE: 3895411]">Gröntoft 1985</a>; <a href="./references#CD008834-bbs2-0043" title="GröntoftK , LarssonR , MulecH , WeissLG , DickinsonJP .Ticlopidine in fistula surgery: double-blind comparison against placebo on the rate of early occlusion of arterio-venous fistulae [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:398. [CENTRAL: CN-00601921] GröntoftKC , LarssonR , MulecH , WeissLG , DickinsonJP .Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scandinavian Journal of Urology &amp; Nephrology1998;32(4):276-83. [MEDLINE: 9764456]">Gröntoft 1998</a>; <a href="./references#CD008834-bbs2-0060" title="KooistraMP , vanEsA , MarxJJ , HertsigM , StruyvenbergA .Effects of low dose aspirin on thrombovascular accidents during treatment with rHuEpo: a multicentre, controlled, cross-over study [abstract]. Nephrology Dialysis Transplantation1993;8:277. [CENTRAL: CN-00260772] KooistraMP , vanEsA , MarxJJ , HertsigML , StruyvenbergA .Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrology Dialysis Transplantation1994;9(8):1115-20. [MEDLINE: 7800210]">Kooistra 1994</a>; <a href="./references#CD008834-bbs2-0112" title="YutoJ , EharaY , ShibataK , IwamotoT , YasudaG , YatsuK , et al.Effect of sarpogrelate on fistula patency of forearm arteriovenous anastomisis in uremic patients [abstract no: 276]. Kidney Research &amp; Clinical Practice2012;31(2):A86. [EMBASE: 70814985]">Yuto 2012</a>), shunt or graft (5 studies, 1063 participants: <a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a>; <a href="./references#CD008834-bbs2-0046" title="HarterHR , BurchJW , MajerusPW , StanfordN , DelmezJA , AndersonCB , et al.Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. New England Journal of Medicine1979;301(11):577-9. [MEDLINE: 112475]">Harter 1979</a>; <a href="./references#CD008834-bbs2-0053" title="KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. New England Journal of Medicine1974;290(6):304-6. [MEDLINE: 4588285]KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation1975;52(3):497-9. [MEDLINE: 1098808]">Kaegi 1974</a>; <a href="./references#CD008834-bbs2-0056" title="ChangJJ , ConcatoJ , WellsCK , CrowleyST .Impact of adherence to clinical guidelines on mortality in hemodialysis patients [abstract no: SA-PO384]. Journal of the American Society of Nephrology2004;15(Oct):386A. [CENTRAL: CN-00583156] KaufmanJS , O'ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology2003;14(9):2313-21. [MEDLINE: 12937308]KaufmanJS , O’ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract no: A1495]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):291A. ">Kaufman 2003</a>; <a href="./references#CD008834-bbs2-0094" title="SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract no: 9P]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):388. [CENTRAL: CN-00485981] SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study. Kidney International1994;45(5):1477-83. [MEDLINE: 8072261]">Sreedhara 1994</a>), fistula or graft (1 study, 16 participants: <a href="./references#CD008834-bbs2-0063" title="MichieDD , WomboltDG .Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research - Clinical &amp; Experimental1977;22(1 II):196-204. [EMBASE: 8152617]">Michie 1977</a>), or central venous catheter (1 study, 58 participants: <a href="./references#CD008834-bbs2-0003" title="Abdul-RahmanIS , Al-HowaishAK .Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23-30. [EMBASE: 2007269768]">Abdul‐Rahman 2007</a>). </p> </section> </section> <section id="CD008834-sec-0045"> <h5 class="title">Antiplatelet versus antiplatelet studies</h5> <p>Thirty‐four studies comparing an antiplatelet drug with a second antiplatelet drug in people with CKD were published between 1980 and 2018. The number of CKD participants ranged from 6 to 4983 participants (median 85 participants) and the mean age of participants ranged from 33 to 74.4 years. The duration of follow‐up ranged from 2 days to 48 months (median four months). </p> <p> <ul id="CD008834-list-0026"> <li> <p>Twelve studies were conducted in people with CKD not yet requiring dialysis (10,958 participants: <a href="./references#CD008834-bbs2-0008" title="FujitaT , YuX , KimS , NakamotoH , OrigasaH , KurumataniH , et al.Effects of sustained-release beraprost sodium in patients with primary glomerular disease or nephrosclerosis: the CASSIOPEIR study [abstract no: SA-PO1096]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):4B. [CENTRAL: CN-01657821] NakamotoH , FujitaT , OrigasaH , IsonoM , KurumataniH , OkadaK , et al.A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrology2014;15:153. [MEDLINE: 25233856]NakamotoH , YuXQ , KimS , OrigasaH , ZhengH , ChenJ , et al.Effects of sustained-release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results. Therapeutic Apheresis &amp; Dialysis2020;24(1):42-55. [MEDLINE: 31119846]">CASSIOPEIR 2014</a>; <a href="./references#CD008834-bbs2-0014" title="LeeMH , SuhJW , LeeSP , ParkKW , LeeHY , KangHJ , et al.The effect of cilostazol on the antiplatelet efficacy of patients with moderate renal dysfunction: post-hoc analysis of CILON-T (Influence of cilostazol based triple antiplatelet therapy on ischemic complication after drug eluting stent implantation) trial [abstract no: TCT-495]. Journal of the American College of Cardiology2011;58(20 Suppl 1):B134-5. [EMBASE: 70581865]LeeSP , SuhJW , ParkKW , LeeHY , KangHJ , KooBK , et al.Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: a multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease. Trials [Electronic Resource]2010;11:87. [MEDLINE: 20735821]SuhJW , LeeSP , ParkKW , LeeHY , KangHJ , KooBK , et al.Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. Journal of the American College of Cardiology2011;57(3):280-9. [MEDLINE: 21232664]">CILON‐T 2010</a>; <a href="./references#CD008834-bbs2-0018" title="DashA , MaitiR , BandakkanavarTK , BhaskarA , PrakashJ , PandeyBL .Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: comparison between clopidogrel and low-dose aspirin. International Journal of Preventive Medicine2013;4(8):902-10. [MEDLINE: 24049616]">Dash 2013</a>; <a href="./references#CD008834-bbs2-0030" title="BaumgartnerI , NorgrenL , FowkesFG , MulderH , PatelMR , BergerJS , et al.Cardiovascular outcomes after lower extremity endovascular or surgical revascularization: the EUCLID trial. Journal of the American College of Cardiology2018;72(14):1563-72. [MEDLINE: 30261955]BergerJS , AbramsonBL , LopesRD , HeizerG , RockholdFW , BaumgartnerI , et al.Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Vascular Medicine2018;23(6):523-30. [MEDLINE: 29992857]HaineA , KavanaghS , BergerJS , HessCN , NorgrenL , FowkesFG , et al.Sex-specific risks of major cardiovascular and limb events in patients with symptomatic peripheral artery disease. Journal of the American College of Cardiology2020;75(6):608-17. [MEDLINE: 32057375]HessCN , HuangZ , PatelMR , BaumgartnerI , BergerJS , BlomsterJI , et al.Acute limb ischemia in peripheral artery disease. Circulation2019;140(7):556-65. [MEDLINE: 31238713]HiattWR , FowkesFG , HeizerG , BergerJS , BaumgartnerI , HeldP , et al.Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. New England Journal of Medicine2017;376(1):32-40. [MEDLINE: 27959717]HopleyCW , KavanaghS , PatelMR , OstromC , BaumgartnerI , BergerJS , et al.Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial. Vascular Medicine2019;24(5):422-30. [MEDLINE: 31339474]JonesWS , BaumgartnerI , HiattWR , HeizerG , ConteMS , WhiteCJ , et al.Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation2017;135(3):241-50. [MEDLINE: 27840336]KollsBJ , SappS , RockholdFW , JordanJD , DombrowskiKE , FowkesFG , et al.Stroke in patients with peripheral artery disease. Stroke2019;50(6):1356-63. [MEDLINE: 31092165]Low WangCC , BlomsterJI , HeizerG , BergerJS , BaumgartnerI , FowkesFG , et al.Cardiovascular and limb outcomes in patients with diabetes and peripheral artery disease: the EUCLID trial. Journal of the American College of Cardiology2018;72(25):3274-84. [MEDLINE: 30573030]NorgrenL , PatelMR , HiattWR , WojdylaDM , FowkesFG , BaumgartnerI , et al.Outcomes of patients with critical limb ischaemia in the EUCLID trial. European Journal of Vascular &amp; Endovascular Surgery2018;55(1):109-17. [MEDLINE: 29273390]OlivierCB , MulderH , HiattWR , JonesWS , FowkesFG , RockholdFW , et al.Incidence, characteristics, and outcomes of myocardial infarction in patients with peripheral artery disease: insights from the EUCLID trial. JAMA Cardiology2019;4(1):7-15. [MEDLINE: 30540355]">EUCLID 2017</a>; <a href="./references#CD008834-bbs2-0057" title="KhajehdehiP , RoozbehJ , MostafaviH .A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scandinavian Journal of Urology &amp; Nephrology2002;36(2):145-8. [MEDLINE: 12028688]">Khajehdehi 2002</a>; <a href="./references#CD008834-bbs2-0062" title="LiangJ , WangZ , ShiD , LiuY , ZhaoY , HanH , et al.High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. Angiology2015;66(4):319-25. [MEDLINE: 24913197]">Liang 2015</a>; <a href="./references#CD008834-bbs2-0066" title="MovchanEA , ChuprovaAV , TovNL , Vol'vichNV .Desaggregation therapy of acute glomerulonephritis [Dezagregatsionnaia terapiia ostrogo glomerulonefrita]. Klinicheskaia Meditsina2001;79(12):44-7. [MEDLINE: 11840813]">Movchan 2001</a>; <a href="./references#CD008834-bbs2-0073" title="OgawaS , MoriT , NakoK , IshizukaT , ItoS .Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):362-8. [MEDLINE: 18235151]">Ogawa 2008</a>; <a href="./references#CD008834-bbs2-0074" title="HanY .Comparison of the pharmacodynamics and pharmacokinetics of ticagrelor versus clopidogrel in patients with chronic kidney disease and non-ST-elevation acute coronary syndromes (OPT-CKD trial) [abstract no: TCT-483]. Journal of the American College of Cardiology2017;70(18 Suppl 1):B200. [EMBASE: 619771602]WangH , QiJ , LiY , TangY , LiC , LiJ , et al.Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. British Journal of Clinical Pharmacology2018;84(1):88-96. [MEDLINE: 28921624]">OPT‐CKD 2018</a>; <a href="./references#CD008834-bbs2-0081" title="AkerblomA , WallentinL , LarssonA , SiegbahnA , BeckerRC , BudajA , et al.Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study. Clinical Chemistry2013;59(9):1369-75. [MEDLINE: 23698074]AkerblomA , WallentinL , SiegbahnA , BeckerRC , BudajA , HorrowJ , et al.Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. American Heart Journal2012;164(5):728-34. [MEDLINE: 23137503]AndellP , JamesSK , CannonCP , CyrDD , HimmelmannA , HustedS , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Journal of the American Heart Association2015;4(10):e002490. [MEDLINE: 26452988]ArmstrongPW , SihaH , FuY , WesterhoutCM , StegPG , JamesSK , et al.ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation2012;125(3):514-21. [MEDLINE: 22179530]ArmstrongPW , WesterhoutCM , FuY , HarringtonRA , StoreyRF , KatusH , et al.Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. American Journal of Medicine2013;126(8):723-9. [MEDLINE: 23795897]BeckerRC , BassandJP , BudajA , WojdylaDM , JamesSK , CornelJH , et al.Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial [Erratum in: Eur Heart J. 2012 Nov;33(21):2750]. European Heart Journal2011;32(23):2933-44. [MEDLINE: 22090660]BellaviaA , WallentinL , OrsiniN , JamesSK , CannonCP , HimmelmannA , et al.Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. Open Heart2017;4(2):e000557. [MEDLINE: 28761675]BrilakisES , HeldC , MeierB , CoolsF , ClaeysMJ , CornelJH , et al.Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. American Heart Journal2013;166(3):474-80. [MEDLINE: 24016496]BuiAH , CannonCP , StegPG , StoreyRF , HustedS , GuoJ , et al.Relationship between early and late nonsustained ventricular tachycardia and cardiovascular death in patients with acute coronary syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation: Arrhythmia and Electrophysiology2016;9(2):e002951. [MEDLINE: 26810596]CapodannoD , CalviV , TamburinoC .Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment. Journal of Cardiovascular Medicine2012;13(2):162-3. [MEDLINE: 22237463]CornelJH , BeckerRC , GoodmanSG , HustedS , KatusH , SantosoA , et al.Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2012;164(3):334-42. [MEDLINE: 22980299]CowperPA , PanW , AnstromKJ , KaulP , WallentinL , Davidson-RayL , et al.Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. Journal of the American College of Cardiology2015;65(5):465-76. [MEDLINE: 25660925]DiNicolantonioJJ , D'AscenzoF , TomekA , ChatterjeeS , NiaziAK , Biondi-ZoccaiG .Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial. International Journal of Cardiology2013;168(3):1739-44. [MEDLINE: 23907035]DiNicolantonioJJ , TomekA .Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial. International Journal of Cardiology2013;168(4):4076-80. [MEDLINE: 23911266]DiNicolantonioJJ , TomekA .Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel. International Journal of Cardiology2013;169(2):145-6. [MEDLINE: 24120213]DucrocqG , SchultePJ , BeckerRC , CannonCP , HarringtonRA , HeldC , et al.Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. Eurointervention2015;11(7):737-45. [MEDLINE: 25254357]FranchiF , JamesSK , GhukasyanLT , BudajAJ , CornelJH , KatusHA , et al.Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y12 receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. Journal of the American Heart Association2019;8(6):e011139. [MEDLINE: 30857464]GiannitsisE , WallentinL , JamesSK , BertilssonM , SiegbahnA , StoreyRF , et al.Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: a Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. European Heart Journal: Acute Cardiovascular Care2017;6(6):500-10. [MEDLINE: 27044282]HagstromE , JamesSK , BertilssonM , BeckerRC , HimmelmannA , HustedS , et al.Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. European Heart Journal2016;37(16):1325-33. [MEDLINE: 26417057]HeldC , AsenbladN , BassandJP , BeckerRC , CannonCP , ClaeysMJ , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology2011;57(6):672-84. [MEDLINE: 21194870]HustedS , JamesS , BeckerRC , HorrowJ , KatusH , StoreyRF , et al.Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circulation. Cardiovascular Quality &amp; Outcomes2012;5(5):680-8. [MEDLINE: 22991347]HustedS , JamesSK , BachRG , BeckerRC , BudajA , HerasM , et al.The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal2014;35(23):1541-50. [MEDLINE: 24682844]JamesS , AkerblomA , CannonCP , EmanuelssonH , HustedS , KatusH , et al.Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2009;157(4):599-605. [MEDLINE: 19332184]JamesS , AngiolilloDJ , CornelJH , ErlingeD , HustedS , KontnyF , et al.Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal2010;31(24):3006-16. [MEDLINE: 20802246]JamesS , BudajA , AylwardP , BuckKK , CannonCP , CornelJH , et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2010;122(11):1056-67. [MEDLINE: 20805430]JamesS , BudajA , AylwardP , BuckKK , CannonCP , CornelJH , et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation2010;122(11):1056-67. [MEDLINE: 20805430]JamesSK , RoeMT , CannonCP , CornelJH , HorrowJ , HustedS , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ2011;342:d3527. [MEDLINE: 21685437]JohanssonA , ErikssonN , BeckerRC , StoreyRF , HimmelmannA , HagstromE , et al.NLRC4 inflammasome is an important regulator of interleukin-18 levels in patients with acute coronary syndromes: genome-wide association study in the PLATelet inhibition and patient Outcomes Trial (PLATO). Circulation. Cardiovascular Genetics2015;8(3):498-506. [MEDLINE: 25747584]KangHJ , ClareRM , GaoR , HeldC , HimmelmannA , JamesSK , et al.Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal2015;169(6):899-905. [MEDLINE: 26027629]KholaifN , ZhengY , JagasiaP , HimmelmannA , JamesSK , StegPG , et al.Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex. American Journal of Medicine2015;128(8):914-9. [MEDLINE: 25818495]KohliP , WallentinL , ReyesE , HorrowJ , HustedS , AngiolilloDJ , et al.Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation2013;127(6):673-80. [MEDLINE: 23277305]KontnyF , UelandT , AukrustP , MichelsenAE , BeckerRC , BertilssonM , et al.Pentraxin 3 (PTX3) predict adverse outcome in acute coronary syndromes-a PLATO biomarker substudy [abstract]. European Heart Journal2014;35(Suppl 1):319. [EMBASE: 71647923]KotsiaA , BrilakisES , HeldC , CannonC , StegGP , MeierB , et al.Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2014;168(1):68-75. [MEDLINE: 24952862]KunadianV , JamesSK , WojdylaDM , ZorkunC , WuJ , StoreyRF , et al.Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). Jacc: Cardiovascular Interventions2013;6(7):671-83. [MEDLINE: 23866179]LevinLA , WallentinL , BernfortL , AnderssonD , StoreyRF , BergstromG , et al.Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. Value in Health2013;16(4):574-80. [MEDLINE: 23796291]LindholmD , VarenhorstC , CannonCP , HarringtonRA , HimmelmannA , MayaJ , et al.Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal2014;35(31):2083-93. [MEDLINE: 24727884]MahaffeyKW , HeldC , WojdylaDM , JamesSK , KatusHA , HustedS , et al.Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology2014;63(15):1493-9. [MEDLINE: 24561148]MahaffeyKW , WojdylaDM , CarrollK , BeckerRC , StoreyRF , AngiolilloDJ , et al.Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2011;124(5):544-54. [MEDLINE: 21709065]NikolicE , JanzonM , HauchO , WallentinL , HenrikssonM , PLATO Health Economic Substudy Group.Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. European Heart Journal2013;34(3):220-8. [MEDLINE: 22719022]OhmanEM , RoeMT .Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany &quot;Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified&quot; (Thromb Haemost 2011; 105.5). Thrombosis &amp; Haemostasis2011;105(5):763-5. [MEDLINE: 21394382]ParkerWA , ErikssonN , BeckerRC , VooraD , AkerblomA , HimmelmannA , et al.Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets2019;30(5):579-88. [MEDLINE: 29851527]PatelMR , BeckerRC , WojdylaDM , EmanuelssonH , HiattWR , HorrowJ , et al.Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. European Journal of Preventive Cardiology2015;22(6):734-42. [MEDLINE: 24830710]Pollack CV Jr, DavoudiF , DiercksDB , BeckerRC , JamesSK , LimST , et al.Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clinical Cardiology2017;40(6):390-8. [MEDLINE: 28598510]RoguinA , MusallamA .Letter by Roguin and Musallam regarding article, &quot;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial&quot;. Circulation2014;129(19):e493. [MEDLINE: 24821831]SciricaBM , BansilalS , DavoudiF , ArmstrongPW , ClareRM , SchultePJ , et al.Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. American Heart Journal2018;202:54-60. [MEDLINE: 29859968]SciricaBM , CannonCP , EmanuelssonH , MichelsonEL , HarringtonRA , HustedS , et al.The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. Journal of the American College of Cardiology2011;57(19):1908-16. [MEDLINE: 21545948]SerebruanyVL , FortmannSD , CherepanovV , LitvinovO , KimMH , MarciniakTA .Excess ticagrelor mortality in the food and drug administration adverse event reporting system: time to recount PLATO trial deaths. American Journal of Medicine2017;130(6):e245-6. [MEDLINE: 28161342]SerebruanyVL .Angiographic outcomes contradict platelet data in the PLATO trial: confusion over official trial substudies. Cardiology2014;127(3):190-5. [MEDLINE: 24457905]SerebruanyVL .Discrepancies in the primary PLATO trial publication and the FDA reviews. International Journal of Cardiology2014;172(1):8-10. [MEDLINE: 24456868]SerebruanyVL .Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review. American Journal of Therapeutics2012;19(2):160-1. [MEDLINE: 22395000]SerebruanyVL .The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent. Cardiology2011;120(3):169-71. [MEDLINE: 22418766]ShimadaYJ , BansilalS , WiviottSD , BeckerRC , HarringtonRA , HimmelmannA , et al.Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal2016;177:1-8. [MEDLINE: 27297843]SihaH , DasD , FuY , ZhengY , WesterhoutCM , StoreyRF , et al.Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. CMAJ Canadian Medical Association Journal2012;184(10):1135-42. [MEDLINE: 22546885]StegPG , HarringtonRA , EmanuelssonH , KatusHA , MahaffeyKW , MeierB , et al.Response to letter regarding article, &quot;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial&quot;. Circulation2014;129(19):e494-5. [MEDLINE: 24821832]StegPG , HarringtonRA , EmanuelssonH , KatusHA , MahaffeyKW , MeierB , et al.Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation2013;128(10):1055-65. [MEDLINE: 23900047]StegPG , JamesS , HarringtonRA , ArdissinoD , BeckerRC , CannonCP , et al.Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation2010;122(21):2131-41. [MEDLINE: 21060072]StoreyRF , AngiolilloDJ , PatilSB , DesaiB , EcobR , HustedS , et al.Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. Journal of the American College of Cardiology2010;56(18):1456-62. [MEDLINE: 20832963]StoreyRF , ArdissinoD , VignaliL , CairnsR , BeckerRC , CannonCP , et al.Ischaemic events and stent thrombosis following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study. Thrombosis &amp; Haemostasis2018;118(2):427-9. [MEDLINE: 29443375]StoreyRF , BeckerRC , HarringtonRA , HustedS , JamesSK , CoolsF , et al.Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. European Heart Journal2011;32(23):2945-53. [MEDLINE: 21804104]StoreyRF , BeckerRC , HarringtonRA , HustedS , JamesSK , CoolsF , et al.Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). American Journal of Cardiology2011;108(11):1542-6. [MEDLINE: 21890085]StoreyRF , JamesSK , SiegbahnA , VarenhorstC , HeldC , YcasJ , et al.Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets2014;25(7):517-25. [MEDLINE: 24127651]SumayaW , WallentinL , JamesSK , SiegbahnA , GabryschK , BertilssonM , et al.Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. European Heart Journal2018;39(13):1078-85. [MEDLINE: 29390064]UelandT , AkerblomA , GhukasyanT , MichelsenAE , AukrustP , BeckerRC , et al.Osteoprotegerin is associated with major bleeding but not with cardiovascular outcomes in patients with acute coronary syndromes: insights from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American Heart Association2018;7(2):e007009. [MEDLINE: 29330256]UelandT , MichelsenA , AukrustP , BeckerR , BertilssonM , JamesSK , et al.Chemokine (CXC motif) ligand 16 (CXCL16) and osteoprotegerin (OPG) as predictors of outcome in patients with acute coronary syndromes (ACS) a PLATO biomarker substudy [abstract]. European Heart Journal2014;35(Suppl 1):486. [EMBASE: 71648554]WallentinL , BeckerRC , BudajA , CannonCP , EmanuelssonH , HeldC , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2009;361(11):1045-57. [MEDLINE: 19717846]WallentinL , BeckerRC , CannonCP , HeldC , HimmelmannA , HustedS , et al.No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. International Journal of Cardiology2014;176(1):300-2. [MEDLINE: 25005338]WallentinL , BeckerRC , CannonCP , HeldC , HimmelmannA , HustedS , et al.Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. International Journal of Cardiology2014;170(3):e59-62. [MEDLINE: 24299581]WallentinL , BeckerRC , JamesSK , HarringtonRA .The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. &quot;Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified&quot; (Thromb Haemost 2011; 105.5). Thrombosis &amp; Haemostasis2011;105(5):760-2. [MEDLINE: 21394383]WallentinL , JamesS , StoreyRF , ArmstrongM , BarrattBJ , HorrowJ , et al.Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet2010;376(9749):1320-8. [MEDLINE: 20801498]WallentinL , LindholmD , SiegbahnA , WernrothL , BeckerRC , CannonCP , et al.Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2014;129(3):293-303. [MEDLINE: 24170388]">PLATO 2009</a>; <a href="./references#CD008834-bbs2-0100" title="BergerPB , BestPJ , TopolEJ , WhiteJ , DiBattistePM , ChanAW , et al.The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal2005;149(5):869-75. [MEDLINE: 15894970]KalyanasundaramA , BlankenshipJC , BergerP , HerrmannH , McClureR , MoliternoD .Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?). Catheterization &amp; Cardiovascular Interventions2007;69(5):623-9. [MEDLINE: 17192960]MoliternoDJ , TopolEJ .A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. American Heart Journal2000;140(5):722-6. [MEDLINE: 11054616]MoliternoDJ , YakubovSJ , DiBattistePM , HerrmannHC , StoneGW , MacayaC , et al.Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet2002;360(9330):355-60. [MEDLINE: 12241774]MukherjeeD , TopolEJ , BertrandME , KristensenSD , HerrmannHC , NeumannFJ , et al.Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. European Heart Journal2005;26(23):2524-8. [MEDLINE: 16107485]RoffiM , MoliternoDJ , MeierB , PowersER , GrinesCL , DiBattistePM , et al.Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation2002;105(23):2730-6. [MEDLINE: 12057986]TopolEJ , MoliternoDJ , HerrmannHC , PowersER , GrinesCL , CohenDJ , et al.Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New England Journal of Medicine2001;344(25):1888-94. [MEDLINE: 11419425]">TARGET 2000</a>; <a href="./references#CD008834-bbs2-0105" title="AbaciA .The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses [Prasugrelin ST yukselmeli ve yukselmesiz miyokart enfarktusunde kullanimi: TRITON TIMI 38 caIismasi ve alt grup sonuclari]. Turk Kardiyoloji Dernegi Arsivi2015;43 Suppl 2:1-6. [MEDLINE: 27326444]AntmanEM , WiviottSD , MurphySA , VoitkJ , HasinY , WidimskyP , et al.Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Journal of the American College of Cardiology2008;51(21):2028-33. [MEDLINE: 18498956]BonacaMP , WiviottSD , BraunwaldE , MurphySA , RuffCT , AntmanEM , et al.American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation2012;125(4):577-83. [MEDLINE: 22199016]CapodannoD , TamburinoC .Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International Journal of Cardiology2011;146(2):242-3. [MEDLINE: 21130510]DammanP , deWinterRJ , WallentinL , FoxKA .Letter by Damman et al regarding articles, &quot;Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)&quot; and &quot;American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)&quot;. Circulation2012;126(9):e136-7. [MEDLINE: 22927480]De ServiS , GoedickeJ , SchirmerA , WidimskyP .Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European Heart Journal: Acute Cardiovascular Care2014;3(4):363-72. [MEDLINE: 24818952]GoodnoughLT , SmithPK , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. Journal of Thoracic &amp; Cardiovascular Surgery2013;145(4):1077-82. [MEDLINE: 22995726]HochholzerW , WiviottSD , AntmanEM , ContantCF , GuoJ , GiuglianoRP , et al.Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation2011;123(23):2681-9. [MEDLINE: 21606391]KohliP , UdellJA , MurphySA , CannonCP , AntmanEM , BraunwaldE , et al.Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Journal of the American College of Cardiology2014;63(3):225-32. [MEDLINE: 24140678]MahoneyEM , WangK , ArnoldSV , ProskorovskyI , WiviottS , AntmanE , et al.Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation2010;121(1):71-9. [MEDLINE: 20026770]MarianiM , MarianiG , De ServiS .Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert Review of Cardiovascular Therapy2009;7(1):17-23. [MEDLINE: 19105763]MegaJL , CloseSL , WiviottSD , ShenL , WalkerJR , SimonT , et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet2010;376(9749):1312-9. [MEDLINE: 20801494]MichelsonAD , Frelinger AL 3rd, BraunwaldE , DowneyWE , AngiolilloDJ , XenopoulosNP , et al.Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal2009;30(14):1753-63. [MEDLINE: 19435740]MogabgabO , WiviottSD , CannonCP , SloanS , SabatineMS , AntmanEM , et al.Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(6):555-9. [MEDLINE: 24064010]MontalescotG , WiviottSD , BraunwaldE , MurphySA , GibsonCM , McCabeCH , et al.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet2009;373(9665):723-31. [MEDLINE: 19249633]MurphySA , AntmanEM , WiviottSD , WeerakkodyG , MorocuttiG , HuberK , et al.Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European Heart Journal2008;29(20):2473-9. [MEDLINE: 18682445]O'DonoghueM , AntmanEM , BraunwaldE , MurphySA , StegPG , FinkelsteinA , et al.The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology2009;54(8):678-85. [MEDLINE: 19679245]OjeifoO , WiviottSD , AntmanEM , MurphySA , UdellJA , BatesER , et al.Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Jacc: Cardiovascular Interventions2013;6(2):1275-81. [MEDLINE: 24239201]PakhomovIM .Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial. Kardiologiia2010;50(6):63-7. [MEDLINE: 20659030]PrideYB , TungP , MohanaveluS , ZorkunC , WiviottSD , AntmanEM , et al.Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. Jacc: Cardiovascular Interventions2010;3(8):306-11. [MEDLINE: 20723851]RiesmeyerJS , SalazarDE , WeerakkodyGJ , NiL , WrishkoRE , Ernest CS 2nd, et al.Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. Journal of Clinical Pharmacology2012;52(6):789-97. [MEDLINE: 21628601]SerebruanyVL .Letter by Serebruany regarding article, &quot;Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38&quot;. Circulation2010;122(8):e436. [MEDLINE: 20733108]SmithPK , GoodnoughLT , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology2012;60(5):388-96. [MEDLINE: 22633653]SorichMJ , VitryA , WardMB , HorowitzJD , McKinnonRA .Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis &amp; Haemostasis2010;8(8):1678-84. [MEDLINE: 20492467]UdellJA , BraunwaldE , AntmanEM , MurphySA , MontalescotG , WiviottSD .Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).[Erratum in: JACC Cardiovasc Interv. 2014 Aug;7(8):946 Note: Antman, Elliot M [Corrected to Antman, Elliott M]]. Jacc: Cardiovascular Interventions2014;7(6):604-12. [MEDLINE: 24947719]WilcoxR , IqbalK , CostiganT , Lopez-SendonJ , RamosY , WidimskyP .An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current Medical Research &amp; Opinion2014;30(11):2193-205. [MEDLINE: 25025610]WiviottSD , AntmanEM , GibsonCM , MontalescotG , RiesmeyerJ , WeerakkodyG , et al.Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). American Heart Journal2006;152(4):627-35. [MEDLINE: 16996826]WiviottSD , BraunwaldE , McCabeCH , HorvathI , KeltaiM , HerrmanJP , et al.Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet2008;371(9621):1353-63. [MEDLINE: 18377975]WiviottSD , BraunwaldE , McCabeCH , MontalescotG , RuzylloW , GottliebS , et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2007;357(20):2001-15. [MEDLINE: 17982182]WiviottSD , DesaiN , MurphySA , MusumeciG , RagostaM , AntmanEM , et al.Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. American Journal of Cardiology2011;108(7):905-11. [MEDLINE: 21816379]WrishkoRE , Ernest CS 2nd, SmallDS , LiYG , WeerakkodyGJ , RiesmeyerJR , et al.Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. Journal of Clinical Pharmacology2009;49(8):984-98. [MEDLINE: 19546250]">TRITON‐TIMI 38 2006</a>). </p> </li> <li> <p>Thirteen studies evaluated treatment in people on HD (786 participants: <a href="./references#CD008834-bbs2-0004" title="AlexopoulosD , PanagiotouA , XanthopoulouI , KomninakisD , KassimisG , DavlourosP , et al.Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. Journal of Thrombosis &amp; Haemostasis2011;9(12):2379-85. [MEDLINE: 21985070]XanthopoulouI , PanagiotouA , KomninakisD , DavlourosP , KassimisG , FourtounasK , et al.Prasugrel versus double clopidpogrel maintenance dose in patients on chronic haemodialysis and high on clopidogrel platelet reactivity [abstract no: P2438]. European Heart Journal2011;32(Suppl 1):417. [EMBASE: 70534608]">Alexopoulos 2011</a>; <a href="./references#CD008834-bbs2-0047" title="HidakaS , KobayashiS , IwagamiM , IsshikiR , TsutsumiD , MochidaY , et al.Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease. Renal Failure2013;35(1):43-8. [MEDLINE: 23110683]">Hidaka 2013</a>; <a href="./references#CD008834-bbs2-0052" title="OhtakeT , SatoM , NakazawaR , KondohM , KobayashiS .Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study [abstract no: Su528]. NDT Plus2010;3(Suppl 3):iii487. [EMBASE: 70484748]OhtakeT , SatoM , NakazawaR , KondohM , MiyajiT , MoriyaH , et al.Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2014;18(1):1-8. [MEDLINE: 24499078]">J‐PADD 2014</a>; <a href="./references#CD008834-bbs2-0075" title="OtaK , TeraokaS , AkiwasaT , MimuraN , HirasawaY , SakaiT , et al.Clinical efficacy of E5510 (satigrel), an antiplatelet agent, for preventing blood clotting in the extracorporeal circuit during hemodialysis (3) - A double-blind comparison with ticlopidine hydrochloride. Rinsho Hyoka1996;24(1):9-38. ">Ota 1996</a>; <a href="./references#CD008834-bbs2-0077" title="KimW , KangWY , WooJS .Objectives: The purpose of this study was to determine the functional impact of cilostazol in patients with chronic kidney disease (CKD) undergoing hemodialysis [abstract no: TCT-497]. Journal of the American College of Cardiology2011;58(20 Suppl 1):B135. [EMBASE: 70581866]WooJS , KimW , HaSJ , JeongKH , LeeTW , IhmCG , et al.A comparison of clopidogrel responsiveness in patients with chronic renal failure: results of the adjunctive cilostazol versus high maintenance dose clopidogrel (PIANO) study [abstract no: AS-252]. American Journal of Cardiology2011;107(8 Suppl 1):100-1A. [EMBASE: 70401953]WooJS , KimW , LeeSR , JungKH , KimWS , LewJH , et al.Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. American Heart Journal2011;162(6):1018-25. [MEDLINE: 22137075]">PIANO‐2 CKD 2011</a>; <a href="./references#CD008834-bbs2-0078" title="JeongKH , ChoJH , WooJS , KimJB , KimWS , LeeTW , et al.Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. American Journal of Kidney Diseases2015;65(6):916-24. [MEDLINE: 25622774]JeongKH , LeeTW , KimJS , LeeSY , LeeSH , MoonJY , et al.Platelet reactivity in patients with end stage renal disease receiving clopidogrel compared with ticagrelor: a randomized crossover study [abstract no: FP610]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii276. [EMBASE: 72207028]WooJS , KimW , KimHS , HwangSJ , KimJB , KimSJ , et al.Randomized assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with chronic kidney disease performing hemodialysis [abstract]. European Heart Journal2014;35(Suppl 1):7-8. [EMBASE: 71646762]">PIANO‐3 2015</a>; <a href="./references#CD008834-bbs2-0079" title="KimJS , LeeTW , IhmC , LeeSH , KimSY , LeeSY , et al.Relationship of ticagrelor dose and platelet reactivity in patients with end stage renal disease on hemodialysis [abstract no: FR-PO727]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):529A. KimJS , WooJS , KimJB , KimWS , LeeTW , KimKS , et al.The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. International Journal of Cardiology2017;238:110-6. [MEDLINE: 28342632]KimW , WooJS , KimWS , KimJB , KimHO , KimJM .Pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis [abstract]. European Heart Journal2016;37(Suppl 1):636. [EMBASE: 612284362]">PIANO‐6 2017</a>; <a href="./references#CD008834-bbs2-0092" title="SchneppM , TeichlerS , MarkauS , RettkowskiO , PriesackJ , DeuberHJ , et al.Platelet function analysis during therapy with clopidogrel in endstage renal disease [abstract]. In: 37th Congress. European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17-20; Nice, France. 2000:191. [CENTRAL: CN-00461687] ">Schnepp 2000</a>; <a href="./references#CD008834-bbs2-0094" title="SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract no: 9P]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):388. [CENTRAL: CN-00485981] SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study. Kidney International1994;45(5):1477-83. [MEDLINE: 8072261]">Sreedhara 1994</a>; <a href="./references#CD008834-bbs2-0102" title="TengR , MuldowneyS , ZhaoY , BergJK , LuJ , KhanND .Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. European Journal of Clinical Pharmacology2018;74(9):1141-8. [MEDLINE: 29850937]">Teng 2018</a>: <a href="./references#CD008834-bbs2-0107" title="WasedaK , SakaY , TakashimaH , KuritaA , AndoH , SakuraiS , et al.Effect of CYP2C19 genotype on inhibition of platelet aggregation in hemodialysis patients with coronary artery disease [abstract]. Circulation2016;134(Suppl 1):A14237. [EMBASE: 619219587]">Waseda 2016</a>; <a href="./references#CD008834-bbs2-0110" title="XydakisD , PapadagiannakisA , SfakianakiM , VakoutiE , PapachristoforouK .The combination of clopidogrel (CL) and acetylsalicylic acid (ASA) inhibits more effective the platelet activation in haemodialysis patients with acute coronary syndromes (ACS) and high C reactive protein [abstract no: MP370]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:355. [CENTRAL: CN-00509568] ">Xydakis 2004</a>; <a href="./references#CD008834-bbs2-0111" title="YangMY , HanB , XuY , TianLY , ZhangY , QiangYW .The effects of different dose of clopidogrel in elderly patients with unstable angina combining chronic kidney disease [abstract no: P12]. Journal of the American Geriatrics Society2016;64(Suppl 2):S320. [EMBASE: 611887576]">Yang 2016b</a>). </p> </li> <li> <p>Two studies enrolled kidney transplant recipients (122 participants: <a href="./references#CD008834-bbs2-0033" title="BonominiV , VangelistaA , StefoniS , ScolariMP , FrascàGM , RaimondiC .Use of defibrotide in renal transplantation in man. Haemostasis1986;16 Suppl 1:48-50. [MEDLINE: 3519383]FrascàGM , VangelistaA , RaimondiC , BonominiV .Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (defibrotide): a controlled study. Life Support Systems1986;4(3):231-7. [MEDLINE: 3537545]">Frascà 1986</a>; <a href="./references#CD008834-bbs2-0055" title="KauffmannHM , AdamsMB , HebertLA , WalczakPM .Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905 ]">Kauffmann 1980</a>). </p> </li> </ul> </p> <p>In the studies that compared an antiplatelet with another antiplatelet, interventions included: </p> <p> <ul id="CD008834-list-0027"> <li> <p>Acetylsalicylic acid</p> <ul id="CD008834-list-0028"> <li> <p>Aspirin versus clopidogrel (3 studies, 202 participants: <a href="./references#CD008834-bbs2-0018" title="DashA , MaitiR , BandakkanavarTK , BhaskarA , PrakashJ , PandeyBL .Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: comparison between clopidogrel and low-dose aspirin. International Journal of Preventive Medicine2013;4(8):902-10. [MEDLINE: 24049616]">Dash 2013</a>; <a href="./references#CD008834-bbs2-0110" title="XydakisD , PapadagiannakisA , SfakianakiM , VakoutiE , PapachristoforouK .The combination of clopidogrel (CL) and acetylsalicylic acid (ASA) inhibits more effective the platelet activation in haemodialysis patients with acute coronary syndromes (ACS) and high C reactive protein [abstract no: MP370]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:355. [CENTRAL: CN-00509568] ">Xydakis 2004</a>; <a href="./references#CD008834-bbs2-0111" title="YangMY , HanB , XuY , TianLY , ZhangY , QiangYW .The effects of different dose of clopidogrel in elderly patients with unstable angina combining chronic kidney disease [abstract no: P12]. Journal of the American Geriatrics Society2016;64(Suppl 2):S320. [EMBASE: 611887576]">Yang 2016b</a>) </p> </li> <li> <p>Aspirin versus clopidogrel versus ticlopidine (1 study, 30 participants: <a href="./references#CD008834-bbs2-0092" title="SchneppM , TeichlerS , MarkauS , RettkowskiO , PriesackJ , DeuberHJ , et al.Platelet function analysis during therapy with clopidogrel in endstage renal disease [abstract]. In: 37th Congress. European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17-20; Nice, France. 2000:191. [CENTRAL: CN-00461687] ">Schnepp 2000</a>) </p> </li> <li> <p>Aspirin versus sarpogrelate (1 study, 40 participants: <a href="./references#CD008834-bbs2-0073" title="OgawaS , MoriT , NakoK , IshizukaT , ItoS .Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):362-8. [MEDLINE: 18235151]">Ogawa 2008</a>) </p> </li> </ul> </li> <li> <p>Adenosine reuptake inhibitors</p> <ul id="CD008834-list-0029"> <li> <p>Dypiridamole versus aspirin (2 studies, 97 participants: <a href="./references#CD008834-bbs2-0055" title="KauffmannHM , AdamsMB , HebertLA , WalczakPM .Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905 ]">Kauffmann 1980</a>; <a href="./references#CD008834-bbs2-0094" title="SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract no: 9P]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):388. [CENTRAL: CN-00485981] SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study. Kidney International1994;45(5):1477-83. [MEDLINE: 8072261]">Sreedhara 1994</a>) </p> </li> <li> <p>Dypiridamole versus defibrotide (1 study, 80 participants: <a href="./references#CD008834-bbs2-0033" title="BonominiV , VangelistaA , StefoniS , ScolariMP , FrascàGM , RaimondiC .Use of defibrotide in renal transplantation in man. Haemostasis1986;16 Suppl 1:48-50. [MEDLINE: 3519383]FrascàGM , VangelistaA , RaimondiC , BonominiV .Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (defibrotide): a controlled study. Life Support Systems1986;4(3):231-7. [MEDLINE: 3537545]">Frascà 1986</a>) </p> </li> <li> <p>Dypiridamole versus aspirin versus dypiridamole plus aspirin versus placebo (1 study, 76 participants: <a href="./references#CD008834-bbs2-0057" title="KhajehdehiP , RoozbehJ , MostafaviH .A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scandinavian Journal of Urology &amp; Nephrology2002;36(2):145-8. [MEDLINE: 12028688]">Khajehdehi 2002</a>) </p> </li> <li> <p>Dypiridamole versus pentoxifylline (1 study, 40 participants: <a href="./references#CD008834-bbs2-0066" title="MovchanEA , ChuprovaAV , TovNL , Vol'vichNV .Desaggregation therapy of acute glomerulonephritis [Dezagregatsionnaia terapiia ostrogo glomerulonefrita]. Klinicheskaia Meditsina2001;79(12):44-7. [MEDLINE: 11840813]">Movchan 2001</a>) </p> </li> </ul> </li> <li> <p>Adenosine diphosphate receptor inhibitors</p> <ul id="CD008834-list-0030"> <li> <p>Clopidogrel versus cilostazol (1 study, 74 participants: <a href="./references#CD008834-bbs2-0077" title="KimW , KangWY , WooJS .Objectives: The purpose of this study was to determine the functional impact of cilostazol in patients with chronic kidney disease (CKD) undergoing hemodialysis [abstract no: TCT-497]. Journal of the American College of Cardiology2011;58(20 Suppl 1):B135. [EMBASE: 70581866]WooJS , KimW , HaSJ , JeongKH , LeeTW , IhmCG , et al.A comparison of clopidogrel responsiveness in patients with chronic renal failure: results of the adjunctive cilostazol versus high maintenance dose clopidogrel (PIANO) study [abstract no: AS-252]. American Journal of Cardiology2011;107(8 Suppl 1):100-1A. [EMBASE: 70401953]WooJS , KimW , LeeSR , JungKH , KimWS , LewJH , et al.Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. American Heart Journal2011;162(6):1018-25. [MEDLINE: 22137075]">PIANO‐2 CKD 2011</a>) </p> </li> <li> <p>Clopidogrel plus cilostazol versus clopidogrel (1 study, 184 participants: <a href="./references#CD008834-bbs2-0014" title="LeeMH , SuhJW , LeeSP , ParkKW , LeeHY , KangHJ , et al.The effect of cilostazol on the antiplatelet efficacy of patients with moderate renal dysfunction: post-hoc analysis of CILON-T (Influence of cilostazol based triple antiplatelet therapy on ischemic complication after drug eluting stent implantation) trial [abstract no: TCT-495]. Journal of the American College of Cardiology2011;58(20 Suppl 1):B134-5. [EMBASE: 70581865]LeeSP , SuhJW , ParkKW , LeeHY , KangHJ , KooBK , et al.Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: a multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease. Trials [Electronic Resource]2010;11:87. [MEDLINE: 20735821]SuhJW , LeeSP , ParkKW , LeeHY , KangHJ , KooBK , et al.Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. Journal of the American College of Cardiology2011;57(3):280-9. [MEDLINE: 21232664]">CILON‐T 2010</a>) </p> </li> <li> <p>Clopidogrel versus ticagrelor (2 studies, 3701 participants: <a href="./references#CD008834-bbs2-0030" title="BaumgartnerI , NorgrenL , FowkesFG , MulderH , PatelMR , BergerJS , et al.Cardiovascular outcomes after lower extremity endovascular or surgical revascularization: the EUCLID trial. Journal of the American College of Cardiology2018;72(14):1563-72. [MEDLINE: 30261955]BergerJS , AbramsonBL , LopesRD , HeizerG , RockholdFW , BaumgartnerI , et al.Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Vascular Medicine2018;23(6):523-30. [MEDLINE: 29992857]HaineA , KavanaghS , BergerJS , HessCN , NorgrenL , FowkesFG , et al.Sex-specific risks of major cardiovascular and limb events in patients with symptomatic peripheral artery disease. Journal of the American College of Cardiology2020;75(6):608-17. [MEDLINE: 32057375]HessCN , HuangZ , PatelMR , BaumgartnerI , BergerJS , BlomsterJI , et al.Acute limb ischemia in peripheral artery disease. Circulation2019;140(7):556-65. [MEDLINE: 31238713]HiattWR , FowkesFG , HeizerG , BergerJS , BaumgartnerI , HeldP , et al.Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. New England Journal of Medicine2017;376(1):32-40. [MEDLINE: 27959717]HopleyCW , KavanaghS , PatelMR , OstromC , BaumgartnerI , BergerJS , et al.Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial. Vascular Medicine2019;24(5):422-30. [MEDLINE: 31339474]JonesWS , BaumgartnerI , HiattWR , HeizerG , ConteMS , WhiteCJ , et al.Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation2017;135(3):241-50. [MEDLINE: 27840336]KollsBJ , SappS , RockholdFW , JordanJD , DombrowskiKE , FowkesFG , et al.Stroke in patients with peripheral artery disease. Stroke2019;50(6):1356-63. [MEDLINE: 31092165]Low WangCC , BlomsterJI , HeizerG , BergerJS , BaumgartnerI , FowkesFG , et al.Cardiovascular and limb outcomes in patients with diabetes and peripheral artery disease: the EUCLID trial. Journal of the American College of Cardiology2018;72(25):3274-84. [MEDLINE: 30573030]NorgrenL , PatelMR , HiattWR , WojdylaDM , FowkesFG , BaumgartnerI , et al.Outcomes of patients with critical limb ischaemia in the EUCLID trial. European Journal of Vascular &amp; Endovascular Surgery2018;55(1):109-17. [MEDLINE: 29273390]OlivierCB , MulderH , HiattWR , JonesWS , FowkesFG , RockholdFW , et al.Incidence, characteristics, and outcomes of myocardial infarction in patients with peripheral artery disease: insights from the EUCLID trial. JAMA Cardiology2019;4(1):7-15. [MEDLINE: 30540355]">EUCLID 2017</a>; <a href="./references#CD008834-bbs2-0079" title="KimJS , LeeTW , IhmC , LeeSH , KimSY , LeeSY , et al.Relationship of ticagrelor dose and platelet reactivity in patients with end stage renal disease on hemodialysis [abstract no: FR-PO727]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):529A. KimJS , WooJS , KimJB , KimWS , LeeTW , KimKS , et al.The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. International Journal of Cardiology2017;238:110-6. [MEDLINE: 28342632]KimW , WooJS , KimWS , KimJB , KimHO , KimJM .Pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis [abstract]. European Heart Journal2016;37(Suppl 1):636. [EMBASE: 612284362]">PIANO‐6 2017</a>) </p> </li> <li> <p>Low‐dose clopidogrel versus high‐dose clopidogrel (1 study, 370 participants: <a href="./references#CD008834-bbs2-0062" title="LiangJ , WangZ , ShiD , LiuY , ZhaoY , HanH , et al.High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. Angiology2015;66(4):319-25. [MEDLINE: 24913197]">Liang 2015</a>) </p> </li> <li> <p>Ticlopidine versus satigrel (1 study, 224 participants: <a href="./references#CD008834-bbs2-0075" title="OtaK , TeraokaS , AkiwasaT , MimuraN , HirasawaY , SakaiT , et al.Clinical efficacy of E5510 (satigrel), an antiplatelet agent, for preventing blood clotting in the extracorporeal circuit during hemodialysis (3) - A double-blind comparison with ticlopidine hydrochloride. Rinsho Hyoka1996;24(1):9-38. ">Ota 1996</a>) </p> </li> </ul> </li> <li> <p>Phosphodiesterase 3 inhibitors</p> <ul id="CD008834-list-0031"> <li> <p>Cilostazol versus beraprost sodium (1 study, 72 participants: <a href="./references#CD008834-bbs2-0052" title="OhtakeT , SatoM , NakazawaR , KondohM , KobayashiS .Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study [abstract no: Su528]. NDT Plus2010;3(Suppl 3):iii487. [EMBASE: 70484748]OhtakeT , SatoM , NakazawaR , KondohM , MiyajiT , MoriyaH , et al.Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2014;18(1):1-8. [MEDLINE: 24499078]">J‐PADD 2014</a>) </p> </li> <li> <p>Cilostazol versus sarpogrelate (1 study, 35 participants: <a href="./references#CD008834-bbs2-0047" title="HidakaS , KobayashiS , IwagamiM , IsshikiR , TsutsumiD , MochidaY , et al.Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease. Renal Failure2013;35(1):43-8. [MEDLINE: 23110683]">Hidaka 2013</a>) </p> </li> </ul> </li> <li> <p>P2Y<sub>12</sub> antagonists </p> <ul id="CD008834-list-0032"> <li> <p>Ticagrelor versus clopidogrel (3 studies, 3322 participants: <a href="./references#CD008834-bbs2-0074" title="HanY .Comparison of the pharmacodynamics and pharmacokinetics of ticagrelor versus clopidogrel in patients with chronic kidney disease and non-ST-elevation acute coronary syndromes (OPT-CKD trial) [abstract no: TCT-483]. Journal of the American College of Cardiology2017;70(18 Suppl 1):B200. [EMBASE: 619771602]WangH , QiJ , LiY , TangY , LiC , LiJ , et al.Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. British Journal of Clinical Pharmacology2018;84(1):88-96. [MEDLINE: 28921624]">OPT‐CKD 2018</a>; <a href="./references#CD008834-bbs2-0078" title="JeongKH , ChoJH , WooJS , KimJB , KimWS , LeeTW , et al.Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. American Journal of Kidney Diseases2015;65(6):916-24. [MEDLINE: 25622774]JeongKH , LeeTW , KimJS , LeeSY , LeeSH , MoonJY , et al.Platelet reactivity in patients with end stage renal disease receiving clopidogrel compared with ticagrelor: a randomized crossover study [abstract no: FP610]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii276. [EMBASE: 72207028]WooJS , KimW , KimHS , HwangSJ , KimJB , KimSJ , et al.Randomized assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with chronic kidney disease performing hemodialysis [abstract]. European Heart Journal2014;35(Suppl 1):7-8. [EMBASE: 71646762]">PIANO‐3 2015</a>; <a href="./references#CD008834-bbs2-0081" title="AkerblomA , WallentinL , LarssonA , SiegbahnA , BeckerRC , BudajA , et al.Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study. Clinical Chemistry2013;59(9):1369-75. [MEDLINE: 23698074]AkerblomA , WallentinL , SiegbahnA , BeckerRC , BudajA , HorrowJ , et al.Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. American Heart Journal2012;164(5):728-34. [MEDLINE: 23137503]AndellP , JamesSK , CannonCP , CyrDD , HimmelmannA , HustedS , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Journal of the American Heart Association2015;4(10):e002490. [MEDLINE: 26452988]ArmstrongPW , SihaH , FuY , WesterhoutCM , StegPG , JamesSK , et al.ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation2012;125(3):514-21. [MEDLINE: 22179530]ArmstrongPW , WesterhoutCM , FuY , HarringtonRA , StoreyRF , KatusH , et al.Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. American Journal of Medicine2013;126(8):723-9. [MEDLINE: 23795897]BeckerRC , BassandJP , BudajA , WojdylaDM , JamesSK , CornelJH , et al.Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial [Erratum in: Eur Heart J. 2012 Nov;33(21):2750]. European Heart Journal2011;32(23):2933-44. [MEDLINE: 22090660]BellaviaA , WallentinL , OrsiniN , JamesSK , CannonCP , HimmelmannA , et al.Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. Open Heart2017;4(2):e000557. [MEDLINE: 28761675]BrilakisES , HeldC , MeierB , CoolsF , ClaeysMJ , CornelJH , et al.Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. American Heart Journal2013;166(3):474-80. [MEDLINE: 24016496]BuiAH , CannonCP , StegPG , StoreyRF , HustedS , GuoJ , et al.Relationship between early and late nonsustained ventricular tachycardia and cardiovascular death in patients with acute coronary syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation: Arrhythmia and Electrophysiology2016;9(2):e002951. [MEDLINE: 26810596]CapodannoD , CalviV , TamburinoC .Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment. Journal of Cardiovascular Medicine2012;13(2):162-3. [MEDLINE: 22237463]CornelJH , BeckerRC , GoodmanSG , HustedS , KatusH , SantosoA , et al.Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2012;164(3):334-42. [MEDLINE: 22980299]CowperPA , PanW , AnstromKJ , KaulP , WallentinL , Davidson-RayL , et al.Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. Journal of the American College of Cardiology2015;65(5):465-76. [MEDLINE: 25660925]DiNicolantonioJJ , D'AscenzoF , TomekA , ChatterjeeS , NiaziAK , Biondi-ZoccaiG .Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial. International Journal of Cardiology2013;168(3):1739-44. [MEDLINE: 23907035]DiNicolantonioJJ , TomekA .Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial. International Journal of Cardiology2013;168(4):4076-80. [MEDLINE: 23911266]DiNicolantonioJJ , TomekA .Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel. International Journal of Cardiology2013;169(2):145-6. [MEDLINE: 24120213]DucrocqG , SchultePJ , BeckerRC , CannonCP , HarringtonRA , HeldC , et al.Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. Eurointervention2015;11(7):737-45. [MEDLINE: 25254357]FranchiF , JamesSK , GhukasyanLT , BudajAJ , CornelJH , KatusHA , et al.Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y12 receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. Journal of the American Heart Association2019;8(6):e011139. [MEDLINE: 30857464]GiannitsisE , WallentinL , JamesSK , BertilssonM , SiegbahnA , StoreyRF , et al.Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: a Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. European Heart Journal: Acute Cardiovascular Care2017;6(6):500-10. [MEDLINE: 27044282]HagstromE , JamesSK , BertilssonM , BeckerRC , HimmelmannA , HustedS , et al.Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. European Heart Journal2016;37(16):1325-33. [MEDLINE: 26417057]HeldC , AsenbladN , BassandJP , BeckerRC , CannonCP , ClaeysMJ , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology2011;57(6):672-84. [MEDLINE: 21194870]HustedS , JamesS , BeckerRC , HorrowJ , KatusH , StoreyRF , et al.Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circulation. Cardiovascular Quality &amp; Outcomes2012;5(5):680-8. [MEDLINE: 22991347]HustedS , JamesSK , BachRG , BeckerRC , BudajA , HerasM , et al.The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal2014;35(23):1541-50. [MEDLINE: 24682844]JamesS , AkerblomA , CannonCP , EmanuelssonH , HustedS , KatusH , et al.Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2009;157(4):599-605. [MEDLINE: 19332184]JamesS , AngiolilloDJ , CornelJH , ErlingeD , HustedS , KontnyF , et al.Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal2010;31(24):3006-16. [MEDLINE: 20802246]JamesS , BudajA , AylwardP , BuckKK , CannonCP , CornelJH , et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2010;122(11):1056-67. [MEDLINE: 20805430]JamesS , BudajA , AylwardP , BuckKK , CannonCP , CornelJH , et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation2010;122(11):1056-67. [MEDLINE: 20805430]JamesSK , RoeMT , CannonCP , CornelJH , HorrowJ , HustedS , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ2011;342:d3527. [MEDLINE: 21685437]JohanssonA , ErikssonN , BeckerRC , StoreyRF , HimmelmannA , HagstromE , et al.NLRC4 inflammasome is an important regulator of interleukin-18 levels in patients with acute coronary syndromes: genome-wide association study in the PLATelet inhibition and patient Outcomes Trial (PLATO). Circulation. Cardiovascular Genetics2015;8(3):498-506. [MEDLINE: 25747584]KangHJ , ClareRM , GaoR , HeldC , HimmelmannA , JamesSK , et al.Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal2015;169(6):899-905. [MEDLINE: 26027629]KholaifN , ZhengY , JagasiaP , HimmelmannA , JamesSK , StegPG , et al.Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex. American Journal of Medicine2015;128(8):914-9. [MEDLINE: 25818495]KohliP , WallentinL , ReyesE , HorrowJ , HustedS , AngiolilloDJ , et al.Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation2013;127(6):673-80. [MEDLINE: 23277305]KontnyF , UelandT , AukrustP , MichelsenAE , BeckerRC , BertilssonM , et al.Pentraxin 3 (PTX3) predict adverse outcome in acute coronary syndromes-a PLATO biomarker substudy [abstract]. European Heart Journal2014;35(Suppl 1):319. [EMBASE: 71647923]KotsiaA , BrilakisES , HeldC , CannonC , StegGP , MeierB , et al.Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2014;168(1):68-75. [MEDLINE: 24952862]KunadianV , JamesSK , WojdylaDM , ZorkunC , WuJ , StoreyRF , et al.Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). Jacc: Cardiovascular Interventions2013;6(7):671-83. [MEDLINE: 23866179]LevinLA , WallentinL , BernfortL , AnderssonD , StoreyRF , BergstromG , et al.Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. Value in Health2013;16(4):574-80. [MEDLINE: 23796291]LindholmD , VarenhorstC , CannonCP , HarringtonRA , HimmelmannA , MayaJ , et al.Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal2014;35(31):2083-93. [MEDLINE: 24727884]MahaffeyKW , HeldC , WojdylaDM , JamesSK , KatusHA , HustedS , et al.Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology2014;63(15):1493-9. [MEDLINE: 24561148]MahaffeyKW , WojdylaDM , CarrollK , BeckerRC , StoreyRF , AngiolilloDJ , et al.Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2011;124(5):544-54. [MEDLINE: 21709065]NikolicE , JanzonM , HauchO , WallentinL , HenrikssonM , PLATO Health Economic Substudy Group.Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. European Heart Journal2013;34(3):220-8. [MEDLINE: 22719022]OhmanEM , RoeMT .Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany &quot;Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified&quot; (Thromb Haemost 2011; 105.5). Thrombosis &amp; Haemostasis2011;105(5):763-5. [MEDLINE: 21394382]ParkerWA , ErikssonN , BeckerRC , VooraD , AkerblomA , HimmelmannA , et al.Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets2019;30(5):579-88. [MEDLINE: 29851527]PatelMR , BeckerRC , WojdylaDM , EmanuelssonH , HiattWR , HorrowJ , et al.Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. European Journal of Preventive Cardiology2015;22(6):734-42. [MEDLINE: 24830710]Pollack CV Jr, DavoudiF , DiercksDB , BeckerRC , JamesSK , LimST , et al.Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clinical Cardiology2017;40(6):390-8. [MEDLINE: 28598510]RoguinA , MusallamA .Letter by Roguin and Musallam regarding article, &quot;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial&quot;. Circulation2014;129(19):e493. [MEDLINE: 24821831]SciricaBM , BansilalS , DavoudiF , ArmstrongPW , ClareRM , SchultePJ , et al.Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. American Heart Journal2018;202:54-60. [MEDLINE: 29859968]SciricaBM , CannonCP , EmanuelssonH , MichelsonEL , HarringtonRA , HustedS , et al.The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. Journal of the American College of Cardiology2011;57(19):1908-16. [MEDLINE: 21545948]SerebruanyVL , FortmannSD , CherepanovV , LitvinovO , KimMH , MarciniakTA .Excess ticagrelor mortality in the food and drug administration adverse event reporting system: time to recount PLATO trial deaths. American Journal of Medicine2017;130(6):e245-6. [MEDLINE: 28161342]SerebruanyVL .Angiographic outcomes contradict platelet data in the PLATO trial: confusion over official trial substudies. Cardiology2014;127(3):190-5. [MEDLINE: 24457905]SerebruanyVL .Discrepancies in the primary PLATO trial publication and the FDA reviews. International Journal of Cardiology2014;172(1):8-10. [MEDLINE: 24456868]SerebruanyVL .Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review. American Journal of Therapeutics2012;19(2):160-1. [MEDLINE: 22395000]SerebruanyVL .The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent. Cardiology2011;120(3):169-71. [MEDLINE: 22418766]ShimadaYJ , BansilalS , WiviottSD , BeckerRC , HarringtonRA , HimmelmannA , et al.Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal2016;177:1-8. [MEDLINE: 27297843]SihaH , DasD , FuY , ZhengY , WesterhoutCM , StoreyRF , et al.Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. CMAJ Canadian Medical Association Journal2012;184(10):1135-42. [MEDLINE: 22546885]StegPG , HarringtonRA , EmanuelssonH , KatusHA , MahaffeyKW , MeierB , et al.Response to letter regarding article, &quot;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial&quot;. Circulation2014;129(19):e494-5. [MEDLINE: 24821832]StegPG , HarringtonRA , EmanuelssonH , KatusHA , MahaffeyKW , MeierB , et al.Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation2013;128(10):1055-65. [MEDLINE: 23900047]StegPG , JamesS , HarringtonRA , ArdissinoD , BeckerRC , CannonCP , et al.Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation2010;122(21):2131-41. [MEDLINE: 21060072]StoreyRF , AngiolilloDJ , PatilSB , DesaiB , EcobR , HustedS , et al.Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. Journal of the American College of Cardiology2010;56(18):1456-62. [MEDLINE: 20832963]StoreyRF , ArdissinoD , VignaliL , CairnsR , BeckerRC , CannonCP , et al.Ischaemic events and stent thrombosis following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study. Thrombosis &amp; Haemostasis2018;118(2):427-9. [MEDLINE: 29443375]StoreyRF , BeckerRC , HarringtonRA , HustedS , JamesSK , CoolsF , et al.Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. European Heart Journal2011;32(23):2945-53. [MEDLINE: 21804104]StoreyRF , BeckerRC , HarringtonRA , HustedS , JamesSK , CoolsF , et al.Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). American Journal of Cardiology2011;108(11):1542-6. [MEDLINE: 21890085]StoreyRF , JamesSK , SiegbahnA , VarenhorstC , HeldC , YcasJ , et al.Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets2014;25(7):517-25. [MEDLINE: 24127651]SumayaW , WallentinL , JamesSK , SiegbahnA , GabryschK , BertilssonM , et al.Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. European Heart Journal2018;39(13):1078-85. [MEDLINE: 29390064]UelandT , AkerblomA , GhukasyanT , MichelsenAE , AukrustP , BeckerRC , et al.Osteoprotegerin is associated with major bleeding but not with cardiovascular outcomes in patients with acute coronary syndromes: insights from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American Heart Association2018;7(2):e007009. [MEDLINE: 29330256]UelandT , MichelsenA , AukrustP , BeckerR , BertilssonM , JamesSK , et al.Chemokine (CXC motif) ligand 16 (CXCL16) and osteoprotegerin (OPG) as predictors of outcome in patients with acute coronary syndromes (ACS) a PLATO biomarker substudy [abstract]. European Heart Journal2014;35(Suppl 1):486. [EMBASE: 71648554]WallentinL , BeckerRC , BudajA , CannonCP , EmanuelssonH , HeldC , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2009;361(11):1045-57. [MEDLINE: 19717846]WallentinL , BeckerRC , CannonCP , HeldC , HimmelmannA , HustedS , et al.No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. International Journal of Cardiology2014;176(1):300-2. [MEDLINE: 25005338]WallentinL , BeckerRC , CannonCP , HeldC , HimmelmannA , HustedS , et al.Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. International Journal of Cardiology2014;170(3):e59-62. [MEDLINE: 24299581]WallentinL , BeckerRC , JamesSK , HarringtonRA .The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. &quot;Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified&quot; (Thromb Haemost 2011; 105.5). Thrombosis &amp; Haemostasis2011;105(5):760-2. [MEDLINE: 21394383]WallentinL , JamesS , StoreyRF , ArmstrongM , BarrattBJ , HorrowJ , et al.Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet2010;376(9749):1320-8. [MEDLINE: 20801498]WallentinL , LindholmD , SiegbahnA , WernrothL , BeckerRC , CannonCP , et al.Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2014;129(3):293-303. [MEDLINE: 24170388]">PLATO 2009</a>) </p> </li> <li> <p>Ticagrerol pre‐dialysis versus ticagrelor post‐dialysis (1 study, 14 participants: <a href="./references#CD008834-bbs2-0102" title="TengR , MuldowneyS , ZhaoY , BergJK , LuJ , KhanND .Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. European Journal of Clinical Pharmacology2018;74(9):1141-8. [MEDLINE: 29850937]">Teng 2018</a>) </p> </li> <li> <p>Prasugrel versus clopidogrel (3 studies, 1544 participants: <a href="./references#CD008834-bbs2-0004" title="AlexopoulosD , PanagiotouA , XanthopoulouI , KomninakisD , KassimisG , DavlourosP , et al.Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. Journal of Thrombosis &amp; Haemostasis2011;9(12):2379-85. [MEDLINE: 21985070]XanthopoulouI , PanagiotouA , KomninakisD , DavlourosP , KassimisG , FourtounasK , et al.Prasugrel versus double clopidpogrel maintenance dose in patients on chronic haemodialysis and high on clopidogrel platelet reactivity [abstract no: P2438]. European Heart Journal2011;32(Suppl 1):417. [EMBASE: 70534608]">Alexopoulos 2011</a>; <a href="./references#CD008834-bbs2-0105" title="AbaciA .The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses [Prasugrelin ST yukselmeli ve yukselmesiz miyokart enfarktusunde kullanimi: TRITON TIMI 38 caIismasi ve alt grup sonuclari]. Turk Kardiyoloji Dernegi Arsivi2015;43 Suppl 2:1-6. [MEDLINE: 27326444]AntmanEM , WiviottSD , MurphySA , VoitkJ , HasinY , WidimskyP , et al.Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Journal of the American College of Cardiology2008;51(21):2028-33. [MEDLINE: 18498956]BonacaMP , WiviottSD , BraunwaldE , MurphySA , RuffCT , AntmanEM , et al.American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation2012;125(4):577-83. [MEDLINE: 22199016]CapodannoD , TamburinoC .Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International Journal of Cardiology2011;146(2):242-3. [MEDLINE: 21130510]DammanP , deWinterRJ , WallentinL , FoxKA .Letter by Damman et al regarding articles, &quot;Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)&quot; and &quot;American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)&quot;. Circulation2012;126(9):e136-7. [MEDLINE: 22927480]De ServiS , GoedickeJ , SchirmerA , WidimskyP .Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European Heart Journal: Acute Cardiovascular Care2014;3(4):363-72. [MEDLINE: 24818952]GoodnoughLT , SmithPK , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. Journal of Thoracic &amp; Cardiovascular Surgery2013;145(4):1077-82. [MEDLINE: 22995726]HochholzerW , WiviottSD , AntmanEM , ContantCF , GuoJ , GiuglianoRP , et al.Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation2011;123(23):2681-9. [MEDLINE: 21606391]KohliP , UdellJA , MurphySA , CannonCP , AntmanEM , BraunwaldE , et al.Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Journal of the American College of Cardiology2014;63(3):225-32. [MEDLINE: 24140678]MahoneyEM , WangK , ArnoldSV , ProskorovskyI , WiviottS , AntmanE , et al.Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation2010;121(1):71-9. [MEDLINE: 20026770]MarianiM , MarianiG , De ServiS .Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert Review of Cardiovascular Therapy2009;7(1):17-23. [MEDLINE: 19105763]MegaJL , CloseSL , WiviottSD , ShenL , WalkerJR , SimonT , et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet2010;376(9749):1312-9. [MEDLINE: 20801494]MichelsonAD , Frelinger AL 3rd, BraunwaldE , DowneyWE , AngiolilloDJ , XenopoulosNP , et al.Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal2009;30(14):1753-63. [MEDLINE: 19435740]MogabgabO , WiviottSD , CannonCP , SloanS , SabatineMS , AntmanEM , et al.Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(6):555-9. [MEDLINE: 24064010]MontalescotG , WiviottSD , BraunwaldE , MurphySA , GibsonCM , McCabeCH , et al.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet2009;373(9665):723-31. [MEDLINE: 19249633]MurphySA , AntmanEM , WiviottSD , WeerakkodyG , MorocuttiG , HuberK , et al.Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European Heart Journal2008;29(20):2473-9. [MEDLINE: 18682445]O'DonoghueM , AntmanEM , BraunwaldE , MurphySA , StegPG , FinkelsteinA , et al.The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology2009;54(8):678-85. [MEDLINE: 19679245]OjeifoO , WiviottSD , AntmanEM , MurphySA , UdellJA , BatesER , et al.Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Jacc: Cardiovascular Interventions2013;6(2):1275-81. [MEDLINE: 24239201]PakhomovIM .Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial. Kardiologiia2010;50(6):63-7. [MEDLINE: 20659030]PrideYB , TungP , MohanaveluS , ZorkunC , WiviottSD , AntmanEM , et al.Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. Jacc: Cardiovascular Interventions2010;3(8):306-11. [MEDLINE: 20723851]RiesmeyerJS , SalazarDE , WeerakkodyGJ , NiL , WrishkoRE , Ernest CS 2nd, et al.Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. Journal of Clinical Pharmacology2012;52(6):789-97. [MEDLINE: 21628601]SerebruanyVL .Letter by Serebruany regarding article, &quot;Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38&quot;. Circulation2010;122(8):e436. [MEDLINE: 20733108]SmithPK , GoodnoughLT , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology2012;60(5):388-96. [MEDLINE: 22633653]SorichMJ , VitryA , WardMB , HorowitzJD , McKinnonRA .Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis &amp; Haemostasis2010;8(8):1678-84. [MEDLINE: 20492467]UdellJA , BraunwaldE , AntmanEM , MurphySA , MontalescotG , WiviottSD .Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).[Erratum in: JACC Cardiovasc Interv. 2014 Aug;7(8):946 Note: Antman, Elliot M [Corrected to Antman, Elliott M]]. Jacc: Cardiovascular Interventions2014;7(6):604-12. [MEDLINE: 24947719]WilcoxR , IqbalK , CostiganT , Lopez-SendonJ , RamosY , WidimskyP .An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current Medical Research &amp; Opinion2014;30(11):2193-205. [MEDLINE: 25025610]WiviottSD , AntmanEM , GibsonCM , MontalescotG , RiesmeyerJ , WeerakkodyG , et al.Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). American Heart Journal2006;152(4):627-35. [MEDLINE: 16996826]WiviottSD , BraunwaldE , McCabeCH , HorvathI , KeltaiM , HerrmanJP , et al.Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet2008;371(9621):1353-63. [MEDLINE: 18377975]WiviottSD , BraunwaldE , McCabeCH , MontalescotG , RuzylloW , GottliebS , et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2007;357(20):2001-15. [MEDLINE: 17982182]WiviottSD , DesaiN , MurphySA , MusumeciG , RagostaM , AntmanEM , et al.Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. American Journal of Cardiology2011;108(7):905-11. [MEDLINE: 21816379]WrishkoRE , Ernest CS 2nd, SmallDS , LiYG , WeerakkodyGJ , RiesmeyerJR , et al.Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. Journal of Clinical Pharmacology2009;49(8):984-98. [MEDLINE: 19546250]">TRITON‐TIMI 38 2006</a>; <a href="./references#CD008834-bbs2-0107" title="WasedaK , SakaY , TakashimaH , KuritaA , AndoH , SakuraiS , et al.Effect of CYP2C19 genotype on inhibition of platelet aggregation in hemodialysis patients with coronary artery disease [abstract]. Circulation2016;134(Suppl 1):A14237. [EMBASE: 619219587]">Waseda 2016</a>) </p> </li> </ul> </li> <li> <p>Glycoprotein IIb/IIIa inhibitor</p> <ul id="CD008834-list-0033"> <li> <p>Abciximab versus tirofiban (1 study, 790 participants: <a href="./references#CD008834-bbs2-0100" title="BergerPB , BestPJ , TopolEJ , WhiteJ , DiBattistePM , ChanAW , et al.The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal2005;149(5):869-75. [MEDLINE: 15894970]KalyanasundaramA , BlankenshipJC , BergerP , HerrmannH , McClureR , MoliternoD .Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?). Catheterization &amp; Cardiovascular Interventions2007;69(5):623-9. [MEDLINE: 17192960]MoliternoDJ , TopolEJ .A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. American Heart Journal2000;140(5):722-6. [MEDLINE: 11054616]MoliternoDJ , YakubovSJ , DiBattistePM , HerrmannHC , StoneGW , MacayaC , et al.Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet2002;360(9330):355-60. [MEDLINE: 12241774]MukherjeeD , TopolEJ , BertrandME , KristensenSD , HerrmannHC , NeumannFJ , et al.Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. European Heart Journal2005;26(23):2524-8. [MEDLINE: 16107485]RoffiM , MoliternoDJ , MeierB , PowersER , GrinesCL , DiBattistePM , et al.Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation2002;105(23):2730-6. [MEDLINE: 12057986]TopolEJ , MoliternoDJ , HerrmannHC , PowersER , GrinesCL , CohenDJ , et al.Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New England Journal of Medicine2001;344(25):1888-94. [MEDLINE: 11419425]">TARGET 2000</a>) </p> </li> </ul> </li> <li> <p>Other</p> <ul id="CD008834-list-0034"> <li> <p>Low versus high‐dose beraprost sodium (1 study, 600 participants: <a href="./references#CD008834-bbs2-0008" title="FujitaT , YuX , KimS , NakamotoH , OrigasaH , KurumataniH , et al.Effects of sustained-release beraprost sodium in patients with primary glomerular disease or nephrosclerosis: the CASSIOPEIR study [abstract no: SA-PO1096]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):4B. [CENTRAL: CN-01657821] NakamotoH , FujitaT , OrigasaH , IsonoM , KurumataniH , OkadaK , et al.A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrology2014;15:153. [MEDLINE: 25233856]NakamotoH , YuXQ , KimS , OrigasaH , ZhengH , ChenJ , et al.Effects of sustained-release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results. Therapeutic Apheresis &amp; Dialysis2020;24(1):42-55. [MEDLINE: 31119846]">CASSIOPEIR 2014</a>) </p> </li> </ul> </li> </ul> </p> </section> </section> <section id="CD008834-sec-0046"> <h4 class="title">Excluded studies</h4> <p>For this update, we reassessed all previously excluded studies. We deleted 15 studies (not randomised or wrong population) and reclassified six studies as included studies; these were previously excluded due to less than two months of follow‐up. For the 2021 search, we excluded 17 new studies (82 reports) and identified 22 new reports of 6 already excluded studies. In total, we have excluded 29 studies (119 reports). </p> <p> <ul id="CD008834-list-0035"> <li> <p>Three studies were the wrong study design (<a href="./references#CD008834-bbs2-0116" title="CaravacaF , Lopez-MinguezJR , ArrobasM , CuberoJ , PizarroJL , CidMC , et al.Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy. Nephrology Dialysis Transplantation1995;10(9):1720-4. [MEDLINE: 8559495]">Caravaca 1995a</a>; <a href="./references#CD008834-bbs2-0137" title="YangY , KongD , WangC , ChenG , ShanF , QiK , et al.Inhibition of platelet activation could decrease thrombotic events in hemodialysis PF4/H antibody-positive patients. Renal Failure2014;36(6):870-6. [MEDLINE: 24665827]">Yang 2014a</a>; <a href="./references#CD008834-bbs2-0138" title="YehCH , HuangTS , WangYC , HuangPF , HuangTY , ChenTP , et al.Initiation of antiplatelet medication after surgical thrombectomy jeopardized arteriovenous graft longevity. Journal of Vascular Access2017;18(3):207-13. [MEDLINE: 28478620]">Yeh 2017</a>) </p> </li> <li> <p>Eleven studies enrolled the wrong population (<a href="./references#CD008834-bbs2-0115" title="BangBK , YangCW , KimYS , ChangYS , YoonYS .Effect of combination therapy of captopril and dipyridamole on proteinuria in patients with IgA nephropathy [abstract]. Journal of the American Society of Nephrology1994;5(3):346. [CENTRAL: CN-00550477] ">Bang 1994</a>; <a href="./references#CD008834-bbs2-0119" title="BrugtsJJ , MercadoN , HuS , GuarneriM , PriceM , SchatzR , et al.Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial). American Journal of Cardiology2009;103(7):917-22. [MEDLINE: 19327416]MercadoN , BrugtsJJ , IxJH , ShlipakMG , DixonSR , GershBJ , et al.Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial). American Journal of Cardiology2008;102(9):1151-5. [MEDLINE: 18940282]O'NeillWW , SerruysP , KnudtsonM , vanEsGA , TimmisGC , van derZwaanC , et al.Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. New England Journal of Medicine2000;342(18):1316-24. [MEDLINE: 10793164]">EXCITE 2000</a>; <a href="./references#CD008834-bbs2-0126" title="ChludzinskiA , IraniC , MaschaEJ , KurzA , DevereauxPJ , SesslerDI .Protocol understanding and anxiety in perioperative clinical trial patients approached for consent on the day of surgery. Mayo Clinic Proceedings2013;88(5):446-54. [MEDLINE: 23639498]DevereauxPJ , POISE-2 Investigators.Rationale and design of the PeriOperative ISchemic Evaluation-2 (POISE-2) trial: an international 2 x 2 factorial randomized controlled trial of acetyl-salicylic acid vs. placebo and clonidine vs. placebo in patients undergoing noncardiac surgery. American Heart Journal2014;167(6):804-9. [MEDLINE: 24890528]GargAX , KurzA , SesslerDI , CuerdenM , RobinsonA , MrkobradaM , et al.Aspirin and clonidine in non-cardiac surgery: acute kidney injury substudy protocol of the Perioperative Ischaemic Evaluation (POISE) 2 randomised controlled trial. BMJ Open2014;4(2):e004886. [MEDLINE: 24568963]GargAX , KurzA , SesslerDI , CuerdenM , RobinsonA , MrkobradaM , et al.Perioperative aspirin and clonidine and risk of acute kidney injury: a randomized clinical trial. JAMA2014;312(21):2254-64. [MEDLINE: 25399007]">POISE‐2 2013</a>; <a href="./references#CD008834-bbs2-0127" title="CampoG , PunzettiS , MalaguM , FerrariR , ValgimigliM .Two-year outcomes after first- or second-generation drug-eluting stent implantation in patients with in-stent restenosis. A PRODIGY trial substudy. International Journal of Cardiology2014;173(2):343-5. [MEDLINE: 24680246]CampoG , TebaldiM , VranckxP , BiscagliaS , TumscitzC , FerrariR , et al.Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). Journal of the American College of Cardiology2014;63(6):506-12. [MEDLINE: 24161321]CostaF , AdamoM , AriottiS , FerranteG , NavareseEP , LeonardiS , et al.Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. Eurointervention2016;11(11):e1222-30. [MEDLINE: 26342472]CostaF , VranckxP , LeonardiS , MoscarellaE , AndoG , CalabroP , et al.Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. European Heart Journal2015;36(20):1242-51. [MEDLINE: 25718355]CrimiG , LeonardiS , CostaF , AdamoM , AriottiS , ValgimigliM .Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial. International Journal of Cardiology2016;212:110-7. [MEDLINE: 27038714]FranzoneA , PiccoloR , GargiuloG , AriottiS , MarinoM , SantucciA , et al.Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: a subgroup analysis of the PRODIGY randomized clinical trial. JAMA Cardiology2016;1(7):795-803. [MEDLINE: 27572001]GargiuloG , AriottiS , SantucciA , PiccoloR , BaldoA , FranzoneA , et al.Impact of sex on 2-year clinical outcomes in patients treated with 6-month or 24-month dual-antiplatelet therapy duration: a pre-specified analysis from the PRODIGY trial. Jacc: Cardiovascular Interventions2016;9(17):1780-9. [MEDLINE: 27544007]GargiuloG , CostaF , AriottiS , BiscagliaS , CampoG , EspositoG , et al.Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial. American Heart Journal2016;174:95-102. [MEDLINE: 26995375]GargiuloG , SantucciA , PiccoloR , FranzoneA , AriottiS , BaldoA , et al.Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: an analysis from the PRODIGY trial. Catheterization &amp; Cardiovascular Interventions2017;90(4):E73-84. [MEDLINE: 28198091]SantucciA , GargiuloG , AriottiS , PiccoloR , FranzoneA , MagnaniG , et al.Impact of chronic kidney disease on two-year clinical outcomes in patients treated with a six-month or 24-month DAPT duration: insights from the PRODIGY trial [abstract]. Eurointervention2016:104. [EMBASE: 611934574]ValgimigliM , BorghesiM , TebaldiM , VranckxP , ParrinelloG , FerrariR , et al.Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). European Heart Journal2013;34(12):909-19. [MEDLINE: 23315904]ValgimigliM , CampoG , MontiM , VranckxP , PercocoG , TumscitzC , et al.Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation2012;125(16):2015-26. [MEDLINE: 22438530]ValgimigliM , CampoG , PercocoG , MontiM , FerrariF , TumscitzC , et al.Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). American Heart Journal2010;160(5):804-11. [MEDLINE: 21095265]ValgimigliM , TebaldiM , BorghesiM , VranckxP , CampoG , TumscitzC , et al.Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY). Jacc: Cardiovascular Interventions2014;7(1):20-8. [MEDLINE: 24332420]">PRODIGY 2010</a>; <a href="./references#CD008834-bbs2-0128" title="MarcantoniC , ZanoliL , RastelliS , TripepiG , MataloneM , Di LandroD , et al.Stenting of renal artery stenosis in coronary artery disease (RAS-CAD) study: a prospective, randomized trial. Journal of Nephrology2009;22(1):13-6. [MEDLINE: 19229814]MarcantoniC , ZanoliL , RastelliS , TripepiG , MataloneM , MangiaficoS , et al.Effect of renal artery stenting on left ventricular mass: a randomized clinical trial. American Journal of Kidney Diseases2012;60(1):39-46. [MEDLINE: 22495466]">RAS‐CAD 2009</a>; <a href="./references#CD008834-bbs2-0129" title="BlankenshipJC , HaldisT , FeitF , HuT , KleimanNS , TopolEJ , et al.Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy). American Journal of Cardiology2006;97(11):1591-6. [MEDLINE: 16728220]ChackoM , LincoffAM , WolskiKE , CohenDJ , BittlJA , LanskyAJ , et al.Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. American Heart Journal2006;151(5):1032-7. [MEDLINE: 16644331]ChewDP , LincoffAM , GurmH , WolskiK , CohenDJ , HenryT , et al.Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). American Journal of Cardiology2005;95(5):581-5. [MEDLINE: 15721095]CohenDJ , LincoffAM , LavelleTA , ChenHL , BakhaiA , BerezinRH , et al.Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. Journal of the American College of Cardiology2004;44(9):1792-800. [MEDLINE: 15519009]ExaireJE , ButmanSM , EbrahimiR , KleimanNS , HarringtonRA , SchweigerMJ , et al.Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. American Heart Journal2006;152(1):157-63. [MEDLINE: 16824849]FeitF , VoeltzMD , AttubatoMJ , LincoffAM , ChewDP , BittlJA , et al.Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. American Journal of Cardiology2007;100(9):1364-9. [MEDLINE: 17950791]GibsonCM , TenY , MurphySA , CiagloLN , SouthardMC , LincoffAM , et al.Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis). American Journal of Cardiology2007;99(12):1687-90. [MEDLINE: 17560876]GurmHS , SarembockIJ , KereiakesDJ , YoungJJ , HarringtonRA , KleimanN , et al.Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial. Journal of the American College of Cardiology2005;45(12):1932-8. [MEDLINE: 15963389]LincoffAM , BittlJA , HarringtonRA , FeitF , KleimanNS , JackmanJD , et al.Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.[Erratum in: JAMA. 2003 Apr 2;289(13):1638]. JAMA2003;289(7):853-63. [MEDLINE: 12588269]LincoffAM , KleimanNS , KereiakesDJ , FeitF , BittlJA , JackmanJD , et al.Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.[Erratum in: JAMA. 2006 Jul 5;296(1):46]. JAMA2004;292(6):696-703. [MEDLINE: 15304466]MarooA , LincoffAM .Bivalirudin in PCI: an overview of the REPLACE-2 trial. Seminars in Thrombosis &amp; Hemostasis2004;30(3):329-36. [MEDLINE: 15282655]RajagopalV , LincoffAM , CohenDJ , GurmHS , HuT , DesmetWJ , et al.Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. American Heart Journal2006;152(1):149-54. [MEDLINE: 16824845]SawJ , LincoffAM , DeSmetW , BetriuA , RutschW , WilcoxRG , et al.Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. Journal of the American College of Cardiology2004;44(6):1194-9. [MEDLINE: 15364319]">REPLACE‐2 2003</a>; <a href="./references#CD008834-bbs2-0131" title="IkemeJC , PergolaPE , ScherzerR , ShlipakMG , BenaventeOR , PeraltaCA .Post hoc analyses of randomized clinical trial for the effect of clopidogrel added to aspirin on kidney function. Clinical Journal of the American Society of Nephrology: CJASN2017;12(7):1040-7. [MEDLINE: 28446537]">SPS3 2018</a>; <a href="./references#CD008834-bbs2-0134" title="BakalJA , RoeMT , OhmanEM , GoodmanSG , FoxKA , ZhengY , et al.Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. European Heart Journal2015;36(6):385-92A. [MEDLINE: 25012156]ChinCT , NeelyB , MagnusOE , ArmstrongPW , CorbalanR , WhiteHD , et al.Time-varying effects of prasugrel versus clopidogrel on the long-term risks of stroke after acute coronary syndromes: results from the TRILOGY ACS trial. Stroke2016;47(4):1135-9. [MEDLINE: 26883498]ChinCT , RoeMT , FoxKA , PrabhakaranD , MarshallDA , PetitjeanH , et al.Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. American Heart Journal2010;160(1):16-22. [MEDLINE: 20598967]CornelJH , OhmanEM , NeelyB , ClemmensenP , SritaraP , ZamoryakhinD , et al.Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: insights from the TRILOGY ACS trial.[Erratum in: Am Heart J. 2014 Oct;168(4):605]. American Heart Journal2014;168(1):76-87. [MEDLINE: 24952863]CornelJH , TricociP , HortonJ , MoliternoD , WallentinL , ArmstrongP , et al.Effects of glycoprotein IIB/IIIA inhibitors in combination with vorapaxar, a platelet thrombin-receptor antagonist, among patients with non-St-segment elevation acute coronary syndromes: Insights from the TRACER trial [abstract]. Journal of the American College of Cardiology2013;61(10 Suppl 1):E102. [EMBASE: 71019466]GurbelPA , ErlingeD , OhmanEM , NeelyB , NeelyM , GoodmanSG , et al.Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA2012;308(17):1785-94. [MEDLINE: 23117779]HagstromE , RoeMT , HafleyG , NeelyML , SidhuMS , WintersKJ , et al.Association between very low levels of high-density lipoprotein cholesterol and long-term outcomes of patients with acute coronary syndrome treated without revascularization: insights from the TRILOGY ACS trial. Clinical Cardiology2016;39(6):329-37. [MEDLINE: 27177240]HinoharaTT , RoeMT , WhiteHD , FoxKA , BhattDL , HammC , et al.Outcomes of patients receiving downstream revascularization after initial medical management for non-st-segment elevation acute coronary syndromes (from the TRILOGY ACS trial). American Journal of Cardiology2018;122(8):1322-9. [MEDLINE: 30135019]Jackson LR 2nd, PicciniJP , CyrDD , RoeMT , NeelyML , MartinezF , et al.Dual antiplatelet therapy and outcomes in patients with atrial fibrillation and acute coronary syndromes managed medically without revascularization: insights from the TRILOGY ACS trial. Clinical Cardiology2016;39(9):497-506. [MEDLINE: 27468086]KaulP , OhmanEM , KnightJD , AnstromKJ , RoeMT , BodenWE , et al.Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial. American Heart Journal2016;178:55-64. [MEDLINE: 27502852]LopesRD , LeonardiS , NeelyB , NeelyML , OhmanEM , ArdissinoD , et al.Spontaneous MI after non-st-segment elevation acute coronary syndrome managed without revascularization: the TRILOGY ACS trial. Journal of the American College of Cardiology2016;67(11):1289-97. [MEDLINE: 26988949]MelloniC , CornelJH , HafleyG , NeelyML , ClemmensenP , ZamoryakhinD , et al.Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. European Heart Journal: Acute Cardiovascular Care2016;5(6):443-54. [MEDLINE: 26228448]WhiteHD , WesterhoutCM , AlexanderKP , RoeMT , WintersKJ , CyrDD , et al.Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. European Heart Journal: Acute Cardiovascular Care2016;5(3):231-42. [MEDLINE: 25897147]WiviottSD , WhiteHD , OhmanEM , FoxKA , ArmstrongPW , PrabhakaranD , et al.Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.[Erratum in: Lancet. 2013 Aug 31;382(9894):768]. Lancet2013;382(9892):605-13. [MEDLINE: 23953385]YanAT , RoeMT , NeelyM , CyrDD , WhiteH , FoxKA , et al.Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial. Coronary Artery Disease2018;29(6):469-76. [MEDLINE: 29652672]">TRILOGY ACS 2010</a>; <a href="./references#CD008834-bbs2-0135" title="WooKT , ChiangGS , LimCH .Follow-up renal biopsies in IgA nephritic patients on triple therapy. Clinical Nephrology1987;28(6):304-5. [MEDLINE: 3442958]WooKT , ChiangGS , YapHK , LimCH .Controlled therapeutic trial of IgA nephritis with follow-up renal biopsies. Annals of the Academy of Medicine, Singapore1988;17(2):226-31. [MEDLINE: 3408224]WooKT , EdmondsonRP , YapHK , WuAY , ChiangGS , LeeEJ , et al.Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis. Clinical Nephrology1987;27(2):56-64. [MEDLINE: 3549083]WooKT , LeeGS , LauYK , ChiangGS , LimCH .Effects of triple therapy in IgA nephritis: a follow-up study 5 years later. Clinical Nephrology1991;36(2):60-6. [MEDLINE: 1934661]WooKT , LeeGSL , LauYK , ChiangGSC , LimCH .Anti platelet therapy in IgA nephritis [abstract]. In: 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan. 1990:13. [CENTRAL: CN-00448412] ">Woo 1987</a>; <a href="./references#CD008834-bbs2-0136" title="WuHB , TianHP , WangXC , BaiSR , LiXN , ZhangLN , et al.Clinical efficacy of ticagrelor in patients undergoing emergency intervention for acute myocardial infarction and its impact on platelet aggregation rate. American Journal of Translational Research2018;10(7):2175-83. [MEDLINE: 30093954]">Wu 2018a</a>; <a href="./references#CD008834-bbs2-0142" title="ZimmermanSW , MoorthyAV , DreherWH , FriedmanA , VaranasiU .Prospective trial of warfarin and dipyridamole in patients with membranoproliferative glomerulonephritis. American Journal of Medicine1983;75(6):920-7. [MEDLINE: 6359877]">Zimmerman 1983</a>). </p> </li> <li> <p>Nine studies used the wrong intervention (<a href="./references#CD008834-bbs2-0118" title="ColiL , DonatiG , CiancioloG , RaimondiC , ComaiG , PanicaliL , et al.Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis. Journal of Vascular Access2006;7(3):118-22. [MEDLINE: 17019663]">Coli 2006</a>; <a href="./references#CD008834-bbs2-0120" title="ForoughiniaF , ForoozmehrM .Effect of pretreatment with omega-3 supplement on cardiac necrosis markers in chronic kidney disease patients undergoing elective percutaneous coronary intervention. Journal of Research in Pharmacy Practice2017;6(2):94-9. [MEDLINE: 28616432]ForoughiniaF , Movahed NouriB , KojuriJ , OstovanMA .Impact of omega-3 supplementation on high sensitive C-reactive protein level and 30-day major adverse cardiac events after the implementation of coronary stent in patients with chronic kidney disease: a randomized clinical study. Advanced Pharmaceutical Bulletin2018;8(3):471-8. [MEDLINE: 30276144]">Foroughinia 2017</a>; <a href="./references#CD008834-bbs2-0122" title="LeeG , ChoongHL , ChianGSC , WooKT .Stabilisation of elevated serum creatinine (CR) in dipyridamole (DYP) and warfarin (WAR) treated patients with IgA nephropathy (IGAN): a three year controlled trial [abstract]. In: 9th Asian Colloquium in Nephrology; 1992 May 17-21; Seoul, Korea. 1992:106. [CENTRAL: CN-00461145] LeeGS , ChoongHL , ChiangGS , WooKT .Three-year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment. Nephrology1997;3(1):117-21. [EMBASE: 27161092]LeeGS , WooKT , LimCH .Controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephritis with renal impairment. Clinical Nephrology1989;31:276. [CENTRAL: CN-00740470] ">Lee 1997</a>; <a href="./references#CD008834-bbs2-0124" title="ScarpioniR , MichielettiE , CristinelliL , UgolottiU , ScolariF , VenturelliC , et al.Atherosclerotic renovascular disease: medical therapy versus medical therapy plus renal artery stenting in preventing renal failure progression: the rationale and study design of a prospective, multicenter and randomized trial (NITER). Journal of Nephrology2005;18(4):423-8. [MEDLINE: 16245247]ScarpioniR , MichielettiE , PavoneL , GandolfiS , RicardiM , PecchiniP , et al.Atherosclerotic renovascular disease (ARVD): medical therapy plus renal artery stenting (PTRS), compared with medical therapy alone, do not offer more chances in preventing cardio-vascular (CV) or renal events, preliminary results of a prospective, multicenter and randomized trial [abstract no: M074]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-00841209] SiddiquiEU , MurphyTP , NaeemSS , SiddiqueA , McEnteggartGE , ScarpioniR .Interaction between albuminuria and treatment group outcomes for patients with renal artery stenosis: The NITER Study. Journal of Vascular &amp; Interventional Radiology2018;29(7):966-70. [MEDLINE: 29843995]">NITER 2005</a>; <a href="./references#CD008834-bbs2-0125" title="PerkovicV , NichollsKM , ForemanA , BeckerGJ .A randomised controlled trial of cardiovascular risk factor modification in end stage renal failure [abstract no: P62]. Nephrology2004;9(Suppl 1):A16. [CENTRAL: CN-00509410] PerkovicV , NichollsKM , ForemanA , WalkerRG , BeckerGJ .A randomised controlled trial of cardiovascular risk factor modification in end stage kidney disease [abstract no: SA-PO348]. Journal of the American Society of Nephrology2004;15(Oct):377-8A. [CENTRAL: CN-00644351] ">Perkovic 2004</a>; <a href="./references#CD008834-bbs2-0132" title="GaedeP , Lund-AndersenH , ParvingHH , PedersenO .Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine2008;358(6):580-91. [MEDLINE: 18256393]GaedeP , ParvingH , PedersenO .Multifactorial intervention in patients with type 2 diabetes: long-term effects on mortality and vascular complications [abstract no: SA-FC042]. Journal of the American Society of Nephrology2007;18(Abstracts):43A. [CENTRAL: CN-00740461] GaedeP , ValentineWJ , PalmerAJ , TuckerDM , LammertM , ParvingHH , et al.Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care2008;31(8):1510-5. [MEDLINE: 18443195]GaedeP , VedelP , LarsenN , JensenG , ParvingH , PedersenO .The Steno-2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. In: 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1-5; Budapest, Hungary. 2002. [CENTRAL: CN-01912459] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO .The STENO-2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F-FC031]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):72A. [CENTRAL: CN-00445410] GaedeP , VedelP , LarsenN , JensenGV , ParvingHH , PedersenO .Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine2003;348(5):383-93. [MEDLINE: 12556541]GaedeP , VedelP , ObelJ , ParvingHH , PedersenO .Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract no: A0561]. Journal of the American Society of Nephrology1996;7(9):1357. [CENTRAL: CN-00445411] GaedeP , VedelP , ParvingHH , PedersenO .Elevated levels of plasma von Willebrand factor and the risk of macro- and microvascular disease in type 2 diabetic patients with microalbuminuria. Nephrology Dialysis Transplantation2001;16(10):2028-33. [MEDLINE: 11572892]GaedeP , VedelP , ParvingHH , PedersenO .Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet1999;353(9153):617-22. [MEDLINE: 10030326]GaedePH , JepsenPV , ParvingHH , PedersenOB .Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno-2 study [Intensiveret multifaktoriel intervention hos patienter med type 2-diabetes mellitus og mikroalbuminuri: Steno-2-studiet]. Ugeskrift for Laeger1999;161(30):4277-85. [MEDLINE: 10439688]OellgaardJ , GaedeP , RossingP , PerssonF , ParvingHH , PedersenO .Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.[Erratum in: Kidney Int. 2017 May;91(5):1257; PMID: 28407880]. Kidney International2017;91(4):982-8. [MEDLINE: 28187983]">STENO‐2 1999</a>; <a href="./references#CD008834-bbs2-0133" title="HalstensonCE , SwanSK , CollinsAJ , EllefsonJ , ParrK , BlueJ , et al.Pharmacologic profile of diaspirin crosslinked hemoglobin (DCLHB) in hemodialysis (HD) patients [abstract no: 84P]. Journal of the American Society of Nephrology1994;5(3):451. [CENTRAL: CN-00583893] SwanSK , HalstensonCE , CollinsAJ , ColburnWA , BlueJ , PrzybelskiRJ .Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. American Journal of Kidney Diseases1995;26(6):918-23. [MEDLINE: 7503066]SwanSK , HalstensonCE , CollinsAJ , EllefsonJ , ParrK , BlueJ , et al.Pharmacodynamic and pharmacokinetic parameters of diaspirin cross-linked hemoglobin (DCLHB) in hemodialysis (HD) patients [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:559. [CENTRAL: CN-00509497] ">Swan 1995a</a>; <a href="./references#CD008834-bbs2-0139" title="ItoH , YoshikawaN .Prospective multicenter controlled therapeutic trial in IgA nephropathy in Japanese children: a preliminary report [abstract no: S-I-2]. Pediatric Nephrology1992;6(6):C208. [CENTRAL: CN-01658022] KameiK , NakanishiK , ItoS , SaitoM , SakoM , IshikuraK , et al.Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clinical Journal of the American Society of Nephrology: CJASN2011;6(6):1301-07. [MEDLINE: 21493743]YoshikawaN , ItoH , SakaiT , TakekoshiY , HondaM , AwazuM , et al.A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. Journal of the American Society of Nephrology1999;10(1):101-9. [MEDLINE: 9890315]YoshikawaN , ItoH .Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy - is it relevant for adult patients?Nephrology Dialysis Transplantation1999;14(5):1097-9. [MEDLINE: 10344344]YoshikawaN , ItoH .Corticosteroids and immunosuppressive drugs [abstract no: S8.2]. Pediatric Nephrology2001;16(8):C31. [CENTRAL: CN-00448482] YoshikawaN , ItohH , Japanese Pediatric IgA Nephropathy Treatment Study Group.A controlled trial of prednisolone (P), azathioprine (A), heparin-warfarin (H-W) and dipyridamole (D) in newly diagnosed severe childhood IgA nephropathy (IGAN) [abstract no: A0779]. Journal of the American Society of Nephrology1996;7(9):1401. [CENTRAL: CN-00583182] ">Yoshikawa 1999</a>; <a href="./references#CD008834-bbs2-0140" title="ZhangY , ZhangXD , MaLL , GuanDL .Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a>) </p> </li> <li> <p>Six studies used the wrong comparator (<a href="./references#CD008834-bbs2-0114" title="AlexanderW , ConnollyS , ArnesenH .European Society of Cardiology: apixaban or aspirin in decreasing stroke risk (The AVERROES Trial) [abstract]. P and T2010;35(10):580-1. [EMBASE: 359918604]AminA , DeitelzweigS , JingY , MakenbaevaD , WiederkehrD , LinJ , et al.Comparison of medical costs of patients with atrial fibrillation unsuitable for warfarin treatment with apixaban or aspirin based on AVERROES trial. Clinical &amp; Applied Thrombosis/Hemostasis2015;21(3):235-40. [MEDLINE: 24108232]BhagirathVC , EikelboomJW , HirshJ , CoppensM , GinsbergJ , VanasscheT , et al.Apixaban- calibrated anti-FXa activity in relation to outcome events and clinical characteristics in patients with atrial fibrillation: results from the AVERROES trial. TH Open2017;1(2):e139-45. [EMBASE: 624302177]ConnollySJ , EikelboomJ , JoynerC , DienerHC , HartR , GolitsynS , et al.Apixaban in patients with atrial fibrillation. New England Journal of Medicine2011;364(9):806-17. [MEDLINE: 21309657]CoppensM , SynhorstD , EikelboomJW , YusufS , ShestakovskaO , ConnollySJ .Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. European Heart Journal2014;35(28):1856-63. [MEDLINE: 24569032]DienerHC , EikelboomJ , ConnollySJ , JoynerCD , HartRG , LipGY , et al.Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurology2012;11(3):225-31. [MEDLINE: 22305462]DienerHC , YusufS , EikelboomJ , O'DonnellMO , ConnollySJ .AVERROES: apixaban versus acetylsalicylic acid (ASA) to prevent strokes [abstract no: 127]. Stroke2011;42(3):e81. [EMBASE: 70362332]EikelboomJ , SynhorstD , WrightR , WangL , AfzalR , YusufS , et al.Efficacy and safety of apixaban compared with aspirin in patients with atrial fibrillation who previously used and discontinued warfarin therapy: A secondary analysis of the AVERROES trial [abstract]. European Heart Journal2011;32(Suppl 1):465. [EMBASE: 70534798]EikelboomJW , ConnollySJ , GaoP , PaolassoE , De CaterinaR , HustedS , et al.Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. Journal of Stroke &amp; Cerebrovascular Diseases2012;21(6):429-35. [MEDLINE: 22818021]EikelboomJW , O'DonnellM , YusufS , DiazR , FlakerG , HartR , et al.Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. American Heart Journal2010;159(3):348-53. [MEDLINE: 20211294]FlakerGC , EikelboomJ , ConnollyS , YusufS , LipG , HartR .Bleeding with aspirin and apixaban in patients unsuitable for vitamin K antagonist therapy: The AVERROES study [abstract]. Journal of the American College of Cardiology2012;59(13 Suppl 1):E572. [EMBASE: 70714012]FlakerGC , EikelboomJW , ShestakovskaO , ConnollySJ , KaatzS , BudajA , et al.Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. Stroke2012;43(12):3291-7. [MEDLINE: 23033347]HartRG , EikelboomJ , YusufS , GaoP , PaolassoE , De CaterinaR , et al.Efficacy and safety of the novel oral factor Xa inhibitor apixaban in atrial fibrillation (AF) patients with chronic kidney disease (CKD): the AVERROES trial [abstract]. European Heart Journal2011;32(Suppl 1):6. [EMBASE: 70533061]HohnloserS , YusufS , EikelboomJ , StegG , AtarD , BudajA , et al.Apixaban in patients with atrial fibrillation and their risk for cardiovascular hospitalization: insights from the AVERROES trial [abstract]. European Heart Journal2011;32(Suppl 1):671. [EMBASE: 70535570]HohnloserSH , ShestakovskaO , EikelboomJ , FranzosiMG , TanRS , ZhuJ , et al.The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. European Heart Journal2013;34(35):2752-9. [MEDLINE: 23892201]LipGY , ConnollyS , YusufS , ShestakovskaO , FlakerG , HartR , et al.Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. Circulation: Arrhythmia and Electrophysiology2013;6(1):31-8. [MEDLINE: 23390125]LipGY , EikelboomJ , YusufS , ShestakovskaO , HartRG , ConnollyS , et al.Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study. Stroke2014;45(7):2127-30. [MEDLINE: 24916911]LipGY , YusufS , EikelboomJ , FlakerG , HartR , Lanas-ZenettiF , et al.Impact of treatment with apixaban and aspirin in patients with atrial fibrillation in relation to the CHADS2 and CHA2DS2-vasc scores: the AVERROES study [abstract no: 15542]. Circulation2011;124(21 Suppl 1). [EMBASE: 70618066]NgKH , ShestakovskaO , ConnollySJ , EikelboomJW , AvezumA , DiazR , et al.Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age &amp; Ageing2016;45(1):77-83. [MEDLINE: 26590293]">AVERROES 2010</a>; <a href="./references#CD008834-bbs2-0117" title="ChangjiangH , JianQ , YuanZ , LiangY , PuqingL , XiaolongG .Tirofiban combined with fondaparinux for post-PCI treatment of patients with acute coronary syndrome and mild renal insufficiency. Cell Biochemistry &amp; Biophysics2015;73(3):603-7. [MEDLINE: 27259300]">Changjiang 2015</a>; <a href="./references#CD008834-bbs2-0121" title="GorterJW .Preventive treatment of patients after non-disabling cerebral ischaemia of presumed arterial origin: Comparative randomized study with intensive anticoagulant therapy or aspirin treatment [Preventieve behandeling van patienten na niet-invaliderende cerebrale ischemie door vermoedelijk arteriele oorzaak: Vergelijkend, gerandomiseerd onderzoek met intensieve antistollingstherapie of behandeling met acetylsalicylzuur]. Nederlands Tijdschrift voor Geneeskunde1998;142(6):306-12. [EMBASE: 28106209]">Gorter 1998</a>; <a href="./references#CD008834-bbs2-0123" title="LindsayRM , FergusonD , PrenticeCR , BurtonJA , McNicolGP .Reduction of thrombus formation on dialyser membranes by aspirin and RA 233. Lancet1972;2(7790):1287-90. [MEDLINE: 4117813]">Lindsay 1972</a>; <a href="./references#CD008834-bbs2-0130" title="SakaiH , WatanabeS , InoueI , TanakaK , YagameM , MachimuraH , et al.Effect of urokinase on preservation of renal function in patients with diabetic nephropathy. Journal of Diabetic Complications1991;5(2-3):95-7. [MEDLINE: 1770066]">Sakai 1991</a>; <a href="./references#CD008834-bbs2-0141" title="ZibariGB , GadallahMF , LandreneauMD , McMillianR , BridgesR , CostleyK , et al.The efficacy and complications of aspirin versus heparin in postoperative prophylaxis against thrombosis in newly placed hemodialysis access [abstract no: 195]. Journal of the American Society of Nephrology1995;6(3):507. [CENTRAL: CN-00486594] ">Zibari 1995</a>). </p> </li> </ul> </p> <p>See <a href="./references#CD008834-sec-0187" title="">Characteristics of excluded studies</a>. </p> <section id="CD008834-sec-0047"> <h5 class="title">Ongoing studies</h5> <p>Twenty‐six studies (27 reports) have yet to be completed (<a href="./references#CD008834-bbs2-0143" title="KimBK .A randomized comparison of CLOpidogrel monotherapy versus extended dual-antiplatelet therapy beyond 12 months after implantation of drug-eluting StEnts in high-risk lesions or patients; A-CLOSE trial. www.cris.nih.go.kr/cris/search/detailSearch.do/18621 (first received 30 April 2019). ">A‐CLOSE 2019</a>; <a href="./references#CD008834-bbs2-0144" title="AlexopoulosD .A randomized, pharmacodynamic comparison of low dose ticagrelor to clopidogrel in patients with prior myocardial infarction (ALTIC). www.clinicaltrials.gov/show/nct02663713 (first received 26 January 2016). ">ALTIC 2016</a>; <a href="./references#CD008834-bbs2-0145" title="AlexopoulosD .Low dose ticagrelor versus low dose prasugrel in patients with prior myocardial infarction (ALTIC-2) [A randomized, pharmacodynamic comparison of low dose ticagrelor (60mg Bid) to low dose prasugrel (5mg od) in patients with prior myocardial infarction]. www.clinicaltrials.gov/show/nct03387826 (first received 2 January 2018 ). EudraCT2016-004959-80.A randomized, pharmacodynamic comparison of ticagrelor 60mg bid vs prasugrel 5mg in patients with prior myocardial infarction. www.clinicaltrialsregister.eu/ctr-search/trial/2016-004959-80/GR (first received 14 June 2017). ">ALTIC‐2 2018</a>; <a href="./references#CD008834-bbs2-0146" title="GallagherH , RoderickP .Aspirin to target arterial events in chronic kidney disease (ATTACK) protocol final version 1.1. www.njl-admin.nihr.ac.uk/document/download/20354362018. ">ATTACK 2018</a>; <a href="./references#CD008834-bbs2-0147" title="ZhaoJ .Antiplatelet therapy for prevention of atherosclerosis in chronic kidney disease: a perspective, multi-center randomized controlled trial [Antiplatelet prophylaxis for atherosclerosis in chronic kidney disease: a multicenter, randomized, pacebo-controlled trial]. www.chictr.org.cn/showproj.aspx?proj=34865 (first received 18 February 2019). ">ChiCTR1900021393</a>; <a href="./references#CD008834-bbs2-0148" title="IRCT2013012412256N1.Evaluation the effect of clopidogrel in prevention of access graft thrombosis in upper extrimity in patients undergoing hemodialysis in Emam Reza's Hospital - Kermanshah,2012-2013. www.en.irct.ir/trial/12352 (first received 10 May 2013). ">IRCT2013012412256N1</a>; <a href="./references#CD008834-bbs2-0149" title="IRCT2013100114333N8.Study of aspirin effects on Permcath function in dialysis patients [Study of effects use and without use of aspirin on Permcath function in dialysis patients]. www.en.irct.ir/trial/13944 (first received 4 October 2013). ">IRCT2013100114333N8</a>; <a href="./references#CD008834-bbs2-0150" title="IRCT20171023036953N1.The effect of Cilostazol on the mean time of arteriovenous fistula maturation and its comparison to control group in patients with chronic renal failure referring to Emam Reza hospital of Mashhad University of Medical Sciences. www.en.irct.ir/trial/27466 (first received 18 December 2017). ">IRCT20171023036953N1</a>; <a href="./references#CD008834-bbs2-0151" title="VioliF , TargherG , VestriA , CarnevaleR , AvernaM , FarcomeniA , et al.Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design. American Heart Journal2017;189:120-7. [MEDLINE: 28625368]">LEDA 2017</a>; <a href="./references#CD008834-bbs2-0152" title="Lemos CerqueiraT , Fartolino GuerreroA , Perez FerminCK , WangR , BalbinoEE , BreezeJL , et al.The use of aspirin to reduce the risk of thrombotic events in patients with end-stage renal disease: protocol for a randomized controlled trial. JMIR Research Protocols2018;7(8):e10516. [MEDLINE: 30093367]">Lemos Cerqueira 2018</a>; <a href="./references#CD008834-bbs2-0153" title="TongPC .The use of cilostazol in patients with diabetic nephropathy [A randomised, double-blind, placebo-controlled study of cilostazol 100 mg twice daily in the treatment of diabetic nephropathy in Hong Kong Chinese]. www.clinicaltrials.gov/show/nct00272831 (first received 9 January 2006). ">NCT00272831</a>; <a href="./references#CD008834-bbs2-0154" title="TarngDC .Aspirin in the prevention of cardiovascular events in hemodialysis patients [Efficacy of monitoring of aspirin responsiveness in the prevention of cardiovascular events and decrease in bleeding complications in patients with end-stage kidney disease undergoing hemodialysis]. www.clinicaltrials.gov/ct2/show/NCT01198379 (first received 10 September 2010). ">NCT01198379</a>; <a href="./references#CD008834-bbs2-0155" title="BougatsaVF .Ramipril and clopidogrel in oxidative stress, vascular inflammation and endothelial dysfunction in type 2 diabetes and diabetic nephropathy [A prospective, randomized, two period, with an intermediate wash out period, cross-over study to compare the effects of either combined therapy with ramipril and clopidogrel or ramipril monotherapy on oxidative stress, vascular inflammation and endothelial dysfunction in patients with type 2 diabetes and diabetic nephropathy]. www.clinicaltrials.gov/show/nct01743014 (first received 6 December 2012). ">NCT01743014</a>; <a href="./references#CD008834-bbs2-0156" title="KimW , WooJS .Genotype and platelet reactivity in patients on hemodialysis [The relationship between genotype and platelet reactivity in patients treated with ticagrelor versus clopidogrel: PIANO genotype study]. www.clinicaltrials.gov/show/nct02394145 (first received 20 March 2015). ">NCT02394145</a>; <a href="./references#CD008834-bbs2-0157" title="LiuPY .Platelet resistance with ticagrelor or standard-dose clopidogrel among CKD and ACS patients (APPROVE-SCKD) [A comParison on Platelet Resistance with ticagrelor or standard-dose clopidogrel study among SeVerE Chronic Kidney Disease/end-stage-renal-disease patients with recent acute coronary syndrome]. www.clinicaltrials.gov/show/nct02459288 (first received 2 June 2015). ">NCT02459288</a>; <a href="./references#CD008834-bbs2-0158" title="NicolauJC .Platelet aggregation in patients with coronary artery disease and kidney dysfunction taking clopidogrel or ticagrelor [Evaluation of platelet aggregation and adenosine levels in patients with coronary artery disease and chronic kidney dysfunction taking dual antiplatelet therapy with aspirin and clopidogrel or ticagrelor]. www.clinicaltrials.gov/show/nct03039205 (first received 1 February 2017). ">NCT03039205</a>; <a href="./references#CD008834-bbs2-0159" title="BanerjeeS , BaskarA .Study comparing treatment effectiveness of guideline indicated APT for ACS in patients with CKD (CPRS-SKD) [Pragmatic randomized controlled trial comparing treatment effectiveness of guideline indicated anti-platelet therapy for acute coronary syndrome in patients with chronic kidney disease]. www.clinicaltrials.gov/show/nct03150667 (first received 12 May 2017). ">NCT03150667</a>; <a href="./references#CD008834-bbs2-0160" title="NishankJ .Chronic kidney disease (CKD) platelet study [A mechanistic study in patients with non-dialysis chronic kidney disease to investigate altered platelet response to antiplatelet therapy (CKD-Platelet study)]. www.clinicaltrials.gov/show/nct03649711 (first received 28 August 2018). ">NCT03649711</a>; <a href="./references#CD008834-bbs2-0161" title="KiYJ , KwonSA , KimHL , SeoJB , ChungWY .The prevention of contrast induced nephropathy by sarpogrelate: a prospective randomized controlled clinical trial. Journal of Korean Medical Science2019;34(40):e261. [MEDLINE: 31625293]ParkK , ChungWY , SeoJB , KimSH , ZoJH , KimMA , et al.The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial. Trials [Electronic Resource]2010;11:122. [MEDLINE: 21167080]">Park 2010</a>; <a href="./references#CD008834-bbs2-0162" title="JapicCTI-184141.PRASTRO-III: a double-blind study of CS-747S versus clopidogrel sulfate in patients with thrombotic stroke having risk factors for stroke recurrence. www.clinicaltrials.jp/cti-user/trial/ShowDirect jsp?japicId=JapicCTI-184141 (first received 25 October 2018). ">PRASTO‐III 2018</a>; <a href="./references#CD008834-bbs2-0163" title="LeeSA , SuhJW , ParkJJ , YoonCH , ChoYS , YounTJ , et al.Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study. Contemporary Clinical Trials2015;43:20-4. [MEDLINE: 25891091]">SERENADE 2015</a>; <a href="./references#CD008834-bbs2-0164" title="ChoiDS .Effect of sarpogrelate on the nephropathy in type 2 diabetes (SONATA study). www.clinicaltrials.gov/show/NCT01869881 (first received June 5 2013). ">SONATA 2013</a>; <a href="./references#CD008834-bbs2-0165" title="LaineM , LemesleG , BurteyS , CaylaG , RangeG , QuainoG , et al.TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial. American Heart Journal2020;225:19-26. [MEDLINE: 32473355]">TROUPER 2020</a>; <a href="./references#CD008834-bbs2-0166" title="PanditN , ParakhN , GuptaS .TWILIGHT Study The anti platelet therapy with both ticagrelor and aspirin for 3 months after coronary intervention followed by ticagrelor only for a year rather than both aspirin and ticagrelor is better in reducing the ischemic events in high risk patients. www.ctri.nic.in/Clinicaltrials/pdf_generate php?trialid=12839&amp;EncHid=&amp;modid=&amp;compid=%27,%2712839det%27 (first received 13 July 2016). ">TWILIGHT 2016</a>; <a href="./references#CD008834-bbs2-0167" title="UMIN000003891.Examination concerning utility and safety of cilostazol use in patients with PAD conplicated to CKD. www.upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view cgi?recptno=R000003304 (first received 15 July 2010). ">UMIN000003891</a>; <a href="./references#CD008834-bbs2-0168" title="LeeheyDJ , CarlsonK , RedaD , PolzinL , CliseCE , PaineT , et al.Pentoxifylline in diabetic kidney disease: the VA pentoxifylline in diabetic kidney disease PTXRX study [abstract no: PUB074]. Journal of the American Society of Nephrology2019;30(Abstract Suppl):1092. [EMBASE: 633771821]LeeheyDJ , CraigI , RedaD , CarlsonK , ConnerTA , AgarwalR , et al.Design of pentoxifylline in diabetic kidney disease (VA PTXRx) [abstract no: SA-PO154]. Journal of the American Society of Nephrology2018;29(Abstract Suppl):775. [EMBASE: 633732689]">VA PTXRx 2018</a>). </p> <p>See <a href="./references#CD008834-sec-0188" title="">Characteristics of ongoing studies</a>. </p> </section> </section> </section> <section id="CD008834-sec-0048"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias in the included studies is summarised in <a href="#CD008834-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD008834-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD008834-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD008834-sec-0049"> <h4 class="title">Allocation</h4> <section id="CD008834-sec-0050"> <h5 class="title">Random sequence generation</h5> <p>Methods for generating the random sequence were deemed to be at low risk of bias in 16 studies (<a href="./references#CD008834-bbs2-0001" title="GoicoecheaM , deVinuesaMS , QuirogaB , VerdallesU , MoralesE , De SequeraP , et al.Aspirin treatment in primary cardiovascular prevention and renal disease progression in CKD patients: a randomized clinical trials (AASER study) [abstract no: FR-PO1065]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):B5. [EMBASE: 633704620]GoicoecheaM , deVinuesaSG , QuirogaB , VerdeE , BernisC , MoralesE , et al.Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study). Cardiovascular Drugs &amp; Therapy2018;32(3):255-63. [MEDLINE: 29943364]GoicoecheaM , Sanchez-NinoMD , OrtizA , deVinuesaMS , QuirogaB , MoralesE , et al.Low dose aspirin increases 15-epi-lipoxin a4 levels in CKD patients [abstract no: SA-PO186]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):726. [EMBASE: 633701100]GoicoecheaM , Sanchez-NinoMD , OrtizA , Garcia de VinuesaS , QuirogaB , BernisC , et al.Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. Prostaglandins Leukotrienes &amp; Essential Fatty Acids2017;125:8-13. [MEDLINE: 28987723]">AASER 2017</a>; <a href="./references#CD008834-bbs2-0004" title="AlexopoulosD , PanagiotouA , XanthopoulouI , KomninakisD , KassimisG , DavlourosP , et al.Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. Journal of Thrombosis &amp; Haemostasis2011;9(12):2379-85. [MEDLINE: 21985070]XanthopoulouI , PanagiotouA , KomninakisD , DavlourosP , KassimisG , FourtounasK , et al.Prasugrel versus double clopidpogrel maintenance dose in patients on chronic haemodialysis and high on clopidogrel platelet reactivity [abstract no: P2438]. European Heart Journal2011;32(Suppl 1):417. [EMBASE: 70534608]">Alexopoulos 2011</a>; <a href="./references#CD008834-bbs2-0007" title="Di FrancoA , GaudinoM , GirardiLN .Considerations about the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. Journal of Thoracic Disease2016;8(7):E599. [MEDLINE: 27501533]MylesPS , SmithJ , KnightJ , CooperDJ , SilbertB , McNeilJ , et al.Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial: rationale and design. American Heart Journal2008;155(2):224-30. [MEDLINE: 18215590]MylesPS , SmithJA , ForbesA , SilbertB , JayarajahM , PainterT , et al.Stopping vs. continuing aspirin before coronary artery surgery. New England Journal of Medicine2016;374(8):728-37. [MEDLINE: 26933848]MylesPS , SmithJA , ForbesA , SilbertB , JayarajahM , PainterT , et al.Tranexamic acid in patients undergoing coronary-artery surgery [Erratum for: N Engl J Med. 2017 Jan 12;376(2):136-148; PMID: 27774838]. New England Journal of Medicine2017;376(2):136-48. [MEDLINE: 27774838]MylesPS , SmithJA , KaszaJ , SilbertB , JayarajahM , PainterT , et al.Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial. Journal of Thoracic &amp; Cardiovascular Surgery2019;157(2):633-40. [MEDLINE: 30401528]MylesPS , SmithJA , KaszaJ , SilbertB , JayarajahM , PainterT , et al.Tranexamic acid in coronary artery surgery: one-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. Journal of Thoracic &amp; Cardiovascular Surgery2019;157(2):644-52.e9. [MEDLINE: 30459103]">ATACAS 2008</a><a href="./references#CD008834-bbs2-0008" title="FujitaT , YuX , KimS , NakamotoH , OrigasaH , KurumataniH , et al.Effects of sustained-release beraprost sodium in patients with primary glomerular disease or nephrosclerosis: the CASSIOPEIR study [abstract no: SA-PO1096]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):4B. [CENTRAL: CN-01657821] NakamotoH , FujitaT , OrigasaH , IsonoM , KurumataniH , OkadaK , et al.A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrology2014;15:153. [MEDLINE: 25233856]NakamotoH , YuXQ , KimS , OrigasaH , ZhengH , ChenJ , et al.Effects of sustained-release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results. Therapeutic Apheresis &amp; Dialysis2020;24(1):42-55. [MEDLINE: 31119846]">CASSIOPEIR 2014</a>; <a href="./references#CD008834-bbs2-0010" title="JingJ , MengX , ZhaoX , LiuL , WangA , PanY , et al.Dual antiplatelet therapy in transient ischemic attack and minor stroke with different infarction patterns: subgroup analysis of the CHANCE randomized clinical trial. JAMA Neurology2018;75(6):711-9. [MEDLINE: 29582084]LiJ , WangY , LinJ , WangD , WangA , ZhaoX , et al.Soluble CD40L is a useful marker to predict future strokes in patients with minor stroke and transient ischemic attack. Stroke2015;46(7):1990-2. [MEDLINE: 26012640]LiJ , ZhaoX , MengX , LinJ , LiuL , WangC , et al.High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome: subanalysis of the clopidogrel in high-risk patients with acute nondisabling cerebrovascular events trial. Stroke2016;47(8):2025-30. [MEDLINE: 27328699]LinY , WangA , LiJ , LinJ , WangD , MengX , et al.Impact of glycemic control on efficacy of clopidogrel in transient ischemic attack or minor stroke patients with CYP2C19 genetic variants. Stroke2017;48(4):998-1004. [MEDLINE: 28289237]LiuL , WongKS , LengX , PuY , WangY , JingJ , et al.Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology2015;85(13):1154-62. [MEDLINE: 26330567]LiZ , WangY , ZhaoX , LiuL , WangD , WangC , et al.Treatment effect of clopidogrel plus aspirin within 12 hours of acute minor stroke or transient ischemic attack. Journal of the American Heart Association2016;5(3):e003038. [MEDLINE: 27001965]MaY , LiuY , XuJ , WangY , WangY , DuF .Effect of dual antiplatelet on recurrent stroke in minor stroke or TIA depends on bodyweight. Therapeutics &amp; Clinical Risk Management2018;14:861-70. [MEDLINE: 29773949]PanY , CaiX , JingJ , MengX , LiH , WangY , et al.Stress hyperglycemia and prognosis of minor ischemic stroke and transient ischemic attack: the CHANCE study (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). Stroke2017;48(11):3006-11. [MEDLINE: 29051218]PanY , JingJ , ChenW , MengX , LiH , ZhaoX , et al.Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE.[Erratum in: Neurology. 2019 Aug 13;93(7):322; PMID: 31405943]. Neurology2017;88(20):1906-11. [MEDLINE: 28424269]PanY , JingJ , LiH , WangY , WangY , HeY , et al.Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA. Neurology2016;87(15):1551-6. [MEDLINE: 27613582]PanY , MengX , JingJ , LiH , ZhaoX , LiuL , et al.Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA. Neurology2017;88(11):1081-8. [MEDLINE: 28202699]WangA , LiS , ZhangN , DaiL , ZuoY , WangY , et al.Oxidized low-density lipoprotein to high-density lipoprotein ratio predicts recurrent stroke in minor stroke or transient ischemic attack. Stroke2018;49(11):2637-42. [MEDLINE: 30355199]WangA , XuJ , ChenG , WangD , JohnstonSC , MengX , et al.Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA. Neurology2018;91(10):e947-55. [MEDLINE: 30089614]WangD , GuiL , DongY , LiH , LiS , ZhengH , et al.Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial. Stroke &amp; Vascular Neurology2016;1(2):29-36. [MEDLINE: 28959461]WangqinR , WangX , WangY , XianY , ZhaoX , LiuL , et al.Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA: a subgroup analysis of the CHANCE trial. Stroke &amp; Vascular Neurology2017;2(4):176-83. [MEDLINE: 29507777]WangY , PanY , ZhaoX , LiH , WangD , JohnstonSC , et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial: one-year outcomes. Circulation2015;132(1):40-6. [MEDLINE: 25957224]WangY , WangY , ZhaoX , LiuL , WangD , WangC , et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine2013;369(1):11-9. [MEDLINE: 23803136]WangY , ZhaoX , LinJ , LiH , JohnstonSC , LinY , et al.Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA2016;316(1):70-8. [MEDLINE: 27348249]WuY , ZhouY , PanY , ZhaoX , LiuL , WangD , et al.Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. Pharmacogenomics Journal2018;18(6):713-20. [MEDLINE: 29520080]ZhouY , PanY , WuY , ZhaoX , LiH , WangD , et al.Effect of estimated glomerular filtration rate decline on the efficacy and safety of clopidogrel with aspirin in minor stroke or transient ischemic attack: CHANCE substudy (Clopidogrel in high-risk patients with acute nondisabling cerebrovascular events). Stroke2016;47(11):2791-6. [MEDLINE: 27738237]ZhuB , LiuH , PanY , JingJ , LiH , ZhaoX , et al.Elevated neutrophil and presence of intracranial artery stenosis increase the risk of recurrent stroke. Stroke2018;49(10):2294-300. [MEDLINE: 30355101]">CHANCE 2013</a>; <a href="./references#CD008834-bbs2-0015" title="AronowHD , SteinhublSR , BrennanDM , BergerPB , TopolEJ , CREDO Investigators.Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal2009;157(2):369-74. [MEDLINE: 19185647]BeinartSC , KolmP , VeledarE , ZhangZ , MahoneyEM , BouinO , et al.Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Journal of the American College of Cardiology2005;46(5):761-9. [MEDLINE: 16139122]BestPJ , SteinhublSR , BergerPB , DasguptaA , BrennanDM , SzczechLA , et al.The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal2008;155(4):687-93. [MEDLINE: 18371477]BrenerSJ , SteinhublSR , BergerPB , BrennanDM , TopolEJ , CREDO Investigators.Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial. Journal of Invasive Cardiology2007;19(7):287-90. [MEDLINE: 17620671]RingborgA , LindgrenP , JonssonB .The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. European Journal of Health Economics2005;6(4):354-56, 358-62. [MEDLINE: 16267654]SteinhublSR , BergerPB , Mann JT 3rd, FryET , DeLagoA , WilmerC , et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [Erratum in: JAMA. 2003 Feb 26;289(8):987]. JAMA2002;288(19):2411-20. [MEDLINE: 12435254]">CREDO 2005</a>; <a href="./references#CD008834-bbs2-0018" title="DashA , MaitiR , BandakkanavarTK , BhaskarA , PrakashJ , PandeyBL .Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: comparison between clopidogrel and low-dose aspirin. International Journal of Preventive Medicine2013;4(8):902-10. [MEDLINE: 24049616]">Dash 2013</a>; <a href="./references#CD008834-bbs2-0030" title="BaumgartnerI , NorgrenL , FowkesFG , MulderH , PatelMR , BergerJS , et al.Cardiovascular outcomes after lower extremity endovascular or surgical revascularization: the EUCLID trial. Journal of the American College of Cardiology2018;72(14):1563-72. [MEDLINE: 30261955]BergerJS , AbramsonBL , LopesRD , HeizerG , RockholdFW , BaumgartnerI , et al.Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Vascular Medicine2018;23(6):523-30. [MEDLINE: 29992857]HaineA , KavanaghS , BergerJS , HessCN , NorgrenL , FowkesFG , et al.Sex-specific risks of major cardiovascular and limb events in patients with symptomatic peripheral artery disease. Journal of the American College of Cardiology2020;75(6):608-17. [MEDLINE: 32057375]HessCN , HuangZ , PatelMR , BaumgartnerI , BergerJS , BlomsterJI , et al.Acute limb ischemia in peripheral artery disease. Circulation2019;140(7):556-65. [MEDLINE: 31238713]HiattWR , FowkesFG , HeizerG , BergerJS , BaumgartnerI , HeldP , et al.Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. New England Journal of Medicine2017;376(1):32-40. [MEDLINE: 27959717]HopleyCW , KavanaghS , PatelMR , OstromC , BaumgartnerI , BergerJS , et al.Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial. Vascular Medicine2019;24(5):422-30. [MEDLINE: 31339474]JonesWS , BaumgartnerI , HiattWR , HeizerG , ConteMS , WhiteCJ , et al.Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation2017;135(3):241-50. [MEDLINE: 27840336]KollsBJ , SappS , RockholdFW , JordanJD , DombrowskiKE , FowkesFG , et al.Stroke in patients with peripheral artery disease. Stroke2019;50(6):1356-63. [MEDLINE: 31092165]Low WangCC , BlomsterJI , HeizerG , BergerJS , BaumgartnerI , FowkesFG , et al.Cardiovascular and limb outcomes in patients with diabetes and peripheral artery disease: the EUCLID trial. Journal of the American College of Cardiology2018;72(25):3274-84. [MEDLINE: 30573030]NorgrenL , PatelMR , HiattWR , WojdylaDM , FowkesFG , BaumgartnerI , et al.Outcomes of patients with critical limb ischaemia in the EUCLID trial. European Journal of Vascular &amp; Endovascular Surgery2018;55(1):109-17. [MEDLINE: 29273390]OlivierCB , MulderH , HiattWR , JonesWS , FowkesFG , RockholdFW , et al.Incidence, characteristics, and outcomes of myocardial infarction in patients with peripheral artery disease: insights from the EUCLID trial. JAMA Cardiology2019;4(1):7-15. [MEDLINE: 30540355]">EUCLID 2017</a>; <a href="./references#CD008834-bbs2-0031" title="BadveS , HawleyCM , IrishAB , Paul-BrentP .High rate of screening failure in the FAVOURED study [abstract no: PUB345]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):905A. IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al.Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453]IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul-BrentP , et al.Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis-a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804]IrishA , FAVOURED Study Group.High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN-00756870] IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 009]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790]IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. [EMBASE: 70467038]IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul-BrentPA , et al.Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184-93. [MEDLINE: 28055065]IrishAB .The omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo-controlled trial [abstract no: HI-OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2-3. [CENTRAL: CN-01658143] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis-post hoc analysis of the FAVOURED study [abstract no: MO049]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475]ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on the need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology2018;23(Suppl 3):56. [EMBASE: 623841152]ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al.Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract no: SP593]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178]ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract no: FP555]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265]ViecelliA , PascoeE , PolkinghorneK , Paul-BrentP , DarssanD , HooiL , et al.A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115-6. [EMBASE: 612312707]ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul-BrentPA , BadveSV , et al.The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581]ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis - Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217-28. [MEDLINE: 26205903]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study. Nephrology2017;22(10):823-4. [MEDLINE: 27188542]ViecelliAK , PolkinghorneKR , PascoeEM , Paul-BrentPA , HawleyCM , BadveSV , et al.Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS ONE [Electronic Resource]2019;14(3):e0213274. [MEDLINE: 30913208]">FAVOURED 2009</a>; <a href="./references#CD008834-bbs2-0040" title="deMoralesAM , GoicoecheaM , VerdeE , CarbayoJ , BarbieriD , DelgadoA , et al.Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial. Journal of Nephrology2019;32(4):581-7. [MEDLINE: 30949987]GoicoecheaM , Garcia de VinuesaS , QuirogaB , VerdallesU , BarracaD , YusteC , et al.Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. Journal of Nephrology2012;25(6):969-75. [MEDLINE: 22241639]">Goicoechea 2012</a>; <a href="./references#CD008834-bbs2-0051" title="OgawaH , NakayamaM , MorimotoT , UemuraS , KanauchiM , DoiN , et al.Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.[Erratum in: JAMA. 2009 May 13;301(18):1882], [Erratum in: JAMA. 2012 Nov 14;308(18):1861]. JAMA2008;300(18):2134-41. [MEDLINE: 18997198]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , NakayamaM , et al.Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk. Circulation Journal2013;77(12):3023-8. [MEDLINE: 24042256]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , NakayamaM , et al.Is long-term low-dose aspirin therapy associated with renal dysfunction in patients with type 2 diabetes? JPAD2 cohort study. PLoS ONE [Electronic Resource]2016;11(1):e0147635. [MEDLINE: 26808136]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , OhtoriiM , et al.Long-term use of low-dose aspirin develops proteinuria in patients with diabetes: A reanalysis of JPAD study [abstract no: 10863]. Circulation2013;128(22 Suppl 1). [EMBASE: 71337722]SaitoY , MorimotoT , OgawaH , NakayamaM , UemuraS , DoiN , et al.Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care2011;34(2):280-5. [MEDLINE: 21270185]">JPAD 2008</a>; <a href="./references#CD008834-bbs2-0068" title="MozafarM , AlborziM , MoradiA .Effects of clopidogrel on longevity of permanent double-lumen catheter patency in dialysis patients: A single-blind placebo-controlled clinical trial. Nephro-Urology Monthly2018;10(2):e58135. [EMBASE: 622226387]">Mozafar 2018</a>; <a href="./references#CD008834-bbs2-0077" title="KimW , KangWY , WooJS .Objectives: The purpose of this study was to determine the functional impact of cilostazol in patients with chronic kidney disease (CKD) undergoing hemodialysis [abstract no: TCT-497]. Journal of the American College of Cardiology2011;58(20 Suppl 1):B135. [EMBASE: 70581866]WooJS , KimW , HaSJ , JeongKH , LeeTW , IhmCG , et al.A comparison of clopidogrel responsiveness in patients with chronic renal failure: results of the adjunctive cilostazol versus high maintenance dose clopidogrel (PIANO) study [abstract no: AS-252]. American Journal of Cardiology2011;107(8 Suppl 1):100-1A. [EMBASE: 70401953]WooJS , KimW , LeeSR , JungKH , KimWS , LewJH , et al.Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. American Heart Journal2011;162(6):1018-25. [MEDLINE: 22137075]">PIANO‐2 CKD 2011</a>; <a href="./references#CD008834-bbs2-0078" title="JeongKH , ChoJH , WooJS , KimJB , KimWS , LeeTW , et al.Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. American Journal of Kidney Diseases2015;65(6):916-24. [MEDLINE: 25622774]JeongKH , LeeTW , KimJS , LeeSY , LeeSH , MoonJY , et al.Platelet reactivity in patients with end stage renal disease receiving clopidogrel compared with ticagrelor: a randomized crossover study [abstract no: FP610]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii276. [EMBASE: 72207028]WooJS , KimW , KimHS , HwangSJ , KimJB , KimSJ , et al.Randomized assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with chronic kidney disease performing hemodialysis [abstract]. European Heart Journal2014;35(Suppl 1):7-8. [EMBASE: 71646762]">PIANO‐3 2015</a>; <a href="./references#CD008834-bbs2-0079" title="KimJS , LeeTW , IhmC , LeeSH , KimSY , LeeSY , et al.Relationship of ticagrelor dose and platelet reactivity in patients with end stage renal disease on hemodialysis [abstract no: FR-PO727]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):529A. KimJS , WooJS , KimJB , KimWS , LeeTW , KimKS , et al.The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. International Journal of Cardiology2017;238:110-6. [MEDLINE: 28342632]KimW , WooJS , KimWS , KimJB , KimHO , KimJM .Pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis [abstract]. European Heart Journal2016;37(Suppl 1):636. [EMBASE: 612284362]">PIANO‐6 2017</a>; <a href="./references#CD008834-bbs2-0106" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al.First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473-84. [MEDLINE: 15754269]BaigentC , UK-HARP Steering Committee.Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-PO851]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. [CENTRAL: CN-00444305] ">UK‐HARP‐I 2005</a>), at high risk of bias in three studies (<a href="./references#CD008834-bbs2-0044" title="GuoZ , HasbachJ , KoschinskyT .Effect of acetylsalicylic acid on renal function of Type 1 diabetic patients with microalbuminuria [Wirkung von Azetylsalizylsaure auf die Nierenfunktion bei Typ-1- Diabetikern mit Mikroalbuminurie. Placebokontrollierte Crossover-Pilotstudie]. Diabetes und Stoffwechsel1998;7(2):41-7. [EMBASE: 28146337]">Guo 1998</a>; <a href="./references#CD008834-bbs2-0055" title="KauffmannHM , AdamsMB , HebertLA , WalczakPM .Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905 ]">Kauffmann 1980</a>; <a href="./references#CD008834-bbs2-0090" title="RubinJ , AdairC , BarnesT , BowerJD .Augmentation of peritoneal clearance by dipyridamole. Kidney International1982;22(6):658-61. [MEDLINE: 6761488]">Rubin 1982</a>), and unclear in 94 studies. </p> </section> <section id="CD008834-sec-0051"> <h5 class="title">Allocation concealment</h5> <p>Allocation concealment was judged to be a low risk of bias in 22 studies (<a href="./references#CD008834-bbs2-0005" title="AndersonM , DewarP , FlemingLB , HackingPM , MorleyAR , MurrayS , et al.A controlled trial of dipyridamole in human renal transplantation and an assessment of platelet function studies in rejection. Clinical Nephrology1974;2(3):93-9. [MEDLINE: 4603996]">Anderson 1974</a>; <a href="./references#CD008834-bbs2-0007" title="Di FrancoA , GaudinoM , GirardiLN .Considerations about the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. Journal of Thoracic Disease2016;8(7):E599. [MEDLINE: 27501533]MylesPS , SmithJ , KnightJ , CooperDJ , SilbertB , McNeilJ , et al.Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial: rationale and design. American Heart Journal2008;155(2):224-30. [MEDLINE: 18215590]MylesPS , SmithJA , ForbesA , SilbertB , JayarajahM , PainterT , et al.Stopping vs. continuing aspirin before coronary artery surgery. New England Journal of Medicine2016;374(8):728-37. [MEDLINE: 26933848]MylesPS , SmithJA , ForbesA , SilbertB , JayarajahM , PainterT , et al.Tranexamic acid in patients undergoing coronary-artery surgery [Erratum for: N Engl J Med. 2017 Jan 12;376(2):136-148; PMID: 27774838]. New England Journal of Medicine2017;376(2):136-48. [MEDLINE: 27774838]MylesPS , SmithJA , KaszaJ , SilbertB , JayarajahM , PainterT , et al.Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial. Journal of Thoracic &amp; Cardiovascular Surgery2019;157(2):633-40. [MEDLINE: 30401528]MylesPS , SmithJA , KaszaJ , SilbertB , JayarajahM , PainterT , et al.Tranexamic acid in coronary artery surgery: one-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. Journal of Thoracic &amp; Cardiovascular Surgery2019;157(2):644-52.e9. [MEDLINE: 30459103]">ATACAS 2008</a>; <a href="./references#CD008834-bbs2-0008" title="FujitaT , YuX , KimS , NakamotoH , OrigasaH , KurumataniH , et al.Effects of sustained-release beraprost sodium in patients with primary glomerular disease or nephrosclerosis: the CASSIOPEIR study [abstract no: SA-PO1096]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):4B. [CENTRAL: CN-01657821] NakamotoH , FujitaT , OrigasaH , IsonoM , KurumataniH , OkadaK , et al.A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrology2014;15:153. [MEDLINE: 25233856]NakamotoH , YuXQ , KimS , OrigasaH , ZhengH , ChenJ , et al.Effects of sustained-release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results. Therapeutic Apheresis &amp; Dialysis2020;24(1):42-55. [MEDLINE: 31119846]">CASSIOPEIR 2014</a>; <a href="./references#CD008834-bbs2-0011" title="BangaloreS , BhattDL , StegPG , WeberMA , BodenWE , HammCW , et al.beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circulation: Cardiovascular Quality &amp; Outcomes2014;7(6):872-81. [MEDLINE: 25271049]BergerPB , BhattDL , FusterV , StegPG , FoxKA , ShaoM , et al.Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation2010;121(23):2575-83. [MEDLINE: 20516378]BhattDL , FlatherMD , HackeW , BergerPB , BlackHR , BodenWE , et al.Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology2007;49(19):1982-8. [MEDLINE: 17498584]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial [Erratum in: Am Heart J. 2006 Jan;151(1):247]. American Heart Journal2005;150(3):401. [MEDLINE: 16169314]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine2006;354(16):1706-17. [MEDLINE: 16531616]DasguptaA , SteinhublSR , BhattDL , BergerPB , ShaoM , MakKH , et al.Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). American Journal of Cardiology2009;103(10):1359-63. [MEDLINE: 19427428]EikelboomJW , HankeyGJ , ThomJ , BhattDL , StegPG , MontalescotG , et al.Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation2008;118(17):1705-12. [MEDLINE: 18838564]MakKH , BhattDL , ShaoM , HaffnerSM , HammCW , HankeyGJ , et al.The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. European Heart Journal2009;30(7):857-65. [MEDLINE: 19233855]SteinhublSR , BhattDL , BrennanDM , MontalescotG , HankeyGJ , EikelboomJW , et al.Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding [Summary for patients in Ann Intern Med. 2009 Mar 17;150(6):I-22; PMID: 19293067]. Annals of Internal Medicine2009;150(6):379-86. [MEDLINE: 19293071]WangTH , BhattDL , FoxKA , SteinhublSR , BrennanDM , HackeW , et al.An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal2007;28(18):2200-7. [MEDLINE: 17673448]">CHARISMA 2006</a>; <a href="./references#CD008834-bbs2-0017" title="BergerPB , SteinhublS .Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. Circulation2002;106(17):2284-7. [MEDLINE: 12390961]GerschutzGP , BhattDL , Clopidogrel in Unstable Angina to Prevent Recurrent Events study.The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?American Heart Journal2003;145(4):595-601. [MEDLINE: 12679754]KeltaiM , TonelliM , MannJF , SitkeiE , LewisBS , HawkenS , et al.Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. European Journal of Cardiovascular Prevention &amp; Rehabilitation2007;14(2):312-8. [MEDLINE: 17446813]LewisBS , MehtaSR , FoxKA , HalonDA , ZhaoF , PetersRJ , et al.Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. American Heart Journal2005;150(6):1177-84. [MEDLINE: 16338255]MehtaSR , YusufS , PetersRJ , BertrandME , LewisBS , NatarajanMK , et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet2001;358(9281):527-33. [MEDLINE: 11520521]MehtaSR , YusufS , Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators.The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. European Heart Journal2000;21(24):2033-41. [MEDLINE: 11102254]PetersRJ , MehtaSR , FoxKA , ZhaoF , LewisBS , KopeckySL , et al.Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation2003;108(14):1682-7. [MEDLINE: 14504182]YusufS ,  ZhaoF ,  MehtaSR ,  ChrolaviciusS ,  TognoniG ,  FoxKK , et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [Erratum in: N Engl J Med 2001 Dec 6;345(23):1716; Erratum in: N Engl J Med 2001 Nov 15;345(20):1506]. New England Journal of Medicine2001;345(7):494-502. [MEDLINE: 11519503]">CURE 2000</a>; <a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a>; <a href="./references#CD008834-bbs2-0024" title="BagaiA , WhiteJA , LokhnyginaY , GiuglianoRP , Van de WerfF , MontalescotG , et al.Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. American Heart Journal2013;166(3):466-73. [MEDLINE: 24016495]De FerrariGM , Van de WerfF , ArmstrongP , BodeC , LewisBS , TricociP , et al.Contrast induced nephropathy predicts later mortality among patients with non-ST-segment elevation acute coronary syndrome undergoing PCI: a sub-analysis from the EARLY ACS study [abstract no: P3820]. European Heart Journal2011;32(Suppl 1):657. [EMBASE: 70535519]EzekowitzJA , BakalJA , WesterhoutCM , GiuglianoRP , WhiteH , KeltaiM , et al.The relationship between meteorological conditions and index acute coronary events in a global clinical trial. International Journal of Cardiology2013;168(3):2315-21. [MEDLINE: 23416014]FarhanS , ClareRM , JaraiR , GiuglianoRP , LokhnyginaY , HarringtonRA , et al.Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: an analysis from EARLY ACS. International Journal of Cardiology2017;232:264-70. [MEDLINE: 28089149]FarhanS , ClareRM , JaraiR , NewbyLK , MorrowD , GiuglianoRP , et al.Fasting glucose, NT-proBNP, treatment with glycoprotein IIB/IIIA inhibitors, and outcomes in non-st-segment elevation acute coronary syndromes: an analysis from early ACS [abstract no: A14618]. Circulation2013;128(22 Suppl 1). [EMBASE: 71340424]GiuglianoRP , NewbyLK , HarringtonRA , GibsonCM , Van de WerfF , ArmstrongP , et al.The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. American Heart Journal2005;149(6):994-1002. [MEDLINE: 15976780]GiuglianoRP , WhiteJA , BodeC , ArmstrongPW , MontalescotG , LewisBS , et al.Early versus delayed, provisional eptifibatide in acute coronary syndromes. New England Journal of Medicine2009;360(21):2176-90. [MEDLINE: 19332455]HessCN , SchultePJ , NewbyLK , StegPG , DalbyAJ , SchweigerMJ , et al.Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. European Heart Journal: Acute Cardiovascular Care2013;2(3):246-55. [MEDLINE: 24222836]KaulP , TanguayJF , NewbyLK , HochmanJS , WesterhoutCM , CaliffRM , et al.Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. American Heart Journal2013;166(4):723-8. [MEDLINE: 24093853]KlutsteinMW , WesterhoutCM , ArmstrongPW , GiuglianoRP , LewisBS , GibsonCM , et al.Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. American Heart Journal2013;165(4):583-90. [MEDLINE: 23537976]KunadianV , GiuglianoRP , NewbyLK , ZorkunC , GuoJ , BagaiA , et al.Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). American Journal of Cardiology2014;113(8):1297-305. [MEDLINE: 24607027]LopesRD , WhiteJA , TricociP , WhiteHD , ArmstrongPW , BraunwaldE , et al.Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. International Journal of Cardiology2013;167(6):2580-7. [MEDLINE: 22795720]MelloniC , JamesSK , WhiteJA , GiuglianoRP , HarringtonRA , HuberK , et al.Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. American Heart Journal2011;162(5):884-92. [MEDLINE: 22093205]PicciniJP , WhiteJA , MehtaRH , LokhnyginaY , Al-KhatibSM , TricociP , et al.Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. Circulation2012;126(1):41-9. [MEDLINE: 22645292]PrideYB , MohanaveluS , GiuglianoRP , NewbyLK , ZorkunC , KunadianV , et al.Association between angiographic complications during percutaneous coronary intervention and clinical outcomes among patients with acute coronary syndrome: an early ACS angiographic substudy [abstract no: A10394]. Circulation2011;124(21 Suppl 1). [EMBASE: 70620664]PrideYB , MohanaveluS , ZorkunC , KunadianV , GiuglianoRP , NewbyLK , et al.Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. Jacc: Cardiovascular Interventions2012;5(9):927-35. [MEDLINE: 22995880]RoeMT , WhiteJA , KaulP , TricociP , LokhnyginaY , MillerCD , et al.Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. Circulation. Cardiovascular Quality &amp; Outcomes2012;5(2):205-13. [MEDLINE: 22373905]TanguayJF , NewbyLK , HochmanJ , WesterhoutCM , CaliffRM , GibsonCM , et al.Sex differences in high-risk acute coronary syndromes: Insights from early-ACS [abstract]. Journal of the American College of Cardiology2010;55(10 Suppl 1):A120.E1122. [EMBASE: 70096317]TolevaO , WesterhoutCM , SenaratneM , BodeC , LindroosM , ArdissinoD , et al.Association of hub and spoke practice patterns with coronary intervention and outcomes in non ST elevation acute coronary syndromes (NSTE ACS): Insights from the early glycoprotein IIb/IIIa inhibition in NSTE ACS (early-ACS) trial [abstract]. Journal of the American College of Cardiology2011;57(14 Suppl 1):E1101. [EMBASE: 70400778]TolevaO , WesterhoutCM , SenaratneMP , BodeC , LindroosM , SulimovVA , et al.Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial. Catheterization &amp; Cardiovascular Interventions2014;84(6):934-42. [MEDLINE: 24976083]WangT , WhiteJA , GiuglianoRP , TricociP , HarringtonRA , MontalescotG , et al.Upfront clopidogrel use and the efficacy and safety of early eptifibatide use in patients with acute coronary syndrome: An analysis from the early versus delayed provisional eptifibatide in acute coronary syndromes (early ACS) trial [abstract]. Journal of the American College of Cardiology2010;55(10 Suppl 1):A47.E451. [EMBASE: 70095646]WangTY , WhiteJA , TricociP , GiuglianoRP , ZeymerU , HarringtonRA , et al.Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Circulation2011;123(7):722-30. [MEDLINE: 21300952]">EARLY ACS 2005</a>; <a href="./references#CD008834-bbs2-0026" title="AguirreFV , TopolEJ , AndersonKM , KleimanNS , WeismanHF , FitzPatrickSE , et al.Benefit within patient subgroups receiving c7e3 fab (abciximab) during percutaneous coronary revascularization: subgroup analysis from the EPIC trial. Journal of Invasive Cardiology1996;8 Suppl B:21-9B. [MEDLINE: 10785766]AguirreFV , TopolEJ , FergusonJJ , AndersonK , BlankenshipJC , HeuserRR , et al.Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation1995;91(12):2882-90. [MEDLINE: 7796496]BerkowitzSD , SaneDC , SigmonKN , ShavenderJH , HarringtonRA , TchengJE , et al.Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. Journal of the American College of Cardiology1998;32(2):311-9. [MEDLINE: 9708455]BlankenshipJC , HellkampAS , AguirreFV , DemkoSL , TopolEJ , CaliffRM .Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. American Journal of Cardiology1998;81(1):36-40. [MEDLINE: 9462603]BoehrerJD , KereiakesDJ , NavettaFI , CaliffRM , TopolEJ .Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications. American Journal of Cardiology1994;74(11):1166-70. [MEDLINE: 7977081]CaliffRM , LincoffAM , TchengJE , TopolEJ .An overview of the results of the EPIC trial. European Heart Journal1995;16 Suppl L:43-9. [MEDLINE: 8869018]EPIC Investigators.Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New England Journal of Medicine1994;330(14):956-61. [MEDLINE: 8121459]KhanMM , EllisSG , AguirreFV , WeismanHF , WildermannNM , CaliffRM , et al.Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1998;31(1):31-6. [MEDLINE: 9426014]LefkovitsJ , BlankenshipJC , AndersonKM , StonerGL , TalleyJD , WorleySJ , et al.Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. Journal of the American College of Cardiology1996;28(4):849-55. [MEDLINE: 8837559]LefkovitsJ , IvanhoeRJ , CaliffRM , BergelsonBA , AndersonKM , StonerGL , et al.Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. American Journal of Cardiology1996;77(12):1045-51. [MEDLINE: 8644655]LincoffAM , CaliffRM , AndersonKM , WeismanHF , AguirreFV , KleimanNS , et al.Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1997;30(1):149-56. [MEDLINE: 9207636]MakKH , ChallapalliR , EisenbergMJ , AndersonKM , CaliffRM , TopolEJ .Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. American Journal of Cardiology1997;80(8):985-8. [MEDLINE: 9352964]MarkDB , TalleyJD , TopolEJ , BowmanL , LamLC , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation1996;94(4):629-35. [MEDLINE: 8772681]MoliternoDJ , CaliffRM , AguirreFV , AndersonK , SigmonKN , WeismanHF , et al.Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. American Journal of Cardiology1995;75(8):559-62. [MEDLINE: 7887377]NarinsCR , MillerDP , CaliffRM , TopolEJ .The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1999;33(3):647-53. [MEDLINE: 10080464]ThelMC , CaliffRM , TchengJE , SigmonKN , LincoffAM , TopolEJ , et al.Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. American Heart Journal1999;137(2):264-73. [MEDLINE: 9924160]TopolEJ , CaliffRM , WeismanHF , EllisSG , TchengJE , WorleyS , et al.Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet1994;343(8902):881-6. [MEDLINE: 7908357]TopolEJ , FergusonJJ , WeismanHF , TchengJE , EllisSG , KleimanNS , et al.Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA1997;278(6):479-84. [MEDLINE: 9256222]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. American Heart Journal1998;135(4):S98-106. [MEDLINE: 9539500]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. European Heart Journal1998;19 Suppl D:D59-66. [MEDLINE: 9597523]">EPIC 1994</a>; <a href="./references#CD008834-bbs2-0027" title="EPILOG Investigators.Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New England Journal of Medicine1997;336(24):1689-96. [MEDLINE: 9182212]GhaffariS , KereiakesDJ , LincoffAM , KellyTA , TimmisGC , KleimanNS , et al.Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. American Journal of Cardiology1998;82(1):7-12. [MEDLINE: 9671000]KereiakesDJ , LincoffAM , MillerDP , TchengJE , CabotCF , AndersonKM , et al.Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Circulation1998;97(9):857-64. [MEDLINE: 9521334]KleimanNS , LincoffAM , KereiakesDJ , MillerDP , AguirreFV , AndersonKM , et al.Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation1998;97(19):1912-20. [MEDLINE: 9609084]LincoffAM , MarkDB , TchengJE , CaliffRM , BalaMV , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation2000;102(24):2923-9. [MEDLINE: 11113041]LincoffAM , TchengJE , CaliffRM , KereiakesDJ , KellyTA , TimmisGC , et al.Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. One-year outcome in the EPILOG trial. Circulation1999;99(15):1951-8. [MEDLINE: 10208997]">EPILOG 1997</a>; <a href="./references#CD008834-bbs2-0028" title="ChoL , MarsoSP , BhattDL , TopolEJ .Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial. Journal of Womens Health &amp; Gender-Based Medicine2000;9(7):741-6. [MEDLINE: 11025866]De ServiS .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse events. Data from the Evaluation of Platelets IIb/IIIa Inhibitor for Stenting (EPISTENT) trial [Il pretrattamento con ticlopidina nello stent coronarico e associato a significativa riduzione di eventi avversi. Dati dal trial EPISTENT]. Italian Heart Journal Supplement2001;2(7):805-6. [MEDLINE: 11508303]EPISTENT Investigators.Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet1998;352(9122):87-92. [MEDLINE: 9672272]IslamMA , BlankenshipJC , BalogC , IliadisEA , LincoffAM , TchengJE , et al.Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). American Journal of Cardiology2002;90(9):916-21. [MEDLINE: 12398954]LincoffAM .Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial. American Heart Journal2000;139(2 Pt 2):S46-52. [MEDLINE: 10650316]MarsoSP , LincoffAM , EllisSG , BhattDL , TanguayJF , KleimanNS , et al.Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation1999;100(25):2477-84. [MEDLINE: 10604884]SteinhublSR , EllisSG , WolskiK , LincoffAM , TopolEJ .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation2001;103(10):1403-9. [MEDLINE: 11245644]SteinhublSR , TanWA , FoodyJM , TopolEJ .Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA1999;281(9):806-10. [MEDLINE: 10071001]TopolEJ , MarkDB , LincoffAM , CohenE , BurtonJ , KleimanN , et al.Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.[Erratum in: Lancet 2000 Mar 25;355(9209):1104]. Lancet1999;354(9195):2019-24. [MEDLINE: 10636365]Zwart-van RijkomJE , vanHoutBA .Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb/IIIa Inhibitor For Stenting Trial. European Heart Journal2001;22(16):1476-84. [MEDLINE: 11482921]">EPISTENT 1998</a>; <a href="./references#CD008834-bbs2-0030" title="BaumgartnerI , NorgrenL , FowkesFG , MulderH , PatelMR , BergerJS , et al.Cardiovascular outcomes after lower extremity endovascular or surgical revascularization: the EUCLID trial. Journal of the American College of Cardiology2018;72(14):1563-72. [MEDLINE: 30261955]BergerJS , AbramsonBL , LopesRD , HeizerG , RockholdFW , BaumgartnerI , et al.Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Vascular Medicine2018;23(6):523-30. [MEDLINE: 29992857]HaineA , KavanaghS , BergerJS , HessCN , NorgrenL , FowkesFG , et al.Sex-specific risks of major cardiovascular and limb events in patients with symptomatic peripheral artery disease. Journal of the American College of Cardiology2020;75(6):608-17. [MEDLINE: 32057375]HessCN , HuangZ , PatelMR , BaumgartnerI , BergerJS , BlomsterJI , et al.Acute limb ischemia in peripheral artery disease. Circulation2019;140(7):556-65. [MEDLINE: 31238713]HiattWR , FowkesFG , HeizerG , BergerJS , BaumgartnerI , HeldP , et al.Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. New England Journal of Medicine2017;376(1):32-40. [MEDLINE: 27959717]HopleyCW , KavanaghS , PatelMR , OstromC , BaumgartnerI , BergerJS , et al.Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial. Vascular Medicine2019;24(5):422-30. [MEDLINE: 31339474]JonesWS , BaumgartnerI , HiattWR , HeizerG , ConteMS , WhiteCJ , et al.Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation2017;135(3):241-50. [MEDLINE: 27840336]KollsBJ , SappS , RockholdFW , JordanJD , DombrowskiKE , FowkesFG , et al.Stroke in patients with peripheral artery disease. Stroke2019;50(6):1356-63. [MEDLINE: 31092165]Low WangCC , BlomsterJI , HeizerG , BergerJS , BaumgartnerI , FowkesFG , et al.Cardiovascular and limb outcomes in patients with diabetes and peripheral artery disease: the EUCLID trial. Journal of the American College of Cardiology2018;72(25):3274-84. [MEDLINE: 30573030]NorgrenL , PatelMR , HiattWR , WojdylaDM , FowkesFG , BaumgartnerI , et al.Outcomes of patients with critical limb ischaemia in the EUCLID trial. European Journal of Vascular &amp; Endovascular Surgery2018;55(1):109-17. [MEDLINE: 29273390]OlivierCB , MulderH , HiattWR , JonesWS , FowkesFG , RockholdFW , et al.Incidence, characteristics, and outcomes of myocardial infarction in patients with peripheral artery disease: insights from the EUCLID trial. JAMA Cardiology2019;4(1):7-15. [MEDLINE: 30540355]">EUCLID 2017</a>; <a href="./references#CD008834-bbs2-0031" title="BadveS , HawleyCM , IrishAB , Paul-BrentP .High rate of screening failure in the FAVOURED study [abstract no: PUB345]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):905A. IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al.Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453]IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul-BrentP , et al.Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis-a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804]IrishA , FAVOURED Study Group.High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN-00756870] IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 009]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790]IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. [EMBASE: 70467038]IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul-BrentPA , et al.Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184-93. [MEDLINE: 28055065]IrishAB .The omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo-controlled trial [abstract no: HI-OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2-3. [CENTRAL: CN-01658143] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis-post hoc analysis of the FAVOURED study [abstract no: MO049]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475]ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on the need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology2018;23(Suppl 3):56. [EMBASE: 623841152]ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al.Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract no: SP593]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178]ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract no: FP555]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265]ViecelliA , PascoeE , PolkinghorneK , Paul-BrentP , DarssanD , HooiL , et al.A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115-6. [EMBASE: 612312707]ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul-BrentPA , BadveSV , et al.The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581]ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis - Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217-28. [MEDLINE: 26205903]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study. Nephrology2017;22(10):823-4. [MEDLINE: 27188542]ViecelliAK , PolkinghorneKR , PascoeEM , Paul-BrentPA , HawleyCM , BadveSV , et al.Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS ONE [Electronic Resource]2019;14(3):e0213274. [MEDLINE: 30913208]">FAVOURED 2009</a>; <a href="./references#CD008834-bbs2-0036" title="GhorbaniA , AalamshahM , ShahbazianH , EhsanpourA , ArefA .Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian Journal of Nephrology2009;19(2):57-61. [MEDLINE: 20368925]">Ghorbani 2009</a>; <a href="./references#CD008834-bbs2-0037" title="GhorbaniA , Jasemi-ZerganiF .Ticlopidine to prevent primary arteriovenous fistula failure in hemodialysis patients; a randomized controlled trial. Journal of Renal Injury Prevention2013;2(3):109-11. [MEDLINE: 25340144]">Ghorbani 2013</a>; <a href="./references#CD008834-bbs2-0038" title="GiustinaA , PeriniP , DesenzaniP , BossoniS , IannielloP , MilaniM , et al.Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes1998;47(3):423-30. [MEDLINE: 9519749]">Giustina 1998</a>; <a href="./references#CD008834-bbs2-0048" title="HanssonL , ZanchettiA , CarruthersSG , DahlöfB , ElmfeldtD , JuliusS , et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998;351(9118):1755-62. [MEDLINE: 9635947]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Pressure1997;6(5):313-7. [MEDLINE: 9360003]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Pressure1994;3(5):322-7. [MEDLINE: 7866597]HanssonL .The Hypertension Optimal Treatment study and the importance of lowering blood pressure. Journal of Hypertension - Supplement1999;17(1):S9-13. [MEDLINE: 10340838]JardineM , NinomiyaT , CassA , TurnbullF , GallagherM , ZoungasS , et al.Aspirin benefit increases as eGFR declines: results from a randomised controlled trial in a hypertensive population [abstract no: 086]. Nephrology2010;15(Suppl 4):49. [EMBASE: 70467090]JardineMJ , NinomiyaT , PerkovicV , CassA , TurnbullF , GallagherMP , et al.Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology2010;56(12):956-65. [MEDLINE: 20828648]JonesDW , MillerME , WoffordMR , Anderson DC Jr, CameronME , WilloughbyDL , et al.The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. American Journal of Hypertension1999;12(12 Pt 1-2):1175-80. [MEDLINE: 10619579]JonssonB , HanssonL , StalhammarNO .Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Journal of Internal Medicine2003;253(4):472-80. [MEDLINE: 12653877]KjeldsenSE , HednerT , JamersonK , JuliusS , HaleyWE , ZabalgoitiaM , et al.Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects. Hypertension1998;31(4):1014-20. [MEDLINE: 9535429]KjeldsenSE , KollochRE , LeonettiG , MallionJM , ZanchettiA , ElmfeldtD , et al.Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. Journal of Hypertension2000;18(5):629-42. [MEDLINE: 10826567]KollochRE , RahnKH .The Hypertension Optimal Treatment (HOT) study: results of 12-month treatment related to age [Die 'Hyperyension Optimal Treatment' (HOT)-Studie: Behandlungsergebnisse nach Zwolfmonatiger Therapie in Abhangigkeit vom Alter]. Deutsche Medizinische Wochenschrift1998;123(1-2):1-5. [MEDLINE: 9465848]LeonettiG , ZanchettiA .Principal results of hypertension optimal treatment (HOT) study and their clinical impact. HOT cooperative group. Clinical Hemorheology &amp; Microcirculation1999;21(3-4):217-24. [MEDLINE: 10711746]LithellH , BerglundL .Validation of an oscillometric blood pressure measuring device: a substudy of the HOT Study. Hypertension Optimal Treatment. Blood Pressure1998;7(3):149-52. [MEDLINE: 9758084]ManciaG , OmboniS , ParatiG , ClementDL , HaleyWE , RahmanSN , et al.Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(10):1755-63. [MEDLINE: 11593094]RuilopeLM , SalvettiA , JamersonK , HanssonL , WarnoldI , WedelH , et al.Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology2001;12(2):218-25. [MEDLINE: 11158211]Struijker-BoudierH , SafarM , vanBortelL .Effects of individual risk factors on the incidence of cardiovascular event in the treated hypertensive patients of the Hypertension Optimal Treatment Study. Journal of Hypertension2001;19(11):2105-6. [MEDLINE: 11677378]The Hypertension Optimal Treatment Study (the HOT Study). Blood Pressure1993;2(1):62-8. [MEDLINE: 8193735]WaeberB , LeonettiG , KollochR , McInnesGT .Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension1999;17(7):1041-5. [MEDLINE: 10419079]ZanchettiA , HanssonL , DahlofB , ElmfeldtD , KjeldsenS , KollochR , et al.Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. Journal of Hypertension2001;19(6):1149-59. [MEDLINE: 11403365]ZanchettiA , HanssonL , MenardJ , LeonettiG , RahnKH , WarnoldI , et al.Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(4):819-25. [MEDLINE: 11330886]">HOT 1993</a>; <a href="./references#CD008834-bbs2-0056" title="ChangJJ , ConcatoJ , WellsCK , CrowleyST .Impact of adherence to clinical guidelines on mortality in hemodialysis patients [abstract no: SA-PO384]. Journal of the American Society of Nephrology2004;15(Oct):386A. [CENTRAL: CN-00583156] KaufmanJS , O'ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology2003;14(9):2313-21. [MEDLINE: 12937308]KaufmanJS , O’ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract no: A1495]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):291A. ">Kaufman 2003</a>; <a href="./references#CD008834-bbs2-0076" title="BonacaMP , BhattDL , BraunwaldE , CohenM , StegPG , StoreyRF , et al.Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal2014;167(4):437-44. [MEDLINE: 24655690]BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , JensenEC , et al.Long-term use of ticagrelor in patients with prior myocardial infarction. New England Journal of Medicine2015;372(19):1791-800. [MEDLINE: 25773268]BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , CohenM , et al.Prevention of stroke with ticagrelor in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation2016;134(12):861-71. [MEDLINE: 27576775]DellborgM , BonacaMP , StoreyRF , StegPG , ImKA , CohenM , et al.Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: Insights from PEGASUS-TIMI 54 [abstract]. European Heart Journal2017;38(Suppl 1):794-5. [EMBASE: 621235545]LozanoI , RondanJ , VegasJM , SegoviaE .Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):107-8. [MEDLINE: 29301622]MagnaniG , SabatineMS , BhattDL , ChoenM , StegG , StoreyR , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: Insights from the PEGASUS-TIMI 54 trial [abstract]. European Heart Journal2015;36(Suppl 1):520. [EMBASE: 72020712]MagnaniG , StoreyRF , StegG , BhattDL , CohenM , KuderJ , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. European Heart Journal2016;37(4):400-8. [MEDLINE: 26443023]MagnusonEA , BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , et al.Reply: cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):108. [MEDLINE: 29301623]MagnusonEA , LiH , WangK , VilainK , ShafiqA , BonacaMP , et al.Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: results from the PEGASUS-TIMI 54 trial. Journal of the American College of Cardiology2017;70(5):527-38. [MEDLINE: 28750695]MurphySA , BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , et al.Reduction in total cardiovascular events with long-term use of ticagrelor in patients with prior myocardial infarction in the PEGASUS-TIMI 54 trial [abstract no: A17121]. Circulation2015;132(Suppl 3). [EMBASE: 72179983]">PEGASUS‐TIMI 54 2014</a>; <a href="./references#CD008834-bbs2-0084" title="AkkerhuisKM , DeckersJW , BoersmaE , HarringtonRA , StepinskaJ , MahaffeyKW , et al.Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. European Heart Journal2000;21(5):371-81. [MEDLINE: 10666351]AkkerhuisKM , MaasAC , KlootwijkPA , KrucoffMW , MeijS , CaliffRM , et al.Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of Electrocardiology2000;33(2):127-36. [MEDLINE: 10819406]AlexanderJH , HarringtonRA , TuttleRH , BerdanLG , LincoffAM , DeckersJW , et al.Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology1999;83(8):1147-51. [MEDLINE: 10215274]BoersmaE , PieperKS , SteyerbergEW , WilcoxRG , ChangWC , LeeKL , et al.Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation2000;101(22):2557-67. [MEDLINE: 10840005]BrownRE , HendersonRA , KosterD , HuttonJ , SimoonsML .Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy. European Heart Journal2002;23(1):50-8. [MEDLINE: 11741362]ChangWC , HarringtonRA , SimoonsML , CaliffRM , LincoffAM , ArmstrongPW , et al.Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial. European Heart Journal2002;23(14):1102-11. [MEDLINE: 12090748]DykeCM , BhatiaD , LorenzTJ , MarsoSP , TardiffBE , HogeboomC , et al.Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Annals of Thoracic Surgery2000;70(3):866-71. [MEDLINE: 11016325]GreenbaumAB , HarringtonRA , HudsonMP , MacAulayCM , WilcoxRG , SimoonsML , et al.Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. Journal of the American College of Cardiology2001;37(2):492-8. [MEDLINE: 11216968]HarringtonRA .Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology1997;80(4A):34-8B. [MEDLINE: 9291244]HasdaiD , Holmes DR Jr, CrigerDA , TopolEJ , CaliffRM , WilcoxRG , et al.Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators. American Heart Journal2000;139(3):454-60. [MEDLINE: 10689260]KleimanNS , LincoffAM , FlakerGC , PieperKS , WilcoxRG , BerdanLG , et al.Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation2000;101(7):751-7. [MEDLINE: 10683348]LabinazM , KaulP , HarringtonRA , ChangWC , KleimanNS , SimoonsML , et al.Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. Canadian Journal of Cardiology2004;20(8):773-8. [MEDLINE: 15229770]LabinazM , KilaruR , PieperK , MarsoSP , KittMM , SimoonsML , et al.Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2002;105(3):322-7. [MEDLINE: 11804987]LauerMA , HoughtalingPL , PetersonJG , GrangerCB , BhattDL , SappSK , et al.Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2001;104(23):2772-7. [MEDLINE: 11733393]LincoffAM , HarringtonRA , CaliffRM , HochmanJS , GuerciAD , OhmanEM , et al.Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2000;102(10):1093-100. [MEDLINE: 10973836]MahaffeyKW , HarringtonRA , AkkerhuisM , KleimanNS , BerdanLG , CrenshawBS , et al.Systematic adjudication of myocardial infarction end-points in an international clinical trial. Current Controlled Trials in Cardiovascular Medicine2001;2(4):180-6. [MEDLINE: 11806793]MahaffeyKW , HarringtonRA , SimoonsML , GrangerCB , GraffagninoC , AlbertsMJ , et al.Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation1999;99(18):2371-7. [MEDLINE: 10318656]MarkDB , HarringtonRA , LincoffAM , CaliffRM , NelsonCL , TsiatisAA , et al.Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation2000;101(4):366-71. [MEDLINE: 10653826]MarsoSP , BhattDL , RoeMT , HoughtalingPL , LabinazM , KleimanNS , et al.Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators. Circulation2000;102(24):2952-8. [MEDLINE: 11113045]McClureMW , BerkowitzSD , SparapaniR , TuttleR , KleimanNS , BerdanLG , et al.Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation1999;99(22):2892-900. [MEDLINE: 10359733]PetersonJG , TopolEJ , RoeMT , SappSK , LincoffAM , DeckersJW , et al.Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology2001;87(5):532-6. [MEDLINE: 11230834]PURSUIT Trial Investigators.Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. New England Journal of Medicine1998;339(7):436-43. [MEDLINE: 9705684]RoeMT , HarringtonRA , ProsperDM , PieperKS , BhattDL , LincoffAM , et al.Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation2000;102(10):1101-6. [MEDLINE: 10973837]RonnerE , BoersmaE , AkkerhuisKM , HarringtonRA , LincoffAM , DeckersJW , et al.Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. European Heart Journal2002;23(3):239-46. [MEDLINE: 11792139]RonnerE , BoersmaE , LaarmanGJ , SomsenGA , HarringtonRA , DeckersJW , et al.Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of the American College of Cardiology2002;39(12):1924-9. [MEDLINE: 12084589]SrichaiMB , JaberWA , PriorDL , MarsoSP , HoughtalingPL , MenonV , et al.Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes. American Heart Journal2004;147(1):84-90. [MEDLINE: 14691424]">PURSUIT 1997</a>; <a href="./references#CD008834-bbs2-0100" title="BergerPB , BestPJ , TopolEJ , WhiteJ , DiBattistePM , ChanAW , et al.The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal2005;149(5):869-75. [MEDLINE: 15894970]KalyanasundaramA , BlankenshipJC , BergerP , HerrmannH , McClureR , MoliternoD .Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?). Catheterization &amp; Cardiovascular Interventions2007;69(5):623-9. [MEDLINE: 17192960]MoliternoDJ , TopolEJ .A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. American Heart Journal2000;140(5):722-6. [MEDLINE: 11054616]MoliternoDJ , YakubovSJ , DiBattistePM , HerrmannHC , StoneGW , MacayaC , et al.Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet2002;360(9330):355-60. [MEDLINE: 12241774]MukherjeeD , TopolEJ , BertrandME , KristensenSD , HerrmannHC , NeumannFJ , et al.Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. European Heart Journal2005;26(23):2524-8. [MEDLINE: 16107485]RoffiM , MoliternoDJ , MeierB , PowersER , GrinesCL , DiBattistePM , et al.Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation2002;105(23):2730-6. [MEDLINE: 12057986]TopolEJ , MoliternoDJ , HerrmannHC , PowersER , GrinesCL , CohenDJ , et al.Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New England Journal of Medicine2001;344(25):1888-94. [MEDLINE: 11419425]">TARGET 2000</a>; <a href="./references#CD008834-bbs2-0103" title="CorreaS , BonacaMP , SciricaBM , MurphySA , GoodrichEL , MorrowDA , et al.Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. Journal of Thrombosis &amp; Thrombolysis2019;47(3):353-60. [MEDLINE: 30511258]GaviriaSC , BraunwaldE , BonacaMP , MurphySA , GoodrichEL , MorrowDA , et al.The efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function: insights from the TRA 2P-TIMI 50 trial [abstract no: 15480]. Circulation2017;136(Suppl 1). [EMBASE: 619986693]MorrowDA , BraunwaldE , BonacaMP , AmerisoSF , DalbyAJ , FishMP , et al.Vorapaxar in the secondary prevention of atherothrombotic events. New England Journal of Medicine2012;366(15):1404-13. [MEDLINE: 22443427]MorrowDA , SciricaBM , FoxKA , BermanG , StronyJ , VeltriE , et al.Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. American Heart Journal2009;158(3):335-41. [MEDLINE: 19699854]">TRA 2P‐TIMI 50 2009</a>; <a href="./references#CD008834-bbs2-0104" title="CornelJH , TricociP , HortonJ , MoliternoD , WallentinL , ArmstrongP , et al.Effects of glycoprotein IIB/IIIA inhibitors in combination with vorapaxar, a platelet thrombin-receptor antagonist, among patients with non-St-segment elevation acute coronary syndromes: insights from the TRACER trial [abstract]. Journal of the American College of Cardiology2013;61(10 Suppl 1):E102. [EMBASE: 71019466]MahaffeyKW , PieperK , VranckxP , TricociP , Van de WerfF , HeldC , et al.Chronic kidney disease is associated with worse outcomes in ACS patients: results from the TRACER trial [abstract]. European Heart Journal2014;35(Suppl 1):687. [EMBASE: 71649310]">TRACER 2013</a>), and unclear in 91 studies. </p> </section> </section> <section id="CD008834-sec-0052"> <h4 class="title">Blinding</h4> <section id="CD008834-sec-0053"> <h5 class="title">Performance bias</h5> <p>Sixty‐four studies were blinded and considered to be at low risk of bias for performance bias (<a href="./references#CD008834-bbs2-0002" title="AbacilarAF , AtalayH , DoganOF .Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: a randomized controlled study. Indian Journal of Nephrology2015;25(3):136-42. [MEDLINE: 26060361]">Abacilar 2015</a>; <a href="./references#CD008834-bbs2-0003" title="Abdul-RahmanIS , Al-HowaishAK .Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23-30. [EMBASE: 2007269768]">Abdul‐Rahman 2007</a>; <a href="./references#CD008834-bbs2-0005" title="AndersonM , DewarP , FlemingLB , HackingPM , MorleyAR , MurrayS , et al.A controlled trial of dipyridamole in human renal transplantation and an assessment of platelet function studies in rejection. Clinical Nephrology1974;2(3):93-9. [MEDLINE: 4603996]">Anderson 1974</a>; <a href="./references#CD008834-bbs2-0006" title="AndrassyK , MallucheH , BornefeldH , CombergM , RitzE , JesdinskyH , et al.Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: results of a prospective double blind study. Klinische Wochenschrift1974;52(7):348-9. [MEDLINE: 4600820]">Andrassy 1974</a>; <a href="./references#CD008834-bbs2-0007" title="Di FrancoA , GaudinoM , GirardiLN .Considerations about the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. Journal of Thoracic Disease2016;8(7):E599. [MEDLINE: 27501533]MylesPS , SmithJ , KnightJ , CooperDJ , SilbertB , McNeilJ , et al.Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial: rationale and design. American Heart Journal2008;155(2):224-30. [MEDLINE: 18215590]MylesPS , SmithJA , ForbesA , SilbertB , JayarajahM , PainterT , et al.Stopping vs. continuing aspirin before coronary artery surgery. New England Journal of Medicine2016;374(8):728-37. [MEDLINE: 26933848]MylesPS , SmithJA , ForbesA , SilbertB , JayarajahM , PainterT , et al.Tranexamic acid in patients undergoing coronary-artery surgery [Erratum for: N Engl J Med. 2017 Jan 12;376(2):136-148; PMID: 27774838]. New England Journal of Medicine2017;376(2):136-48. [MEDLINE: 27774838]MylesPS , SmithJA , KaszaJ , SilbertB , JayarajahM , PainterT , et al.Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial. Journal of Thoracic &amp; Cardiovascular Surgery2019;157(2):633-40. [MEDLINE: 30401528]MylesPS , SmithJA , KaszaJ , SilbertB , JayarajahM , PainterT , et al.Tranexamic acid in coronary artery surgery: one-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. Journal of Thoracic &amp; Cardiovascular Surgery2019;157(2):644-52.e9. [MEDLINE: 30459103]">ATACAS 2008</a>; <a href="./references#CD008834-bbs2-0008" title="FujitaT , YuX , KimS , NakamotoH , OrigasaH , KurumataniH , et al.Effects of sustained-release beraprost sodium in patients with primary glomerular disease or nephrosclerosis: the CASSIOPEIR study [abstract no: SA-PO1096]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):4B. [CENTRAL: CN-01657821] NakamotoH , FujitaT , OrigasaH , IsonoM , KurumataniH , OkadaK , et al.A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrology2014;15:153. [MEDLINE: 25233856]NakamotoH , YuXQ , KimS , OrigasaH , ZhengH , ChenJ , et al.Effects of sustained-release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results. Therapeutic Apheresis &amp; Dialysis2020;24(1):42-55. [MEDLINE: 31119846]">CASSIOPEIR 2014</a>; <a href="./references#CD008834-bbs2-0010" title="JingJ , MengX , ZhaoX , LiuL , WangA , PanY , et al.Dual antiplatelet therapy in transient ischemic attack and minor stroke with different infarction patterns: subgroup analysis of the CHANCE randomized clinical trial. JAMA Neurology2018;75(6):711-9. [MEDLINE: 29582084]LiJ , WangY , LinJ , WangD , WangA , ZhaoX , et al.Soluble CD40L is a useful marker to predict future strokes in patients with minor stroke and transient ischemic attack. Stroke2015;46(7):1990-2. [MEDLINE: 26012640]LiJ , ZhaoX , MengX , LinJ , LiuL , WangC , et al.High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome: subanalysis of the clopidogrel in high-risk patients with acute nondisabling cerebrovascular events trial. Stroke2016;47(8):2025-30. [MEDLINE: 27328699]LinY , WangA , LiJ , LinJ , WangD , MengX , et al.Impact of glycemic control on efficacy of clopidogrel in transient ischemic attack or minor stroke patients with CYP2C19 genetic variants. Stroke2017;48(4):998-1004. [MEDLINE: 28289237]LiuL , WongKS , LengX , PuY , WangY , JingJ , et al.Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology2015;85(13):1154-62. [MEDLINE: 26330567]LiZ , WangY , ZhaoX , LiuL , WangD , WangC , et al.Treatment effect of clopidogrel plus aspirin within 12 hours of acute minor stroke or transient ischemic attack. Journal of the American Heart Association2016;5(3):e003038. [MEDLINE: 27001965]MaY , LiuY , XuJ , WangY , WangY , DuF .Effect of dual antiplatelet on recurrent stroke in minor stroke or TIA depends on bodyweight. Therapeutics &amp; Clinical Risk Management2018;14:861-70. [MEDLINE: 29773949]PanY , CaiX , JingJ , MengX , LiH , WangY , et al.Stress hyperglycemia and prognosis of minor ischemic stroke and transient ischemic attack: the CHANCE study (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). Stroke2017;48(11):3006-11. [MEDLINE: 29051218]PanY , JingJ , ChenW , MengX , LiH , ZhaoX , et al.Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE.[Erratum in: Neurology. 2019 Aug 13;93(7):322; PMID: 31405943]. Neurology2017;88(20):1906-11. [MEDLINE: 28424269]PanY , JingJ , LiH , WangY , WangY , HeY , et al.Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA. Neurology2016;87(15):1551-6. [MEDLINE: 27613582]PanY , MengX , JingJ , LiH , ZhaoX , LiuL , et al.Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA. Neurology2017;88(11):1081-8. [MEDLINE: 28202699]WangA , LiS , ZhangN , DaiL , ZuoY , WangY , et al.Oxidized low-density lipoprotein to high-density lipoprotein ratio predicts recurrent stroke in minor stroke or transient ischemic attack. Stroke2018;49(11):2637-42. [MEDLINE: 30355199]WangA , XuJ , ChenG , WangD , JohnstonSC , MengX , et al.Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA. Neurology2018;91(10):e947-55. [MEDLINE: 30089614]WangD , GuiL , DongY , LiH , LiS , ZhengH , et al.Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial. Stroke &amp; Vascular Neurology2016;1(2):29-36. [MEDLINE: 28959461]WangqinR , WangX , WangY , XianY , ZhaoX , LiuL , et al.Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA: a subgroup analysis of the CHANCE trial. Stroke &amp; Vascular Neurology2017;2(4):176-83. [MEDLINE: 29507777]WangY , PanY , ZhaoX , LiH , WangD , JohnstonSC , et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial: one-year outcomes. Circulation2015;132(1):40-6. [MEDLINE: 25957224]WangY , WangY , ZhaoX , LiuL , WangD , WangC , et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine2013;369(1):11-9. [MEDLINE: 23803136]WangY , ZhaoX , LinJ , LiH , JohnstonSC , LinY , et al.Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA2016;316(1):70-8. [MEDLINE: 27348249]WuY , ZhouY , PanY , ZhaoX , LiuL , WangD , et al.Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. Pharmacogenomics Journal2018;18(6):713-20. [MEDLINE: 29520080]ZhouY , PanY , WuY , ZhaoX , LiH , WangD , et al.Effect of estimated glomerular filtration rate decline on the efficacy and safety of clopidogrel with aspirin in minor stroke or transient ischemic attack: CHANCE substudy (Clopidogrel in high-risk patients with acute nondisabling cerebrovascular events). Stroke2016;47(11):2791-6. [MEDLINE: 27738237]ZhuB , LiuH , PanY , JingJ , LiH , ZhaoX , et al.Elevated neutrophil and presence of intracranial artery stenosis increase the risk of recurrent stroke. Stroke2018;49(10):2294-300. [MEDLINE: 30355101]">CHANCE 2013</a>; <a href="./references#CD008834-bbs2-0011" title="BangaloreS , BhattDL , StegPG , WeberMA , BodenWE , HammCW , et al.beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circulation: Cardiovascular Quality &amp; Outcomes2014;7(6):872-81. [MEDLINE: 25271049]BergerPB , BhattDL , FusterV , StegPG , FoxKA , ShaoM , et al.Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation2010;121(23):2575-83. [MEDLINE: 20516378]BhattDL , FlatherMD , HackeW , BergerPB , BlackHR , BodenWE , et al.Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology2007;49(19):1982-8. [MEDLINE: 17498584]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial [Erratum in: Am Heart J. 2006 Jan;151(1):247]. American Heart Journal2005;150(3):401. [MEDLINE: 16169314]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine2006;354(16):1706-17. [MEDLINE: 16531616]DasguptaA , SteinhublSR , BhattDL , BergerPB , ShaoM , MakKH , et al.Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). American Journal of Cardiology2009;103(10):1359-63. [MEDLINE: 19427428]EikelboomJW , HankeyGJ , ThomJ , BhattDL , StegPG , MontalescotG , et al.Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation2008;118(17):1705-12. [MEDLINE: 18838564]MakKH , BhattDL , ShaoM , HaffnerSM , HammCW , HankeyGJ , et al.The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. European Heart Journal2009;30(7):857-65. [MEDLINE: 19233855]SteinhublSR , BhattDL , BrennanDM , MontalescotG , HankeyGJ , EikelboomJW , et al.Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding [Summary for patients in Ann Intern Med. 2009 Mar 17;150(6):I-22; PMID: 19293067]. Annals of Internal Medicine2009;150(6):379-86. [MEDLINE: 19293071]WangTH , BhattDL , FoxKA , SteinhublSR , BrennanDM , HackeW , et al.An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal2007;28(18):2200-7. [MEDLINE: 17673448]">CHARISMA 2006</a>; <a href="./references#CD008834-bbs2-0013" title="ChristopherTG , SamelsK .A study of aspirin and dipyridamole in slowing the progression of diabetic glomerulosclerosis [abstract]. Kidney International1987;31(1):194. ChristopherTG , SamelsK .A study of the treatment effect of aspirin and dipyridamole in diabetic glomerulosclerosis [abstract]. In: 10th International Congress of Nephrology; 1987 Jul 26-31; London, UK. 1987:56. ">Christopher 1987</a>; <a href="./references#CD008834-bbs2-0015" title="AronowHD , SteinhublSR , BrennanDM , BergerPB , TopolEJ , CREDO Investigators.Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal2009;157(2):369-74. [MEDLINE: 19185647]BeinartSC , KolmP , VeledarE , ZhangZ , MahoneyEM , BouinO , et al.Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Journal of the American College of Cardiology2005;46(5):761-9. [MEDLINE: 16139122]BestPJ , SteinhublSR , BergerPB , DasguptaA , BrennanDM , SzczechLA , et al.The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal2008;155(4):687-93. [MEDLINE: 18371477]BrenerSJ , SteinhublSR , BergerPB , BrennanDM , TopolEJ , CREDO Investigators.Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial. Journal of Invasive Cardiology2007;19(7):287-90. [MEDLINE: 17620671]RingborgA , LindgrenP , JonssonB .The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. European Journal of Health Economics2005;6(4):354-56, 358-62. [MEDLINE: 16267654]SteinhublSR , BergerPB , Mann JT 3rd, FryET , DeLagoA , WilmerC , et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [Erratum in: JAMA. 2003 Feb 26;289(8):987]. JAMA2002;288(19):2411-20. [MEDLINE: 12435254]">CREDO 2005</a>; <a href="./references#CD008834-bbs2-0017" title="BergerPB , SteinhublS .Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. Circulation2002;106(17):2284-7. [MEDLINE: 12390961]GerschutzGP , BhattDL , Clopidogrel in Unstable Angina to Prevent Recurrent Events study.The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?American Heart Journal2003;145(4):595-601. [MEDLINE: 12679754]KeltaiM , TonelliM , MannJF , SitkeiE , LewisBS , HawkenS , et al.Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. European Journal of Cardiovascular Prevention &amp; Rehabilitation2007;14(2):312-8. [MEDLINE: 17446813]LewisBS , MehtaSR , FoxKA , HalonDA , ZhaoF , PetersRJ , et al.Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. American Heart Journal2005;150(6):1177-84. [MEDLINE: 16338255]MehtaSR , YusufS , PetersRJ , BertrandME , LewisBS , NatarajanMK , et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet2001;358(9281):527-33. [MEDLINE: 11520521]MehtaSR , YusufS , Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators.The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. European Heart Journal2000;21(24):2033-41. [MEDLINE: 11102254]PetersRJ , MehtaSR , FoxKA , ZhaoF , LewisBS , KopeckySL , et al.Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation2003;108(14):1682-7. [MEDLINE: 14504182]YusufS ,  ZhaoF ,  MehtaSR ,  ChrolaviciusS ,  TognoniG ,  FoxKK , et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [Erratum in: N Engl J Med 2001 Dec 6;345(23):1716; Erratum in: N Engl J Med 2001 Nov 15;345(20):1506]. New England Journal of Medicine2001;345(7):494-502. [MEDLINE: 11519503]">CURE 2000</a>; <a href="./references#CD008834-bbs2-0019" title="DemberL , AllonM , DelmezJ , DixonB , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00550593] DemberLM , BeckGJ , AllonM , DelmezJA , DixonBS , GreenbergA , et al.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008;299(18):2164-71. [MEDLINE: 18477783]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials2005;2(5):413-22. [MEDLINE: 16317810]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):229A. [CENTRAL: CN-00445067] ">Dember 2005</a>; <a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a>; <a href="./references#CD008834-bbs2-0022" title="DoddNJ , TurneyJH , WestonMJ .Ticlopidine preserves vascular access for haemodialysis [abstract no: 326F]. In: Proceedings of the VI International Congress of Mediterranean League Against Thrombosis; 1980 Oct 25-26; Montecarlo, Monaco. 1980. ">Dodd 1980</a>; <a href="./references#CD008834-bbs2-0023" title="DonadioJV , AndersonCF , MitchellJC , HolleyKE , IlstrupDM , FusterV .Membranoproliferative glomerulonephritis (MPGN): a prospective clinical trial of platelet inhibitor therapy [abstract]. Kidney International1983;23(1):121. [CENTRAL: CN-00602010] Donadio JV Jr, AndersonCF , Mitchell JC 3rd, HolleyKH , IlstrupDM , FusterV , et al.Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. New England Journal of Medicine1984;310(22):1421-6. [MEDLINE: 6371535]">Donadio 1984</a>; <a href="./references#CD008834-bbs2-0024" title="BagaiA , WhiteJA , LokhnyginaY , GiuglianoRP , Van de WerfF , MontalescotG , et al.Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. American Heart Journal2013;166(3):466-73. [MEDLINE: 24016495]De FerrariGM , Van de WerfF , ArmstrongP , BodeC , LewisBS , TricociP , et al.Contrast induced nephropathy predicts later mortality among patients with non-ST-segment elevation acute coronary syndrome undergoing PCI: a sub-analysis from the EARLY ACS study [abstract no: P3820]. European Heart Journal2011;32(Suppl 1):657. [EMBASE: 70535519]EzekowitzJA , BakalJA , WesterhoutCM , GiuglianoRP , WhiteH , KeltaiM , et al.The relationship between meteorological conditions and index acute coronary events in a global clinical trial. International Journal of Cardiology2013;168(3):2315-21. [MEDLINE: 23416014]FarhanS , ClareRM , JaraiR , GiuglianoRP , LokhnyginaY , HarringtonRA , et al.Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: an analysis from EARLY ACS. International Journal of Cardiology2017;232:264-70. [MEDLINE: 28089149]FarhanS , ClareRM , JaraiR , NewbyLK , MorrowD , GiuglianoRP , et al.Fasting glucose, NT-proBNP, treatment with glycoprotein IIB/IIIA inhibitors, and outcomes in non-st-segment elevation acute coronary syndromes: an analysis from early ACS [abstract no: A14618]. Circulation2013;128(22 Suppl 1). [EMBASE: 71340424]GiuglianoRP , NewbyLK , HarringtonRA , GibsonCM , Van de WerfF , ArmstrongP , et al.The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. American Heart Journal2005;149(6):994-1002. [MEDLINE: 15976780]GiuglianoRP , WhiteJA , BodeC , ArmstrongPW , MontalescotG , LewisBS , et al.Early versus delayed, provisional eptifibatide in acute coronary syndromes. New England Journal of Medicine2009;360(21):2176-90. [MEDLINE: 19332455]HessCN , SchultePJ , NewbyLK , StegPG , DalbyAJ , SchweigerMJ , et al.Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. European Heart Journal: Acute Cardiovascular Care2013;2(3):246-55. [MEDLINE: 24222836]KaulP , TanguayJF , NewbyLK , HochmanJS , WesterhoutCM , CaliffRM , et al.Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. American Heart Journal2013;166(4):723-8. [MEDLINE: 24093853]KlutsteinMW , WesterhoutCM , ArmstrongPW , GiuglianoRP , LewisBS , GibsonCM , et al.Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. American Heart Journal2013;165(4):583-90. [MEDLINE: 23537976]KunadianV , GiuglianoRP , NewbyLK , ZorkunC , GuoJ , BagaiA , et al.Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). American Journal of Cardiology2014;113(8):1297-305. [MEDLINE: 24607027]LopesRD , WhiteJA , TricociP , WhiteHD , ArmstrongPW , BraunwaldE , et al.Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. International Journal of Cardiology2013;167(6):2580-7. [MEDLINE: 22795720]MelloniC , JamesSK , WhiteJA , GiuglianoRP , HarringtonRA , HuberK , et al.Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. American Heart Journal2011;162(5):884-92. [MEDLINE: 22093205]PicciniJP , WhiteJA , MehtaRH , LokhnyginaY , Al-KhatibSM , TricociP , et al.Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. Circulation2012;126(1):41-9. [MEDLINE: 22645292]PrideYB , MohanaveluS , GiuglianoRP , NewbyLK , ZorkunC , KunadianV , et al.Association between angiographic complications during percutaneous coronary intervention and clinical outcomes among patients with acute coronary syndrome: an early ACS angiographic substudy [abstract no: A10394]. Circulation2011;124(21 Suppl 1). [EMBASE: 70620664]PrideYB , MohanaveluS , ZorkunC , KunadianV , GiuglianoRP , NewbyLK , et al.Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. Jacc: Cardiovascular Interventions2012;5(9):927-35. [MEDLINE: 22995880]RoeMT , WhiteJA , KaulP , TricociP , LokhnyginaY , MillerCD , et al.Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. Circulation. Cardiovascular Quality &amp; Outcomes2012;5(2):205-13. [MEDLINE: 22373905]TanguayJF , NewbyLK , HochmanJ , WesterhoutCM , CaliffRM , GibsonCM , et al.Sex differences in high-risk acute coronary syndromes: Insights from early-ACS [abstract]. Journal of the American College of Cardiology2010;55(10 Suppl 1):A120.E1122. [EMBASE: 70096317]TolevaO , WesterhoutCM , SenaratneM , BodeC , LindroosM , ArdissinoD , et al.Association of hub and spoke practice patterns with coronary intervention and outcomes in non ST elevation acute coronary syndromes (NSTE ACS): Insights from the early glycoprotein IIb/IIIa inhibition in NSTE ACS (early-ACS) trial [abstract]. Journal of the American College of Cardiology2011;57(14 Suppl 1):E1101. [EMBASE: 70400778]TolevaO , WesterhoutCM , SenaratneMP , BodeC , LindroosM , SulimovVA , et al.Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial. Catheterization &amp; Cardiovascular Interventions2014;84(6):934-42. [MEDLINE: 24976083]WangT , WhiteJA , GiuglianoRP , TricociP , HarringtonRA , MontalescotG , et al.Upfront clopidogrel use and the efficacy and safety of early eptifibatide use in patients with acute coronary syndrome: An analysis from the early versus delayed provisional eptifibatide in acute coronary syndromes (early ACS) trial [abstract]. Journal of the American College of Cardiology2010;55(10 Suppl 1):A47.E451. [EMBASE: 70095646]WangTY , WhiteJA , TricociP , GiuglianoRP , ZeymerU , HarringtonRA , et al.Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Circulation2011;123(7):722-30. [MEDLINE: 21300952]">EARLY ACS 2005</a>; <a href="./references#CD008834-bbs2-0026" title="AguirreFV , TopolEJ , AndersonKM , KleimanNS , WeismanHF , FitzPatrickSE , et al.Benefit within patient subgroups receiving c7e3 fab (abciximab) during percutaneous coronary revascularization: subgroup analysis from the EPIC trial. Journal of Invasive Cardiology1996;8 Suppl B:21-9B. [MEDLINE: 10785766]AguirreFV , TopolEJ , FergusonJJ , AndersonK , BlankenshipJC , HeuserRR , et al.Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation1995;91(12):2882-90. [MEDLINE: 7796496]BerkowitzSD , SaneDC , SigmonKN , ShavenderJH , HarringtonRA , TchengJE , et al.Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. Journal of the American College of Cardiology1998;32(2):311-9. [MEDLINE: 9708455]BlankenshipJC , HellkampAS , AguirreFV , DemkoSL , TopolEJ , CaliffRM .Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. American Journal of Cardiology1998;81(1):36-40. [MEDLINE: 9462603]BoehrerJD , KereiakesDJ , NavettaFI , CaliffRM , TopolEJ .Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications. American Journal of Cardiology1994;74(11):1166-70. [MEDLINE: 7977081]CaliffRM , LincoffAM , TchengJE , TopolEJ .An overview of the results of the EPIC trial. European Heart Journal1995;16 Suppl L:43-9. [MEDLINE: 8869018]EPIC Investigators.Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New England Journal of Medicine1994;330(14):956-61. [MEDLINE: 8121459]KhanMM , EllisSG , AguirreFV , WeismanHF , WildermannNM , CaliffRM , et al.Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1998;31(1):31-6. [MEDLINE: 9426014]LefkovitsJ , BlankenshipJC , AndersonKM , StonerGL , TalleyJD , WorleySJ , et al.Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. Journal of the American College of Cardiology1996;28(4):849-55. [MEDLINE: 8837559]LefkovitsJ , IvanhoeRJ , CaliffRM , BergelsonBA , AndersonKM , StonerGL , et al.Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. American Journal of Cardiology1996;77(12):1045-51. [MEDLINE: 8644655]LincoffAM , CaliffRM , AndersonKM , WeismanHF , AguirreFV , KleimanNS , et al.Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1997;30(1):149-56. [MEDLINE: 9207636]MakKH , ChallapalliR , EisenbergMJ , AndersonKM , CaliffRM , TopolEJ .Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. American Journal of Cardiology1997;80(8):985-8. [MEDLINE: 9352964]MarkDB , TalleyJD , TopolEJ , BowmanL , LamLC , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation1996;94(4):629-35. [MEDLINE: 8772681]MoliternoDJ , CaliffRM , AguirreFV , AndersonK , SigmonKN , WeismanHF , et al.Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. American Journal of Cardiology1995;75(8):559-62. [MEDLINE: 7887377]NarinsCR , MillerDP , CaliffRM , TopolEJ .The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1999;33(3):647-53. [MEDLINE: 10080464]ThelMC , CaliffRM , TchengJE , SigmonKN , LincoffAM , TopolEJ , et al.Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. American Heart Journal1999;137(2):264-73. [MEDLINE: 9924160]TopolEJ , CaliffRM , WeismanHF , EllisSG , TchengJE , WorleyS , et al.Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet1994;343(8902):881-6. [MEDLINE: 7908357]TopolEJ , FergusonJJ , WeismanHF , TchengJE , EllisSG , KleimanNS , et al.Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA1997;278(6):479-84. [MEDLINE: 9256222]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. American Heart Journal1998;135(4):S98-106. [MEDLINE: 9539500]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. European Heart Journal1998;19 Suppl D:D59-66. [MEDLINE: 9597523]">EPIC 1994</a>; <a href="./references#CD008834-bbs2-0027" title="EPILOG Investigators.Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New England Journal of Medicine1997;336(24):1689-96. [MEDLINE: 9182212]GhaffariS , KereiakesDJ , LincoffAM , KellyTA , TimmisGC , KleimanNS , et al.Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. American Journal of Cardiology1998;82(1):7-12. [MEDLINE: 9671000]KereiakesDJ , LincoffAM , MillerDP , TchengJE , CabotCF , AndersonKM , et al.Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Circulation1998;97(9):857-64. [MEDLINE: 9521334]KleimanNS , LincoffAM , KereiakesDJ , MillerDP , AguirreFV , AndersonKM , et al.Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation1998;97(19):1912-20. [MEDLINE: 9609084]LincoffAM , MarkDB , TchengJE , CaliffRM , BalaMV , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation2000;102(24):2923-9. [MEDLINE: 11113041]LincoffAM , TchengJE , CaliffRM , KereiakesDJ , KellyTA , TimmisGC , et al.Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. One-year outcome in the EPILOG trial. Circulation1999;99(15):1951-8. [MEDLINE: 10208997]">EPILOG 1997</a>; <a href="./references#CD008834-bbs2-0028" title="ChoL , MarsoSP , BhattDL , TopolEJ .Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial. Journal of Womens Health &amp; Gender-Based Medicine2000;9(7):741-6. [MEDLINE: 11025866]De ServiS .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse events. Data from the Evaluation of Platelets IIb/IIIa Inhibitor for Stenting (EPISTENT) trial [Il pretrattamento con ticlopidina nello stent coronarico e associato a significativa riduzione di eventi avversi. Dati dal trial EPISTENT]. Italian Heart Journal Supplement2001;2(7):805-6. [MEDLINE: 11508303]EPISTENT Investigators.Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet1998;352(9122):87-92. [MEDLINE: 9672272]IslamMA , BlankenshipJC , BalogC , IliadisEA , LincoffAM , TchengJE , et al.Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). American Journal of Cardiology2002;90(9):916-21. [MEDLINE: 12398954]LincoffAM .Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial. American Heart Journal2000;139(2 Pt 2):S46-52. [MEDLINE: 10650316]MarsoSP , LincoffAM , EllisSG , BhattDL , TanguayJF , KleimanNS , et al.Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation1999;100(25):2477-84. [MEDLINE: 10604884]SteinhublSR , EllisSG , WolskiK , LincoffAM , TopolEJ .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation2001;103(10):1403-9. [MEDLINE: 11245644]SteinhublSR , TanWA , FoodyJM , TopolEJ .Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA1999;281(9):806-10. [MEDLINE: 10071001]TopolEJ , MarkDB , LincoffAM , CohenE , BurtonJ , KleimanN , et al.Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.[Erratum in: Lancet 2000 Mar 25;355(9209):1104]. Lancet1999;354(9195):2019-24. [MEDLINE: 10636365]Zwart-van RijkomJE , vanHoutBA .Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb/IIIa Inhibitor For Stenting Trial. European Heart Journal2001;22(16):1476-84. [MEDLINE: 11482921]">EPISTENT 1998</a>; <a href="./references#CD008834-bbs2-0029" title="Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA1992;268(10):1292-300. [MEDLINE: 1507375]">ETDRS 1992</a>; <a href="./references#CD008834-bbs2-0031" title="BadveS , HawleyCM , IrishAB , Paul-BrentP .High rate of screening failure in the FAVOURED study [abstract no: PUB345]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):905A. IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al.Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453]IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul-BrentP , et al.Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis-a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804]IrishA , FAVOURED Study Group.High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN-00756870] IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 009]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790]IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. [EMBASE: 70467038]IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul-BrentPA , et al.Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184-93. [MEDLINE: 28055065]IrishAB .The omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo-controlled trial [abstract no: HI-OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2-3. [CENTRAL: CN-01658143] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis-post hoc analysis of the FAVOURED study [abstract no: MO049]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475]ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on the need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology2018;23(Suppl 3):56. [EMBASE: 623841152]ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al.Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract no: SP593]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178]ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract no: FP555]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265]ViecelliA , PascoeE , PolkinghorneK , Paul-BrentP , DarssanD , HooiL , et al.A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115-6. [EMBASE: 612312707]ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul-BrentPA , BadveSV , et al.The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581]ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis - Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217-28. [MEDLINE: 26205903]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study. Nephrology2017;22(10):823-4. [MEDLINE: 27188542]ViecelliAK , PolkinghorneKR , PascoeEM , Paul-BrentPA , HawleyCM , BadveSV , et al.Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS ONE [Electronic Resource]2019;14(3):e0213274. [MEDLINE: 30913208]">FAVOURED 2009</a>; <a href="./references#CD008834-bbs2-0032" title="FiskerstrandCE , ThompsonIW , BurnetME , WilliamsP , AndertonJL .Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artificial Organs1985;9(1):61-3. [MEDLINE: 3888153]">Fiskerstrand 1985</a>; <a href="./references#CD008834-bbs2-0035" title="GaedeP , HansenHP , ParvingHH , PedersenO .Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrology Dialysis Transplantation2003;18(3):539-42. [MEDLINE: 12584276]GaedeP , ParvingH , PedersenO .Lack of impact of low-dose acetylsalisyic acid (ASA) on albuminuria in type 2 diabetic patients [abstract no: A0660]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):128A. [CENTRAL: CN-00583369] ">Gaede 2003</a>; <a href="./references#CD008834-bbs2-0036" title="GhorbaniA , AalamshahM , ShahbazianH , EhsanpourA , ArefA .Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian Journal of Nephrology2009;19(2):57-61. [MEDLINE: 20368925]">Ghorbani 2009</a>; <a href="./references#CD008834-bbs2-0037" title="GhorbaniA , Jasemi-ZerganiF .Ticlopidine to prevent primary arteriovenous fistula failure in hemodialysis patients; a randomized controlled trial. Journal of Renal Injury Prevention2013;2(3):109-11. [MEDLINE: 25340144]">Ghorbani 2013</a>; <a href="./references#CD008834-bbs2-0038" title="GiustinaA , PeriniP , DesenzaniP , BossoniS , IannielloP , MilaniM , et al.Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes1998;47(3):423-30. [MEDLINE: 9519749]">Giustina 1998</a>; <a href="./references#CD008834-bbs2-0042" title="GröntoftKC , MulecH , GutierrezA , OlanderR .Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scandinavian Journal of Urology &amp; Nephrology1985;19(1):55-7. [MEDLINE: 3895411]">Gröntoft 1985</a>; <a href="./references#CD008834-bbs2-0043" title="GröntoftK , LarssonR , MulecH , WeissLG , DickinsonJP .Ticlopidine in fistula surgery: double-blind comparison against placebo on the rate of early occlusion of arterio-venous fistulae [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:398. [CENTRAL: CN-00601921] GröntoftKC , LarssonR , MulecH , WeissLG , DickinsonJP .Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scandinavian Journal of Urology &amp; Nephrology1998;32(4):276-83. [MEDLINE: 9764456]">Gröntoft 1998</a>; <a href="./references#CD008834-bbs2-0044" title="GuoZ , HasbachJ , KoschinskyT .Effect of acetylsalicylic acid on renal function of Type 1 diabetic patients with microalbuminuria [Wirkung von Azetylsalizylsaure auf die Nierenfunktion bei Typ-1- Diabetikern mit Mikroalbuminurie. Placebokontrollierte Crossover-Pilotstudie]. Diabetes und Stoffwechsel1998;7(2):41-7. [EMBASE: 28146337]">Guo 1998</a>; <a href="./references#CD008834-bbs2-0045" title="HansenHP , GaedePH , JensenBR , ParvingHH .Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria. Diabetes Care2000;23(12):1742-5. [MEDLINE: 11128344]">Hansen 2000</a>; <a href="./references#CD008834-bbs2-0046" title="HarterHR , BurchJW , MajerusPW , StanfordN , DelmezJA , AndersonCB , et al.Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. New England Journal of Medicine1979;301(11):577-9. [MEDLINE: 112475]">Harter 1979</a>; <a href="./references#CD008834-bbs2-0048" title="HanssonL , ZanchettiA , CarruthersSG , DahlöfB , ElmfeldtD , JuliusS , et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998;351(9118):1755-62. [MEDLINE: 9635947]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Pressure1997;6(5):313-7. [MEDLINE: 9360003]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Pressure1994;3(5):322-7. [MEDLINE: 7866597]HanssonL .The Hypertension Optimal Treatment study and the importance of lowering blood pressure. Journal of Hypertension - Supplement1999;17(1):S9-13. [MEDLINE: 10340838]JardineM , NinomiyaT , CassA , TurnbullF , GallagherM , ZoungasS , et al.Aspirin benefit increases as eGFR declines: results from a randomised controlled trial in a hypertensive population [abstract no: 086]. Nephrology2010;15(Suppl 4):49. [EMBASE: 70467090]JardineMJ , NinomiyaT , PerkovicV , CassA , TurnbullF , GallagherMP , et al.Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology2010;56(12):956-65. [MEDLINE: 20828648]JonesDW , MillerME , WoffordMR , Anderson DC Jr, CameronME , WilloughbyDL , et al.The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. American Journal of Hypertension1999;12(12 Pt 1-2):1175-80. [MEDLINE: 10619579]JonssonB , HanssonL , StalhammarNO .Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Journal of Internal Medicine2003;253(4):472-80. [MEDLINE: 12653877]KjeldsenSE , HednerT , JamersonK , JuliusS , HaleyWE , ZabalgoitiaM , et al.Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects. Hypertension1998;31(4):1014-20. [MEDLINE: 9535429]KjeldsenSE , KollochRE , LeonettiG , MallionJM , ZanchettiA , ElmfeldtD , et al.Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. Journal of Hypertension2000;18(5):629-42. [MEDLINE: 10826567]KollochRE , RahnKH .The Hypertension Optimal Treatment (HOT) study: results of 12-month treatment related to age [Die 'Hyperyension Optimal Treatment' (HOT)-Studie: Behandlungsergebnisse nach Zwolfmonatiger Therapie in Abhangigkeit vom Alter]. Deutsche Medizinische Wochenschrift1998;123(1-2):1-5. [MEDLINE: 9465848]LeonettiG , ZanchettiA .Principal results of hypertension optimal treatment (HOT) study and their clinical impact. HOT cooperative group. Clinical Hemorheology &amp; Microcirculation1999;21(3-4):217-24. [MEDLINE: 10711746]LithellH , BerglundL .Validation of an oscillometric blood pressure measuring device: a substudy of the HOT Study. Hypertension Optimal Treatment. Blood Pressure1998;7(3):149-52. [MEDLINE: 9758084]ManciaG , OmboniS , ParatiG , ClementDL , HaleyWE , RahmanSN , et al.Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(10):1755-63. [MEDLINE: 11593094]RuilopeLM , SalvettiA , JamersonK , HanssonL , WarnoldI , WedelH , et al.Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology2001;12(2):218-25. [MEDLINE: 11158211]Struijker-BoudierH , SafarM , vanBortelL .Effects of individual risk factors on the incidence of cardiovascular event in the treated hypertensive patients of the Hypertension Optimal Treatment Study. Journal of Hypertension2001;19(11):2105-6. [MEDLINE: 11677378]The Hypertension Optimal Treatment Study (the HOT Study). Blood Pressure1993;2(1):62-8. [MEDLINE: 8193735]WaeberB , LeonettiG , KollochR , McInnesGT .Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension1999;17(7):1041-5. [MEDLINE: 10419079]ZanchettiA , HanssonL , DahlofB , ElmfeldtD , KjeldsenS , KollochR , et al.Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. Journal of Hypertension2001;19(6):1149-59. [MEDLINE: 11403365]ZanchettiA , HanssonL , MenardJ , LeonettiG , RahnKH , WarnoldI , et al.Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(4):819-25. [MEDLINE: 11330886]">HOT 1993</a>; <a href="./references#CD008834-bbs2-0049" title="BlankenshipJC , SigmonKN , PieperKS , O'SheaC , TardiffBE , TchengJE , et al.Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial. American Journal of Cardiology2001;88(9):969-73. [MEDLINE: 11703991]GilchristIC , GardnerLH , MuhlesteinJB , ArnoldAM , LincoffAM , CaliffRM , et al.Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience. American Heart Journal1999;138(5 Pt 1):976-82. [MEDLINE: 10539832]MandakJS , BlankenshipJC , GardnerLH , BerkowitzSD , AguirreFV , SigmonKN , et al.Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Journal of the American College of Cardiology1998;31(7):1518-24. [MEDLINE: 9626829]Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet1997;349(9063):1422-8. [MEDLINE: 9164315]TardiffBE , CaliffRM , TchengJE , LincoffAM , SigmonKN , HarringtonRA , et al.Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. Journal of the American College of Cardiology1999;33(1):88-96. [MEDLINE: 9935014]ThelMC , CaliffRM , TardiffBE , GardnerLH , SigmonKN , LincoffAM , et al.Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. American Journal of Cardiology2000;85(4):427-34. [MEDLINE: 10728945]">IMPACT II 1997</a>; <a href="./references#CD008834-bbs2-0053" title="KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. New England Journal of Medicine1974;290(6):304-6. [MEDLINE: 4588285]KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation1975;52(3):497-9. [MEDLINE: 1098808]">Kaegi 1974</a>; <a href="./references#CD008834-bbs2-0055" title="KauffmannHM , AdamsMB , HebertLA , WalczakPM .Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905 ]">Kauffmann 1980</a>; <a href="./references#CD008834-bbs2-0056" title="ChangJJ , ConcatoJ , WellsCK , CrowleyST .Impact of adherence to clinical guidelines on mortality in hemodialysis patients [abstract no: SA-PO384]. Journal of the American Society of Nephrology2004;15(Oct):386A. [CENTRAL: CN-00583156] KaufmanJS , O'ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology2003;14(9):2313-21. [MEDLINE: 12937308]KaufmanJS , O’ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract no: A1495]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):291A. ">Kaufman 2003</a>; <a href="./references#CD008834-bbs2-0058" title="KobayashiK , MaedaK , KoshikawaS , KawaguchiY , ShimizuN , NaitoC .Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis: a multicenter collaborative double blind study. Thrombosis Research1980;20(2):255-61. [MEDLINE: 7209880]">Kobayashi 1980</a>; <a href="./references#CD008834-bbs2-0059" title="KontessisPS , JonesSL , BarrowSE , StrattonPD , AlessandriniP , De CosmoS , et al.Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy. Journal of Laboratory &amp; Clinical Medicine1993;121(3):415-23. [MEDLINE: 8445289]">Kontessis 1993</a>; <a href="./references#CD008834-bbs2-0060" title="KooistraMP , vanEsA , MarxJJ , HertsigM , StruyvenbergA .Effects of low dose aspirin on thrombovascular accidents during treatment with rHuEpo: a multicentre, controlled, cross-over study [abstract]. Nephrology Dialysis Transplantation1993;8:277. [CENTRAL: CN-00260772] KooistraMP , vanEsA , MarxJJ , HertsigML , StruyvenbergA .Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrology Dialysis Transplantation1994;9(8):1115-20. [MEDLINE: 7800210]">Kooistra 1994</a>; <a href="./references#CD008834-bbs2-0061" title="KoyamaA , NaritaM , TojoS .Therapeutic effects of dipyridamole on primary glomerulonephritis [abstract]. In: 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan. 1990:12. [CENTRAL: CN-00446186] ">Koyama 1990</a>; <a href="./references#CD008834-bbs2-0063" title="MichieDD , WomboltDG .Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research - Clinical &amp; Experimental1977;22(1 II):196-204. [EMBASE: 8152617]">Michie 1977</a>; <a href="./references#CD008834-bbs2-0065" title="MilutinovicS , GasparovicV , MilutinovicE , Buturovic-PonikvarJ .Ticlopidine improves dialysis clearance of solutes in uremic patients by reducing blood clotting in dialyser fibers. International Journal of Artificial Organs1993;16(5):249-52. [MEDLINE: 8354583]">Milutinovic 1993</a>; <a href="./references#CD008834-bbs2-0067" title="MozafarM , SamsamiM , SobhiyehMR , JabbehdariS , FallahZM .Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourology Monthly2013;5(2):762-5. [MEDLINE: 23841041]">Mozafar 2013</a>; <a href="./references#CD008834-bbs2-0072" title="NybergG , LarssonO , WestbergNG , AurellM , JagenburgR , BlohmeG .A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study. Clinical Nephrology1984;21(3):184-7. [MEDLINE: 6705280]">Nyberg 1984</a>; <a href="./references#CD008834-bbs2-0075" title="OtaK , TeraokaS , AkiwasaT , MimuraN , HirasawaY , SakaiT , et al.Clinical efficacy of E5510 (satigrel), an antiplatelet agent, for preventing blood clotting in the extracorporeal circuit during hemodialysis (3) - A double-blind comparison with ticlopidine hydrochloride. Rinsho Hyoka1996;24(1):9-38. ">Ota 1996</a>; <a href="./references#CD008834-bbs2-0076" title="BonacaMP , BhattDL , BraunwaldE , CohenM , StegPG , StoreyRF , et al.Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal2014;167(4):437-44. [MEDLINE: 24655690]BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , JensenEC , et al.Long-term use of ticagrelor in patients with prior myocardial infarction. New England Journal of Medicine2015;372(19):1791-800. [MEDLINE: 25773268]BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , CohenM , et al.Prevention of stroke with ticagrelor in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation2016;134(12):861-71. [MEDLINE: 27576775]DellborgM , BonacaMP , StoreyRF , StegPG , ImKA , CohenM , et al.Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: Insights from PEGASUS-TIMI 54 [abstract]. European Heart Journal2017;38(Suppl 1):794-5. [EMBASE: 621235545]LozanoI , RondanJ , VegasJM , SegoviaE .Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):107-8. [MEDLINE: 29301622]MagnaniG , SabatineMS , BhattDL , ChoenM , StegG , StoreyR , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: Insights from the PEGASUS-TIMI 54 trial [abstract]. European Heart Journal2015;36(Suppl 1):520. [EMBASE: 72020712]MagnaniG , StoreyRF , StegG , BhattDL , CohenM , KuderJ , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. European Heart Journal2016;37(4):400-8. [MEDLINE: 26443023]MagnusonEA , BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , et al.Reply: cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):108. [MEDLINE: 29301623]MagnusonEA , LiH , WangK , VilainK , ShafiqA , BonacaMP , et al.Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: results from the PEGASUS-TIMI 54 trial. Journal of the American College of Cardiology2017;70(5):527-38. [MEDLINE: 28750695]MurphySA , BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , et al.Reduction in total cardiovascular events with long-term use of ticagrelor in patients with prior myocardial infarction in the PEGASUS-TIMI 54 trial [abstract no: A17121]. Circulation2015;132(Suppl 3). [EMBASE: 72179983]">PEGASUS‐TIMI 54 2014</a>; <a href="./references#CD008834-bbs2-0080" title="PierucciA , SimonettiBM , PecciG , FeriozziS , MavrikakisG , CinottiGA , et al.Low dose aspirin in patients with lupus nephritis [abstract]. Kidney International1988;33(1):281. [CENTRAL: CN-00583819] PierucciA , SimonettiBM , PecciG , MavrikakisG , FeriozziS , CinottiGA , et al.Acute effects of a thromboxane receptor antagonist on renal function in patients with lupus nephritis [abstract]. Kidney International1987;31(1):283. [CENTRAL: CN-00724956] PierucciA , SimonettiBM , PecciG , MavrikakisG , FeriozziS , CinottiGA , et al.Improvement of renal function with selective thromboxane antagonism in lupus nephritis. New England Journal of Medicine1989;320(7):421-5. [MEDLINE: 2643773]">Pierucci 1989</a>; <a href="./references#CD008834-bbs2-0081" title="AkerblomA , WallentinL , LarssonA , SiegbahnA , BeckerRC , BudajA , et al.Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study. Clinical Chemistry2013;59(9):1369-75. [MEDLINE: 23698074]AkerblomA , WallentinL , SiegbahnA , BeckerRC , BudajA , HorrowJ , et al.Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. American Heart Journal2012;164(5):728-34. [MEDLINE: 23137503]AndellP , JamesSK , CannonCP , CyrDD , HimmelmannA , HustedS , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Journal of the American Heart Association2015;4(10):e002490. [MEDLINE: 26452988]ArmstrongPW , SihaH , FuY , WesterhoutCM , StegPG , JamesSK , et al.ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation2012;125(3):514-21. [MEDLINE: 22179530]ArmstrongPW , WesterhoutCM , FuY , HarringtonRA , StoreyRF , KatusH , et al.Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. American Journal of Medicine2013;126(8):723-9. [MEDLINE: 23795897]BeckerRC , BassandJP , BudajA , WojdylaDM , JamesSK , CornelJH , et al.Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial [Erratum in: Eur Heart J. 2012 Nov;33(21):2750]. European Heart Journal2011;32(23):2933-44. [MEDLINE: 22090660]BellaviaA , WallentinL , OrsiniN , JamesSK , CannonCP , HimmelmannA , et al.Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. Open Heart2017;4(2):e000557. [MEDLINE: 28761675]BrilakisES , HeldC , MeierB , CoolsF , ClaeysMJ , CornelJH , et al.Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. American Heart Journal2013;166(3):474-80. [MEDLINE: 24016496]BuiAH , CannonCP , StegPG , StoreyRF , HustedS , GuoJ , et al.Relationship between early and late nonsustained ventricular tachycardia and cardiovascular death in patients with acute coronary syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation: Arrhythmia and Electrophysiology2016;9(2):e002951. [MEDLINE: 26810596]CapodannoD , CalviV , TamburinoC .Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment. Journal of Cardiovascular Medicine2012;13(2):162-3. [MEDLINE: 22237463]CornelJH , BeckerRC , GoodmanSG , HustedS , KatusH , SantosoA , et al.Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2012;164(3):334-42. [MEDLINE: 22980299]CowperPA , PanW , AnstromKJ , KaulP , WallentinL , Davidson-RayL , et al.Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. Journal of the American College of Cardiology2015;65(5):465-76. [MEDLINE: 25660925]DiNicolantonioJJ , D'AscenzoF , TomekA , ChatterjeeS , NiaziAK , Biondi-ZoccaiG .Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial. International Journal of Cardiology2013;168(3):1739-44. [MEDLINE: 23907035]DiNicolantonioJJ , TomekA .Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial. International Journal of Cardiology2013;168(4):4076-80. [MEDLINE: 23911266]DiNicolantonioJJ , TomekA .Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel. International Journal of Cardiology2013;169(2):145-6. [MEDLINE: 24120213]DucrocqG , SchultePJ , BeckerRC , CannonCP , HarringtonRA , HeldC , et al.Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. Eurointervention2015;11(7):737-45. [MEDLINE: 25254357]FranchiF , JamesSK , GhukasyanLT , BudajAJ , CornelJH , KatusHA , et al.Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y12 receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. Journal of the American Heart Association2019;8(6):e011139. [MEDLINE: 30857464]GiannitsisE , WallentinL , JamesSK , BertilssonM , SiegbahnA , StoreyRF , et al.Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: a Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. European Heart Journal: Acute Cardiovascular Care2017;6(6):500-10. [MEDLINE: 27044282]HagstromE , JamesSK , BertilssonM , BeckerRC , HimmelmannA , HustedS , et al.Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. European Heart Journal2016;37(16):1325-33. [MEDLINE: 26417057]HeldC , AsenbladN , BassandJP , BeckerRC , CannonCP , ClaeysMJ , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology2011;57(6):672-84. [MEDLINE: 21194870]HustedS , JamesS , BeckerRC , HorrowJ , KatusH , StoreyRF , et al.Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circulation. Cardiovascular Quality &amp; Outcomes2012;5(5):680-8. [MEDLINE: 22991347]HustedS , JamesSK , BachRG , BeckerRC , BudajA , HerasM , et al.The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal2014;35(23):1541-50. [MEDLINE: 24682844]JamesS , AkerblomA , CannonCP , EmanuelssonH , HustedS , KatusH , et al.Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2009;157(4):599-605. [MEDLINE: 19332184]JamesS , AngiolilloDJ , CornelJH , ErlingeD , HustedS , KontnyF , et al.Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal2010;31(24):3006-16. [MEDLINE: 20802246]JamesS , BudajA , AylwardP , BuckKK , CannonCP , CornelJH , et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2010;122(11):1056-67. [MEDLINE: 20805430]JamesS , BudajA , AylwardP , BuckKK , CannonCP , CornelJH , et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation2010;122(11):1056-67. [MEDLINE: 20805430]JamesSK , RoeMT , CannonCP , CornelJH , HorrowJ , HustedS , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ2011;342:d3527. [MEDLINE: 21685437]JohanssonA , ErikssonN , BeckerRC , StoreyRF , HimmelmannA , HagstromE , et al.NLRC4 inflammasome is an important regulator of interleukin-18 levels in patients with acute coronary syndromes: genome-wide association study in the PLATelet inhibition and patient Outcomes Trial (PLATO). Circulation. Cardiovascular Genetics2015;8(3):498-506. [MEDLINE: 25747584]KangHJ , ClareRM , GaoR , HeldC , HimmelmannA , JamesSK , et al.Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal2015;169(6):899-905. [MEDLINE: 26027629]KholaifN , ZhengY , JagasiaP , HimmelmannA , JamesSK , StegPG , et al.Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex. American Journal of Medicine2015;128(8):914-9. [MEDLINE: 25818495]KohliP , WallentinL , ReyesE , HorrowJ , HustedS , AngiolilloDJ , et al.Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation2013;127(6):673-80. [MEDLINE: 23277305]KontnyF , UelandT , AukrustP , MichelsenAE , BeckerRC , BertilssonM , et al.Pentraxin 3 (PTX3) predict adverse outcome in acute coronary syndromes-a PLATO biomarker substudy [abstract]. European Heart Journal2014;35(Suppl 1):319. [EMBASE: 71647923]KotsiaA , BrilakisES , HeldC , CannonC , StegGP , MeierB , et al.Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2014;168(1):68-75. [MEDLINE: 24952862]KunadianV , JamesSK , WojdylaDM , ZorkunC , WuJ , StoreyRF , et al.Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). Jacc: Cardiovascular Interventions2013;6(7):671-83. [MEDLINE: 23866179]LevinLA , WallentinL , BernfortL , AnderssonD , StoreyRF , BergstromG , et al.Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. Value in Health2013;16(4):574-80. [MEDLINE: 23796291]LindholmD , VarenhorstC , CannonCP , HarringtonRA , HimmelmannA , MayaJ , et al.Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal2014;35(31):2083-93. [MEDLINE: 24727884]MahaffeyKW , HeldC , WojdylaDM , JamesSK , KatusHA , HustedS , et al.Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology2014;63(15):1493-9. [MEDLINE: 24561148]MahaffeyKW , WojdylaDM , CarrollK , BeckerRC , StoreyRF , AngiolilloDJ , et al.Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2011;124(5):544-54. [MEDLINE: 21709065]NikolicE , JanzonM , HauchO , WallentinL , HenrikssonM , PLATO Health Economic Substudy Group.Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. European Heart Journal2013;34(3):220-8. [MEDLINE: 22719022]OhmanEM , RoeMT .Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany &quot;Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified&quot; (Thromb Haemost 2011; 105.5). Thrombosis &amp; Haemostasis2011;105(5):763-5. [MEDLINE: 21394382]ParkerWA , ErikssonN , BeckerRC , VooraD , AkerblomA , HimmelmannA , et al.Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets2019;30(5):579-88. [MEDLINE: 29851527]PatelMR , BeckerRC , WojdylaDM , EmanuelssonH , HiattWR , HorrowJ , et al.Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. European Journal of Preventive Cardiology2015;22(6):734-42. [MEDLINE: 24830710]Pollack CV Jr, DavoudiF , DiercksDB , BeckerRC , JamesSK , LimST , et al.Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clinical Cardiology2017;40(6):390-8. [MEDLINE: 28598510]RoguinA , MusallamA .Letter by Roguin and Musallam regarding article, &quot;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial&quot;. Circulation2014;129(19):e493. [MEDLINE: 24821831]SciricaBM , BansilalS , DavoudiF , ArmstrongPW , ClareRM , SchultePJ , et al.Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. American Heart Journal2018;202:54-60. [MEDLINE: 29859968]SciricaBM , CannonCP , EmanuelssonH , MichelsonEL , HarringtonRA , HustedS , et al.The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. Journal of the American College of Cardiology2011;57(19):1908-16. [MEDLINE: 21545948]SerebruanyVL , FortmannSD , CherepanovV , LitvinovO , KimMH , MarciniakTA .Excess ticagrelor mortality in the food and drug administration adverse event reporting system: time to recount PLATO trial deaths. American Journal of Medicine2017;130(6):e245-6. [MEDLINE: 28161342]SerebruanyVL .Angiographic outcomes contradict platelet data in the PLATO trial: confusion over official trial substudies. Cardiology2014;127(3):190-5. [MEDLINE: 24457905]SerebruanyVL .Discrepancies in the primary PLATO trial publication and the FDA reviews. International Journal of Cardiology2014;172(1):8-10. [MEDLINE: 24456868]SerebruanyVL .Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review. American Journal of Therapeutics2012;19(2):160-1. [MEDLINE: 22395000]SerebruanyVL .The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent. Cardiology2011;120(3):169-71. [MEDLINE: 22418766]ShimadaYJ , BansilalS , WiviottSD , BeckerRC , HarringtonRA , HimmelmannA , et al.Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal2016;177:1-8. [MEDLINE: 27297843]SihaH , DasD , FuY , ZhengY , WesterhoutCM , StoreyRF , et al.Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. CMAJ Canadian Medical Association Journal2012;184(10):1135-42. [MEDLINE: 22546885]StegPG , HarringtonRA , EmanuelssonH , KatusHA , MahaffeyKW , MeierB , et al.Response to letter regarding article, &quot;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial&quot;. Circulation2014;129(19):e494-5. [MEDLINE: 24821832]StegPG , HarringtonRA , EmanuelssonH , KatusHA , MahaffeyKW , MeierB , et al.Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation2013;128(10):1055-65. [MEDLINE: 23900047]StegPG , JamesS , HarringtonRA , ArdissinoD , BeckerRC , CannonCP , et al.Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation2010;122(21):2131-41. [MEDLINE: 21060072]StoreyRF , AngiolilloDJ , PatilSB , DesaiB , EcobR , HustedS , et al.Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. Journal of the American College of Cardiology2010;56(18):1456-62. [MEDLINE: 20832963]StoreyRF , ArdissinoD , VignaliL , CairnsR , BeckerRC , CannonCP , et al.Ischaemic events and stent thrombosis following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study. Thrombosis &amp; Haemostasis2018;118(2):427-9. [MEDLINE: 29443375]StoreyRF , BeckerRC , HarringtonRA , HustedS , JamesSK , CoolsF , et al.Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. European Heart Journal2011;32(23):2945-53. [MEDLINE: 21804104]StoreyRF , BeckerRC , HarringtonRA , HustedS , JamesSK , CoolsF , et al.Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). American Journal of Cardiology2011;108(11):1542-6. [MEDLINE: 21890085]StoreyRF , JamesSK , SiegbahnA , VarenhorstC , HeldC , YcasJ , et al.Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets2014;25(7):517-25. [MEDLINE: 24127651]SumayaW , WallentinL , JamesSK , SiegbahnA , GabryschK , BertilssonM , et al.Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. European Heart Journal2018;39(13):1078-85. [MEDLINE: 29390064]UelandT , AkerblomA , GhukasyanT , MichelsenAE , AukrustP , BeckerRC , et al.Osteoprotegerin is associated with major bleeding but not with cardiovascular outcomes in patients with acute coronary syndromes: insights from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American Heart Association2018;7(2):e007009. [MEDLINE: 29330256]UelandT , MichelsenA , AukrustP , BeckerR , BertilssonM , JamesSK , et al.Chemokine (CXC motif) ligand 16 (CXCL16) and osteoprotegerin (OPG) as predictors of outcome in patients with acute coronary syndromes (ACS) a PLATO biomarker substudy [abstract]. European Heart Journal2014;35(Suppl 1):486. [EMBASE: 71648554]WallentinL , BeckerRC , BudajA , CannonCP , EmanuelssonH , HeldC , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2009;361(11):1045-57. [MEDLINE: 19717846]WallentinL , BeckerRC , CannonCP , HeldC , HimmelmannA , HustedS , et al.No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. International Journal of Cardiology2014;176(1):300-2. [MEDLINE: 25005338]WallentinL , BeckerRC , CannonCP , HeldC , HimmelmannA , HustedS , et al.Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. International Journal of Cardiology2014;170(3):e59-62. [MEDLINE: 24299581]WallentinL , BeckerRC , JamesSK , HarringtonRA .The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. &quot;Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified&quot; (Thromb Haemost 2011; 105.5). Thrombosis &amp; Haemostasis2011;105(5):760-2. [MEDLINE: 21394383]WallentinL , JamesS , StoreyRF , ArmstrongM , BarrattBJ , HorrowJ , et al.Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet2010;376(9749):1320-8. [MEDLINE: 20801498]WallentinL , LindholmD , SiegbahnA , WernrothL , BeckerRC , CannonCP , et al.Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2014;129(3):293-303. [MEDLINE: 24170388]">PLATO 2009</a>; <a href="./references#CD008834-bbs2-0083" title="HuynhT , NasmithJ , LuongTM , BernierM , PharandC , Xue-QiaoZ , et al.Complementary prognostic values of ST segment deviation and Thrombolysis In Myocardial Infarction (TIMI) risk score in non-ST elevation acute coronary syndromes: insights from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Canadian Journal of Cardiology 2009 Dec;25(12):e417-21. [MEDLINE: 19960136]HuynhT , PiazzaN , DiBattistePM , SnapinnSM , WanY , PharandC , et al.Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study. International Journal of Cardiology2005;100(1):73-8. [MEDLINE: 15820288]HuynhT , TherouxP , SnapinnS , WanY , PRISM-PLUS Investigators.Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). American Heart Journal2003;146(4):668-73. [MEDLINE: 14564321]Januzzi JL Jr, SnapinnSM , DiBattistePM , JangIK , TherouxP .Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation2002;105(20):2361-6. [MEDLINE: 12021221]MegaJL , MorrowDA , SabatineMS , ZhaoXQ , SnapinnSM , DiBattistePM , et al.Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. American Heart Journal2005;149(5):846-50. [MEDLINE: 15894966]MorrowDA , SabatineMS , AntmanEM , CannonCP , BraunwaldE , TherouxP .Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). American Journal of Cardiology2004;94(6):774-6. [MEDLINE: 15374786]Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New England Journal of Medicine1998;338(21):1488-97. [MEDLINE: 9599103]ServossSJ , WanY , SnapinnSM , DiBattistePM , ZhaoXQ , TherouxP , et al.Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. American Journal of Cardiology2004;93(7):843-7. [MEDLINE: 15050486]SzucsTD , MeyerBJ , KiowskiW .Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial. European Heart Journal1999;20(17):1253-60. [MEDLINE: 10454977]TherouxP , AlexanderJ , PharandC , BarrE , SnapinnS , GhannamAF , et al.Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation2000;102(20):2466-72. [MEDLINE: 11076818]TherouxP , Alexander J Jr, DupuisJ , PesantY , GervaisP , GrandmontD , et al.Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators. American Journal of Cardiology2001;87(4):375-80. [MEDLINE: 11179517]ZhaoXQ , TherouxP , SnapinnSM , SaxFL .Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Circulation1999;100(15):1609-15. [MEDLINE: 10517731]">PRISM‐PLUS 1998</a>; <a href="./references#CD008834-bbs2-0084" title="AkkerhuisKM , DeckersJW , BoersmaE , HarringtonRA , StepinskaJ , MahaffeyKW , et al.Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. European Heart Journal2000;21(5):371-81. [MEDLINE: 10666351]AkkerhuisKM , MaasAC , KlootwijkPA , KrucoffMW , MeijS , CaliffRM , et al.Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of Electrocardiology2000;33(2):127-36. [MEDLINE: 10819406]AlexanderJH , HarringtonRA , TuttleRH , BerdanLG , LincoffAM , DeckersJW , et al.Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology1999;83(8):1147-51. [MEDLINE: 10215274]BoersmaE , PieperKS , SteyerbergEW , WilcoxRG , ChangWC , LeeKL , et al.Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation2000;101(22):2557-67. [MEDLINE: 10840005]BrownRE , HendersonRA , KosterD , HuttonJ , SimoonsML .Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy. European Heart Journal2002;23(1):50-8. [MEDLINE: 11741362]ChangWC , HarringtonRA , SimoonsML , CaliffRM , LincoffAM , ArmstrongPW , et al.Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial. European Heart Journal2002;23(14):1102-11. [MEDLINE: 12090748]DykeCM , BhatiaD , LorenzTJ , MarsoSP , TardiffBE , HogeboomC , et al.Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Annals of Thoracic Surgery2000;70(3):866-71. [MEDLINE: 11016325]GreenbaumAB , HarringtonRA , HudsonMP , MacAulayCM , WilcoxRG , SimoonsML , et al.Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. Journal of the American College of Cardiology2001;37(2):492-8. [MEDLINE: 11216968]HarringtonRA .Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology1997;80(4A):34-8B. [MEDLINE: 9291244]HasdaiD , Holmes DR Jr, CrigerDA , TopolEJ , CaliffRM , WilcoxRG , et al.Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators. American Heart Journal2000;139(3):454-60. [MEDLINE: 10689260]KleimanNS , LincoffAM , FlakerGC , PieperKS , WilcoxRG , BerdanLG , et al.Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation2000;101(7):751-7. [MEDLINE: 10683348]LabinazM , KaulP , HarringtonRA , ChangWC , KleimanNS , SimoonsML , et al.Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. Canadian Journal of Cardiology2004;20(8):773-8. [MEDLINE: 15229770]LabinazM , KilaruR , PieperK , MarsoSP , KittMM , SimoonsML , et al.Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2002;105(3):322-7. [MEDLINE: 11804987]LauerMA , HoughtalingPL , PetersonJG , GrangerCB , BhattDL , SappSK , et al.Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2001;104(23):2772-7. [MEDLINE: 11733393]LincoffAM , HarringtonRA , CaliffRM , HochmanJS , GuerciAD , OhmanEM , et al.Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2000;102(10):1093-100. [MEDLINE: 10973836]MahaffeyKW , HarringtonRA , AkkerhuisM , KleimanNS , BerdanLG , CrenshawBS , et al.Systematic adjudication of myocardial infarction end-points in an international clinical trial. Current Controlled Trials in Cardiovascular Medicine2001;2(4):180-6. [MEDLINE: 11806793]MahaffeyKW , HarringtonRA , SimoonsML , GrangerCB , GraffagninoC , AlbertsMJ , et al.Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation1999;99(18):2371-7. [MEDLINE: 10318656]MarkDB , HarringtonRA , LincoffAM , CaliffRM , NelsonCL , TsiatisAA , et al.Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation2000;101(4):366-71. [MEDLINE: 10653826]MarsoSP , BhattDL , RoeMT , HoughtalingPL , LabinazM , KleimanNS , et al.Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators. Circulation2000;102(24):2952-8. [MEDLINE: 11113045]McClureMW , BerkowitzSD , SparapaniR , TuttleR , KleimanNS , BerdanLG , et al.Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation1999;99(22):2892-900. [MEDLINE: 10359733]PetersonJG , TopolEJ , RoeMT , SappSK , LincoffAM , DeckersJW , et al.Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology2001;87(5):532-6. [MEDLINE: 11230834]PURSUIT Trial Investigators.Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. New England Journal of Medicine1998;339(7):436-43. [MEDLINE: 9705684]RoeMT , HarringtonRA , ProsperDM , PieperKS , BhattDL , LincoffAM , et al.Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation2000;102(10):1101-6. [MEDLINE: 10973837]RonnerE , BoersmaE , AkkerhuisKM , HarringtonRA , LincoffAM , DeckersJW , et al.Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. European Heart Journal2002;23(3):239-46. [MEDLINE: 11792139]RonnerE , BoersmaE , LaarmanGJ , SomsenGA , HarringtonRA , DeckersJW , et al.Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of the American College of Cardiology2002;39(12):1924-9. [MEDLINE: 12084589]SrichaiMB , JaberWA , PriorDL , MarsoSP , HoughtalingPL , MenonV , et al.Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes. American Heart Journal2004;147(1):84-90. [MEDLINE: 14691424]">PURSUIT 1997</a>; <a href="./references#CD008834-bbs2-0085" title="Quarto Di PaloF , ElliA , RivoltaR , ParentiM , PalazziP , ZanussiC .Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide. Transplantation Proceedings1991;23(1 Pt 2):969-71. [MEDLINE: 1989347]">Quarto Di Palo 1991</a>; <a href="./references#CD008834-bbs2-0086" title="BrenerSJ , BarrLA , BurchenalJE , KatzS , GeorgeBS , JonesAA , et al.Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation1998;98(8):734-41. [MEDLINE: 9727542]BrenerSJ , BarrLA , BurchenalJE , WolskiKE , EffronMB , TopolEJ .Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial. American Journal of Cardiology1999;84(6):728-30. [MEDLINE: 10498145]">RAPPORT 1998</a>; <a href="./references#CD008834-bbs2-0087" title="ReamsGP , YoungM , SorkinM , TwardowskiZ , GloorH , MooreH , et al.Effects of dipyridamole on peritoneal clearances. Uremia Investigation1985;9(1):27-33. [MEDLINE: 3915163]">Reams 1985</a>; <a href="./references#CD008834-bbs2-0088" title="CooperCJ , HallerST , ColyerW , SteffesM , BurketMW , ThomasWJ , et al.Embolic protection and platelet inhibition during renal artery stenting. Circulation2008;117(21):2752-60. [MEDLINE: 18490527]HeW , CheJ , ZhanD , DawsoT , KanjwaS , HalleS , et al.Time dependant changes in systolic blood pressure after renal artery stenting: role of stenosis severity [abstract no: 14283]. Circulation2012;126(21 Suppl 1). [EMBASE: 70958797]KanjwalK , CooperCJ , VirmaniR , HallerS , ShapiroJI , BurketMW , et al.Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy. Catheterization &amp; Cardiovascular Interventions2010;76(1):16-23. [MEDLINE: 20209644]KanjwalK , HallerS , SteffesM , VirmaniR , ShapiroJI , BurketMW , et al.Complete versus partial distal embolic protection during renal artery stenting. Catheterization &amp; Cardiovascular Interventions2009;73(6):725-30. [MEDLINE: 19198007]TianJ , HallerS , PeriyasamyS , BrewsterP , ZhangH , AdlakhaS , et al.Renal ischemia regulates marinobufagenin release in humans. Hypertension2010;56(5):914-9. [MEDLINE: 20823380]YuH , ZhangD , HallerS , KanjwalK , ColyerW , BrewsterP , et al.Determinants of renal function in patients with renal artery stenosis. Vascular Medicine2011;16(5):331-8. [MEDLINE: 21908683]">RESIST 2008</a>; <a href="./references#CD008834-bbs2-0090" title="RubinJ , AdairC , BarnesT , BowerJD .Augmentation of peritoneal clearance by dipyridamole. Kidney International1982;22(6):658-61. [MEDLINE: 6761488]">Rubin 1982</a>; <a href="./references#CD008834-bbs2-0091" title="SalterMC , CrowMJ , DonaldsonDR , RobertsTG , RajahSM , DavisonAM .Prevention of platelet deposition and thrombus formation on hemodialysis membranes: a double-blind randomized trial of aspirin and dipyridamole. Artificial Organs1984;8(1):57-61. [MEDLINE: 6703927]">Salter 1984</a>; <a href="./references#CD008834-bbs2-0094" title="SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract no: 9P]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):388. [CENTRAL: CN-00485981] SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study. Kidney International1994;45(5):1477-83. [MEDLINE: 8072261]">Sreedhara 1994</a>; <a href="./references#CD008834-bbs2-0096" title="MiletiM , De PetriG , BacchiM , OgliariV , PecchiniF , BufanoG , et al.A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients. Journal of Nephrology1995;8(2):167-72. [EMBASE: 25209311]">STOP 1995</a>; <a href="./references#CD008834-bbs2-0100" title="BergerPB , BestPJ , TopolEJ , WhiteJ , DiBattistePM , ChanAW , et al.The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal2005;149(5):869-75. [MEDLINE: 15894970]KalyanasundaramA , BlankenshipJC , BergerP , HerrmannH , McClureR , MoliternoD .Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?). Catheterization &amp; Cardiovascular Interventions2007;69(5):623-9. [MEDLINE: 17192960]MoliternoDJ , TopolEJ .A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. American Heart Journal2000;140(5):722-6. [MEDLINE: 11054616]MoliternoDJ , YakubovSJ , DiBattistePM , HerrmannHC , StoneGW , MacayaC , et al.Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet2002;360(9330):355-60. [MEDLINE: 12241774]MukherjeeD , TopolEJ , BertrandME , KristensenSD , HerrmannHC , NeumannFJ , et al.Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. European Heart Journal2005;26(23):2524-8. [MEDLINE: 16107485]RoffiM , MoliternoDJ , MeierB , PowersER , GrinesCL , DiBattistePM , et al.Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation2002;105(23):2730-6. [MEDLINE: 12057986]TopolEJ , MoliternoDJ , HerrmannHC , PowersER , GrinesCL , CohenDJ , et al.Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New England Journal of Medicine2001;344(25):1888-94. [MEDLINE: 11419425]">TARGET 2000</a>; <a href="./references#CD008834-bbs2-0101" title="TayebiP , KazemzadehG , BanihashemA , RavariH .Effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients: a randomized double-blind placebo-controlled trial. Electronic Physician [Electronic Resource]2018;10(1):6135-9. [MEDLINE: 29588811]">Tayebi 2018</a>; <a href="./references#CD008834-bbs2-0103" title="CorreaS , BonacaMP , SciricaBM , MurphySA , GoodrichEL , MorrowDA , et al.Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. Journal of Thrombosis &amp; Thrombolysis2019;47(3):353-60. [MEDLINE: 30511258]GaviriaSC , BraunwaldE , BonacaMP , MurphySA , GoodrichEL , MorrowDA , et al.The efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function: insights from the TRA 2P-TIMI 50 trial [abstract no: 15480]. Circulation2017;136(Suppl 1). [EMBASE: 619986693]MorrowDA , BraunwaldE , BonacaMP , AmerisoSF , DalbyAJ , FishMP , et al.Vorapaxar in the secondary prevention of atherothrombotic events. New England Journal of Medicine2012;366(15):1404-13. [MEDLINE: 22443427]MorrowDA , SciricaBM , FoxKA , BermanG , StronyJ , VeltriE , et al.Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. American Heart Journal2009;158(3):335-41. [MEDLINE: 19699854]">TRA 2P‐TIMI 50 2009</a>; <a href="./references#CD008834-bbs2-0104" title="CornelJH , TricociP , HortonJ , MoliternoD , WallentinL , ArmstrongP , et al.Effects of glycoprotein IIB/IIIA inhibitors in combination with vorapaxar, a platelet thrombin-receptor antagonist, among patients with non-St-segment elevation acute coronary syndromes: insights from the TRACER trial [abstract]. Journal of the American College of Cardiology2013;61(10 Suppl 1):E102. [EMBASE: 71019466]MahaffeyKW , PieperK , VranckxP , TricociP , Van de WerfF , HeldC , et al.Chronic kidney disease is associated with worse outcomes in ACS patients: results from the TRACER trial [abstract]. European Heart Journal2014;35(Suppl 1):687. [EMBASE: 71649310]">TRACER 2013</a>; <a href="./references#CD008834-bbs2-0105" title="AbaciA .The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses [Prasugrelin ST yukselmeli ve yukselmesiz miyokart enfarktusunde kullanimi: TRITON TIMI 38 caIismasi ve alt grup sonuclari]. Turk Kardiyoloji Dernegi Arsivi2015;43 Suppl 2:1-6. [MEDLINE: 27326444]AntmanEM , WiviottSD , MurphySA , VoitkJ , HasinY , WidimskyP , et al.Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Journal of the American College of Cardiology2008;51(21):2028-33. [MEDLINE: 18498956]BonacaMP , WiviottSD , BraunwaldE , MurphySA , RuffCT , AntmanEM , et al.American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation2012;125(4):577-83. [MEDLINE: 22199016]CapodannoD , TamburinoC .Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International Journal of Cardiology2011;146(2):242-3. [MEDLINE: 21130510]DammanP , deWinterRJ , WallentinL , FoxKA .Letter by Damman et al regarding articles, &quot;Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)&quot; and &quot;American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)&quot;. Circulation2012;126(9):e136-7. [MEDLINE: 22927480]De ServiS , GoedickeJ , SchirmerA , WidimskyP .Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European Heart Journal: Acute Cardiovascular Care2014;3(4):363-72. [MEDLINE: 24818952]GoodnoughLT , SmithPK , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. Journal of Thoracic &amp; Cardiovascular Surgery2013;145(4):1077-82. [MEDLINE: 22995726]HochholzerW , WiviottSD , AntmanEM , ContantCF , GuoJ , GiuglianoRP , et al.Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation2011;123(23):2681-9. [MEDLINE: 21606391]KohliP , UdellJA , MurphySA , CannonCP , AntmanEM , BraunwaldE , et al.Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Journal of the American College of Cardiology2014;63(3):225-32. [MEDLINE: 24140678]MahoneyEM , WangK , ArnoldSV , ProskorovskyI , WiviottS , AntmanE , et al.Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation2010;121(1):71-9. [MEDLINE: 20026770]MarianiM , MarianiG , De ServiS .Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert Review of Cardiovascular Therapy2009;7(1):17-23. [MEDLINE: 19105763]MegaJL , CloseSL , WiviottSD , ShenL , WalkerJR , SimonT , et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet2010;376(9749):1312-9. [MEDLINE: 20801494]MichelsonAD , Frelinger AL 3rd, BraunwaldE , DowneyWE , AngiolilloDJ , XenopoulosNP , et al.Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal2009;30(14):1753-63. [MEDLINE: 19435740]MogabgabO , WiviottSD , CannonCP , SloanS , SabatineMS , AntmanEM , et al.Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(6):555-9. [MEDLINE: 24064010]MontalescotG , WiviottSD , BraunwaldE , MurphySA , GibsonCM , McCabeCH , et al.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet2009;373(9665):723-31. [MEDLINE: 19249633]MurphySA , AntmanEM , WiviottSD , WeerakkodyG , MorocuttiG , HuberK , et al.Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European Heart Journal2008;29(20):2473-9. [MEDLINE: 18682445]O'DonoghueM , AntmanEM , BraunwaldE , MurphySA , StegPG , FinkelsteinA , et al.The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology2009;54(8):678-85. [MEDLINE: 19679245]OjeifoO , WiviottSD , AntmanEM , MurphySA , UdellJA , BatesER , et al.Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Jacc: Cardiovascular Interventions2013;6(2):1275-81. [MEDLINE: 24239201]PakhomovIM .Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial. Kardiologiia2010;50(6):63-7. [MEDLINE: 20659030]PrideYB , TungP , MohanaveluS , ZorkunC , WiviottSD , AntmanEM , et al.Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. Jacc: Cardiovascular Interventions2010;3(8):306-11. [MEDLINE: 20723851]RiesmeyerJS , SalazarDE , WeerakkodyGJ , NiL , WrishkoRE , Ernest CS 2nd, et al.Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. Journal of Clinical Pharmacology2012;52(6):789-97. [MEDLINE: 21628601]SerebruanyVL .Letter by Serebruany regarding article, &quot;Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38&quot;. Circulation2010;122(8):e436. [MEDLINE: 20733108]SmithPK , GoodnoughLT , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology2012;60(5):388-96. [MEDLINE: 22633653]SorichMJ , VitryA , WardMB , HorowitzJD , McKinnonRA .Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis &amp; Haemostasis2010;8(8):1678-84. [MEDLINE: 20492467]UdellJA , BraunwaldE , AntmanEM , MurphySA , MontalescotG , WiviottSD .Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).[Erratum in: JACC Cardiovasc Interv. 2014 Aug;7(8):946 Note: Antman, Elliot M [Corrected to Antman, Elliott M]]. Jacc: Cardiovascular Interventions2014;7(6):604-12. [MEDLINE: 24947719]WilcoxR , IqbalK , CostiganT , Lopez-SendonJ , RamosY , WidimskyP .An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current Medical Research &amp; Opinion2014;30(11):2193-205. [MEDLINE: 25025610]WiviottSD , AntmanEM , GibsonCM , MontalescotG , RiesmeyerJ , WeerakkodyG , et al.Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). American Heart Journal2006;152(4):627-35. [MEDLINE: 16996826]WiviottSD , BraunwaldE , McCabeCH , HorvathI , KeltaiM , HerrmanJP , et al.Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet2008;371(9621):1353-63. [MEDLINE: 18377975]WiviottSD , BraunwaldE , McCabeCH , MontalescotG , RuzylloW , GottliebS , et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2007;357(20):2001-15. [MEDLINE: 17982182]WiviottSD , DesaiN , MurphySA , MusumeciG , RagostaM , AntmanEM , et al.Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. American Journal of Cardiology2011;108(7):905-11. [MEDLINE: 21816379]WrishkoRE , Ernest CS 2nd, SmallDS , LiYG , WeerakkodyGJ , RiesmeyerJR , et al.Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. Journal of Clinical Pharmacology2009;49(8):984-98. [MEDLINE: 19546250]">TRITON‐TIMI 38 2006</a>; <a href="./references#CD008834-bbs2-0109" title="WeseleyS , GoodmanA .The effect of dipyridamole (Di) on the peritoneal dialysis (PD) clearance of creatinine and urea - a double-blind study [abstract]. Kidney International1982;21(1):182. ">Weseley 1982</a>). One study was judged to have unclear risk of bias (<a href="./references#CD008834-bbs2-0030" title="BaumgartnerI , NorgrenL , FowkesFG , MulderH , PatelMR , BergerJS , et al.Cardiovascular outcomes after lower extremity endovascular or surgical revascularization: the EUCLID trial. Journal of the American College of Cardiology2018;72(14):1563-72. [MEDLINE: 30261955]BergerJS , AbramsonBL , LopesRD , HeizerG , RockholdFW , BaumgartnerI , et al.Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Vascular Medicine2018;23(6):523-30. [MEDLINE: 29992857]HaineA , KavanaghS , BergerJS , HessCN , NorgrenL , FowkesFG , et al.Sex-specific risks of major cardiovascular and limb events in patients with symptomatic peripheral artery disease. Journal of the American College of Cardiology2020;75(6):608-17. [MEDLINE: 32057375]HessCN , HuangZ , PatelMR , BaumgartnerI , BergerJS , BlomsterJI , et al.Acute limb ischemia in peripheral artery disease. Circulation2019;140(7):556-65. [MEDLINE: 31238713]HiattWR , FowkesFG , HeizerG , BergerJS , BaumgartnerI , HeldP , et al.Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. New England Journal of Medicine2017;376(1):32-40. [MEDLINE: 27959717]HopleyCW , KavanaghS , PatelMR , OstromC , BaumgartnerI , BergerJS , et al.Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial. Vascular Medicine2019;24(5):422-30. [MEDLINE: 31339474]JonesWS , BaumgartnerI , HiattWR , HeizerG , ConteMS , WhiteCJ , et al.Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation2017;135(3):241-50. [MEDLINE: 27840336]KollsBJ , SappS , RockholdFW , JordanJD , DombrowskiKE , FowkesFG , et al.Stroke in patients with peripheral artery disease. Stroke2019;50(6):1356-63. [MEDLINE: 31092165]Low WangCC , BlomsterJI , HeizerG , BergerJS , BaumgartnerI , FowkesFG , et al.Cardiovascular and limb outcomes in patients with diabetes and peripheral artery disease: the EUCLID trial. Journal of the American College of Cardiology2018;72(25):3274-84. [MEDLINE: 30573030]NorgrenL , PatelMR , HiattWR , WojdylaDM , FowkesFG , BaumgartnerI , et al.Outcomes of patients with critical limb ischaemia in the EUCLID trial. European Journal of Vascular &amp; Endovascular Surgery2018;55(1):109-17. [MEDLINE: 29273390]OlivierCB , MulderH , HiattWR , JonesWS , FowkesFG , RockholdFW , et al.Incidence, characteristics, and outcomes of myocardial infarction in patients with peripheral artery disease: insights from the EUCLID trial. JAMA Cardiology2019;4(1):7-15. [MEDLINE: 30540355]">EUCLID 2017</a>) and 48 studies were not blinded and were considered at high risk of performance bias. </p> </section> <section id="CD008834-sec-0054"> <h5 class="title">Detection bias</h5> <p>Blinding of outcome assessment was judged to be at low risk of bias for 41 studies (<a href="./references#CD008834-bbs2-0001" title="GoicoecheaM , deVinuesaMS , QuirogaB , VerdallesU , MoralesE , De SequeraP , et al.Aspirin treatment in primary cardiovascular prevention and renal disease progression in CKD patients: a randomized clinical trials (AASER study) [abstract no: FR-PO1065]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):B5. [EMBASE: 633704620]GoicoecheaM , deVinuesaSG , QuirogaB , VerdeE , BernisC , MoralesE , et al.Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study). Cardiovascular Drugs &amp; Therapy2018;32(3):255-63. [MEDLINE: 29943364]GoicoecheaM , Sanchez-NinoMD , OrtizA , deVinuesaMS , QuirogaB , MoralesE , et al.Low dose aspirin increases 15-epi-lipoxin a4 levels in CKD patients [abstract no: SA-PO186]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):726. [EMBASE: 633701100]GoicoecheaM , Sanchez-NinoMD , OrtizA , Garcia de VinuesaS , QuirogaB , BernisC , et al.Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. Prostaglandins Leukotrienes &amp; Essential Fatty Acids2017;125:8-13. [MEDLINE: 28987723]">AASER 2017</a>; <a href="./references#CD008834-bbs2-0007" title="Di FrancoA , GaudinoM , GirardiLN .Considerations about the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. Journal of Thoracic Disease2016;8(7):E599. [MEDLINE: 27501533]MylesPS , SmithJ , KnightJ , CooperDJ , SilbertB , McNeilJ , et al.Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial: rationale and design. American Heart Journal2008;155(2):224-30. [MEDLINE: 18215590]MylesPS , SmithJA , ForbesA , SilbertB , JayarajahM , PainterT , et al.Stopping vs. continuing aspirin before coronary artery surgery. New England Journal of Medicine2016;374(8):728-37. [MEDLINE: 26933848]MylesPS , SmithJA , ForbesA , SilbertB , JayarajahM , PainterT , et al.Tranexamic acid in patients undergoing coronary-artery surgery [Erratum for: N Engl J Med. 2017 Jan 12;376(2):136-148; PMID: 27774838]. New England Journal of Medicine2017;376(2):136-48. [MEDLINE: 27774838]MylesPS , SmithJA , KaszaJ , SilbertB , JayarajahM , PainterT , et al.Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial. Journal of Thoracic &amp; Cardiovascular Surgery2019;157(2):633-40. [MEDLINE: 30401528]MylesPS , SmithJA , KaszaJ , SilbertB , JayarajahM , PainterT , et al.Tranexamic acid in coronary artery surgery: one-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. Journal of Thoracic &amp; Cardiovascular Surgery2019;157(2):644-52.e9. [MEDLINE: 30459103]">ATACAS 2008</a>; <a href="./references#CD008834-bbs2-0008" title="FujitaT , YuX , KimS , NakamotoH , OrigasaH , KurumataniH , et al.Effects of sustained-release beraprost sodium in patients with primary glomerular disease or nephrosclerosis: the CASSIOPEIR study [abstract no: SA-PO1096]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):4B. [CENTRAL: CN-01657821] NakamotoH , FujitaT , OrigasaH , IsonoM , KurumataniH , OkadaK , et al.A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrology2014;15:153. [MEDLINE: 25233856]NakamotoH , YuXQ , KimS , OrigasaH , ZhengH , ChenJ , et al.Effects of sustained-release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results. Therapeutic Apheresis &amp; Dialysis2020;24(1):42-55. [MEDLINE: 31119846]">CASSIOPEIR 2014</a>; <a href="./references#CD008834-bbs2-0009" title="ChanMK , KwanSY , ChanKW , YeungCK .Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis. American Journal of Kidney Diseases1987;9(5):417-21. [MEDLINE: 3555016]">Chan 1987</a>; <a href="./references#CD008834-bbs2-0010" title="JingJ , MengX , ZhaoX , LiuL , WangA , PanY , et al.Dual antiplatelet therapy in transient ischemic attack and minor stroke with different infarction patterns: subgroup analysis of the CHANCE randomized clinical trial. JAMA Neurology2018;75(6):711-9. [MEDLINE: 29582084]LiJ , WangY , LinJ , WangD , WangA , ZhaoX , et al.Soluble CD40L is a useful marker to predict future strokes in patients with minor stroke and transient ischemic attack. Stroke2015;46(7):1990-2. [MEDLINE: 26012640]LiJ , ZhaoX , MengX , LinJ , LiuL , WangC , et al.High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome: subanalysis of the clopidogrel in high-risk patients with acute nondisabling cerebrovascular events trial. Stroke2016;47(8):2025-30. [MEDLINE: 27328699]LinY , WangA , LiJ , LinJ , WangD , MengX , et al.Impact of glycemic control on efficacy of clopidogrel in transient ischemic attack or minor stroke patients with CYP2C19 genetic variants. Stroke2017;48(4):998-1004. [MEDLINE: 28289237]LiuL , WongKS , LengX , PuY , WangY , JingJ , et al.Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology2015;85(13):1154-62. [MEDLINE: 26330567]LiZ , WangY , ZhaoX , LiuL , WangD , WangC , et al.Treatment effect of clopidogrel plus aspirin within 12 hours of acute minor stroke or transient ischemic attack. Journal of the American Heart Association2016;5(3):e003038. [MEDLINE: 27001965]MaY , LiuY , XuJ , WangY , WangY , DuF .Effect of dual antiplatelet on recurrent stroke in minor stroke or TIA depends on bodyweight. Therapeutics &amp; Clinical Risk Management2018;14:861-70. [MEDLINE: 29773949]PanY , CaiX , JingJ , MengX , LiH , WangY , et al.Stress hyperglycemia and prognosis of minor ischemic stroke and transient ischemic attack: the CHANCE study (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). Stroke2017;48(11):3006-11. [MEDLINE: 29051218]PanY , JingJ , ChenW , MengX , LiH , ZhaoX , et al.Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE.[Erratum in: Neurology. 2019 Aug 13;93(7):322; PMID: 31405943]. Neurology2017;88(20):1906-11. [MEDLINE: 28424269]PanY , JingJ , LiH , WangY , WangY , HeY , et al.Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA. Neurology2016;87(15):1551-6. [MEDLINE: 27613582]PanY , MengX , JingJ , LiH , ZhaoX , LiuL , et al.Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA. Neurology2017;88(11):1081-8. [MEDLINE: 28202699]WangA , LiS , ZhangN , DaiL , ZuoY , WangY , et al.Oxidized low-density lipoprotein to high-density lipoprotein ratio predicts recurrent stroke in minor stroke or transient ischemic attack. Stroke2018;49(11):2637-42. [MEDLINE: 30355199]WangA , XuJ , ChenG , WangD , JohnstonSC , MengX , et al.Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA. Neurology2018;91(10):e947-55. [MEDLINE: 30089614]WangD , GuiL , DongY , LiH , LiS , ZhengH , et al.Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial. Stroke &amp; Vascular Neurology2016;1(2):29-36. [MEDLINE: 28959461]WangqinR , WangX , WangY , XianY , ZhaoX , LiuL , et al.Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA: a subgroup analysis of the CHANCE trial. Stroke &amp; Vascular Neurology2017;2(4):176-83. [MEDLINE: 29507777]WangY , PanY , ZhaoX , LiH , WangD , JohnstonSC , et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial: one-year outcomes. Circulation2015;132(1):40-6. [MEDLINE: 25957224]WangY , WangY , ZhaoX , LiuL , WangD , WangC , et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine2013;369(1):11-9. [MEDLINE: 23803136]WangY , ZhaoX , LinJ , LiH , JohnstonSC , LinY , et al.Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA2016;316(1):70-8. [MEDLINE: 27348249]WuY , ZhouY , PanY , ZhaoX , LiuL , WangD , et al.Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. Pharmacogenomics Journal2018;18(6):713-20. [MEDLINE: 29520080]ZhouY , PanY , WuY , ZhaoX , LiH , WangD , et al.Effect of estimated glomerular filtration rate decline on the efficacy and safety of clopidogrel with aspirin in minor stroke or transient ischemic attack: CHANCE substudy (Clopidogrel in high-risk patients with acute nondisabling cerebrovascular events). Stroke2016;47(11):2791-6. [MEDLINE: 27738237]ZhuB , LiuH , PanY , JingJ , LiH , ZhaoX , et al.Elevated neutrophil and presence of intracranial artery stenosis increase the risk of recurrent stroke. Stroke2018;49(10):2294-300. [MEDLINE: 30355101]">CHANCE 2013</a>; <a href="./references#CD008834-bbs2-0012" title="ChengIK , FangGX , WongMC , JiYL , ChanKW , YeungHW .A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy. Nephrology1998;4(1-2):19-26. [EMBASE: 28282953]ChengIK , FangGX , WongMC , JiYL , YeungH .A randomised prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA glomerulonephritis (IgAN) [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:45. [CENTRAL: CN-00550664] ">Cheng 1998a</a>; <a href="./references#CD008834-bbs2-0013" title="ChristopherTG , SamelsK .A study of aspirin and dipyridamole in slowing the progression of diabetic glomerulosclerosis [abstract]. Kidney International1987;31(1):194. ChristopherTG , SamelsK .A study of the treatment effect of aspirin and dipyridamole in diabetic glomerulosclerosis [abstract]. In: 10th International Congress of Nephrology; 1987 Jul 26-31; London, UK. 1987:56. ">Christopher 1987</a>; <a href="./references#CD008834-bbs2-0014" title="LeeMH , SuhJW , LeeSP , ParkKW , LeeHY , KangHJ , et al.The effect of cilostazol on the antiplatelet efficacy of patients with moderate renal dysfunction: post-hoc analysis of CILON-T (Influence of cilostazol based triple antiplatelet therapy on ischemic complication after drug eluting stent implantation) trial [abstract no: TCT-495]. Journal of the American College of Cardiology2011;58(20 Suppl 1):B134-5. [EMBASE: 70581865]LeeSP , SuhJW , ParkKW , LeeHY , KangHJ , KooBK , et al.Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: a multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease. Trials [Electronic Resource]2010;11:87. [MEDLINE: 20735821]SuhJW , LeeSP , ParkKW , LeeHY , KangHJ , KooBK , et al.Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. Journal of the American College of Cardiology2011;57(3):280-9. [MEDLINE: 21232664]">CILON‐T 2010</a>; <a href="./references#CD008834-bbs2-0017" title="BergerPB , SteinhublS .Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. Circulation2002;106(17):2284-7. [MEDLINE: 12390961]GerschutzGP , BhattDL , Clopidogrel in Unstable Angina to Prevent Recurrent Events study.The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?American Heart Journal2003;145(4):595-601. [MEDLINE: 12679754]KeltaiM , TonelliM , MannJF , SitkeiE , LewisBS , HawkenS , et al.Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. European Journal of Cardiovascular Prevention &amp; Rehabilitation2007;14(2):312-8. [MEDLINE: 17446813]LewisBS , MehtaSR , FoxKA , HalonDA , ZhaoF , PetersRJ , et al.Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. American Heart Journal2005;150(6):1177-84. [MEDLINE: 16338255]MehtaSR , YusufS , PetersRJ , BertrandME , LewisBS , NatarajanMK , et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet2001;358(9281):527-33. [MEDLINE: 11520521]MehtaSR , YusufS , Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators.The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. European Heart Journal2000;21(24):2033-41. [MEDLINE: 11102254]PetersRJ , MehtaSR , FoxKA , ZhaoF , LewisBS , KopeckySL , et al.Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation2003;108(14):1682-7. [MEDLINE: 14504182]YusufS ,  ZhaoF ,  MehtaSR ,  ChrolaviciusS ,  TognoniG ,  FoxKK , et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [Erratum in: N Engl J Med 2001 Dec 6;345(23):1716; Erratum in: N Engl J Med 2001 Nov 15;345(20):1506]. New England Journal of Medicine2001;345(7):494-502. [MEDLINE: 11519503]">CURE 2000</a>; <a href="./references#CD008834-bbs2-0018" title="DashA , MaitiR , BandakkanavarTK , BhaskarA , PrakashJ , PandeyBL .Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: comparison between clopidogrel and low-dose aspirin. International Journal of Preventive Medicine2013;4(8):902-10. [MEDLINE: 24049616]">Dash 2013</a>; <a href="./references#CD008834-bbs2-0026" title="AguirreFV , TopolEJ , AndersonKM , KleimanNS , WeismanHF , FitzPatrickSE , et al.Benefit within patient subgroups receiving c7e3 fab (abciximab) during percutaneous coronary revascularization: subgroup analysis from the EPIC trial. Journal of Invasive Cardiology1996;8 Suppl B:21-9B. [MEDLINE: 10785766]AguirreFV , TopolEJ , FergusonJJ , AndersonK , BlankenshipJC , HeuserRR , et al.Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation1995;91(12):2882-90. [MEDLINE: 7796496]BerkowitzSD , SaneDC , SigmonKN , ShavenderJH , HarringtonRA , TchengJE , et al.Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. Journal of the American College of Cardiology1998;32(2):311-9. [MEDLINE: 9708455]BlankenshipJC , HellkampAS , AguirreFV , DemkoSL , TopolEJ , CaliffRM .Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. American Journal of Cardiology1998;81(1):36-40. [MEDLINE: 9462603]BoehrerJD , KereiakesDJ , NavettaFI , CaliffRM , TopolEJ .Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications. American Journal of Cardiology1994;74(11):1166-70. [MEDLINE: 7977081]CaliffRM , LincoffAM , TchengJE , TopolEJ .An overview of the results of the EPIC trial. European Heart Journal1995;16 Suppl L:43-9. [MEDLINE: 8869018]EPIC Investigators.Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New England Journal of Medicine1994;330(14):956-61. [MEDLINE: 8121459]KhanMM , EllisSG , AguirreFV , WeismanHF , WildermannNM , CaliffRM , et al.Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1998;31(1):31-6. [MEDLINE: 9426014]LefkovitsJ , BlankenshipJC , AndersonKM , StonerGL , TalleyJD , WorleySJ , et al.Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. Journal of the American College of Cardiology1996;28(4):849-55. [MEDLINE: 8837559]LefkovitsJ , IvanhoeRJ , CaliffRM , BergelsonBA , AndersonKM , StonerGL , et al.Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. American Journal of Cardiology1996;77(12):1045-51. [MEDLINE: 8644655]LincoffAM , CaliffRM , AndersonKM , WeismanHF , AguirreFV , KleimanNS , et al.Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1997;30(1):149-56. [MEDLINE: 9207636]MakKH , ChallapalliR , EisenbergMJ , AndersonKM , CaliffRM , TopolEJ .Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. American Journal of Cardiology1997;80(8):985-8. [MEDLINE: 9352964]MarkDB , TalleyJD , TopolEJ , BowmanL , LamLC , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation1996;94(4):629-35. [MEDLINE: 8772681]MoliternoDJ , CaliffRM , AguirreFV , AndersonK , SigmonKN , WeismanHF , et al.Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. American Journal of Cardiology1995;75(8):559-62. [MEDLINE: 7887377]NarinsCR , MillerDP , CaliffRM , TopolEJ .The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1999;33(3):647-53. [MEDLINE: 10080464]ThelMC , CaliffRM , TchengJE , SigmonKN , LincoffAM , TopolEJ , et al.Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. American Heart Journal1999;137(2):264-73. [MEDLINE: 9924160]TopolEJ , CaliffRM , WeismanHF , EllisSG , TchengJE , WorleyS , et al.Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet1994;343(8902):881-6. [MEDLINE: 7908357]TopolEJ , FergusonJJ , WeismanHF , TchengJE , EllisSG , KleimanNS , et al.Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA1997;278(6):479-84. [MEDLINE: 9256222]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. American Heart Journal1998;135(4):S98-106. [MEDLINE: 9539500]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. European Heart Journal1998;19 Suppl D:D59-66. [MEDLINE: 9597523]">EPIC 1994</a>; <a href="./references#CD008834-bbs2-0027" title="EPILOG Investigators.Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New England Journal of Medicine1997;336(24):1689-96. [MEDLINE: 9182212]GhaffariS , KereiakesDJ , LincoffAM , KellyTA , TimmisGC , KleimanNS , et al.Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. American Journal of Cardiology1998;82(1):7-12. [MEDLINE: 9671000]KereiakesDJ , LincoffAM , MillerDP , TchengJE , CabotCF , AndersonKM , et al.Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Circulation1998;97(9):857-64. [MEDLINE: 9521334]KleimanNS , LincoffAM , KereiakesDJ , MillerDP , AguirreFV , AndersonKM , et al.Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation1998;97(19):1912-20. [MEDLINE: 9609084]LincoffAM , MarkDB , TchengJE , CaliffRM , BalaMV , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation2000;102(24):2923-9. [MEDLINE: 11113041]LincoffAM , TchengJE , CaliffRM , KereiakesDJ , KellyTA , TimmisGC , et al.Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. One-year outcome in the EPILOG trial. Circulation1999;99(15):1951-8. [MEDLINE: 10208997]">EPILOG 1997</a>; <a href="./references#CD008834-bbs2-0028" title="ChoL , MarsoSP , BhattDL , TopolEJ .Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial. Journal of Womens Health &amp; Gender-Based Medicine2000;9(7):741-6. [MEDLINE: 11025866]De ServiS .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse events. Data from the Evaluation of Platelets IIb/IIIa Inhibitor for Stenting (EPISTENT) trial [Il pretrattamento con ticlopidina nello stent coronarico e associato a significativa riduzione di eventi avversi. Dati dal trial EPISTENT]. Italian Heart Journal Supplement2001;2(7):805-6. [MEDLINE: 11508303]EPISTENT Investigators.Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet1998;352(9122):87-92. [MEDLINE: 9672272]IslamMA , BlankenshipJC , BalogC , IliadisEA , LincoffAM , TchengJE , et al.Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). American Journal of Cardiology2002;90(9):916-21. [MEDLINE: 12398954]LincoffAM .Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial. American Heart Journal2000;139(2 Pt 2):S46-52. [MEDLINE: 10650316]MarsoSP , LincoffAM , EllisSG , BhattDL , TanguayJF , KleimanNS , et al.Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation1999;100(25):2477-84. [MEDLINE: 10604884]SteinhublSR , EllisSG , WolskiK , LincoffAM , TopolEJ .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation2001;103(10):1403-9. [MEDLINE: 11245644]SteinhublSR , TanWA , FoodyJM , TopolEJ .Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA1999;281(9):806-10. [MEDLINE: 10071001]TopolEJ , MarkDB , LincoffAM , CohenE , BurtonJ , KleimanN , et al.Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.[Erratum in: Lancet 2000 Mar 25;355(9209):1104]. Lancet1999;354(9195):2019-24. [MEDLINE: 10636365]Zwart-van RijkomJE , vanHoutBA .Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb/IIIa Inhibitor For Stenting Trial. European Heart Journal2001;22(16):1476-84. [MEDLINE: 11482921]">EPISTENT 1998</a>; <a href="./references#CD008834-bbs2-0029" title="Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA1992;268(10):1292-300. [MEDLINE: 1507375]">ETDRS 1992</a>; <a href="./references#CD008834-bbs2-0030" title="BaumgartnerI , NorgrenL , FowkesFG , MulderH , PatelMR , BergerJS , et al.Cardiovascular outcomes after lower extremity endovascular or surgical revascularization: the EUCLID trial. Journal of the American College of Cardiology2018;72(14):1563-72. [MEDLINE: 30261955]BergerJS , AbramsonBL , LopesRD , HeizerG , RockholdFW , BaumgartnerI , et al.Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Vascular Medicine2018;23(6):523-30. [MEDLINE: 29992857]HaineA , KavanaghS , BergerJS , HessCN , NorgrenL , FowkesFG , et al.Sex-specific risks of major cardiovascular and limb events in patients with symptomatic peripheral artery disease. Journal of the American College of Cardiology2020;75(6):608-17. [MEDLINE: 32057375]HessCN , HuangZ , PatelMR , BaumgartnerI , BergerJS , BlomsterJI , et al.Acute limb ischemia in peripheral artery disease. Circulation2019;140(7):556-65. [MEDLINE: 31238713]HiattWR , FowkesFG , HeizerG , BergerJS , BaumgartnerI , HeldP , et al.Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. New England Journal of Medicine2017;376(1):32-40. [MEDLINE: 27959717]HopleyCW , KavanaghS , PatelMR , OstromC , BaumgartnerI , BergerJS , et al.Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial. Vascular Medicine2019;24(5):422-30. [MEDLINE: 31339474]JonesWS , BaumgartnerI , HiattWR , HeizerG , ConteMS , WhiteCJ , et al.Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation2017;135(3):241-50. [MEDLINE: 27840336]KollsBJ , SappS , RockholdFW , JordanJD , DombrowskiKE , FowkesFG , et al.Stroke in patients with peripheral artery disease. Stroke2019;50(6):1356-63. [MEDLINE: 31092165]Low WangCC , BlomsterJI , HeizerG , BergerJS , BaumgartnerI , FowkesFG , et al.Cardiovascular and limb outcomes in patients with diabetes and peripheral artery disease: the EUCLID trial. Journal of the American College of Cardiology2018;72(25):3274-84. [MEDLINE: 30573030]NorgrenL , PatelMR , HiattWR , WojdylaDM , FowkesFG , BaumgartnerI , et al.Outcomes of patients with critical limb ischaemia in the EUCLID trial. European Journal of Vascular &amp; Endovascular Surgery2018;55(1):109-17. [MEDLINE: 29273390]OlivierCB , MulderH , HiattWR , JonesWS , FowkesFG , RockholdFW , et al.Incidence, characteristics, and outcomes of myocardial infarction in patients with peripheral artery disease: insights from the EUCLID trial. JAMA Cardiology2019;4(1):7-15. [MEDLINE: 30540355]">EUCLID 2017</a>; <a href="./references#CD008834-bbs2-0048" title="HanssonL , ZanchettiA , CarruthersSG , DahlöfB , ElmfeldtD , JuliusS , et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998;351(9118):1755-62. [MEDLINE: 9635947]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Pressure1997;6(5):313-7. [MEDLINE: 9360003]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Pressure1994;3(5):322-7. [MEDLINE: 7866597]HanssonL .The Hypertension Optimal Treatment study and the importance of lowering blood pressure. Journal of Hypertension - Supplement1999;17(1):S9-13. [MEDLINE: 10340838]JardineM , NinomiyaT , CassA , TurnbullF , GallagherM , ZoungasS , et al.Aspirin benefit increases as eGFR declines: results from a randomised controlled trial in a hypertensive population [abstract no: 086]. Nephrology2010;15(Suppl 4):49. [EMBASE: 70467090]JardineMJ , NinomiyaT , PerkovicV , CassA , TurnbullF , GallagherMP , et al.Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology2010;56(12):956-65. [MEDLINE: 20828648]JonesDW , MillerME , WoffordMR , Anderson DC Jr, CameronME , WilloughbyDL , et al.The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. American Journal of Hypertension1999;12(12 Pt 1-2):1175-80. [MEDLINE: 10619579]JonssonB , HanssonL , StalhammarNO .Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Journal of Internal Medicine2003;253(4):472-80. [MEDLINE: 12653877]KjeldsenSE , HednerT , JamersonK , JuliusS , HaleyWE , ZabalgoitiaM , et al.Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects. Hypertension1998;31(4):1014-20. [MEDLINE: 9535429]KjeldsenSE , KollochRE , LeonettiG , MallionJM , ZanchettiA , ElmfeldtD , et al.Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. Journal of Hypertension2000;18(5):629-42. [MEDLINE: 10826567]KollochRE , RahnKH .The Hypertension Optimal Treatment (HOT) study: results of 12-month treatment related to age [Die 'Hyperyension Optimal Treatment' (HOT)-Studie: Behandlungsergebnisse nach Zwolfmonatiger Therapie in Abhangigkeit vom Alter]. Deutsche Medizinische Wochenschrift1998;123(1-2):1-5. [MEDLINE: 9465848]LeonettiG , ZanchettiA .Principal results of hypertension optimal treatment (HOT) study and their clinical impact. HOT cooperative group. Clinical Hemorheology &amp; Microcirculation1999;21(3-4):217-24. [MEDLINE: 10711746]LithellH , BerglundL .Validation of an oscillometric blood pressure measuring device: a substudy of the HOT Study. Hypertension Optimal Treatment. Blood Pressure1998;7(3):149-52. [MEDLINE: 9758084]ManciaG , OmboniS , ParatiG , ClementDL , HaleyWE , RahmanSN , et al.Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(10):1755-63. [MEDLINE: 11593094]RuilopeLM , SalvettiA , JamersonK , HanssonL , WarnoldI , WedelH , et al.Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology2001;12(2):218-25. [MEDLINE: 11158211]Struijker-BoudierH , SafarM , vanBortelL .Effects of individual risk factors on the incidence of cardiovascular event in the treated hypertensive patients of the Hypertension Optimal Treatment Study. Journal of Hypertension2001;19(11):2105-6. [MEDLINE: 11677378]The Hypertension Optimal Treatment Study (the HOT Study). Blood Pressure1993;2(1):62-8. [MEDLINE: 8193735]WaeberB , LeonettiG , KollochR , McInnesGT .Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension1999;17(7):1041-5. [MEDLINE: 10419079]ZanchettiA , HanssonL , DahlofB , ElmfeldtD , KjeldsenS , KollochR , et al.Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. Journal of Hypertension2001;19(6):1149-59. [MEDLINE: 11403365]ZanchettiA , HanssonL , MenardJ , LeonettiG , RahnKH , WarnoldI , et al.Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(4):819-25. [MEDLINE: 11330886]">HOT 1993</a>; <a href="./references#CD008834-bbs2-0049" title="BlankenshipJC , SigmonKN , PieperKS , O'SheaC , TardiffBE , TchengJE , et al.Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial. American Journal of Cardiology2001;88(9):969-73. [MEDLINE: 11703991]GilchristIC , GardnerLH , MuhlesteinJB , ArnoldAM , LincoffAM , CaliffRM , et al.Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience. American Heart Journal1999;138(5 Pt 1):976-82. [MEDLINE: 10539832]MandakJS , BlankenshipJC , GardnerLH , BerkowitzSD , AguirreFV , SigmonKN , et al.Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Journal of the American College of Cardiology1998;31(7):1518-24. [MEDLINE: 9626829]Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet1997;349(9063):1422-8. [MEDLINE: 9164315]TardiffBE , CaliffRM , TchengJE , LincoffAM , SigmonKN , HarringtonRA , et al.Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. Journal of the American College of Cardiology1999;33(1):88-96. [MEDLINE: 9935014]ThelMC , CaliffRM , TardiffBE , GardnerLH , SigmonKN , LincoffAM , et al.Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. American Journal of Cardiology2000;85(4):427-34. [MEDLINE: 10728945]">IMPACT II 1997</a>; <a href="./references#CD008834-bbs2-0050" title="JiaoXM , JiaoXJ , ZhangXG , XuXP , WuJX , YaoL , et al.Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy. Chinese Medical Journal2013;126(22):4395-6. [MEDLINE: 24238537]">Jiao 2013</a>; <a href="./references#CD008834-bbs2-0051" title="OgawaH , NakayamaM , MorimotoT , UemuraS , KanauchiM , DoiN , et al.Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.[Erratum in: JAMA. 2009 May 13;301(18):1882], [Erratum in: JAMA. 2012 Nov 14;308(18):1861]. JAMA2008;300(18):2134-41. [MEDLINE: 18997198]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , NakayamaM , et al.Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk. Circulation Journal2013;77(12):3023-8. [MEDLINE: 24042256]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , NakayamaM , et al.Is long-term low-dose aspirin therapy associated with renal dysfunction in patients with type 2 diabetes? JPAD2 cohort study. PLoS ONE [Electronic Resource]2016;11(1):e0147635. [MEDLINE: 26808136]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , OhtoriiM , et al.Long-term use of low-dose aspirin develops proteinuria in patients with diabetes: A reanalysis of JPAD study [abstract no: 10863]. Circulation2013;128(22 Suppl 1). [EMBASE: 71337722]SaitoY , MorimotoT , OgawaH , NakayamaM , UemuraS , DoiN , et al.Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care2011;34(2):280-5. [MEDLINE: 21270185]">JPAD 2008</a>; <a href="./references#CD008834-bbs2-0059" title="KontessisPS , JonesSL , BarrowSE , StrattonPD , AlessandriniP , De CosmoS , et al.Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy. Journal of Laboratory &amp; Clinical Medicine1993;121(3):415-23. [MEDLINE: 8445289]">Kontessis 1993</a>; <a href="./references#CD008834-bbs2-0061" title="KoyamaA , NaritaM , TojoS .Therapeutic effects of dipyridamole on primary glomerulonephritis [abstract]. In: 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan. 1990:12. [CENTRAL: CN-00446186] ">Koyama 1990</a>; <a href="./references#CD008834-bbs2-0066" title="MovchanEA , ChuprovaAV , TovNL , Vol'vichNV .Desaggregation therapy of acute glomerulonephritis [Dezagregatsionnaia terapiia ostrogo glomerulonefrita]. Klinicheskaia Meditsina2001;79(12):44-7. [MEDLINE: 11840813]">Movchan 2001</a>; <a href="./references#CD008834-bbs2-0069" title="NakamuraT , UshiyamaC , TakahashiY , TanakaA , ShimadaN , EbiharaI , et al.Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease. Nephron2001;88(1):80-2. [MEDLINE: 11340355]">Nakamura 2001d</a>; <a href="./references#CD008834-bbs2-0070" title="NakamuraT , UshiyamaC , OsadaS , UgaiK , TakahashiY , TanakaA , et al.Effect of dilazep dihydrochloride on serum cardiac troponin T levels in hemodialysis patients. Kidney &amp; Blood Pressure Research2002;25(1):50-4. [MEDLINE: 11834877]">Nakamura 2002b</a>; <a href="./references#CD008834-bbs2-0073" title="OgawaS , MoriT , NakoK , IshizukaT , ItoS .Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):362-8. [MEDLINE: 18235151]">Ogawa 2008</a>; <a href="./references#CD008834-bbs2-0076" title="BonacaMP , BhattDL , BraunwaldE , CohenM , StegPG , StoreyRF , et al.Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal2014;167(4):437-44. [MEDLINE: 24655690]BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , JensenEC , et al.Long-term use of ticagrelor in patients with prior myocardial infarction. New England Journal of Medicine2015;372(19):1791-800. [MEDLINE: 25773268]BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , CohenM , et al.Prevention of stroke with ticagrelor in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation2016;134(12):861-71. [MEDLINE: 27576775]DellborgM , BonacaMP , StoreyRF , StegPG , ImKA , CohenM , et al.Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: Insights from PEGASUS-TIMI 54 [abstract]. European Heart Journal2017;38(Suppl 1):794-5. [EMBASE: 621235545]LozanoI , RondanJ , VegasJM , SegoviaE .Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):107-8. [MEDLINE: 29301622]MagnaniG , SabatineMS , BhattDL , ChoenM , StegG , StoreyR , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: Insights from the PEGASUS-TIMI 54 trial [abstract]. European Heart Journal2015;36(Suppl 1):520. [EMBASE: 72020712]MagnaniG , StoreyRF , StegG , BhattDL , CohenM , KuderJ , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. European Heart Journal2016;37(4):400-8. [MEDLINE: 26443023]MagnusonEA , BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , et al.Reply: cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):108. [MEDLINE: 29301623]MagnusonEA , LiH , WangK , VilainK , ShafiqA , BonacaMP , et al.Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: results from the PEGASUS-TIMI 54 trial. Journal of the American College of Cardiology2017;70(5):527-38. [MEDLINE: 28750695]MurphySA , BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , et al.Reduction in total cardiovascular events with long-term use of ticagrelor in patients with prior myocardial infarction in the PEGASUS-TIMI 54 trial [abstract no: A17121]. Circulation2015;132(Suppl 3). [EMBASE: 72179983]">PEGASUS‐TIMI 54 2014</a>; <a href="./references#CD008834-bbs2-0077" title="KimW , KangWY , WooJS .Objectives: The purpose of this study was to determine the functional impact of cilostazol in patients with chronic kidney disease (CKD) undergoing hemodialysis [abstract no: TCT-497]. Journal of the American College of Cardiology2011;58(20 Suppl 1):B135. [EMBASE: 70581866]WooJS , KimW , HaSJ , JeongKH , LeeTW , IhmCG , et al.A comparison of clopidogrel responsiveness in patients with chronic renal failure: results of the adjunctive cilostazol versus high maintenance dose clopidogrel (PIANO) study [abstract no: AS-252]. American Journal of Cardiology2011;107(8 Suppl 1):100-1A. [EMBASE: 70401953]WooJS , KimW , LeeSR , JungKH , KimWS , LewJH , et al.Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. American Heart Journal2011;162(6):1018-25. [MEDLINE: 22137075]">PIANO‐2 CKD 2011</a>; <a href="./references#CD008834-bbs2-0082" title="Navarro-GonzalezJF , Sanchez-NinoMD , Donate-CorreaJ , Martin-NunezE , FerriC , Perez-DelgadoN , et al.Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease. Diabetes Care2018;41(8):1817-20. [MEDLINE: 29866645]">PREDIAN 2011</a>; <a href="./references#CD008834-bbs2-0083" title="HuynhT , NasmithJ , LuongTM , BernierM , PharandC , Xue-QiaoZ , et al.Complementary prognostic values of ST segment deviation and Thrombolysis In Myocardial Infarction (TIMI) risk score in non-ST elevation acute coronary syndromes: insights from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Canadian Journal of Cardiology 2009 Dec;25(12):e417-21. [MEDLINE: 19960136]HuynhT , PiazzaN , DiBattistePM , SnapinnSM , WanY , PharandC , et al.Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study. International Journal of Cardiology2005;100(1):73-8. [MEDLINE: 15820288]HuynhT , TherouxP , SnapinnS , WanY , PRISM-PLUS Investigators.Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). American Heart Journal2003;146(4):668-73. [MEDLINE: 14564321]Januzzi JL Jr, SnapinnSM , DiBattistePM , JangIK , TherouxP .Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation2002;105(20):2361-6. [MEDLINE: 12021221]MegaJL , MorrowDA , SabatineMS , ZhaoXQ , SnapinnSM , DiBattistePM , et al.Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. American Heart Journal2005;149(5):846-50. [MEDLINE: 15894966]MorrowDA , SabatineMS , AntmanEM , CannonCP , BraunwaldE , TherouxP .Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). American Journal of Cardiology2004;94(6):774-6. [MEDLINE: 15374786]Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New England Journal of Medicine1998;338(21):1488-97. [MEDLINE: 9599103]ServossSJ , WanY , SnapinnSM , DiBattistePM , ZhaoXQ , TherouxP , et al.Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. American Journal of Cardiology2004;93(7):843-7. [MEDLINE: 15050486]SzucsTD , MeyerBJ , KiowskiW .Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial. European Heart Journal1999;20(17):1253-60. [MEDLINE: 10454977]TherouxP , AlexanderJ , PharandC , BarrE , SnapinnS , GhannamAF , et al.Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation2000;102(20):2466-72. [MEDLINE: 11076818]TherouxP , Alexander J Jr, DupuisJ , PesantY , GervaisP , GrandmontD , et al.Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators. American Journal of Cardiology2001;87(4):375-80. [MEDLINE: 11179517]ZhaoXQ , TherouxP , SnapinnSM , SaxFL .Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Circulation1999;100(15):1609-15. [MEDLINE: 10517731]">PRISM‐PLUS 1998</a>; <a href="./references#CD008834-bbs2-0084" title="AkkerhuisKM , DeckersJW , BoersmaE , HarringtonRA , StepinskaJ , MahaffeyKW , et al.Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. European Heart Journal2000;21(5):371-81. [MEDLINE: 10666351]AkkerhuisKM , MaasAC , KlootwijkPA , KrucoffMW , MeijS , CaliffRM , et al.Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of Electrocardiology2000;33(2):127-36. [MEDLINE: 10819406]AlexanderJH , HarringtonRA , TuttleRH , BerdanLG , LincoffAM , DeckersJW , et al.Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology1999;83(8):1147-51. [MEDLINE: 10215274]BoersmaE , PieperKS , SteyerbergEW , WilcoxRG , ChangWC , LeeKL , et al.Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation2000;101(22):2557-67. [MEDLINE: 10840005]BrownRE , HendersonRA , KosterD , HuttonJ , SimoonsML .Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy. European Heart Journal2002;23(1):50-8. [MEDLINE: 11741362]ChangWC , HarringtonRA , SimoonsML , CaliffRM , LincoffAM , ArmstrongPW , et al.Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial. European Heart Journal2002;23(14):1102-11. [MEDLINE: 12090748]DykeCM , BhatiaD , LorenzTJ , MarsoSP , TardiffBE , HogeboomC , et al.Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Annals of Thoracic Surgery2000;70(3):866-71. [MEDLINE: 11016325]GreenbaumAB , HarringtonRA , HudsonMP , MacAulayCM , WilcoxRG , SimoonsML , et al.Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. Journal of the American College of Cardiology2001;37(2):492-8. [MEDLINE: 11216968]HarringtonRA .Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology1997;80(4A):34-8B. [MEDLINE: 9291244]HasdaiD , Holmes DR Jr, CrigerDA , TopolEJ , CaliffRM , WilcoxRG , et al.Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators. American Heart Journal2000;139(3):454-60. [MEDLINE: 10689260]KleimanNS , LincoffAM , FlakerGC , PieperKS , WilcoxRG , BerdanLG , et al.Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation2000;101(7):751-7. [MEDLINE: 10683348]LabinazM , KaulP , HarringtonRA , ChangWC , KleimanNS , SimoonsML , et al.Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. Canadian Journal of Cardiology2004;20(8):773-8. [MEDLINE: 15229770]LabinazM , KilaruR , PieperK , MarsoSP , KittMM , SimoonsML , et al.Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2002;105(3):322-7. [MEDLINE: 11804987]LauerMA , HoughtalingPL , PetersonJG , GrangerCB , BhattDL , SappSK , et al.Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2001;104(23):2772-7. [MEDLINE: 11733393]LincoffAM , HarringtonRA , CaliffRM , HochmanJS , GuerciAD , OhmanEM , et al.Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2000;102(10):1093-100. [MEDLINE: 10973836]MahaffeyKW , HarringtonRA , AkkerhuisM , KleimanNS , BerdanLG , CrenshawBS , et al.Systematic adjudication of myocardial infarction end-points in an international clinical trial. Current Controlled Trials in Cardiovascular Medicine2001;2(4):180-6. [MEDLINE: 11806793]MahaffeyKW , HarringtonRA , SimoonsML , GrangerCB , GraffagninoC , AlbertsMJ , et al.Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation1999;99(18):2371-7. [MEDLINE: 10318656]MarkDB , HarringtonRA , LincoffAM , CaliffRM , NelsonCL , TsiatisAA , et al.Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation2000;101(4):366-71. [MEDLINE: 10653826]MarsoSP , BhattDL , RoeMT , HoughtalingPL , LabinazM , KleimanNS , et al.Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators. Circulation2000;102(24):2952-8. [MEDLINE: 11113045]McClureMW , BerkowitzSD , SparapaniR , TuttleR , KleimanNS , BerdanLG , et al.Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation1999;99(22):2892-900. [MEDLINE: 10359733]PetersonJG , TopolEJ , RoeMT , SappSK , LincoffAM , DeckersJW , et al.Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology2001;87(5):532-6. [MEDLINE: 11230834]PURSUIT Trial Investigators.Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. New England Journal of Medicine1998;339(7):436-43. [MEDLINE: 9705684]RoeMT , HarringtonRA , ProsperDM , PieperKS , BhattDL , LincoffAM , et al.Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation2000;102(10):1101-6. [MEDLINE: 10973837]RonnerE , BoersmaE , AkkerhuisKM , HarringtonRA , LincoffAM , DeckersJW , et al.Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. European Heart Journal2002;23(3):239-46. [MEDLINE: 11792139]RonnerE , BoersmaE , LaarmanGJ , SomsenGA , HarringtonRA , DeckersJW , et al.Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of the American College of Cardiology2002;39(12):1924-9. [MEDLINE: 12084589]SrichaiMB , JaberWA , PriorDL , MarsoSP , HoughtalingPL , MenonV , et al.Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes. American Heart Journal2004;147(1):84-90. [MEDLINE: 14691424]">PURSUIT 1997</a>; <a href="./references#CD008834-bbs2-0086" title="BrenerSJ , BarrLA , BurchenalJE , KatzS , GeorgeBS , JonesAA , et al.Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation1998;98(8):734-41. [MEDLINE: 9727542]BrenerSJ , BarrLA , BurchenalJE , WolskiKE , EffronMB , TopolEJ .Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial. American Journal of Cardiology1999;84(6):728-30. [MEDLINE: 10498145]">RAPPORT 1998</a>; <a href="./references#CD008834-bbs2-0090" title="RubinJ , AdairC , BarnesT , BowerJD .Augmentation of peritoneal clearance by dipyridamole. Kidney International1982;22(6):658-61. [MEDLINE: 6761488]">Rubin 1982</a>; <a href="./references#CD008834-bbs2-0092" title="SchneppM , TeichlerS , MarkauS , RettkowskiO , PriesackJ , DeuberHJ , et al.Platelet function analysis during therapy with clopidogrel in endstage renal disease [abstract]. In: 37th Congress. European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17-20; Nice, France. 2000:191. [CENTRAL: CN-00461687] ">Schnepp 2000</a>; <a href="./references#CD008834-bbs2-0097" title="StorckM , SchillingM , MickleyV , TechtB , AbendrothD .Influence of systemic cyclooxygenase inhibition with single-dose aspisol on kinetics of arachidonic acid metabolites in the venous effluate of transplanted kidney grafts in humans. Transplantation Proceedings1996;28(1):312-3. [MEDLINE: 8644237]">Storck 1996</a>; <a href="./references#CD008834-bbs2-0103" title="CorreaS , BonacaMP , SciricaBM , MurphySA , GoodrichEL , MorrowDA , et al.Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. Journal of Thrombosis &amp; Thrombolysis2019;47(3):353-60. [MEDLINE: 30511258]GaviriaSC , BraunwaldE , BonacaMP , MurphySA , GoodrichEL , MorrowDA , et al.The efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function: insights from the TRA 2P-TIMI 50 trial [abstract no: 15480]. Circulation2017;136(Suppl 1). [EMBASE: 619986693]MorrowDA , BraunwaldE , BonacaMP , AmerisoSF , DalbyAJ , FishMP , et al.Vorapaxar in the secondary prevention of atherothrombotic events. New England Journal of Medicine2012;366(15):1404-13. [MEDLINE: 22443427]MorrowDA , SciricaBM , FoxKA , BermanG , StronyJ , VeltriE , et al.Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. American Heart Journal2009;158(3):335-41. [MEDLINE: 19699854]">TRA 2P‐TIMI 50 2009</a>; <a href="./references#CD008834-bbs2-0104" title="CornelJH , TricociP , HortonJ , MoliternoD , WallentinL , ArmstrongP , et al.Effects of glycoprotein IIB/IIIA inhibitors in combination with vorapaxar, a platelet thrombin-receptor antagonist, among patients with non-St-segment elevation acute coronary syndromes: insights from the TRACER trial [abstract]. Journal of the American College of Cardiology2013;61(10 Suppl 1):E102. [EMBASE: 71019466]MahaffeyKW , PieperK , VranckxP , TricociP , Van de WerfF , HeldC , et al.Chronic kidney disease is associated with worse outcomes in ACS patients: results from the TRACER trial [abstract]. European Heart Journal2014;35(Suppl 1):687. [EMBASE: 71649310]">TRACER 2013</a>; <a href="./references#CD008834-bbs2-0105" title="AbaciA .The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses [Prasugrelin ST yukselmeli ve yukselmesiz miyokart enfarktusunde kullanimi: TRITON TIMI 38 caIismasi ve alt grup sonuclari]. Turk Kardiyoloji Dernegi Arsivi2015;43 Suppl 2:1-6. [MEDLINE: 27326444]AntmanEM , WiviottSD , MurphySA , VoitkJ , HasinY , WidimskyP , et al.Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Journal of the American College of Cardiology2008;51(21):2028-33. [MEDLINE: 18498956]BonacaMP , WiviottSD , BraunwaldE , MurphySA , RuffCT , AntmanEM , et al.American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation2012;125(4):577-83. [MEDLINE: 22199016]CapodannoD , TamburinoC .Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International Journal of Cardiology2011;146(2):242-3. [MEDLINE: 21130510]DammanP , deWinterRJ , WallentinL , FoxKA .Letter by Damman et al regarding articles, &quot;Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)&quot; and &quot;American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)&quot;. Circulation2012;126(9):e136-7. [MEDLINE: 22927480]De ServiS , GoedickeJ , SchirmerA , WidimskyP .Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European Heart Journal: Acute Cardiovascular Care2014;3(4):363-72. [MEDLINE: 24818952]GoodnoughLT , SmithPK , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. Journal of Thoracic &amp; Cardiovascular Surgery2013;145(4):1077-82. [MEDLINE: 22995726]HochholzerW , WiviottSD , AntmanEM , ContantCF , GuoJ , GiuglianoRP , et al.Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation2011;123(23):2681-9. [MEDLINE: 21606391]KohliP , UdellJA , MurphySA , CannonCP , AntmanEM , BraunwaldE , et al.Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Journal of the American College of Cardiology2014;63(3):225-32. [MEDLINE: 24140678]MahoneyEM , WangK , ArnoldSV , ProskorovskyI , WiviottS , AntmanE , et al.Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation2010;121(1):71-9. [MEDLINE: 20026770]MarianiM , MarianiG , De ServiS .Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert Review of Cardiovascular Therapy2009;7(1):17-23. [MEDLINE: 19105763]MegaJL , CloseSL , WiviottSD , ShenL , WalkerJR , SimonT , et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet2010;376(9749):1312-9. [MEDLINE: 20801494]MichelsonAD , Frelinger AL 3rd, BraunwaldE , DowneyWE , AngiolilloDJ , XenopoulosNP , et al.Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal2009;30(14):1753-63. [MEDLINE: 19435740]MogabgabO , WiviottSD , CannonCP , SloanS , SabatineMS , AntmanEM , et al.Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(6):555-9. [MEDLINE: 24064010]MontalescotG , WiviottSD , BraunwaldE , MurphySA , GibsonCM , McCabeCH , et al.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet2009;373(9665):723-31. [MEDLINE: 19249633]MurphySA , AntmanEM , WiviottSD , WeerakkodyG , MorocuttiG , HuberK , et al.Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European Heart Journal2008;29(20):2473-9. [MEDLINE: 18682445]O'DonoghueM , AntmanEM , BraunwaldE , MurphySA , StegPG , FinkelsteinA , et al.The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology2009;54(8):678-85. [MEDLINE: 19679245]OjeifoO , WiviottSD , AntmanEM , MurphySA , UdellJA , BatesER , et al.Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Jacc: Cardiovascular Interventions2013;6(2):1275-81. [MEDLINE: 24239201]PakhomovIM .Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial. Kardiologiia2010;50(6):63-7. [MEDLINE: 20659030]PrideYB , TungP , MohanaveluS , ZorkunC , WiviottSD , AntmanEM , et al.Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. Jacc: Cardiovascular Interventions2010;3(8):306-11. [MEDLINE: 20723851]RiesmeyerJS , SalazarDE , WeerakkodyGJ , NiL , WrishkoRE , Ernest CS 2nd, et al.Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. Journal of Clinical Pharmacology2012;52(6):789-97. [MEDLINE: 21628601]SerebruanyVL .Letter by Serebruany regarding article, &quot;Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38&quot;. Circulation2010;122(8):e436. [MEDLINE: 20733108]SmithPK , GoodnoughLT , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology2012;60(5):388-96. [MEDLINE: 22633653]SorichMJ , VitryA , WardMB , HorowitzJD , McKinnonRA .Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis &amp; Haemostasis2010;8(8):1678-84. [MEDLINE: 20492467]UdellJA , BraunwaldE , AntmanEM , MurphySA , MontalescotG , WiviottSD .Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).[Erratum in: JACC Cardiovasc Interv. 2014 Aug;7(8):946 Note: Antman, Elliot M [Corrected to Antman, Elliott M]]. Jacc: Cardiovascular Interventions2014;7(6):604-12. [MEDLINE: 24947719]WilcoxR , IqbalK , CostiganT , Lopez-SendonJ , RamosY , WidimskyP .An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current Medical Research &amp; Opinion2014;30(11):2193-205. [MEDLINE: 25025610]WiviottSD , AntmanEM , GibsonCM , MontalescotG , RiesmeyerJ , WeerakkodyG , et al.Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). American Heart Journal2006;152(4):627-35. [MEDLINE: 16996826]WiviottSD , BraunwaldE , McCabeCH , HorvathI , KeltaiM , HerrmanJP , et al.Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet2008;371(9621):1353-63. [MEDLINE: 18377975]WiviottSD , BraunwaldE , McCabeCH , MontalescotG , RuzylloW , GottliebS , et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2007;357(20):2001-15. [MEDLINE: 17982182]WiviottSD , DesaiN , MurphySA , MusumeciG , RagostaM , AntmanEM , et al.Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. American Journal of Cardiology2011;108(7):905-11. [MEDLINE: 21816379]WrishkoRE , Ernest CS 2nd, SmallDS , LiYG , WeerakkodyGJ , RiesmeyerJR , et al.Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. Journal of Clinical Pharmacology2009;49(8):984-98. [MEDLINE: 19546250]">TRITON‐TIMI 38 2006</a>; <a href="./references#CD008834-bbs2-0107" title="WasedaK , SakaY , TakashimaH , KuritaA , AndoH , SakuraiS , et al.Effect of CYP2C19 genotype on inhibition of platelet aggregation in hemodialysis patients with coronary artery disease [abstract]. Circulation2016;134(Suppl 1):A14237. [EMBASE: 619219587]">Waseda 2016</a>; <a href="./references#CD008834-bbs2-0109" title="WeseleyS , GoodmanA .The effect of dipyridamole (Di) on the peritoneal dialysis (PD) clearance of creatinine and urea - a double-blind study [abstract]. Kidney International1982;21(1):182. ">Weseley 1982</a>; <a href="./references#CD008834-bbs2-0110" title="XydakisD , PapadagiannakisA , SfakianakiM , VakoutiE , PapachristoforouK .The combination of clopidogrel (CL) and acetylsalicylic acid (ASA) inhibits more effective the platelet activation in haemodialysis patients with acute coronary syndromes (ACS) and high C reactive protein [abstract no: MP370]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:355. [CENTRAL: CN-00509568] ">Xydakis 2004</a>; <a href="./references#CD008834-bbs2-0113" title="ZäunerI , BöhlerJ , BraunN , GruppC , HeeringP , SchollmeyerP .Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Nephrology Dialysis Transplantation1994;9(6):619-22. [MEDLINE: 7970086]">Zäuner 1994</a>). Seventy‐two studies were considered at high risk of detection bias. </p> </section> </section> <section id="CD008834-sec-0055"> <h4 class="title">Incomplete outcome data</h4> <p>Follow‐up data was complete and judged to be at low risk of bias for 41 studies (<a href="./references#CD008834-bbs2-0001" title="GoicoecheaM , deVinuesaMS , QuirogaB , VerdallesU , MoralesE , De SequeraP , et al.Aspirin treatment in primary cardiovascular prevention and renal disease progression in CKD patients: a randomized clinical trials (AASER study) [abstract no: FR-PO1065]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):B5. [EMBASE: 633704620]GoicoecheaM , deVinuesaSG , QuirogaB , VerdeE , BernisC , MoralesE , et al.Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study). Cardiovascular Drugs &amp; Therapy2018;32(3):255-63. [MEDLINE: 29943364]GoicoecheaM , Sanchez-NinoMD , OrtizA , deVinuesaMS , QuirogaB , MoralesE , et al.Low dose aspirin increases 15-epi-lipoxin a4 levels in CKD patients [abstract no: SA-PO186]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):726. [EMBASE: 633701100]GoicoecheaM , Sanchez-NinoMD , OrtizA , Garcia de VinuesaS , QuirogaB , BernisC , et al.Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. Prostaglandins Leukotrienes &amp; Essential Fatty Acids2017;125:8-13. [MEDLINE: 28987723]">AASER 2017</a>; <a href="./references#CD008834-bbs2-0002" title="AbacilarAF , AtalayH , DoganOF .Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: a randomized controlled study. Indian Journal of Nephrology2015;25(3):136-42. [MEDLINE: 26060361]">Abacilar 2015</a>; <a href="./references#CD008834-bbs2-0003" title="Abdul-RahmanIS , Al-HowaishAK .Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23-30. [EMBASE: 2007269768]">Abdul‐Rahman 2007</a>; <a href="./references#CD008834-bbs2-0004" title="AlexopoulosD , PanagiotouA , XanthopoulouI , KomninakisD , KassimisG , DavlourosP , et al.Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. Journal of Thrombosis &amp; Haemostasis2011;9(12):2379-85. [MEDLINE: 21985070]XanthopoulouI , PanagiotouA , KomninakisD , DavlourosP , KassimisG , FourtounasK , et al.Prasugrel versus double clopidpogrel maintenance dose in patients on chronic haemodialysis and high on clopidogrel platelet reactivity [abstract no: P2438]. European Heart Journal2011;32(Suppl 1):417. [EMBASE: 70534608]">Alexopoulos 2011</a>; <a href="./references#CD008834-bbs2-0006" title="AndrassyK , MallucheH , BornefeldH , CombergM , RitzE , JesdinskyH , et al.Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: results of a prospective double blind study. Klinische Wochenschrift1974;52(7):348-9. [MEDLINE: 4600820]">Andrassy 1974</a>; <a href="./references#CD008834-bbs2-0008" title="FujitaT , YuX , KimS , NakamotoH , OrigasaH , KurumataniH , et al.Effects of sustained-release beraprost sodium in patients with primary glomerular disease or nephrosclerosis: the CASSIOPEIR study [abstract no: SA-PO1096]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):4B. [CENTRAL: CN-01657821] NakamotoH , FujitaT , OrigasaH , IsonoM , KurumataniH , OkadaK , et al.A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrology2014;15:153. [MEDLINE: 25233856]NakamotoH , YuXQ , KimS , OrigasaH , ZhengH , ChenJ , et al.Effects of sustained-release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results. Therapeutic Apheresis &amp; Dialysis2020;24(1):42-55. [MEDLINE: 31119846]">CASSIOPEIR 2014</a>; <a href="./references#CD008834-bbs2-0011" title="BangaloreS , BhattDL , StegPG , WeberMA , BodenWE , HammCW , et al.beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circulation: Cardiovascular Quality &amp; Outcomes2014;7(6):872-81. [MEDLINE: 25271049]BergerPB , BhattDL , FusterV , StegPG , FoxKA , ShaoM , et al.Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation2010;121(23):2575-83. [MEDLINE: 20516378]BhattDL , FlatherMD , HackeW , BergerPB , BlackHR , BodenWE , et al.Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology2007;49(19):1982-8. [MEDLINE: 17498584]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial [Erratum in: Am Heart J. 2006 Jan;151(1):247]. American Heart Journal2005;150(3):401. [MEDLINE: 16169314]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine2006;354(16):1706-17. [MEDLINE: 16531616]DasguptaA , SteinhublSR , BhattDL , BergerPB , ShaoM , MakKH , et al.Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). American Journal of Cardiology2009;103(10):1359-63. [MEDLINE: 19427428]EikelboomJW , HankeyGJ , ThomJ , BhattDL , StegPG , MontalescotG , et al.Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation2008;118(17):1705-12. [MEDLINE: 18838564]MakKH , BhattDL , ShaoM , HaffnerSM , HammCW , HankeyGJ , et al.The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. European Heart Journal2009;30(7):857-65. [MEDLINE: 19233855]SteinhublSR , BhattDL , BrennanDM , MontalescotG , HankeyGJ , EikelboomJW , et al.Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding [Summary for patients in Ann Intern Med. 2009 Mar 17;150(6):I-22; PMID: 19293067]. Annals of Internal Medicine2009;150(6):379-86. [MEDLINE: 19293071]WangTH , BhattDL , FoxKA , SteinhublSR , BrennanDM , HackeW , et al.An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal2007;28(18):2200-7. [MEDLINE: 17673448]">CHARISMA 2006</a>; <a href="./references#CD008834-bbs2-0015" title="AronowHD , SteinhublSR , BrennanDM , BergerPB , TopolEJ , CREDO Investigators.Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal2009;157(2):369-74. [MEDLINE: 19185647]BeinartSC , KolmP , VeledarE , ZhangZ , MahoneyEM , BouinO , et al.Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Journal of the American College of Cardiology2005;46(5):761-9. [MEDLINE: 16139122]BestPJ , SteinhublSR , BergerPB , DasguptaA , BrennanDM , SzczechLA , et al.The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal2008;155(4):687-93. [MEDLINE: 18371477]BrenerSJ , SteinhublSR , BergerPB , BrennanDM , TopolEJ , CREDO Investigators.Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial. Journal of Invasive Cardiology2007;19(7):287-90. [MEDLINE: 17620671]RingborgA , LindgrenP , JonssonB .The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. European Journal of Health Economics2005;6(4):354-56, 358-62. [MEDLINE: 16267654]SteinhublSR , BergerPB , Mann JT 3rd, FryET , DeLagoA , WilmerC , et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [Erratum in: JAMA. 2003 Feb 26;289(8):987]. JAMA2002;288(19):2411-20. [MEDLINE: 12435254]">CREDO 2005</a>; <a href="./references#CD008834-bbs2-0017" title="BergerPB , SteinhublS .Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. Circulation2002;106(17):2284-7. [MEDLINE: 12390961]GerschutzGP , BhattDL , Clopidogrel in Unstable Angina to Prevent Recurrent Events study.The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?American Heart Journal2003;145(4):595-601. [MEDLINE: 12679754]KeltaiM , TonelliM , MannJF , SitkeiE , LewisBS , HawkenS , et al.Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. European Journal of Cardiovascular Prevention &amp; Rehabilitation2007;14(2):312-8. [MEDLINE: 17446813]LewisBS , MehtaSR , FoxKA , HalonDA , ZhaoF , PetersRJ , et al.Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. American Heart Journal2005;150(6):1177-84. [MEDLINE: 16338255]MehtaSR , YusufS , PetersRJ , BertrandME , LewisBS , NatarajanMK , et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet2001;358(9281):527-33. [MEDLINE: 11520521]MehtaSR , YusufS , Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators.The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. European Heart Journal2000;21(24):2033-41. [MEDLINE: 11102254]PetersRJ , MehtaSR , FoxKA , ZhaoF , LewisBS , KopeckySL , et al.Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation2003;108(14):1682-7. [MEDLINE: 14504182]YusufS ,  ZhaoF ,  MehtaSR ,  ChrolaviciusS ,  TognoniG ,  FoxKK , et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [Erratum in: N Engl J Med 2001 Dec 6;345(23):1716; Erratum in: N Engl J Med 2001 Nov 15;345(20):1506]. New England Journal of Medicine2001;345(7):494-502. [MEDLINE: 11519503]">CURE 2000</a>; <a href="./references#CD008834-bbs2-0019" title="DemberL , AllonM , DelmezJ , DixonB , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00550593] DemberLM , BeckGJ , AllonM , DelmezJA , DixonBS , GreenbergA , et al.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008;299(18):2164-71. [MEDLINE: 18477783]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials2005;2(5):413-22. [MEDLINE: 16317810]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):229A. [CENTRAL: CN-00445067] ">Dember 2005</a>; <a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a>; <a href="./references#CD008834-bbs2-0026" title="AguirreFV , TopolEJ , AndersonKM , KleimanNS , WeismanHF , FitzPatrickSE , et al.Benefit within patient subgroups receiving c7e3 fab (abciximab) during percutaneous coronary revascularization: subgroup analysis from the EPIC trial. Journal of Invasive Cardiology1996;8 Suppl B:21-9B. [MEDLINE: 10785766]AguirreFV , TopolEJ , FergusonJJ , AndersonK , BlankenshipJC , HeuserRR , et al.Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation1995;91(12):2882-90. [MEDLINE: 7796496]BerkowitzSD , SaneDC , SigmonKN , ShavenderJH , HarringtonRA , TchengJE , et al.Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. Journal of the American College of Cardiology1998;32(2):311-9. [MEDLINE: 9708455]BlankenshipJC , HellkampAS , AguirreFV , DemkoSL , TopolEJ , CaliffRM .Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. American Journal of Cardiology1998;81(1):36-40. [MEDLINE: 9462603]BoehrerJD , KereiakesDJ , NavettaFI , CaliffRM , TopolEJ .Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications. American Journal of Cardiology1994;74(11):1166-70. [MEDLINE: 7977081]CaliffRM , LincoffAM , TchengJE , TopolEJ .An overview of the results of the EPIC trial. European Heart Journal1995;16 Suppl L:43-9. [MEDLINE: 8869018]EPIC Investigators.Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New England Journal of Medicine1994;330(14):956-61. [MEDLINE: 8121459]KhanMM , EllisSG , AguirreFV , WeismanHF , WildermannNM , CaliffRM , et al.Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1998;31(1):31-6. [MEDLINE: 9426014]LefkovitsJ , BlankenshipJC , AndersonKM , StonerGL , TalleyJD , WorleySJ , et al.Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. Journal of the American College of Cardiology1996;28(4):849-55. [MEDLINE: 8837559]LefkovitsJ , IvanhoeRJ , CaliffRM , BergelsonBA , AndersonKM , StonerGL , et al.Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. American Journal of Cardiology1996;77(12):1045-51. [MEDLINE: 8644655]LincoffAM , CaliffRM , AndersonKM , WeismanHF , AguirreFV , KleimanNS , et al.Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1997;30(1):149-56. [MEDLINE: 9207636]MakKH , ChallapalliR , EisenbergMJ , AndersonKM , CaliffRM , TopolEJ .Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. American Journal of Cardiology1997;80(8):985-8. [MEDLINE: 9352964]MarkDB , TalleyJD , TopolEJ , BowmanL , LamLC , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation1996;94(4):629-35. [MEDLINE: 8772681]MoliternoDJ , CaliffRM , AguirreFV , AndersonK , SigmonKN , WeismanHF , et al.Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. American Journal of Cardiology1995;75(8):559-62. [MEDLINE: 7887377]NarinsCR , MillerDP , CaliffRM , TopolEJ .The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1999;33(3):647-53. [MEDLINE: 10080464]ThelMC , CaliffRM , TchengJE , SigmonKN , LincoffAM , TopolEJ , et al.Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. American Heart Journal1999;137(2):264-73. [MEDLINE: 9924160]TopolEJ , CaliffRM , WeismanHF , EllisSG , TchengJE , WorleyS , et al.Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet1994;343(8902):881-6. [MEDLINE: 7908357]TopolEJ , FergusonJJ , WeismanHF , TchengJE , EllisSG , KleimanNS , et al.Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA1997;278(6):479-84. [MEDLINE: 9256222]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. American Heart Journal1998;135(4):S98-106. [MEDLINE: 9539500]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. European Heart Journal1998;19 Suppl D:D59-66. [MEDLINE: 9597523]">EPIC 1994</a>; <a href="./references#CD008834-bbs2-0027" title="EPILOG Investigators.Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New England Journal of Medicine1997;336(24):1689-96. [MEDLINE: 9182212]GhaffariS , KereiakesDJ , LincoffAM , KellyTA , TimmisGC , KleimanNS , et al.Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. American Journal of Cardiology1998;82(1):7-12. [MEDLINE: 9671000]KereiakesDJ , LincoffAM , MillerDP , TchengJE , CabotCF , AndersonKM , et al.Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Circulation1998;97(9):857-64. [MEDLINE: 9521334]KleimanNS , LincoffAM , KereiakesDJ , MillerDP , AguirreFV , AndersonKM , et al.Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation1998;97(19):1912-20. [MEDLINE: 9609084]LincoffAM , MarkDB , TchengJE , CaliffRM , BalaMV , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation2000;102(24):2923-9. [MEDLINE: 11113041]LincoffAM , TchengJE , CaliffRM , KereiakesDJ , KellyTA , TimmisGC , et al.Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. One-year outcome in the EPILOG trial. Circulation1999;99(15):1951-8. [MEDLINE: 10208997]">EPILOG 1997</a>; <a href="./references#CD008834-bbs2-0028" title="ChoL , MarsoSP , BhattDL , TopolEJ .Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial. Journal of Womens Health &amp; Gender-Based Medicine2000;9(7):741-6. [MEDLINE: 11025866]De ServiS .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse events. Data from the Evaluation of Platelets IIb/IIIa Inhibitor for Stenting (EPISTENT) trial [Il pretrattamento con ticlopidina nello stent coronarico e associato a significativa riduzione di eventi avversi. Dati dal trial EPISTENT]. Italian Heart Journal Supplement2001;2(7):805-6. [MEDLINE: 11508303]EPISTENT Investigators.Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet1998;352(9122):87-92. [MEDLINE: 9672272]IslamMA , BlankenshipJC , BalogC , IliadisEA , LincoffAM , TchengJE , et al.Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). American Journal of Cardiology2002;90(9):916-21. [MEDLINE: 12398954]LincoffAM .Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial. American Heart Journal2000;139(2 Pt 2):S46-52. [MEDLINE: 10650316]MarsoSP , LincoffAM , EllisSG , BhattDL , TanguayJF , KleimanNS , et al.Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation1999;100(25):2477-84. [MEDLINE: 10604884]SteinhublSR , EllisSG , WolskiK , LincoffAM , TopolEJ .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation2001;103(10):1403-9. [MEDLINE: 11245644]SteinhublSR , TanWA , FoodyJM , TopolEJ .Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA1999;281(9):806-10. [MEDLINE: 10071001]TopolEJ , MarkDB , LincoffAM , CohenE , BurtonJ , KleimanN , et al.Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.[Erratum in: Lancet 2000 Mar 25;355(9209):1104]. Lancet1999;354(9195):2019-24. [MEDLINE: 10636365]Zwart-van RijkomJE , vanHoutBA .Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb/IIIa Inhibitor For Stenting Trial. European Heart Journal2001;22(16):1476-84. [MEDLINE: 11482921]">EPISTENT 1998</a>; <a href="./references#CD008834-bbs2-0029" title="Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA1992;268(10):1292-300. [MEDLINE: 1507375]">ETDRS 1992</a>; <a href="./references#CD008834-bbs2-0035" title="GaedeP , HansenHP , ParvingHH , PedersenO .Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrology Dialysis Transplantation2003;18(3):539-42. [MEDLINE: 12584276]GaedeP , ParvingH , PedersenO .Lack of impact of low-dose acetylsalisyic acid (ASA) on albuminuria in type 2 diabetic patients [abstract no: A0660]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):128A. [CENTRAL: CN-00583369] ">Gaede 2003</a>; <a href="./references#CD008834-bbs2-0037" title="GhorbaniA , Jasemi-ZerganiF .Ticlopidine to prevent primary arteriovenous fistula failure in hemodialysis patients; a randomized controlled trial. Journal of Renal Injury Prevention2013;2(3):109-11. [MEDLINE: 25340144]">Ghorbani 2013</a>; <a href="./references#CD008834-bbs2-0040" title="deMoralesAM , GoicoecheaM , VerdeE , CarbayoJ , BarbieriD , DelgadoA , et al.Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial. Journal of Nephrology2019;32(4):581-7. [MEDLINE: 30949987]GoicoecheaM , Garcia de VinuesaS , QuirogaB , VerdallesU , BarracaD , YusteC , et al.Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. Journal of Nephrology2012;25(6):969-75. [MEDLINE: 22241639]">Goicoechea 2012</a>; <a href="./references#CD008834-bbs2-0043" title="GröntoftK , LarssonR , MulecH , WeissLG , DickinsonJP .Ticlopidine in fistula surgery: double-blind comparison against placebo on the rate of early occlusion of arterio-venous fistulae [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:398. [CENTRAL: CN-00601921] GröntoftKC , LarssonR , MulecH , WeissLG , DickinsonJP .Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scandinavian Journal of Urology &amp; Nephrology1998;32(4):276-83. [MEDLINE: 9764456]">Gröntoft 1998</a>; <a href="./references#CD008834-bbs2-0045" title="HansenHP , GaedePH , JensenBR , ParvingHH .Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria. Diabetes Care2000;23(12):1742-5. [MEDLINE: 11128344]">Hansen 2000</a>; <a href="./references#CD008834-bbs2-0047" title="HidakaS , KobayashiS , IwagamiM , IsshikiR , TsutsumiD , MochidaY , et al.Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease. Renal Failure2013;35(1):43-8. [MEDLINE: 23110683]">Hidaka 2013</a>: <a href="./references#CD008834-bbs2-0048" title="HanssonL , ZanchettiA , CarruthersSG , DahlöfB , ElmfeldtD , JuliusS , et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998;351(9118):1755-62. [MEDLINE: 9635947]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Pressure1997;6(5):313-7. [MEDLINE: 9360003]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Pressure1994;3(5):322-7. [MEDLINE: 7866597]HanssonL .The Hypertension Optimal Treatment study and the importance of lowering blood pressure. Journal of Hypertension - Supplement1999;17(1):S9-13. [MEDLINE: 10340838]JardineM , NinomiyaT , CassA , TurnbullF , GallagherM , ZoungasS , et al.Aspirin benefit increases as eGFR declines: results from a randomised controlled trial in a hypertensive population [abstract no: 086]. Nephrology2010;15(Suppl 4):49. [EMBASE: 70467090]JardineMJ , NinomiyaT , PerkovicV , CassA , TurnbullF , GallagherMP , et al.Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology2010;56(12):956-65. [MEDLINE: 20828648]JonesDW , MillerME , WoffordMR , Anderson DC Jr, CameronME , WilloughbyDL , et al.The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. American Journal of Hypertension1999;12(12 Pt 1-2):1175-80. [MEDLINE: 10619579]JonssonB , HanssonL , StalhammarNO .Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Journal of Internal Medicine2003;253(4):472-80. [MEDLINE: 12653877]KjeldsenSE , HednerT , JamersonK , JuliusS , HaleyWE , ZabalgoitiaM , et al.Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects. Hypertension1998;31(4):1014-20. [MEDLINE: 9535429]KjeldsenSE , KollochRE , LeonettiG , MallionJM , ZanchettiA , ElmfeldtD , et al.Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. Journal of Hypertension2000;18(5):629-42. [MEDLINE: 10826567]KollochRE , RahnKH .The Hypertension Optimal Treatment (HOT) study: results of 12-month treatment related to age [Die 'Hyperyension Optimal Treatment' (HOT)-Studie: Behandlungsergebnisse nach Zwolfmonatiger Therapie in Abhangigkeit vom Alter]. Deutsche Medizinische Wochenschrift1998;123(1-2):1-5. [MEDLINE: 9465848]LeonettiG , ZanchettiA .Principal results of hypertension optimal treatment (HOT) study and their clinical impact. HOT cooperative group. Clinical Hemorheology &amp; Microcirculation1999;21(3-4):217-24. [MEDLINE: 10711746]LithellH , BerglundL .Validation of an oscillometric blood pressure measuring device: a substudy of the HOT Study. Hypertension Optimal Treatment. Blood Pressure1998;7(3):149-52. [MEDLINE: 9758084]ManciaG , OmboniS , ParatiG , ClementDL , HaleyWE , RahmanSN , et al.Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(10):1755-63. [MEDLINE: 11593094]RuilopeLM , SalvettiA , JamersonK , HanssonL , WarnoldI , WedelH , et al.Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology2001;12(2):218-25. [MEDLINE: 11158211]Struijker-BoudierH , SafarM , vanBortelL .Effects of individual risk factors on the incidence of cardiovascular event in the treated hypertensive patients of the Hypertension Optimal Treatment Study. Journal of Hypertension2001;19(11):2105-6. [MEDLINE: 11677378]The Hypertension Optimal Treatment Study (the HOT Study). Blood Pressure1993;2(1):62-8. [MEDLINE: 8193735]WaeberB , LeonettiG , KollochR , McInnesGT .Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension1999;17(7):1041-5. [MEDLINE: 10419079]ZanchettiA , HanssonL , DahlofB , ElmfeldtD , KjeldsenS , KollochR , et al.Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. Journal of Hypertension2001;19(6):1149-59. [MEDLINE: 11403365]ZanchettiA , HanssonL , MenardJ , LeonettiG , RahnKH , WarnoldI , et al.Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(4):819-25. [MEDLINE: 11330886]">HOT 1993</a>; <a href="./references#CD008834-bbs2-0051" title="OgawaH , NakayamaM , MorimotoT , UemuraS , KanauchiM , DoiN , et al.Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.[Erratum in: JAMA. 2009 May 13;301(18):1882], [Erratum in: JAMA. 2012 Nov 14;308(18):1861]. JAMA2008;300(18):2134-41. [MEDLINE: 18997198]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , NakayamaM , et al.Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk. Circulation Journal2013;77(12):3023-8. [MEDLINE: 24042256]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , NakayamaM , et al.Is long-term low-dose aspirin therapy associated with renal dysfunction in patients with type 2 diabetes? JPAD2 cohort study. PLoS ONE [Electronic Resource]2016;11(1):e0147635. [MEDLINE: 26808136]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , OhtoriiM , et al.Long-term use of low-dose aspirin develops proteinuria in patients with diabetes: A reanalysis of JPAD study [abstract no: 10863]. Circulation2013;128(22 Suppl 1). [EMBASE: 71337722]SaitoY , MorimotoT , OgawaH , NakayamaM , UemuraS , DoiN , et al.Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care2011;34(2):280-5. [MEDLINE: 21270185]">JPAD 2008</a>; <a href="./references#CD008834-bbs2-0054" title="KamperAM , LinsRL , ZacheeP , Van BergenS , HostenS , DaelemansR .Safety of combining ticlopidine with nadroparin in the routine treatment of chronic hemodialysis patients. Nephron1997;77(4):484-5. [MEDLINE: 9434075]">Kamper 1997</a>; <a href="./references#CD008834-bbs2-0056" title="ChangJJ , ConcatoJ , WellsCK , CrowleyST .Impact of adherence to clinical guidelines on mortality in hemodialysis patients [abstract no: SA-PO384]. Journal of the American Society of Nephrology2004;15(Oct):386A. [CENTRAL: CN-00583156] KaufmanJS , O'ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology2003;14(9):2313-21. [MEDLINE: 12937308]KaufmanJS , O’ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract no: A1495]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):291A. ">Kaufman 2003</a>; <a href="./references#CD008834-bbs2-0057" title="KhajehdehiP , RoozbehJ , MostafaviH .A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scandinavian Journal of Urology &amp; Nephrology2002;36(2):145-8. [MEDLINE: 12028688]">Khajehdehi 2002</a>; <a href="./references#CD008834-bbs2-0058" title="KobayashiK , MaedaK , KoshikawaS , KawaguchiY , ShimizuN , NaitoC .Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis: a multicenter collaborative double blind study. Thrombosis Research1980;20(2):255-61. [MEDLINE: 7209880]">Kobayashi 1980</a>; <a href="./references#CD008834-bbs2-0062" title="LiangJ , WangZ , ShiD , LiuY , ZhaoY , HanH , et al.High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. Angiology2015;66(4):319-25. [MEDLINE: 24913197]">Liang 2015</a>; <a href="./references#CD008834-bbs2-0072" title="NybergG , LarssonO , WestbergNG , AurellM , JagenburgR , BlohmeG .A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study. Clinical Nephrology1984;21(3):184-7. [MEDLINE: 6705280]">Nyberg 1984</a>; <a href="./references#CD008834-bbs2-0074" title="HanY .Comparison of the pharmacodynamics and pharmacokinetics of ticagrelor versus clopidogrel in patients with chronic kidney disease and non-ST-elevation acute coronary syndromes (OPT-CKD trial) [abstract no: TCT-483]. Journal of the American College of Cardiology2017;70(18 Suppl 1):B200. [EMBASE: 619771602]WangH , QiJ , LiY , TangY , LiC , LiJ , et al.Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. British Journal of Clinical Pharmacology2018;84(1):88-96. [MEDLINE: 28921624]">OPT‐CKD 2018</a>; <a href="./references#CD008834-bbs2-0075" title="OtaK , TeraokaS , AkiwasaT , MimuraN , HirasawaY , SakaiT , et al.Clinical efficacy of E5510 (satigrel), an antiplatelet agent, for preventing blood clotting in the extracorporeal circuit during hemodialysis (3) - A double-blind comparison with ticlopidine hydrochloride. Rinsho Hyoka1996;24(1):9-38. ">Ota 1996</a>; <a href="./references#CD008834-bbs2-0076" title="BonacaMP , BhattDL , BraunwaldE , CohenM , StegPG , StoreyRF , et al.Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal2014;167(4):437-44. [MEDLINE: 24655690]BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , JensenEC , et al.Long-term use of ticagrelor in patients with prior myocardial infarction. New England Journal of Medicine2015;372(19):1791-800. [MEDLINE: 25773268]BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , CohenM , et al.Prevention of stroke with ticagrelor in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation2016;134(12):861-71. [MEDLINE: 27576775]DellborgM , BonacaMP , StoreyRF , StegPG , ImKA , CohenM , et al.Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: Insights from PEGASUS-TIMI 54 [abstract]. European Heart Journal2017;38(Suppl 1):794-5. [EMBASE: 621235545]LozanoI , RondanJ , VegasJM , SegoviaE .Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):107-8. [MEDLINE: 29301622]MagnaniG , SabatineMS , BhattDL , ChoenM , StegG , StoreyR , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: Insights from the PEGASUS-TIMI 54 trial [abstract]. European Heart Journal2015;36(Suppl 1):520. [EMBASE: 72020712]MagnaniG , StoreyRF , StegG , BhattDL , CohenM , KuderJ , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. European Heart Journal2016;37(4):400-8. [MEDLINE: 26443023]MagnusonEA , BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , et al.Reply: cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):108. [MEDLINE: 29301623]MagnusonEA , LiH , WangK , VilainK , ShafiqA , BonacaMP , et al.Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: results from the PEGASUS-TIMI 54 trial. Journal of the American College of Cardiology2017;70(5):527-38. [MEDLINE: 28750695]MurphySA , BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , et al.Reduction in total cardiovascular events with long-term use of ticagrelor in patients with prior myocardial infarction in the PEGASUS-TIMI 54 trial [abstract no: A17121]. Circulation2015;132(Suppl 3). [EMBASE: 72179983]">PEGASUS‐TIMI 54 2014</a>; <a href="./references#CD008834-bbs2-0081" title="AkerblomA , WallentinL , LarssonA , SiegbahnA , BeckerRC , BudajA , et al.Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study. Clinical Chemistry2013;59(9):1369-75. [MEDLINE: 23698074]AkerblomA , WallentinL , SiegbahnA , BeckerRC , BudajA , HorrowJ , et al.Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. American Heart Journal2012;164(5):728-34. [MEDLINE: 23137503]AndellP , JamesSK , CannonCP , CyrDD , HimmelmannA , HustedS , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Journal of the American Heart Association2015;4(10):e002490. [MEDLINE: 26452988]ArmstrongPW , SihaH , FuY , WesterhoutCM , StegPG , JamesSK , et al.ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation2012;125(3):514-21. [MEDLINE: 22179530]ArmstrongPW , WesterhoutCM , FuY , HarringtonRA , StoreyRF , KatusH , et al.Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. American Journal of Medicine2013;126(8):723-9. [MEDLINE: 23795897]BeckerRC , BassandJP , BudajA , WojdylaDM , JamesSK , CornelJH , et al.Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial [Erratum in: Eur Heart J. 2012 Nov;33(21):2750]. European Heart Journal2011;32(23):2933-44. [MEDLINE: 22090660]BellaviaA , WallentinL , OrsiniN , JamesSK , CannonCP , HimmelmannA , et al.Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. Open Heart2017;4(2):e000557. [MEDLINE: 28761675]BrilakisES , HeldC , MeierB , CoolsF , ClaeysMJ , CornelJH , et al.Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. American Heart Journal2013;166(3):474-80. [MEDLINE: 24016496]BuiAH , CannonCP , StegPG , StoreyRF , HustedS , GuoJ , et al.Relationship between early and late nonsustained ventricular tachycardia and cardiovascular death in patients with acute coronary syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation: Arrhythmia and Electrophysiology2016;9(2):e002951. [MEDLINE: 26810596]CapodannoD , CalviV , TamburinoC .Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment. Journal of Cardiovascular Medicine2012;13(2):162-3. [MEDLINE: 22237463]CornelJH , BeckerRC , GoodmanSG , HustedS , KatusH , SantosoA , et al.Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2012;164(3):334-42. [MEDLINE: 22980299]CowperPA , PanW , AnstromKJ , KaulP , WallentinL , Davidson-RayL , et al.Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. Journal of the American College of Cardiology2015;65(5):465-76. [MEDLINE: 25660925]DiNicolantonioJJ , D'AscenzoF , TomekA , ChatterjeeS , NiaziAK , Biondi-ZoccaiG .Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial. International Journal of Cardiology2013;168(3):1739-44. [MEDLINE: 23907035]DiNicolantonioJJ , TomekA .Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial. International Journal of Cardiology2013;168(4):4076-80. [MEDLINE: 23911266]DiNicolantonioJJ , TomekA .Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel. International Journal of Cardiology2013;169(2):145-6. [MEDLINE: 24120213]DucrocqG , SchultePJ , BeckerRC , CannonCP , HarringtonRA , HeldC , et al.Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. Eurointervention2015;11(7):737-45. [MEDLINE: 25254357]FranchiF , JamesSK , GhukasyanLT , BudajAJ , CornelJH , KatusHA , et al.Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y12 receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. Journal of the American Heart Association2019;8(6):e011139. [MEDLINE: 30857464]GiannitsisE , WallentinL , JamesSK , BertilssonM , SiegbahnA , StoreyRF , et al.Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: a Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. European Heart Journal: Acute Cardiovascular Care2017;6(6):500-10. [MEDLINE: 27044282]HagstromE , JamesSK , BertilssonM , BeckerRC , HimmelmannA , HustedS , et al.Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. European Heart Journal2016;37(16):1325-33. [MEDLINE: 26417057]HeldC , AsenbladN , BassandJP , BeckerRC , CannonCP , ClaeysMJ , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology2011;57(6):672-84. [MEDLINE: 21194870]HustedS , JamesS , BeckerRC , HorrowJ , KatusH , StoreyRF , et al.Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circulation. Cardiovascular Quality &amp; Outcomes2012;5(5):680-8. [MEDLINE: 22991347]HustedS , JamesSK , BachRG , BeckerRC , BudajA , HerasM , et al.The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal2014;35(23):1541-50. [MEDLINE: 24682844]JamesS , AkerblomA , CannonCP , EmanuelssonH , HustedS , KatusH , et al.Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2009;157(4):599-605. [MEDLINE: 19332184]JamesS , AngiolilloDJ , CornelJH , ErlingeD , HustedS , KontnyF , et al.Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal2010;31(24):3006-16. [MEDLINE: 20802246]JamesS , BudajA , AylwardP , BuckKK , CannonCP , CornelJH , et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2010;122(11):1056-67. [MEDLINE: 20805430]JamesS , BudajA , AylwardP , BuckKK , CannonCP , CornelJH , et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation2010;122(11):1056-67. [MEDLINE: 20805430]JamesSK , RoeMT , CannonCP , CornelJH , HorrowJ , HustedS , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ2011;342:d3527. [MEDLINE: 21685437]JohanssonA , ErikssonN , BeckerRC , StoreyRF , HimmelmannA , HagstromE , et al.NLRC4 inflammasome is an important regulator of interleukin-18 levels in patients with acute coronary syndromes: genome-wide association study in the PLATelet inhibition and patient Outcomes Trial (PLATO). Circulation. Cardiovascular Genetics2015;8(3):498-506. [MEDLINE: 25747584]KangHJ , ClareRM , GaoR , HeldC , HimmelmannA , JamesSK , et al.Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal2015;169(6):899-905. [MEDLINE: 26027629]KholaifN , ZhengY , JagasiaP , HimmelmannA , JamesSK , StegPG , et al.Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex. American Journal of Medicine2015;128(8):914-9. [MEDLINE: 25818495]KohliP , WallentinL , ReyesE , HorrowJ , HustedS , AngiolilloDJ , et al.Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation2013;127(6):673-80. [MEDLINE: 23277305]KontnyF , UelandT , AukrustP , MichelsenAE , BeckerRC , BertilssonM , et al.Pentraxin 3 (PTX3) predict adverse outcome in acute coronary syndromes-a PLATO biomarker substudy [abstract]. European Heart Journal2014;35(Suppl 1):319. [EMBASE: 71647923]KotsiaA , BrilakisES , HeldC , CannonC , StegGP , MeierB , et al.Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2014;168(1):68-75. [MEDLINE: 24952862]KunadianV , JamesSK , WojdylaDM , ZorkunC , WuJ , StoreyRF , et al.Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). Jacc: Cardiovascular Interventions2013;6(7):671-83. [MEDLINE: 23866179]LevinLA , WallentinL , BernfortL , AnderssonD , StoreyRF , BergstromG , et al.Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. Value in Health2013;16(4):574-80. [MEDLINE: 23796291]LindholmD , VarenhorstC , CannonCP , HarringtonRA , HimmelmannA , MayaJ , et al.Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal2014;35(31):2083-93. [MEDLINE: 24727884]MahaffeyKW , HeldC , WojdylaDM , JamesSK , KatusHA , HustedS , et al.Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology2014;63(15):1493-9. [MEDLINE: 24561148]MahaffeyKW , WojdylaDM , CarrollK , BeckerRC , StoreyRF , AngiolilloDJ , et al.Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2011;124(5):544-54. [MEDLINE: 21709065]NikolicE , JanzonM , HauchO , WallentinL , HenrikssonM , PLATO Health Economic Substudy Group.Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. European Heart Journal2013;34(3):220-8. [MEDLINE: 22719022]OhmanEM , RoeMT .Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany &quot;Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified&quot; (Thromb Haemost 2011; 105.5). Thrombosis &amp; Haemostasis2011;105(5):763-5. [MEDLINE: 21394382]ParkerWA , ErikssonN , BeckerRC , VooraD , AkerblomA , HimmelmannA , et al.Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets2019;30(5):579-88. [MEDLINE: 29851527]PatelMR , BeckerRC , WojdylaDM , EmanuelssonH , HiattWR , HorrowJ , et al.Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. European Journal of Preventive Cardiology2015;22(6):734-42. [MEDLINE: 24830710]Pollack CV Jr, DavoudiF , DiercksDB , BeckerRC , JamesSK , LimST , et al.Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clinical Cardiology2017;40(6):390-8. [MEDLINE: 28598510]RoguinA , MusallamA .Letter by Roguin and Musallam regarding article, &quot;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial&quot;. Circulation2014;129(19):e493. [MEDLINE: 24821831]SciricaBM , BansilalS , DavoudiF , ArmstrongPW , ClareRM , SchultePJ , et al.Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. American Heart Journal2018;202:54-60. [MEDLINE: 29859968]SciricaBM , CannonCP , EmanuelssonH , MichelsonEL , HarringtonRA , HustedS , et al.The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. Journal of the American College of Cardiology2011;57(19):1908-16. [MEDLINE: 21545948]SerebruanyVL , FortmannSD , CherepanovV , LitvinovO , KimMH , MarciniakTA .Excess ticagrelor mortality in the food and drug administration adverse event reporting system: time to recount PLATO trial deaths. American Journal of Medicine2017;130(6):e245-6. [MEDLINE: 28161342]SerebruanyVL .Angiographic outcomes contradict platelet data in the PLATO trial: confusion over official trial substudies. Cardiology2014;127(3):190-5. [MEDLINE: 24457905]SerebruanyVL .Discrepancies in the primary PLATO trial publication and the FDA reviews. International Journal of Cardiology2014;172(1):8-10. [MEDLINE: 24456868]SerebruanyVL .Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review. American Journal of Therapeutics2012;19(2):160-1. [MEDLINE: 22395000]SerebruanyVL .The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent. Cardiology2011;120(3):169-71. [MEDLINE: 22418766]ShimadaYJ , BansilalS , WiviottSD , BeckerRC , HarringtonRA , HimmelmannA , et al.Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal2016;177:1-8. [MEDLINE: 27297843]SihaH , DasD , FuY , ZhengY , WesterhoutCM , StoreyRF , et al.Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. CMAJ Canadian Medical Association Journal2012;184(10):1135-42. [MEDLINE: 22546885]StegPG , HarringtonRA , EmanuelssonH , KatusHA , MahaffeyKW , MeierB , et al.Response to letter regarding article, &quot;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial&quot;. Circulation2014;129(19):e494-5. [MEDLINE: 24821832]StegPG , HarringtonRA , EmanuelssonH , KatusHA , MahaffeyKW , MeierB , et al.Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation2013;128(10):1055-65. [MEDLINE: 23900047]StegPG , JamesS , HarringtonRA , ArdissinoD , BeckerRC , CannonCP , et al.Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation2010;122(21):2131-41. [MEDLINE: 21060072]StoreyRF , AngiolilloDJ , PatilSB , DesaiB , EcobR , HustedS , et al.Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. Journal of the American College of Cardiology2010;56(18):1456-62. [MEDLINE: 20832963]StoreyRF , ArdissinoD , VignaliL , CairnsR , BeckerRC , CannonCP , et al.Ischaemic events and stent thrombosis following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study. Thrombosis &amp; Haemostasis2018;118(2):427-9. [MEDLINE: 29443375]StoreyRF , BeckerRC , HarringtonRA , HustedS , JamesSK , CoolsF , et al.Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. European Heart Journal2011;32(23):2945-53. [MEDLINE: 21804104]StoreyRF , BeckerRC , HarringtonRA , HustedS , JamesSK , CoolsF , et al.Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). American Journal of Cardiology2011;108(11):1542-6. [MEDLINE: 21890085]StoreyRF , JamesSK , SiegbahnA , VarenhorstC , HeldC , YcasJ , et al.Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets2014;25(7):517-25. [MEDLINE: 24127651]SumayaW , WallentinL , JamesSK , SiegbahnA , GabryschK , BertilssonM , et al.Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. European Heart Journal2018;39(13):1078-85. [MEDLINE: 29390064]UelandT , AkerblomA , GhukasyanT , MichelsenAE , AukrustP , BeckerRC , et al.Osteoprotegerin is associated with major bleeding but not with cardiovascular outcomes in patients with acute coronary syndromes: insights from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American Heart Association2018;7(2):e007009. [MEDLINE: 29330256]UelandT , MichelsenA , AukrustP , BeckerR , BertilssonM , JamesSK , et al.Chemokine (CXC motif) ligand 16 (CXCL16) and osteoprotegerin (OPG) as predictors of outcome in patients with acute coronary syndromes (ACS) a PLATO biomarker substudy [abstract]. European Heart Journal2014;35(Suppl 1):486. [EMBASE: 71648554]WallentinL , BeckerRC , BudajA , CannonCP , EmanuelssonH , HeldC , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2009;361(11):1045-57. [MEDLINE: 19717846]WallentinL , BeckerRC , CannonCP , HeldC , HimmelmannA , HustedS , et al.No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. International Journal of Cardiology2014;176(1):300-2. [MEDLINE: 25005338]WallentinL , BeckerRC , CannonCP , HeldC , HimmelmannA , HustedS , et al.Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. International Journal of Cardiology2014;170(3):e59-62. [MEDLINE: 24299581]WallentinL , BeckerRC , JamesSK , HarringtonRA .The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. &quot;Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified&quot; (Thromb Haemost 2011; 105.5). Thrombosis &amp; Haemostasis2011;105(5):760-2. [MEDLINE: 21394383]WallentinL , JamesS , StoreyRF , ArmstrongM , BarrattBJ , HorrowJ , et al.Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet2010;376(9749):1320-8. [MEDLINE: 20801498]WallentinL , LindholmD , SiegbahnA , WernrothL , BeckerRC , CannonCP , et al.Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2014;129(3):293-303. [MEDLINE: 24170388]">PLATO 2009</a>; <a href="./references#CD008834-bbs2-0085" title="Quarto Di PaloF , ElliA , RivoltaR , ParentiM , PalazziP , ZanussiC .Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide. Transplantation Proceedings1991;23(1 Pt 2):969-71. [MEDLINE: 1989347]">Quarto Di Palo 1991</a>; <a href="./references#CD008834-bbs2-0086" title="BrenerSJ , BarrLA , BurchenalJE , KatzS , GeorgeBS , JonesAA , et al.Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation1998;98(8):734-41. [MEDLINE: 9727542]BrenerSJ , BarrLA , BurchenalJE , WolskiKE , EffronMB , TopolEJ .Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial. American Journal of Cardiology1999;84(6):728-30. [MEDLINE: 10498145]">RAPPORT 1998</a>; <a href="./references#CD008834-bbs2-0087" title="ReamsGP , YoungM , SorkinM , TwardowskiZ , GloorH , MooreH , et al.Effects of dipyridamole on peritoneal clearances. Uremia Investigation1985;9(1):27-33. [MEDLINE: 3915163]">Reams 1985</a>; <a href="./references#CD008834-bbs2-0097" title="StorckM , SchillingM , MickleyV , TechtB , AbendrothD .Influence of systemic cyclooxygenase inhibition with single-dose aspisol on kinetics of arachidonic acid metabolites in the venous effluate of transplanted kidney grafts in humans. Transplantation Proceedings1996;28(1):312-3. [MEDLINE: 8644237]">Storck 1996</a>; <a href="./references#CD008834-bbs2-0099" title="TangWH , LinFH , LeeCH , KuoFC , HsiehCH , HsiaoFC , et al.Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. Endocrine2014;45(2):293-301. [MEDLINE: 23775007]">Tang 2014</a>; <a href="./references#CD008834-bbs2-0104" title="CornelJH , TricociP , HortonJ , MoliternoD , WallentinL , ArmstrongP , et al.Effects of glycoprotein IIB/IIIA inhibitors in combination with vorapaxar, a platelet thrombin-receptor antagonist, among patients with non-St-segment elevation acute coronary syndromes: insights from the TRACER trial [abstract]. Journal of the American College of Cardiology2013;61(10 Suppl 1):E102. [EMBASE: 71019466]MahaffeyKW , PieperK , VranckxP , TricociP , Van de WerfF , HeldC , et al.Chronic kidney disease is associated with worse outcomes in ACS patients: results from the TRACER trial [abstract]. European Heart Journal2014;35(Suppl 1):687. [EMBASE: 71649310]">TRACER 2013</a>; <a href="./references#CD008834-bbs2-0105" title="AbaciA .The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses [Prasugrelin ST yukselmeli ve yukselmesiz miyokart enfarktusunde kullanimi: TRITON TIMI 38 caIismasi ve alt grup sonuclari]. Turk Kardiyoloji Dernegi Arsivi2015;43 Suppl 2:1-6. [MEDLINE: 27326444]AntmanEM , WiviottSD , MurphySA , VoitkJ , HasinY , WidimskyP , et al.Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Journal of the American College of Cardiology2008;51(21):2028-33. [MEDLINE: 18498956]BonacaMP , WiviottSD , BraunwaldE , MurphySA , RuffCT , AntmanEM , et al.American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation2012;125(4):577-83. [MEDLINE: 22199016]CapodannoD , TamburinoC .Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International Journal of Cardiology2011;146(2):242-3. [MEDLINE: 21130510]DammanP , deWinterRJ , WallentinL , FoxKA .Letter by Damman et al regarding articles, &quot;Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)&quot; and &quot;American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)&quot;. Circulation2012;126(9):e136-7. [MEDLINE: 22927480]De ServiS , GoedickeJ , SchirmerA , WidimskyP .Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European Heart Journal: Acute Cardiovascular Care2014;3(4):363-72. [MEDLINE: 24818952]GoodnoughLT , SmithPK , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. Journal of Thoracic &amp; Cardiovascular Surgery2013;145(4):1077-82. [MEDLINE: 22995726]HochholzerW , WiviottSD , AntmanEM , ContantCF , GuoJ , GiuglianoRP , et al.Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation2011;123(23):2681-9. [MEDLINE: 21606391]KohliP , UdellJA , MurphySA , CannonCP , AntmanEM , BraunwaldE , et al.Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Journal of the American College of Cardiology2014;63(3):225-32. [MEDLINE: 24140678]MahoneyEM , WangK , ArnoldSV , ProskorovskyI , WiviottS , AntmanE , et al.Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation2010;121(1):71-9. [MEDLINE: 20026770]MarianiM , MarianiG , De ServiS .Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert Review of Cardiovascular Therapy2009;7(1):17-23. [MEDLINE: 19105763]MegaJL , CloseSL , WiviottSD , ShenL , WalkerJR , SimonT , et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet2010;376(9749):1312-9. [MEDLINE: 20801494]MichelsonAD , Frelinger AL 3rd, BraunwaldE , DowneyWE , AngiolilloDJ , XenopoulosNP , et al.Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal2009;30(14):1753-63. [MEDLINE: 19435740]MogabgabO , WiviottSD , CannonCP , SloanS , SabatineMS , AntmanEM , et al.Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(6):555-9. [MEDLINE: 24064010]MontalescotG , WiviottSD , BraunwaldE , MurphySA , GibsonCM , McCabeCH , et al.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet2009;373(9665):723-31. [MEDLINE: 19249633]MurphySA , AntmanEM , WiviottSD , WeerakkodyG , MorocuttiG , HuberK , et al.Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European Heart Journal2008;29(20):2473-9. [MEDLINE: 18682445]O'DonoghueM , AntmanEM , BraunwaldE , MurphySA , StegPG , FinkelsteinA , et al.The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology2009;54(8):678-85. [MEDLINE: 19679245]OjeifoO , WiviottSD , AntmanEM , MurphySA , UdellJA , BatesER , et al.Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Jacc: Cardiovascular Interventions2013;6(2):1275-81. [MEDLINE: 24239201]PakhomovIM .Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial. Kardiologiia2010;50(6):63-7. [MEDLINE: 20659030]PrideYB , TungP , MohanaveluS , ZorkunC , WiviottSD , AntmanEM , et al.Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. Jacc: Cardiovascular Interventions2010;3(8):306-11. [MEDLINE: 20723851]RiesmeyerJS , SalazarDE , WeerakkodyGJ , NiL , WrishkoRE , Ernest CS 2nd, et al.Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. Journal of Clinical Pharmacology2012;52(6):789-97. [MEDLINE: 21628601]SerebruanyVL .Letter by Serebruany regarding article, &quot;Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38&quot;. Circulation2010;122(8):e436. [MEDLINE: 20733108]SmithPK , GoodnoughLT , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology2012;60(5):388-96. [MEDLINE: 22633653]SorichMJ , VitryA , WardMB , HorowitzJD , McKinnonRA .Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis &amp; Haemostasis2010;8(8):1678-84. [MEDLINE: 20492467]UdellJA , BraunwaldE , AntmanEM , MurphySA , MontalescotG , WiviottSD .Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).[Erratum in: JACC Cardiovasc Interv. 2014 Aug;7(8):946 Note: Antman, Elliot M [Corrected to Antman, Elliott M]]. Jacc: Cardiovascular Interventions2014;7(6):604-12. [MEDLINE: 24947719]WilcoxR , IqbalK , CostiganT , Lopez-SendonJ , RamosY , WidimskyP .An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current Medical Research &amp; Opinion2014;30(11):2193-205. [MEDLINE: 25025610]WiviottSD , AntmanEM , GibsonCM , MontalescotG , RiesmeyerJ , WeerakkodyG , et al.Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). American Heart Journal2006;152(4):627-35. [MEDLINE: 16996826]WiviottSD , BraunwaldE , McCabeCH , HorvathI , KeltaiM , HerrmanJP , et al.Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet2008;371(9621):1353-63. [MEDLINE: 18377975]WiviottSD , BraunwaldE , McCabeCH , MontalescotG , RuzylloW , GottliebS , et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2007;357(20):2001-15. [MEDLINE: 17982182]WiviottSD , DesaiN , MurphySA , MusumeciG , RagostaM , AntmanEM , et al.Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. American Journal of Cardiology2011;108(7):905-11. [MEDLINE: 21816379]WrishkoRE , Ernest CS 2nd, SmallDS , LiYG , WeerakkodyGJ , RiesmeyerJR , et al.Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. Journal of Clinical Pharmacology2009;49(8):984-98. [MEDLINE: 19546250]">TRITON‐TIMI 38 2006</a>; <a href="./references#CD008834-bbs2-0113" title="ZäunerI , BöhlerJ , BraunN , GruppC , HeeringP , SchollmeyerP .Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Nephrology Dialysis Transplantation1994;9(6):619-22. [MEDLINE: 7970086]">Zäuner 1994</a>), incomplete, and judged to be at high risk of bias for 24 studies (<a href="./references#CD008834-bbs2-0009" title="ChanMK , KwanSY , ChanKW , YeungCK .Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis. American Journal of Kidney Diseases1987;9(5):417-21. [MEDLINE: 3555016]">Chan 1987</a>; <a href="./references#CD008834-bbs2-0012" title="ChengIK , FangGX , WongMC , JiYL , ChanKW , YeungHW .A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy. Nephrology1998;4(1-2):19-26. [EMBASE: 28282953]ChengIK , FangGX , WongMC , JiYL , YeungH .A randomised prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA glomerulonephritis (IgAN) [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:45. [CENTRAL: CN-00550664] ">Cheng 1998a</a>; <a href="./references#CD008834-bbs2-0018" title="DashA , MaitiR , BandakkanavarTK , BhaskarA , PrakashJ , PandeyBL .Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: comparison between clopidogrel and low-dose aspirin. International Journal of Preventive Medicine2013;4(8):902-10. [MEDLINE: 24049616]">Dash 2013</a>; <a href="./references#CD008834-bbs2-0023" title="DonadioJV , AndersonCF , MitchellJC , HolleyKE , IlstrupDM , FusterV .Membranoproliferative glomerulonephritis (MPGN): a prospective clinical trial of platelet inhibitor therapy [abstract]. Kidney International1983;23(1):121. [CENTRAL: CN-00602010] Donadio JV Jr, AndersonCF , Mitchell JC 3rd, HolleyKH , IlstrupDM , FusterV , et al.Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. New England Journal of Medicine1984;310(22):1421-6. [MEDLINE: 6371535]">Donadio 1984</a>; <a href="./references#CD008834-bbs2-0030" title="BaumgartnerI , NorgrenL , FowkesFG , MulderH , PatelMR , BergerJS , et al.Cardiovascular outcomes after lower extremity endovascular or surgical revascularization: the EUCLID trial. Journal of the American College of Cardiology2018;72(14):1563-72. [MEDLINE: 30261955]BergerJS , AbramsonBL , LopesRD , HeizerG , RockholdFW , BaumgartnerI , et al.Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Vascular Medicine2018;23(6):523-30. [MEDLINE: 29992857]HaineA , KavanaghS , BergerJS , HessCN , NorgrenL , FowkesFG , et al.Sex-specific risks of major cardiovascular and limb events in patients with symptomatic peripheral artery disease. Journal of the American College of Cardiology2020;75(6):608-17. [MEDLINE: 32057375]HessCN , HuangZ , PatelMR , BaumgartnerI , BergerJS , BlomsterJI , et al.Acute limb ischemia in peripheral artery disease. Circulation2019;140(7):556-65. [MEDLINE: 31238713]HiattWR , FowkesFG , HeizerG , BergerJS , BaumgartnerI , HeldP , et al.Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. New England Journal of Medicine2017;376(1):32-40. [MEDLINE: 27959717]HopleyCW , KavanaghS , PatelMR , OstromC , BaumgartnerI , BergerJS , et al.Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial. Vascular Medicine2019;24(5):422-30. [MEDLINE: 31339474]JonesWS , BaumgartnerI , HiattWR , HeizerG , ConteMS , WhiteCJ , et al.Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation2017;135(3):241-50. [MEDLINE: 27840336]KollsBJ , SappS , RockholdFW , JordanJD , DombrowskiKE , FowkesFG , et al.Stroke in patients with peripheral artery disease. Stroke2019;50(6):1356-63. [MEDLINE: 31092165]Low WangCC , BlomsterJI , HeizerG , BergerJS , BaumgartnerI , FowkesFG , et al.Cardiovascular and limb outcomes in patients with diabetes and peripheral artery disease: the EUCLID trial. Journal of the American College of Cardiology2018;72(25):3274-84. [MEDLINE: 30573030]NorgrenL , PatelMR , HiattWR , WojdylaDM , FowkesFG , BaumgartnerI , et al.Outcomes of patients with critical limb ischaemia in the EUCLID trial. European Journal of Vascular &amp; Endovascular Surgery2018;55(1):109-17. [MEDLINE: 29273390]OlivierCB , MulderH , HiattWR , JonesWS , FowkesFG , RockholdFW , et al.Incidence, characteristics, and outcomes of myocardial infarction in patients with peripheral artery disease: insights from the EUCLID trial. JAMA Cardiology2019;4(1):7-15. [MEDLINE: 30540355]">EUCLID 2017</a>; <a href="./references#CD008834-bbs2-0032" title="FiskerstrandCE , ThompsonIW , BurnetME , WilliamsP , AndertonJL .Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artificial Organs1985;9(1):61-3. [MEDLINE: 3888153]">Fiskerstrand 1985</a>; <a href="./references#CD008834-bbs2-0033" title="BonominiV , VangelistaA , StefoniS , ScolariMP , FrascàGM , RaimondiC .Use of defibrotide in renal transplantation in man. Haemostasis1986;16 Suppl 1:48-50. [MEDLINE: 3519383]FrascàGM , VangelistaA , RaimondiC , BonominiV .Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (defibrotide): a controlled study. Life Support Systems1986;4(3):231-7. [MEDLINE: 3537545]">Frascà 1986</a>; <a href="./references#CD008834-bbs2-0036" title="GhorbaniA , AalamshahM , ShahbazianH , EhsanpourA , ArefA .Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian Journal of Nephrology2009;19(2):57-61. [MEDLINE: 20368925]">Ghorbani 2009</a>; <a href="./references#CD008834-bbs2-0038" title="GiustinaA , PeriniP , DesenzaniP , BossoniS , IannielloP , MilaniM , et al.Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes1998;47(3):423-30. [MEDLINE: 9519749]">Giustina 1998</a>; <a href="./references#CD008834-bbs2-0041" title="GonzalezMT , CastelaoAM , VallesM , CruzadoJM , MauriJM .Platelet antiaggregants (PA) could decrease the rate of progression of chronic renal failure (CRF) in diabetic patients (DP) treated previously with angiotensin converting enzyme inhibitors (ACEi) [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:200. [CENTRAL: CN-00509215] ">Gonzalez 1995</a>; <a href="./references#CD008834-bbs2-0042" title="GröntoftKC , MulecH , GutierrezA , OlanderR .Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scandinavian Journal of Urology &amp; Nephrology1985;19(1):55-7. [MEDLINE: 3895411]">Gröntoft 1985</a>; <a href="./references#CD008834-bbs2-0046" title="HarterHR , BurchJW , MajerusPW , StanfordN , DelmezJA , AndersonCB , et al.Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. New England Journal of Medicine1979;301(11):577-9. [MEDLINE: 112475]">Harter 1979</a>; <a href="./references#CD008834-bbs2-0052" title="OhtakeT , SatoM , NakazawaR , KondohM , KobayashiS .Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study [abstract no: Su528]. NDT Plus2010;3(Suppl 3):iii487. [EMBASE: 70484748]OhtakeT , SatoM , NakazawaR , KondohM , MiyajiT , MoriyaH , et al.Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2014;18(1):1-8. [MEDLINE: 24499078]">J‐PADD 2014</a>; <a href="./references#CD008834-bbs2-0053" title="KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. New England Journal of Medicine1974;290(6):304-6. [MEDLINE: 4588285]KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation1975;52(3):497-9. [MEDLINE: 1098808]">Kaegi 1974</a>; <a href="./references#CD008834-bbs2-0060" title="KooistraMP , vanEsA , MarxJJ , HertsigM , StruyvenbergA .Effects of low dose aspirin on thrombovascular accidents during treatment with rHuEpo: a multicentre, controlled, cross-over study [abstract]. Nephrology Dialysis Transplantation1993;8:277. [CENTRAL: CN-00260772] KooistraMP , vanEsA , MarxJJ , HertsigML , StruyvenbergA .Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrology Dialysis Transplantation1994;9(8):1115-20. [MEDLINE: 7800210]">Kooistra 1994</a>; <a href="./references#CD008834-bbs2-0063" title="MichieDD , WomboltDG .Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research - Clinical &amp; Experimental1977;22(1 II):196-204. [EMBASE: 8152617]">Michie 1977</a>; <a href="./references#CD008834-bbs2-0078" title="JeongKH , ChoJH , WooJS , KimJB , KimWS , LeeTW , et al.Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. American Journal of Kidney Diseases2015;65(6):916-24. [MEDLINE: 25622774]JeongKH , LeeTW , KimJS , LeeSY , LeeSH , MoonJY , et al.Platelet reactivity in patients with end stage renal disease receiving clopidogrel compared with ticagrelor: a randomized crossover study [abstract no: FP610]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii276. [EMBASE: 72207028]WooJS , KimW , KimHS , HwangSJ , KimJB , KimSJ , et al.Randomized assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with chronic kidney disease performing hemodialysis [abstract]. European Heart Journal2014;35(Suppl 1):7-8. [EMBASE: 71646762]">PIANO‐3 2015</a>; <a href="./references#CD008834-bbs2-0079" title="KimJS , LeeTW , IhmC , LeeSH , KimSY , LeeSY , et al.Relationship of ticagrelor dose and platelet reactivity in patients with end stage renal disease on hemodialysis [abstract no: FR-PO727]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):529A. KimJS , WooJS , KimJB , KimWS , LeeTW , KimKS , et al.The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. International Journal of Cardiology2017;238:110-6. [MEDLINE: 28342632]KimW , WooJS , KimWS , KimJB , KimHO , KimJM .Pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis [abstract]. European Heart Journal2016;37(Suppl 1):636. [EMBASE: 612284362]">PIANO‐6 2017</a>; <a href="./references#CD008834-bbs2-0089" title="RouzrokhM , AbbasiMR , MirshemiraniAR , SobhiyehMR .The effect of antiplatelet drugs on the patency rate of arterio-venous fistulae in hemodialysis patients. Iranian Journal of Pharmaceutical Research2010;9(4):451-7. [EMBASE: 2011024056]">Rouzrokh 2010</a>; <a href="./references#CD008834-bbs2-0094" title="SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract no: 9P]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):388. [CENTRAL: CN-00485981] SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study. Kidney International1994;45(5):1477-83. [MEDLINE: 8072261]">Sreedhara 1994</a>; <a href="./references#CD008834-bbs2-0095" title="SteinessE , BrunN , SkarsfeldtT , DerwahlKM .Low dose anti-thromboxane reduces urinary albumin in patients with diabetic kidney disease [abstract no: SA-PO148]. Journal of the American Society of Nephrology2018;29:773. [EMBASE: 633731990]">Steiness 2018</a>; <a href="./references#CD008834-bbs2-0103" title="CorreaS , BonacaMP , SciricaBM , MurphySA , GoodrichEL , MorrowDA , et al.Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. Journal of Thrombosis &amp; Thrombolysis2019;47(3):353-60. [MEDLINE: 30511258]GaviriaSC , BraunwaldE , BonacaMP , MurphySA , GoodrichEL , MorrowDA , et al.The efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function: insights from the TRA 2P-TIMI 50 trial [abstract no: 15480]. Circulation2017;136(Suppl 1). [EMBASE: 619986693]MorrowDA , BraunwaldE , BonacaMP , AmerisoSF , DalbyAJ , FishMP , et al.Vorapaxar in the secondary prevention of atherothrombotic events. New England Journal of Medicine2012;366(15):1404-13. [MEDLINE: 22443427]MorrowDA , SciricaBM , FoxKA , BermanG , StronyJ , VeltriE , et al.Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. American Heart Journal2009;158(3):335-41. [MEDLINE: 19699854]">TRA 2P‐TIMI 50 2009</a>; <a href="./references#CD008834-bbs2-0106" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al.First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473-84. [MEDLINE: 15754269]BaigentC , UK-HARP Steering Committee.Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-PO851]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. [CENTRAL: CN-00444305] ">UK‐HARP‐I 2005</a>; <a href="./references#CD008834-bbs2-0111" title="YangMY , HanB , XuY , TianLY , ZhangY , QiangYW .The effects of different dose of clopidogrel in elderly patients with unstable angina combining chronic kidney disease [abstract no: P12]. Journal of the American Geriatrics Society2016;64(Suppl 2):S320. [EMBASE: 611887576]">Yang 2016b</a>) and unclear in 48 studies. </p> </section> <section id="CD008834-sec-0056"> <h4 class="title">Selective reporting</h4> <p>Fifty studies reported expected and clinically‐relevant outcomes and were deemed to be at low risk of bias (<a href="./references#CD008834-bbs2-0001" title="GoicoecheaM , deVinuesaMS , QuirogaB , VerdallesU , MoralesE , De SequeraP , et al.Aspirin treatment in primary cardiovascular prevention and renal disease progression in CKD patients: a randomized clinical trials (AASER study) [abstract no: FR-PO1065]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):B5. [EMBASE: 633704620]GoicoecheaM , deVinuesaSG , QuirogaB , VerdeE , BernisC , MoralesE , et al.Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study). Cardiovascular Drugs &amp; Therapy2018;32(3):255-63. [MEDLINE: 29943364]GoicoecheaM , Sanchez-NinoMD , OrtizA , deVinuesaMS , QuirogaB , MoralesE , et al.Low dose aspirin increases 15-epi-lipoxin a4 levels in CKD patients [abstract no: SA-PO186]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):726. [EMBASE: 633701100]GoicoecheaM , Sanchez-NinoMD , OrtizA , Garcia de VinuesaS , QuirogaB , BernisC , et al.Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. Prostaglandins Leukotrienes &amp; Essential Fatty Acids2017;125:8-13. [MEDLINE: 28987723]">AASER 2017</a>; <a href="./references#CD008834-bbs2-0002" title="AbacilarAF , AtalayH , DoganOF .Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: a randomized controlled study. Indian Journal of Nephrology2015;25(3):136-42. [MEDLINE: 26060361]">Abacilar 2015</a>; <a href="./references#CD008834-bbs2-0004" title="AlexopoulosD , PanagiotouA , XanthopoulouI , KomninakisD , KassimisG , DavlourosP , et al.Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. Journal of Thrombosis &amp; Haemostasis2011;9(12):2379-85. [MEDLINE: 21985070]XanthopoulouI , PanagiotouA , KomninakisD , DavlourosP , KassimisG , FourtounasK , et al.Prasugrel versus double clopidpogrel maintenance dose in patients on chronic haemodialysis and high on clopidogrel platelet reactivity [abstract no: P2438]. European Heart Journal2011;32(Suppl 1):417. [EMBASE: 70534608]">Alexopoulos 2011</a>; <a href="./references#CD008834-bbs2-0007" title="Di FrancoA , GaudinoM , GirardiLN .Considerations about the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. Journal of Thoracic Disease2016;8(7):E599. [MEDLINE: 27501533]MylesPS , SmithJ , KnightJ , CooperDJ , SilbertB , McNeilJ , et al.Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial: rationale and design. American Heart Journal2008;155(2):224-30. [MEDLINE: 18215590]MylesPS , SmithJA , ForbesA , SilbertB , JayarajahM , PainterT , et al.Stopping vs. continuing aspirin before coronary artery surgery. New England Journal of Medicine2016;374(8):728-37. [MEDLINE: 26933848]MylesPS , SmithJA , ForbesA , SilbertB , JayarajahM , PainterT , et al.Tranexamic acid in patients undergoing coronary-artery surgery [Erratum for: N Engl J Med. 2017 Jan 12;376(2):136-148; PMID: 27774838]. New England Journal of Medicine2017;376(2):136-48. [MEDLINE: 27774838]MylesPS , SmithJA , KaszaJ , SilbertB , JayarajahM , PainterT , et al.Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial. Journal of Thoracic &amp; Cardiovascular Surgery2019;157(2):633-40. [MEDLINE: 30401528]MylesPS , SmithJA , KaszaJ , SilbertB , JayarajahM , PainterT , et al.Tranexamic acid in coronary artery surgery: one-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. Journal of Thoracic &amp; Cardiovascular Surgery2019;157(2):644-52.e9. [MEDLINE: 30459103]">ATACAS 2008</a>; <a href="./references#CD008834-bbs2-0008" title="FujitaT , YuX , KimS , NakamotoH , OrigasaH , KurumataniH , et al.Effects of sustained-release beraprost sodium in patients with primary glomerular disease or nephrosclerosis: the CASSIOPEIR study [abstract no: SA-PO1096]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):4B. [CENTRAL: CN-01657821] NakamotoH , FujitaT , OrigasaH , IsonoM , KurumataniH , OkadaK , et al.A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrology2014;15:153. [MEDLINE: 25233856]NakamotoH , YuXQ , KimS , OrigasaH , ZhengH , ChenJ , et al.Effects of sustained-release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results. Therapeutic Apheresis &amp; Dialysis2020;24(1):42-55. [MEDLINE: 31119846]">CASSIOPEIR 2014</a>; <a href="./references#CD008834-bbs2-0010" title="JingJ , MengX , ZhaoX , LiuL , WangA , PanY , et al.Dual antiplatelet therapy in transient ischemic attack and minor stroke with different infarction patterns: subgroup analysis of the CHANCE randomized clinical trial. JAMA Neurology2018;75(6):711-9. [MEDLINE: 29582084]LiJ , WangY , LinJ , WangD , WangA , ZhaoX , et al.Soluble CD40L is a useful marker to predict future strokes in patients with minor stroke and transient ischemic attack. Stroke2015;46(7):1990-2. [MEDLINE: 26012640]LiJ , ZhaoX , MengX , LinJ , LiuL , WangC , et al.High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome: subanalysis of the clopidogrel in high-risk patients with acute nondisabling cerebrovascular events trial. Stroke2016;47(8):2025-30. [MEDLINE: 27328699]LinY , WangA , LiJ , LinJ , WangD , MengX , et al.Impact of glycemic control on efficacy of clopidogrel in transient ischemic attack or minor stroke patients with CYP2C19 genetic variants. Stroke2017;48(4):998-1004. [MEDLINE: 28289237]LiuL , WongKS , LengX , PuY , WangY , JingJ , et al.Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology2015;85(13):1154-62. [MEDLINE: 26330567]LiZ , WangY , ZhaoX , LiuL , WangD , WangC , et al.Treatment effect of clopidogrel plus aspirin within 12 hours of acute minor stroke or transient ischemic attack. Journal of the American Heart Association2016;5(3):e003038. [MEDLINE: 27001965]MaY , LiuY , XuJ , WangY , WangY , DuF .Effect of dual antiplatelet on recurrent stroke in minor stroke or TIA depends on bodyweight. Therapeutics &amp; Clinical Risk Management2018;14:861-70. [MEDLINE: 29773949]PanY , CaiX , JingJ , MengX , LiH , WangY , et al.Stress hyperglycemia and prognosis of minor ischemic stroke and transient ischemic attack: the CHANCE study (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). Stroke2017;48(11):3006-11. [MEDLINE: 29051218]PanY , JingJ , ChenW , MengX , LiH , ZhaoX , et al.Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE.[Erratum in: Neurology. 2019 Aug 13;93(7):322; PMID: 31405943]. Neurology2017;88(20):1906-11. [MEDLINE: 28424269]PanY , JingJ , LiH , WangY , WangY , HeY , et al.Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA. Neurology2016;87(15):1551-6. [MEDLINE: 27613582]PanY , MengX , JingJ , LiH , ZhaoX , LiuL , et al.Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA. Neurology2017;88(11):1081-8. [MEDLINE: 28202699]WangA , LiS , ZhangN , DaiL , ZuoY , WangY , et al.Oxidized low-density lipoprotein to high-density lipoprotein ratio predicts recurrent stroke in minor stroke or transient ischemic attack. Stroke2018;49(11):2637-42. [MEDLINE: 30355199]WangA , XuJ , ChenG , WangD , JohnstonSC , MengX , et al.Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA. Neurology2018;91(10):e947-55. [MEDLINE: 30089614]WangD , GuiL , DongY , LiH , LiS , ZhengH , et al.Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial. Stroke &amp; Vascular Neurology2016;1(2):29-36. [MEDLINE: 28959461]WangqinR , WangX , WangY , XianY , ZhaoX , LiuL , et al.Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA: a subgroup analysis of the CHANCE trial. Stroke &amp; Vascular Neurology2017;2(4):176-83. [MEDLINE: 29507777]WangY , PanY , ZhaoX , LiH , WangD , JohnstonSC , et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial: one-year outcomes. Circulation2015;132(1):40-6. [MEDLINE: 25957224]WangY , WangY , ZhaoX , LiuL , WangD , WangC , et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine2013;369(1):11-9. [MEDLINE: 23803136]WangY , ZhaoX , LinJ , LiH , JohnstonSC , LinY , et al.Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA2016;316(1):70-8. [MEDLINE: 27348249]WuY , ZhouY , PanY , ZhaoX , LiuL , WangD , et al.Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. Pharmacogenomics Journal2018;18(6):713-20. [MEDLINE: 29520080]ZhouY , PanY , WuY , ZhaoX , LiH , WangD , et al.Effect of estimated glomerular filtration rate decline on the efficacy and safety of clopidogrel with aspirin in minor stroke or transient ischemic attack: CHANCE substudy (Clopidogrel in high-risk patients with acute nondisabling cerebrovascular events). Stroke2016;47(11):2791-6. [MEDLINE: 27738237]ZhuB , LiuH , PanY , JingJ , LiH , ZhaoX , et al.Elevated neutrophil and presence of intracranial artery stenosis increase the risk of recurrent stroke. Stroke2018;49(10):2294-300. [MEDLINE: 30355101]">CHANCE 2013</a>; <a href="./references#CD008834-bbs2-0011" title="BangaloreS , BhattDL , StegPG , WeberMA , BodenWE , HammCW , et al.beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circulation: Cardiovascular Quality &amp; Outcomes2014;7(6):872-81. [MEDLINE: 25271049]BergerPB , BhattDL , FusterV , StegPG , FoxKA , ShaoM , et al.Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation2010;121(23):2575-83. [MEDLINE: 20516378]BhattDL , FlatherMD , HackeW , BergerPB , BlackHR , BodenWE , et al.Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology2007;49(19):1982-8. [MEDLINE: 17498584]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial [Erratum in: Am Heart J. 2006 Jan;151(1):247]. American Heart Journal2005;150(3):401. [MEDLINE: 16169314]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine2006;354(16):1706-17. [MEDLINE: 16531616]DasguptaA , SteinhublSR , BhattDL , BergerPB , ShaoM , MakKH , et al.Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). American Journal of Cardiology2009;103(10):1359-63. [MEDLINE: 19427428]EikelboomJW , HankeyGJ , ThomJ , BhattDL , StegPG , MontalescotG , et al.Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation2008;118(17):1705-12. [MEDLINE: 18838564]MakKH , BhattDL , ShaoM , HaffnerSM , HammCW , HankeyGJ , et al.The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. European Heart Journal2009;30(7):857-65. [MEDLINE: 19233855]SteinhublSR , BhattDL , BrennanDM , MontalescotG , HankeyGJ , EikelboomJW , et al.Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding [Summary for patients in Ann Intern Med. 2009 Mar 17;150(6):I-22; PMID: 19293067]. Annals of Internal Medicine2009;150(6):379-86. [MEDLINE: 19293071]WangTH , BhattDL , FoxKA , SteinhublSR , BrennanDM , HackeW , et al.An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal2007;28(18):2200-7. [MEDLINE: 17673448]">CHARISMA 2006</a>; <a href="./references#CD008834-bbs2-0015" title="AronowHD , SteinhublSR , BrennanDM , BergerPB , TopolEJ , CREDO Investigators.Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal2009;157(2):369-74. [MEDLINE: 19185647]BeinartSC , KolmP , VeledarE , ZhangZ , MahoneyEM , BouinO , et al.Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Journal of the American College of Cardiology2005;46(5):761-9. [MEDLINE: 16139122]BestPJ , SteinhublSR , BergerPB , DasguptaA , BrennanDM , SzczechLA , et al.The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal2008;155(4):687-93. [MEDLINE: 18371477]BrenerSJ , SteinhublSR , BergerPB , BrennanDM , TopolEJ , CREDO Investigators.Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial. Journal of Invasive Cardiology2007;19(7):287-90. [MEDLINE: 17620671]RingborgA , LindgrenP , JonssonB .The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. European Journal of Health Economics2005;6(4):354-56, 358-62. [MEDLINE: 16267654]SteinhublSR , BergerPB , Mann JT 3rd, FryET , DeLagoA , WilmerC , et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [Erratum in: JAMA. 2003 Feb 26;289(8):987]. JAMA2002;288(19):2411-20. [MEDLINE: 12435254]">CREDO 2005</a>; <a href="./references#CD008834-bbs2-0016" title="CreekR .Ticlopidine. Patency of haemodialysis access sites. Guildford Sanofi Winthrop. Internal report1990. ">Creek 1990</a>; <a href="./references#CD008834-bbs2-0017" title="BergerPB , SteinhublS .Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. Circulation2002;106(17):2284-7. [MEDLINE: 12390961]GerschutzGP , BhattDL , Clopidogrel in Unstable Angina to Prevent Recurrent Events study.The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?American Heart Journal2003;145(4):595-601. [MEDLINE: 12679754]KeltaiM , TonelliM , MannJF , SitkeiE , LewisBS , HawkenS , et al.Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. European Journal of Cardiovascular Prevention &amp; Rehabilitation2007;14(2):312-8. [MEDLINE: 17446813]LewisBS , MehtaSR , FoxKA , HalonDA , ZhaoF , PetersRJ , et al.Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. American Heart Journal2005;150(6):1177-84. [MEDLINE: 16338255]MehtaSR , YusufS , PetersRJ , BertrandME , LewisBS , NatarajanMK , et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet2001;358(9281):527-33. [MEDLINE: 11520521]MehtaSR , YusufS , Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators.The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. European Heart Journal2000;21(24):2033-41. [MEDLINE: 11102254]PetersRJ , MehtaSR , FoxKA , ZhaoF , LewisBS , KopeckySL , et al.Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation2003;108(14):1682-7. [MEDLINE: 14504182]YusufS ,  ZhaoF ,  MehtaSR ,  ChrolaviciusS ,  TognoniG ,  FoxKK , et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [Erratum in: N Engl J Med 2001 Dec 6;345(23):1716; Erratum in: N Engl J Med 2001 Nov 15;345(20):1506]. New England Journal of Medicine2001;345(7):494-502. [MEDLINE: 11519503]">CURE 2000</a>; <a href="./references#CD008834-bbs2-0019" title="DemberL , AllonM , DelmezJ , DixonB , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00550593] DemberLM , BeckGJ , AllonM , DelmezJA , DixonBS , GreenbergA , et al.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008;299(18):2164-71. [MEDLINE: 18477783]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials2005;2(5):413-22. [MEDLINE: 16317810]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):229A. [CENTRAL: CN-00445067] ">Dember 2005</a>; <a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a>; <a href="./references#CD008834-bbs2-0024" title="BagaiA , WhiteJA , LokhnyginaY , GiuglianoRP , Van de WerfF , MontalescotG , et al.Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. American Heart Journal2013;166(3):466-73. [MEDLINE: 24016495]De FerrariGM , Van de WerfF , ArmstrongP , BodeC , LewisBS , TricociP , et al.Contrast induced nephropathy predicts later mortality among patients with non-ST-segment elevation acute coronary syndrome undergoing PCI: a sub-analysis from the EARLY ACS study [abstract no: P3820]. European Heart Journal2011;32(Suppl 1):657. [EMBASE: 70535519]EzekowitzJA , BakalJA , WesterhoutCM , GiuglianoRP , WhiteH , KeltaiM , et al.The relationship between meteorological conditions and index acute coronary events in a global clinical trial. International Journal of Cardiology2013;168(3):2315-21. [MEDLINE: 23416014]FarhanS , ClareRM , JaraiR , GiuglianoRP , LokhnyginaY , HarringtonRA , et al.Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: an analysis from EARLY ACS. International Journal of Cardiology2017;232:264-70. [MEDLINE: 28089149]FarhanS , ClareRM , JaraiR , NewbyLK , MorrowD , GiuglianoRP , et al.Fasting glucose, NT-proBNP, treatment with glycoprotein IIB/IIIA inhibitors, and outcomes in non-st-segment elevation acute coronary syndromes: an analysis from early ACS [abstract no: A14618]. Circulation2013;128(22 Suppl 1). [EMBASE: 71340424]GiuglianoRP , NewbyLK , HarringtonRA , GibsonCM , Van de WerfF , ArmstrongP , et al.The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. American Heart Journal2005;149(6):994-1002. [MEDLINE: 15976780]GiuglianoRP , WhiteJA , BodeC , ArmstrongPW , MontalescotG , LewisBS , et al.Early versus delayed, provisional eptifibatide in acute coronary syndromes. New England Journal of Medicine2009;360(21):2176-90. [MEDLINE: 19332455]HessCN , SchultePJ , NewbyLK , StegPG , DalbyAJ , SchweigerMJ , et al.Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. European Heart Journal: Acute Cardiovascular Care2013;2(3):246-55. [MEDLINE: 24222836]KaulP , TanguayJF , NewbyLK , HochmanJS , WesterhoutCM , CaliffRM , et al.Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. American Heart Journal2013;166(4):723-8. [MEDLINE: 24093853]KlutsteinMW , WesterhoutCM , ArmstrongPW , GiuglianoRP , LewisBS , GibsonCM , et al.Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. American Heart Journal2013;165(4):583-90. [MEDLINE: 23537976]KunadianV , GiuglianoRP , NewbyLK , ZorkunC , GuoJ , BagaiA , et al.Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). American Journal of Cardiology2014;113(8):1297-305. [MEDLINE: 24607027]LopesRD , WhiteJA , TricociP , WhiteHD , ArmstrongPW , BraunwaldE , et al.Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. International Journal of Cardiology2013;167(6):2580-7. [MEDLINE: 22795720]MelloniC , JamesSK , WhiteJA , GiuglianoRP , HarringtonRA , HuberK , et al.Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. American Heart Journal2011;162(5):884-92. [MEDLINE: 22093205]PicciniJP , WhiteJA , MehtaRH , LokhnyginaY , Al-KhatibSM , TricociP , et al.Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. Circulation2012;126(1):41-9. [MEDLINE: 22645292]PrideYB , MohanaveluS , GiuglianoRP , NewbyLK , ZorkunC , KunadianV , et al.Association between angiographic complications during percutaneous coronary intervention and clinical outcomes among patients with acute coronary syndrome: an early ACS angiographic substudy [abstract no: A10394]. Circulation2011;124(21 Suppl 1). [EMBASE: 70620664]PrideYB , MohanaveluS , ZorkunC , KunadianV , GiuglianoRP , NewbyLK , et al.Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. Jacc: Cardiovascular Interventions2012;5(9):927-35. [MEDLINE: 22995880]RoeMT , WhiteJA , KaulP , TricociP , LokhnyginaY , MillerCD , et al.Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. Circulation. Cardiovascular Quality &amp; Outcomes2012;5(2):205-13. [MEDLINE: 22373905]TanguayJF , NewbyLK , HochmanJ , WesterhoutCM , CaliffRM , GibsonCM , et al.Sex differences in high-risk acute coronary syndromes: Insights from early-ACS [abstract]. Journal of the American College of Cardiology2010;55(10 Suppl 1):A120.E1122. [EMBASE: 70096317]TolevaO , WesterhoutCM , SenaratneM , BodeC , LindroosM , ArdissinoD , et al.Association of hub and spoke practice patterns with coronary intervention and outcomes in non ST elevation acute coronary syndromes (NSTE ACS): Insights from the early glycoprotein IIb/IIIa inhibition in NSTE ACS (early-ACS) trial [abstract]. Journal of the American College of Cardiology2011;57(14 Suppl 1):E1101. [EMBASE: 70400778]TolevaO , WesterhoutCM , SenaratneMP , BodeC , LindroosM , SulimovVA , et al.Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial. Catheterization &amp; Cardiovascular Interventions2014;84(6):934-42. [MEDLINE: 24976083]WangT , WhiteJA , GiuglianoRP , TricociP , HarringtonRA , MontalescotG , et al.Upfront clopidogrel use and the efficacy and safety of early eptifibatide use in patients with acute coronary syndrome: An analysis from the early versus delayed provisional eptifibatide in acute coronary syndromes (early ACS) trial [abstract]. Journal of the American College of Cardiology2010;55(10 Suppl 1):A47.E451. [EMBASE: 70095646]WangTY , WhiteJA , TricociP , GiuglianoRP , ZeymerU , HarringtonRA , et al.Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Circulation2011;123(7):722-30. [MEDLINE: 21300952]">EARLY ACS 2005</a>; <a href="./references#CD008834-bbs2-0025" title="EllS , MihindukulasuriyaJC , O'BrienJR , PolakA , VernhamG .Ticlopidine in the prevention of blockage of fistulae and shunts [abstract no: 332]. Haemostasis1982;12:180. ">Ell 1982</a>; <a href="./references#CD008834-bbs2-0026" title="AguirreFV , TopolEJ , AndersonKM , KleimanNS , WeismanHF , FitzPatrickSE , et al.Benefit within patient subgroups receiving c7e3 fab (abciximab) during percutaneous coronary revascularization: subgroup analysis from the EPIC trial. Journal of Invasive Cardiology1996;8 Suppl B:21-9B. [MEDLINE: 10785766]AguirreFV , TopolEJ , FergusonJJ , AndersonK , BlankenshipJC , HeuserRR , et al.Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation1995;91(12):2882-90. [MEDLINE: 7796496]BerkowitzSD , SaneDC , SigmonKN , ShavenderJH , HarringtonRA , TchengJE , et al.Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. Journal of the American College of Cardiology1998;32(2):311-9. [MEDLINE: 9708455]BlankenshipJC , HellkampAS , AguirreFV , DemkoSL , TopolEJ , CaliffRM .Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. American Journal of Cardiology1998;81(1):36-40. [MEDLINE: 9462603]BoehrerJD , KereiakesDJ , NavettaFI , CaliffRM , TopolEJ .Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications. American Journal of Cardiology1994;74(11):1166-70. [MEDLINE: 7977081]CaliffRM , LincoffAM , TchengJE , TopolEJ .An overview of the results of the EPIC trial. European Heart Journal1995;16 Suppl L:43-9. [MEDLINE: 8869018]EPIC Investigators.Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New England Journal of Medicine1994;330(14):956-61. [MEDLINE: 8121459]KhanMM , EllisSG , AguirreFV , WeismanHF , WildermannNM , CaliffRM , et al.Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1998;31(1):31-6. [MEDLINE: 9426014]LefkovitsJ , BlankenshipJC , AndersonKM , StonerGL , TalleyJD , WorleySJ , et al.Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. Journal of the American College of Cardiology1996;28(4):849-55. [MEDLINE: 8837559]LefkovitsJ , IvanhoeRJ , CaliffRM , BergelsonBA , AndersonKM , StonerGL , et al.Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. American Journal of Cardiology1996;77(12):1045-51. [MEDLINE: 8644655]LincoffAM , CaliffRM , AndersonKM , WeismanHF , AguirreFV , KleimanNS , et al.Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1997;30(1):149-56. [MEDLINE: 9207636]MakKH , ChallapalliR , EisenbergMJ , AndersonKM , CaliffRM , TopolEJ .Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. American Journal of Cardiology1997;80(8):985-8. [MEDLINE: 9352964]MarkDB , TalleyJD , TopolEJ , BowmanL , LamLC , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation1996;94(4):629-35. [MEDLINE: 8772681]MoliternoDJ , CaliffRM , AguirreFV , AndersonK , SigmonKN , WeismanHF , et al.Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. American Journal of Cardiology1995;75(8):559-62. [MEDLINE: 7887377]NarinsCR , MillerDP , CaliffRM , TopolEJ .The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1999;33(3):647-53. [MEDLINE: 10080464]ThelMC , CaliffRM , TchengJE , SigmonKN , LincoffAM , TopolEJ , et al.Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. American Heart Journal1999;137(2):264-73. [MEDLINE: 9924160]TopolEJ , CaliffRM , WeismanHF , EllisSG , TchengJE , WorleyS , et al.Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet1994;343(8902):881-6. [MEDLINE: 7908357]TopolEJ , FergusonJJ , WeismanHF , TchengJE , EllisSG , KleimanNS , et al.Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA1997;278(6):479-84. [MEDLINE: 9256222]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. American Heart Journal1998;135(4):S98-106. [MEDLINE: 9539500]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. European Heart Journal1998;19 Suppl D:D59-66. [MEDLINE: 9597523]">EPIC 1994</a>; <a href="./references#CD008834-bbs2-0027" title="EPILOG Investigators.Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New England Journal of Medicine1997;336(24):1689-96. [MEDLINE: 9182212]GhaffariS , KereiakesDJ , LincoffAM , KellyTA , TimmisGC , KleimanNS , et al.Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. American Journal of Cardiology1998;82(1):7-12. [MEDLINE: 9671000]KereiakesDJ , LincoffAM , MillerDP , TchengJE , CabotCF , AndersonKM , et al.Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Circulation1998;97(9):857-64. [MEDLINE: 9521334]KleimanNS , LincoffAM , KereiakesDJ , MillerDP , AguirreFV , AndersonKM , et al.Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation1998;97(19):1912-20. [MEDLINE: 9609084]LincoffAM , MarkDB , TchengJE , CaliffRM , BalaMV , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation2000;102(24):2923-9. [MEDLINE: 11113041]LincoffAM , TchengJE , CaliffRM , KereiakesDJ , KellyTA , TimmisGC , et al.Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. One-year outcome in the EPILOG trial. Circulation1999;99(15):1951-8. [MEDLINE: 10208997]">EPILOG 1997</a>; <a href="./references#CD008834-bbs2-0028" title="ChoL , MarsoSP , BhattDL , TopolEJ .Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial. Journal of Womens Health &amp; Gender-Based Medicine2000;9(7):741-6. [MEDLINE: 11025866]De ServiS .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse events. Data from the Evaluation of Platelets IIb/IIIa Inhibitor for Stenting (EPISTENT) trial [Il pretrattamento con ticlopidina nello stent coronarico e associato a significativa riduzione di eventi avversi. Dati dal trial EPISTENT]. Italian Heart Journal Supplement2001;2(7):805-6. [MEDLINE: 11508303]EPISTENT Investigators.Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet1998;352(9122):87-92. [MEDLINE: 9672272]IslamMA , BlankenshipJC , BalogC , IliadisEA , LincoffAM , TchengJE , et al.Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). American Journal of Cardiology2002;90(9):916-21. [MEDLINE: 12398954]LincoffAM .Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial. American Heart Journal2000;139(2 Pt 2):S46-52. [MEDLINE: 10650316]MarsoSP , LincoffAM , EllisSG , BhattDL , TanguayJF , KleimanNS , et al.Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation1999;100(25):2477-84. [MEDLINE: 10604884]SteinhublSR , EllisSG , WolskiK , LincoffAM , TopolEJ .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation2001;103(10):1403-9. [MEDLINE: 11245644]SteinhublSR , TanWA , FoodyJM , TopolEJ .Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA1999;281(9):806-10. [MEDLINE: 10071001]TopolEJ , MarkDB , LincoffAM , CohenE , BurtonJ , KleimanN , et al.Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.[Erratum in: Lancet 2000 Mar 25;355(9209):1104]. Lancet1999;354(9195):2019-24. [MEDLINE: 10636365]Zwart-van RijkomJE , vanHoutBA .Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb/IIIa Inhibitor For Stenting Trial. European Heart Journal2001;22(16):1476-84. [MEDLINE: 11482921]">EPISTENT 1998</a>; <a href="./references#CD008834-bbs2-0029" title="Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA1992;268(10):1292-300. [MEDLINE: 1507375]">ETDRS 1992</a>; <a href="./references#CD008834-bbs2-0031" title="BadveS , HawleyCM , IrishAB , Paul-BrentP .High rate of screening failure in the FAVOURED study [abstract no: PUB345]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):905A. IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al.Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453]IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul-BrentP , et al.Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis-a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804]IrishA , FAVOURED Study Group.High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN-00756870] IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 009]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790]IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. [EMBASE: 70467038]IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul-BrentPA , et al.Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184-93. [MEDLINE: 28055065]IrishAB .The omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo-controlled trial [abstract no: HI-OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2-3. [CENTRAL: CN-01658143] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis-post hoc analysis of the FAVOURED study [abstract no: MO049]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475]ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on the need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology2018;23(Suppl 3):56. [EMBASE: 623841152]ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al.Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract no: SP593]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178]ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract no: FP555]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265]ViecelliA , PascoeE , PolkinghorneK , Paul-BrentP , DarssanD , HooiL , et al.A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115-6. [EMBASE: 612312707]ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul-BrentPA , BadveSV , et al.The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581]ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis - Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217-28. [MEDLINE: 26205903]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study. Nephrology2017;22(10):823-4. [MEDLINE: 27188542]ViecelliAK , PolkinghorneKR , PascoeEM , Paul-BrentPA , HawleyCM , BadveSV , et al.Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS ONE [Electronic Resource]2019;14(3):e0213274. [MEDLINE: 30913208]">FAVOURED 2009</a>; <a href="./references#CD008834-bbs2-0033" title="BonominiV , VangelistaA , StefoniS , ScolariMP , FrascàGM , RaimondiC .Use of defibrotide in renal transplantation in man. Haemostasis1986;16 Suppl 1:48-50. [MEDLINE: 3519383]FrascàGM , VangelistaA , RaimondiC , BonominiV .Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (defibrotide): a controlled study. Life Support Systems1986;4(3):231-7. [MEDLINE: 3537545]">Frascà 1986</a>; <a href="./references#CD008834-bbs2-0036" title="GhorbaniA , AalamshahM , ShahbazianH , EhsanpourA , ArefA .Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian Journal of Nephrology2009;19(2):57-61. [MEDLINE: 20368925]">Ghorbani 2009</a>; <a href="./references#CD008834-bbs2-0037" title="GhorbaniA , Jasemi-ZerganiF .Ticlopidine to prevent primary arteriovenous fistula failure in hemodialysis patients; a randomized controlled trial. Journal of Renal Injury Prevention2013;2(3):109-11. [MEDLINE: 25340144]">Ghorbani 2013</a>; <a href="./references#CD008834-bbs2-0043" title="GröntoftK , LarssonR , MulecH , WeissLG , DickinsonJP .Ticlopidine in fistula surgery: double-blind comparison against placebo on the rate of early occlusion of arterio-venous fistulae [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:398. [CENTRAL: CN-00601921] GröntoftKC , LarssonR , MulecH , WeissLG , DickinsonJP .Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scandinavian Journal of Urology &amp; Nephrology1998;32(4):276-83. [MEDLINE: 9764456]">Gröntoft 1998</a>; <a href="./references#CD008834-bbs2-0046" title="HarterHR , BurchJW , MajerusPW , StanfordN , DelmezJA , AndersonCB , et al.Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. New England Journal of Medicine1979;301(11):577-9. [MEDLINE: 112475]">Harter 1979</a>; <a href="./references#CD008834-bbs2-0048" title="HanssonL , ZanchettiA , CarruthersSG , DahlöfB , ElmfeldtD , JuliusS , et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998;351(9118):1755-62. [MEDLINE: 9635947]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Pressure1997;6(5):313-7. [MEDLINE: 9360003]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Pressure1994;3(5):322-7. [MEDLINE: 7866597]HanssonL .The Hypertension Optimal Treatment study and the importance of lowering blood pressure. Journal of Hypertension - Supplement1999;17(1):S9-13. [MEDLINE: 10340838]JardineM , NinomiyaT , CassA , TurnbullF , GallagherM , ZoungasS , et al.Aspirin benefit increases as eGFR declines: results from a randomised controlled trial in a hypertensive population [abstract no: 086]. Nephrology2010;15(Suppl 4):49. [EMBASE: 70467090]JardineMJ , NinomiyaT , PerkovicV , CassA , TurnbullF , GallagherMP , et al.Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology2010;56(12):956-65. [MEDLINE: 20828648]JonesDW , MillerME , WoffordMR , Anderson DC Jr, CameronME , WilloughbyDL , et al.The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. American Journal of Hypertension1999;12(12 Pt 1-2):1175-80. [MEDLINE: 10619579]JonssonB , HanssonL , StalhammarNO .Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Journal of Internal Medicine2003;253(4):472-80. [MEDLINE: 12653877]KjeldsenSE , HednerT , JamersonK , JuliusS , HaleyWE , ZabalgoitiaM , et al.Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects. Hypertension1998;31(4):1014-20. [MEDLINE: 9535429]KjeldsenSE , KollochRE , LeonettiG , MallionJM , ZanchettiA , ElmfeldtD , et al.Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. Journal of Hypertension2000;18(5):629-42. [MEDLINE: 10826567]KollochRE , RahnKH .The Hypertension Optimal Treatment (HOT) study: results of 12-month treatment related to age [Die 'Hyperyension Optimal Treatment' (HOT)-Studie: Behandlungsergebnisse nach Zwolfmonatiger Therapie in Abhangigkeit vom Alter]. Deutsche Medizinische Wochenschrift1998;123(1-2):1-5. [MEDLINE: 9465848]LeonettiG , ZanchettiA .Principal results of hypertension optimal treatment (HOT) study and their clinical impact. HOT cooperative group. Clinical Hemorheology &amp; Microcirculation1999;21(3-4):217-24. [MEDLINE: 10711746]LithellH , BerglundL .Validation of an oscillometric blood pressure measuring device: a substudy of the HOT Study. Hypertension Optimal Treatment. Blood Pressure1998;7(3):149-52. [MEDLINE: 9758084]ManciaG , OmboniS , ParatiG , ClementDL , HaleyWE , RahmanSN , et al.Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(10):1755-63. [MEDLINE: 11593094]RuilopeLM , SalvettiA , JamersonK , HanssonL , WarnoldI , WedelH , et al.Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology2001;12(2):218-25. [MEDLINE: 11158211]Struijker-BoudierH , SafarM , vanBortelL .Effects of individual risk factors on the incidence of cardiovascular event in the treated hypertensive patients of the Hypertension Optimal Treatment Study. Journal of Hypertension2001;19(11):2105-6. [MEDLINE: 11677378]The Hypertension Optimal Treatment Study (the HOT Study). Blood Pressure1993;2(1):62-8. [MEDLINE: 8193735]WaeberB , LeonettiG , KollochR , McInnesGT .Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension1999;17(7):1041-5. [MEDLINE: 10419079]ZanchettiA , HanssonL , DahlofB , ElmfeldtD , KjeldsenS , KollochR , et al.Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. Journal of Hypertension2001;19(6):1149-59. [MEDLINE: 11403365]ZanchettiA , HanssonL , MenardJ , LeonettiG , RahnKH , WarnoldI , et al.Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(4):819-25. [MEDLINE: 11330886]">HOT 1993</a>; <a href="./references#CD008834-bbs2-0049" title="BlankenshipJC , SigmonKN , PieperKS , O'SheaC , TardiffBE , TchengJE , et al.Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial. American Journal of Cardiology2001;88(9):969-73. [MEDLINE: 11703991]GilchristIC , GardnerLH , MuhlesteinJB , ArnoldAM , LincoffAM , CaliffRM , et al.Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience. American Heart Journal1999;138(5 Pt 1):976-82. [MEDLINE: 10539832]MandakJS , BlankenshipJC , GardnerLH , BerkowitzSD , AguirreFV , SigmonKN , et al.Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Journal of the American College of Cardiology1998;31(7):1518-24. [MEDLINE: 9626829]Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet1997;349(9063):1422-8. [MEDLINE: 9164315]TardiffBE , CaliffRM , TchengJE , LincoffAM , SigmonKN , HarringtonRA , et al.Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. Journal of the American College of Cardiology1999;33(1):88-96. [MEDLINE: 9935014]ThelMC , CaliffRM , TardiffBE , GardnerLH , SigmonKN , LincoffAM , et al.Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. American Journal of Cardiology2000;85(4):427-34. [MEDLINE: 10728945]">IMPACT II 1997</a>; <a href="./references#CD008834-bbs2-0051" title="OgawaH , NakayamaM , MorimotoT , UemuraS , KanauchiM , DoiN , et al.Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.[Erratum in: JAMA. 2009 May 13;301(18):1882], [Erratum in: JAMA. 2012 Nov 14;308(18):1861]. JAMA2008;300(18):2134-41. [MEDLINE: 18997198]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , NakayamaM , et al.Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk. Circulation Journal2013;77(12):3023-8. [MEDLINE: 24042256]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , NakayamaM , et al.Is long-term low-dose aspirin therapy associated with renal dysfunction in patients with type 2 diabetes? JPAD2 cohort study. PLoS ONE [Electronic Resource]2016;11(1):e0147635. [MEDLINE: 26808136]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , OhtoriiM , et al.Long-term use of low-dose aspirin develops proteinuria in patients with diabetes: A reanalysis of JPAD study [abstract no: 10863]. Circulation2013;128(22 Suppl 1). [EMBASE: 71337722]SaitoY , MorimotoT , OgawaH , NakayamaM , UemuraS , DoiN , et al.Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care2011;34(2):280-5. [MEDLINE: 21270185]">JPAD 2008</a>; <a href="./references#CD008834-bbs2-0052" title="OhtakeT , SatoM , NakazawaR , KondohM , KobayashiS .Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study [abstract no: Su528]. NDT Plus2010;3(Suppl 3):iii487. [EMBASE: 70484748]OhtakeT , SatoM , NakazawaR , KondohM , MiyajiT , MoriyaH , et al.Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2014;18(1):1-8. [MEDLINE: 24499078]">J‐PADD 2014</a>; <a href="./references#CD008834-bbs2-0053" title="KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. New England Journal of Medicine1974;290(6):304-6. [MEDLINE: 4588285]KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation1975;52(3):497-9. [MEDLINE: 1098808]">Kaegi 1974</a>; <a href="./references#CD008834-bbs2-0056" title="ChangJJ , ConcatoJ , WellsCK , CrowleyST .Impact of adherence to clinical guidelines on mortality in hemodialysis patients [abstract no: SA-PO384]. Journal of the American Society of Nephrology2004;15(Oct):386A. [CENTRAL: CN-00583156] KaufmanJS , O'ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology2003;14(9):2313-21. [MEDLINE: 12937308]KaufmanJS , O’ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract no: A1495]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):291A. ">Kaufman 2003</a>; <a href="./references#CD008834-bbs2-0060" title="KooistraMP , vanEsA , MarxJJ , HertsigM , StruyvenbergA .Effects of low dose aspirin on thrombovascular accidents during treatment with rHuEpo: a multicentre, controlled, cross-over study [abstract]. Nephrology Dialysis Transplantation1993;8:277. [CENTRAL: CN-00260772] KooistraMP , vanEsA , MarxJJ , HertsigML , StruyvenbergA .Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrology Dialysis Transplantation1994;9(8):1115-20. [MEDLINE: 7800210]">Kooistra 1994</a>; <a href="./references#CD008834-bbs2-0062" title="LiangJ , WangZ , ShiD , LiuY , ZhaoY , HanH , et al.High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. Angiology2015;66(4):319-25. [MEDLINE: 24913197]">Liang 2015</a>; <a href="./references#CD008834-bbs2-0063" title="MichieDD , WomboltDG .Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research - Clinical &amp; Experimental1977;22(1 II):196-204. [EMBASE: 8152617]">Michie 1977</a>; <a href="./references#CD008834-bbs2-0064" title="MiddletonDA , DeichselG .The prophylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole. Boehringer Ingelheim. Internal report1992. ">Middleton 1992</a>; <a href="./references#CD008834-bbs2-0072" title="NybergG , LarssonO , WestbergNG , AurellM , JagenburgR , BlohmeG .A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study. Clinical Nephrology1984;21(3):184-7. [MEDLINE: 6705280]">Nyberg 1984</a>; <a href="./references#CD008834-bbs2-0074" title="HanY .Comparison of the pharmacodynamics and pharmacokinetics of ticagrelor versus clopidogrel in patients with chronic kidney disease and non-ST-elevation acute coronary syndromes (OPT-CKD trial) [abstract no: TCT-483]. Journal of the American College of Cardiology2017;70(18 Suppl 1):B200. [EMBASE: 619771602]WangH , QiJ , LiY , TangY , LiC , LiJ , et al.Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. British Journal of Clinical Pharmacology2018;84(1):88-96. [MEDLINE: 28921624]">OPT‐CKD 2018</a>; <a href="./references#CD008834-bbs2-0075" title="OtaK , TeraokaS , AkiwasaT , MimuraN , HirasawaY , SakaiT , et al.Clinical efficacy of E5510 (satigrel), an antiplatelet agent, for preventing blood clotting in the extracorporeal circuit during hemodialysis (3) - A double-blind comparison with ticlopidine hydrochloride. Rinsho Hyoka1996;24(1):9-38. ">Ota 1996</a>; <a href="./references#CD008834-bbs2-0076" title="BonacaMP , BhattDL , BraunwaldE , CohenM , StegPG , StoreyRF , et al.Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal2014;167(4):437-44. [MEDLINE: 24655690]BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , JensenEC , et al.Long-term use of ticagrelor in patients with prior myocardial infarction. New England Journal of Medicine2015;372(19):1791-800. [MEDLINE: 25773268]BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , CohenM , et al.Prevention of stroke with ticagrelor in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation2016;134(12):861-71. [MEDLINE: 27576775]DellborgM , BonacaMP , StoreyRF , StegPG , ImKA , CohenM , et al.Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: Insights from PEGASUS-TIMI 54 [abstract]. European Heart Journal2017;38(Suppl 1):794-5. [EMBASE: 621235545]LozanoI , RondanJ , VegasJM , SegoviaE .Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):107-8. [MEDLINE: 29301622]MagnaniG , SabatineMS , BhattDL , ChoenM , StegG , StoreyR , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: Insights from the PEGASUS-TIMI 54 trial [abstract]. European Heart Journal2015;36(Suppl 1):520. [EMBASE: 72020712]MagnaniG , StoreyRF , StegG , BhattDL , CohenM , KuderJ , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. European Heart Journal2016;37(4):400-8. [MEDLINE: 26443023]MagnusonEA , BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , et al.Reply: cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):108. [MEDLINE: 29301623]MagnusonEA , LiH , WangK , VilainK , ShafiqA , BonacaMP , et al.Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: results from the PEGASUS-TIMI 54 trial. Journal of the American College of Cardiology2017;70(5):527-38. [MEDLINE: 28750695]MurphySA , BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , et al.Reduction in total cardiovascular events with long-term use of ticagrelor in patients with prior myocardial infarction in the PEGASUS-TIMI 54 trial [abstract no: A17121]. Circulation2015;132(Suppl 3). [EMBASE: 72179983]">PEGASUS‐TIMI 54 2014</a>; <a href="./references#CD008834-bbs2-0081" title="AkerblomA , WallentinL , LarssonA , SiegbahnA , BeckerRC , BudajA , et al.Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study. Clinical Chemistry2013;59(9):1369-75. [MEDLINE: 23698074]AkerblomA , WallentinL , SiegbahnA , BeckerRC , BudajA , HorrowJ , et al.Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. American Heart Journal2012;164(5):728-34. [MEDLINE: 23137503]AndellP , JamesSK , CannonCP , CyrDD , HimmelmannA , HustedS , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Journal of the American Heart Association2015;4(10):e002490. [MEDLINE: 26452988]ArmstrongPW , SihaH , FuY , WesterhoutCM , StegPG , JamesSK , et al.ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation2012;125(3):514-21. [MEDLINE: 22179530]ArmstrongPW , WesterhoutCM , FuY , HarringtonRA , StoreyRF , KatusH , et al.Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. American Journal of Medicine2013;126(8):723-9. [MEDLINE: 23795897]BeckerRC , BassandJP , BudajA , WojdylaDM , JamesSK , CornelJH , et al.Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial [Erratum in: Eur Heart J. 2012 Nov;33(21):2750]. European Heart Journal2011;32(23):2933-44. [MEDLINE: 22090660]BellaviaA , WallentinL , OrsiniN , JamesSK , CannonCP , HimmelmannA , et al.Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. Open Heart2017;4(2):e000557. [MEDLINE: 28761675]BrilakisES , HeldC , MeierB , CoolsF , ClaeysMJ , CornelJH , et al.Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. American Heart Journal2013;166(3):474-80. [MEDLINE: 24016496]BuiAH , CannonCP , StegPG , StoreyRF , HustedS , GuoJ , et al.Relationship between early and late nonsustained ventricular tachycardia and cardiovascular death in patients with acute coronary syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation: Arrhythmia and Electrophysiology2016;9(2):e002951. [MEDLINE: 26810596]CapodannoD , CalviV , TamburinoC .Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment. Journal of Cardiovascular Medicine2012;13(2):162-3. [MEDLINE: 22237463]CornelJH , BeckerRC , GoodmanSG , HustedS , KatusH , SantosoA , et al.Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2012;164(3):334-42. [MEDLINE: 22980299]CowperPA , PanW , AnstromKJ , KaulP , WallentinL , Davidson-RayL , et al.Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. Journal of the American College of Cardiology2015;65(5):465-76. [MEDLINE: 25660925]DiNicolantonioJJ , D'AscenzoF , TomekA , ChatterjeeS , NiaziAK , Biondi-ZoccaiG .Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial. International Journal of Cardiology2013;168(3):1739-44. [MEDLINE: 23907035]DiNicolantonioJJ , TomekA .Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial. International Journal of Cardiology2013;168(4):4076-80. [MEDLINE: 23911266]DiNicolantonioJJ , TomekA .Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel. International Journal of Cardiology2013;169(2):145-6. [MEDLINE: 24120213]DucrocqG , SchultePJ , BeckerRC , CannonCP , HarringtonRA , HeldC , et al.Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. Eurointervention2015;11(7):737-45. [MEDLINE: 25254357]FranchiF , JamesSK , GhukasyanLT , BudajAJ , CornelJH , KatusHA , et al.Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y12 receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. Journal of the American Heart Association2019;8(6):e011139. [MEDLINE: 30857464]GiannitsisE , WallentinL , JamesSK , BertilssonM , SiegbahnA , StoreyRF , et al.Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: a Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. European Heart Journal: Acute Cardiovascular Care2017;6(6):500-10. [MEDLINE: 27044282]HagstromE , JamesSK , BertilssonM , BeckerRC , HimmelmannA , HustedS , et al.Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. European Heart Journal2016;37(16):1325-33. [MEDLINE: 26417057]HeldC , AsenbladN , BassandJP , BeckerRC , CannonCP , ClaeysMJ , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology2011;57(6):672-84. [MEDLINE: 21194870]HustedS , JamesS , BeckerRC , HorrowJ , KatusH , StoreyRF , et al.Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circulation. Cardiovascular Quality &amp; Outcomes2012;5(5):680-8. [MEDLINE: 22991347]HustedS , JamesSK , BachRG , BeckerRC , BudajA , HerasM , et al.The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal2014;35(23):1541-50. [MEDLINE: 24682844]JamesS , AkerblomA , CannonCP , EmanuelssonH , HustedS , KatusH , et al.Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2009;157(4):599-605. [MEDLINE: 19332184]JamesS , AngiolilloDJ , CornelJH , ErlingeD , HustedS , KontnyF , et al.Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal2010;31(24):3006-16. [MEDLINE: 20802246]JamesS , BudajA , AylwardP , BuckKK , CannonCP , CornelJH , et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2010;122(11):1056-67. [MEDLINE: 20805430]JamesS , BudajA , AylwardP , BuckKK , CannonCP , CornelJH , et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation2010;122(11):1056-67. [MEDLINE: 20805430]JamesSK , RoeMT , CannonCP , CornelJH , HorrowJ , HustedS , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ2011;342:d3527. [MEDLINE: 21685437]JohanssonA , ErikssonN , BeckerRC , StoreyRF , HimmelmannA , HagstromE , et al.NLRC4 inflammasome is an important regulator of interleukin-18 levels in patients with acute coronary syndromes: genome-wide association study in the PLATelet inhibition and patient Outcomes Trial (PLATO). Circulation. Cardiovascular Genetics2015;8(3):498-506. [MEDLINE: 25747584]KangHJ , ClareRM , GaoR , HeldC , HimmelmannA , JamesSK , et al.Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal2015;169(6):899-905. [MEDLINE: 26027629]KholaifN , ZhengY , JagasiaP , HimmelmannA , JamesSK , StegPG , et al.Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex. American Journal of Medicine2015;128(8):914-9. [MEDLINE: 25818495]KohliP , WallentinL , ReyesE , HorrowJ , HustedS , AngiolilloDJ , et al.Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation2013;127(6):673-80. [MEDLINE: 23277305]KontnyF , UelandT , AukrustP , MichelsenAE , BeckerRC , BertilssonM , et al.Pentraxin 3 (PTX3) predict adverse outcome in acute coronary syndromes-a PLATO biomarker substudy [abstract]. European Heart Journal2014;35(Suppl 1):319. [EMBASE: 71647923]KotsiaA , BrilakisES , HeldC , CannonC , StegGP , MeierB , et al.Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2014;168(1):68-75. [MEDLINE: 24952862]KunadianV , JamesSK , WojdylaDM , ZorkunC , WuJ , StoreyRF , et al.Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). Jacc: Cardiovascular Interventions2013;6(7):671-83. [MEDLINE: 23866179]LevinLA , WallentinL , BernfortL , AnderssonD , StoreyRF , BergstromG , et al.Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. Value in Health2013;16(4):574-80. [MEDLINE: 23796291]LindholmD , VarenhorstC , CannonCP , HarringtonRA , HimmelmannA , MayaJ , et al.Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal2014;35(31):2083-93. [MEDLINE: 24727884]MahaffeyKW , HeldC , WojdylaDM , JamesSK , KatusHA , HustedS , et al.Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology2014;63(15):1493-9. [MEDLINE: 24561148]MahaffeyKW , WojdylaDM , CarrollK , BeckerRC , StoreyRF , AngiolilloDJ , et al.Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2011;124(5):544-54. [MEDLINE: 21709065]NikolicE , JanzonM , HauchO , WallentinL , HenrikssonM , PLATO Health Economic Substudy Group.Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. European Heart Journal2013;34(3):220-8. [MEDLINE: 22719022]OhmanEM , RoeMT .Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany &quot;Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified&quot; (Thromb Haemost 2011; 105.5). Thrombosis &amp; Haemostasis2011;105(5):763-5. [MEDLINE: 21394382]ParkerWA , ErikssonN , BeckerRC , VooraD , AkerblomA , HimmelmannA , et al.Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets2019;30(5):579-88. [MEDLINE: 29851527]PatelMR , BeckerRC , WojdylaDM , EmanuelssonH , HiattWR , HorrowJ , et al.Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. European Journal of Preventive Cardiology2015;22(6):734-42. [MEDLINE: 24830710]Pollack CV Jr, DavoudiF , DiercksDB , BeckerRC , JamesSK , LimST , et al.Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clinical Cardiology2017;40(6):390-8. [MEDLINE: 28598510]RoguinA , MusallamA .Letter by Roguin and Musallam regarding article, &quot;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial&quot;. Circulation2014;129(19):e493. [MEDLINE: 24821831]SciricaBM , BansilalS , DavoudiF , ArmstrongPW , ClareRM , SchultePJ , et al.Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. American Heart Journal2018;202:54-60. [MEDLINE: 29859968]SciricaBM , CannonCP , EmanuelssonH , MichelsonEL , HarringtonRA , HustedS , et al.The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. Journal of the American College of Cardiology2011;57(19):1908-16. [MEDLINE: 21545948]SerebruanyVL , FortmannSD , CherepanovV , LitvinovO , KimMH , MarciniakTA .Excess ticagrelor mortality in the food and drug administration adverse event reporting system: time to recount PLATO trial deaths. American Journal of Medicine2017;130(6):e245-6. [MEDLINE: 28161342]SerebruanyVL .Angiographic outcomes contradict platelet data in the PLATO trial: confusion over official trial substudies. Cardiology2014;127(3):190-5. [MEDLINE: 24457905]SerebruanyVL .Discrepancies in the primary PLATO trial publication and the FDA reviews. International Journal of Cardiology2014;172(1):8-10. [MEDLINE: 24456868]SerebruanyVL .Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review. American Journal of Therapeutics2012;19(2):160-1. [MEDLINE: 22395000]SerebruanyVL .The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent. Cardiology2011;120(3):169-71. [MEDLINE: 22418766]ShimadaYJ , BansilalS , WiviottSD , BeckerRC , HarringtonRA , HimmelmannA , et al.Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal2016;177:1-8. [MEDLINE: 27297843]SihaH , DasD , FuY , ZhengY , WesterhoutCM , StoreyRF , et al.Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. CMAJ Canadian Medical Association Journal2012;184(10):1135-42. [MEDLINE: 22546885]StegPG , HarringtonRA , EmanuelssonH , KatusHA , MahaffeyKW , MeierB , et al.Response to letter regarding article, &quot;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial&quot;. Circulation2014;129(19):e494-5. [MEDLINE: 24821832]StegPG , HarringtonRA , EmanuelssonH , KatusHA , MahaffeyKW , MeierB , et al.Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation2013;128(10):1055-65. [MEDLINE: 23900047]StegPG , JamesS , HarringtonRA , ArdissinoD , BeckerRC , CannonCP , et al.Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation2010;122(21):2131-41. [MEDLINE: 21060072]StoreyRF , AngiolilloDJ , PatilSB , DesaiB , EcobR , HustedS , et al.Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. Journal of the American College of Cardiology2010;56(18):1456-62. [MEDLINE: 20832963]StoreyRF , ArdissinoD , VignaliL , CairnsR , BeckerRC , CannonCP , et al.Ischaemic events and stent thrombosis following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study. Thrombosis &amp; Haemostasis2018;118(2):427-9. [MEDLINE: 29443375]StoreyRF , BeckerRC , HarringtonRA , HustedS , JamesSK , CoolsF , et al.Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. European Heart Journal2011;32(23):2945-53. [MEDLINE: 21804104]StoreyRF , BeckerRC , HarringtonRA , HustedS , JamesSK , CoolsF , et al.Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). American Journal of Cardiology2011;108(11):1542-6. [MEDLINE: 21890085]StoreyRF , JamesSK , SiegbahnA , VarenhorstC , HeldC , YcasJ , et al.Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets2014;25(7):517-25. [MEDLINE: 24127651]SumayaW , WallentinL , JamesSK , SiegbahnA , GabryschK , BertilssonM , et al.Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. European Heart Journal2018;39(13):1078-85. [MEDLINE: 29390064]UelandT , AkerblomA , GhukasyanT , MichelsenAE , AukrustP , BeckerRC , et al.Osteoprotegerin is associated with major bleeding but not with cardiovascular outcomes in patients with acute coronary syndromes: insights from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American Heart Association2018;7(2):e007009. [MEDLINE: 29330256]UelandT , MichelsenA , AukrustP , BeckerR , BertilssonM , JamesSK , et al.Chemokine (CXC motif) ligand 16 (CXCL16) and osteoprotegerin (OPG) as predictors of outcome in patients with acute coronary syndromes (ACS) a PLATO biomarker substudy [abstract]. European Heart Journal2014;35(Suppl 1):486. [EMBASE: 71648554]WallentinL , BeckerRC , BudajA , CannonCP , EmanuelssonH , HeldC , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2009;361(11):1045-57. [MEDLINE: 19717846]WallentinL , BeckerRC , CannonCP , HeldC , HimmelmannA , HustedS , et al.No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. International Journal of Cardiology2014;176(1):300-2. [MEDLINE: 25005338]WallentinL , BeckerRC , CannonCP , HeldC , HimmelmannA , HustedS , et al.Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. International Journal of Cardiology2014;170(3):e59-62. [MEDLINE: 24299581]WallentinL , BeckerRC , JamesSK , HarringtonRA .The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. &quot;Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified&quot; (Thromb Haemost 2011; 105.5). Thrombosis &amp; Haemostasis2011;105(5):760-2. [MEDLINE: 21394383]WallentinL , JamesS , StoreyRF , ArmstrongM , BarrattBJ , HorrowJ , et al.Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet2010;376(9749):1320-8. [MEDLINE: 20801498]WallentinL , LindholmD , SiegbahnA , WernrothL , BeckerRC , CannonCP , et al.Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2014;129(3):293-303. [MEDLINE: 24170388]">PLATO 2009</a>; <a href="./references#CD008834-bbs2-0083" title="HuynhT , NasmithJ , LuongTM , BernierM , PharandC , Xue-QiaoZ , et al.Complementary prognostic values of ST segment deviation and Thrombolysis In Myocardial Infarction (TIMI) risk score in non-ST elevation acute coronary syndromes: insights from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Canadian Journal of Cardiology 2009 Dec;25(12):e417-21. [MEDLINE: 19960136]HuynhT , PiazzaN , DiBattistePM , SnapinnSM , WanY , PharandC , et al.Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study. International Journal of Cardiology2005;100(1):73-8. [MEDLINE: 15820288]HuynhT , TherouxP , SnapinnS , WanY , PRISM-PLUS Investigators.Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). American Heart Journal2003;146(4):668-73. [MEDLINE: 14564321]Januzzi JL Jr, SnapinnSM , DiBattistePM , JangIK , TherouxP .Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation2002;105(20):2361-6. [MEDLINE: 12021221]MegaJL , MorrowDA , SabatineMS , ZhaoXQ , SnapinnSM , DiBattistePM , et al.Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. American Heart Journal2005;149(5):846-50. [MEDLINE: 15894966]MorrowDA , SabatineMS , AntmanEM , CannonCP , BraunwaldE , TherouxP .Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). American Journal of Cardiology2004;94(6):774-6. [MEDLINE: 15374786]Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New England Journal of Medicine1998;338(21):1488-97. [MEDLINE: 9599103]ServossSJ , WanY , SnapinnSM , DiBattistePM , ZhaoXQ , TherouxP , et al.Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. American Journal of Cardiology2004;93(7):843-7. [MEDLINE: 15050486]SzucsTD , MeyerBJ , KiowskiW .Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial. European Heart Journal1999;20(17):1253-60. [MEDLINE: 10454977]TherouxP , AlexanderJ , PharandC , BarrE , SnapinnS , GhannamAF , et al.Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation2000;102(20):2466-72. [MEDLINE: 11076818]TherouxP , Alexander J Jr, DupuisJ , PesantY , GervaisP , GrandmontD , et al.Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators. American Journal of Cardiology2001;87(4):375-80. [MEDLINE: 11179517]ZhaoXQ , TherouxP , SnapinnSM , SaxFL .Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Circulation1999;100(15):1609-15. [MEDLINE: 10517731]">PRISM‐PLUS 1998</a>; <a href="./references#CD008834-bbs2-0084" title="AkkerhuisKM , DeckersJW , BoersmaE , HarringtonRA , StepinskaJ , MahaffeyKW , et al.Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. European Heart Journal2000;21(5):371-81. [MEDLINE: 10666351]AkkerhuisKM , MaasAC , KlootwijkPA , KrucoffMW , MeijS , CaliffRM , et al.Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of Electrocardiology2000;33(2):127-36. [MEDLINE: 10819406]AlexanderJH , HarringtonRA , TuttleRH , BerdanLG , LincoffAM , DeckersJW , et al.Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology1999;83(8):1147-51. [MEDLINE: 10215274]BoersmaE , PieperKS , SteyerbergEW , WilcoxRG , ChangWC , LeeKL , et al.Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation2000;101(22):2557-67. [MEDLINE: 10840005]BrownRE , HendersonRA , KosterD , HuttonJ , SimoonsML .Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy. European Heart Journal2002;23(1):50-8. [MEDLINE: 11741362]ChangWC , HarringtonRA , SimoonsML , CaliffRM , LincoffAM , ArmstrongPW , et al.Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial. European Heart Journal2002;23(14):1102-11. [MEDLINE: 12090748]DykeCM , BhatiaD , LorenzTJ , MarsoSP , TardiffBE , HogeboomC , et al.Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Annals of Thoracic Surgery2000;70(3):866-71. [MEDLINE: 11016325]GreenbaumAB , HarringtonRA , HudsonMP , MacAulayCM , WilcoxRG , SimoonsML , et al.Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. Journal of the American College of Cardiology2001;37(2):492-8. [MEDLINE: 11216968]HarringtonRA .Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology1997;80(4A):34-8B. [MEDLINE: 9291244]HasdaiD , Holmes DR Jr, CrigerDA , TopolEJ , CaliffRM , WilcoxRG , et al.Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators. American Heart Journal2000;139(3):454-60. [MEDLINE: 10689260]KleimanNS , LincoffAM , FlakerGC , PieperKS , WilcoxRG , BerdanLG , et al.Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation2000;101(7):751-7. [MEDLINE: 10683348]LabinazM , KaulP , HarringtonRA , ChangWC , KleimanNS , SimoonsML , et al.Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. Canadian Journal of Cardiology2004;20(8):773-8. [MEDLINE: 15229770]LabinazM , KilaruR , PieperK , MarsoSP , KittMM , SimoonsML , et al.Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2002;105(3):322-7. [MEDLINE: 11804987]LauerMA , HoughtalingPL , PetersonJG , GrangerCB , BhattDL , SappSK , et al.Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2001;104(23):2772-7. [MEDLINE: 11733393]LincoffAM , HarringtonRA , CaliffRM , HochmanJS , GuerciAD , OhmanEM , et al.Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2000;102(10):1093-100. [MEDLINE: 10973836]MahaffeyKW , HarringtonRA , AkkerhuisM , KleimanNS , BerdanLG , CrenshawBS , et al.Systematic adjudication of myocardial infarction end-points in an international clinical trial. Current Controlled Trials in Cardiovascular Medicine2001;2(4):180-6. [MEDLINE: 11806793]MahaffeyKW , HarringtonRA , SimoonsML , GrangerCB , GraffagninoC , AlbertsMJ , et al.Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation1999;99(18):2371-7. [MEDLINE: 10318656]MarkDB , HarringtonRA , LincoffAM , CaliffRM , NelsonCL , TsiatisAA , et al.Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation2000;101(4):366-71. [MEDLINE: 10653826]MarsoSP , BhattDL , RoeMT , HoughtalingPL , LabinazM , KleimanNS , et al.Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators. Circulation2000;102(24):2952-8. [MEDLINE: 11113045]McClureMW , BerkowitzSD , SparapaniR , TuttleR , KleimanNS , BerdanLG , et al.Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation1999;99(22):2892-900. [MEDLINE: 10359733]PetersonJG , TopolEJ , RoeMT , SappSK , LincoffAM , DeckersJW , et al.Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology2001;87(5):532-6. [MEDLINE: 11230834]PURSUIT Trial Investigators.Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. New England Journal of Medicine1998;339(7):436-43. [MEDLINE: 9705684]RoeMT , HarringtonRA , ProsperDM , PieperKS , BhattDL , LincoffAM , et al.Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation2000;102(10):1101-6. [MEDLINE: 10973837]RonnerE , BoersmaE , AkkerhuisKM , HarringtonRA , LincoffAM , DeckersJW , et al.Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. European Heart Journal2002;23(3):239-46. [MEDLINE: 11792139]RonnerE , BoersmaE , LaarmanGJ , SomsenGA , HarringtonRA , DeckersJW , et al.Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of the American College of Cardiology2002;39(12):1924-9. [MEDLINE: 12084589]SrichaiMB , JaberWA , PriorDL , MarsoSP , HoughtalingPL , MenonV , et al.Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes. American Heart Journal2004;147(1):84-90. [MEDLINE: 14691424]">PURSUIT 1997</a>; <a href="./references#CD008834-bbs2-0086" title="BrenerSJ , BarrLA , BurchenalJE , KatzS , GeorgeBS , JonesAA , et al.Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation1998;98(8):734-41. [MEDLINE: 9727542]BrenerSJ , BarrLA , BurchenalJE , WolskiKE , EffronMB , TopolEJ .Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial. American Journal of Cardiology1999;84(6):728-30. [MEDLINE: 10498145]">RAPPORT 1998</a>; <a href="./references#CD008834-bbs2-0094" title="SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract no: 9P]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):388. [CENTRAL: CN-00485981] SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study. Kidney International1994;45(5):1477-83. [MEDLINE: 8072261]">Sreedhara 1994</a>; <a href="./references#CD008834-bbs2-0096" title="MiletiM , De PetriG , BacchiM , OgliariV , PecchiniF , BufanoG , et al.A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients. Journal of Nephrology1995;8(2):167-72. [EMBASE: 25209311]">STOP 1995</a>; <a href="./references#CD008834-bbs2-0100" title="BergerPB , BestPJ , TopolEJ , WhiteJ , DiBattistePM , ChanAW , et al.The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal2005;149(5):869-75. [MEDLINE: 15894970]KalyanasundaramA , BlankenshipJC , BergerP , HerrmannH , McClureR , MoliternoD .Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?). Catheterization &amp; Cardiovascular Interventions2007;69(5):623-9. [MEDLINE: 17192960]MoliternoDJ , TopolEJ .A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. American Heart Journal2000;140(5):722-6. [MEDLINE: 11054616]MoliternoDJ , YakubovSJ , DiBattistePM , HerrmannHC , StoneGW , MacayaC , et al.Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet2002;360(9330):355-60. [MEDLINE: 12241774]MukherjeeD , TopolEJ , BertrandME , KristensenSD , HerrmannHC , NeumannFJ , et al.Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. European Heart Journal2005;26(23):2524-8. [MEDLINE: 16107485]RoffiM , MoliternoDJ , MeierB , PowersER , GrinesCL , DiBattistePM , et al.Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation2002;105(23):2730-6. [MEDLINE: 12057986]TopolEJ , MoliternoDJ , HerrmannHC , PowersER , GrinesCL , CohenDJ , et al.Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New England Journal of Medicine2001;344(25):1888-94. [MEDLINE: 11419425]">TARGET 2000</a>; <a href="./references#CD008834-bbs2-0103" title="CorreaS , BonacaMP , SciricaBM , MurphySA , GoodrichEL , MorrowDA , et al.Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. Journal of Thrombosis &amp; Thrombolysis2019;47(3):353-60. [MEDLINE: 30511258]GaviriaSC , BraunwaldE , BonacaMP , MurphySA , GoodrichEL , MorrowDA , et al.The efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function: insights from the TRA 2P-TIMI 50 trial [abstract no: 15480]. Circulation2017;136(Suppl 1). [EMBASE: 619986693]MorrowDA , BraunwaldE , BonacaMP , AmerisoSF , DalbyAJ , FishMP , et al.Vorapaxar in the secondary prevention of atherothrombotic events. New England Journal of Medicine2012;366(15):1404-13. [MEDLINE: 22443427]MorrowDA , SciricaBM , FoxKA , BermanG , StronyJ , VeltriE , et al.Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. American Heart Journal2009;158(3):335-41. [MEDLINE: 19699854]">TRA 2P‐TIMI 50 2009</a>; <a href="./references#CD008834-bbs2-0104" title="CornelJH , TricociP , HortonJ , MoliternoD , WallentinL , ArmstrongP , et al.Effects of glycoprotein IIB/IIIA inhibitors in combination with vorapaxar, a platelet thrombin-receptor antagonist, among patients with non-St-segment elevation acute coronary syndromes: insights from the TRACER trial [abstract]. Journal of the American College of Cardiology2013;61(10 Suppl 1):E102. [EMBASE: 71019466]MahaffeyKW , PieperK , VranckxP , TricociP , Van de WerfF , HeldC , et al.Chronic kidney disease is associated with worse outcomes in ACS patients: results from the TRACER trial [abstract]. European Heart Journal2014;35(Suppl 1):687. [EMBASE: 71649310]">TRACER 2013</a>; <a href="./references#CD008834-bbs2-0105" title="AbaciA .The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses [Prasugrelin ST yukselmeli ve yukselmesiz miyokart enfarktusunde kullanimi: TRITON TIMI 38 caIismasi ve alt grup sonuclari]. Turk Kardiyoloji Dernegi Arsivi2015;43 Suppl 2:1-6. [MEDLINE: 27326444]AntmanEM , WiviottSD , MurphySA , VoitkJ , HasinY , WidimskyP , et al.Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Journal of the American College of Cardiology2008;51(21):2028-33. [MEDLINE: 18498956]BonacaMP , WiviottSD , BraunwaldE , MurphySA , RuffCT , AntmanEM , et al.American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation2012;125(4):577-83. [MEDLINE: 22199016]CapodannoD , TamburinoC .Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International Journal of Cardiology2011;146(2):242-3. [MEDLINE: 21130510]DammanP , deWinterRJ , WallentinL , FoxKA .Letter by Damman et al regarding articles, &quot;Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)&quot; and &quot;American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)&quot;. Circulation2012;126(9):e136-7. [MEDLINE: 22927480]De ServiS , GoedickeJ , SchirmerA , WidimskyP .Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European Heart Journal: Acute Cardiovascular Care2014;3(4):363-72. [MEDLINE: 24818952]GoodnoughLT , SmithPK , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. Journal of Thoracic &amp; Cardiovascular Surgery2013;145(4):1077-82. [MEDLINE: 22995726]HochholzerW , WiviottSD , AntmanEM , ContantCF , GuoJ , GiuglianoRP , et al.Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation2011;123(23):2681-9. [MEDLINE: 21606391]KohliP , UdellJA , MurphySA , CannonCP , AntmanEM , BraunwaldE , et al.Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Journal of the American College of Cardiology2014;63(3):225-32. [MEDLINE: 24140678]MahoneyEM , WangK , ArnoldSV , ProskorovskyI , WiviottS , AntmanE , et al.Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation2010;121(1):71-9. [MEDLINE: 20026770]MarianiM , MarianiG , De ServiS .Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert Review of Cardiovascular Therapy2009;7(1):17-23. [MEDLINE: 19105763]MegaJL , CloseSL , WiviottSD , ShenL , WalkerJR , SimonT , et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet2010;376(9749):1312-9. [MEDLINE: 20801494]MichelsonAD , Frelinger AL 3rd, BraunwaldE , DowneyWE , AngiolilloDJ , XenopoulosNP , et al.Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal2009;30(14):1753-63. [MEDLINE: 19435740]MogabgabO , WiviottSD , CannonCP , SloanS , SabatineMS , AntmanEM , et al.Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(6):555-9. [MEDLINE: 24064010]MontalescotG , WiviottSD , BraunwaldE , MurphySA , GibsonCM , McCabeCH , et al.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet2009;373(9665):723-31. [MEDLINE: 19249633]MurphySA , AntmanEM , WiviottSD , WeerakkodyG , MorocuttiG , HuberK , et al.Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European Heart Journal2008;29(20):2473-9. [MEDLINE: 18682445]O'DonoghueM , AntmanEM , BraunwaldE , MurphySA , StegPG , FinkelsteinA , et al.The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology2009;54(8):678-85. [MEDLINE: 19679245]OjeifoO , WiviottSD , AntmanEM , MurphySA , UdellJA , BatesER , et al.Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Jacc: Cardiovascular Interventions2013;6(2):1275-81. [MEDLINE: 24239201]PakhomovIM .Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial. Kardiologiia2010;50(6):63-7. [MEDLINE: 20659030]PrideYB , TungP , MohanaveluS , ZorkunC , WiviottSD , AntmanEM , et al.Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. Jacc: Cardiovascular Interventions2010;3(8):306-11. [MEDLINE: 20723851]RiesmeyerJS , SalazarDE , WeerakkodyGJ , NiL , WrishkoRE , Ernest CS 2nd, et al.Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. Journal of Clinical Pharmacology2012;52(6):789-97. [MEDLINE: 21628601]SerebruanyVL .Letter by Serebruany regarding article, &quot;Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38&quot;. Circulation2010;122(8):e436. [MEDLINE: 20733108]SmithPK , GoodnoughLT , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology2012;60(5):388-96. [MEDLINE: 22633653]SorichMJ , VitryA , WardMB , HorowitzJD , McKinnonRA .Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis &amp; Haemostasis2010;8(8):1678-84. [MEDLINE: 20492467]UdellJA , BraunwaldE , AntmanEM , MurphySA , MontalescotG , WiviottSD .Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).[Erratum in: JACC Cardiovasc Interv. 2014 Aug;7(8):946 Note: Antman, Elliot M [Corrected to Antman, Elliott M]]. Jacc: Cardiovascular Interventions2014;7(6):604-12. [MEDLINE: 24947719]WilcoxR , IqbalK , CostiganT , Lopez-SendonJ , RamosY , WidimskyP .An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current Medical Research &amp; Opinion2014;30(11):2193-205. [MEDLINE: 25025610]WiviottSD , AntmanEM , GibsonCM , MontalescotG , RiesmeyerJ , WeerakkodyG , et al.Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). American Heart Journal2006;152(4):627-35. [MEDLINE: 16996826]WiviottSD , BraunwaldE , McCabeCH , HorvathI , KeltaiM , HerrmanJP , et al.Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet2008;371(9621):1353-63. [MEDLINE: 18377975]WiviottSD , BraunwaldE , McCabeCH , MontalescotG , RuzylloW , GottliebS , et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2007;357(20):2001-15. [MEDLINE: 17982182]WiviottSD , DesaiN , MurphySA , MusumeciG , RagostaM , AntmanEM , et al.Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. American Journal of Cardiology2011;108(7):905-11. [MEDLINE: 21816379]WrishkoRE , Ernest CS 2nd, SmallDS , LiYG , WeerakkodyGJ , RiesmeyerJR , et al.Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. Journal of Clinical Pharmacology2009;49(8):984-98. [MEDLINE: 19546250]">TRITON‐TIMI 38 2006</a>; <a href="./references#CD008834-bbs2-0106" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al.First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473-84. [MEDLINE: 15754269]BaigentC , UK-HARP Steering Committee.Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-PO851]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. [CENTRAL: CN-00444305] ">UK‐HARP‐I 2005</a>; <a href="./references#CD008834-bbs2-0111" title="YangMY , HanB , XuY , TianLY , ZhangY , QiangYW .The effects of different dose of clopidogrel in elderly patients with unstable angina combining chronic kidney disease [abstract no: P12]. Journal of the American Geriatrics Society2016;64(Suppl 2):S320. [EMBASE: 611887576]">Yang 2016b</a>), and 63 studies did not report patient‐centred outcomes of bleeding, cardiovascular events, adverse events, or death and were judged to be at high risk of bias. </p> </section> <section id="CD008834-sec-0057"> <h4 class="title">Other potential sources of bias</h4> <p>Fifty‐seven studies appeared to be free from other sources of bias (<a href="./references#CD008834-bbs2-0001" title="GoicoecheaM , deVinuesaMS , QuirogaB , VerdallesU , MoralesE , De SequeraP , et al.Aspirin treatment in primary cardiovascular prevention and renal disease progression in CKD patients: a randomized clinical trials (AASER study) [abstract no: FR-PO1065]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):B5. [EMBASE: 633704620]GoicoecheaM , deVinuesaSG , QuirogaB , VerdeE , BernisC , MoralesE , et al.Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study). Cardiovascular Drugs &amp; Therapy2018;32(3):255-63. [MEDLINE: 29943364]GoicoecheaM , Sanchez-NinoMD , OrtizA , deVinuesaMS , QuirogaB , MoralesE , et al.Low dose aspirin increases 15-epi-lipoxin a4 levels in CKD patients [abstract no: SA-PO186]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):726. [EMBASE: 633701100]GoicoecheaM , Sanchez-NinoMD , OrtizA , Garcia de VinuesaS , QuirogaB , BernisC , et al.Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. Prostaglandins Leukotrienes &amp; Essential Fatty Acids2017;125:8-13. [MEDLINE: 28987723]">AASER 2017</a>; <a href="./references#CD008834-bbs2-0002" title="AbacilarAF , AtalayH , DoganOF .Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: a randomized controlled study. Indian Journal of Nephrology2015;25(3):136-42. [MEDLINE: 26060361]">Abacilar 2015</a>; <a href="./references#CD008834-bbs2-0003" title="Abdul-RahmanIS , Al-HowaishAK .Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23-30. [EMBASE: 2007269768]">Abdul‐Rahman 2007</a>, <a href="./references#CD008834-bbs2-0004" title="AlexopoulosD , PanagiotouA , XanthopoulouI , KomninakisD , KassimisG , DavlourosP , et al.Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. Journal of Thrombosis &amp; Haemostasis2011;9(12):2379-85. [MEDLINE: 21985070]XanthopoulouI , PanagiotouA , KomninakisD , DavlourosP , KassimisG , FourtounasK , et al.Prasugrel versus double clopidpogrel maintenance dose in patients on chronic haemodialysis and high on clopidogrel platelet reactivity [abstract no: P2438]. European Heart Journal2011;32(Suppl 1):417. [EMBASE: 70534608]">Alexopoulos 2011</a>; <a href="./references#CD008834-bbs2-0005" title="AndersonM , DewarP , FlemingLB , HackingPM , MorleyAR , MurrayS , et al.A controlled trial of dipyridamole in human renal transplantation and an assessment of platelet function studies in rejection. Clinical Nephrology1974;2(3):93-9. [MEDLINE: 4603996]">Anderson 1974</a>; <a href="./references#CD008834-bbs2-0008" title="FujitaT , YuX , KimS , NakamotoH , OrigasaH , KurumataniH , et al.Effects of sustained-release beraprost sodium in patients with primary glomerular disease or nephrosclerosis: the CASSIOPEIR study [abstract no: SA-PO1096]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):4B. [CENTRAL: CN-01657821] NakamotoH , FujitaT , OrigasaH , IsonoM , KurumataniH , OkadaK , et al.A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrology2014;15:153. [MEDLINE: 25233856]NakamotoH , YuXQ , KimS , OrigasaH , ZhengH , ChenJ , et al.Effects of sustained-release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results. Therapeutic Apheresis &amp; Dialysis2020;24(1):42-55. [MEDLINE: 31119846]">CASSIOPEIR 2014</a>; <a href="./references#CD008834-bbs2-0009" title="ChanMK , KwanSY , ChanKW , YeungCK .Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis. American Journal of Kidney Diseases1987;9(5):417-21. [MEDLINE: 3555016]">Chan 1987</a>; <a href="./references#CD008834-bbs2-0010" title="JingJ , MengX , ZhaoX , LiuL , WangA , PanY , et al.Dual antiplatelet therapy in transient ischemic attack and minor stroke with different infarction patterns: subgroup analysis of the CHANCE randomized clinical trial. JAMA Neurology2018;75(6):711-9. [MEDLINE: 29582084]LiJ , WangY , LinJ , WangD , WangA , ZhaoX , et al.Soluble CD40L is a useful marker to predict future strokes in patients with minor stroke and transient ischemic attack. Stroke2015;46(7):1990-2. [MEDLINE: 26012640]LiJ , ZhaoX , MengX , LinJ , LiuL , WangC , et al.High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome: subanalysis of the clopidogrel in high-risk patients with acute nondisabling cerebrovascular events trial. Stroke2016;47(8):2025-30. [MEDLINE: 27328699]LinY , WangA , LiJ , LinJ , WangD , MengX , et al.Impact of glycemic control on efficacy of clopidogrel in transient ischemic attack or minor stroke patients with CYP2C19 genetic variants. Stroke2017;48(4):998-1004. [MEDLINE: 28289237]LiuL , WongKS , LengX , PuY , WangY , JingJ , et al.Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology2015;85(13):1154-62. [MEDLINE: 26330567]LiZ , WangY , ZhaoX , LiuL , WangD , WangC , et al.Treatment effect of clopidogrel plus aspirin within 12 hours of acute minor stroke or transient ischemic attack. Journal of the American Heart Association2016;5(3):e003038. [MEDLINE: 27001965]MaY , LiuY , XuJ , WangY , WangY , DuF .Effect of dual antiplatelet on recurrent stroke in minor stroke or TIA depends on bodyweight. Therapeutics &amp; Clinical Risk Management2018;14:861-70. [MEDLINE: 29773949]PanY , CaiX , JingJ , MengX , LiH , WangY , et al.Stress hyperglycemia and prognosis of minor ischemic stroke and transient ischemic attack: the CHANCE study (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). Stroke2017;48(11):3006-11. [MEDLINE: 29051218]PanY , JingJ , ChenW , MengX , LiH , ZhaoX , et al.Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE.[Erratum in: Neurology. 2019 Aug 13;93(7):322; PMID: 31405943]. Neurology2017;88(20):1906-11. [MEDLINE: 28424269]PanY , JingJ , LiH , WangY , WangY , HeY , et al.Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA. Neurology2016;87(15):1551-6. [MEDLINE: 27613582]PanY , MengX , JingJ , LiH , ZhaoX , LiuL , et al.Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA. Neurology2017;88(11):1081-8. [MEDLINE: 28202699]WangA , LiS , ZhangN , DaiL , ZuoY , WangY , et al.Oxidized low-density lipoprotein to high-density lipoprotein ratio predicts recurrent stroke in minor stroke or transient ischemic attack. Stroke2018;49(11):2637-42. [MEDLINE: 30355199]WangA , XuJ , ChenG , WangD , JohnstonSC , MengX , et al.Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA. Neurology2018;91(10):e947-55. [MEDLINE: 30089614]WangD , GuiL , DongY , LiH , LiS , ZhengH , et al.Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial. Stroke &amp; Vascular Neurology2016;1(2):29-36. [MEDLINE: 28959461]WangqinR , WangX , WangY , XianY , ZhaoX , LiuL , et al.Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA: a subgroup analysis of the CHANCE trial. Stroke &amp; Vascular Neurology2017;2(4):176-83. [MEDLINE: 29507777]WangY , PanY , ZhaoX , LiH , WangD , JohnstonSC , et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial: one-year outcomes. Circulation2015;132(1):40-6. [MEDLINE: 25957224]WangY , WangY , ZhaoX , LiuL , WangD , WangC , et al.Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine2013;369(1):11-9. [MEDLINE: 23803136]WangY , ZhaoX , LinJ , LiH , JohnstonSC , LinY , et al.Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA2016;316(1):70-8. [MEDLINE: 27348249]WuY , ZhouY , PanY , ZhaoX , LiuL , WangD , et al.Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. Pharmacogenomics Journal2018;18(6):713-20. [MEDLINE: 29520080]ZhouY , PanY , WuY , ZhaoX , LiH , WangD , et al.Effect of estimated glomerular filtration rate decline on the efficacy and safety of clopidogrel with aspirin in minor stroke or transient ischemic attack: CHANCE substudy (Clopidogrel in high-risk patients with acute nondisabling cerebrovascular events). Stroke2016;47(11):2791-6. [MEDLINE: 27738237]ZhuB , LiuH , PanY , JingJ , LiH , ZhaoX , et al.Elevated neutrophil and presence of intracranial artery stenosis increase the risk of recurrent stroke. Stroke2018;49(10):2294-300. [MEDLINE: 30355101]">CHANCE 2013</a>; <a href="./references#CD008834-bbs2-0017" title="BergerPB , SteinhublS .Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. Circulation2002;106(17):2284-7. [MEDLINE: 12390961]GerschutzGP , BhattDL , Clopidogrel in Unstable Angina to Prevent Recurrent Events study.The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?American Heart Journal2003;145(4):595-601. [MEDLINE: 12679754]KeltaiM , TonelliM , MannJF , SitkeiE , LewisBS , HawkenS , et al.Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. European Journal of Cardiovascular Prevention &amp; Rehabilitation2007;14(2):312-8. [MEDLINE: 17446813]LewisBS , MehtaSR , FoxKA , HalonDA , ZhaoF , PetersRJ , et al.Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. American Heart Journal2005;150(6):1177-84. [MEDLINE: 16338255]MehtaSR , YusufS , PetersRJ , BertrandME , LewisBS , NatarajanMK , et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet2001;358(9281):527-33. [MEDLINE: 11520521]MehtaSR , YusufS , Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators.The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. European Heart Journal2000;21(24):2033-41. [MEDLINE: 11102254]PetersRJ , MehtaSR , FoxKA , ZhaoF , LewisBS , KopeckySL , et al.Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation2003;108(14):1682-7. [MEDLINE: 14504182]YusufS ,  ZhaoF ,  MehtaSR ,  ChrolaviciusS ,  TognoniG ,  FoxKK , et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [Erratum in: N Engl J Med 2001 Dec 6;345(23):1716; Erratum in: N Engl J Med 2001 Nov 15;345(20):1506]. New England Journal of Medicine2001;345(7):494-502. [MEDLINE: 11519503]">CURE 2000</a>; <a href="./references#CD008834-bbs2-0018" title="DashA , MaitiR , BandakkanavarTK , BhaskarA , PrakashJ , PandeyBL .Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: comparison between clopidogrel and low-dose aspirin. International Journal of Preventive Medicine2013;4(8):902-10. [MEDLINE: 24049616]">Dash 2013</a>; <a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a>; <a href="./references#CD008834-bbs2-0024" title="BagaiA , WhiteJA , LokhnyginaY , GiuglianoRP , Van de WerfF , MontalescotG , et al.Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. American Heart Journal2013;166(3):466-73. [MEDLINE: 24016495]De FerrariGM , Van de WerfF , ArmstrongP , BodeC , LewisBS , TricociP , et al.Contrast induced nephropathy predicts later mortality among patients with non-ST-segment elevation acute coronary syndrome undergoing PCI: a sub-analysis from the EARLY ACS study [abstract no: P3820]. European Heart Journal2011;32(Suppl 1):657. [EMBASE: 70535519]EzekowitzJA , BakalJA , WesterhoutCM , GiuglianoRP , WhiteH , KeltaiM , et al.The relationship between meteorological conditions and index acute coronary events in a global clinical trial. International Journal of Cardiology2013;168(3):2315-21. [MEDLINE: 23416014]FarhanS , ClareRM , JaraiR , GiuglianoRP , LokhnyginaY , HarringtonRA , et al.Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: an analysis from EARLY ACS. International Journal of Cardiology2017;232:264-70. [MEDLINE: 28089149]FarhanS , ClareRM , JaraiR , NewbyLK , MorrowD , GiuglianoRP , et al.Fasting glucose, NT-proBNP, treatment with glycoprotein IIB/IIIA inhibitors, and outcomes in non-st-segment elevation acute coronary syndromes: an analysis from early ACS [abstract no: A14618]. Circulation2013;128(22 Suppl 1). [EMBASE: 71340424]GiuglianoRP , NewbyLK , HarringtonRA , GibsonCM , Van de WerfF , ArmstrongP , et al.The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. American Heart Journal2005;149(6):994-1002. [MEDLINE: 15976780]GiuglianoRP , WhiteJA , BodeC , ArmstrongPW , MontalescotG , LewisBS , et al.Early versus delayed, provisional eptifibatide in acute coronary syndromes. New England Journal of Medicine2009;360(21):2176-90. [MEDLINE: 19332455]HessCN , SchultePJ , NewbyLK , StegPG , DalbyAJ , SchweigerMJ , et al.Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. European Heart Journal: Acute Cardiovascular Care2013;2(3):246-55. [MEDLINE: 24222836]KaulP , TanguayJF , NewbyLK , HochmanJS , WesterhoutCM , CaliffRM , et al.Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. American Heart Journal2013;166(4):723-8. [MEDLINE: 24093853]KlutsteinMW , WesterhoutCM , ArmstrongPW , GiuglianoRP , LewisBS , GibsonCM , et al.Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. American Heart Journal2013;165(4):583-90. [MEDLINE: 23537976]KunadianV , GiuglianoRP , NewbyLK , ZorkunC , GuoJ , BagaiA , et al.Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). American Journal of Cardiology2014;113(8):1297-305. [MEDLINE: 24607027]LopesRD , WhiteJA , TricociP , WhiteHD , ArmstrongPW , BraunwaldE , et al.Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. International Journal of Cardiology2013;167(6):2580-7. [MEDLINE: 22795720]MelloniC , JamesSK , WhiteJA , GiuglianoRP , HarringtonRA , HuberK , et al.Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. American Heart Journal2011;162(5):884-92. [MEDLINE: 22093205]PicciniJP , WhiteJA , MehtaRH , LokhnyginaY , Al-KhatibSM , TricociP , et al.Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. Circulation2012;126(1):41-9. [MEDLINE: 22645292]PrideYB , MohanaveluS , GiuglianoRP , NewbyLK , ZorkunC , KunadianV , et al.Association between angiographic complications during percutaneous coronary intervention and clinical outcomes among patients with acute coronary syndrome: an early ACS angiographic substudy [abstract no: A10394]. Circulation2011;124(21 Suppl 1). [EMBASE: 70620664]PrideYB , MohanaveluS , ZorkunC , KunadianV , GiuglianoRP , NewbyLK , et al.Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. Jacc: Cardiovascular Interventions2012;5(9):927-35. [MEDLINE: 22995880]RoeMT , WhiteJA , KaulP , TricociP , LokhnyginaY , MillerCD , et al.Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. Circulation. Cardiovascular Quality &amp; Outcomes2012;5(2):205-13. [MEDLINE: 22373905]TanguayJF , NewbyLK , HochmanJ , WesterhoutCM , CaliffRM , GibsonCM , et al.Sex differences in high-risk acute coronary syndromes: Insights from early-ACS [abstract]. Journal of the American College of Cardiology2010;55(10 Suppl 1):A120.E1122. [EMBASE: 70096317]TolevaO , WesterhoutCM , SenaratneM , BodeC , LindroosM , ArdissinoD , et al.Association of hub and spoke practice patterns with coronary intervention and outcomes in non ST elevation acute coronary syndromes (NSTE ACS): Insights from the early glycoprotein IIb/IIIa inhibition in NSTE ACS (early-ACS) trial [abstract]. Journal of the American College of Cardiology2011;57(14 Suppl 1):E1101. [EMBASE: 70400778]TolevaO , WesterhoutCM , SenaratneMP , BodeC , LindroosM , SulimovVA , et al.Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial. Catheterization &amp; Cardiovascular Interventions2014;84(6):934-42. [MEDLINE: 24976083]WangT , WhiteJA , GiuglianoRP , TricociP , HarringtonRA , MontalescotG , et al.Upfront clopidogrel use and the efficacy and safety of early eptifibatide use in patients with acute coronary syndrome: An analysis from the early versus delayed provisional eptifibatide in acute coronary syndromes (early ACS) trial [abstract]. Journal of the American College of Cardiology2010;55(10 Suppl 1):A47.E451. [EMBASE: 70095646]WangTY , WhiteJA , TricociP , GiuglianoRP , ZeymerU , HarringtonRA , et al.Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Circulation2011;123(7):722-30. [MEDLINE: 21300952]">EARLY ACS 2005</a>; <a href="./references#CD008834-bbs2-0028" title="ChoL , MarsoSP , BhattDL , TopolEJ .Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial. Journal of Womens Health &amp; Gender-Based Medicine2000;9(7):741-6. [MEDLINE: 11025866]De ServiS .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse events. Data from the Evaluation of Platelets IIb/IIIa Inhibitor for Stenting (EPISTENT) trial [Il pretrattamento con ticlopidina nello stent coronarico e associato a significativa riduzione di eventi avversi. Dati dal trial EPISTENT]. Italian Heart Journal Supplement2001;2(7):805-6. [MEDLINE: 11508303]EPISTENT Investigators.Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet1998;352(9122):87-92. [MEDLINE: 9672272]IslamMA , BlankenshipJC , BalogC , IliadisEA , LincoffAM , TchengJE , et al.Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). American Journal of Cardiology2002;90(9):916-21. [MEDLINE: 12398954]LincoffAM .Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial. American Heart Journal2000;139(2 Pt 2):S46-52. [MEDLINE: 10650316]MarsoSP , LincoffAM , EllisSG , BhattDL , TanguayJF , KleimanNS , et al.Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation1999;100(25):2477-84. [MEDLINE: 10604884]SteinhublSR , EllisSG , WolskiK , LincoffAM , TopolEJ .Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation2001;103(10):1403-9. [MEDLINE: 11245644]SteinhublSR , TanWA , FoodyJM , TopolEJ .Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA1999;281(9):806-10. [MEDLINE: 10071001]TopolEJ , MarkDB , LincoffAM , CohenE , BurtonJ , KleimanN , et al.Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.[Erratum in: Lancet 2000 Mar 25;355(9209):1104]. Lancet1999;354(9195):2019-24. [MEDLINE: 10636365]Zwart-van RijkomJE , vanHoutBA .Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb/IIIa Inhibitor For Stenting Trial. European Heart Journal2001;22(16):1476-84. [MEDLINE: 11482921]">EPISTENT 1998</a>; <a href="./references#CD008834-bbs2-0029" title="Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA1992;268(10):1292-300. [MEDLINE: 1507375]">ETDRS 1992</a>; <a href="./references#CD008834-bbs2-0033" title="BonominiV , VangelistaA , StefoniS , ScolariMP , FrascàGM , RaimondiC .Use of defibrotide in renal transplantation in man. Haemostasis1986;16 Suppl 1:48-50. [MEDLINE: 3519383]FrascàGM , VangelistaA , RaimondiC , BonominiV .Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (defibrotide): a controlled study. Life Support Systems1986;4(3):231-7. [MEDLINE: 3537545]">Frascà 1986</a>; <a href="./references#CD008834-bbs2-0034" title="FrascàGM , CiancioloG .A clinical trial with defibrotide in IgA nephritis (IgA-GN) with impaired renal function [abstract]. Nephrology Dialysis Transplantation1995;10(6):968. [CENTRAL: CN-00261099] FrascàGM , MartelloM , CanovaC , IsolaE , VangelistaA , BonominiV .Defibrotide treatment and disease progression in patients with IgA nephropathy and impaired renal function at diagnosis. Clinical Drug Investigation1997;13(4):185-91. [EMBASE: 27192802]FrascàGM , MartelloM , SestigianiE , CanovaC , VangelistaA , BonominiV .Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function. Nephrology Dialysis Transplantation1996;11(2):392-3. [MEDLINE: 8700366]">Frascà 1997</a>; <a href="./references#CD008834-bbs2-0036" title="GhorbaniA , AalamshahM , ShahbazianH , EhsanpourA , ArefA .Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian Journal of Nephrology2009;19(2):57-61. [MEDLINE: 20368925]">Ghorbani 2009</a>; <a href="./references#CD008834-bbs2-0037" title="GhorbaniA , Jasemi-ZerganiF .Ticlopidine to prevent primary arteriovenous fistula failure in hemodialysis patients; a randomized controlled trial. Journal of Renal Injury Prevention2013;2(3):109-11. [MEDLINE: 25340144]">Ghorbani 2013</a>; <a href="./references#CD008834-bbs2-0038" title="GiustinaA , PeriniP , DesenzaniP , BossoniS , IannielloP , MilaniM , et al.Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes1998;47(3):423-30. [MEDLINE: 9519749]">Giustina 1998</a>; <a href="./references#CD008834-bbs2-0040" title="deMoralesAM , GoicoecheaM , VerdeE , CarbayoJ , BarbieriD , DelgadoA , et al.Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial. Journal of Nephrology2019;32(4):581-7. [MEDLINE: 30949987]GoicoecheaM , Garcia de VinuesaS , QuirogaB , VerdallesU , BarracaD , YusteC , et al.Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. Journal of Nephrology2012;25(6):969-75. [MEDLINE: 22241639]">Goicoechea 2012</a>; <a href="./references#CD008834-bbs2-0042" title="GröntoftKC , MulecH , GutierrezA , OlanderR .Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scandinavian Journal of Urology &amp; Nephrology1985;19(1):55-7. [MEDLINE: 3895411]">Gröntoft 1985</a>; <a href="./references#CD008834-bbs2-0045" title="HansenHP , GaedePH , JensenBR , ParvingHH .Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria. Diabetes Care2000;23(12):1742-5. [MEDLINE: 11128344]">Hansen 2000</a>; <a href="./references#CD008834-bbs2-0047" title="HidakaS , KobayashiS , IwagamiM , IsshikiR , TsutsumiD , MochidaY , et al.Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease. Renal Failure2013;35(1):43-8. [MEDLINE: 23110683]">Hidaka 2013</a>; <a href="./references#CD008834-bbs2-0050" title="JiaoXM , JiaoXJ , ZhangXG , XuXP , WuJX , YaoL , et al.Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy. Chinese Medical Journal2013;126(22):4395-6. [MEDLINE: 24238537]">Jiao 2013</a>; <a href="./references#CD008834-bbs2-0051" title="OgawaH , NakayamaM , MorimotoT , UemuraS , KanauchiM , DoiN , et al.Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.[Erratum in: JAMA. 2009 May 13;301(18):1882], [Erratum in: JAMA. 2012 Nov 14;308(18):1861]. JAMA2008;300(18):2134-41. [MEDLINE: 18997198]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , NakayamaM , et al.Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk. Circulation Journal2013;77(12):3023-8. [MEDLINE: 24042256]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , NakayamaM , et al.Is long-term low-dose aspirin therapy associated with renal dysfunction in patients with type 2 diabetes? JPAD2 cohort study. PLoS ONE [Electronic Resource]2016;11(1):e0147635. [MEDLINE: 26808136]OkadaS , MorimotoT , OgawaH , SakumaM , SoejimaH , OhtoriiM , et al.Long-term use of low-dose aspirin develops proteinuria in patients with diabetes: A reanalysis of JPAD study [abstract no: 10863]. Circulation2013;128(22 Suppl 1). [EMBASE: 71337722]SaitoY , MorimotoT , OgawaH , NakayamaM , UemuraS , DoiN , et al.Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care2011;34(2):280-5. [MEDLINE: 21270185]">JPAD 2008</a>; <a href="./references#CD008834-bbs2-0052" title="OhtakeT , SatoM , NakazawaR , KondohM , KobayashiS .Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study [abstract no: Su528]. NDT Plus2010;3(Suppl 3):iii487. [EMBASE: 70484748]OhtakeT , SatoM , NakazawaR , KondohM , MiyajiT , MoriyaH , et al.Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2014;18(1):1-8. [MEDLINE: 24499078]">J‐PADD 2014</a>; <a href="./references#CD008834-bbs2-0053" title="KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. New England Journal of Medicine1974;290(6):304-6. [MEDLINE: 4588285]KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation1975;52(3):497-9. [MEDLINE: 1098808]">Kaegi 1974</a>; <a href="./references#CD008834-bbs2-0055" title="KauffmannHM , AdamsMB , HebertLA , WalczakPM .Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905 ]">Kauffmann 1980</a>; <a href="./references#CD008834-bbs2-0057" title="KhajehdehiP , RoozbehJ , MostafaviH .A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scandinavian Journal of Urology &amp; Nephrology2002;36(2):145-8. [MEDLINE: 12028688]">Khajehdehi 2002</a>; <a href="./references#CD008834-bbs2-0058" title="KobayashiK , MaedaK , KoshikawaS , KawaguchiY , ShimizuN , NaitoC .Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis: a multicenter collaborative double blind study. Thrombosis Research1980;20(2):255-61. [MEDLINE: 7209880]">Kobayashi 1980</a>; <a href="./references#CD008834-bbs2-0059" title="KontessisPS , JonesSL , BarrowSE , StrattonPD , AlessandriniP , De CosmoS , et al.Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy. Journal of Laboratory &amp; Clinical Medicine1993;121(3):415-23. [MEDLINE: 8445289]">Kontessis 1993</a>; <a href="./references#CD008834-bbs2-0060" title="KooistraMP , vanEsA , MarxJJ , HertsigM , StruyvenbergA .Effects of low dose aspirin on thrombovascular accidents during treatment with rHuEpo: a multicentre, controlled, cross-over study [abstract]. Nephrology Dialysis Transplantation1993;8:277. [CENTRAL: CN-00260772] KooistraMP , vanEsA , MarxJJ , HertsigML , StruyvenbergA .Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrology Dialysis Transplantation1994;9(8):1115-20. [MEDLINE: 7800210]">Kooistra 1994</a>; <a href="./references#CD008834-bbs2-0062" title="LiangJ , WangZ , ShiD , LiuY , ZhaoY , HanH , et al.High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. Angiology2015;66(4):319-25. [MEDLINE: 24913197]">Liang 2015</a>; <a href="./references#CD008834-bbs2-0063" title="MichieDD , WomboltDG .Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research - Clinical &amp; Experimental1977;22(1 II):196-204. [EMBASE: 8152617]">Michie 1977</a>; <a href="./references#CD008834-bbs2-0065" title="MilutinovicS , GasparovicV , MilutinovicE , Buturovic-PonikvarJ .Ticlopidine improves dialysis clearance of solutes in uremic patients by reducing blood clotting in dialyser fibers. International Journal of Artificial Organs1993;16(5):249-52. [MEDLINE: 8354583]">Milutinovic 1993</a>; <a href="./references#CD008834-bbs2-0067" title="MozafarM , SamsamiM , SobhiyehMR , JabbehdariS , FallahZM .Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourology Monthly2013;5(2):762-5. [MEDLINE: 23841041]">Mozafar 2013</a>; <a href="./references#CD008834-bbs2-0068" title="MozafarM , AlborziM , MoradiA .Effects of clopidogrel on longevity of permanent double-lumen catheter patency in dialysis patients: A single-blind placebo-controlled clinical trial. Nephro-Urology Monthly2018;10(2):e58135. [EMBASE: 622226387]">Mozafar 2018</a>; <a href="./references#CD008834-bbs2-0069" title="NakamuraT , UshiyamaC , TakahashiY , TanakaA , ShimadaN , EbiharaI , et al.Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease. Nephron2001;88(1):80-2. [MEDLINE: 11340355]">Nakamura 2001d</a>; <a href="./references#CD008834-bbs2-0070" title="NakamuraT , UshiyamaC , OsadaS , UgaiK , TakahashiY , TanakaA , et al.Effect of dilazep dihydrochloride on serum cardiac troponin T levels in hemodialysis patients. Kidney &amp; Blood Pressure Research2002;25(1):50-4. [MEDLINE: 11834877]">Nakamura 2002b</a>; <a href="./references#CD008834-bbs2-0072" title="NybergG , LarssonO , WestbergNG , AurellM , JagenburgR , BlohmeG .A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study. Clinical Nephrology1984;21(3):184-7. [MEDLINE: 6705280]">Nyberg 1984</a>; <a href="./references#CD008834-bbs2-0073" title="OgawaS , MoriT , NakoK , IshizukaT , ItoS .Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):362-8. [MEDLINE: 18235151]">Ogawa 2008</a>; <a href="./references#CD008834-bbs2-0077" title="KimW , KangWY , WooJS .Objectives: The purpose of this study was to determine the functional impact of cilostazol in patients with chronic kidney disease (CKD) undergoing hemodialysis [abstract no: TCT-497]. Journal of the American College of Cardiology2011;58(20 Suppl 1):B135. [EMBASE: 70581866]WooJS , KimW , HaSJ , JeongKH , LeeTW , IhmCG , et al.A comparison of clopidogrel responsiveness in patients with chronic renal failure: results of the adjunctive cilostazol versus high maintenance dose clopidogrel (PIANO) study [abstract no: AS-252]. American Journal of Cardiology2011;107(8 Suppl 1):100-1A. [EMBASE: 70401953]WooJS , KimW , LeeSR , JungKH , KimWS , LewJH , et al.Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. American Heart Journal2011;162(6):1018-25. [MEDLINE: 22137075]">PIANO‐2 CKD 2011</a>; <a href="./references#CD008834-bbs2-0078" title="JeongKH , ChoJH , WooJS , KimJB , KimWS , LeeTW , et al.Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. American Journal of Kidney Diseases2015;65(6):916-24. [MEDLINE: 25622774]JeongKH , LeeTW , KimJS , LeeSY , LeeSH , MoonJY , et al.Platelet reactivity in patients with end stage renal disease receiving clopidogrel compared with ticagrelor: a randomized crossover study [abstract no: FP610]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii276. [EMBASE: 72207028]WooJS , KimW , KimHS , HwangSJ , KimJB , KimSJ , et al.Randomized assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with chronic kidney disease performing hemodialysis [abstract]. European Heart Journal2014;35(Suppl 1):7-8. [EMBASE: 71646762]">PIANO‐3 2015</a>; <a href="./references#CD008834-bbs2-0079" title="KimJS , LeeTW , IhmC , LeeSH , KimSY , LeeSY , et al.Relationship of ticagrelor dose and platelet reactivity in patients with end stage renal disease on hemodialysis [abstract no: FR-PO727]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):529A. KimJS , WooJS , KimJB , KimWS , LeeTW , KimKS , et al.The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. International Journal of Cardiology2017;238:110-6. [MEDLINE: 28342632]KimW , WooJS , KimWS , KimJB , KimHO , KimJM .Pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis [abstract]. European Heart Journal2016;37(Suppl 1):636. [EMBASE: 612284362]">PIANO‐6 2017</a>; <a href="./references#CD008834-bbs2-0085" title="Quarto Di PaloF , ElliA , RivoltaR , ParentiM , PalazziP , ZanussiC .Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide. Transplantation Proceedings1991;23(1 Pt 2):969-71. [MEDLINE: 1989347]">Quarto Di Palo 1991</a>; <a href="./references#CD008834-bbs2-0088" title="CooperCJ , HallerST , ColyerW , SteffesM , BurketMW , ThomasWJ , et al.Embolic protection and platelet inhibition during renal artery stenting. Circulation2008;117(21):2752-60. [MEDLINE: 18490527]HeW , CheJ , ZhanD , DawsoT , KanjwaS , HalleS , et al.Time dependant changes in systolic blood pressure after renal artery stenting: role of stenosis severity [abstract no: 14283]. Circulation2012;126(21 Suppl 1). [EMBASE: 70958797]KanjwalK , CooperCJ , VirmaniR , HallerS , ShapiroJI , BurketMW , et al.Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy. Catheterization &amp; Cardiovascular Interventions2010;76(1):16-23. [MEDLINE: 20209644]KanjwalK , HallerS , SteffesM , VirmaniR , ShapiroJI , BurketMW , et al.Complete versus partial distal embolic protection during renal artery stenting. Catheterization &amp; Cardiovascular Interventions2009;73(6):725-30. [MEDLINE: 19198007]TianJ , HallerS , PeriyasamyS , BrewsterP , ZhangH , AdlakhaS , et al.Renal ischemia regulates marinobufagenin release in humans. Hypertension2010;56(5):914-9. [MEDLINE: 20823380]YuH , ZhangD , HallerS , KanjwalK , ColyerW , BrewsterP , et al.Determinants of renal function in patients with renal artery stenosis. Vascular Medicine2011;16(5):331-8. [MEDLINE: 21908683]">RESIST 2008</a>; <a href="./references#CD008834-bbs2-0089" title="RouzrokhM , AbbasiMR , MirshemiraniAR , SobhiyehMR .The effect of antiplatelet drugs on the patency rate of arterio-venous fistulae in hemodialysis patients. Iranian Journal of Pharmaceutical Research2010;9(4):451-7. [EMBASE: 2011024056]">Rouzrokh 2010</a>; <a href="./references#CD008834-bbs2-0090" title="RubinJ , AdairC , BarnesT , BowerJD .Augmentation of peritoneal clearance by dipyridamole. Kidney International1982;22(6):658-61. [MEDLINE: 6761488]">Rubin 1982</a>; <a href="./references#CD008834-bbs2-0091" title="SalterMC , CrowMJ , DonaldsonDR , RobertsTG , RajahSM , DavisonAM .Prevention of platelet deposition and thrombus formation on hemodialysis membranes: a double-blind randomized trial of aspirin and dipyridamole. Artificial Organs1984;8(1):57-61. [MEDLINE: 6703927]">Salter 1984</a>; <a href="./references#CD008834-bbs2-0093" title="SchulzeR , LangkopfB , SziegoleitW .The effect of dipyridamole on the results of allogenic kidney transplantation [Der Einfluss von Dipyridamol auf die Ergebnisse der allogenen Nieren-transplantation]. Zeitschrift für Urologie und Nephrologie1990;83(5):255-9. [MEDLINE: 2203215]">Schulze 1990</a>; <a href="./references#CD008834-bbs2-0097" title="StorckM , SchillingM , MickleyV , TechtB , AbendrothD .Influence of systemic cyclooxygenase inhibition with single-dose aspisol on kinetics of arachidonic acid metabolites in the venous effluate of transplanted kidney grafts in humans. Transplantation Proceedings1996;28(1):312-3. [MEDLINE: 8644237]">Storck 1996</a>; <a href="./references#CD008834-bbs2-0099" title="TangWH , LinFH , LeeCH , KuoFC , HsiehCH , HsiaoFC , et al.Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. Endocrine2014;45(2):293-301. [MEDLINE: 23775007]">Tang 2014</a>; <a href="./references#CD008834-bbs2-0100" title="BergerPB , BestPJ , TopolEJ , WhiteJ , DiBattistePM , ChanAW , et al.The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal2005;149(5):869-75. [MEDLINE: 15894970]KalyanasundaramA , BlankenshipJC , BergerP , HerrmannH , McClureR , MoliternoD .Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?). Catheterization &amp; Cardiovascular Interventions2007;69(5):623-9. [MEDLINE: 17192960]MoliternoDJ , TopolEJ .A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. American Heart Journal2000;140(5):722-6. [MEDLINE: 11054616]MoliternoDJ , YakubovSJ , DiBattistePM , HerrmannHC , StoneGW , MacayaC , et al.Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet2002;360(9330):355-60. [MEDLINE: 12241774]MukherjeeD , TopolEJ , BertrandME , KristensenSD , HerrmannHC , NeumannFJ , et al.Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. European Heart Journal2005;26(23):2524-8. [MEDLINE: 16107485]RoffiM , MoliternoDJ , MeierB , PowersER , GrinesCL , DiBattistePM , et al.Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation2002;105(23):2730-6. [MEDLINE: 12057986]TopolEJ , MoliternoDJ , HerrmannHC , PowersER , GrinesCL , CohenDJ , et al.Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New England Journal of Medicine2001;344(25):1888-94. [MEDLINE: 11419425]">TARGET 2000</a>; <a href="./references#CD008834-bbs2-0101" title="TayebiP , KazemzadehG , BanihashemA , RavariH .Effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients: a randomized double-blind placebo-controlled trial. Electronic Physician [Electronic Resource]2018;10(1):6135-9. [MEDLINE: 29588811]">Tayebi 2018</a>; <a href="./references#CD008834-bbs2-0105" title="AbaciA .The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses [Prasugrelin ST yukselmeli ve yukselmesiz miyokart enfarktusunde kullanimi: TRITON TIMI 38 caIismasi ve alt grup sonuclari]. Turk Kardiyoloji Dernegi Arsivi2015;43 Suppl 2:1-6. [MEDLINE: 27326444]AntmanEM , WiviottSD , MurphySA , VoitkJ , HasinY , WidimskyP , et al.Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Journal of the American College of Cardiology2008;51(21):2028-33. [MEDLINE: 18498956]BonacaMP , WiviottSD , BraunwaldE , MurphySA , RuffCT , AntmanEM , et al.American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation2012;125(4):577-83. [MEDLINE: 22199016]CapodannoD , TamburinoC .Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International Journal of Cardiology2011;146(2):242-3. [MEDLINE: 21130510]DammanP , deWinterRJ , WallentinL , FoxKA .Letter by Damman et al regarding articles, &quot;Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)&quot; and &quot;American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)&quot;. Circulation2012;126(9):e136-7. [MEDLINE: 22927480]De ServiS , GoedickeJ , SchirmerA , WidimskyP .Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European Heart Journal: Acute Cardiovascular Care2014;3(4):363-72. [MEDLINE: 24818952]GoodnoughLT , SmithPK , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. Journal of Thoracic &amp; Cardiovascular Surgery2013;145(4):1077-82. [MEDLINE: 22995726]HochholzerW , WiviottSD , AntmanEM , ContantCF , GuoJ , GiuglianoRP , et al.Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation2011;123(23):2681-9. [MEDLINE: 21606391]KohliP , UdellJA , MurphySA , CannonCP , AntmanEM , BraunwaldE , et al.Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Journal of the American College of Cardiology2014;63(3):225-32. [MEDLINE: 24140678]MahoneyEM , WangK , ArnoldSV , ProskorovskyI , WiviottS , AntmanE , et al.Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation2010;121(1):71-9. [MEDLINE: 20026770]MarianiM , MarianiG , De ServiS .Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert Review of Cardiovascular Therapy2009;7(1):17-23. [MEDLINE: 19105763]MegaJL , CloseSL , WiviottSD , ShenL , WalkerJR , SimonT , et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet2010;376(9749):1312-9. [MEDLINE: 20801494]MichelsonAD , Frelinger AL 3rd, BraunwaldE , DowneyWE , AngiolilloDJ , XenopoulosNP , et al.Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal2009;30(14):1753-63. [MEDLINE: 19435740]MogabgabO , WiviottSD , CannonCP , SloanS , SabatineMS , AntmanEM , et al.Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(6):555-9. [MEDLINE: 24064010]MontalescotG , WiviottSD , BraunwaldE , MurphySA , GibsonCM , McCabeCH , et al.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet2009;373(9665):723-31. [MEDLINE: 19249633]MurphySA , AntmanEM , WiviottSD , WeerakkodyG , MorocuttiG , HuberK , et al.Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European Heart Journal2008;29(20):2473-9. [MEDLINE: 18682445]O'DonoghueM , AntmanEM , BraunwaldE , MurphySA , StegPG , FinkelsteinA , et al.The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology2009;54(8):678-85. [MEDLINE: 19679245]OjeifoO , WiviottSD , AntmanEM , MurphySA , UdellJA , BatesER , et al.Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Jacc: Cardiovascular Interventions2013;6(2):1275-81. [MEDLINE: 24239201]PakhomovIM .Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial. Kardiologiia2010;50(6):63-7. [MEDLINE: 20659030]PrideYB , TungP , MohanaveluS , ZorkunC , WiviottSD , AntmanEM , et al.Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. Jacc: Cardiovascular Interventions2010;3(8):306-11. [MEDLINE: 20723851]RiesmeyerJS , SalazarDE , WeerakkodyGJ , NiL , WrishkoRE , Ernest CS 2nd, et al.Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. Journal of Clinical Pharmacology2012;52(6):789-97. [MEDLINE: 21628601]SerebruanyVL .Letter by Serebruany regarding article, &quot;Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38&quot;. Circulation2010;122(8):e436. [MEDLINE: 20733108]SmithPK , GoodnoughLT , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology2012;60(5):388-96. [MEDLINE: 22633653]SorichMJ , VitryA , WardMB , HorowitzJD , McKinnonRA .Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis &amp; Haemostasis2010;8(8):1678-84. [MEDLINE: 20492467]UdellJA , BraunwaldE , AntmanEM , MurphySA , MontalescotG , WiviottSD .Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).[Erratum in: JACC Cardiovasc Interv. 2014 Aug;7(8):946 Note: Antman, Elliot M [Corrected to Antman, Elliott M]]. Jacc: Cardiovascular Interventions2014;7(6):604-12. [MEDLINE: 24947719]WilcoxR , IqbalK , CostiganT , Lopez-SendonJ , RamosY , WidimskyP .An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current Medical Research &amp; Opinion2014;30(11):2193-205. [MEDLINE: 25025610]WiviottSD , AntmanEM , GibsonCM , MontalescotG , RiesmeyerJ , WeerakkodyG , et al.Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). American Heart Journal2006;152(4):627-35. [MEDLINE: 16996826]WiviottSD , BraunwaldE , McCabeCH , HorvathI , KeltaiM , HerrmanJP , et al.Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet2008;371(9621):1353-63. [MEDLINE: 18377975]WiviottSD , BraunwaldE , McCabeCH , MontalescotG , RuzylloW , GottliebS , et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2007;357(20):2001-15. [MEDLINE: 17982182]WiviottSD , DesaiN , MurphySA , MusumeciG , RagostaM , AntmanEM , et al.Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. American Journal of Cardiology2011;108(7):905-11. [MEDLINE: 21816379]WrishkoRE , Ernest CS 2nd, SmallDS , LiYG , WeerakkodyGJ , RiesmeyerJR , et al.Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. Journal of Clinical Pharmacology2009;49(8):984-98. [MEDLINE: 19546250]">TRITON‐TIMI 38 2006</a>; <a href="./references#CD008834-bbs2-0111" title="YangMY , HanB , XuY , TianLY , ZhangY , QiangYW .The effects of different dose of clopidogrel in elderly patients with unstable angina combining chronic kidney disease [abstract no: P12]. Journal of the American Geriatrics Society2016;64(Suppl 2):S320. [EMBASE: 611887576]">Yang 2016b</a>; <a href="./references#CD008834-bbs2-0113" title="ZäunerI , BöhlerJ , BraunN , GruppC , HeeringP , SchollmeyerP .Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Nephrology Dialysis Transplantation1994;9(6):619-22. [MEDLINE: 7970086]">Zäuner 1994</a>), 33 studies reported other sources of bias and were judged to be at high risk (<a href="./references#CD008834-bbs2-0006" title="AndrassyK , MallucheH , BornefeldH , CombergM , RitzE , JesdinskyH , et al.Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: results of a prospective double blind study. Klinische Wochenschrift1974;52(7):348-9. [MEDLINE: 4600820]">Andrassy 1974</a>; <a href="./references#CD008834-bbs2-0011" title="BangaloreS , BhattDL , StegPG , WeberMA , BodenWE , HammCW , et al.beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circulation: Cardiovascular Quality &amp; Outcomes2014;7(6):872-81. [MEDLINE: 25271049]BergerPB , BhattDL , FusterV , StegPG , FoxKA , ShaoM , et al.Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation2010;121(23):2575-83. [MEDLINE: 20516378]BhattDL , FlatherMD , HackeW , BergerPB , BlackHR , BodenWE , et al.Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology2007;49(19):1982-8. [MEDLINE: 17498584]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial [Erratum in: Am Heart J. 2006 Jan;151(1):247]. American Heart Journal2005;150(3):401. [MEDLINE: 16169314]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine2006;354(16):1706-17. [MEDLINE: 16531616]DasguptaA , SteinhublSR , BhattDL , BergerPB , ShaoM , MakKH , et al.Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). American Journal of Cardiology2009;103(10):1359-63. [MEDLINE: 19427428]EikelboomJW , HankeyGJ , ThomJ , BhattDL , StegPG , MontalescotG , et al.Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation2008;118(17):1705-12. [MEDLINE: 18838564]MakKH , BhattDL , ShaoM , HaffnerSM , HammCW , HankeyGJ , et al.The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. European Heart Journal2009;30(7):857-65. [MEDLINE: 19233855]SteinhublSR , BhattDL , BrennanDM , MontalescotG , HankeyGJ , EikelboomJW , et al.Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding [Summary for patients in Ann Intern Med. 2009 Mar 17;150(6):I-22; PMID: 19293067]. Annals of Internal Medicine2009;150(6):379-86. [MEDLINE: 19293071]WangTH , BhattDL , FoxKA , SteinhublSR , BrennanDM , HackeW , et al.An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal2007;28(18):2200-7. [MEDLINE: 17673448]">CHARISMA 2006</a>; <a href="./references#CD008834-bbs2-0012" title="ChengIK , FangGX , WongMC , JiYL , ChanKW , YeungHW .A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy. Nephrology1998;4(1-2):19-26. [EMBASE: 28282953]ChengIK , FangGX , WongMC , JiYL , YeungH .A randomised prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA glomerulonephritis (IgAN) [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:45. [CENTRAL: CN-00550664] ">Cheng 1998a</a>; <a href="./references#CD008834-bbs2-0015" title="AronowHD , SteinhublSR , BrennanDM , BergerPB , TopolEJ , CREDO Investigators.Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal2009;157(2):369-74. [MEDLINE: 19185647]BeinartSC , KolmP , VeledarE , ZhangZ , MahoneyEM , BouinO , et al.Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Journal of the American College of Cardiology2005;46(5):761-9. [MEDLINE: 16139122]BestPJ , SteinhublSR , BergerPB , DasguptaA , BrennanDM , SzczechLA , et al.The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal2008;155(4):687-93. [MEDLINE: 18371477]BrenerSJ , SteinhublSR , BergerPB , BrennanDM , TopolEJ , CREDO Investigators.Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial. Journal of Invasive Cardiology2007;19(7):287-90. [MEDLINE: 17620671]RingborgA , LindgrenP , JonssonB .The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. European Journal of Health Economics2005;6(4):354-56, 358-62. [MEDLINE: 16267654]SteinhublSR , BergerPB , Mann JT 3rd, FryET , DeLagoA , WilmerC , et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [Erratum in: JAMA. 2003 Feb 26;289(8):987]. JAMA2002;288(19):2411-20. [MEDLINE: 12435254]">CREDO 2005</a>; <a href="./references#CD008834-bbs2-0016" title="CreekR .Ticlopidine. Patency of haemodialysis access sites. Guildford Sanofi Winthrop. Internal report1990. ">Creek 1990</a>; <a href="./references#CD008834-bbs2-0019" title="DemberL , AllonM , DelmezJ , DixonB , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00550593] DemberLM , BeckGJ , AllonM , DelmezJA , DixonBS , GreenbergA , et al.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008;299(18):2164-71. [MEDLINE: 18477783]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials2005;2(5):413-22. [MEDLINE: 16317810]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):229A. [CENTRAL: CN-00445067] ">Dember 2005</a>; <a href="./references#CD008834-bbs2-0025" title="EllS , MihindukulasuriyaJC , O'BrienJR , PolakA , VernhamG .Ticlopidine in the prevention of blockage of fistulae and shunts [abstract no: 332]. Haemostasis1982;12:180. ">Ell 1982</a>; <a href="./references#CD008834-bbs2-0026" title="AguirreFV , TopolEJ , AndersonKM , KleimanNS , WeismanHF , FitzPatrickSE , et al.Benefit within patient subgroups receiving c7e3 fab (abciximab) during percutaneous coronary revascularization: subgroup analysis from the EPIC trial. Journal of Invasive Cardiology1996;8 Suppl B:21-9B. [MEDLINE: 10785766]AguirreFV , TopolEJ , FergusonJJ , AndersonK , BlankenshipJC , HeuserRR , et al.Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation1995;91(12):2882-90. [MEDLINE: 7796496]BerkowitzSD , SaneDC , SigmonKN , ShavenderJH , HarringtonRA , TchengJE , et al.Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. Journal of the American College of Cardiology1998;32(2):311-9. [MEDLINE: 9708455]BlankenshipJC , HellkampAS , AguirreFV , DemkoSL , TopolEJ , CaliffRM .Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. American Journal of Cardiology1998;81(1):36-40. [MEDLINE: 9462603]BoehrerJD , KereiakesDJ , NavettaFI , CaliffRM , TopolEJ .Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications. American Journal of Cardiology1994;74(11):1166-70. [MEDLINE: 7977081]CaliffRM , LincoffAM , TchengJE , TopolEJ .An overview of the results of the EPIC trial. European Heart Journal1995;16 Suppl L:43-9. [MEDLINE: 8869018]EPIC Investigators.Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New England Journal of Medicine1994;330(14):956-61. [MEDLINE: 8121459]KhanMM , EllisSG , AguirreFV , WeismanHF , WildermannNM , CaliffRM , et al.Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1998;31(1):31-6. [MEDLINE: 9426014]LefkovitsJ , BlankenshipJC , AndersonKM , StonerGL , TalleyJD , WorleySJ , et al.Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. Journal of the American College of Cardiology1996;28(4):849-55. [MEDLINE: 8837559]LefkovitsJ , IvanhoeRJ , CaliffRM , BergelsonBA , AndersonKM , StonerGL , et al.Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. American Journal of Cardiology1996;77(12):1045-51. [MEDLINE: 8644655]LincoffAM , CaliffRM , AndersonKM , WeismanHF , AguirreFV , KleimanNS , et al.Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1997;30(1):149-56. [MEDLINE: 9207636]MakKH , ChallapalliR , EisenbergMJ , AndersonKM , CaliffRM , TopolEJ .Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. American Journal of Cardiology1997;80(8):985-8. [MEDLINE: 9352964]MarkDB , TalleyJD , TopolEJ , BowmanL , LamLC , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation1996;94(4):629-35. [MEDLINE: 8772681]MoliternoDJ , CaliffRM , AguirreFV , AndersonK , SigmonKN , WeismanHF , et al.Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. American Journal of Cardiology1995;75(8):559-62. [MEDLINE: 7887377]NarinsCR , MillerDP , CaliffRM , TopolEJ .The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Journal of the American College of Cardiology1999;33(3):647-53. [MEDLINE: 10080464]ThelMC , CaliffRM , TchengJE , SigmonKN , LincoffAM , TopolEJ , et al.Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. American Heart Journal1999;137(2):264-73. [MEDLINE: 9924160]TopolEJ , CaliffRM , WeismanHF , EllisSG , TchengJE , WorleyS , et al.Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet1994;343(8902):881-6. [MEDLINE: 7908357]TopolEJ , FergusonJJ , WeismanHF , TchengJE , EllisSG , KleimanNS , et al.Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA1997;278(6):479-84. [MEDLINE: 9256222]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. American Heart Journal1998;135(4):S98-106. [MEDLINE: 9539500]vanHoutBA , BowmanL , ZelingerDJ , SimoonsML .Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. European Heart Journal1998;19 Suppl D:D59-66. [MEDLINE: 9597523]">EPIC 1994</a>; <a href="./references#CD008834-bbs2-0027" title="EPILOG Investigators.Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New England Journal of Medicine1997;336(24):1689-96. [MEDLINE: 9182212]GhaffariS , KereiakesDJ , LincoffAM , KellyTA , TimmisGC , KleimanNS , et al.Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. American Journal of Cardiology1998;82(1):7-12. [MEDLINE: 9671000]KereiakesDJ , LincoffAM , MillerDP , TchengJE , CabotCF , AndersonKM , et al.Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Circulation1998;97(9):857-64. [MEDLINE: 9521334]KleimanNS , LincoffAM , KereiakesDJ , MillerDP , AguirreFV , AndersonKM , et al.Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation1998;97(19):1912-20. [MEDLINE: 9609084]LincoffAM , MarkDB , TchengJE , CaliffRM , BalaMV , AndersonKM , et al.Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation2000;102(24):2923-9. [MEDLINE: 11113041]LincoffAM , TchengJE , CaliffRM , KereiakesDJ , KellyTA , TimmisGC , et al.Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. One-year outcome in the EPILOG trial. Circulation1999;99(15):1951-8. [MEDLINE: 10208997]">EPILOG 1997</a>; <a href="./references#CD008834-bbs2-0031" title="BadveS , HawleyCM , IrishAB , Paul-BrentP .High rate of screening failure in the FAVOURED study [abstract no: PUB345]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):905A. IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al.Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453]IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul-BrentP , et al.Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis-a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804]IrishA , FAVOURED Study Group.High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN-00756870] IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 009]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790]IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. [EMBASE: 70467038]IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul-BrentPA , et al.Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184-93. [MEDLINE: 28055065]IrishAB .The omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo-controlled trial [abstract no: HI-OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2-3. [CENTRAL: CN-01658143] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis-post hoc analysis of the FAVOURED study [abstract no: MO049]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475]ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on the need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology2018;23(Suppl 3):56. [EMBASE: 623841152]ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al.Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract no: SP593]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178]ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract no: FP555]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265]ViecelliA , PascoeE , PolkinghorneK , Paul-BrentP , DarssanD , HooiL , et al.A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115-6. [EMBASE: 612312707]ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul-BrentPA , BadveSV , et al.The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581]ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis - Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217-28. [MEDLINE: 26205903]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study. Nephrology2017;22(10):823-4. [MEDLINE: 27188542]ViecelliAK , PolkinghorneKR , PascoeEM , Paul-BrentPA , HawleyCM , BadveSV , et al.Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS ONE [Electronic Resource]2019;14(3):e0213274. [MEDLINE: 30913208]">FAVOURED 2009</a>; <a href="./references#CD008834-bbs2-0032" title="FiskerstrandCE , ThompsonIW , BurnetME , WilliamsP , AndertonJL .Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artificial Organs1985;9(1):61-3. [MEDLINE: 3888153]">Fiskerstrand 1985</a>; <a href="./references#CD008834-bbs2-0035" title="GaedeP , HansenHP , ParvingHH , PedersenO .Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrology Dialysis Transplantation2003;18(3):539-42. [MEDLINE: 12584276]GaedeP , ParvingH , PedersenO .Lack of impact of low-dose acetylsalisyic acid (ASA) on albuminuria in type 2 diabetic patients [abstract no: A0660]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):128A. [CENTRAL: CN-00583369] ">Gaede 2003</a>; <a href="./references#CD008834-bbs2-0039" title="GaoC , TomaniakM , TakahashiK , KawashimaH , WangR , HaraH , et al.Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovascular Diabetology2020;19(1):179. [MEDLINE: 33066794]TomaniakM , ChichareonP , Klimczak-TomaniakD , TakahashiK , KogameN , ModoloR , et al.Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Clinical Research in Cardiology2020;109(7):930-43. [MEDLINE: 31925529]VranckxP , ValgimigliM , JuniP , HammC , StegPG , HegD , et al.Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet2018;392(10151):940-9. [MEDLINE: 30166073]">GLOBAL LEADERS 2018</a>; <a href="./references#CD008834-bbs2-0043" title="GröntoftK , LarssonR , MulecH , WeissLG , DickinsonJP .Ticlopidine in fistula surgery: double-blind comparison against placebo on the rate of early occlusion of arterio-venous fistulae [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:398. [CENTRAL: CN-00601921] GröntoftKC , LarssonR , MulecH , WeissLG , DickinsonJP .Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scandinavian Journal of Urology &amp; Nephrology1998;32(4):276-83. [MEDLINE: 9764456]">Gröntoft 1998</a>; <a href="./references#CD008834-bbs2-0044" title="GuoZ , HasbachJ , KoschinskyT .Effect of acetylsalicylic acid on renal function of Type 1 diabetic patients with microalbuminuria [Wirkung von Azetylsalizylsaure auf die Nierenfunktion bei Typ-1- Diabetikern mit Mikroalbuminurie. Placebokontrollierte Crossover-Pilotstudie]. Diabetes und Stoffwechsel1998;7(2):41-7. [EMBASE: 28146337]">Guo 1998</a>; <a href="./references#CD008834-bbs2-0046" title="HarterHR , BurchJW , MajerusPW , StanfordN , DelmezJA , AndersonCB , et al.Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. New England Journal of Medicine1979;301(11):577-9. [MEDLINE: 112475]">Harter 1979</a>; <a href="./references#CD008834-bbs2-0048" title="HanssonL , ZanchettiA , CarruthersSG , DahlöfB , ElmfeldtD , JuliusS , et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998;351(9118):1755-62. [MEDLINE: 9635947]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Pressure1997;6(5):313-7. [MEDLINE: 9360003]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Pressure1994;3(5):322-7. [MEDLINE: 7866597]HanssonL .The Hypertension Optimal Treatment study and the importance of lowering blood pressure. Journal of Hypertension - Supplement1999;17(1):S9-13. [MEDLINE: 10340838]JardineM , NinomiyaT , CassA , TurnbullF , GallagherM , ZoungasS , et al.Aspirin benefit increases as eGFR declines: results from a randomised controlled trial in a hypertensive population [abstract no: 086]. Nephrology2010;15(Suppl 4):49. [EMBASE: 70467090]JardineMJ , NinomiyaT , PerkovicV , CassA , TurnbullF , GallagherMP , et al.Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology2010;56(12):956-65. [MEDLINE: 20828648]JonesDW , MillerME , WoffordMR , Anderson DC Jr, CameronME , WilloughbyDL , et al.The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. American Journal of Hypertension1999;12(12 Pt 1-2):1175-80. [MEDLINE: 10619579]JonssonB , HanssonL , StalhammarNO .Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Journal of Internal Medicine2003;253(4):472-80. [MEDLINE: 12653877]KjeldsenSE , HednerT , JamersonK , JuliusS , HaleyWE , ZabalgoitiaM , et al.Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects. Hypertension1998;31(4):1014-20. [MEDLINE: 9535429]KjeldsenSE , KollochRE , LeonettiG , MallionJM , ZanchettiA , ElmfeldtD , et al.Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. Journal of Hypertension2000;18(5):629-42. [MEDLINE: 10826567]KollochRE , RahnKH .The Hypertension Optimal Treatment (HOT) study: results of 12-month treatment related to age [Die 'Hyperyension Optimal Treatment' (HOT)-Studie: Behandlungsergebnisse nach Zwolfmonatiger Therapie in Abhangigkeit vom Alter]. Deutsche Medizinische Wochenschrift1998;123(1-2):1-5. [MEDLINE: 9465848]LeonettiG , ZanchettiA .Principal results of hypertension optimal treatment (HOT) study and their clinical impact. HOT cooperative group. Clinical Hemorheology &amp; Microcirculation1999;21(3-4):217-24. [MEDLINE: 10711746]LithellH , BerglundL .Validation of an oscillometric blood pressure measuring device: a substudy of the HOT Study. Hypertension Optimal Treatment. Blood Pressure1998;7(3):149-52. [MEDLINE: 9758084]ManciaG , OmboniS , ParatiG , ClementDL , HaleyWE , RahmanSN , et al.Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(10):1755-63. [MEDLINE: 11593094]RuilopeLM , SalvettiA , JamersonK , HanssonL , WarnoldI , WedelH , et al.Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology2001;12(2):218-25. [MEDLINE: 11158211]Struijker-BoudierH , SafarM , vanBortelL .Effects of individual risk factors on the incidence of cardiovascular event in the treated hypertensive patients of the Hypertension Optimal Treatment Study. Journal of Hypertension2001;19(11):2105-6. [MEDLINE: 11677378]The Hypertension Optimal Treatment Study (the HOT Study). Blood Pressure1993;2(1):62-8. [MEDLINE: 8193735]WaeberB , LeonettiG , KollochR , McInnesGT .Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension1999;17(7):1041-5. [MEDLINE: 10419079]ZanchettiA , HanssonL , DahlofB , ElmfeldtD , KjeldsenS , KollochR , et al.Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. Journal of Hypertension2001;19(6):1149-59. [MEDLINE: 11403365]ZanchettiA , HanssonL , MenardJ , LeonettiG , RahnKH , WarnoldI , et al.Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(4):819-25. [MEDLINE: 11330886]">HOT 1993</a>; <a href="./references#CD008834-bbs2-0049" title="BlankenshipJC , SigmonKN , PieperKS , O'SheaC , TardiffBE , TchengJE , et al.Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial. American Journal of Cardiology2001;88(9):969-73. [MEDLINE: 11703991]GilchristIC , GardnerLH , MuhlesteinJB , ArnoldAM , LincoffAM , CaliffRM , et al.Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience. American Heart Journal1999;138(5 Pt 1):976-82. [MEDLINE: 10539832]MandakJS , BlankenshipJC , GardnerLH , BerkowitzSD , AguirreFV , SigmonKN , et al.Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Journal of the American College of Cardiology1998;31(7):1518-24. [MEDLINE: 9626829]Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet1997;349(9063):1422-8. [MEDLINE: 9164315]TardiffBE , CaliffRM , TchengJE , LincoffAM , SigmonKN , HarringtonRA , et al.Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. Journal of the American College of Cardiology1999;33(1):88-96. [MEDLINE: 9935014]ThelMC , CaliffRM , TardiffBE , GardnerLH , SigmonKN , LincoffAM , et al.Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. American Journal of Cardiology2000;85(4):427-34. [MEDLINE: 10728945]">IMPACT II 1997</a>; <a href="./references#CD008834-bbs2-0054" title="KamperAM , LinsRL , ZacheeP , Van BergenS , HostenS , DaelemansR .Safety of combining ticlopidine with nadroparin in the routine treatment of chronic hemodialysis patients. Nephron1997;77(4):484-5. [MEDLINE: 9434075]">Kamper 1997</a>; <a href="./references#CD008834-bbs2-0056" title="ChangJJ , ConcatoJ , WellsCK , CrowleyST .Impact of adherence to clinical guidelines on mortality in hemodialysis patients [abstract no: SA-PO384]. Journal of the American Society of Nephrology2004;15(Oct):386A. [CENTRAL: CN-00583156] KaufmanJS , O'ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology2003;14(9):2313-21. [MEDLINE: 12937308]KaufmanJS , O’ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract no: A1495]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):291A. ">Kaufman 2003</a>; <a href="./references#CD008834-bbs2-0064" title="MiddletonDA , DeichselG .The prophylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole. Boehringer Ingelheim. Internal report1992. ">Middleton 1992</a>; <a href="./references#CD008834-bbs2-0074" title="HanY .Comparison of the pharmacodynamics and pharmacokinetics of ticagrelor versus clopidogrel in patients with chronic kidney disease and non-ST-elevation acute coronary syndromes (OPT-CKD trial) [abstract no: TCT-483]. Journal of the American College of Cardiology2017;70(18 Suppl 1):B200. [EMBASE: 619771602]WangH , QiJ , LiY , TangY , LiC , LiJ , et al.Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. British Journal of Clinical Pharmacology2018;84(1):88-96. [MEDLINE: 28921624]">OPT‐CKD 2018</a>; <a href="./references#CD008834-bbs2-0076" title="BonacaMP , BhattDL , BraunwaldE , CohenM , StegPG , StoreyRF , et al.Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal2014;167(4):437-44. [MEDLINE: 24655690]BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , JensenEC , et al.Long-term use of ticagrelor in patients with prior myocardial infarction. New England Journal of Medicine2015;372(19):1791-800. [MEDLINE: 25773268]BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , CohenM , et al.Prevention of stroke with ticagrelor in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation2016;134(12):861-71. [MEDLINE: 27576775]DellborgM , BonacaMP , StoreyRF , StegPG , ImKA , CohenM , et al.Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: Insights from PEGASUS-TIMI 54 [abstract]. European Heart Journal2017;38(Suppl 1):794-5. [EMBASE: 621235545]LozanoI , RondanJ , VegasJM , SegoviaE .Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):107-8. [MEDLINE: 29301622]MagnaniG , SabatineMS , BhattDL , ChoenM , StegG , StoreyR , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: Insights from the PEGASUS-TIMI 54 trial [abstract]. European Heart Journal2015;36(Suppl 1):520. [EMBASE: 72020712]MagnaniG , StoreyRF , StegG , BhattDL , CohenM , KuderJ , et al.Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. European Heart Journal2016;37(4):400-8. [MEDLINE: 26443023]MagnusonEA , BonacaMP , BhattDL , CohenM , StegPG , StoreyRF , et al.Reply: cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology2018;71(1):108. [MEDLINE: 29301623]MagnusonEA , LiH , WangK , VilainK , ShafiqA , BonacaMP , et al.Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: results from the PEGASUS-TIMI 54 trial. Journal of the American College of Cardiology2017;70(5):527-38. [MEDLINE: 28750695]MurphySA , BonacaMP , GotoS , BhattDL , StegPG , StoreyRF , et al.Reduction in total cardiovascular events with long-term use of ticagrelor in patients with prior myocardial infarction in the PEGASUS-TIMI 54 trial [abstract no: A17121]. Circulation2015;132(Suppl 3). [EMBASE: 72179983]">PEGASUS‐TIMI 54 2014</a>; <a href="./references#CD008834-bbs2-0081" title="AkerblomA , WallentinL , LarssonA , SiegbahnA , BeckerRC , BudajA , et al.Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study. Clinical Chemistry2013;59(9):1369-75. [MEDLINE: 23698074]AkerblomA , WallentinL , SiegbahnA , BeckerRC , BudajA , HorrowJ , et al.Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. American Heart Journal2012;164(5):728-34. [MEDLINE: 23137503]AndellP , JamesSK , CannonCP , CyrDD , HimmelmannA , HustedS , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Journal of the American Heart Association2015;4(10):e002490. [MEDLINE: 26452988]ArmstrongPW , SihaH , FuY , WesterhoutCM , StegPG , JamesSK , et al.ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation2012;125(3):514-21. [MEDLINE: 22179530]ArmstrongPW , WesterhoutCM , FuY , HarringtonRA , StoreyRF , KatusH , et al.Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. American Journal of Medicine2013;126(8):723-9. [MEDLINE: 23795897]BeckerRC , BassandJP , BudajA , WojdylaDM , JamesSK , CornelJH , et al.Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial [Erratum in: Eur Heart J. 2012 Nov;33(21):2750]. European Heart Journal2011;32(23):2933-44. [MEDLINE: 22090660]BellaviaA , WallentinL , OrsiniN , JamesSK , CannonCP , HimmelmannA , et al.Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. Open Heart2017;4(2):e000557. [MEDLINE: 28761675]BrilakisES , HeldC , MeierB , CoolsF , ClaeysMJ , CornelJH , et al.Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. American Heart Journal2013;166(3):474-80. [MEDLINE: 24016496]BuiAH , CannonCP , StegPG , StoreyRF , HustedS , GuoJ , et al.Relationship between early and late nonsustained ventricular tachycardia and cardiovascular death in patients with acute coronary syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation: Arrhythmia and Electrophysiology2016;9(2):e002951. [MEDLINE: 26810596]CapodannoD , CalviV , TamburinoC .Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment. Journal of Cardiovascular Medicine2012;13(2):162-3. [MEDLINE: 22237463]CornelJH , BeckerRC , GoodmanSG , HustedS , KatusH , SantosoA , et al.Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2012;164(3):334-42. [MEDLINE: 22980299]CowperPA , PanW , AnstromKJ , KaulP , WallentinL , Davidson-RayL , et al.Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. Journal of the American College of Cardiology2015;65(5):465-76. [MEDLINE: 25660925]DiNicolantonioJJ , D'AscenzoF , TomekA , ChatterjeeS , NiaziAK , Biondi-ZoccaiG .Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial. International Journal of Cardiology2013;168(3):1739-44. [MEDLINE: 23907035]DiNicolantonioJJ , TomekA .Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial. International Journal of Cardiology2013;168(4):4076-80. [MEDLINE: 23911266]DiNicolantonioJJ , TomekA .Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel. International Journal of Cardiology2013;169(2):145-6. [MEDLINE: 24120213]DucrocqG , SchultePJ , BeckerRC , CannonCP , HarringtonRA , HeldC , et al.Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. Eurointervention2015;11(7):737-45. [MEDLINE: 25254357]FranchiF , JamesSK , GhukasyanLT , BudajAJ , CornelJH , KatusHA , et al.Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y12 receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. Journal of the American Heart Association2019;8(6):e011139. [MEDLINE: 30857464]GiannitsisE , WallentinL , JamesSK , BertilssonM , SiegbahnA , StoreyRF , et al.Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: a Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. European Heart Journal: Acute Cardiovascular Care2017;6(6):500-10. [MEDLINE: 27044282]HagstromE , JamesSK , BertilssonM , BeckerRC , HimmelmannA , HustedS , et al.Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. European Heart Journal2016;37(16):1325-33. [MEDLINE: 26417057]HeldC , AsenbladN , BassandJP , BeckerRC , CannonCP , ClaeysMJ , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology2011;57(6):672-84. [MEDLINE: 21194870]HustedS , JamesS , BeckerRC , HorrowJ , KatusH , StoreyRF , et al.Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circulation. Cardiovascular Quality &amp; Outcomes2012;5(5):680-8. [MEDLINE: 22991347]HustedS , JamesSK , BachRG , BeckerRC , BudajA , HerasM , et al.The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal2014;35(23):1541-50. [MEDLINE: 24682844]JamesS , AkerblomA , CannonCP , EmanuelssonH , HustedS , KatusH , et al.Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2009;157(4):599-605. [MEDLINE: 19332184]JamesS , AngiolilloDJ , CornelJH , ErlingeD , HustedS , KontnyF , et al.Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal2010;31(24):3006-16. [MEDLINE: 20802246]JamesS , BudajA , AylwardP , BuckKK , CannonCP , CornelJH , et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2010;122(11):1056-67. [MEDLINE: 20805430]JamesS , BudajA , AylwardP , BuckKK , CannonCP , CornelJH , et al.Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation2010;122(11):1056-67. [MEDLINE: 20805430]JamesSK , RoeMT , CannonCP , CornelJH , HorrowJ , HustedS , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ2011;342:d3527. [MEDLINE: 21685437]JohanssonA , ErikssonN , BeckerRC , StoreyRF , HimmelmannA , HagstromE , et al.NLRC4 inflammasome is an important regulator of interleukin-18 levels in patients with acute coronary syndromes: genome-wide association study in the PLATelet inhibition and patient Outcomes Trial (PLATO). Circulation. Cardiovascular Genetics2015;8(3):498-506. [MEDLINE: 25747584]KangHJ , ClareRM , GaoR , HeldC , HimmelmannA , JamesSK , et al.Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal2015;169(6):899-905. [MEDLINE: 26027629]KholaifN , ZhengY , JagasiaP , HimmelmannA , JamesSK , StegPG , et al.Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex. American Journal of Medicine2015;128(8):914-9. [MEDLINE: 25818495]KohliP , WallentinL , ReyesE , HorrowJ , HustedS , AngiolilloDJ , et al.Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation2013;127(6):673-80. [MEDLINE: 23277305]KontnyF , UelandT , AukrustP , MichelsenAE , BeckerRC , BertilssonM , et al.Pentraxin 3 (PTX3) predict adverse outcome in acute coronary syndromes-a PLATO biomarker substudy [abstract]. European Heart Journal2014;35(Suppl 1):319. [EMBASE: 71647923]KotsiaA , BrilakisES , HeldC , CannonC , StegGP , MeierB , et al.Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal2014;168(1):68-75. [MEDLINE: 24952862]KunadianV , JamesSK , WojdylaDM , ZorkunC , WuJ , StoreyRF , et al.Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). Jacc: Cardiovascular Interventions2013;6(7):671-83. [MEDLINE: 23866179]LevinLA , WallentinL , BernfortL , AnderssonD , StoreyRF , BergstromG , et al.Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. Value in Health2013;16(4):574-80. [MEDLINE: 23796291]LindholmD , VarenhorstC , CannonCP , HarringtonRA , HimmelmannA , MayaJ , et al.Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal2014;35(31):2083-93. [MEDLINE: 24727884]MahaffeyKW , HeldC , WojdylaDM , JamesSK , KatusHA , HustedS , et al.Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology2014;63(15):1493-9. [MEDLINE: 24561148]MahaffeyKW , WojdylaDM , CarrollK , BeckerRC , StoreyRF , AngiolilloDJ , et al.Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2011;124(5):544-54. [MEDLINE: 21709065]NikolicE , JanzonM , HauchO , WallentinL , HenrikssonM , PLATO Health Economic Substudy Group.Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. European Heart Journal2013;34(3):220-8. [MEDLINE: 22719022]OhmanEM , RoeMT .Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany &quot;Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified&quot; (Thromb Haemost 2011; 105.5). Thrombosis &amp; Haemostasis2011;105(5):763-5. [MEDLINE: 21394382]ParkerWA , ErikssonN , BeckerRC , VooraD , AkerblomA , HimmelmannA , et al.Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets2019;30(5):579-88. [MEDLINE: 29851527]PatelMR , BeckerRC , WojdylaDM , EmanuelssonH , HiattWR , HorrowJ , et al.Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. European Journal of Preventive Cardiology2015;22(6):734-42. [MEDLINE: 24830710]Pollack CV Jr, DavoudiF , DiercksDB , BeckerRC , JamesSK , LimST , et al.Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clinical Cardiology2017;40(6):390-8. [MEDLINE: 28598510]RoguinA , MusallamA .Letter by Roguin and Musallam regarding article, &quot;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial&quot;. Circulation2014;129(19):e493. [MEDLINE: 24821831]SciricaBM , BansilalS , DavoudiF , ArmstrongPW , ClareRM , SchultePJ , et al.Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. American Heart Journal2018;202:54-60. [MEDLINE: 29859968]SciricaBM , CannonCP , EmanuelssonH , MichelsonEL , HarringtonRA , HustedS , et al.The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. Journal of the American College of Cardiology2011;57(19):1908-16. [MEDLINE: 21545948]SerebruanyVL , FortmannSD , CherepanovV , LitvinovO , KimMH , MarciniakTA .Excess ticagrelor mortality in the food and drug administration adverse event reporting system: time to recount PLATO trial deaths. American Journal of Medicine2017;130(6):e245-6. [MEDLINE: 28161342]SerebruanyVL .Angiographic outcomes contradict platelet data in the PLATO trial: confusion over official trial substudies. Cardiology2014;127(3):190-5. [MEDLINE: 24457905]SerebruanyVL .Discrepancies in the primary PLATO trial publication and the FDA reviews. International Journal of Cardiology2014;172(1):8-10. [MEDLINE: 24456868]SerebruanyVL .Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review. American Journal of Therapeutics2012;19(2):160-1. [MEDLINE: 22395000]SerebruanyVL .The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent. Cardiology2011;120(3):169-71. [MEDLINE: 22418766]ShimadaYJ , BansilalS , WiviottSD , BeckerRC , HarringtonRA , HimmelmannA , et al.Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal2016;177:1-8. [MEDLINE: 27297843]SihaH , DasD , FuY , ZhengY , WesterhoutCM , StoreyRF , et al.Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. CMAJ Canadian Medical Association Journal2012;184(10):1135-42. [MEDLINE: 22546885]StegPG , HarringtonRA , EmanuelssonH , KatusHA , MahaffeyKW , MeierB , et al.Response to letter regarding article, &quot;Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial&quot;. Circulation2014;129(19):e494-5. [MEDLINE: 24821832]StegPG , HarringtonRA , EmanuelssonH , KatusHA , MahaffeyKW , MeierB , et al.Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation2013;128(10):1055-65. [MEDLINE: 23900047]StegPG , JamesS , HarringtonRA , ArdissinoD , BeckerRC , CannonCP , et al.Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation2010;122(21):2131-41. [MEDLINE: 21060072]StoreyRF , AngiolilloDJ , PatilSB , DesaiB , EcobR , HustedS , et al.Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. Journal of the American College of Cardiology2010;56(18):1456-62. [MEDLINE: 20832963]StoreyRF , ArdissinoD , VignaliL , CairnsR , BeckerRC , CannonCP , et al.Ischaemic events and stent thrombosis following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study. Thrombosis &amp; Haemostasis2018;118(2):427-9. [MEDLINE: 29443375]StoreyRF , BeckerRC , HarringtonRA , HustedS , JamesSK , CoolsF , et al.Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. European Heart Journal2011;32(23):2945-53. [MEDLINE: 21804104]StoreyRF , BeckerRC , HarringtonRA , HustedS , JamesSK , CoolsF , et al.Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). American Journal of Cardiology2011;108(11):1542-6. [MEDLINE: 21890085]StoreyRF , JamesSK , SiegbahnA , VarenhorstC , HeldC , YcasJ , et al.Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets2014;25(7):517-25. [MEDLINE: 24127651]SumayaW , WallentinL , JamesSK , SiegbahnA , GabryschK , BertilssonM , et al.Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. European Heart Journal2018;39(13):1078-85. [MEDLINE: 29390064]UelandT , AkerblomA , GhukasyanT , MichelsenAE , AukrustP , BeckerRC , et al.Osteoprotegerin is associated with major bleeding but not with cardiovascular outcomes in patients with acute coronary syndromes: insights from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American Heart Association2018;7(2):e007009. [MEDLINE: 29330256]UelandT , MichelsenA , AukrustP , BeckerR , BertilssonM , JamesSK , et al.Chemokine (CXC motif) ligand 16 (CXCL16) and osteoprotegerin (OPG) as predictors of outcome in patients with acute coronary syndromes (ACS) a PLATO biomarker substudy [abstract]. European Heart Journal2014;35(Suppl 1):486. [EMBASE: 71648554]WallentinL , BeckerRC , BudajA , CannonCP , EmanuelssonH , HeldC , et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2009;361(11):1045-57. [MEDLINE: 19717846]WallentinL , BeckerRC , CannonCP , HeldC , HimmelmannA , HustedS , et al.No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. International Journal of Cardiology2014;176(1):300-2. [MEDLINE: 25005338]WallentinL , BeckerRC , CannonCP , HeldC , HimmelmannA , HustedS , et al.Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. International Journal of Cardiology2014;170(3):e59-62. [MEDLINE: 24299581]WallentinL , BeckerRC , JamesSK , HarringtonRA .The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. &quot;Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified&quot; (Thromb Haemost 2011; 105.5). Thrombosis &amp; Haemostasis2011;105(5):760-2. [MEDLINE: 21394383]WallentinL , JamesS , StoreyRF , ArmstrongM , BarrattBJ , HorrowJ , et al.Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet2010;376(9749):1320-8. [MEDLINE: 20801498]WallentinL , LindholmD , SiegbahnA , WernrothL , BeckerRC , CannonCP , et al.Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation2014;129(3):293-303. [MEDLINE: 24170388]">PLATO 2009</a>; <a href="./references#CD008834-bbs2-0083" title="HuynhT , NasmithJ , LuongTM , BernierM , PharandC , Xue-QiaoZ , et al.Complementary prognostic values of ST segment deviation and Thrombolysis In Myocardial Infarction (TIMI) risk score in non-ST elevation acute coronary syndromes: insights from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Canadian Journal of Cardiology 2009 Dec;25(12):e417-21. [MEDLINE: 19960136]HuynhT , PiazzaN , DiBattistePM , SnapinnSM , WanY , PharandC , et al.Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study. International Journal of Cardiology2005;100(1):73-8. [MEDLINE: 15820288]HuynhT , TherouxP , SnapinnS , WanY , PRISM-PLUS Investigators.Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). American Heart Journal2003;146(4):668-73. [MEDLINE: 14564321]Januzzi JL Jr, SnapinnSM , DiBattistePM , JangIK , TherouxP .Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation2002;105(20):2361-6. [MEDLINE: 12021221]MegaJL , MorrowDA , SabatineMS , ZhaoXQ , SnapinnSM , DiBattistePM , et al.Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. American Heart Journal2005;149(5):846-50. [MEDLINE: 15894966]MorrowDA , SabatineMS , AntmanEM , CannonCP , BraunwaldE , TherouxP .Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). American Journal of Cardiology2004;94(6):774-6. [MEDLINE: 15374786]Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New England Journal of Medicine1998;338(21):1488-97. [MEDLINE: 9599103]ServossSJ , WanY , SnapinnSM , DiBattistePM , ZhaoXQ , TherouxP , et al.Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. American Journal of Cardiology2004;93(7):843-7. [MEDLINE: 15050486]SzucsTD , MeyerBJ , KiowskiW .Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial. European Heart Journal1999;20(17):1253-60. [MEDLINE: 10454977]TherouxP , AlexanderJ , PharandC , BarrE , SnapinnS , GhannamAF , et al.Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation2000;102(20):2466-72. [MEDLINE: 11076818]TherouxP , Alexander J Jr, DupuisJ , PesantY , GervaisP , GrandmontD , et al.Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators. American Journal of Cardiology2001;87(4):375-80. [MEDLINE: 11179517]ZhaoXQ , TherouxP , SnapinnSM , SaxFL .Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Circulation1999;100(15):1609-15. [MEDLINE: 10517731]">PRISM‐PLUS 1998</a>; <a href="./references#CD008834-bbs2-0084" title="AkkerhuisKM , DeckersJW , BoersmaE , HarringtonRA , StepinskaJ , MahaffeyKW , et al.Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. European Heart Journal2000;21(5):371-81. [MEDLINE: 10666351]AkkerhuisKM , MaasAC , KlootwijkPA , KrucoffMW , MeijS , CaliffRM , et al.Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of Electrocardiology2000;33(2):127-36. [MEDLINE: 10819406]AlexanderJH , HarringtonRA , TuttleRH , BerdanLG , LincoffAM , DeckersJW , et al.Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology1999;83(8):1147-51. [MEDLINE: 10215274]BoersmaE , PieperKS , SteyerbergEW , WilcoxRG , ChangWC , LeeKL , et al.Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation2000;101(22):2557-67. [MEDLINE: 10840005]BrownRE , HendersonRA , KosterD , HuttonJ , SimoonsML .Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy. European Heart Journal2002;23(1):50-8. [MEDLINE: 11741362]ChangWC , HarringtonRA , SimoonsML , CaliffRM , LincoffAM , ArmstrongPW , et al.Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial. European Heart Journal2002;23(14):1102-11. [MEDLINE: 12090748]DykeCM , BhatiaD , LorenzTJ , MarsoSP , TardiffBE , HogeboomC , et al.Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Annals of Thoracic Surgery2000;70(3):866-71. [MEDLINE: 11016325]GreenbaumAB , HarringtonRA , HudsonMP , MacAulayCM , WilcoxRG , SimoonsML , et al.Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. Journal of the American College of Cardiology2001;37(2):492-8. [MEDLINE: 11216968]HarringtonRA .Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology1997;80(4A):34-8B. [MEDLINE: 9291244]HasdaiD , Holmes DR Jr, CrigerDA , TopolEJ , CaliffRM , WilcoxRG , et al.Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators. American Heart Journal2000;139(3):454-60. [MEDLINE: 10689260]KleimanNS , LincoffAM , FlakerGC , PieperKS , WilcoxRG , BerdanLG , et al.Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation2000;101(7):751-7. [MEDLINE: 10683348]LabinazM , KaulP , HarringtonRA , ChangWC , KleimanNS , SimoonsML , et al.Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. Canadian Journal of Cardiology2004;20(8):773-8. [MEDLINE: 15229770]LabinazM , KilaruR , PieperK , MarsoSP , KittMM , SimoonsML , et al.Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2002;105(3):322-7. [MEDLINE: 11804987]LauerMA , HoughtalingPL , PetersonJG , GrangerCB , BhattDL , SappSK , et al.Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2001;104(23):2772-7. [MEDLINE: 11733393]LincoffAM , HarringtonRA , CaliffRM , HochmanJS , GuerciAD , OhmanEM , et al.Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation2000;102(10):1093-100. [MEDLINE: 10973836]MahaffeyKW , HarringtonRA , AkkerhuisM , KleimanNS , BerdanLG , CrenshawBS , et al.Systematic adjudication of myocardial infarction end-points in an international clinical trial. Current Controlled Trials in Cardiovascular Medicine2001;2(4):180-6. [MEDLINE: 11806793]MahaffeyKW , HarringtonRA , SimoonsML , GrangerCB , GraffagninoC , AlbertsMJ , et al.Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation1999;99(18):2371-7. [MEDLINE: 10318656]MarkDB , HarringtonRA , LincoffAM , CaliffRM , NelsonCL , TsiatisAA , et al.Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation2000;101(4):366-71. [MEDLINE: 10653826]MarsoSP , BhattDL , RoeMT , HoughtalingPL , LabinazM , KleimanNS , et al.Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators. Circulation2000;102(24):2952-8. [MEDLINE: 11113045]McClureMW , BerkowitzSD , SparapaniR , TuttleR , KleimanNS , BerdanLG , et al.Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation1999;99(22):2892-900. [MEDLINE: 10359733]PetersonJG , TopolEJ , RoeMT , SappSK , LincoffAM , DeckersJW , et al.Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology2001;87(5):532-6. [MEDLINE: 11230834]PURSUIT Trial Investigators.Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. New England Journal of Medicine1998;339(7):436-43. [MEDLINE: 9705684]RoeMT , HarringtonRA , ProsperDM , PieperKS , BhattDL , LincoffAM , et al.Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation2000;102(10):1101-6. [MEDLINE: 10973837]RonnerE , BoersmaE , AkkerhuisKM , HarringtonRA , LincoffAM , DeckersJW , et al.Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. European Heart Journal2002;23(3):239-46. [MEDLINE: 11792139]RonnerE , BoersmaE , LaarmanGJ , SomsenGA , HarringtonRA , DeckersJW , et al.Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of the American College of Cardiology2002;39(12):1924-9. [MEDLINE: 12084589]SrichaiMB , JaberWA , PriorDL , MarsoSP , HoughtalingPL , MenonV , et al.Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes. American Heart Journal2004;147(1):84-90. [MEDLINE: 14691424]">PURSUIT 1997</a>; <a href="./references#CD008834-bbs2-0086" title="BrenerSJ , BarrLA , BurchenalJE , KatzS , GeorgeBS , JonesAA , et al.Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation1998;98(8):734-41. [MEDLINE: 9727542]BrenerSJ , BarrLA , BurchenalJE , WolskiKE , EffronMB , TopolEJ .Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial. American Journal of Cardiology1999;84(6):728-30. [MEDLINE: 10498145]">RAPPORT 1998</a>; <a href="./references#CD008834-bbs2-0094" title="SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract no: 9P]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):388. [CENTRAL: CN-00485981] SreedharaR , HimmelfarbJ , LazarusJM , HakimRM .Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study. Kidney International1994;45(5):1477-83. [MEDLINE: 8072261]">Sreedhara 1994</a>; <a href="./references#CD008834-bbs2-0096" title="MiletiM , De PetriG , BacchiM , OgliariV , PecchiniF , BufanoG , et al.A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients. Journal of Nephrology1995;8(2):167-72. [EMBASE: 25209311]">STOP 1995</a>; <a href="./references#CD008834-bbs2-0102" title="TengR , MuldowneyS , ZhaoY , BergJK , LuJ , KhanND .Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. European Journal of Clinical Pharmacology2018;74(9):1141-8. [MEDLINE: 29850937]">Teng 2018</a>; <a href="./references#CD008834-bbs2-0103" title="CorreaS , BonacaMP , SciricaBM , MurphySA , GoodrichEL , MorrowDA , et al.Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. Journal of Thrombosis &amp; Thrombolysis2019;47(3):353-60. [MEDLINE: 30511258]GaviriaSC , BraunwaldE , BonacaMP , MurphySA , GoodrichEL , MorrowDA , et al.The efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function: insights from the TRA 2P-TIMI 50 trial [abstract no: 15480]. Circulation2017;136(Suppl 1). [EMBASE: 619986693]MorrowDA , BraunwaldE , BonacaMP , AmerisoSF , DalbyAJ , FishMP , et al.Vorapaxar in the secondary prevention of atherothrombotic events. New England Journal of Medicine2012;366(15):1404-13. [MEDLINE: 22443427]MorrowDA , SciricaBM , FoxKA , BermanG , StronyJ , VeltriE , et al.Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. American Heart Journal2009;158(3):335-41. [MEDLINE: 19699854]">TRA 2P‐TIMI 50 2009</a>; <a href="./references#CD008834-bbs2-0104" title="CornelJH , TricociP , HortonJ , MoliternoD , WallentinL , ArmstrongP , et al.Effects of glycoprotein IIB/IIIA inhibitors in combination with vorapaxar, a platelet thrombin-receptor antagonist, among patients with non-St-segment elevation acute coronary syndromes: insights from the TRACER trial [abstract]. Journal of the American College of Cardiology2013;61(10 Suppl 1):E102. [EMBASE: 71019466]MahaffeyKW , PieperK , VranckxP , TricociP , Van de WerfF , HeldC , et al.Chronic kidney disease is associated with worse outcomes in ACS patients: results from the TRACER trial [abstract]. European Heart Journal2014;35(Suppl 1):687. [EMBASE: 71649310]">TRACER 2013</a>; <a href="./references#CD008834-bbs2-0106" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al.First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473-84. [MEDLINE: 15754269]BaigentC , UK-HARP Steering Committee.Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-PO851]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. [CENTRAL: CN-00444305] ">UK‐HARP‐I 2005</a>), and risk of bias was judged to be unclear in 23 studies. </p> </section> </section> <section id="CD008834-sec-0058"> <h3 class="title" id="CD008834-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD008834-tbl-0001"><b>Summary of findings 1</b> Antiplatelet agents versus control for chronic kidney disease</a> </p> <section id="CD008834-sec-0059"> <h4 class="title">Antiplatelet agents versus control</h4> <section id="CD008834-sec-0060"> <h5 class="title">Fatal or nonfatal myocardial infarction</h5> <p>Antiplatelet agents probably reduced the risk of fatal or nonfatal MI in people with CKD (<a href="./references#CD008834-fig-0004" title="">Analysis 1.1</a> (18 studies, 15,289 participants): RR 0.88, 95% CI 0.79 to 0.99; I² = 0%; moderate certainty evidence). The evidence was downgraded for risk of bias. </p> </section> <section id="CD008834-sec-0061"> <h5 class="title">Fatal or nonfatal stroke</h5> <p>It is uncertain whether antiplatelet agents made any difference to fatal or nonfatal stroke in people with CKD (<a href="./references#CD008834-fig-0005" title="">Analysis 1.2</a> (12 studies, 10,382 participants): RR 1.01, 95% CI 0.64 to 1.59; I² = 37%; very low certainty evidence). The evidence was downgraded for risk of bias, inconsistency and imprecision. There was moderate heterogeneity observed between studies. Antiplatelet agents were used both for primary and secondary prevention. </p> </section> <section id="CD008834-sec-0062"> <h5 class="title">Death (any cause)</h5> <p>Antiplatelet agents may have little or no effect on death (any cause) in people with CKD (<a href="./references#CD008834-fig-0006" title="">Analysis 1.3</a> (35 studies, 18,241 participants): RR 0.94, 95% CI 0.84 to 1.06; I² = 14%; low certainty evidence). The evidence was downgraded for risk of bias and imprecision. </p> </section> <section id="CD008834-sec-0063"> <h5 class="title">Haemorrhagic stroke</h5> <p>Antiplatelet agents had uncertain effects on haemorrhagic stroke in people with CKD (<a href="./references#CD008834-fig-0007" title="">Analysis 1.4</a> (9 studies, 6844 participants): RR 1.22, 95% CI 0.69 to 2.17; I² = 0%; low certainty evidence). The evidence was downgraded for risk of bias and imprecision. </p> </section> <section id="CD008834-sec-0064"> <h5 class="title">Cardiovascular death</h5> <p>It is uncertain whether antiplatelet agents made any difference to cardiovascular death in people with CKD (<a href="./references#CD008834-fig-0008" title="">Analysis 1.5</a> (21 studies, 9606 participants): RR 0.87, 95% CI 0.65 to 1.15; I² = 32%; very low certainty evidence). The evidence was downgraded for risk of bias, imprecision, and inconsistency. There was moderate heterogeneity observed between studies. </p> </section> <section id="CD008834-sec-0065"> <h5 class="title">Fatal bleeding</h5> <p>It is uncertain whether antiplatelet agents made any difference to fatal bleeding in people with CKD (<a href="./references#CD008834-fig-0009" title="">Analysis 1.6</a> (21 studies, 7629 participants): RR 1.39, 95% CI 0.10 to 19.48; I² = 30%; very low certainty evidence). The evidence was downgraded for Risk of Bias, imprecision, and inconsistency. There was moderate heterogeneity observed between studies. </p> </section> <section id="CD008834-sec-0066"> <h5 class="title">Major bleeding</h5> <p>Major bleeding events included: retroperitoneal; intra‐articular; intra‐ocular, intracranial or intracerebral haemorrhage; gastrointestinal bleeding; bleeding that was fatal, life‐threatening, disabling or required transfusion; corrective surgery or hospitalisation, with or without a fall in haemoglobin (Hb) level of at least 2 g/dL; or melena. </p> <p>Antiplatelet agents probably increased major bleeding in people CKD (<a href="./references#CD008834-fig-0010" title="">Analysis 1.7</a> (29 studies, 16,194 participants): RR 1.35, 95% CI 1.10 to 1.65; I² = 12%; moderate certainty evidence). The evidence was downgraded for risk of bias. </p> </section> <section id="CD008834-sec-0067"> <h5 class="title">Minor bleeding</h5> <p>Minor bleeding events were described as follows: not serious or significant; epistaxis; ecchymoses or bruising; blood loss and a drop of more than 10% points in the HCT or of 3 g/dL or more in the Hb concentration; not requiring transfusion; hospitalisation; and event‐related study visit; bleeding from cannulation sites, or haematuria. </p> <p>Antiplatelet agents may increase the risk of minor bleeding in people with CKD (<a href="./references#CD008834-fig-0011" title="">Analysis 1.8</a> (21 studies, 13218 participants): RR 1.55, 95% CI 1.27 to 1.90; I² = 58%; low certainty evidence). The was heterogeneity was moderate. The evidence was downgraded for risk of bias and inconsistency. </p> </section> <section id="CD008834-sec-0068"> <h5 class="title">Kidney failure (end‐stage kidney disease)</h5> <p>Antiplatelet agents may have little or no effect on kidney failure (<a href="./references#CD008834-fig-0012" title="">Analysis 1.9</a> (11 studies, 1722 participants): RR 0.89, 95% CI 0.70 to 1.14; I² = 23%; low certainty evidence). The evidence was downgraded for risk of bias and imprecision. There was low heterogeneity observed between the studies. </p> </section> <section id="CD008834-sec-0069"> <h5 class="title">Doubling of serum creatinine</h5> <p>Antiplatelet agents may reduce doubling of SCr in people with CKD (<a href="./references#CD008834-fig-0013" title="">Analysis 1.10</a> (3 studies, 217 participants): RR 0.39, 95% CI 0.17 to 0.86; I² = 0%; low certainty evidence). The evidence was downgraded for risk of bias and imprecision. </p> </section> <section id="CD008834-sec-0070"> <h5 class="title">Kidney transplant graft loss</h5> <p>Antiplatelet agents had uncertain effects on kidney transplant graft loss (<a href="./references#CD008834-fig-0014" title="">Analysis 1.11</a> (2 studies, 91 participants): RR 1.08, 95% CI 0.58 to 2.01; I² = 0%; low certainty evidence). The evidence was downgraded for risk of bias and imprecision. </p> </section> <section id="CD008834-sec-0071"> <h5 class="title">Transplant rejection</h5> <p>Antiplatelet agents may have little or no effect on kidney transplant rejection (<a href="./references#CD008834-fig-0015" title="">Analysis 1.12</a> (2 studies, 97 participants): RR 0.95, 95% CI 0.77 to 1.19; low certainty evidence). The evidence was downgraded for risk of bias and imprecision. </p> </section> <section id="CD008834-sec-0072"> <h5 class="title">Creatinine clearance</h5> <p>It is uncertain whether antiplatelet agents made any difference to CrCl in people with CKD (<a href="./references#CD008834-fig-0016" title="">Analysis 1.13</a> (3 studies, 90 participants): MD ‐5.46 mL/min, 95% CI ‐12.33 to 1.41; I² = 38%; very low certainty evidence). The evidence was downgraded for risk of bias, inconsistency and imprecision. There was moderate heterogeneity observed between studies. </p> </section> <section id="CD008834-sec-0073"> <h5 class="title">Proteinuria</h5> <p>It is uncertain whether antiplatelet agents made any difference to proteinuria in people with CKD (<a href="./references#CD008834-fig-0017" title="">Analysis 1.14</a> (3 studies, 80 participants): MD ‐0.74 g/day, 95% CI ‐1.35 to ‐0.13; very low certainty evidenc<i>e</i>) with substantial heterogeneity in the analysis (I² = 94%) which was as a result of <a href="./references#CD008834-bbs2-0113" title="ZäunerI , BöhlerJ , BraunN , GruppC , HeeringP , SchollmeyerP .Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Nephrology Dialysis Transplantation1994;9(6):619-22. [MEDLINE: 7970086]">Zäuner 1994</a>; however, there was no difference in the direction of the effect when this study was removed from the meta‐analysis (MD ‐0.14 g/day, 95% CI ‐0.20 to ‐0.08). The evidence was downgraded for risk of bias, inconsistency, and optimal information size not met. </p> </section> <section id="CD008834-sec-0074"> <h5 class="title">Dialysis access failure (thrombosis or loss of patency)</h5> <p>For all access types, it is uncertain whether antiplatelet agents made any difference in reducing the risk of HD access failure (<a href="./references#CD008834-fig-0018" title="">Analysis 1.15</a> (17 studies, 2847 participants): RR 0.62, 95% CI 0.50 to 0.78; I² = 46%; very low certainty evidence). The evidence was downgraded for risk of bias, indirectness, and inconsistency. There was moderate heterogeneity in this analysis which we explored using subgroup analysis by access type. In these analyses, it is uncertain whether antiplatelet agents (aspirin, sarpogrelate, ticlopidine, or clopidogrel with or without prostacyclin) made any difference in reducing the risk of fistula thrombosis or patency failure by 50% (<a href="./references#CD008834-fig-0018" title="">Analysis 1.15</a>.1 (10 studies, 1741 participants): RR 0.50, 95% CI 0.36 to 0.69; I² = 17%; very low certainty evidence), or shunt or graft failure (<a href="./references#CD008834-fig-0018" title="">Analysis 1.15</a>.2 (5 studies, 1052 participants): RR 0.80, 95% CI 0.62 to 1.03; I² = 49%; very low certainty evidence). It is uncertain whether antiplatelet agents made any difference to fistula or graft, or central venous catheter thrombosis (<a href="./references#CD008834-fig-0018" title="">Analysis 1.15</a>.3 (1 study, 16 participants): RR 0.50, 95% 0.06 to 4.47; very low certainty evidence) (<a href="./references#CD008834-fig-0018" title="">Analysis 1.15</a>.4 (1 study, 38 participants); 0.44, 95% CI 0.16 to 1.20; very low certainty evidence) respectively. Overall, there was no evidence of subgroup interaction based on access type across all types, suggesting the specific vascular access (fistula, graft, shunt, or central venous catheter) (P = 0.13%) was not an effect modifier for the treatment effects observed and indicating the overall effect estimate was the most appropriate. </p> </section> <section id="CD008834-sec-0075"> <h5 class="title">Early access failure (within eight weeks of access creation)</h5> <p>Antiplatelet agents may reduce early dialysis vascular access thrombosis (<a href="./references#CD008834-fig-0019" title="">Analysis 1.16</a> (8 studies, 1525 participants): RR 0.52, 95% CI 0.38 to 0.70; I²= 8%; low certainty evidence). The evidence was downgraded for risk of bias and optimal information size not met. </p> </section> <section id="CD008834-sec-0076"> <h5 class="title">Loss of primary unassisted patency</h5> <p>Two studies (<a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a>; <a href="./references#CD008834-bbs2-0063" title="MichieDD , WomboltDG .Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research - Clinical &amp; Experimental1977;22(1 II):196-204. [EMBASE: 8152617]">Michie 1977</a>) reported a loss of unassisted patency with <a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a> providing 99% of the events. Antiplatelet agents may have little or no effect on reduction of loss of unassisted patency (<a href="./references#CD008834-fig-0020" title="">Analysis 1.17</a> (2 studies, 665 participants): RR 0.95, 95% 0.89 to 1.03; I² = 0%; low certainty evidence). The evidence was downgraded for risk of bias and imprecision. </p> </section> <section id="CD008834-sec-0077"> <h5 class="title">Failure to attain access suitability of dialysis (maturation)</h5> <p>The definitions of access suitability included: the ability to use the fistula for dialysis with two needles and maintain a blood flow rate ≥ 300 mL/min during eight of 12 dialysis sessions occurring during a 30 day suitability ascertainment period (<a href="./references#CD008834-bbs2-0019" title="DemberL , AllonM , DelmezJ , DixonB , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00550593] DemberLM , BeckGJ , AllonM , DelmezJA , DixonBS , GreenbergA , et al.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008;299(18):2164-71. [MEDLINE: 18477783]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials2005;2(5):413-22. [MEDLINE: 16317810]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):229A. [CENTRAL: CN-00445067] ">Dember 2005</a>); failure to use graft by week 12 in patients with a catheter for access (<a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a>); fistula ceased to function (<a href="./references#CD008834-bbs2-0042" title="GröntoftKC , MulecH , GutierrezA , OlanderR .Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scandinavian Journal of Urology &amp; Nephrology1985;19(1):55-7. [MEDLINE: 3895411]">Gröntoft 1985</a>); permanent shunt thrombosis (<a href="./references#CD008834-bbs2-0046" title="HarterHR , BurchJW , MajerusPW , StanfordN , DelmezJA , AndersonCB , et al.Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. New England Journal of Medicine1979;301(11):577-9. [MEDLINE: 112475]">Harter 1979</a>); and failure to develop adequate flow (<a href="./references#CD008834-bbs2-0063" title="MichieDD , WomboltDG .Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research - Clinical &amp; Experimental1977;22(1 II):196-204. [EMBASE: 8152617]">Michie 1977</a>). It is uncertain whether antiplatelet agents made any difference in the reduction of failure to attain access suitability (<a href="./references#CD008834-fig-0021" title="">Analysis 1.18</a> (5 studies, 1503 participants): RR 0.63, 95% CI 0.34 to 1.15; I² = 59%, very low certainty evidence). The evidence was downgraded for risk of bias, inconsistency and imprecision. There was moderate heterogeneity potentially due to the differences in definitions of access suitability. </p> </section> <section id="CD008834-sec-0078"> <h5 class="title">Need for intervention to attain patency or assist maturation</h5> <p>The need for the intervention to attain patency or assist maturation was described: as surgical revision (<a href="./references#CD008834-bbs2-0031" title="BadveS , HawleyCM , IrishAB , Paul-BrentP .High rate of screening failure in the FAVOURED study [abstract no: PUB345]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):905A. IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al.Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453]IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul-BrentP , et al.Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis-a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804]IrishA , FAVOURED Study Group.High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN-00756870] IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 009]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790]IrishA .Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. [EMBASE: 70467038]IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul-BrentPA , et al.Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184-93. [MEDLINE: 28055065]IrishAB .The omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo-controlled trial [abstract no: HI-OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2-3. [CENTRAL: CN-01658143] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis-post hoc analysis of the FAVOURED study [abstract no: MO049]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475]ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on the need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology2018;23(Suppl 3):56. [EMBASE: 623841152]ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al.Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract no: SP593]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178]ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al.Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract no: FP555]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265]ViecelliA , PascoeE , PolkinghorneK , Paul-BrentP , DarssanD , HooiL , et al.A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115-6. [EMBASE: 612312707]ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul-BrentPA , BadveSV , et al.The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581]ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al.Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis - Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217-28. [MEDLINE: 26205903]ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul-BrentPA , BadveSV , et al.Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study. Nephrology2017;22(10):823-4. [MEDLINE: 27188542]ViecelliAK , PolkinghorneKR , PascoeEM , Paul-BrentPA , HawleyCM , BadveSV , et al.Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS ONE [Electronic Resource]2019;14(3):e0213274. [MEDLINE: 30913208]">FAVOURED 2009</a>: <a href="./references#CD008834-bbs2-0053" title="KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. New England Journal of Medicine1974;290(6):304-6. [MEDLINE: 4588285]KaegiA , PineoGF , ShimizuA , TrivediH , HirshJ , GentM .The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation1975;52(3):497-9. [MEDLINE: 1098808]">Kaegi 1974</a>); thrombectomy (<a href="./references#CD008834-bbs2-0002" title="AbacilarAF , AtalayH , DoganOF .Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: a randomized controlled study. Indian Journal of Nephrology2015;25(3):136-42. [MEDLINE: 26060361]">Abacilar 2015</a>; <a href="./references#CD008834-bbs2-0063" title="MichieDD , WomboltDG .Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research - Clinical &amp; Experimental1977;22(1 II):196-204. [EMBASE: 8152617]">Michie 1977</a>); percutaneous intervention to restore patency or promote maturation (<a href="./references#CD008834-bbs2-0019" title="DemberL , AllonM , DelmezJ , DixonB , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00550593] DemberLM , BeckGJ , AllonM , DelmezJA , DixonBS , GreenbergA , et al.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008;299(18):2164-71. [MEDLINE: 18477783]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials2005;2(5):413-22. [MEDLINE: 16317810]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):229A. [CENTRAL: CN-00445067] ">Dember 2005</a>); or angioplasty (<a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a>). </p> <p>Antiplatelet agents may have little or no effect on the reduction of the risk for the need for the intervention to attain patency or assist maturation in people treated with HD (<a href="./references#CD008834-fig-0022" title="">Analysis 1.19</a> (6 studies, 2067 participants): RR 0.87, 95% CI 0.72 to 1.05; I² = 0%: low certainty evidence). The evidence was downgraded for risk of bias and imprecision. </p> </section> <section id="CD008834-sec-0079"> <h5 class="title">All‐cause hospitalisation</h5> <p>Antiplatelet agents may have little or no effect on all‐cause hospitalisation in people treated with HD (<a href="./references#CD008834-fig-0023" title="">Analysis 1.20</a> (3 studies, 3535 participants): RR 0.97, 95% CI 0.87 to 1.10; I² = 0%; low certainty evidence). The evidence was downgraded for risk of bias and imprecision. </p> </section> <section id="CD008834-sec-0080"> <h5 class="title">Cardiovascular hospitalisation</h5> <p>It is uncertain whether antiplatelet agents made any difference in cardiovascular hospitalisation in CKD and HD (<a href="./references#CD008834-fig-0024" title="">Analysis 1.21</a> (3 studies, 3535 participants): RR 0.93, 95% CI 0.76 to 1.14; I² = 46%; very low certainty evidence). The evidence was downgraded for Risk of Bias, inconsistency and imprecision. There was moderate heterogeneity potentially due to differences in the adjudication of the outcome. </p> </section> <section id="CD008834-sec-0081"> <h5 class="title">Treatment withdrawal</h5> <p>Antiplatelet agents may have little or no effect on withdrawal from treatment compared with placebo or no treatment in CKD and HD (<a href="./references#CD008834-fig-0025" title="">Analysis 1.22</a> (15 studies, 2669 participants): RR 0.97, 95% CI 0.83 to 1.14; I² = 0%; low certainty evidence). The evidence was downgraded for risk of bias and imprecision. </p> </section> </section> <section id="CD008834-sec-0082"> <h4 class="title">Prasugrel versus clopidogrel</h4> <p><a href="./references#CD008834-bbs2-0105" title="AbaciA .The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses [Prasugrelin ST yukselmeli ve yukselmesiz miyokart enfarktusunde kullanimi: TRITON TIMI 38 caIismasi ve alt grup sonuclari]. Turk Kardiyoloji Dernegi Arsivi2015;43 Suppl 2:1-6. [MEDLINE: 27326444]AntmanEM , WiviottSD , MurphySA , VoitkJ , HasinY , WidimskyP , et al.Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Journal of the American College of Cardiology2008;51(21):2028-33. [MEDLINE: 18498956]BonacaMP , WiviottSD , BraunwaldE , MurphySA , RuffCT , AntmanEM , et al.American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation2012;125(4):577-83. [MEDLINE: 22199016]CapodannoD , TamburinoC .Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International Journal of Cardiology2011;146(2):242-3. [MEDLINE: 21130510]DammanP , deWinterRJ , WallentinL , FoxKA .Letter by Damman et al regarding articles, &quot;Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)&quot; and &quot;American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)&quot;. Circulation2012;126(9):e136-7. [MEDLINE: 22927480]De ServiS , GoedickeJ , SchirmerA , WidimskyP .Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European Heart Journal: Acute Cardiovascular Care2014;3(4):363-72. [MEDLINE: 24818952]GoodnoughLT , SmithPK , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. Journal of Thoracic &amp; Cardiovascular Surgery2013;145(4):1077-82. [MEDLINE: 22995726]HochholzerW , WiviottSD , AntmanEM , ContantCF , GuoJ , GiuglianoRP , et al.Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation2011;123(23):2681-9. [MEDLINE: 21606391]KohliP , UdellJA , MurphySA , CannonCP , AntmanEM , BraunwaldE , et al.Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Journal of the American College of Cardiology2014;63(3):225-32. [MEDLINE: 24140678]MahoneyEM , WangK , ArnoldSV , ProskorovskyI , WiviottS , AntmanE , et al.Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation2010;121(1):71-9. [MEDLINE: 20026770]MarianiM , MarianiG , De ServiS .Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert Review of Cardiovascular Therapy2009;7(1):17-23. [MEDLINE: 19105763]MegaJL , CloseSL , WiviottSD , ShenL , WalkerJR , SimonT , et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet2010;376(9749):1312-9. [MEDLINE: 20801494]MichelsonAD , Frelinger AL 3rd, BraunwaldE , DowneyWE , AngiolilloDJ , XenopoulosNP , et al.Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal2009;30(14):1753-63. [MEDLINE: 19435740]MogabgabO , WiviottSD , CannonCP , SloanS , SabatineMS , AntmanEM , et al.Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(6):555-9. [MEDLINE: 24064010]MontalescotG , WiviottSD , BraunwaldE , MurphySA , GibsonCM , McCabeCH , et al.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet2009;373(9665):723-31. [MEDLINE: 19249633]MurphySA , AntmanEM , WiviottSD , WeerakkodyG , MorocuttiG , HuberK , et al.Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European Heart Journal2008;29(20):2473-9. [MEDLINE: 18682445]O'DonoghueM , AntmanEM , BraunwaldE , MurphySA , StegPG , FinkelsteinA , et al.The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology2009;54(8):678-85. [MEDLINE: 19679245]OjeifoO , WiviottSD , AntmanEM , MurphySA , UdellJA , BatesER , et al.Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Jacc: Cardiovascular Interventions2013;6(2):1275-81. [MEDLINE: 24239201]PakhomovIM .Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial. Kardiologiia2010;50(6):63-7. [MEDLINE: 20659030]PrideYB , TungP , MohanaveluS , ZorkunC , WiviottSD , AntmanEM , et al.Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. Jacc: Cardiovascular Interventions2010;3(8):306-11. [MEDLINE: 20723851]RiesmeyerJS , SalazarDE , WeerakkodyGJ , NiL , WrishkoRE , Ernest CS 2nd, et al.Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. Journal of Clinical Pharmacology2012;52(6):789-97. [MEDLINE: 21628601]SerebruanyVL .Letter by Serebruany regarding article, &quot;Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38&quot;. Circulation2010;122(8):e436. [MEDLINE: 20733108]SmithPK , GoodnoughLT , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology2012;60(5):388-96. [MEDLINE: 22633653]SorichMJ , VitryA , WardMB , HorowitzJD , McKinnonRA .Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis &amp; Haemostasis2010;8(8):1678-84. [MEDLINE: 20492467]UdellJA , BraunwaldE , AntmanEM , MurphySA , MontalescotG , WiviottSD .Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).[Erratum in: JACC Cardiovasc Interv. 2014 Aug;7(8):946 Note: Antman, Elliot M [Corrected to Antman, Elliott M]]. Jacc: Cardiovascular Interventions2014;7(6):604-12. [MEDLINE: 24947719]WilcoxR , IqbalK , CostiganT , Lopez-SendonJ , RamosY , WidimskyP .An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current Medical Research &amp; Opinion2014;30(11):2193-205. [MEDLINE: 25025610]WiviottSD , AntmanEM , GibsonCM , MontalescotG , RiesmeyerJ , WeerakkodyG , et al.Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). American Heart Journal2006;152(4):627-35. [MEDLINE: 16996826]WiviottSD , BraunwaldE , McCabeCH , HorvathI , KeltaiM , HerrmanJP , et al.Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet2008;371(9621):1353-63. [MEDLINE: 18377975]WiviottSD , BraunwaldE , McCabeCH , MontalescotG , RuzylloW , GottliebS , et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2007;357(20):2001-15. [MEDLINE: 17982182]WiviottSD , DesaiN , MurphySA , MusumeciG , RagostaM , AntmanEM , et al.Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. American Journal of Cardiology2011;108(7):905-11. [MEDLINE: 21816379]WrishkoRE , Ernest CS 2nd, SmallDS , LiYG , WeerakkodyGJ , RiesmeyerJR , et al.Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. Journal of Clinical Pharmacology2009;49(8):984-98. [MEDLINE: 19546250]">TRITON‐TIMI 38 2006</a> compared prasugrel plus aspirin with clopidogrel plus aspirin and provided data for 1490 people with CKD during a median follow‐up of 14.5 months. Data were not available for fatal or nonfatal stroke, haemorrhagic stroke, fatal bleeding, kidney failure, doubling of SCr, kidney transplant graft loss, transplant rejection, CrCl, proteinuria, dialysis access failure, early access thrombosis, loss of primary unassisted patency, failure to attain suitability for dialysis, need for intervention to attain patency or assist maturation, all‐cause hospitalisation, cardiovascular hospitalisation, and treatment withdrawal. </p> <section id="CD008834-sec-0083"> <h5 class="title">Fatal or nonfatal myocardial infarction</h5> <p><a href="./references#CD008834-bbs2-0105" title="AbaciA .The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses [Prasugrelin ST yukselmeli ve yukselmesiz miyokart enfarktusunde kullanimi: TRITON TIMI 38 caIismasi ve alt grup sonuclari]. Turk Kardiyoloji Dernegi Arsivi2015;43 Suppl 2:1-6. [MEDLINE: 27326444]AntmanEM , WiviottSD , MurphySA , VoitkJ , HasinY , WidimskyP , et al.Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Journal of the American College of Cardiology2008;51(21):2028-33. [MEDLINE: 18498956]BonacaMP , WiviottSD , BraunwaldE , MurphySA , RuffCT , AntmanEM , et al.American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation2012;125(4):577-83. [MEDLINE: 22199016]CapodannoD , TamburinoC .Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International Journal of Cardiology2011;146(2):242-3. [MEDLINE: 21130510]DammanP , deWinterRJ , WallentinL , FoxKA .Letter by Damman et al regarding articles, &quot;Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)&quot; and &quot;American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)&quot;. Circulation2012;126(9):e136-7. [MEDLINE: 22927480]De ServiS , GoedickeJ , SchirmerA , WidimskyP .Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European Heart Journal: Acute Cardiovascular Care2014;3(4):363-72. [MEDLINE: 24818952]GoodnoughLT , SmithPK , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. Journal of Thoracic &amp; Cardiovascular Surgery2013;145(4):1077-82. [MEDLINE: 22995726]HochholzerW , WiviottSD , AntmanEM , ContantCF , GuoJ , GiuglianoRP , et al.Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation2011;123(23):2681-9. [MEDLINE: 21606391]KohliP , UdellJA , MurphySA , CannonCP , AntmanEM , BraunwaldE , et al.Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Journal of the American College of Cardiology2014;63(3):225-32. [MEDLINE: 24140678]MahoneyEM , WangK , ArnoldSV , ProskorovskyI , WiviottS , AntmanE , et al.Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation2010;121(1):71-9. [MEDLINE: 20026770]MarianiM , MarianiG , De ServiS .Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert Review of Cardiovascular Therapy2009;7(1):17-23. [MEDLINE: 19105763]MegaJL , CloseSL , WiviottSD , ShenL , WalkerJR , SimonT , et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet2010;376(9749):1312-9. [MEDLINE: 20801494]MichelsonAD , Frelinger AL 3rd, BraunwaldE , DowneyWE , AngiolilloDJ , XenopoulosNP , et al.Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal2009;30(14):1753-63. [MEDLINE: 19435740]MogabgabO , WiviottSD , CannonCP , SloanS , SabatineMS , AntmanEM , et al.Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(6):555-9. [MEDLINE: 24064010]MontalescotG , WiviottSD , BraunwaldE , MurphySA , GibsonCM , McCabeCH , et al.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet2009;373(9665):723-31. [MEDLINE: 19249633]MurphySA , AntmanEM , WiviottSD , WeerakkodyG , MorocuttiG , HuberK , et al.Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European Heart Journal2008;29(20):2473-9. [MEDLINE: 18682445]O'DonoghueM , AntmanEM , BraunwaldE , MurphySA , StegPG , FinkelsteinA , et al.The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology2009;54(8):678-85. [MEDLINE: 19679245]OjeifoO , WiviottSD , AntmanEM , MurphySA , UdellJA , BatesER , et al.Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Jacc: Cardiovascular Interventions2013;6(2):1275-81. [MEDLINE: 24239201]PakhomovIM .Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial. Kardiologiia2010;50(6):63-7. [MEDLINE: 20659030]PrideYB , TungP , MohanaveluS , ZorkunC , WiviottSD , AntmanEM , et al.Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. Jacc: Cardiovascular Interventions2010;3(8):306-11. [MEDLINE: 20723851]RiesmeyerJS , SalazarDE , WeerakkodyGJ , NiL , WrishkoRE , Ernest CS 2nd, et al.Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. Journal of Clinical Pharmacology2012;52(6):789-97. [MEDLINE: 21628601]SerebruanyVL .Letter by Serebruany regarding article, &quot;Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38&quot;. Circulation2010;122(8):e436. [MEDLINE: 20733108]SmithPK , GoodnoughLT , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology2012;60(5):388-96. [MEDLINE: 22633653]SorichMJ , VitryA , WardMB , HorowitzJD , McKinnonRA .Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis &amp; Haemostasis2010;8(8):1678-84. [MEDLINE: 20492467]UdellJA , BraunwaldE , AntmanEM , MurphySA , MontalescotG , WiviottSD .Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).[Erratum in: JACC Cardiovasc Interv. 2014 Aug;7(8):946 Note: Antman, Elliot M [Corrected to Antman, Elliott M]]. Jacc: Cardiovascular Interventions2014;7(6):604-12. [MEDLINE: 24947719]WilcoxR , IqbalK , CostiganT , Lopez-SendonJ , RamosY , WidimskyP .An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current Medical Research &amp; Opinion2014;30(11):2193-205. [MEDLINE: 25025610]WiviottSD , AntmanEM , GibsonCM , MontalescotG , RiesmeyerJ , WeerakkodyG , et al.Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). American Heart Journal2006;152(4):627-35. [MEDLINE: 16996826]WiviottSD , BraunwaldE , McCabeCH , HorvathI , KeltaiM , HerrmanJP , et al.Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet2008;371(9621):1353-63. [MEDLINE: 18377975]WiviottSD , BraunwaldE , McCabeCH , MontalescotG , RuzylloW , GottliebS , et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2007;357(20):2001-15. [MEDLINE: 17982182]WiviottSD , DesaiN , MurphySA , MusumeciG , RagostaM , AntmanEM , et al.Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. American Journal of Cardiology2011;108(7):905-11. [MEDLINE: 21816379]WrishkoRE , Ernest CS 2nd, SmallDS , LiYG , WeerakkodyGJ , RiesmeyerJR , et al.Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. Journal of Clinical Pharmacology2009;49(8):984-98. [MEDLINE: 19546250]">TRITON‐TIMI 38 2006</a> reported no difference between prasugrel plus aspirin compared to clopidogrel plus aspirin on fatal or nonfatal MI (<a href="./references#CD008834-fig-0026" title="">Analysis 2.1</a> (1 study, 1490 participants): RR 0.78, 95% CI 0.58 to 1.05). Since not all participants experienced MI before treatment allocation, antiplatelet agents were used both for primary and secondary prevention. </p> </section> <section id="CD008834-sec-0084"> <h5 class="title">Death (any cause)</h5> <p><a href="./references#CD008834-bbs2-0105" title="AbaciA .The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses [Prasugrelin ST yukselmeli ve yukselmesiz miyokart enfarktusunde kullanimi: TRITON TIMI 38 caIismasi ve alt grup sonuclari]. Turk Kardiyoloji Dernegi Arsivi2015;43 Suppl 2:1-6. [MEDLINE: 27326444]AntmanEM , WiviottSD , MurphySA , VoitkJ , HasinY , WidimskyP , et al.Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Journal of the American College of Cardiology2008;51(21):2028-33. [MEDLINE: 18498956]BonacaMP , WiviottSD , BraunwaldE , MurphySA , RuffCT , AntmanEM , et al.American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation2012;125(4):577-83. [MEDLINE: 22199016]CapodannoD , TamburinoC .Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International Journal of Cardiology2011;146(2):242-3. [MEDLINE: 21130510]DammanP , deWinterRJ , WallentinL , FoxKA .Letter by Damman et al regarding articles, &quot;Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)&quot; and &quot;American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)&quot;. Circulation2012;126(9):e136-7. [MEDLINE: 22927480]De ServiS , GoedickeJ , SchirmerA , WidimskyP .Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European Heart Journal: Acute Cardiovascular Care2014;3(4):363-72. [MEDLINE: 24818952]GoodnoughLT , SmithPK , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. Journal of Thoracic &amp; Cardiovascular Surgery2013;145(4):1077-82. [MEDLINE: 22995726]HochholzerW , WiviottSD , AntmanEM , ContantCF , GuoJ , GiuglianoRP , et al.Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation2011;123(23):2681-9. [MEDLINE: 21606391]KohliP , UdellJA , MurphySA , CannonCP , AntmanEM , BraunwaldE , et al.Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Journal of the American College of Cardiology2014;63(3):225-32. [MEDLINE: 24140678]MahoneyEM , WangK , ArnoldSV , ProskorovskyI , WiviottS , AntmanE , et al.Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation2010;121(1):71-9. [MEDLINE: 20026770]MarianiM , MarianiG , De ServiS .Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert Review of Cardiovascular Therapy2009;7(1):17-23. [MEDLINE: 19105763]MegaJL , CloseSL , WiviottSD , ShenL , WalkerJR , SimonT , et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet2010;376(9749):1312-9. [MEDLINE: 20801494]MichelsonAD , Frelinger AL 3rd, BraunwaldE , DowneyWE , AngiolilloDJ , XenopoulosNP , et al.Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal2009;30(14):1753-63. [MEDLINE: 19435740]MogabgabO , WiviottSD , CannonCP , SloanS , SabatineMS , AntmanEM , et al.Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(6):555-9. [MEDLINE: 24064010]MontalescotG , WiviottSD , BraunwaldE , MurphySA , GibsonCM , McCabeCH , et al.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet2009;373(9665):723-31. [MEDLINE: 19249633]MurphySA , AntmanEM , WiviottSD , WeerakkodyG , MorocuttiG , HuberK , et al.Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European Heart Journal2008;29(20):2473-9. [MEDLINE: 18682445]O'DonoghueM , AntmanEM , BraunwaldE , MurphySA , StegPG , FinkelsteinA , et al.The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology2009;54(8):678-85. [MEDLINE: 19679245]OjeifoO , WiviottSD , AntmanEM , MurphySA , UdellJA , BatesER , et al.Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Jacc: Cardiovascular Interventions2013;6(2):1275-81. [MEDLINE: 24239201]PakhomovIM .Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial. Kardiologiia2010;50(6):63-7. [MEDLINE: 20659030]PrideYB , TungP , MohanaveluS , ZorkunC , WiviottSD , AntmanEM , et al.Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. Jacc: Cardiovascular Interventions2010;3(8):306-11. [MEDLINE: 20723851]RiesmeyerJS , SalazarDE , WeerakkodyGJ , NiL , WrishkoRE , Ernest CS 2nd, et al.Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. Journal of Clinical Pharmacology2012;52(6):789-97. [MEDLINE: 21628601]SerebruanyVL .Letter by Serebruany regarding article, &quot;Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38&quot;. Circulation2010;122(8):e436. [MEDLINE: 20733108]SmithPK , GoodnoughLT , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology2012;60(5):388-96. [MEDLINE: 22633653]SorichMJ , VitryA , WardMB , HorowitzJD , McKinnonRA .Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis &amp; Haemostasis2010;8(8):1678-84. [MEDLINE: 20492467]UdellJA , BraunwaldE , AntmanEM , MurphySA , MontalescotG , WiviottSD .Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).[Erratum in: JACC Cardiovasc Interv. 2014 Aug;7(8):946 Note: Antman, Elliot M [Corrected to Antman, Elliott M]]. Jacc: Cardiovascular Interventions2014;7(6):604-12. [MEDLINE: 24947719]WilcoxR , IqbalK , CostiganT , Lopez-SendonJ , RamosY , WidimskyP .An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current Medical Research &amp; Opinion2014;30(11):2193-205. [MEDLINE: 25025610]WiviottSD , AntmanEM , GibsonCM , MontalescotG , RiesmeyerJ , WeerakkodyG , et al.Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). American Heart Journal2006;152(4):627-35. [MEDLINE: 16996826]WiviottSD , BraunwaldE , McCabeCH , HorvathI , KeltaiM , HerrmanJP , et al.Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet2008;371(9621):1353-63. [MEDLINE: 18377975]WiviottSD , BraunwaldE , McCabeCH , MontalescotG , RuzylloW , GottliebS , et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2007;357(20):2001-15. [MEDLINE: 17982182]WiviottSD , DesaiN , MurphySA , MusumeciG , RagostaM , AntmanEM , et al.Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. American Journal of Cardiology2011;108(7):905-11. [MEDLINE: 21816379]WrishkoRE , Ernest CS 2nd, SmallDS , LiYG , WeerakkodyGJ , RiesmeyerJR , et al.Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. Journal of Clinical Pharmacology2009;49(8):984-98. [MEDLINE: 19546250]">TRITON‐TIMI 38 2006</a> reported no difference between prasugrel plus aspirin compared to clopidogrel plus aspirin death (any cause) (<a href="./references#CD008834-fig-0027" title="">Analysis 2.2</a> (1 study, 1490 participants): RR 0.81, 95% CI 0.56 to 1.18). </p> </section> <section id="CD008834-sec-0085"> <h5 class="title">Cardiovascular death</h5> <p><a href="./references#CD008834-bbs2-0105" title="AbaciA .The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses [Prasugrelin ST yukselmeli ve yukselmesiz miyokart enfarktusunde kullanimi: TRITON TIMI 38 caIismasi ve alt grup sonuclari]. Turk Kardiyoloji Dernegi Arsivi2015;43 Suppl 2:1-6. [MEDLINE: 27326444]AntmanEM , WiviottSD , MurphySA , VoitkJ , HasinY , WidimskyP , et al.Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Journal of the American College of Cardiology2008;51(21):2028-33. [MEDLINE: 18498956]BonacaMP , WiviottSD , BraunwaldE , MurphySA , RuffCT , AntmanEM , et al.American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation2012;125(4):577-83. [MEDLINE: 22199016]CapodannoD , TamburinoC .Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International Journal of Cardiology2011;146(2):242-3. [MEDLINE: 21130510]DammanP , deWinterRJ , WallentinL , FoxKA .Letter by Damman et al regarding articles, &quot;Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)&quot; and &quot;American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)&quot;. Circulation2012;126(9):e136-7. [MEDLINE: 22927480]De ServiS , GoedickeJ , SchirmerA , WidimskyP .Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European Heart Journal: Acute Cardiovascular Care2014;3(4):363-72. [MEDLINE: 24818952]GoodnoughLT , SmithPK , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. Journal of Thoracic &amp; Cardiovascular Surgery2013;145(4):1077-82. [MEDLINE: 22995726]HochholzerW , WiviottSD , AntmanEM , ContantCF , GuoJ , GiuglianoRP , et al.Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation2011;123(23):2681-9. [MEDLINE: 21606391]KohliP , UdellJA , MurphySA , CannonCP , AntmanEM , BraunwaldE , et al.Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Journal of the American College of Cardiology2014;63(3):225-32. [MEDLINE: 24140678]MahoneyEM , WangK , ArnoldSV , ProskorovskyI , WiviottS , AntmanE , et al.Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation2010;121(1):71-9. [MEDLINE: 20026770]MarianiM , MarianiG , De ServiS .Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert Review of Cardiovascular Therapy2009;7(1):17-23. [MEDLINE: 19105763]MegaJL , CloseSL , WiviottSD , ShenL , WalkerJR , SimonT , et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet2010;376(9749):1312-9. [MEDLINE: 20801494]MichelsonAD , Frelinger AL 3rd, BraunwaldE , DowneyWE , AngiolilloDJ , XenopoulosNP , et al.Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal2009;30(14):1753-63. [MEDLINE: 19435740]MogabgabO , WiviottSD , CannonCP , SloanS , SabatineMS , AntmanEM , et al.Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(6):555-9. [MEDLINE: 24064010]MontalescotG , WiviottSD , BraunwaldE , MurphySA , GibsonCM , McCabeCH , et al.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet2009;373(9665):723-31. [MEDLINE: 19249633]MurphySA , AntmanEM , WiviottSD , WeerakkodyG , MorocuttiG , HuberK , et al.Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European Heart Journal2008;29(20):2473-9. [MEDLINE: 18682445]O'DonoghueM , AntmanEM , BraunwaldE , MurphySA , StegPG , FinkelsteinA , et al.The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology2009;54(8):678-85. [MEDLINE: 19679245]OjeifoO , WiviottSD , AntmanEM , MurphySA , UdellJA , BatesER , et al.Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Jacc: Cardiovascular Interventions2013;6(2):1275-81. [MEDLINE: 24239201]PakhomovIM .Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial. Kardiologiia2010;50(6):63-7. [MEDLINE: 20659030]PrideYB , TungP , MohanaveluS , ZorkunC , WiviottSD , AntmanEM , et al.Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. Jacc: Cardiovascular Interventions2010;3(8):306-11. [MEDLINE: 20723851]RiesmeyerJS , SalazarDE , WeerakkodyGJ , NiL , WrishkoRE , Ernest CS 2nd, et al.Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. Journal of Clinical Pharmacology2012;52(6):789-97. [MEDLINE: 21628601]SerebruanyVL .Letter by Serebruany regarding article, &quot;Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38&quot;. Circulation2010;122(8):e436. [MEDLINE: 20733108]SmithPK , GoodnoughLT , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology2012;60(5):388-96. [MEDLINE: 22633653]SorichMJ , VitryA , WardMB , HorowitzJD , McKinnonRA .Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis &amp; Haemostasis2010;8(8):1678-84. [MEDLINE: 20492467]UdellJA , BraunwaldE , AntmanEM , MurphySA , MontalescotG , WiviottSD .Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).[Erratum in: JACC Cardiovasc Interv. 2014 Aug;7(8):946 Note: Antman, Elliot M [Corrected to Antman, Elliott M]]. Jacc: Cardiovascular Interventions2014;7(6):604-12. [MEDLINE: 24947719]WilcoxR , IqbalK , CostiganT , Lopez-SendonJ , RamosY , WidimskyP .An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current Medical Research &amp; Opinion2014;30(11):2193-205. [MEDLINE: 25025610]WiviottSD , AntmanEM , GibsonCM , MontalescotG , RiesmeyerJ , WeerakkodyG , et al.Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). American Heart Journal2006;152(4):627-35. [MEDLINE: 16996826]WiviottSD , BraunwaldE , McCabeCH , HorvathI , KeltaiM , HerrmanJP , et al.Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet2008;371(9621):1353-63. [MEDLINE: 18377975]WiviottSD , BraunwaldE , McCabeCH , MontalescotG , RuzylloW , GottliebS , et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2007;357(20):2001-15. [MEDLINE: 17982182]WiviottSD , DesaiN , MurphySA , MusumeciG , RagostaM , AntmanEM , et al.Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. American Journal of Cardiology2011;108(7):905-11. [MEDLINE: 21816379]WrishkoRE , Ernest CS 2nd, SmallDS , LiYG , WeerakkodyGJ , RiesmeyerJR , et al.Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. Journal of Clinical Pharmacology2009;49(8):984-98. [MEDLINE: 19546250]">TRITON‐TIMI 38 2006</a> reported no difference between prasugrel plus aspirin compared to clopidogrel plus aspirin on cardiovascular death (<a href="./references#CD008834-fig-0028" title="">Analysis 2.3</a> (1 study, 1469 participants): RR 1.35, 95% CI 0.87 to 2.10). </p> </section> <section id="CD008834-sec-0086"> <h5 class="title">Major bleeding</h5> <p>Major bleeding was defined according to the Thrombolysis In Myocardial Infarction (TIMI) criteria for major bleeding (intracranial haemorrhage, clinically evident bleeding including imaging and a drop in the Hb of ≥5 g/dL). <a href="./references#CD008834-bbs2-0105" title="AbaciA .The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses [Prasugrelin ST yukselmeli ve yukselmesiz miyokart enfarktusunde kullanimi: TRITON TIMI 38 caIismasi ve alt grup sonuclari]. Turk Kardiyoloji Dernegi Arsivi2015;43 Suppl 2:1-6. [MEDLINE: 27326444]AntmanEM , WiviottSD , MurphySA , VoitkJ , HasinY , WidimskyP , et al.Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Journal of the American College of Cardiology2008;51(21):2028-33. [MEDLINE: 18498956]BonacaMP , WiviottSD , BraunwaldE , MurphySA , RuffCT , AntmanEM , et al.American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation2012;125(4):577-83. [MEDLINE: 22199016]CapodannoD , TamburinoC .Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International Journal of Cardiology2011;146(2):242-3. [MEDLINE: 21130510]DammanP , deWinterRJ , WallentinL , FoxKA .Letter by Damman et al regarding articles, &quot;Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)&quot; and &quot;American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)&quot;. Circulation2012;126(9):e136-7. [MEDLINE: 22927480]De ServiS , GoedickeJ , SchirmerA , WidimskyP .Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European Heart Journal: Acute Cardiovascular Care2014;3(4):363-72. [MEDLINE: 24818952]GoodnoughLT , SmithPK , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. Journal of Thoracic &amp; Cardiovascular Surgery2013;145(4):1077-82. [MEDLINE: 22995726]HochholzerW , WiviottSD , AntmanEM , ContantCF , GuoJ , GiuglianoRP , et al.Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation2011;123(23):2681-9. [MEDLINE: 21606391]KohliP , UdellJA , MurphySA , CannonCP , AntmanEM , BraunwaldE , et al.Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Journal of the American College of Cardiology2014;63(3):225-32. [MEDLINE: 24140678]MahoneyEM , WangK , ArnoldSV , ProskorovskyI , WiviottS , AntmanE , et al.Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation2010;121(1):71-9. [MEDLINE: 20026770]MarianiM , MarianiG , De ServiS .Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert Review of Cardiovascular Therapy2009;7(1):17-23. [MEDLINE: 19105763]MegaJL , CloseSL , WiviottSD , ShenL , WalkerJR , SimonT , et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet2010;376(9749):1312-9. [MEDLINE: 20801494]MichelsonAD , Frelinger AL 3rd, BraunwaldE , DowneyWE , AngiolilloDJ , XenopoulosNP , et al.Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal2009;30(14):1753-63. [MEDLINE: 19435740]MogabgabO , WiviottSD , CannonCP , SloanS , SabatineMS , AntmanEM , et al.Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(6):555-9. [MEDLINE: 24064010]MontalescotG , WiviottSD , BraunwaldE , MurphySA , GibsonCM , McCabeCH , et al.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet2009;373(9665):723-31. [MEDLINE: 19249633]MurphySA , AntmanEM , WiviottSD , WeerakkodyG , MorocuttiG , HuberK , et al.Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European Heart Journal2008;29(20):2473-9. [MEDLINE: 18682445]O'DonoghueM , AntmanEM , BraunwaldE , MurphySA , StegPG , FinkelsteinA , et al.The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology2009;54(8):678-85. [MEDLINE: 19679245]OjeifoO , WiviottSD , AntmanEM , MurphySA , UdellJA , BatesER , et al.Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Jacc: Cardiovascular Interventions2013;6(2):1275-81. [MEDLINE: 24239201]PakhomovIM .Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial. Kardiologiia2010;50(6):63-7. [MEDLINE: 20659030]PrideYB , TungP , MohanaveluS , ZorkunC , WiviottSD , AntmanEM , et al.Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. Jacc: Cardiovascular Interventions2010;3(8):306-11. [MEDLINE: 20723851]RiesmeyerJS , SalazarDE , WeerakkodyGJ , NiL , WrishkoRE , Ernest CS 2nd, et al.Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. Journal of Clinical Pharmacology2012;52(6):789-97. [MEDLINE: 21628601]SerebruanyVL .Letter by Serebruany regarding article, &quot;Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38&quot;. Circulation2010;122(8):e436. [MEDLINE: 20733108]SmithPK , GoodnoughLT , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology2012;60(5):388-96. [MEDLINE: 22633653]SorichMJ , VitryA , WardMB , HorowitzJD , McKinnonRA .Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis &amp; Haemostasis2010;8(8):1678-84. [MEDLINE: 20492467]UdellJA , BraunwaldE , AntmanEM , MurphySA , MontalescotG , WiviottSD .Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).[Erratum in: JACC Cardiovasc Interv. 2014 Aug;7(8):946 Note: Antman, Elliot M [Corrected to Antman, Elliott M]]. Jacc: Cardiovascular Interventions2014;7(6):604-12. [MEDLINE: 24947719]WilcoxR , IqbalK , CostiganT , Lopez-SendonJ , RamosY , WidimskyP .An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current Medical Research &amp; Opinion2014;30(11):2193-205. [MEDLINE: 25025610]WiviottSD , AntmanEM , GibsonCM , MontalescotG , RiesmeyerJ , WeerakkodyG , et al.Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). American Heart Journal2006;152(4):627-35. [MEDLINE: 16996826]WiviottSD , BraunwaldE , McCabeCH , HorvathI , KeltaiM , HerrmanJP , et al.Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet2008;371(9621):1353-63. [MEDLINE: 18377975]WiviottSD , BraunwaldE , McCabeCH , MontalescotG , RuzylloW , GottliebS , et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2007;357(20):2001-15. [MEDLINE: 17982182]WiviottSD , DesaiN , MurphySA , MusumeciG , RagostaM , AntmanEM , et al.Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. American Journal of Cardiology2011;108(7):905-11. [MEDLINE: 21816379]WrishkoRE , Ernest CS 2nd, SmallDS , LiYG , WeerakkodyGJ , RiesmeyerJR , et al.Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. Journal of Clinical Pharmacology2009;49(8):984-98. [MEDLINE: 19546250]">TRITON‐TIMI 38 2006</a> reported no difference between prasugrel plus aspirin compared to clopidogrel plus aspirin on major bleeding (<a href="./references#CD008834-fig-0029" title="">Analysis 2.4</a> (1 study, 1475 participants): RR 1.49, 95% CI 0.83 to 2.66). </p> </section> <section id="CD008834-sec-0087"> <h5 class="title">Minor bleeding</h5> <p>Minor bleeding was defined as clinically evident bleeding including imaging and a fall in the Hb of between 3 and 5 g/dL. <a href="./references#CD008834-bbs2-0105" title="AbaciA .The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses [Prasugrelin ST yukselmeli ve yukselmesiz miyokart enfarktusunde kullanimi: TRITON TIMI 38 caIismasi ve alt grup sonuclari]. Turk Kardiyoloji Dernegi Arsivi2015;43 Suppl 2:1-6. [MEDLINE: 27326444]AntmanEM , WiviottSD , MurphySA , VoitkJ , HasinY , WidimskyP , et al.Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Journal of the American College of Cardiology2008;51(21):2028-33. [MEDLINE: 18498956]BonacaMP , WiviottSD , BraunwaldE , MurphySA , RuffCT , AntmanEM , et al.American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation2012;125(4):577-83. [MEDLINE: 22199016]CapodannoD , TamburinoC .Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International Journal of Cardiology2011;146(2):242-3. [MEDLINE: 21130510]DammanP , deWinterRJ , WallentinL , FoxKA .Letter by Damman et al regarding articles, &quot;Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)&quot; and &quot;American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)&quot;. Circulation2012;126(9):e136-7. [MEDLINE: 22927480]De ServiS , GoedickeJ , SchirmerA , WidimskyP .Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European Heart Journal: Acute Cardiovascular Care2014;3(4):363-72. [MEDLINE: 24818952]GoodnoughLT , SmithPK , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. Journal of Thoracic &amp; Cardiovascular Surgery2013;145(4):1077-82. [MEDLINE: 22995726]HochholzerW , WiviottSD , AntmanEM , ContantCF , GuoJ , GiuglianoRP , et al.Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation2011;123(23):2681-9. [MEDLINE: 21606391]KohliP , UdellJA , MurphySA , CannonCP , AntmanEM , BraunwaldE , et al.Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Journal of the American College of Cardiology2014;63(3):225-32. [MEDLINE: 24140678]MahoneyEM , WangK , ArnoldSV , ProskorovskyI , WiviottS , AntmanE , et al.Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation2010;121(1):71-9. [MEDLINE: 20026770]MarianiM , MarianiG , De ServiS .Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert Review of Cardiovascular Therapy2009;7(1):17-23. [MEDLINE: 19105763]MegaJL , CloseSL , WiviottSD , ShenL , WalkerJR , SimonT , et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet2010;376(9749):1312-9. [MEDLINE: 20801494]MichelsonAD , Frelinger AL 3rd, BraunwaldE , DowneyWE , AngiolilloDJ , XenopoulosNP , et al.Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal2009;30(14):1753-63. [MEDLINE: 19435740]MogabgabO , WiviottSD , CannonCP , SloanS , SabatineMS , AntmanEM , et al.Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(6):555-9. [MEDLINE: 24064010]MontalescotG , WiviottSD , BraunwaldE , MurphySA , GibsonCM , McCabeCH , et al.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet2009;373(9665):723-31. [MEDLINE: 19249633]MurphySA , AntmanEM , WiviottSD , WeerakkodyG , MorocuttiG , HuberK , et al.Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European Heart Journal2008;29(20):2473-9. [MEDLINE: 18682445]O'DonoghueM , AntmanEM , BraunwaldE , MurphySA , StegPG , FinkelsteinA , et al.The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology2009;54(8):678-85. [MEDLINE: 19679245]OjeifoO , WiviottSD , AntmanEM , MurphySA , UdellJA , BatesER , et al.Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Jacc: Cardiovascular Interventions2013;6(2):1275-81. [MEDLINE: 24239201]PakhomovIM .Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial. Kardiologiia2010;50(6):63-7. [MEDLINE: 20659030]PrideYB , TungP , MohanaveluS , ZorkunC , WiviottSD , AntmanEM , et al.Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. Jacc: Cardiovascular Interventions2010;3(8):306-11. [MEDLINE: 20723851]RiesmeyerJS , SalazarDE , WeerakkodyGJ , NiL , WrishkoRE , Ernest CS 2nd, et al.Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. Journal of Clinical Pharmacology2012;52(6):789-97. [MEDLINE: 21628601]SerebruanyVL .Letter by Serebruany regarding article, &quot;Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38&quot;. Circulation2010;122(8):e436. [MEDLINE: 20733108]SmithPK , GoodnoughLT , LevyJH , PostonRS , ShortMA , WeerakkodyGJ , et al.Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology2012;60(5):388-96. [MEDLINE: 22633653]SorichMJ , VitryA , WardMB , HorowitzJD , McKinnonRA .Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis &amp; Haemostasis2010;8(8):1678-84. [MEDLINE: 20492467]UdellJA , BraunwaldE , AntmanEM , MurphySA , MontalescotG , WiviottSD .Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).[Erratum in: JACC Cardiovasc Interv. 2014 Aug;7(8):946 Note: Antman, Elliot M [Corrected to Antman, Elliott M]]. Jacc: Cardiovascular Interventions2014;7(6):604-12. [MEDLINE: 24947719]WilcoxR , IqbalK , CostiganT , Lopez-SendonJ , RamosY , WidimskyP .An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current Medical Research &amp; Opinion2014;30(11):2193-205. [MEDLINE: 25025610]WiviottSD , AntmanEM , GibsonCM , MontalescotG , RiesmeyerJ , WeerakkodyG , et al.Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). American Heart Journal2006;152(4):627-35. [MEDLINE: 16996826]WiviottSD , BraunwaldE , McCabeCH , HorvathI , KeltaiM , HerrmanJP , et al.Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet2008;371(9621):1353-63. [MEDLINE: 18377975]WiviottSD , BraunwaldE , McCabeCH , MontalescotG , RuzylloW , GottliebS , et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine2007;357(20):2001-15. [MEDLINE: 17982182]WiviottSD , DesaiN , MurphySA , MusumeciG , RagostaM , AntmanEM , et al.Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. American Journal of Cardiology2011;108(7):905-11. [MEDLINE: 21816379]WrishkoRE , Ernest CS 2nd, SmallDS , LiYG , WeerakkodyGJ , RiesmeyerJR , et al.Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. Journal of Clinical Pharmacology2009;49(8):984-98. [MEDLINE: 19546250]">TRITON‐TIMI 38 2006</a> reported no difference between prasugrel plus aspirin compared to clopidogrel plus aspirin on minor bleeding (<a href="./references#CD008834-fig-0030" title="">Analysis 2.5</a> (1 study, 1469 participants): RR 1.35, 95% CI 0.87 to 2.10). </p> </section> </section> <section id="CD008834-sec-0088"> <h4 class="title">Ticagrelor versus clopidogrel</h4> <p>Three studies (<a href="./references#CD008834-bbs2-0074" title="HanY .Comparison of the pharmacodynamics and pharmacokinetics of ticagrelor versus clopidogrel in patients with chronic kidney disease and non-ST-elevation acute coronary syndromes (OPT-CKD trial) [abstract no: TCT-483]. Journal of the American College of Cardiology2017;70(18 Suppl 1):B200. [EMBASE: 619771602]WangH , QiJ , LiY , TangY , LiC , LiJ , et al.Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. British Journal of Clinical Pharmacology2018;84(1):88-96. [MEDLINE: 28921624]">OPT‐CKD 2018</a>; <a href="./references#CD008834-bbs2-0078" title="JeongKH , ChoJH , WooJS , KimJB , KimWS , LeeTW , et al.Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. American Journal of Kidney Diseases2015;65(6):916-24. [MEDLINE: 25622774]JeongKH , LeeTW , KimJS , LeeSY , LeeSH , MoonJY , et al.Platelet reactivity in patients with end stage renal disease receiving clopidogrel compared with ticagrelor: a randomized crossover study [abstract no: FP610]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii276. [EMBASE: 72207028]WooJS , KimW , KimHS , HwangSJ , KimJB , KimSJ , et al.Randomized assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with chronic kidney disease performing hemodialysis [abstract]. European Heart Journal2014;35(Suppl 1):7-8. [EMBASE: 71646762]">PIANO‐3 2015</a>; <a href="./references#CD008834-bbs2-0079" title="KimJS , LeeTW , IhmC , LeeSH , KimSY , LeeSY , et al.Relationship of ticagrelor dose and platelet reactivity in patients with end stage renal disease on hemodialysis [abstract no: FR-PO727]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):529A. KimJS , WooJS , KimJB , KimWS , LeeTW , KimKS , et al.The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. International Journal of Cardiology2017;238:110-6. [MEDLINE: 28342632]KimW , WooJS , KimWS , KimJB , KimHO , KimJM .Pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis [abstract]. European Heart Journal2016;37(Suppl 1):636. [EMBASE: 612284362]">PIANO‐6 2017</a>) compared ticagrelor with or without aspirin with clopidogrel alone or in combination with aspirin. Data were not available for haemorrhagic stroke, kidney failure, doubling of SCr, kidney transplant graft loss, transplant rejection, CrCl, proteinuria, dialysis access failure, early access thrombosis, loss of primary unassisted patency, failure to attain suitability for dialysis, need for intervention to attain patency or assist maturation, all‐cause hospitalisation, and cardiovascular hospitalisation. </p> <section id="CD008834-sec-0089"> <h5 class="title">Fatal or nonfatal myocardial infarction</h5> <p><a href="./references#CD008834-bbs2-0074" title="HanY .Comparison of the pharmacodynamics and pharmacokinetics of ticagrelor versus clopidogrel in patients with chronic kidney disease and non-ST-elevation acute coronary syndromes (OPT-CKD trial) [abstract no: TCT-483]. Journal of the American College of Cardiology2017;70(18 Suppl 1):B200. [EMBASE: 619771602]WangH , QiJ , LiY , TangY , LiC , LiJ , et al.Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. British Journal of Clinical Pharmacology2018;84(1):88-96. [MEDLINE: 28921624]">OPT‐CKD 2018</a> reported no difference between ticagrelor compared to clopidogrel on fatal or nonfatal MI in CKD during 30 days follow‐up (<a href="./references#CD008834-fig-0031" title="">Analysis 3.1</a> (1 study, 60 participants): RR 3.00, 95% CI 0.13 to 70.83). Since not all participants experienced MI before treatment allocation, antiplatelet agents were used both for primary and secondary prevention. </p> </section> <section id="CD008834-sec-0090"> <h5 class="title">Fatal or nonfatal stroke</h5> <p><a href="./references#CD008834-bbs2-0074" title="HanY .Comparison of the pharmacodynamics and pharmacokinetics of ticagrelor versus clopidogrel in patients with chronic kidney disease and non-ST-elevation acute coronary syndromes (OPT-CKD trial) [abstract no: TCT-483]. Journal of the American College of Cardiology2017;70(18 Suppl 1):B200. [EMBASE: 619771602]WangH , QiJ , LiY , TangY , LiC , LiJ , et al.Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. British Journal of Clinical Pharmacology2018;84(1):88-96. [MEDLINE: 28921624]">OPT‐CKD 2018</a> reported no difference between ticagrelor compared to clopidogrel on fatal or nonfatal MI in CKD during 30 days follow‐up (<a href="./references#CD008834-fig-0032" title="">Analysis 3.2</a> (1 study, 60 participants): RR 3.00, 95% CI 0.13 to 70.83). Since it was not reported if all participants experienced a stroke before treatment allocation, it was not clear if antiplatelet agents were used either for primary or secondary prevention. </p> </section> <section id="CD008834-sec-0091"> <h5 class="title">Death (any cause)</h5> <p><a href="./references#CD008834-bbs2-0074" title="HanY .Comparison of the pharmacodynamics and pharmacokinetics of ticagrelor versus clopidogrel in patients with chronic kidney disease and non-ST-elevation acute coronary syndromes (OPT-CKD trial) [abstract no: TCT-483]. Journal of the American College of Cardiology2017;70(18 Suppl 1):B200. [EMBASE: 619771602]WangH , QiJ , LiY , TangY , LiC , LiJ , et al.Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. British Journal of Clinical Pharmacology2018;84(1):88-96. [MEDLINE: 28921624]">OPT‐CKD 2018</a> and <a href="./references#CD008834-bbs2-0079" title="KimJS , LeeTW , IhmC , LeeSH , KimSY , LeeSY , et al.Relationship of ticagrelor dose and platelet reactivity in patients with end stage renal disease on hemodialysis [abstract no: FR-PO727]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):529A. KimJS , WooJS , KimJB , KimWS , LeeTW , KimKS , et al.The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. International Journal of Cardiology2017;238:110-6. [MEDLINE: 28342632]KimW , WooJS , KimWS , KimJB , KimHO , KimJM .Pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis [abstract]. European Heart Journal2016;37(Suppl 1):636. [EMBASE: 612284362]">PIANO‐6 2017</a> reported the effect of ticagrelor with clopidogrel while <a href="./references#CD008834-bbs2-0078" title="JeongKH , ChoJH , WooJS , KimJB , KimWS , LeeTW , et al.Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. American Journal of Kidney Diseases2015;65(6):916-24. [MEDLINE: 25622774]JeongKH , LeeTW , KimJS , LeeSY , LeeSH , MoonJY , et al.Platelet reactivity in patients with end stage renal disease receiving clopidogrel compared with ticagrelor: a randomized crossover study [abstract no: FP610]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii276. [EMBASE: 72207028]WooJS , KimW , KimHS , HwangSJ , KimJB , KimSJ , et al.Randomized assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with chronic kidney disease performing hemodialysis [abstract]. European Heart Journal2014;35(Suppl 1):7-8. [EMBASE: 71646762]">PIANO‐3 2015</a> reported the effect of ticagrelor plus aspirin with clopidogrel plus aspirin between 14 to 30 days follow‐up. Antiplatelet agents had uncertain effects on death (any cause) in CKD and HD (<a href="./references#CD008834-fig-0033" title="">Analysis 3.3</a> (3 studies, 137 participants): RR 2.00, 95% CI 0.19 to 20.90; very low certainty evidence). The evidence was downgraded for risk of bias and imprecision. </p> </section> <section id="CD008834-sec-0092"> <h5 class="title">Cardiovascular death</h5> <p><a href="./references#CD008834-bbs2-0074" title="HanY .Comparison of the pharmacodynamics and pharmacokinetics of ticagrelor versus clopidogrel in patients with chronic kidney disease and non-ST-elevation acute coronary syndromes (OPT-CKD trial) [abstract no: TCT-483]. Journal of the American College of Cardiology2017;70(18 Suppl 1):B200. [EMBASE: 619771602]WangH , QiJ , LiY , TangY , LiC , LiJ , et al.Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. British Journal of Clinical Pharmacology2018;84(1):88-96. [MEDLINE: 28921624]">OPT‐CKD 2018</a> and <a href="./references#CD008834-bbs2-0079" title="KimJS , LeeTW , IhmC , LeeSH , KimSY , LeeSY , et al.Relationship of ticagrelor dose and platelet reactivity in patients with end stage renal disease on hemodialysis [abstract no: FR-PO727]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):529A. KimJS , WooJS , KimJB , KimWS , LeeTW , KimKS , et al.The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. International Journal of Cardiology2017;238:110-6. [MEDLINE: 28342632]KimW , WooJS , KimWS , KimJB , KimHO , KimJM .Pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis [abstract]. European Heart Journal2016;37(Suppl 1):636. [EMBASE: 612284362]">PIANO‐6 2017</a> reported the effect of ticagrelor with clopidogrel while <a href="./references#CD008834-bbs2-0078" title="JeongKH , ChoJH , WooJS , KimJB , KimWS , LeeTW , et al.Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. American Journal of Kidney Diseases2015;65(6):916-24. [MEDLINE: 25622774]JeongKH , LeeTW , KimJS , LeeSY , LeeSH , MoonJY , et al.Platelet reactivity in patients with end stage renal disease receiving clopidogrel compared with ticagrelor: a randomized crossover study [abstract no: FP610]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii276. [EMBASE: 72207028]WooJS , KimW , KimHS , HwangSJ , KimJB , KimSJ , et al.Randomized assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with chronic kidney disease performing hemodialysis [abstract]. European Heart Journal2014;35(Suppl 1):7-8. [EMBASE: 71646762]">PIANO‐3 2015</a> reported the effect of ticagrelor plus aspirin with clopidogrel plus aspirin between 14 to 30 days follow‐up. Antiplatelet agents had uncertain effects on cardiovascular death in CKD and HD (<a href="./references#CD008834-fig-0034" title="">Analysis 3.4</a> (3 studies, 137 participants): RR 5.00, 95% CI 0.25 to 99.59; low certainty evidence). The evidence was downgraded for risk of bias and imprecision. </p> </section> <section id="CD008834-sec-0093"> <h5 class="title">Fatal bleeding</h5> <p><a href="./references#CD008834-bbs2-0078" title="JeongKH , ChoJH , WooJS , KimJB , KimWS , LeeTW , et al.Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. American Journal of Kidney Diseases2015;65(6):916-24. [MEDLINE: 25622774]JeongKH , LeeTW , KimJS , LeeSY , LeeSH , MoonJY , et al.Platelet reactivity in patients with end stage renal disease receiving clopidogrel compared with ticagrelor: a randomized crossover study [abstract no: FP610]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii276. [EMBASE: 72207028]WooJS , KimW , KimHS , HwangSJ , KimJB , KimSJ , et al.Randomized assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with chronic kidney disease performing hemodialysis [abstract]. European Heart Journal2014;35(Suppl 1):7-8. [EMBASE: 71646762]">PIANO‐3 2015</a> reported the effect of ticagrelor plus aspirin with clopidogrel plus aspirin and <a href="./references#CD008834-bbs2-0079" title="KimJS , LeeTW , IhmC , LeeSH , KimSY , LeeSY , et al.Relationship of ticagrelor dose and platelet reactivity in patients with end stage renal disease on hemodialysis [abstract no: FR-PO727]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):529A. KimJS , WooJS , KimJB , KimWS , LeeTW , KimKS , et al.The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. International Journal of Cardiology2017;238:110-6. [MEDLINE: 28342632]KimW , WooJS , KimWS , KimJB , KimHO , KimJM .Pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis [abstract]. European Heart Journal2016;37(Suppl 1):636. [EMBASE: 612284362]">PIANO‐6 2017</a> reported the effect of ticagrelor with clopidogrel in HD during 14 days follow‐up. No fatal bleeding events were reported in either study (<a href="./references#CD008834-fig-0035" title="">Analysis 3.5</a>; 2 studies, 77 participants). </p> </section> <section id="CD008834-sec-0094"> <h5 class="title">Major bleeding</h5> <p>Major bleeding was assessed using the Bleeding Academic Research Consortium (BARC) (<a href="./references#CD008834-bbs2-0074" title="HanY .Comparison of the pharmacodynamics and pharmacokinetics of ticagrelor versus clopidogrel in patients with chronic kidney disease and non-ST-elevation acute coronary syndromes (OPT-CKD trial) [abstract no: TCT-483]. Journal of the American College of Cardiology2017;70(18 Suppl 1):B200. [EMBASE: 619771602]WangH , QiJ , LiY , TangY , LiC , LiJ , et al.Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. British Journal of Clinical Pharmacology2018;84(1):88-96. [MEDLINE: 28921624]">OPT‐CKD 2018</a>) or according to the PLATO criteria (<a href="./references#CD008834-bbs2-0078" title="JeongKH , ChoJH , WooJS , KimJB , KimWS , LeeTW , et al.Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. American Journal of Kidney Diseases2015;65(6):916-24. [MEDLINE: 25622774]JeongKH , LeeTW , KimJS , LeeSY , LeeSH , MoonJY , et al.Platelet reactivity in patients with end stage renal disease receiving clopidogrel compared with ticagrelor: a randomized crossover study [abstract no: FP610]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii276. [EMBASE: 72207028]WooJS , KimW , KimHS , HwangSJ , KimJB , KimSJ , et al.Randomized assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with chronic kidney disease performing hemodialysis [abstract]. European Heart Journal2014;35(Suppl 1):7-8. [EMBASE: 71646762]">PIANO‐3 2015</a>). <a href="./references#CD008834-bbs2-0074" title="HanY .Comparison of the pharmacodynamics and pharmacokinetics of ticagrelor versus clopidogrel in patients with chronic kidney disease and non-ST-elevation acute coronary syndromes (OPT-CKD trial) [abstract no: TCT-483]. Journal of the American College of Cardiology2017;70(18 Suppl 1):B200. [EMBASE: 619771602]WangH , QiJ , LiY , TangY , LiC , LiJ , et al.Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. British Journal of Clinical Pharmacology2018;84(1):88-96. [MEDLINE: 28921624]">OPT‐CKD 2018</a> reported the effect of ticagrelor with clopidogrel during 30 days follow‐up, while <a href="./references#CD008834-bbs2-0078" title="JeongKH , ChoJH , WooJS , KimJB , KimWS , LeeTW , et al.Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. American Journal of Kidney Diseases2015;65(6):916-24. [MEDLINE: 25622774]JeongKH , LeeTW , KimJS , LeeSY , LeeSH , MoonJY , et al.Platelet reactivity in patients with end stage renal disease receiving clopidogrel compared with ticagrelor: a randomized crossover study [abstract no: FP610]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii276. [EMBASE: 72207028]WooJS , KimW , KimHS , HwangSJ , KimJB , KimSJ , et al.Randomized assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with chronic kidney disease performing hemodialysis [abstract]. European Heart Journal2014;35(Suppl 1):7-8. [EMBASE: 71646762]">PIANO‐3 2015</a> reported the effect of ticagrelor plus aspirin with clopidogrel plus aspirin during 14 days follow‐up. Antiplatelet agents had uncertain effects on major bleeding in CKD and HD (<a href="./references#CD008834-fig-0036" title="">Analysis 3.6</a> (2 studies, 85 participants): RR 0.33, 95% CI 0.01 to 7.87; low certainty evidence). The evidence was downgraded for risk of bias and imprecision. </p> </section> <section id="CD008834-sec-0095"> <h5 class="title">Minor bleeding</h5> <p>Minor bleeding was assessed using the Bleeding Academic Research Consortium (BARC). <a href="./references#CD008834-bbs2-0079" title="KimJS , LeeTW , IhmC , LeeSH , KimSY , LeeSY , et al.Relationship of ticagrelor dose and platelet reactivity in patients with end stage renal disease on hemodialysis [abstract no: FR-PO727]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):529A. KimJS , WooJS , KimJB , KimWS , LeeTW , KimKS , et al.The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. International Journal of Cardiology2017;238:110-6. [MEDLINE: 28342632]KimW , WooJS , KimWS , KimJB , KimHO , KimJM .Pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis [abstract]. European Heart Journal2016;37(Suppl 1):636. [EMBASE: 612284362]">PIANO‐6 2017</a> reported no difference between ticagrelor compared to clopidogrel on minor bleeding in HD during 14 days follow‐up (<a href="./references#CD008834-fig-0037" title="">Analysis 3.7</a> (1 study, 52 participants): RR 1.06, 95% CI 0.10 to 10.90). </p> </section> <section id="CD008834-sec-0096"> <h5 class="title">Treatment withdrawal</h5> <p><a href="./references#CD008834-bbs2-0079" title="KimJS , LeeTW , IhmC , LeeSH , KimSY , LeeSY , et al.Relationship of ticagrelor dose and platelet reactivity in patients with end stage renal disease on hemodialysis [abstract no: FR-PO727]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):529A. KimJS , WooJS , KimJB , KimWS , LeeTW , KimKS , et al.The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. International Journal of Cardiology2017;238:110-6. [MEDLINE: 28342632]KimW , WooJS , KimWS , KimJB , KimHO , KimJM .Pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis [abstract]. European Heart Journal2016;37(Suppl 1):636. [EMBASE: 612284362]">PIANO‐6 2017</a> reported no difference between ticagrelor compared to clopidogrel on treatment withdrawal in HD during 14 days follow‐up (<a href="./references#CD008834-fig-0038" title="">Analysis 3.8</a> (1 study, 52 participants): RR 1.59, 95% CI 0.18 to 14.19). </p> </section> </section> <section id="CD008834-sec-0097"> <h4 class="title">Clopidogrel (low‐dose) versus clopidogrel (high‐dose)</h4> <p><a href="./references#CD008834-bbs2-0062" title="LiangJ , WangZ , ShiD , LiuY , ZhaoY , HanH , et al.High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. Angiology2015;66(4):319-25. [MEDLINE: 24913197]">Liang 2015</a>, which compared a low‐ versus high‐dose clopidogrel, provided data for 370 people with CKD during 30 days follow‐up. Data were not available for fatal or nonfatal MI, fatal or nonfatal stroke, death (any cause), fatal bleeding, major bleeding, minor bleeding, kidney failure, doubling of SCr, kidney transplant graft loss, transplant rejection, CrCl, proteinuria, dialysis access failure, early access thrombosis, loss of primary unassisted patency, failure to attain suitability for dialysis, need for intervention to attain patency or assist maturation, all‐cause hospitalisation, cardiovascular hospitalisation, and treatment withdrawal. </p> <section id="CD008834-sec-0098"> <h5 class="title">Haemorrhagic stroke</h5> <p><a href="./references#CD008834-bbs2-0062" title="LiangJ , WangZ , ShiD , LiuY , ZhaoY , HanH , et al.High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. Angiology2015;66(4):319-25. [MEDLINE: 24913197]">Liang 2015</a> reported no haemorrhagic stroke events with either low‐dose or high‐dose clopidogrel (<a href="./references#CD008834-fig-0039" title="">Analysis 4.1</a> (1 study, 370 participants)). </p> </section> <section id="CD008834-sec-0099"> <h5 class="title">Cardiovascular death</h5> <p><a href="./references#CD008834-bbs2-0062" title="LiangJ , WangZ , ShiD , LiuY , ZhaoY , HanH , et al.High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. Angiology2015;66(4):319-25. [MEDLINE: 24913197]">Liang 2015</a> reported no difference between low‐ versus high‐dose clopidogrel on cardiovascular death (<a href="./references#CD008834-fig-0040" title="">Analysis 4.2</a> (1 study, 370 participants): RR 4.04, 95% CI 0.46 to 35.83). </p> </section> </section> <section id="CD008834-sec-0100"> <h4 class="title">Abciximab versus tirofiban</h4> <p><a href="./references#CD008834-bbs2-0100" title="BergerPB , BestPJ , TopolEJ , WhiteJ , DiBattistePM , ChanAW , et al.The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal2005;149(5):869-75. [MEDLINE: 15894970]KalyanasundaramA , BlankenshipJC , BergerP , HerrmannH , McClureR , MoliternoD .Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?). Catheterization &amp; Cardiovascular Interventions2007;69(5):623-9. [MEDLINE: 17192960]MoliternoDJ , TopolEJ .A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. American Heart Journal2000;140(5):722-6. [MEDLINE: 11054616]MoliternoDJ , YakubovSJ , DiBattistePM , HerrmannHC , StoneGW , MacayaC , et al.Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet2002;360(9330):355-60. [MEDLINE: 12241774]MukherjeeD , TopolEJ , BertrandME , KristensenSD , HerrmannHC , NeumannFJ , et al.Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. European Heart Journal2005;26(23):2524-8. [MEDLINE: 16107485]RoffiM , MoliternoDJ , MeierB , PowersER , GrinesCL , DiBattistePM , et al.Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation2002;105(23):2730-6. [MEDLINE: 12057986]TopolEJ , MoliternoDJ , HerrmannHC , PowersER , GrinesCL , CohenDJ , et al.Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New England Journal of Medicine2001;344(25):1888-94. [MEDLINE: 11419425]">TARGET 2000</a> compared abciximab plus aspirin with tirofiban plus aspirin and provided unpublished data for 790 people with CKD between 6 and 12 months follow‐up. Data were not available for fatal or nonfatal stroke, haemorrhagic stroke, cardiovascular death, fatal bleeding, major bleeding, minor bleeding, kidney failure, doubling of SCr, kidney transplant graft loss, transplant rejection, CrCl, proteinuria, dialysis access failure, early access thrombosis, loss of primary unassisted patency, failure to attain suitability for dialysis, need for intervention to attain patency or assist maturation, all‐cause hospitalisation, cardiovascular hospitalisation, and treatment withdrawal. </p> <section id="CD008834-sec-0101"> <h5 class="title">Fatal or nonfatal myocardial infarction</h5> <p><a href="./references#CD008834-bbs2-0100" title="BergerPB , BestPJ , TopolEJ , WhiteJ , DiBattistePM , ChanAW , et al.The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal2005;149(5):869-75. [MEDLINE: 15894970]KalyanasundaramA , BlankenshipJC , BergerP , HerrmannH , McClureR , MoliternoD .Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?). Catheterization &amp; Cardiovascular Interventions2007;69(5):623-9. [MEDLINE: 17192960]MoliternoDJ , TopolEJ .A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. American Heart Journal2000;140(5):722-6. [MEDLINE: 11054616]MoliternoDJ , YakubovSJ , DiBattistePM , HerrmannHC , StoneGW , MacayaC , et al.Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet2002;360(9330):355-60. [MEDLINE: 12241774]MukherjeeD , TopolEJ , BertrandME , KristensenSD , HerrmannHC , NeumannFJ , et al.Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. European Heart Journal2005;26(23):2524-8. [MEDLINE: 16107485]RoffiM , MoliternoDJ , MeierB , PowersER , GrinesCL , DiBattistePM , et al.Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation2002;105(23):2730-6. [MEDLINE: 12057986]TopolEJ , MoliternoDJ , HerrmannHC , PowersER , GrinesCL , CohenDJ , et al.Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New England Journal of Medicine2001;344(25):1888-94. [MEDLINE: 11419425]">TARGET 2000</a> reported abciximab plus aspirin may decrease fatal or nonfatal MI compared to tirofiban plus aspirin during 6 months follow‐up (<a href="./references#CD008834-fig-0041" title="">Analysis 5.1</a> (1 study, 790 participants): RR 2.33, 95% CI 1.57 to 3.45). Since not all participants experienced MI before treatment allocation, antiplatelet agents were used both for primary and secondary prevention. </p> </section> <section id="CD008834-sec-0102"> <h5 class="title">Death (any cause)</h5> <p><a href="./references#CD008834-bbs2-0100" title="BergerPB , BestPJ , TopolEJ , WhiteJ , DiBattistePM , ChanAW , et al.The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal2005;149(5):869-75. [MEDLINE: 15894970]KalyanasundaramA , BlankenshipJC , BergerP , HerrmannH , McClureR , MoliternoD .Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?). Catheterization &amp; Cardiovascular Interventions2007;69(5):623-9. [MEDLINE: 17192960]MoliternoDJ , TopolEJ .A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. American Heart Journal2000;140(5):722-6. [MEDLINE: 11054616]MoliternoDJ , YakubovSJ , DiBattistePM , HerrmannHC , StoneGW , MacayaC , et al.Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet2002;360(9330):355-60. [MEDLINE: 12241774]MukherjeeD , TopolEJ , BertrandME , KristensenSD , HerrmannHC , NeumannFJ , et al.Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. European Heart Journal2005;26(23):2524-8. [MEDLINE: 16107485]RoffiM , MoliternoDJ , MeierB , PowersER , GrinesCL , DiBattistePM , et al.Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation2002;105(23):2730-6. [MEDLINE: 12057986]TopolEJ , MoliternoDJ , HerrmannHC , PowersER , GrinesCL , CohenDJ , et al.Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New England Journal of Medicine2001;344(25):1888-94. [MEDLINE: 11419425]">TARGET 2000</a> reported no difference between abciximab plus aspirin compared to tirofiban plus aspirin on death (any cause) during 12 months follow‐up (<a href="./references#CD008834-fig-0042" title="">Analysis 5.2</a> (1 study, 790 participants): RR 1.73, 95% CI 0.92 to 3.23). </p> </section> </section> <section id="CD008834-sec-0103"> <h4 class="title">Defibrotide versus dypiridamole</h4> <p><a href="./references#CD008834-bbs2-0033" title="BonominiV , VangelistaA , StefoniS , ScolariMP , FrascàGM , RaimondiC .Use of defibrotide in renal transplantation in man. Haemostasis1986;16 Suppl 1:48-50. [MEDLINE: 3519383]FrascàGM , VangelistaA , RaimondiC , BonominiV .Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (defibrotide): a controlled study. Life Support Systems1986;4(3):231-7. [MEDLINE: 3537545]">Frascà 1986</a> compared defibrotide with dypiridamole and provided data for 80 people that received a kidney transplant during 4 years of follow‐up. Data were not available for fatal or nonfatal MI, fatal or nonfatal stroke, haemorrhagic stroke, major bleeding, minor bleeding, kidney failure, doubling of SCr, transplant rejection, CrCl, proteinuria, dialysis access failure, early access thrombosis, loss of primary unassisted patency, failure to attain suitability for dialysis, need for intervention to attain patency or assist maturation, all‐cause hospitalisation, cardiovascular hospitalisation, and treatment withdrawal. </p> <section id="CD008834-sec-0104"> <h5 class="title">Death (any cause)</h5> <p><a href="./references#CD008834-bbs2-0033" title="BonominiV , VangelistaA , StefoniS , ScolariMP , FrascàGM , RaimondiC .Use of defibrotide in renal transplantation in man. Haemostasis1986;16 Suppl 1:48-50. [MEDLINE: 3519383]FrascàGM , VangelistaA , RaimondiC , BonominiV .Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (defibrotide): a controlled study. Life Support Systems1986;4(3):231-7. [MEDLINE: 3537545]">Frascà 1986</a> reported no difference between defibrotide compared to dypiridamole on death (any cause) (<a href="./references#CD008834-fig-0043" title="">Analysis 6.1</a> (1 study, 76 participants): RR 0.30, 95% CI 0.01 to 7.16). </p> </section> <section id="CD008834-sec-0105"> <h5 class="title">Cardiovascular death</h5> <p><a href="./references#CD008834-bbs2-0033" title="BonominiV , VangelistaA , StefoniS , ScolariMP , FrascàGM , RaimondiC .Use of defibrotide in renal transplantation in man. Haemostasis1986;16 Suppl 1:48-50. [MEDLINE: 3519383]FrascàGM , VangelistaA , RaimondiC , BonominiV .Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (defibrotide): a controlled study. Life Support Systems1986;4(3):231-7. [MEDLINE: 3537545]">Frascà 1986</a> reported no difference between defibrotide compared to dypiridamole on cardiovascular death (<a href="./references#CD008834-fig-0044" title="">Analysis 6.2</a> (1 study, 76 participants): RR 0.30, 95% CI 0.01 to 7.16). </p> </section> <section id="CD008834-sec-0106"> <h5 class="title">Fatal bleeding</h5> <p><a href="./references#CD008834-bbs2-0033" title="BonominiV , VangelistaA , StefoniS , ScolariMP , FrascàGM , RaimondiC .Use of defibrotide in renal transplantation in man. Haemostasis1986;16 Suppl 1:48-50. [MEDLINE: 3519383]FrascàGM , VangelistaA , RaimondiC , BonominiV .Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (defibrotide): a controlled study. Life Support Systems1986;4(3):231-7. [MEDLINE: 3537545]">Frascà 1986</a> reported no fatal bleeding events with either defibrotide or dypiridamole (<a href="./references#CD008834-fig-0045" title="">Analysis 6.3</a> (1 study, 76 participants)). </p> </section> <section id="CD008834-sec-0107"> <h5 class="title">Kidney transplant graft loss</h5> <p><a href="./references#CD008834-bbs2-0033" title="BonominiV , VangelistaA , StefoniS , ScolariMP , FrascàGM , RaimondiC .Use of defibrotide in renal transplantation in man. Haemostasis1986;16 Suppl 1:48-50. [MEDLINE: 3519383]FrascàGM , VangelistaA , RaimondiC , BonominiV .Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (defibrotide): a controlled study. Life Support Systems1986;4(3):231-7. [MEDLINE: 3537545]">Frascà 1986</a> reported no difference between defibrotide compared to dypiridamole on kidney transplant graft loss (<a href="./references#CD008834-fig-0046" title="">Analysis 6.4</a> (1 study, 76 participants): RR 0.13, 95% CI 0.02 to 1.00). </p> </section> </section> <section id="CD008834-sec-0108"> <h4 class="title">Cilostazol versus sarpogrelate</h4> <p><a href="./references#CD008834-bbs2-0047" title="HidakaS , KobayashiS , IwagamiM , IsshikiR , TsutsumiD , MochidaY , et al.Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease. Renal Failure2013;35(1):43-8. [MEDLINE: 23110683]">Hidaka 2013</a> compared cilostazol with sarpogrelate and provided data for 35 people undergoing HD during 24 weeks follow‐up. Data were not available for fatal or nonfatal MI, fatal or nonfatal stroke, death (any cause), haemorrhagic stroke, cardiovascular death, fatal bleeding, minor bleeding, kidney failure, doubling of SCr, kidney transplant graft loss, transplant rejection, CrCl, proteinuria, dialysis access failure, early access thrombosis, loss of primary unassisted patency, failure to attain suitability for dialysis, need for intervention to attain patency or assist maturation, all‐cause hospitalisation, cardiovascular hospitalisation and treatment withdrawal. </p> <section id="CD008834-sec-0109"> <h5 class="title">Major bleeding</h5> <p><a href="./references#CD008834-bbs2-0047" title="HidakaS , KobayashiS , IwagamiM , IsshikiR , TsutsumiD , MochidaY , et al.Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease. Renal Failure2013;35(1):43-8. [MEDLINE: 23110683]">Hidaka 2013</a> reported no major bleeding events with either cilostazol or sarpogrelate (<a href="./references#CD008834-fig-0047" title="">Analysis 7.1</a> (1 study, 35 participants)). </p> </section> </section> <section id="CD008834-sec-0110"> <h4 class="title">Beraprost versus cilostazol or sarpogrelate</h4> <p><a href="./references#CD008834-bbs2-0052" title="OhtakeT , SatoM , NakazawaR , KondohM , KobayashiS .Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study [abstract no: Su528]. NDT Plus2010;3(Suppl 3):iii487. [EMBASE: 70484748]OhtakeT , SatoM , NakazawaR , KondohM , MiyajiT , MoriyaH , et al.Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2014;18(1):1-8. [MEDLINE: 24499078]">J‐PADD 2014</a>, which compared beraprost with cilostazol or sarpogrelate, provided data for 72 people undergoing HD during 24 weeks follow‐up. Data were not available for haemorrhagic stroke, major bleeding, minor bleeding, kidney failure, doubling of SCr, kidney transplant graft loss, transplant rejection, CrCl, proteinuria, dialysis access failure, early access thrombosis, loss of primary unassisted patency, failure to attain suitability for dialysis, need for intervention to attain patency or assist maturation, all‐cause hospitalisation, cardiovascular hospitalisation, and treatment withdrawal. </p> <section id="CD008834-sec-0111"> <h5 class="title">Fatal or nonfatal myocardial infarction</h5> <p><a href="./references#CD008834-bbs2-0052" title="OhtakeT , SatoM , NakazawaR , KondohM , KobayashiS .Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study [abstract no: Su528]. NDT Plus2010;3(Suppl 3):iii487. [EMBASE: 70484748]OhtakeT , SatoM , NakazawaR , KondohM , MiyajiT , MoriyaH , et al.Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2014;18(1):1-8. [MEDLINE: 24499078]">J‐PADD 2014</a> reported no fatal or nonfatal MI events with beraprost, cilostazol or sarpogrelate (<a href="./references#CD008834-fig-0048" title="">Analysis 8.1</a> (1 study, 68 participants)). The treatment was performed for secondary prevention of MI. </p> </section> <section id="CD008834-sec-0112"> <h5 class="title">Fatal or nonfatal stroke</h5> <p><a href="./references#CD008834-bbs2-0052" title="OhtakeT , SatoM , NakazawaR , KondohM , KobayashiS .Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study [abstract no: Su528]. NDT Plus2010;3(Suppl 3):iii487. [EMBASE: 70484748]OhtakeT , SatoM , NakazawaR , KondohM , MiyajiT , MoriyaH , et al.Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2014;18(1):1-8. [MEDLINE: 24499078]">J‐PADD 2014</a> reported no difference between beraprost compared to cilostazol or sarpogrelate on fatal or nonfatal stroke (<a href="./references#CD008834-fig-0049" title="">Analysis 8.2</a> (1 study, 68 participants): RR 0.19, 95% CI 0.01 to 3.79). The treatment was performed for secondary prevention of stroke. </p> </section> <section id="CD008834-sec-0113"> <h5 class="title">Death (any cause)</h5> <p><a href="./references#CD008834-bbs2-0052" title="OhtakeT , SatoM , NakazawaR , KondohM , KobayashiS .Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study [abstract no: Su528]. NDT Plus2010;3(Suppl 3):iii487. [EMBASE: 70484748]OhtakeT , SatoM , NakazawaR , KondohM , MiyajiT , MoriyaH , et al.Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2014;18(1):1-8. [MEDLINE: 24499078]">J‐PADD 2014</a> reported no difference between beraprost compared to cilostazol or sarpogrelate on death (any cause) (<a href="./references#CD008834-fig-0050" title="">Analysis 8.3</a> (1 study, 68 participants): RR 0.94, 95% CI 0.06 to 14.47). </p> </section> <section id="CD008834-sec-0114"> <h5 class="title">Cardiovascular death</h5> <p><a href="./references#CD008834-bbs2-0052" title="OhtakeT , SatoM , NakazawaR , KondohM , KobayashiS .Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study [abstract no: Su528]. NDT Plus2010;3(Suppl 3):iii487. [EMBASE: 70484748]OhtakeT , SatoM , NakazawaR , KondohM , MiyajiT , MoriyaH , et al.Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2014;18(1):1-8. [MEDLINE: 24499078]">J‐PADD 2014</a> reported no difference between beraprost compared to cilostazol or sarpogrelate on cardiovascular death (<a href="./references#CD008834-fig-0051" title="">Analysis 8.4</a> (1 study, 68 participants): RR 0.94, 95% CI 0.06 to 14.47). </p> </section> <section id="CD008834-sec-0115"> <h5 class="title">Fatal bleeding</h5> <p><a href="./references#CD008834-bbs2-0052" title="OhtakeT , SatoM , NakazawaR , KondohM , KobayashiS .Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study [abstract no: Su528]. NDT Plus2010;3(Suppl 3):iii487. [EMBASE: 70484748]OhtakeT , SatoM , NakazawaR , KondohM , MiyajiT , MoriyaH , et al.Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic Apheresis &amp; Dialysis2014;18(1):1-8. [MEDLINE: 24499078]">J‐PADD 2014</a> reported no fatal bleeding events with beraprost, cilostazol or sarpogrelate (<a href="./references#CD008834-fig-0052" title="">Analysis 8.5</a> (1 study, 68 participants)). </p> </section> </section> <section id="CD008834-sec-0116"> <h4 class="title">Sensitivity and subgroups analyses</h4> <section id="CD008834-sec-0117"> <h5 class="title">Antiplatelet agents versus placebo</h5> <section id="CD008834-sec-0118"> <h6 class="title">Fatal or nonfatal myocardial infarction</h6> <p>Since not all participants experienced MI before treatment allocation, antiplatelet agents could be used for primary and secondary prevention. Five studies (<a href="./references#CD008834-bbs2-0016" title="CreekR .Ticlopidine. Patency of haemodialysis access sites. Guildford Sanofi Winthrop. Internal report1990. ">Creek 1990</a>; <a href="./references#CD008834-bbs2-0025" title="EllS , MihindukulasuriyaJC , O'BrienJR , PolakA , VernhamG .Ticlopidine in the prevention of blockage of fistulae and shunts [abstract no: 332]. Haemostasis1982;12:180. ">Ell 1982</a>; <a href="./references#CD008834-bbs2-0056" title="ChangJJ , ConcatoJ , WellsCK , CrowleyST .Impact of adherence to clinical guidelines on mortality in hemodialysis patients [abstract no: SA-PO384]. Journal of the American Society of Nephrology2004;15(Oct):386A. [CENTRAL: CN-00583156] KaufmanJS , O'ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology2003;14(9):2313-21. [MEDLINE: 12937308]KaufmanJS , O’ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract no: A1495]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):291A. ">Kaufman 2003</a>; <a href="./references#CD008834-bbs2-0096" title="MiletiM , De PetriG , BacchiM , OgliariV , PecchiniF , BufanoG , et al.A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients. Journal of Nephrology1995;8(2):167-72. [EMBASE: 25209311]">STOP 1995</a>; <a href="./references#CD008834-bbs2-0106" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al.First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473-84. [MEDLINE: 15754269]BaigentC , UK-HARP Steering Committee.Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-PO851]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. [CENTRAL: CN-00444305] ">UK‐HARP‐I 2005</a>) reported insufficient information to assess if the intervention was performed either for primary or secondary prevention. These studies were not included in the subgroup analyses for primary/secondary prevention against MI. Four studies (<a href="./references#CD008834-bbs2-0019" title="DemberL , AllonM , DelmezJ , DixonB , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00550593] DemberLM , BeckGJ , AllonM , DelmezJA , DixonBS , GreenbergA , et al.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008;299(18):2164-71. [MEDLINE: 18477783]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials2005;2(5):413-22. [MEDLINE: 16317810]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):229A. [CENTRAL: CN-00445067] ">Dember 2005</a>; <a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a>; <a href="./references#CD008834-bbs2-0029" title="Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA1992;268(10):1292-300. [MEDLINE: 1507375]">ETDRS 1992</a>; <a href="./references#CD008834-bbs2-0048" title="HanssonL , ZanchettiA , CarruthersSG , DahlöfB , ElmfeldtD , JuliusS , et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998;351(9118):1755-62. [MEDLINE: 9635947]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Pressure1997;6(5):313-7. [MEDLINE: 9360003]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Pressure1994;3(5):322-7. [MEDLINE: 7866597]HanssonL .The Hypertension Optimal Treatment study and the importance of lowering blood pressure. Journal of Hypertension - Supplement1999;17(1):S9-13. [MEDLINE: 10340838]JardineM , NinomiyaT , CassA , TurnbullF , GallagherM , ZoungasS , et al.Aspirin benefit increases as eGFR declines: results from a randomised controlled trial in a hypertensive population [abstract no: 086]. Nephrology2010;15(Suppl 4):49. [EMBASE: 70467090]JardineMJ , NinomiyaT , PerkovicV , CassA , TurnbullF , GallagherMP , et al.Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology2010;56(12):956-65. [MEDLINE: 20828648]JonesDW , MillerME , WoffordMR , Anderson DC Jr, CameronME , WilloughbyDL , et al.The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. American Journal of Hypertension1999;12(12 Pt 1-2):1175-80. [MEDLINE: 10619579]JonssonB , HanssonL , StalhammarNO .Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Journal of Internal Medicine2003;253(4):472-80. [MEDLINE: 12653877]KjeldsenSE , HednerT , JamersonK , JuliusS , HaleyWE , ZabalgoitiaM , et al.Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects. Hypertension1998;31(4):1014-20. [MEDLINE: 9535429]KjeldsenSE , KollochRE , LeonettiG , MallionJM , ZanchettiA , ElmfeldtD , et al.Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. Journal of Hypertension2000;18(5):629-42. [MEDLINE: 10826567]KollochRE , RahnKH .The Hypertension Optimal Treatment (HOT) study: results of 12-month treatment related to age [Die 'Hyperyension Optimal Treatment' (HOT)-Studie: Behandlungsergebnisse nach Zwolfmonatiger Therapie in Abhangigkeit vom Alter]. Deutsche Medizinische Wochenschrift1998;123(1-2):1-5. [MEDLINE: 9465848]LeonettiG , ZanchettiA .Principal results of hypertension optimal treatment (HOT) study and their clinical impact. HOT cooperative group. Clinical Hemorheology &amp; Microcirculation1999;21(3-4):217-24. [MEDLINE: 10711746]LithellH , BerglundL .Validation of an oscillometric blood pressure measuring device: a substudy of the HOT Study. Hypertension Optimal Treatment. Blood Pressure1998;7(3):149-52. [MEDLINE: 9758084]ManciaG , OmboniS , ParatiG , ClementDL , HaleyWE , RahmanSN , et al.Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(10):1755-63. [MEDLINE: 11593094]RuilopeLM , SalvettiA , JamersonK , HanssonL , WarnoldI , WedelH , et al.Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology2001;12(2):218-25. [MEDLINE: 11158211]Struijker-BoudierH , SafarM , vanBortelL .Effects of individual risk factors on the incidence of cardiovascular event in the treated hypertensive patients of the Hypertension Optimal Treatment Study. Journal of Hypertension2001;19(11):2105-6. [MEDLINE: 11677378]The Hypertension Optimal Treatment Study (the HOT Study). Blood Pressure1993;2(1):62-8. [MEDLINE: 8193735]WaeberB , LeonettiG , KollochR , McInnesGT .Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension1999;17(7):1041-5. [MEDLINE: 10419079]ZanchettiA , HanssonL , DahlofB , ElmfeldtD , KjeldsenS , KollochR , et al.Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. Journal of Hypertension2001;19(6):1149-59. [MEDLINE: 11403365]ZanchettiA , HanssonL , MenardJ , LeonettiG , RahnKH , WarnoldI , et al.Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(4):819-25. [MEDLINE: 11330886]">HOT 1993</a>) prescribed antiplatelet agents both for primary and secondary prevention. Since data were not reported separately for patients with or without previous MI, it was not possible to include these studies in the subgroup analyses for primary/secondary prevention against MI. </p> <section id="CD008834-sec-0119"> <p><b>Subgroup analysis for primary prevention against myocardial infarction ‐ stratified by stage of CKD</b></p> <p>There were no studies that assessed the intervention for primary prevention against MI, and subgroup analyses were not performed. </p> </section> <section id="CD008834-sec-0120"> <p><b>Subgroup analysis for secondary prevention against myocardial infarction ‐ stratified by stage of CKD</b></p> <p>Antiplatelet agents may have little or no effect on MI for secondary prevention in CKD (<a href="./references#CD008834-fig-0053" title="">Analysis 9.1</a> (8 studies, 7270 participants): RR 0.93, 95% CI 0.81 to 1.06: I² = 0%; low certainty evidence). The evidence was downgraded for risk of bias and imprecision. However, a small number of studies contributed data to predialysis and no data were available for dialysis and transplant, meaning that the analysis may not be able to detect subgroup differences within different stages of CKD. </p> </section> <section id="CD008834-sec-0121"> <p><b>Sensitivity analysis for fatal or nonfatal myocardial infarction ‐ stratified by adequate allocation concealment</b></p> <p>Considering only studies with adequate allocation concealment, antiplatelet agents may reduce the risk of fatal or nonfatal MI in CKD (<a href="./references#CD008834-fig-0054" title="">Analysis 10.1</a>.1 (8 studies, 10,459 participants): RR 0.80, 95% CI 0.65 to 0.98; I² = 31%; low certainty evidence). The evidence was downgraded for risk of bias and inconsistency. There was moderate heterogeneity. </p> </section> <section id="CD008834-sec-0122"> <p><b>Sensitivity analysis for fatal or nonfatal myocardial infarction ‐ stratified by a low risk of attrition bias</b></p> <p>Considering only studies with low risk of attrition, antiplatelet agents probably reduce the risk of fatal or nonfatal MI in CKD (<a href="./references#CD008834-fig-0058" title="">Analysis 11.1</a>.1 (11 studies, 9387 participants): RR 0.75, 95% CI 0.62 to 0.90; I² = 0%; moderate certainty evidence). The evidence was downgraded for risk of bias. </p> </section> </section> <section id="CD008834-sec-0123"> <h6 class="title">Fatal or nonfatal stroke</h6> <p>Five studies (<a href="./references#CD008834-bbs2-0016" title="CreekR .Ticlopidine. Patency of haemodialysis access sites. Guildford Sanofi Winthrop. Internal report1990. ">Creek 1990</a>; <a href="./references#CD008834-bbs2-0025" title="EllS , MihindukulasuriyaJC , O'BrienJR , PolakA , VernhamG .Ticlopidine in the prevention of blockage of fistulae and shunts [abstract no: 332]. Haemostasis1982;12:180. ">Ell 1982</a>; <a href="./references#CD008834-bbs2-0056" title="ChangJJ , ConcatoJ , WellsCK , CrowleyST .Impact of adherence to clinical guidelines on mortality in hemodialysis patients [abstract no: SA-PO384]. Journal of the American Society of Nephrology2004;15(Oct):386A. [CENTRAL: CN-00583156] KaufmanJS , O'ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology2003;14(9):2313-21. [MEDLINE: 12937308]KaufmanJS , O’ConnorTZ , ZhangJH , CroninRE , FioreLD , GanzMB , et al.Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract no: A1495]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):291A. ">Kaufman 2003</a>; <a href="./references#CD008834-bbs2-0096" title="MiletiM , De PetriG , BacchiM , OgliariV , PecchiniF , BufanoG , et al.A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients. Journal of Nephrology1995;8(2):167-72. [EMBASE: 25209311]">STOP 1995</a>; <a href="./references#CD008834-bbs2-0106" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al.First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473-84. [MEDLINE: 15754269]BaigentC , UK-HARP Steering Committee.Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-PO851]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. [CENTRAL: CN-00444305] ">UK‐HARP‐I 2005</a>) reported insufficient information to assess if the intervention was performed either for primary or secondary prevention. These studies were not included in the subgroup analyses for primary/secondary prevention against stroke. Four studies (<a href="./references#CD008834-bbs2-0019" title="DemberL , AllonM , DelmezJ , DixonB , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00550593] DemberLM , BeckGJ , AllonM , DelmezJA , DixonBS , GreenbergA , et al.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008;299(18):2164-71. [MEDLINE: 18477783]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials2005;2(5):413-22. [MEDLINE: 16317810]DemberLM , KaufmanJS , BeckGJ , DixonBS , GassmanJJ , GreeneT , et al.Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):229A. [CENTRAL: CN-00445067] ">Dember 2005</a>; <a href="./references#CD008834-bbs2-0020" title="AllonM , ZhangL , MayaID , BrayMS , FernandezJR , Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases2012;59(5):682-8. [MEDLINE: 22281051]DixonB , BeckG , MeyersC , KusekJ , FeldmanH , DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048] DixonBS , AllonM , DelmezJ , DemberL , GreenbergA , HimmelfarbJ , et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology2003;14(Nov):506A. [CENTRAL: CN-00583294] DixonBS , BeckGJ , DemberLM , DepnerTA , GassmanJJ , GreeneT , et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials2005;2(5):400-12. [MEDLINE: 16317809]DixonBS , BeckGJ , DemberLM , VazquezMA , GreenbergA , DelmezJA , et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology2011;22(4):773-81. [MEDLINE: 21415156]DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Dialysis Access Consortium (DAC) trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract no: F-PO841]. Journal of the American Society of Nephrology2002;10(Abstract Issue):232A. [CENTRAL: CN-00677737] DixonBS , BeckGJ , VazquezMA , GreenbergA , DelmezJA , AllonM , et al.Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal of Medicine2009;360(21):2191-201. [MEDLINE: 19458364]FarberA , HuB , DemberL , BeckG , DixonB , KusekJ .Patency of forearm and upper arm hemodialysis arteriovenous grafts: does configuration or location matter? [abstract]. Journal of Vascular Surgery2013;57(5 Suppl 1):31-2S. [EMBASE: 71055757]FarberA , TanTW , HuB , DemberLM , BeckGJ , DixonBS , et al.The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery2015;62(5):1258-64. [MEDLINE: 26254823]NeeR , ParkerAL , LittleDJ , YuanCM , HimmelfarbJ , LoweSR , et al.Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Clinical Nephrology2014;81(1):38-51. [MEDLINE: 24161074]">Dixon 2005</a>; <a href="./references#CD008834-bbs2-0029" title="Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA1992;268(10):1292-300. [MEDLINE: 1507375]">ETDRS 1992</a>; <a href="./references#CD008834-bbs2-0048" title="HanssonL , ZanchettiA , CarruthersSG , DahlöfB , ElmfeldtD , JuliusS , et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998;351(9118):1755-62. [MEDLINE: 9635947]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Pressure1997;6(5):313-7. [MEDLINE: 9360003]HanssonL , ZanchettiA .The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Pressure1994;3(5):322-7. [MEDLINE: 7866597]HanssonL .The Hypertension Optimal Treatment study and the importance of lowering blood pressure. Journal of Hypertension - Supplement1999;17(1):S9-13. [MEDLINE: 10340838]JardineM , NinomiyaT , CassA , TurnbullF , GallagherM , ZoungasS , et al.Aspirin benefit increases as eGFR declines: results from a randomised controlled trial in a hypertensive population [abstract no: 086]. Nephrology2010;15(Suppl 4):49. [EMBASE: 70467090]JardineMJ , NinomiyaT , PerkovicV , CassA , TurnbullF , GallagherMP , et al.Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology2010;56(12):956-65. [MEDLINE: 20828648]JonesDW , MillerME , WoffordMR , Anderson DC Jr, CameronME , WilloughbyDL , et al.The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. American Journal of Hypertension1999;12(12 Pt 1-2):1175-80. [MEDLINE: 10619579]JonssonB , HanssonL , StalhammarNO .Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Journal of Internal Medicine2003;253(4):472-80. [MEDLINE: 12653877]KjeldsenSE , HednerT , JamersonK , JuliusS , HaleyWE , ZabalgoitiaM , et al.Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects. Hypertension1998;31(4):1014-20. [MEDLINE: 9535429]KjeldsenSE , KollochRE , LeonettiG , MallionJM , ZanchettiA , ElmfeldtD , et al.Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. Journal of Hypertension2000;18(5):629-42. [MEDLINE: 10826567]KollochRE , RahnKH .The Hypertension Optimal Treatment (HOT) study: results of 12-month treatment related to age [Die 'Hyperyension Optimal Treatment' (HOT)-Studie: Behandlungsergebnisse nach Zwolfmonatiger Therapie in Abhangigkeit vom Alter]. Deutsche Medizinische Wochenschrift1998;123(1-2):1-5. [MEDLINE: 9465848]LeonettiG , ZanchettiA .Principal results of hypertension optimal treatment (HOT) study and their clinical impact. HOT cooperative group. Clinical Hemorheology &amp; Microcirculation1999;21(3-4):217-24. [MEDLINE: 10711746]LithellH , BerglundL .Validation of an oscillometric blood pressure measuring device: a substudy of the HOT Study. Hypertension Optimal Treatment. Blood Pressure1998;7(3):149-52. [MEDLINE: 9758084]ManciaG , OmboniS , ParatiG , ClementDL , HaleyWE , RahmanSN , et al.Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(10):1755-63. [MEDLINE: 11593094]RuilopeLM , SalvettiA , JamersonK , HanssonL , WarnoldI , WedelH , et al.Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology2001;12(2):218-25. [MEDLINE: 11158211]Struijker-BoudierH , SafarM , vanBortelL .Effects of individual risk factors on the incidence of cardiovascular event in the treated hypertensive patients of the Hypertension Optimal Treatment Study. Journal of Hypertension2001;19(11):2105-6. [MEDLINE: 11677378]The Hypertension Optimal Treatment Study (the HOT Study). Blood Pressure1993;2(1):62-8. [MEDLINE: 8193735]WaeberB , LeonettiG , KollochR , McInnesGT .Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. Journal of Hypertension1999;17(7):1041-5. [MEDLINE: 10419079]ZanchettiA , HanssonL , DahlofB , ElmfeldtD , KjeldsenS , KollochR , et al.Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. Journal of Hypertension2001;19(6):1149-59. [MEDLINE: 11403365]ZanchettiA , HanssonL , MenardJ , LeonettiG , RahnKH , WarnoldI , et al.Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study. Journal of Hypertension2001;19(4):819-25. [MEDLINE: 11330886]">HOT 1993</a>) prescribed antiplatelet agents both for primary and secondary prevention. Since data were not reported separately for patients with or without previous stroke, it was not possible to include these studies in the subgroup analyses for primary/secondary prevention against stroke. </p> <section id="CD008834-sec-0124"> <p><b>Subgroup analysis for stroke ‐ stratified by stage of CKD</b></p> <p>It is uncertain whether antiplatelet agents made any difference in stroke for secondary prevention in CKD (<a href="./references#CD008834-fig-0062" title="">Analysis 12.1</a> (11 studies, 9544 participants): RR 1.00, 95% CI 0.58 to 1.72: I² = 43%; very low certainty evidence). The evidence was downgraded for risk of bias, inconsistency, and imprecision. The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.63), suggesting that different stages of CKD do not modify the effect of antiplatelet agents on the risk of stroke.<br/>  </p> </section> <section id="CD008834-sec-0125"> <p><b>Subgroup analysis for stroke ‐ stratified by diabetes</b></p> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.59), suggesting that diabetes does not modify the effect of antiplatelet agents on the risk of stroke (<a href="./references#CD008834-fig-0063" title="">Analysis 12.2</a> (6 studies, 4368 participants): RR 1.49, 95% CI 0.68 to 3.25; I² = 40%; very low certainty evidence). The evidence was downgraded for risk of bias, inconsistency and imprecision.<br/>The pooled effect estimate for studies with &lt; 50% of diabetic patients favoured antiplatelet agents (<a href="./references#CD008834-fig-0063" title="">Analysis 12.2</a>.1 (3 studies, 1525 participants): RR 0.96, 95% CI 0.15 to 6.03; I² = 22%), while the pooled effects for studies where at least 50% of participants had diabetes (<a href="./references#CD008834-fig-0063" title="">Analysis 12.2</a>.2 (3 studies, 2843 participants): RR 1.70, 95% CI 0.64 to 4.49; I² = 64%) and favoured control. </p> </section> <section id="CD008834-sec-0126"> <p><b>Subgroup analysis for stroke ‐ stratified by males</b></p> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.34), suggesting that gender does not modify the effect of antiplatelet agents on the risk of stroke (<a href="./references#CD008834-fig-0064" title="">Analysis 12.3</a> (7 studies, 7987 participants): RR 1.19, 95% CI 0.68 to 2.07; I² = 43%; very low certainty evidence). The evidence was downgraded for risk of bias, inconsistency and imprecision.<br/>However, a different number of studies and participants contributed data to the studies with less than 50% of males subgroup compared to the studies with at least 50% of males subgroup, meaning that the analysis may not be able to detect subgroup differences. </p> </section> <section id="CD008834-sec-0127"> <p><b>Subgroup analysis for stroke ‐ stratified by duration of intervention</b></p> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.15), suggesting that duration of intervention does not modify the effect of antiplatelet agents on the risk of stroke (<a href="./references#CD008834-fig-0065" title="">Analysis 12.4</a> (11 studies, 9544 participants): RR 1.00, 95% CI 0.58 to 1.72; I² = 43%; very low certainty evidence). The evidence was downgraded for risk of bias, inconsistency and imprecision.<br/>However, a smaller number of studies and/or participants contributed data to the duration of intervention lower than 6 months and between 6 and 12 months subgroups than to the duration of the treatment greater than 12 months subgroup, meaning that the analysis may not be able to detect subgroup differences. </p> </section> </section> <section id="CD008834-sec-0128"> <h6 class="title">Death from any cause</h6> <section id="CD008834-sec-0129"> <p><b>Sensitivity analysis for death (any cause) ‐ stratified by adequate allocation concealment</b></p> <p>Considering only studies with adequate allocation concealment, it is uncertain whether antiplatelet agents made any difference to death (any cause) in CKD (<a href="./references#CD008834-fig-0055" title="">Analysis 10.2</a> (10 studies, 11,443 participants): RR 1.00, 95% CI 0.83 to 1.22; I² = 37%; very low certainty evidence). The evidence was downgraded for risk of bias, inconsistency and imprecision. The heterogeneity was moderate. </p> </section> <section id="CD008834-sec-0130"> <p><b>Sensitivity analysis for death (any cause) ‐ stratified by a low risk of attrition bias</b></p> <p>Considering only studies with low risk of attrition, it is uncertain whether antiplatelet agents made any difference to death (any cause) in CKD and HD (<a href="./references#CD008834-fig-0059" title="">Analysis 11.2</a> (19 studies, 10,966 participants): RR 0.99, 95% CI 0.82 to 1.20; I² = 30%; very low certainty evidence). The evidence was downgraded for risk of bias, inconsistency and imprecision. The heterogeneity was moderate. </p> </section> </section> <section id="CD008834-sec-0131"> <h6 class="title">Cardiovascular death</h6> <section id="CD008834-sec-0132"> <p><b>Sensitivity analysis for cardiovascular death ‐ stratified by adequate allocation concealment</b></p> <p>Considering only studies with adequate allocation concealment, it is uncertain whether antiplatelet agents made any difference to cardiovascular death mortality in CKD (<a href="./references#CD008834-fig-0056" title="">Analysis 10.3</a> (2 studies, 5628 participants): RR 1.08, 95% CI 0.48 to 2.44; I² = 85%; very low certainty evidence). The evidence was downgraded for risk of bias, inconsistency and imprecision. There was substantial heterogeneity. </p> </section> <section id="CD008834-sec-0133"> <p><b>Sensitivity analysis for cardiovascular death ‐ stratified by a low risk of attrition bias</b></p> <p>Considering only studies with low risk of attrition, it is uncertain whether antiplatelet agents made any difference to cardiovascular death mortality in CKD, HD and transplant recipients (<a href="./references#CD008834-fig-0060" title="">Analysis 11.3</a> (11 studies, 6872 participants): RR 0.94, 95% CI 0.60 to 1.47; I² = 66%; very low certainty evidence). The evidence was downgraded for risk of bias, inconsistency and imprecision. There was moderate heterogeneity. </p> </section> </section> <section id="CD008834-sec-0134"> <h6 class="title">Major bleeding</h6> <section id="CD008834-sec-0135"> <p><b>Sensitivity analysis for major bleeding ‐ stratified by adequate allocation concealment</b></p> <p>Considering only studies with adequate allocation concealment, antiplatelet agents may increase major bleeding in CKD (<a href="./references#CD008834-fig-0057" title="">Analysis 10.4</a> (9 studies, 10,360 participants): RR 1.53, 95% CI 1.07 to 2.20; I² = 52%; low certainty evidence). The evidence was downgraded for risk of bias and inconsistency. There was moderate heterogeneity. </p> </section> <section id="CD008834-sec-0136"> <p><b>Sensitivity analysis for major bleeding ‐ stratified by a low risk of attrition bias</b></p> <p>Considering only studies with low risk of attrition, antiplatelet agents probably increased major bleeding in CKD and HD (<a href="./references#CD008834-fig-0061" title="">Analysis 11.4</a> (17 studies, 9549 participants): RR 1.62, 95% CI 1.19 to 2.20; I² = 15%; moderate certainty evidence). The evidence was downgraded for risk of bias. There was low heterogeneity. </p> </section> </section> <section id="CD008834-sec-0137"> <h6 class="title">Minor bleeding</h6> <section id="CD008834-sec-0138"> <p><b>Subgroup analysis for minor bleeding ‐ stratified by stage of CKD</b></p> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.16), suggesting that different stages of CKD do not modify the effect of antiplatelet agents on the risk of minor bleeding (<a href="./references#CD008834-fig-0066" title="">Analysis 13.1</a>).<br/>However, a smaller number of studies and participants contributed data to both predialysis, dialysis and transplant and HD subgroups than to the CKD subgroup, meaning that the analysis may not be able to detect subgroup differences. </p> </section> <section id="CD008834-sec-0139"> <p><b>Subgroup analysis for minor bleeding ‐ stratified by diabetes</b></p> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.08), suggesting that diabetes does not modify the effect of antiplatelet agents on the risk of minor bleeding (<a href="./references#CD008834-fig-0067" title="">Analysis 13.2</a>). </p> </section> <section id="CD008834-sec-0140"> <p><b>Subgroup analysis for minor bleeding ‐ stratified by sex</b></p> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.42), suggesting that gender does not modify the effect of antiplatelet agents on the risk of minor bleeding (<a href="./references#CD008834-fig-0068" title="">Analysis 13.3</a>). </p> </section> <section id="CD008834-sec-0141"> <p><b>Subgroup analysis for minor bleeding ‐ stratified by duration of intervention</b></p> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.74), suggesting that duration of intervention does not modify the effect of antiplatelet agents on the risk of minor bleeding (<a href="./references#CD008834-fig-0069" title="">Analysis 13.4</a>).<br/>However, a smaller number of studies and participants contributed data to the duration of intervention lower than 6 months and greater than 12 months subgroups than to the duration of the treatment between 6 and 12 months subgroup, meaning that the analysis may not be able to detect subgroup differences. </p> </section> </section> <section id="CD008834-sec-0142"> <h6 class="title">Dialysis access failure</h6> <section id="CD008834-sec-0143"> <p><b>Subgroup analysis for dialysis access failure ‐ stratified by stage of CKD</b></p> <p>Subgroup analyses based on the stage of CKD were not possible due to insufficient numbers of studies. </p> </section> <section id="CD008834-sec-0144"> <p><b>Subgroup analysis for dialysis access failure ‐ stratified by diabetes</b></p> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.77), suggesting that diabetes does not modify the effect of antiplatelet agents on dialysis access failure (<a href="./references#CD008834-fig-0070" title="">Analysis 14.1</a>). </p> </section> <section id="CD008834-sec-0145"> <p><b>Subgroup analysis for dialysis access failure ‐ stratified by male</b></p> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.34), suggesting that gender does not modify the effect of antiplatelet agents on dialysis access failure (<a href="./references#CD008834-fig-0071" title="">Analysis 14.2</a>). </p> </section> <section id="CD008834-sec-0146"> <p><b>Subgroup analysis for dialysis access failure ‐ stratified by duration of intervention</b></p> <p>The test for subgroup differences suggests that there is a statistically significant subgroup effect (P = 0.001), meaning that duration of intervention significantly modifies the effect of antiplatelet agents on dialysis access failure (<a href="./references#CD008834-fig-0072" title="">Analysis 14.3</a> (17 studies, 2847 participants): RR 0.62, 95% CI 0.50 to 0.78; I² = 46%; low certainty evidence). The evidence was downgraded for risk of bias and inconsistency. There was moderate heterogeneity.<br/>A sufficient number of studies and participants were not included in each subgroup, so the covariate distribution could be a concern for this subgroup analysis. Both the pooled effect estimate for the duration of the intervention less than 6 months (<a href="./references#CD008834-fig-0072" title="">Analysis 14.3</a>.1 (11 studies, 1705 participants): RR 0.55, 95% CI 0.44 to 0.70; I² = 0%; low certainty evidence), between 6 and 12 months (<a href="./references#CD008834-fig-0072" title="">Analysis 14.3</a>.2 (4 studies, 386 participants): RR 0.59, 95% CI 0.37 to 0.96; I² = 58%; very low certainty evidence) and greater than 12 months (<a href="./references#CD008834-fig-0072" title="">Analysis 14.3</a>.3 (2 studies, 756 participants): RR 0.94, 95% CI 0.79 to 1.11; I² = 0%; very low certainty evidence) favoured antiplatelet agents. There was substantial unexplained heterogeneity between the studies and the validity of the treatment effect estimated for each subgroup was uncertain, as individual study results were inconsistent. </p> </section> </section> <section id="CD008834-sec-0147"> <h6 class="title">Failure to attain access suitability of dialysis</h6> <section id="CD008834-sec-0148"> <p><b>Subgroup analysis for failure to attain access suitability of dialysis ‐ stratified by stage of CKD</b></p> <p>Subgroup analyses based on the stage of CKD were not possible due to insufficient numbers of studies. </p> </section> <section id="CD008834-sec-0149"> <p><b>Subgroup analysis for failure to attain access suitability of dialysis ‐ stratified by diabetes</b></p> <p>Subgroup analyses based on diabetes were not possible due to insufficient numbers of studies. </p> </section> <section id="CD008834-sec-0150"> <p><b>Subgroup analysis for failure to attain access suitability of dialysis ‐ stratified by male</b></p> <p>Subgroup analyses based on the prevalence of males were not possible due to insufficient numbers of studies. </p> </section> <section id="CD008834-sec-0151"> <p><b>Subgroup analysis for failure to attain access suitability of dialysis ‐ stratified by duration of intervention</b></p> <p>The test for subgroup differences indicates that there is no statistically significant subgroup effect (P = 0.75), suggesting that duration of intervention does not modify the effect of antiplatelet agents on the failure to attain access suitability of dialysis (<a href="./references#CD008834-fig-0073" title="">Analysis 15.1</a>).<br/>However, a smaller number of studies and participants contributed data to the duration of intervention greater than 12 months subgroup than to the duration of the treatment less than 6 months subgroup, meaning that the analysis may not be able to detect subgroup differences. </p> </section> </section> </section> <section id="CD008834-sec-0152"> <h5 class="title">Antiplatelet agents versus antiplatelet agents</h5> <p>Sensitivity and subgroup analyses were not possible when comparing one antiplatelet with another antiplatelet due to the insufficient number of available studies. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008834-sec-0153" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008834-sec-0153"></div> <section id="CD008834-sec-0154"> <h3 class="title" id="CD008834-sec-0154">Summary of main results</h3> <p>This updated review indicated that antiplatelet agents (acetylsalicylic acid, adenosine diphosphate receptor inhibitors, adenosine reuptake inhibitors, glycoprotein IIb/IIIa inhibitors, picotamide, or sulphinpyrazone) probably prevents fatal or nonfatal MI in people with CKD. Antiplatelet treatment probably increases major bleeding (including bleeding events that result in hospital admission, transfusion, or disability) and may increase minor bleeding in people with CKD. There is insufficient available evidence to define clearly the role of antiplatelet treatment in primary prevention (preventing cardiovascular events in people without existing cardiovascular disease) in those with CKD. Few studies reported the efficacy of antiplatelet therapies for secondary prevention against MI or stroke in CKD, and sparse or no data were available for dialysis and transplant recipients. </p> <p>Antiplatelet agents started around the time of vascular access surgery may reduce early vascular access thrombosis or patency failure, but there was insufficient evidence to show that antiplatelet therapy improves dialysis access maturation, access suitability for dialysis or reduces the need for intervention to attain patency. Overall, the effect of antiplatelet agents on the prevention of kidney failure in people with CKD, kidney transplant loss, or transplant rejection is uncertain. </p> <p>Direct comparisons of antiplatelet agents are limited to a few studies in which data for the subgroup of participants with CKD, HD and kidney transplant have been recently reported or provided. Currently, there are scant data to recommend that one antiplatelet agent is more efficacious than another in any clinical setting (primary prevention or secondary prevention), particularly for people with acute coronary syndromes or those undergoing percutaneous coronary interventions who frequently have coexistent CKD. </p> </section> <section id="CD008834-sec-0155"> <h3 class="title" id="CD008834-sec-0155">Overall completeness and applicability of evidence</h3> <p>While the analyses included data obtained from a comprehensive search and unpublished data from numerous investigators, particularly for cardiovascular events, the data were incomplete in several areas. Firstly, data for transplant recipients were limited and provided by smaller and older studies, published between 1974 and 1996. A study of aspirin included transplant recipients in addition to individuals with CKD and those requiring dialysis (<a href="./references#CD008834-bbs2-0106" title="BaigentC , LandrayM , LeaperC , AltmannP , ArmitageJ , BaxterA , et al.First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases2005;45(3):473-84. [MEDLINE: 15754269]BaigentC , UK-HARP Steering Committee.Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-PO851]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):437A. [CENTRAL: CN-00444305] ">UK‐HARP‐I 2005</a>) but data for the transplant subgroup (133 participants) were not available and would have provided very few events for relevant clinical outcomes. Outcome data for kidney transplant recipients were restricted generally to transplant function or rejection in two studies, and information about major cardiovascular events was scarce. Further, only <a href="./references#CD008834-bbs2-0033" title="BonominiV , VangelistaA , StefoniS , ScolariMP , FrascàGM , RaimondiC .Use of defibrotide in renal transplantation in man. Haemostasis1986;16 Suppl 1:48-50. [MEDLINE: 3519383]FrascàGM , VangelistaA , RaimondiC , BonominiV .Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (defibrotide): a controlled study. Life Support Systems1986;4(3):231-7. [MEDLINE: 3537545]">Frascà 1986</a> showed a head‐to‐head comparison of antiplatelet agents (glycoprotein IIb/IIIa inhibitor versus adenosine reuptake inhibitor) in kidney transplant recipients and further research is needed in these populations. Secondly<i>,</i> very few or no data for cardiovascular death were available in studies of glycoprotein IIb/IIIa inhibitors administered in addition to standard therapy, low dose versus high dose clopidogrel and cilostazol versus sarpogrelate in patients with CKD or undergoing HD. </p> </section> <section id="CD008834-sec-0156"> <h3 class="title" id="CD008834-sec-0156">Quality of the evidence</h3> <p>Although this review found consistent effect estimates for important clinical outcomes (MI and bleeding) in analyses that include approximately 16,000 people with CKD and between 500 to 1000 events, our conclusions must be considered more cautiously due to several potential limitations in the available data. Studies with zero events in both arms could not be analysed because they did not yield information on both the magnitude and direction of the relative treatment effects. </p> <section id="CD008834-sec-0157"> <h4 class="title">Study limitations</h4> <p>In this updated review, selective reporting of outcomes may reduce the strength of our conclusions. Data for MI in smaller studies with smaller treatment benefits were absent because these (less precise) studies did not systematically report cardiovascular events. Accordingly, selective outcome reporting reduced the reliability of this treatment effect (13% reduction) in both magnitude and direction, although the effect of bias could not be determined in the absence of all data for this outcome. The small proportion of studies reporting vascular access outcomes including approximately 6500 participants reduced the strength of evidence for antiplatelet agents on vascular access function and maturation. Only 50% of such studies reported access failure or thrombosis, and only 15% reported on maturation and suitability for dialysis outcomes in these people. Overall, some studies did not report adequate blinding, allocation concealment or random sequence generation, although sensitivity analyses did not find differences in treatment effects when analyses were restricted to studies of higher methodological quality, because lower quality studies tended to be smaller and contributed fewer events to analyses. In addition, the number of major bleeding events in studies of dual antiplatelet agents was insufficient to determine in indirect evidence whether the bleeding risk was increased with dual antiplatelet agents compared with monotherapy. Data from studies that directly compared two antiplatelet agents against a single antiplatelet agent were rarely reported. </p> </section> <section id="CD008834-sec-0158"> <h4 class="title">Consistency of results</h4> <p>Our major findings were that antiplatelet agents probably reduce MI, probably increase major bleeding, and may increase minor bleeding in CKD and HD. More than one‐third of studies reported death (any cause) in over 17,000 participants and showed no treatment effect in the majority of studies. The null result of antiplatelet agents on death (any cause) was due both to the lack of effect on aspirin on non‐cardiovascular causes of death and to the competing non‐atherosclerotic cardiovascular causes. Only <a href="./references#CD008834-bbs2-0011" title="BangaloreS , BhattDL , StegPG , WeberMA , BodenWE , HammCW , et al.beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circulation: Cardiovascular Quality &amp; Outcomes2014;7(6):872-81. [MEDLINE: 25271049]BergerPB , BhattDL , FusterV , StegPG , FoxKA , ShaoM , et al.Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation2010;121(23):2575-83. [MEDLINE: 20516378]BhattDL , FlatherMD , HackeW , BergerPB , BlackHR , BodenWE , et al.Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology2007;49(19):1982-8. [MEDLINE: 17498584]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial [Erratum in: Am Heart J. 2006 Jan;151(1):247]. American Heart Journal2005;150(3):401. [MEDLINE: 16169314]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine2006;354(16):1706-17. [MEDLINE: 16531616]DasguptaA , SteinhublSR , BhattDL , BergerPB , ShaoM , MakKH , et al.Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). American Journal of Cardiology2009;103(10):1359-63. [MEDLINE: 19427428]EikelboomJW , HankeyGJ , ThomJ , BhattDL , StegPG , MontalescotG , et al.Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation2008;118(17):1705-12. [MEDLINE: 18838564]MakKH , BhattDL , ShaoM , HaffnerSM , HammCW , HankeyGJ , et al.The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. European Heart Journal2009;30(7):857-65. [MEDLINE: 19233855]SteinhublSR , BhattDL , BrennanDM , MontalescotG , HankeyGJ , EikelboomJW , et al.Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding [Summary for patients in Ann Intern Med. 2009 Mar 17;150(6):I-22; PMID: 19293067]. Annals of Internal Medicine2009;150(6):379-86. [MEDLINE: 19293071]WangTH , BhattDL , FoxKA , SteinhublSR , BrennanDM , HackeW , et al.An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal2007;28(18):2200-7. [MEDLINE: 17673448]">CHARISMA 2006</a>, which compared clopidogrel and aspirin versus aspirin alone in people with diabetic kidney disease, showed that there were more deaths amongst participants allocated to clopidogrel, although the reasons for this finding remain unclear. Similarly, in analyses for cardiovascular death that included 21 studies and nearly 10,000 participants, only <a href="./references#CD008834-bbs2-0011" title="BangaloreS , BhattDL , StegPG , WeberMA , BodenWE , HammCW , et al.beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circulation: Cardiovascular Quality &amp; Outcomes2014;7(6):872-81. [MEDLINE: 25271049]BergerPB , BhattDL , FusterV , StegPG , FoxKA , ShaoM , et al.Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation2010;121(23):2575-83. [MEDLINE: 20516378]BhattDL , FlatherMD , HackeW , BergerPB , BlackHR , BodenWE , et al.Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology2007;49(19):1982-8. [MEDLINE: 17498584]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial [Erratum in: Am Heart J. 2006 Jan;151(1):247]. American Heart Journal2005;150(3):401. [MEDLINE: 16169314]BhattDL , FoxKA , HackeW , BergerPB , BlackHR , BodenWE , et al.Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine2006;354(16):1706-17. [MEDLINE: 16531616]DasguptaA , SteinhublSR , BhattDL , BergerPB , ShaoM , MakKH , et al.Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). American Journal of Cardiology2009;103(10):1359-63. [MEDLINE: 19427428]EikelboomJW , HankeyGJ , ThomJ , BhattDL , StegPG , MontalescotG , et al.Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation2008;118(17):1705-12. [MEDLINE: 18838564]MakKH , BhattDL , ShaoM , HaffnerSM , HammCW , HankeyGJ , et al.The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. European Heart Journal2009;30(7):857-65. [MEDLINE: 19233855]SteinhublSR , BhattDL , BrennanDM , MontalescotG , HankeyGJ , EikelboomJW , et al.Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding [Summary for patients in Ann Intern Med. 2009 Mar 17;150(6):I-22; PMID: 19293067]. Annals of Internal Medicine2009;150(6):379-86. [MEDLINE: 19293071]WangTH , BhattDL , FoxKA , SteinhublSR , BrennanDM , HackeW , et al.An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal2007;28(18):2200-7. [MEDLINE: 17673448]">CHARISMA 2006</a> had a 95% CI that did not include '1' suggesting the null effect of antiplatelet agents on cause‐specific death is robust. There was also very low heterogeneity in the summary estimate for MI, although only 18/90 potentially eligible studies reported this outcome. Approximately one‐third of placebo/no treatment studies reported major bleeding events with a consistent risk across all contributing studies of over 16,000 participants and nearly 600 events. The highly variable definitions of major bleeding in the included studies, together with the relative lack of specific reporting on intracranial haemorrhage, reduced the ability to weigh the relative benefits of treatment (reducing MI) with the comprehensive potential risks of harm for people with CKD and HD. The risks of minor bleeding varied among studies beyond chance alone and subgroup analyses, which included analyses for age, gender, pre‐existing comorbidities or time on dialysis, did not reduce the reliability of the effect estimate identified for this outcome. </p> </section> <section id="CD008834-sec-0159"> <h4 class="title">Directness of evidence</h4> <p>There were 27 studies reporting direct comparisons, and 14 were meta‐analysed. . The small number of studies that directly compared different agents (prasugrel versus clopidogrel in one study; ticagrelor versus clopidogrel in three studies; different doses of clopidogrel in one study; abciximab versus tirofiban in one study; defibrotide versus dypiridamole in one study; sarpogrelate versus cilostazol in one study and beraprost versus cilostazol or sarpogrelate in one study) precluded indirect comparisons of the magnitude of the effect of each drug class (although such evidence is of lower quality than head‐to‐head comparisons of antiplatelet agents). Although we planned to identify whether a specific antiplatelet agent was particularly beneficial (or harmful) and if treatment effects varied with stage of CKD (dialysis versus earlier stages of CKD) using prespecified subgroup analyses, these analyses were not performed due to the small number of studies. </p> </section> <section id="CD008834-sec-0160"> <h4 class="title">Precision</h4> <p>Effect estimates for major treatment benefits and harms (MI and major bleeding) had narrow confidence intervals, increasing their certainty and strengthening the evidence within the review for these clinical events. Several outcomes, however, included few participants and events, indicating the available evidence for benefits (and toxicities) of antiplatelet agents for these outcomes is of lower quality. These outcomes included death (any cause) and cardiovascular death, bleeding‐related death, fatal and nonfatal stroke, haemorrhagic stroke, kidney failure, transplant function and rejection, dialysis vascular access maturation, and hospitalisation. Effect estimates for direct antiplatelet versus antiplatelet comparisons were also very imprecise. </p> </section> </section> <section id="CD008834-sec-0161"> <h3 class="title" id="CD008834-sec-0161">Potential biases in the review process</h3> <p>This review was carried out using standard Cochrane methods. Each step was completed independently by at least two authors including the selection of studies, data management, and risk of bias assessment, thus reducing the risks of errors in the identification of eligible studies and adjudication of evidence certainty. A highly sensitive search of the Cochrane Kidney Transplant specialised register was completed without language restriction in July 2021. The registry contains hand‐searched literature and conference proceedings, maximising the inclusion of grey literature in this review. We additionally requested data from authors. Some studies did not report key outcomes in a format available for meta‐analysis. </p> <p>Potential biases in this review were related to the data available in the individual studies. First, there was heterogeneity in treatment interventions and comparisons; due to the small number of data observations and the different number of participants in each subgroup category, robust statistical estimates of heterogeneity could not be estimated. Second, we could not assess for potential reporting bias because most studies did not report key outcomes in a format available for meta‐analysis. Third, while most participants were on CKD (stage 1‐5) not requiring dialysis, there was wide variation in the definition of kidney disease for inclusion in eligible studies. Fourth, adverse event reporting in the available studies was infrequent and inconsistent. Finally, selective outcome reporting was a limitation across the included studies. </p> <p>Visual inspection of funnel plots did not suggest any evidence of small study effects indicating possible publication bias for MI (<a href="#CD008834-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD008834-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison of antiplatelet agents versus control for the outcome of fatal or nonfatal myocardial infarction" data-id="CD008834-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison of antiplatelet agents versus control for the outcome of fatal or nonfatal myocardial infarction </p> </div> </div> </div> </section> <section id="CD008834-sec-0162"> <h3 class="title" id="CD008834-sec-0162">Agreements and disagreements with other studies or reviews</h3> <p>The updated results of this review expand the available evidence for people with CKD including data for 51,959 participants. An earlier collaborative systematic overview of 287 RCTs of an antiplatelet agent versus control (130,000 participants) or of one antiplatelet treatment versus another (77,000 participants) in people at high risk of cardiovascular disease (acute or previous vascular disease or other predisposing condition) included 2632 people requiring HD (<a href="./references#CD008834-bbs2-0172" title="Antithrombotic Trialists' Collaboration.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.[Erratum in: BMJ 2002 Jan 19;324(7330):141]. BMJ2002;324(7329):71-86. [MEDLINE: 11786451]">ATT 2002</a>). This review found that antiplatelet agents produced a 41% proportional reduction in serious vascular events in this population. However, only 99 vascular events and 46 major extracranial bleeds were available at the time of publication, limiting the reliability of the conclusions drawn (<a href="./references#CD008834-bbs2-0172" title="Antithrombotic Trialists' Collaboration.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.[Erratum in: BMJ 2002 Jan 19;324(7330):141]. BMJ2002;324(7329):71-86. [MEDLINE: 11786451]">ATT 2002</a>). Data for people with earlier stages of CKD were not available in this earlier review and have only recently become more available. Another systematic review of individual patient data for aspirin in the primary and secondary prevention of vascular disease did not provide specific analyses for individuals based on the presence of CKD (<a href="./references#CD008834-bbs2-0173" title="Antithrombotic Trialists' (ATT) Collaboration, BaigentC , BlackwellL , CollinsR , EmbersonJ , GodwinJ , et al.Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet2009;373(9678):1849-60. [MEDLINE: 19482214]">ATT 2009</a>). </p> <p>Notably, our systematic review (that finds that antiplatelet agents probably lower by 12% the risk of MI, increase major bleeding, may reduce death (any cause), and may increase minor bleeding) differs from these two previous studies. We suggest that the benefits of antiplatelet agents on cardiovascular events may be smaller in people with CKD compared with other populations at risk of cardiovascular events. The relatively reduced efficacy for antiplatelet agents on total death in CKD is potentially explained by the competing mechanisms for cardiovascular death in this population. Progressive kidney dysfunction is characterised by vascular stiffening and calcification, cardiomyopathy, hyperkalaemia, and sudden cardiac death, in addition to occlusive vascular disease. About half of cardiovascular deaths in both dialysis and transplant patients are caused by cardiac arrest and heart failure (<a href="./references#CD008834-bbs2-0171" title="Australia &amp; New Zealand Dialysis &amp; Transplant Registry.The 42nd Annual Report 2019 (Data to 2018). www.anzdata.org.au/?s=annual+report&amp;data-group=anzdata (accessed 24 October 2021).">ANZDATA 2019</a>) for which the predominant pathogenetic mechanisms include hypertension, volume expansion, vascular calcification, and arrhythmia, rather than platelet aggregation and thrombosis. Therefore, while we find that antiplatelet agents prevent occlusive vascular events (MI) in CKD as expected, they have a lower overall effect on non‐thrombotic causes of death (both vascular and nonvascular). The results of the present review are consistent with the effects of antiplatelet agents in primary prevention of cardiovascular events, which reduce nonfatal MI by 20% but do not prevent stroke or vascular death with similar effects in men and women (<a href="./references#CD008834-bbs2-0173" title="Antithrombotic Trialists' (ATT) Collaboration, BaigentC , BlackwellL , CollinsR , EmbersonJ , GodwinJ , et al.Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet2009;373(9678):1849-60. [MEDLINE: 19482214]">ATT 2009</a>). Notably, in that review, the authors concluded that aspirin may be of uncertain net value, because reducing occlusive events may not be outweighed by risks of major bleeding. </p> <p>A previous meta‐analysis of medical adjuvant treatment to increase the patency of arteriovenous fistulae and grafts included placebo‐controlled studies of antiplatelet agents, low‐dose warfarin, or fish oil was published in 2008 (<a href="./references#CD008834-bbs2-0209" title="OsbornG , EscofetX , Da SilvaA .Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database of Systematic Reviews2008, Issue 4. Art. No: CD002786. [DOI: 10.1002/14651858.CD002786.pub2]">Osborn 2008</a>). In that systematic review, antiplatelet agents were considered separately in analyses that combined access types (graft or fistula) and analyses included a maximum of only three studies and 41 events. Analyses in that review may have been insufficient to provide reliable estimates of the benefits or toxicity of antiplatelet agents on vascular access outcomes. Our review also differs from the second review of antiplatelet agents for the prevention of arteriovenous fistula thrombosis of 10 studies (approximately 2000 participants), as we considered the outcomes of suitability for dialysis or access maturation, summarised study risks of bias, and explored sources of heterogeneity within treatment effects (<a href="./references#CD008834-bbs2-0180" title="ColemanCI , TuttleLA , TeevanC , BakerWL , WhiteCM , ReinhartKM .Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta analysis. International Journal of Clinical Practice2010;64(9):1239-44. [MEDLINE: 20455955]">Coleman 2010</a>). </p> <p>Our review showed similar results compared with a recent meta‐analysis that provided data for approximately 28,000 CKD patients, where the risk of MI decreased, major and minor bleeding increased in the antiplatelet agent group compared with control (<a href="./references#CD008834-bbs2-0220" title="SuX , YanB , WangL , LVJ , ChengH , ChenY .Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. BMC Nephrology2019;20(1):309. [MEDLINE: 31390997]">Su 2019</a>). Moreover, the authors reported that the effects of antiplatelet agents on HD patients or kidney transplant patients were rarely or not reported. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008834-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram; study identification and selection process." data-id="CD008834-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram; study identification and selection process.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/full#CD008834-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD008834-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/full#CD008834-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison of antiplatelet agents versus control for the outcome of fatal or nonfatal myocardial infarction" data-id="CD008834-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison of antiplatelet agents versus control for the outcome of fatal or nonfatal myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/full#CD008834-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 1: Fatal or nonfatal myocardial infarction" data-id="CD008834-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 1: Fatal or nonfatal myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 2: Fatal or nonfatal stroke" data-id="CD008834-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 2: Fatal or nonfatal stroke</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 3: Death (any cause)" data-id="CD008834-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 3: Death (any cause)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 4: Haemorrhagic stroke" data-id="CD008834-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 4: Haemorrhagic stroke</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 5: Cardiovascular death" data-id="CD008834-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 5: Cardiovascular death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 6: Fatal bleeding" data-id="CD008834-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 6: Fatal bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 7: Major bleeding" data-id="CD008834-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 7: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 8: Minor bleeding" data-id="CD008834-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 8: Minor bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 9: Kidney failure" data-id="CD008834-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 9: Kidney failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 10: Doubling of serum creatinine" data-id="CD008834-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 10: Doubling of serum creatinine</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 11: Kidney transplant graft loss" data-id="CD008834-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 11: Kidney transplant graft loss </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 12: Transplant rejection" data-id="CD008834-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 12: Transplant rejection</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 13: Creatinine clearance" data-id="CD008834-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 13: Creatinine clearance</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 14: Proteinuria" data-id="CD008834-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 14: Proteinuria</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 15: Dialysis access failure (thrombosis or loss of patency)" data-id="CD008834-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 15: Dialysis access failure (thrombosis or loss of patency) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 16: Early access thrombosis (before 8 weeks)" data-id="CD008834-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 16: Early access thrombosis (before 8 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 17: Loss of primary unassisted patency" data-id="CD008834-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 17: Loss of primary unassisted patency </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 18: Failure to attain suitability for dialysis" data-id="CD008834-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 18: Failure to attain suitability for dialysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 19: Need for intervention to attain patency or assist maturation" data-id="CD008834-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 19: Need for intervention to attain patency or assist maturation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 20: Hospitalisation (any cause)" data-id="CD008834-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 20: Hospitalisation (any cause) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 21: Cardiovascular hospitalisation" data-id="CD008834-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 21: Cardiovascular hospitalisation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet agents versus control, Outcome 22: Treatment withdrawal" data-id="CD008834-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet agents versus control, Outcome 22: Treatment withdrawal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Prasugrel versus clopidogrel, Outcome 1: Fatal or nonfatal myocardial infarction" data-id="CD008834-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Prasugrel versus clopidogrel, Outcome 1: Fatal or nonfatal myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Prasugrel versus clopidogrel, Outcome 2: Death (any cause)" data-id="CD008834-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Prasugrel versus clopidogrel, Outcome 2: Death (any cause)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Prasugrel versus clopidogrel, Outcome 3: Cardiovascular death" data-id="CD008834-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Prasugrel versus clopidogrel, Outcome 3: Cardiovascular death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Prasugrel versus clopidogrel, Outcome 4: Major bleeding" data-id="CD008834-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Prasugrel versus clopidogrel, Outcome 4: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Prasugrel versus clopidogrel, Outcome 5: Minor bleeding" data-id="CD008834-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Prasugrel versus clopidogrel, Outcome 5: Minor bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ticagrelor versus clopidogrel, Outcome 1: Fatal or nonfatal myocardial infarction" data-id="CD008834-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Ticagrelor versus clopidogrel, Outcome 1: Fatal or nonfatal myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ticagrelor versus clopidogrel, Outcome 2: Fatal or nonfatal stroke" data-id="CD008834-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Ticagrelor versus clopidogrel, Outcome 2: Fatal or nonfatal stroke</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ticagrelor versus clopidogrel, Outcome 3: Death (any cause)" data-id="CD008834-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Ticagrelor versus clopidogrel, Outcome 3: Death (any cause)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ticagrelor versus clopidogrel, Outcome 4: Cardiovascular death" data-id="CD008834-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Ticagrelor versus clopidogrel, Outcome 4: Cardiovascular death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ticagrelor versus clopidogrel, Outcome 5: Fatal bleeding" data-id="CD008834-fig-0035" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Ticagrelor versus clopidogrel, Outcome 5: Fatal bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ticagrelor versus clopidogrel, Outcome 6: Major bleeding" data-id="CD008834-fig-0036" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Ticagrelor versus clopidogrel, Outcome 6: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ticagrelor versus clopidogrel, Outcome 7: Minor bleeding" data-id="CD008834-fig-0037" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Ticagrelor versus clopidogrel, Outcome 7: Minor bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ticagrelor versus clopidogrel, Outcome 8: Treatment withdrawal" data-id="CD008834-fig-0038" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Ticagrelor versus clopidogrel, Outcome 8: Treatment withdrawal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Clopidogrel (low dose) versus clopidogrel (high dose), Outcome 1: Haemorragic stroke" data-id="CD008834-fig-0039" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Clopidogrel (low dose) versus clopidogrel (high dose), Outcome 1: Haemorragic stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Clopidogrel (low dose) versus clopidogrel (high dose), Outcome 2: Cardiovascular death" data-id="CD008834-fig-0040" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Clopidogrel (low dose) versus clopidogrel (high dose), Outcome 2: Cardiovascular death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Abciximab versus tirofiban, Outcome 1: Fatal or nonfatal myocardial infarction" data-id="CD008834-fig-0041" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Abciximab versus tirofiban, Outcome 1: Fatal or nonfatal myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Abciximab versus tirofiban, Outcome 2: Death (any cause)" data-id="CD008834-fig-0042" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Abciximab versus tirofiban, Outcome 2: Death (any cause)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Defibrotide versus dypiridamole, Outcome 1: Death (any cause)" data-id="CD008834-fig-0043" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Defibrotide versus dypiridamole, Outcome 1: Death (any cause)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Defibrotide versus dypiridamole, Outcome 2: Cardiovascular death" data-id="CD008834-fig-0044" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Defibrotide versus dypiridamole, Outcome 2: Cardiovascular death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Defibrotide versus dypiridamole, Outcome 3: Fatal bleeding" data-id="CD008834-fig-0045" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Defibrotide versus dypiridamole, Outcome 3: Fatal bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Defibrotide versus dypiridamole, Outcome 4: Kidney transplant graft loss" data-id="CD008834-fig-0046" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Defibrotide versus dypiridamole, Outcome 4: Kidney transplant graft loss </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Cilostazol versus sarpogrelate, Outcome 1: Major bleeding" data-id="CD008834-fig-0047" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Cilostazol versus sarpogrelate, Outcome 1: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Beraprost versus cilostazol or sarpogrelate, Outcome 1: Fatal or nonfatal myocardial infarction" data-id="CD008834-fig-0048" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Beraprost versus cilostazol or sarpogrelate, Outcome 1: Fatal or nonfatal myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Beraprost versus cilostazol or sarpogrelate, Outcome 2: Fatal or nonfatal stroke" data-id="CD008834-fig-0049" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Beraprost versus cilostazol or sarpogrelate, Outcome 2: Fatal or nonfatal stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Beraprost versus cilostazol or sarpogrelate, Outcome 3: Death (any cause)" data-id="CD008834-fig-0050" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Beraprost versus cilostazol or sarpogrelate, Outcome 3: Death (any cause)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Beraprost versus cilostazol or sarpogrelate, Outcome 4: Cardiovascular death" data-id="CD008834-fig-0051" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Beraprost versus cilostazol or sarpogrelate, Outcome 4: Cardiovascular death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Beraprost versus cilostazol or sarpogrelate, Outcome 5: Fatal bleeding" data-id="CD008834-fig-0052" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Beraprost versus cilostazol or sarpogrelate, Outcome 5: Fatal bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Primary/secondary prevention for fatal/non fatal myocardial infarction (subgroup analysis), Outcome 1: Secondary prevention" data-id="CD008834-fig-0053" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Primary/secondary prevention for fatal/non fatal myocardial infarction (subgroup analysis), Outcome 1: Secondary prevention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sensitivity analysis (adequate allocation concealment), Outcome 1: Fatal or nonfatal myocardial infarction" data-id="CD008834-fig-0054" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Sensitivity analysis (adequate allocation concealment), Outcome 1: Fatal or nonfatal myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sensitivity analysis (adequate allocation concealment), Outcome 2: Death (any cause)" data-id="CD008834-fig-0055" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Sensitivity analysis (adequate allocation concealment), Outcome 2: Death (any cause) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sensitivity analysis (adequate allocation concealment), Outcome 3: Cardiovascular death" data-id="CD008834-fig-0056" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Sensitivity analysis (adequate allocation concealment), Outcome 3: Cardiovascular death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sensitivity analysis (adequate allocation concealment), Outcome 4: Major bleeding" data-id="CD008834-fig-0057" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: Sensitivity analysis (adequate allocation concealment), Outcome 4: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Sensitivity analysis (low risk of attrition), Outcome 1: Fatal or nonfatal myocardial infarction" data-id="CD008834-fig-0058" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Sensitivity analysis (low risk of attrition), Outcome 1: Fatal or nonfatal myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Sensitivity analysis (low risk of attrition), Outcome 2: Death (any cause)" data-id="CD008834-fig-0059" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Sensitivity analysis (low risk of attrition), Outcome 2: Death (any cause) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Sensitivity analysis (low risk of attrition), Outcome 3: Cardiovascular death" data-id="CD008834-fig-0060" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Sensitivity analysis (low risk of attrition), Outcome 3: Cardiovascular death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-011.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Sensitivity analysis (low risk of attrition), Outcome 4: Major bleeding" data-id="CD008834-fig-0061" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-011.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-011.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11: Sensitivity analysis (low risk of attrition), Outcome 4: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-011.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Stroke (subgroup analysis), Outcome 1: Stage of CKD" data-id="CD008834-fig-0062" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Stroke (subgroup analysis), Outcome 1: Stage of CKD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Stroke (subgroup analysis), Outcome 2: Diabetes" data-id="CD008834-fig-0063" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Stroke (subgroup analysis), Outcome 2: Diabetes</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Stroke (subgroup analysis), Outcome 3: Sex" data-id="CD008834-fig-0064" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: Stroke (subgroup analysis), Outcome 3: Sex</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-012.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Stroke (subgroup analysis), Outcome 4: Duration of intervention" data-id="CD008834-fig-0065" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-012.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-012.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12: Stroke (subgroup analysis), Outcome 4: Duration of intervention</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-012.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Minor bleeding (subgroup analysis), Outcome 1: Stage of CKD" data-id="CD008834-fig-0066" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Minor bleeding (subgroup analysis), Outcome 1: Stage of CKD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Minor bleeding (subgroup analysis), Outcome 2: Diabetes" data-id="CD008834-fig-0067" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Minor bleeding (subgroup analysis), Outcome 2: Diabetes</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Minor bleeding (subgroup analysis), Outcome 3: Sex" data-id="CD008834-fig-0068" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: Minor bleeding (subgroup analysis), Outcome 3: Sex</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-013.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Minor bleeding (subgroup analysis), Outcome 4: Duration of intervention" data-id="CD008834-fig-0069" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-013.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-013.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13: Minor bleeding (subgroup analysis), Outcome 4: Duration of intervention</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-013.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Dialysis access failure (subgroup analysis), Outcome 1: Diabetes" data-id="CD008834-fig-0070" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Dialysis access failure (subgroup analysis), Outcome 1: Diabetes</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Dialysis access failure (subgroup analysis), Outcome 2: Sex" data-id="CD008834-fig-0071" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: Dialysis access failure (subgroup analysis), Outcome 2: Sex</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Dialysis access failure (subgroup analysis), Outcome 3: Duration of intervention" data-id="CD008834-fig-0072" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: Dialysis access failure (subgroup analysis), Outcome 3: Duration of intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008834-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/urn:x-wiley:14651858:media:CD008834:CD008834-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Failure to attain suitability for dialysis (subgroup analysis), Outcome 1: Duration of intervention" data-id="CD008834-fig-0073" src="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_t/tCD008834-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: Failure to attain suitability for dialysis (subgroup analysis), Outcome 1: Duration of intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/media/CDSR/CD008834/image_n/nCD008834-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008834-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antiplatelet agents versus control for chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Antiplatelet agents versus control for chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients) </p> <p><b>Settings:</b> all settings involving people with any stage of CKD </p> <p><b>Intervention:</b> antiplatelet agents (abciximab, aspirin, beraprost sodium, cilostazol, clopidogrel, dypiridamole, eptidifibatide, pentoxifylline, picotamide, prasugrel, prostacyclin, sarpogrelate, sulphinpyrazone, ticlopidine, tirofiban, alone or in combination) </p> <p><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antiplatelet agents</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Fatal or nonfatal myocardial infarction</b> </p> <p>Follow‐up: 3 to 61.2 months</p> <p>(median 12 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>All patients (predialysis, dialysis, transplant recipients)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/>(0.79 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15,289 (18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>moderate <sup>1</sup> </b> </p> <p>⊕⊕⊕⊝</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 fewer per 1,000<br/>(1 to 15 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>CKD patients (GFR 15 to 60 mL/min/1.73 m²)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/>(0.74 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11,912 (11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>moderate <sup>1</sup> </b> </p> <p>⊕⊕⊕⊝</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 fewer per 1,000<br/>(1 to 22 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>HD patients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.49 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2929 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>moderate <sup>1</sup> </b> </p> <p>⊕⊕⊕⊝</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 fewer per 1,000<br/>(10 fewer to 8 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Fatal or nonfatal stroke</b> </p> <p>Follow‐up: 3 to 61.2 months</p> <p>(median 12 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>All patients (predialysis, dialysis, transplant recipients)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.64 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,382 (12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>very low <sup>1,2,3</sup> </b> </p> <p>⊕⊝⊝⊝</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/>(7 fewer to 12 more) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>CKD patients (GFR 15 to 60 mL/min/1.73 m²)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.06<br/>(0.64 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7062 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>very low <sup>1,2,3</sup> </b> </p> <p>⊕⊝⊝⊝</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 more per 1,000<br/>(9 fewer to 19 more) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>HD patients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.62<br/>(0.15 to 2.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2872 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>very low <sup>1,2,3</sup> </b> </p> <p>⊕⊝⊝⊝</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 fewer per 1,000<br/>(8 fewer to 16 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Death (any cause)</b> </p> <p>Follow‐up: 0.9 to 88.2 months</p> <p>(median 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>All patients (predialysis, dialysis, transplant recipients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/>(0.84 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>18,241 (35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>low <sup>1,2</sup> </b> </p> <p>⊕⊕⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>74 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4 fewer per 1,000<br/>(12 fewer to 4 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>CKD patients (GFR 15 to 60 mL/min/1.73 m²)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.97<br/>(0.81 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>13,234 (19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>low <sup>1,2</sup> </b> </p> <p>⊕⊕⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>72 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2 fewer per 1,000<br/>(14 fewer to 12 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>HD patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.86<br/>(0.72 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>4523 (14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>low <sup>1,2</sup> </b> </p> <p>⊕⊕⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>87 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>12 fewer per 1,000<br/>(24 fewer to 3 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Cardiovascular death</b> </p> <p>Follow‐up: 0.9 to 88.2 months</p> <p>(median 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>All patients (predialysis, dialysis, transplant recipients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.87<br/>(0.65 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>9606 (21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>very low <sup>1,2,3</sup> </b> </p> <p>⊕⊝⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>36 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 fewer per 1,000<br/>(13 fewer to 5 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>CKD patients (GFR 15 to 60 mL/min/1.73 m²)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.98<br/>(0.60 to 1.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>6525 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>very low <sup>1,2,3</sup> </b> </p> <p>⊕⊝⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>37 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 fewer per 1,000<br/>(15 fewer to 22 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>HD patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.71<br/>(0.47 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2597 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>very low <sup>1,2,3</sup> </b> </p> <p>⊕⊝⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>38 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 fewer per 1,000<br/>(20 fewer to 3 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Major bleeding</b> </p> <p>Follow‐up: 0.7 to 61.2 months</p> <p>(median 6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>All patients (predialysis, dialysis, transplant recipients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.35<br/>(1.10 to 1.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>16,194 (29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>moderate <sup>1</sup> </b> </p> <p>⊕⊕⊕⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>29 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>10 more per 1,000<br/>(3 to 19 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>CKD patients (GFR 15 to 60 mL/min/1.73 m²)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.51<br/>(1.15 to 1.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>11591 (12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>moderate <sup>1</sup> </b> </p> <p>⊕⊕⊕⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>35 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18 more per 1,000<br/>(5 to 34 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>HD patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.90<br/>(0.53 to 1.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>4119 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>moderate <sup>1</sup> </b> </p> <p>⊕⊕⊕⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>13 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 fewer per 1,000<br/>(6 fewer to 7 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Minor bleeding</b> </p> <p>Follow‐up: 0.5 to 84 months</p> <p>(median 6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>All patients (predialysis, dialysis, transplant recipients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.55<br/>(1.27 to 1.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>13,218 (21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>low <sup>1,3</sup> </b> </p> <p>⊕⊕⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>92 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>51 more per 1,000<br/>(25 to 83 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>CKD patients (GFR 15 to 60 mL/min/1.73 m²)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.48<br/>(1.20 to 1.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>11,530 (12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>low <sup>1,3</sup> </b> </p> <p>⊕⊕⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>103 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 more per 1,000<br/>(21 to 86 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>HD patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.87<br/>(0.65 to 5.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1240 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>low <sup>1,3</sup> </b> </p> <p>⊕⊕⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>8 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>7 per 1,000<br/>(3 fewer to 35 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Early access thrombosis (before 8 weeks)</b> </p> <p>Follow‐up: 0.9 to 12 months</p> <p>(median 1.4 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>HD patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.52<br/>(0.38 to 0.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1525 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>low <sup>1,4</sup> </b> </p> <p>⊕⊕⊝⊝</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>200 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>6 fewer per 1,000<br/>(60 to 124 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>CKD:</b> chronic kidney disease; <b>GFR:</b> glomerular filtration rate; <b>HD:</b> haemodialysis; <b>OIS:</b> Optimal Information Size </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Some or all studies were not blinded (participants and/or investigators) </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>3</sup> Evidence certainty was downgraded by one level due to moderate between‐study heterogeneity </p> <p><sup>4</sup> Evidence certainty was downgraded by one level due to imprecision (OIS criteria) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antiplatelet agents versus control for chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/full#CD008834-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008834-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antiplatelet agents versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Fatal or nonfatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.79, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.74, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2929</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.49, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 CKD, dialysis and transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.06, 15.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Fatal or nonfatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.64, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.64, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.15, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 CKD, dialysis and transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.97 [0.12, 72.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.84, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.81, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.72, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 CKD, dialysis and transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.14, 6.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Haemorrhagic stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6844</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.69, 2.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6655</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.69, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.65, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.60, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.47, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 CKD, dialysis and transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.06, 15.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Fatal bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7629</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.10, 19.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.10, 19.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.4 CKD, dialysis and transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.10, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.15, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.53, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.4 CKD, dialysis and transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.19, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Minor bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.27, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.20, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.65, 5.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 CKD, dialysis and transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [1.49, 5.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Kidney failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.70, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.59, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.73, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 CKD, dialysis and transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.40, 3.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Doubling of serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.17, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.17, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Kidney transplant graft loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.58, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Transplant rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.77, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Creatinine clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.46 [‐12.33, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.46 [‐12.33, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Proteinuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.74 [‐1.35, ‐0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.74 [‐1.35, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Dialysis access failure (thrombosis or loss of patency) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2847</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.50, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Fistula</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1741</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.36, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Shunt or graft</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.62, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.3 Fistula or graft</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.06, 4.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.4 Catheter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.16, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Early access thrombosis (before 8 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.38, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Loss of primary unassisted patency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.89, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Failure to attain suitability for dialysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.34, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Need for intervention to attain patency or assist maturation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.72, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Hospitalisation (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.87, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.72, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.78, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Cardiovascular hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.76, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.72, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.58, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Treatment withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.83, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.27, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.83, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.3 PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.4 Transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.5 CKD, dialysis and transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.66, 1.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antiplatelet agents versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008834-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Prasugrel versus clopidogrel</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Fatal or nonfatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Minor bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Prasugrel versus clopidogrel</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008834-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Ticagrelor versus clopidogrel</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Fatal or nonfatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Fatal or nonfatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.19, 20.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.19, 20.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.25, 99.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.25, 99.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Fatal bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Minor bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Treatment withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Ticagrelor versus clopidogrel</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008834-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Clopidogrel (low dose) versus clopidogrel (high dose)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Haemorragic stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Clopidogrel (low dose) versus clopidogrel (high dose)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008834-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Abciximab versus tirofiban</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Fatal or nonfatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Abciximab versus tirofiban</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008834-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Defibrotide versus dypiridamole</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Fatal bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Kidney transplant graft loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Defibrotide versus dypiridamole</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008834-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Cilostazol versus sarpogrelate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Cilostazol versus sarpogrelate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008834-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Beraprost versus cilostazol or sarpogrelate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Fatal or nonfatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Fatal or nonfatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Fatal bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Beraprost versus cilostazol or sarpogrelate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008834-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Primary/secondary prevention for fatal/non fatal myocardial infarction (subgroup analysis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.81, 1.06]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Primary/secondary prevention for fatal/non fatal myocardial infarction (subgroup analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008834-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Sensitivity analysis (adequate allocation concealment)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Fatal or nonfatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.65, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.83, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.48, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.07, 2.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Sensitivity analysis (adequate allocation concealment)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008834-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Sensitivity analysis (low risk of attrition)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Fatal or nonfatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.62, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Death (any cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.82, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.60, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.4 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.19, 2.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Sensitivity analysis (low risk of attrition)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008834-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Stroke (subgroup analysis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Stage of CKD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.58, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.1 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.15, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.2 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.57, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.3 Predialysis, dialysis and transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.97 [0.12, 72.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Diabetes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.68, 3.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.1 Less than 50% diabetic patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.15, 6.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.2 At least 50% diabetic patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.64, 4.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Sex <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.68, 2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.1 Less than 50% males</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.56, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.2 At least 50% males</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.53, 3.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.4 Duration of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.58, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.1 Less than 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.18, 21.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.2 Between 6 and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.12, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.3 More than 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.67, 2.32]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Stroke (subgroup analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008834-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Minor bleeding (subgroup analysis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Stage of CKD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.27, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.65, 5.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.2 CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.20, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.3 Predialysis, dialysis and transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [1.49, 5.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Diabetes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [1.24, 2.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.1 Less than 50% diabetic patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [1.51, 5.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.2 At least 50% diabetic patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.37, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Sex <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.29, 2.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.1 Less than 50% males</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [1.29, 4.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.2 At least 50% males</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.12, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.4 Duration of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.27, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.1 Less than 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.65, 5.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.2 Between 6 and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [1.11, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.3 More than 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.28, 2.27]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Minor bleeding (subgroup analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008834-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Dialysis access failure (subgroup analysis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Diabetes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.49, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.1 Less than 50% diabetic patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.45, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.2 At least 50% diabetic patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.16, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Sex <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.51, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.1 Less than 50% males</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.52, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.2 At least 50% males</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.45, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 Duration of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2847</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.50, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.1 Less than 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.44, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.2 Between 6 and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.37, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.3 More than 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>756</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.79, 1.11]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Dialysis access failure (subgroup analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008834-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Failure to attain suitability for dialysis (subgroup analysis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Duration of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.34, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.1 Less than 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.31, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.2 More than 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.16, 1.68]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Failure to attain suitability for dialysis (subgroup analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008834.pub4/references#CD008834-tbl-0016">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008834.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008834-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008834-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008834-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008834-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD008834-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD008834-note-0007">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD008834-note-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008834-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008834-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008834\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008834\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008834\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008834\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008834\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008834\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008834\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008834\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008834\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008834\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008834\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008834\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008834\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008834\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008834\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008834\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008834\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008834\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008834.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008834.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008834.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008834.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008834.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715123933"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008834.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715123937"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008834.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7f60deaa1bde',t:'MTc0MDcxNTEyNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 